62nd AAN Annual Meeting A p r i l 1 0 — A p r i l 1 7, 2 0 1 0 Scientific Abstract Listing and Annual Meeting Information Early Registration Deadline: March 10, 2010 Science · Education · People · Progress 2010 Locations and Deadlines-At-A-Glance Highlights of the 2010 Annual Meeting Dates and Deadlines Integrated Neuroscience Sessions NEW! Highlights in the Field MARCH 10, 2010 Sunday, April 11–Friday, April 16 Annual Meeting Early Registration and Housing Deadline Visit www.aan.com/am Provides in-depth subspecialty concentration around a topic using a combination of presentations, such as scientific sessions, case studies, short poster talks, discussions, invited speakers, and poster sessions. MAY 13, 2010 xx Emerging Concepts in Genetics (see page 25) xx Pediatric Demyelinating Disorders (see page 26) xx Global Neurology: Toxins and Infections (see page 29) xx Current Concepts in Cognitive Neuroscience: Implications for Neurological Disease (see page 30) xx Proteins, Genes, Neurodegeneration, and the Clinical Presentations (see page 41) xx Emerging Treatments in Neuromuscular Disease (see page 64) xx Multiple Sclerosis Imaging (see page 65) xx Deep Brain Stimulation: Where Are We and Where Do We Go From Here? (see page 89) xx Ischemic Stroke, Interventional, and Endovascular Therapies/Large Vessel Disease (see page 102) xx Molecular Markers and Targets in Neuro-oncology (see page 103) These new sessions bring you all you need to know for your subspecialty or area of special interest. Get overviews in subspecialty topics from the past year featuring scientific and educational abstracts, journal articles, subspecialty society updates, tips, resources, and more. Look for highlights from AAN Sections. See page 79 for list of participating sections and details. Course Proposal Deadline for 2011 Annual Meeting Locations Metro Toronto Convention Centre Co-Headquarters Hotels: Fairmont Royal York Sheraton Centre Toronto Hotel www.aan.com/am Table of Contents New! Clinical Trials Session Meeting-at-a-Glance. . . . . . . . . . . . . . . . . . . . . . . . . 2 Thursday, April 15 Highlights. . . . . . . . . . . . . . . . 78 Industry Relations Message . . . . . . . . . . . . . . . . . . . 4 Thursday Poster Session V. . . . . . . . . . . . . . . . . . . 80 Program Legend. . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Thursday Integrated Neuroscience Session. . . . . . 89 Meeting Overview. . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Thursday Scientific Sessions. . . . . . . . . . . . . . . . . . 90 Scientific Sessions-At-A-Glance. . . . . . . . . . . . . . . 15 Thursday Poster Session VI . . . . . . . . . . . . . . . . . . 94 Award Recipients. . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Friday, April 16 Highlights . . . . . . . . . . . . . . . . . 101 Saturday, April 10 Highlights. . . . . . . . . . . . . . . . 23 Friday Integrated Neuroscience Session. . . . . . . . 102 Sunday, April 11 Highlights. . . . . . . . . . . . . . . . . 24 Friday Integrated Neuroscience Session. . . . . . . . 103 Sunday Integrated Neuroscience Session . . . . . . . 25 2010 Virtual Annual Meeting Products (Syllabi CD, Webcast-on-Demand, Practice CD). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104 Sunday Integrated Neuroscience Session . . . . . . . 26 Monday, April 12 Highlights. . . . . . . . . . . . . . . . . 27 Monday Integrated Neuroscience Session. . . . . . . 29 Monday Integrated Neuroscience Session. . . . . . . 30 Tuesday, April 13 Highlights . . . . . . . . . . . . . . . . 31 Poster Session Floor Plan. . . . . . . . . . . . . . . . . . . . 33 Tuesday Poster Session I. . . . . . . . . . . . . . . . . . . . 34 Tuesday Integrated Neuroscience Session. . . . . . . 41 Tuesday Scientific Sessions. . . . . . . . . . . . . . . . . . 42 Tuesday Poster Session II. . . . . . . . . . . . . . . . . . . . 44 Tuesday Scientific Sessions. . . . . . . . . . . . . . . . . . 52 Wednesday, April 14 Highlights. . . . . . . . . . . . . . 54 Wednesday Poster Session III . . . . . . . . . . . . . . . . 56 Wednesday Integrated Neuroscience Session. . . . 64 Wednesday Integrated Neuroscience Session. . . . 65 Wednesday Scientific Sessions. . . . . . . . . . . . . . . . 66 Wednesday Poster Session IV . . . . . . . . . . . . . . . . 68 Wednesday Scientific Sessions. . . . . . . . . . . . . . . . 76 General Information. . . . . . . . . . . . . . . . . . . . . . . . 106 CME/Accreditation. . . . . . . . . . . . . . . . . . . . . 106 Disclaimers/Disclosures . . . . . . . . . . . . . . . . 106 Services. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 Guidelines. . . . . . . . . . . . . . . . . . . . . . . . . . . 107 Volunteer Opportunities. . . . . . . . . . . . . . . . . 107 Weather/Attire. . . . . . . . . . . . . . . . . . . . . . . . 107 Registration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 What’s Free With Your Badge. . . . . . . . . . . . . . . . 110 Hotel Reservations . . . . . . . . . . . . . . . . . . . . . . . . 114 Travel Information. . . . . . . . . . . . . . . . . . . . . . . . . 116 Alliance Tour Information. . . . . . . . . . . . . . . . . . . . 116 Students, Residents, and Fellows Events. . . . . . . 117 Education Programs and Scientific Sessions . by Topic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 Annual Meeting Exhibitors. . . . . . . . . . . . . . . . . . . 122 Committee Members and Staff. . . . . . . . . . . . . . . 124 Offices and Hours of Operation. . . . . . . . . . . . . . . 126 Friday, April 16, 12:00 p.m.–1:30 p.m. MTCC, Theatre 102 This midday seminar covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented with a question and answer period following. The session will cover several scientific topics. NEW! The AAN Awards Plenary Session Thursday, April 15, 4:00 p.m.–6:00 p.m. MTCC, Exhibit Hall FG This session highlights some of the best and brightest in the field today, featuring presentations by the recipients of four top 2010 awards: The Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases, the Sheila Essey Award—An Award for ALS Research, the John Dystel Prize for Multiple Sclerosis Research, and the Dreifuss-Penry Epilepsy Award in a rotating slot. (See page 78) NEW! Thursday Afternoon Half-Day Course Times Thursday afternoon half-day courses begin at 1:15 p.m. and end at 5:00 p.m. to allow time to attend Plenary Sessions. Academy Central Saturday, April 10–Friday, April 16 Academy Central offers a variety of resources central to the career of any neurology professional. Explore science and education publications such as Neurology ® and Continuum: Lifelong Learning in Neurology ®. Learn about clinical guidelines and shop for tools that can make your practice more effective and efficient. Find out how social networking is revolutionizing health care, and why the Academy is advocating on your behalf in Washington, DC. Enjoy a range of speakers who will address a variety of topics. Watch for a list of events and speakers. Academy Central helps demonstrate how the Academy is delivering on its promise to be an indispensable part of your career, each step of the way. Changes to Syllabi Process—Download in Advance Obtaining your Education Program syllabi is quicker and easier than ever. All registered attendees will be able to download the full syllabi for their selected programs, starting in late March. All registered attendees will receive an email notification once syllabi are available. Printed syllabi will not be available. Printed slides will be available in program rooms. Future of Neuroscience Conference: Frontiers in Neuroimaging: Coming Soon to a Scanner Near You Friday, April 16, 9:00 a.m.–5:00 p.m. MTCC, Room 718A This interactive day-long program focuses on neuroimaging. The program will feature poster sessions, platform presentations, a series of case vignettes, and several invited lecturers discussing new developments in the field. The presenters will combine high-level science with practical clinical application. Registration is required. Attendees may register to attend the Future of Neuroscience Conference only. This fee includes Thursday and Friday scientific events. Medical Students and PhD candidates may attend at no charge but MUST register. New! Platform Session Times New time slots this year allow registrants to attend the Highlights in the Field program of their choice. 3 Meeting At-A-Glance 7:00 a.m. 8:00 a.m. Programs and dates of presentation are subject to change. Current as of 2/8/2010 9:00 a.m. 10:00 a.m. 11:00 a.m. 12:00 p.m. 1:00 p.m. 2:00 p.m. 3:00 p.m. 4:00 p.m. 5:00 p.m. 6:00 p.m. 7:00 p.m. 8:00 p.m. 9:00 p.m. 10:00 p.m. Clerkship and Program Directors’ Conference BRAINS Colloquium Basic Science Resident Program APRIL 10 th Basic Science Resident Program Neurology Skills Pavilion Breakfast Seminars Full-Day Courses Skills Workshop SUN A.M. Half-Day Courses APRIL 11 th Scientific Program: P.M. Half-Day Courses Neurology Skills Pavilion Skills Workshop Dinner Seminars Full-Day Courses Scientific Program: Integrated Neuroscience APRIL th Luncheon Seminar Education Colloquium P.M. Half-Day Courses ABPN MOC Exhibits Opening and Reception ABPN Resident Session Exhibits NIH Sponsored Clinical Trials Collo Poster Session I (With Discussion Session) Breakfast Seminars th -quium Scientific Program: Presidential Plenary Session 13 AAN/ AANPA Business Meeting Poster Session II (With Discussion Session) Integrated Neuroscience Luncheon Seminar Corporate Therapeutic Updates Hot Topics Plenary Session Scientific Sessions P.M. Half-Day Courses Ethics Colloquium Neurology Skills Pavilion Breakfast Seminars Exhibits Poster Session III (With Discussion Session) Skills Workshop Contemporary Clinical Issues & Case Studies Plenary Session APRIL After-Dinner Seminars Web Wonders Run/Walk for Brain Research WED Neuro Flashes Best Care Expo International Attendee Summit APRIL Residents & Fellows Career Forum & Reception Scientific Program: Integrated Neuroscience A.M. Half-Day Courses TUE Dinner Seminars Practice Colloquium Luncheon Seminars Morning Reports MON Celebration for Research Integrated Neuroscience Patient Safety Colloquium Scientific Program: Integrated Neuroscience Breakfast Seminars 12 Kick-Off Programs Full-Day Course SAT Awards Luncheon Case Study Programs Scientific Program: Integrated Neuroscience 14 th Scientific Program: Integrated Neuroscience P.M. Half-Day Courses Poster Session IV (With Discussion Session) Scientific Sessions Current Practice Issues in Neurology: Health Reform Breakfast Seminars THU APRIL 15 th Exhibits Poster Session V (With Discussion Session) Scientific Program: Integrated Frontiers in Clinical Neuroscience Plenary Session Scientific Clinical Trials Session Scientific Program: Integrated Neuroscience P.M. Skills Workshop Scientific Program: th 17 4 Scientific Program Highlights Plenary Session P.M. Half-Day Courses Neurology Skills Pavilion SAT Breakfast Seminars 7:00 a.m. 8:00 a.m. Educational Program Scientific Program Other Event Plenary Session Exhibits Events Neuro Flashes Future of Neuroscience Conference A.M. Half-Day Courses Color Key: Integrated Neuroscience Full-Day Courses APRIL th Case Study Programs Therapy Programs Poster Session VI (With Discussion Session) FRI APRIL AAN Awards Plenary Session Sessions P.M. Half-Day Courses Breakfast Seminars 16 Neuroscience Therapy Programs A.M. Half-Day Courses 9:00 a.m. 10:00 a.m. 11:00 a.m. 12:00 p.m. 1:00 p.m. 2:00 p.m. 3:00 p.m. 4:00 p.m. 5:00 p.m. 6:00 p.m. 7:00 p.m. 8:00 p.m. 9:00 p.m. 10:00 p.m. Industry Relations Message Continuing medical education is one of the most important and well-regarded member services provided by the American Academy of Neurology (AAN). The Annual Meeting is the AAN’s premier continuing medical education event. It is internationally recognized in the neurologic community for the quality of its education and scientific programs as well as many networking opportunities. The AAN benefits from its relationship with corporate sponsors who provide financial support for a variety of Annual Meeting events and programs. The AAN recognizes members’ concerns regarding industry involvement in the Annual Meeting and the potential for commercial bias, overt, or otherwise. The AAN annually reviews and revises its guidelines that govern industry participation to ensure that they are appropriate, comprehensive, and unambiguous. The AAN’s zero tolerance policy for any real or perceived commercial bias in AAN education or scientific programs is the fundamental and unwavering principle that guides its interactions with industry. Note: All programs have limited enrollment. Register early to ensure your selection. with infractions and perceptions of bias in a rigorous and impartial manner, the Committee frequently seeks input on these issues from the AAN’s Ethics, Law, and Humanities Committee. The AAN values its relationship with industry. However, the AAN cannot and will not compromise the independence and credibility of its programs through its relationships with corporate sponsors. Appropriate guidelines and input from attendees are essential components of managing these relationships so that the AAN maintains its integrity as an organization and the confidence of the medical profession. The AAN’s Annual Meeting policies and processes are based on, and closely follow, guidelines established by the Accreditation Council for Continuing Medical Education, American Medical Association, and US Food and Drug Administration. Programs at the Annual Meeting are developed and implemented solely by the AAN’s Education Committee, Science Committee, their respective subcommittees, and AAN staff. Industry has absolutely no role in selecting program topics, faculty and directors, or planning program content. Industry influence or promotion on slides or computer-based presentations is prohibited, and any use of product brand names should be avoided. All speakers must personally disclose, in writing, any actual or perceived relationships with industry, regardless of whether these relate to a specific presentation or not. These disclosures are published in Neurology ® and AAN Annual Meeting publications. Industry and presenters are required to sign letters of agreement explicitly stating that they understand and will adhere to the AAN guidelines. The AAN Foundation sponsors a Corporate Roundtable, comprised of representatives from both the AAN and industry, which promotes awareness of, and compliance with, the AAN’s policies governing industry participation in the Annual Meeting and other activities. The great majority of the AAN’s industry supporters and presenters abide by the AAN guidelines, but occasional infractions do occur. Although most of these are minor, the AAN’s zero-tolerance policy specifies sanctions for those who violate its guidelines. In addition, the AAN has revised all education and scientific evaluation forms to provide attendees with an opportunity to report any perceived commercial bias. Although the Meeting Management Committee deals 6 Education Program Legend First Digit = Day of Program EC 2 Day Two: Sunday, April 11 Didactic program offered as morning or afternoon half-day programs. Free to all registered attendees. 7 Day Seven: Friday, April 16 8 Day Eight: Saturday, April 17 FC PC Letters = Type of Program Didactic program begins at 9:00 a.m. and ends at 5:00 p.m. Refreshments will be served during the morning and afternoon break. Lunch will not be served. 6 Day Six: Thursday, April 15 AC Cynthia L. Comella, MD, FAAN, Chair, Education Committee and Chair, Annual Meeting Subcommittee NP NEW! Neurology Skills Pavilion Interactive program offered only on Saturday, April 10. Program begins at 8:30 a.m. and ends at 4:00 p.m. 4 Day Four: Tuesday, April 13 5 Day Five: Wednesday, April 14 Stefan M. Pulst, MD, FAAN, Chair, Science Committee and Scientific Program Subcommittee Colloquium Hands-on, interactive program beginning at 2:15 p.m. and ending at 6:00 p.m. Participants rotate through multiple learning stations in small groups. Refreshments will be served during the break. Note: The Friday Neurology Skills Pavilion begins at 1:15 p.m. and ends at 5:00 p.m. to allow time to attend the Scientific Program Highlights Plenary Session. 3 Day Three: Monday, April 12 The Principles Governing AAN Relationships with External Sources of Support state: It is the AAN’s policy to avoid even the appearance of a conflict of interest between the AAN and industry. Visit www.aan.com/go/am/education for complete course listings. 1 Day One: Saturday, April 10 Stanley Fahn, MD, FAAN, Chair, Meeting Management Committee Education Program Legend Morning Half-Day Course Didactic program begins at 9:00 a.m. and ends at 12:45 p.m. Refreshments will be served during the break. AS After-Dinner Seminar Interactive program begins at 7:30 p.m. and ends at 10:30 p.m. Desserts, light snacks, and beverages will be served. BS Breakfast Seminar Interactive program begins at 6:45 a.m. and ends at 8:30 a.m. A plated breakfast will be available at the start of the program. Participants are encouraged to arrive early. CS Case Studies Program Interactive program begins at 7:00 p.m. and ends at 10:00 p.m. Desserts, light snacks, and beverages will be served. DS Dinner Seminar Interactive program begins at 6:00 p.m. and ends at 9:00 p.m. on Sunday, April 11, and begins at 6:30 p.m. and ends at 9:30 p.m. on Monday, April 12. A plated dinner will be available at the beginning of the program. Participants are encouraged to arrive early. EPClerkship and Program Directors Conference KP Full-Day Course Kick-Off Program Interactive program offered only on Saturday, April 10. Program begins at 6:00 p.m. and ends at 8:00 p.m. A light snack will be served. LS Luncheon Seminar Interactive program begins at 12:00 p.m. and ends at 1:30 p.m. A plated lunch will be available at the beginning of the program. Participants are encouraged to arrive early. MR NEW! Morning Report Interactive program beginning at 7:00 a.m. and ending at 8:30 a.m. The director will present a case with focused questions directed to the program attendees. All Morning Report programs will be utilizing the Audience Response System. Coffee and a light snack will be served. NF NEW! Neuro Flash Quick updates on the pertinent issues about a clinical topic beginning at 6:30 p.m. and ending at 8:00 p.m. Three half-hour talks will be interspersed with interactive Q&A. All Neuro Flash programs will be utilizing the Audience Response System. A light snack will be served. Afternoon Half-Day Course Didactic program begins at 2:15 p.m. and ends at 6:00 p.m. Refreshments will be served during the break. Note: Thursday and Friday afternoon half-day courses begin at 1:15 p.m. and end at 5:00 p.m. to allow time to attend Plenary Sessions. PW Afternoon Skills Workshop Hands-on, interactive program begins at 1:30 p.m. and ends at 6:00 p.m. Available to physicians only. Lunch will not be provided. SC Science Conference Interactive program offered only on Friday, April 16. Program begins at 9:00 a.m. and ends at 5:00 p.m. Lunch will be served. SW Skills Workshop Hands-on, interactive program begins at 9:00 a.m. and ends at 6:00 p.m. Box lunches will be provided. Available to physicians only. Note: Wednesday Skills Workshop begins at noon and ends at 7:00 p.m. to allow time to attend the Contemporary Clinical Issues and Case Studies Plenary Session. TP Therapy Program Didactic program begins at 7:00 p.m. and ends at 9:00 p.m. Desserts, light snacks, and beverages will be served. 7 Meeting Overview SATURDAY, APRIL 10 Education Directors Program 8:30 a.m.–4:00 p.m. 1EP.001 Clerkship and Program Directors Conference A.M. Half-Day Course 9:00 a.m.–12:45 p.m. 1AC.001 Resident Basic Science I: Neuropathology Full-Day Course 9:00 a.m.–5:00 p.m. 1FC.001 The Practice of Neurology: Issues in Coding and Reimbursement Colloquium 1:00 p.m.–5:00 p.m. Developing Countries 2BS.004 Canalith Repositioning for Benign Paroxysmal Positional Vertigo 2BS.005 Clinical Grant Writing 2BS.006 Peripheral Nerve Blocks and Other Interventional Procedures for Headache and Facial Pain Integrated Neuroscience Session: Emerging Concepts in Genetics 8:00 a.m.–12:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 8:00 a.m.–9:30 a.m. Platform Session 9:30 a.m.–10:30 a.m. Poster Session/Poster Rounds 10:30 a.m.–12:00 p.m. Invited Speaker Session 1EC.001 BRAINS (Business and Research Administrators in Neurology Society) Colloquium Colloquium 9:00 a.m.–12:00 p.m. P.M. Half-Day Course 2:15 p.m.–6:00 p.m. 2EC.001 Patient Safety Colloquium: Diagnostic Errors in Neurology 1PC.001 Resident Basic Science II: Clinical Application of Neuropathology Neurology Skills Pavilion 2:15 p.m.–6:00 p.m. 1NP.001 Neurology Skills Pavilion: Health Information Technology for Neurology: The Electronic Frontier Kick-Off Programs 6:00 p.m.–8:00 p.m. 1KP.001 Assessment of Rapidly Progressive Dementias and Related Neurologic Conditions 1KP.002 Diagnosis and Management of Motor Neuron Disease: ALS 1KP.003 Movement Disorder Emergencies: Adults and Children 1KP.004 Surviving Stroke Call: A Guide for Non-vascular Neurologists 1KP.005 Starting Your Career: The Early Years 1KP.006 Intractable Epilepsy: What to Do When Nothing Works 1KP.007 Multiple Sclerosis (Quint)Essentials 1KP.008 Top 10 Neuro-ophthalmic Diagnoses You Can’t Afford to Miss 1KP.009 Biological Rhythms and Neurologic Disease SUNDAY, APRIL 11 Breakfast Seminars 6:45 a.m.–8:30 a.m. 2BS.001 Attention Deficit Hyperactivity Disorder Across the Lifespan 2BS.002 Update on Myotonias 2BS.003 Global Health Challenges: Neurology in A.M. Half-Day Courses 9:00 a.m.–12:45 p.m. 2AC.001 Structure Function Correlations in Behavioral Neurology 2AC.002 Making Sure Your Electronic Health Record System is a Success 2AC.003 Update on Multiple Sclerosis I: Basic Science 2AC.004 Clinical Research Methods I 2AC.005 Neuromuscular Junction Disorders 2AC.006 Advanced Topics in Pediatric Neurology I: Neurodegenerative Diseases Full-Day Courses 9:00 a.m.–5:00 p.m. 2FC.001 2FC.002 2FC.003 2FC.004 2FC.005 Movement Disorders Neurology Update I Neurology of Sleep Update in Neuroimaging: Essentials and Beyond–Part I Continuum Test Your Knowledge: A Multiple-Choice Question Review 2FC.006 Cerebrovascular Diseases Skills Workshop 9:00 a.m.–6:00 p.m. 2SW.001 EMG Skills Workshop: Basic Luncheon Seminars 12:00 p.m.–1:30 p.m. 2LS.001 E/M: Minimize Mistakes, Maximize Reimbursement 2LS.002 Bulletproof Your Practice: What You Need to Know About Compliance and Regulatory Issues to Stay Ahead of the Curve 9 Meeting Overview Integrated Neuroscience Session: Pediatric Demyelinating Disorders 1:00 p.m.–5:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 1:00 p.m.–2:45 p.m. Invited Speaker Session 2:45 p.m.–3:45 p.m. Poster Session 3:45 p.m.–5:00 p.m. Platform Session Colloquium 1:30 p.m.–4:30 p.m. 2EC.002 Practice Colloquium: Dialogue with the Insurer Medical Directors: A Conversation You Don’t Have Every Day P.M. Half-Day Courses 2:15 p.m.–6:00 p.m. 2PC.001 2PC.002 2PC.003 2PC.004 2PC.005 2PC.006 How to Analyze Spells by Video-EEG Genetic Testing in Clinical Neurology Update on Multiple Sclerosis II: Clinical Clinical Research Methods II Myelopathies Bedside Evidence-Based Medicine: How to Deconstruct Articles in Order to Take Care of Patients Neurology Skills Pavilion 2:15 p.m.–6:00 p.m. 2NP.001 Neurology Skills Pavilion: Neuromuscular Bedside Rounds Dinner Seminars 6:00 p.m.–9:00 p.m. 2DS.001 Mild Cognitive Impairment: Implications for Clinicians 2DS.002 The Dystonias: Diagnosis, Treatment, and Update on Causes 2DS.003 Practice Survival for Neurologists: Business Strategies for Success 2DS.004 The Interface of Sleep and Neurologic Disorders 2DS.005 Important Drug Interactions for Neurologists and Psychiatrists 2DS.006 Implications of Combat Related Traumatic Brain Injury Celebration for Research 6:00 p.m.–11:00 p.m. Neurobowl® 6:00 p.m.–8:00 p.m. Main Stage: Featuring Second City and Billy McLaughlin 8:30 p.m.–10:30 p.m. 10 Neuro Film Festival 8:30 p.m.–10:30 p.m. Neuro Hop 8:30 p.m.–11:00 p.m. Meeting Overview MONDAY, APRIL 12 Breakfast Seminars 6:45 a.m.–8:30 a.m. 3BS.001 Can I Drive? Can I Fly? 3BS.002 Career Development for Clinician Educators 3BS.003 Blink and You Live: Coma Prognosis in Child Neurology Kenneth M. Viste, Jr., MD, Neurology Public Policy Fellowship Informational Session 12:00 p.m.–1:00 p.m. 3DS.004 Mitochondrial Disorders in Neurology International Attendee Summit 12:00 p.m.–1:00 p.m. 3NF.001 3NF.002 3NF.003 3NF.004 Luncheon Seminar 12:00 p.m.–1:30 p.m. State Society Leadership Roundtable 7:00 a.m.–9:30 a.m. 3LS.001 Primary and Comprehensive Stroke Centers: The Future of Stroke Care Morning Reports 7:00 a.m.–8:30 a.m. Integrated Neuroscience Session: Current Concepts in Cognitive Neuroscience: Implications for Neurological Disease 2:00 p.m.–6:00 p.m. 3MR.001 Morning Report: Behavioral Neurology 3MR.002 Morning Report: Chronic Migraine: Basis and Tools for Management 3MR.003 Morning Report: Multiple Sclerosis Integrated Neuroscience Session: Global Neurology: Toxins and Infections 8:00 a.m.–12:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 8:00 a.m.–9:30 a.m. Platform Session 9:30 a.m.–10:30 p.m. Poster Session/Poster Rounds 10:30 a.m.–12:00 p.m. Invited Speaker Session Colloquium 8:30 a.m.–12:00 p.m. 3EC.001 Education Colloquium: International Education A.M. Half-Day Courses 9:00 a.m.–12:45 p.m. 3AC.001 3AC.002 3AC.003 3AC.004 Advanced Topics in Pediatric Neurology II: Neuro-oncology Update in Neuroimaging: Essentials and Beyond–Part II Traumatic Brain Injury Update on Endovascular Treatment of Cerebrovascular Diseases Full-Day Courses 9:00 a.m.–5:00 p.m. 3FC.001 3FC.002 3FC.003 3FC.004 3FC.005 3FC.006 3FC.007 Challenging Pain Patients Therapy in Neurology Clinical Epilepsy Headaches in Adults Infections of the Nervous System Peripheral Neuropathy Neuro-ophthalmology Skills Workshop 9:00 a.m.–6:00 p.m. 3SW.001 Advanced Techniques in EMG and Neuromuscular Disease Scientific platform and poster presentations along with an invited speaker session. 2:00 p.m.–3:30 p.m. Invited Speaker Session 3:30 p.m.–4:30 p.m. Poster Session 4:30 p.m.–6:00 p.m. Platform Session P.M. Half-Day Courses 2:15 p.m.–6:00 p.m. 3PC.001 3PC.002 3PC.003 3PC.004 Diagnostic Dilemmas in Multiple Sclerosis Traumatic Spinal Cord Injury Non-Alzheimer’s Dementia Stroke Prevention in 2010 Web Wonders: The Must-Have Technologies for Neurologists in 2010 2:30 p.m.–5:30 p.m. Neuro Flashes 6:30 p.m.–8:00 p.m. Neuro Flash: Acute Stroke Management Neuro Flash: Neurogenetics Neuro Flash: Multiple Sclerosis Neuro Flash: Neuro-ophthalmology After-Dinner Seminars 7:30 p.m.–10:30 p.m. 3AS.001 Improving Accuracy of Dementia Diagnosis: Case Studies with Both Imaging and Neuropathology 3AS.002 Stroke Rehabilitation for Spatial Neglect: Win-Win Treatment Science 3AS.003 Clinical Pearls in Bedside Neurology 3AS.004 EEG in Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates 3AS.005 Brain Computer Interfaces: Frontiers in Neurology and Neuroscience 3AS.006 Diagnosis and Management of Leukodystrophies TUESDAY, APRIL 13 Run/Walk for Brain Research 6:30 a.m.–8:30 a.m. Breakfast Seminars 6:45 a.m.–8:30 a.m. Student Interest Group in Neurology (SIGN) Meeting 5:00 p.m.–6:30 p.m. 4BS.001 The Neurology of Social Behavior 4BS.002 Introduction to the Evaluation and Therapy of Restless Legs Syndrome and Periodic Limb Movements in Sleep 4BS.003 Advanced Palliative Care and Symptom Management of ALS, Alzheimer’s Disease, or Parkinson’s Disease 4BS.004 Approach to Acute CNS Infections 4BS.005 Recognition and Management of the Many Types of Status Epilepticus 4BS.006 Bone Disease for the Practicing Neurologist Consortium of Neurology Residents and Fellows Meeting 5:00 p.m.–6:00 p.m. Palatucci Advocacy Action Planning Roundtable 7:30 a.m.–9:30 a.m. Exhibit Hall Opening Reception 5:00 p.m.–7:00 p.m. Poster Session I (With Discussion Session) 7:30 a.m.–12:00 p.m. Residents and Fellows Career Forum and Reception 6:30 p.m–9:00 p.m. Presidential Plenary Session 9:00 a.m.–12:00 p.m. Dinner Seminars 6:30 p.m.–9:30 p.m. AAN/AAN Professional Association Business Meeting Best Care Expo: Guidelines, Government Relations and Getting Paid 3:00 p.m.–5:00 p.m. ABPN Resident Informational Session 4:00 p.m.–5:00 p.m. 3DS.001 Top 10 Pitfalls in the Diagnosis of Parkinson’s Disease 3DS.002 Stroke in Children and Neonates 3DS.003 Common and Important Ophthalmoscopic Findings (Immediately follows the last Presidential Plenary Session lecture) 11 Meeting Overview 4NP.001 Neurology Skills Pavilion: Acute Stroke Alert American Academy of Neurology and American Academy of Neurology Foundation Awards Luncheon 12:00 p.m.–1:30 p.m. Poster Session II (With Discussion Session) 3:00 p.m.–7:30 p.m. Skills Workshop 12:00 p.m.–7:00 p.m. Neurology Skills Pavilion 2:15 p.m.–6:00 p.m. Exhibits 11:30 a.m.–5:00 p.m. Exhibit Hall Lunch 12:00 p.m.–2:00 p.m. Luncheon Seminar 12:00 p.m.–1:30 p.m. 4LS.001 Telemedicine Increases Options for Successful Stroke Treatment: Nuts and Bolts Scientific Platform Sessions 4:00 p.m.–5:15 p.m. S11 Multiple Sclerosis: Clinical Trials I S12 Cerebrovascular Disease: Acute Stroke Therapy Colloquium 12:30 p.m.–2:00 p.m. 4EC.001 Ethics Colloquium Colloquium 1:00 p.m.–3:00 p.m. S13 Movement Disorders: Huntington’s Disease: Pathophysiology and Clinical Assessment S14 Aging and Dementia: Epidemiology S15 Epilepsy: Clinical Neurophysiology and Imaging 4EC.002 NIH Sponsored Clinical Trials in Neurology: What’s Going On? How to Participate? How Can We Do Better? S16 Anterior Horn: Clinical Studies Integrated Neuroscience Session: Proteins, Genes, Neurodegeneration, and the Clinical Presentations 1:00 p.m.–5:00 p.m. S18 Interventional Neurology Scientific platform and poster presentations along with an invited speaker session. 1:00 p.m.–3:00 p.m. Invited Speaker Session 3:00 p.m.–3:30 p.m. Poster Session 3:30 p.m.–5:00 p.m. Platform Session S17 Critical Care, Trauma, and Inpatient Neurology S19 Movement Disorders: Dystonia S20 Neurologic Education Hot Topics Plenary Session 5:30 p.m.–6:30 p.m. Corporate Therapeutic Updates 7:30 p.m.–10:00 p.m. Scientific Platform Sessions 1:45 p.m.–3:45 p.m. WEDNESDAY, APRIL 14 S01 Multiple Sclerosis: Clinical Research I Breakfast Seminars 6:45 a.m.–8:30 a.m. S02 Cerebrovascular Disease: Stroke Epidemiology I S03 Movement Disorders: Epidemiology of Parkinson’s Disease S04 Sleep Disorders S05 Epilepsy: Clinical Epilepsy S06 Neuromuscular Junction and Muscle Disorders S07 Headache I S08 Behavioral Neurology: From Genetics to Brain Function to Behavior S09 History of Neurology S10 Multiple Sclerosis: MRI I P.M. Half-Day Courses 2:15 p.m.–6:00 p.m. 4PC.001 4PC.002 4PC.003 4PC.004 4PC.005 12 Meeting Overview Spine Neuroimaging: Clinical-Radiologic Correlation Evaluation and Management of Autonomic Disorders Localization in Clinical Neurology Practical Legal Issues for Neurologists Neurotoxicology 5BS.001 Anosognosia and Anosodiaphoria in Stroke and Dementia 5BS.002 Archival Neurologic Films 5BS.003 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia 5BS.004 Case Studies: Clinical Ethics, Professionalism, and Evidence-Based Care of Patients with Severe Life-Limiting Neurologic Disease 5BS.005 Hyperkinetic Movement Disorders: Diagnosis and Treatment Poster Session III (With Discussion Session) 7:30 a.m.–12:00 p.m. Contemporary Clinical Issues and Case Studies Plenary Session 9:00 a.m.–12:00 p.m. Exhibits 11:30 a.m.–5:00 p.m. Exhibit Hall Lunch 12:00 p.m.–2:00 p.m. 5SW.001 Neurophysiologic Intraoperative Monitoring Scientific Platform Sessions 2:00 p.m.–4:00 p.m. S21 Multiple Sclerosis: Clinical Trials II S22 Cerebrovascular Disease I S23 Movement Disorders: Parkinson’s Disease / Non-Motor Symptoms 5PC.004 History of Neurology: Landmark Case Studies of Neurological Giants 5PC.005 Perioperative Stroke: A Practical Approach to Risk Stratification and Modification During the Preoperative Evaluation Poster Session IV (With Discussion Session) 3:00 p.m.–7:30 p.m. Scientific Platform Sessions 4:15 p.m.–5:30 p.m. S31 Multiple Sclerosis: Biomarkers S32 Cerebrovascular Disease: Stroke Imaging S33 Current and Future Treatment of Parkinson’s Disease S24 Aging and Dementia: Imaging S34 Aging and Dementia: Recognition and Treatment S25 Epilepsy: Antiepileptic Drug Therapy S35 Headache II S26 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy S36 Anterior Horn: Spinal Muscular Atrophy S27 Infections S37 Neurologic Manifestations: Imaging and Therapeutics S28 Neuro-ophthalmology/ Neuro-otology S38 Neurogenetics: Basic Science and Therapeutics S29 Neuroepidemiology S39 Neuro-oncology: Paraneoplastic Disorders S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis S40 Multiple Sclerosis: Epidemiology Integrated Neuroscience Sessions: Emerging Treatments in Neuromuscular Disease 2:00 p.m.–6:00 p.m. Current Practice Issues in Neurology: Health Care Reform 5:30 p.m.–7:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 2:00 p.m.–3:15 p.m. Platform Session 3:15 p.m.–4:30 p.m. Poster Session 4:30 p.m.–5:00 p.m. Invited Speaker Session 5:00 p.m.–6:00 p.m. Platform Session Integrated Neuroscience Sessions: Multiple Sclerosis Imaging 2:00 p.m.–6:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 2:00 p.m.–3:30 p.m. Platform Session 3:30 p.m.–4:30 p.m. Poster Session 4:30 p.m.–6:00 p.m. Invited Speaker Session P.M. Half-Day Courses 2:15 p.m.–6:00 p.m. 5PC.001 Primer of Cognitive Neurology 5PC.002 Diagnosis and Management of Movement Disorders in Children 5PC.003 Emergency Neurology Case Study Programs 7:00 p.m.–10:00 p.m. 5CS.001 Case Studies: Dementia 5CS.002 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease 5CS.003 Case Studies: Unusual Movement Disorders 5CS.004 Case Studies: Multiple Sclerosis THURSDAY, APRIL 15 Breakfast Seminars 6:45 a.m.–8:30 a.m. 6BS.001 Differential Diagnosis of Dementia: Linking Clinical Syndromes to Pathology 6BS.002 Critical Care Epilepsy/EEG 6BS.003 Criteria for Stopping and Starting Multiple Sclerosis Therapy 6BS.004 Nystagmus: An Organized Approach 6BS.005 Small Fiber Neuropathies: Somatic, Autonomic, or a Mixture of Both Poster Session V (With Discussion Session) 7:30 a.m.–12:00 p.m. Frontiers in Clinical Neuroscience Plenary Session 9:00 a.m.–11:00 a.m. 13 Meeting Overview Exhibits 11:30 a.m.–4:00 p.m. S56 Anterior Horn: Basic Science S57 Neural Repair and Neurorehabilitation Exhibit Hall Lunch S58 Behavioral Neurology: Language, Action, and Memory 12:00 p.m.–2:00 p.m. S59 Ethics Integrated Neuroscience Session: Deep Brain Stimulation: Where Are We and Where Do We Go From Here? 12:00 p.m.–4:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 12:00 p.m.–1:30 p.m. Invited Speaker Session 1:30 p.m.–2:30 p.m. Poster Session 2:30 p.m.–4:00 p.m. Platform Session Scientific Platform Sessions 1:15 p.m.–2:30 p.m. S41 Multiple Sclerosis: Clinical Immunology S42 Cerebrovascular Disease: Stroke Prevention S43 Movement Disorders: Essential Tremor and Ataxia S60 Multiple Sclerosis: MRI II Poster Session VI (With Discussion Session) 3:00 p.m.–7:30 p.m. NEW! AAN Awards Plenary Session 4:00 p.m.–6:00 p.m. Therapy Programs 7:00 p.m.–9:00 p.m. 6TP.001 Therapy Program: Epilepsy 6TP.002 Therapy Program: Multiple Sclerosis 6TP.003 Therapy Program: Stroke Case Study Programs 7:00 p.m.–10:00 p.m. S46 Peripheral Nerve: Molecular Mechanisms of Peripheral Neuropathy 6CS.001 Now You See It, Now You Know It; (Nearly) Pathognomonic Signs in Neuro-ophthalmology Findings 6CS.002 Case Studies: Sleep Medicine 6CS.003 Case Studies: Adult Metabolic Disorders 6CS.004 Case Studies: Neuroimaging S47 Neurologic Manifestations: Clinical Neurophysiology and Epidemiology FRIDAY, APRIL 16 S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology S45 Child Neurology: Developmental Neurobiology S48 Autonomic Disorders: Frontiers of Autonomic Neurology S49 Cerebrovascular Disease: Hemorrhagic Stroke S50 Multiple Sclerosis: EAE/Animal Models P.M. Half-Day Courses 1:15 p.m.–5:00 p.m. (Note time change) 6PC.001 6PC.002 6PC.003 6PC.004 6PC.005 Psychiatry for the Neurologist Neurologic Consultations in the ICU Neuro-oncology Update I: Primary Brain Tumors Women’s Neurologic Issues in Pregnancy Common Spine Disorders Scientific Platform Sessions 2:45 p.m.–3:45 p.m. S51 Multiple Sclerosis: Clinical Research II S52 Cerebrovascular Disease II S53 Movement Disorders: Parkinson’s Disease and Atypical Parkinsonism S54 Aging and Dementia: Genetics S55 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials 14 Meeting Overview Breakfast Seminars 6:45 a.m.–8:30 a.m. 7BS.001 Diagnosing Spells in Older Adults 7BS.002 Rapid Quantitation in EMG: Learning Accurate and Efficient Motor Unit Potential Analysis 7BS.003 Neurologic Complications of Nutritional Deficiencies 7BS.004 Unruptured Intracranial Aneurysms and Intracranial Vascular Malformations: What a Practicing Neurologist Needs to Know 7BS.005 Case Studies in Neuro-oncology 7BS.006 Update on Ataxias A.M. Half-Day Courses 9:00 a.m.–12:45 p.m. P.M. Skills Workshop 1:30 p.m.–6:00 p.m. 7AC.001 Deep Brain Stimulation Management 7AC.002 Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists 7AC.003 Clinical Issues in Multiple Sclerosis 7AC.004 Neuro-oncology Update II: Systemic Cancer 7AC.005 Clinical EMG I 7AC.006 Child Neurology I 7PW.001 Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia Full-Day Courses 9:00 a.m.–5:00 p.m. 7FC.001 7FC.002 7FC.003 7FC.004 7FC.005 Genetics in Neurology Dementia Update Neurology Update II Neurologic Intensive Care Clinical EEG Scientific Program Highlights Plenary Session 5:15 p.m.–6:15 p.m. Neuro Flashes 6:30 p.m.–8:00 p.m. 7NF.001 Neuro Flash: Child Neurology 7NF.002 Neuro Flash: Epilepsy Therapy Programs 7:00 p.m.–9:00 p.m. 7TP.001 Therapy Program: Neuromuscular Disease 7TP.002 Therapy Program: Movement Disorders 7TP.003 Therapy Program: Headache SATURDAY, APRIL 17 Neuroscience Conference 9:00 a.m.–5:00 p.m. 7SC.001 Future of Neuroscience Conference: Frontiers in Neuroimaging: Coming Soon to a Scanner Near You New! Clinical Trials Session 12:00 p.m.–1:30 p.m. Integrated Neuroscience Session: Molecular Markers and Targets in Neuro-oncology 1:00 p.m.–5:00 p.m. Scientific platform and poster presentations along with an invited speaker session. 1:00 p.m.–2:30 p.m. Platform Session 2:30 p.m.–3:30 p.m. Poster Session 3:30 p.m.–5:00 p.m. Invited Speaker Session P.M. Half-Day Courses 1:15 p.m.–5:00 p.m. Integrated Neuroscience Session: Ischemic Stroke, Interventional, and Endovascular Therapies/Large Vessel Disease 8:00 a.m.–12:00 p.m. 7PC.001 7PC.002 7PC.003 7PC.004 7PC.005 7PC.006 Scientific platform and poster presentations along with an invited speaker session. Neurology Skills Pavilion 1:15 p.m.–5:00 p.m. 8:00 a.m.–9:30 a.m. Invited Speaker Session 9:30 a.m.–10:30 a.m. Poster Session 7NP.001 Neurology Skills Pavilion: Neuro-ophthalmology and Neurovestibular Exam Lab 10:30 a.m.–12:00 p.m. Platform Session Behavioral Neurology: Contemporary Topics: Vision Emergency Room Neuro-ophthalmology MRI and Multiple Sclerosis Stroke In Young Adults Clinical EMG II Child Neurology II Breakfast Seminars 6:45 a.m.–8:30 a.m. 8BS.001 Vascular Cognitive Impairment and Dementia: Current Status and Future 8BS.002 Autoimmune Testing in Neuropathy: Indications for the Practicing Clinician 8BS.003 Balance and Gait Disorders 8BS.004 Neurologic Complications of Immunosuppressive and Immunomodulatory Therapy 8BS.005 Advances in the Care of Brain Injury After Resuscitation from Cardiac Arrest A.M. Half-Day Courses 9:00 a.m.–12:45 p.m. 8AC.001 8AC.002 8AC.003 8AC.004 8AC.005 8AC.006 8AC.007 Neurologic Complications of Medical Disease Women’s Issues In Cerebrovascular Diseases Neuromyelitis Optica: Scientific and Clinical Update Hot Topics in Headaches and Related Disorders Clinical Approach to Muscle Disease Parkinson’s Disease and Movement Disorders Update Neuro-otology 15 Scientific Sessions-at-a-Glance All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted) Sunday, April 11, 2010 8:00 a.m.–12:00 p.m. Integrated Neuroscience Session: Emerging Concepts in Genetics . . . . . . . . . . . . . . Reception Hall 104A–D 8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session/Poster Rounds 10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 1:00 p.m.–5:00 p.m. Integrated Neuroscience Session: Pediatric Demyelinating Disorders . . . . . . . . . . Reception Hall 104A–D 1:00 p.m.–2:45 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 2:45 p.m.–3:45 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 3:45 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session Monday, April 12, 2010 8:00 a.m.–12:00 p.m. Integrated Neuroscience Session: Global Neurology: Toxins and Infections . . . . . Reception Hall 104A–D 8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session/Poster Rounds 10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 2:00 p.m.–6:00 p.m. Integrated Neuroscience Session: Current Concepts in Cognitive Neuroscience: Implications for Neurological Disease . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 2:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 3:30 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 4:30 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session Tuesday, April 13, 2010 7:30 a.m.–12:00 p.m. Poster Session I (with Aging and Dementia: Risk Factors Poster Discussion Session) . . . . . . . . . Room 808 9:00 a.m.–12:00 p.m. Presidential Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG 1:00 p.m.–5:00 p.m. Integrated Neuroscience Session: Proteins, Genes, Neurodegeneration, and the Clinical Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 1:00 p.m.–3:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 3:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 3:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 1:45 p.m.–3:45 p.m. Scientific Sessions S01 Multiple Sclerosis: Clinical Research I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S02 Cerebrovascular Disease: Stroke Epidemiology I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 S03 Movement Disorders: Epidemiology of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB Presentation of the Movement Disorders Research Award S04 Sleep Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 Presentation of the Sleep Science Award S05 Epilepsy: Clinical Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A S06 Neuromuscular Junction and Muscle Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105 S07 Headache I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B S08 Behavioral Neurology: From Genetics to Brain Function to Behavior . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A Presentation of the Norman Geschwind Prize in Behavioral Neurology S09 History of Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB Presentation of the Lawrence C. McHenry Award S10 Multiple Sclerosis: MRI I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB 3:00 p.m.–7:30 p.m. Poster Session II (with Epilepsy Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808 4:00 p.m.–5:15 p.m. Scientific Sessions S11 Multiple Sclerosis: Clinical Trials I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S12 Cerebrovascular Disease: Acute Stroke Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 S13 Movement Disorders: Huntington’s Disease: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . 718AB Presentation of the Jon Stolk Award in Movement Disorders for Young Investigators S14 Aging and Dementia: Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 S15 Epilepsy: Clinical Neurophysiology and Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A S16 Anterior Horn: Clinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105 17 Scientific Sessions-at-a-Glance Scientific Sessions-at-a-Glance All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted) S17 Critical Care, Trauma, and Inpatient Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B Presentation of the AAN Alliance: Founders Award S18 Interventional Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A S19 Movement Disorders: Dystonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB S20 Neurologic Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB 12:00 p.m.–4:00 p.m. Integrated Neuroscience Session: Deep Brain Stimulation: Where Are We and Where Do We Go From Here? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 12:00 p.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 1:30 p.m.–2:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 2:30 p.m.–4:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 5:30 p.m.–6:30 p.m. Hot Topics Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG 1:15 p.m.–2:30 p.m. Scientific Sessions S41 Multiple Sclerosis: Clinical Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S42 Cerebrovascular Disease: Stroke Prevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 S43 Movement Disorders: Essential Tremor and Ataxia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 S45 Child Neurology: Developmental Neurobiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B S46 Peripheral Nerve: Molecular Mechanisms of Peripheral Neuropathy . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105 S47 Neurologic Manifestations: Clinical Neurophysiology and Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB S48 Autonomic Disorders: Frontiers of Autonomic Neurology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB S49 Cerebrovascular Disease: Hemorrhagic Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A S50 Multiple Sclerosis: EAE/Animal Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A 2:45 p.m.–3:45 p.m. Scientific Sessions S51 Multiple Sclerosis: Clinical Research II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S52 Cerebrovascular Disease II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 Presentation of the Michael S. Pessin Stroke Leadership Prize S53 Movement Disorders: Parkinson’s Disease and Atypical Parkinsonism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB S54 Aging and Dementia: Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 S55 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials . . . . . . . . . . . . . . . . . 701B S56 Anterior Horn: Basic Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 105 S57 Neural Repair and Neurorehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB S58 Behavioral Neurology: Language, Action, and Memory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB S59 Ethics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714A S60 Multiple Sclerosis: MRI II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A 3:00 p.m.–7:30 p.m. Poster Session VI (with Cerebrovascular Disease: Acute Stroke Therapy Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808 4:00 p.m.–6:00 p.m. New! AAN Awards Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG Presentation of the Sheila Essey Award: An Award for ALS Research Presentation of the Dreifuss-Penry Epilepsy Award Presentation of the Potamkin Prize for Research in Picks, Alzheimers, and Related Diseases Presentation of the John Dystel Prize for Multiple Sclerosis Research Wednesday, April 14, 2010 7:30 a.m.–12:00 p.m. Poster Session III (with Anterior Horn: Therapeutics Poster Discussion Session) . . . . . . . . . . . . . Room 808 9:00 a.m.–12:00 p.m. Contemporary Clinical Issues and Case Studies Plenary Session . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG 2:00 p.m.–4:00 p.m. Scientific Sessions S21 Multiple Sclerosis: Clinical Trials II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S22 Cerebrovascular Disease I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 S23 Movement Disorders: Parkinson’s Disease / Non-Motor Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB S24 Aging and Dementia: Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 S25 Epilepsy: Antiepileptic Drug Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716A S26 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B S27 Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A S28 Neuro-ophthalmology/ Neuro-otology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714B S29 Neuroepidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB Presentation of the Bruce S. Schoenberg International Award in Neuroepidemiology S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB 2:00 p.m.–6:00 p.m. Integrated Neuroscience Session: Emerging Treatments in Neuromuscular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 2:00 p.m.–3:15 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 3:15 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 4:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 5:00 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 2:00 p.m.–6:00 p.m. Integrated Neuroscience Session: Multiple Sclerosis Imaging . . . . . . . . . . . . . . . . . . . . Constitution Hall 105 2:00 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 3:30 p.m.–4:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 4:30 p.m.–6:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 3:00 p.m.–7:30 p.m. Poster Session IV (with Movement Disorders: Parkinson’s Disease: Treatment Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808 4:15 p.m.–5:30 p.m. Scientific Sessions S31 Multiple Sclerosis: Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 S32 Cerebrovascular Disease: Stroke Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 106 S33 Current and Future Treatment of Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718AB S34 Aging and Dementia: Recognition and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Constitution Hall 107 S35 Headache II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716A Presentation of the Harold Wolff-John Graham Award S36 Anterior Horn: Spinal Muscular Atrophy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701B S37 Neurologic Manifestations: Imaging and Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701A S38 Neurogenetics: Basic Science and Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714B Presentation of the AAN Alliance: S. Weir Mitchell Award S39 Neuro-oncology: Paraneoplastic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 713AB S40 Multiple Sclerosis: Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717AB Thursday, April 15, 2010 18 All scientific presentations will be held at the Metro Toronto Convention Centre (unless otherwise noted) 7:30 a.m.–12:00 p.m. Poster Session V (with Multiple Sclerosis and Related Diseases: Drug Mechanisms Poster Discussion Session) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Room 808 9:00 a.m.–11:00 a.m. Frontiers in Clinical Neuroscience Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Exhibit Hall FG Friday, April 16, 2010 8:00 a.m.–12:00 p.m. Integrated Neuroscience Session: Ischemic Stroke, Interventional, and Endovascular Therapies / Large Vessel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 8:00 a.m.–9:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 9:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 10:30 a.m.–12:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 9:00 a.m.–5:00 p.m. Future of Neuroscience Conference: Frontiers in Neuroimaging: Coming Soon to a Scanner Near You . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 718A 12:00 p.m.–1:30 p.m. NEW! Clinical Trials Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 1:00 p.m.–5:00 p.m. Integrated Neuroscience Session: Molecular Markers and Targets in Neuro-oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reception Hall 104A–D 1:00 p.m.–2:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Platform Session 2:30 p.m.–3:30 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Poster Session 3:30 p.m.–5:00 p.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Invited Speaker Session 5:15 p.m.–6:15 p.m. Scientific Program Highlights Plenary Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theatre 102 19 2010 Award Recipients 2010 Award Recipients Rooms and locations are subject to change. AAN Alliance Awards xx Founders Award Sponsored by the American Academy of Neurology Alliance. Recipient: Farrah Mateen, MD / Baltimore, MD Presentation: S17: Critical Care, Trauma, and Inpatient Neurology Date and Time: Tuesday, April 13, 4:00 p.m., Room 701B Title: “Long-Term Cognitive and Neurological Outcomes following Successful Cardiac Defibrillation for Out-of-Hospital Cardiac Arrest: A Population-based Study” xx S. Weir Mitchell Award Sponsored by the American Academy of Neurology Alliance. Recipient: Peter Todd, MD, PhD / Ann Arbor, MI Presentation: S38: Neurogenetics: Basic Science and Therapeutics Date and Time: Wednesday, April 14, 4:15 p.m., Room 714B Title: “Histone Deacetylases Suppress CGG Repeat Induced Neurodegeneration in Drosophila Model of FXTAS” A. B. Baker Award for Lifetime Achievement in Neurologic Education Supported by the AAN, the AAN Foundation, and the generous donors to the Doctors Vincent Di Carlo, Milton Alter, and Lawrence Brass Stroke Research Funds, the Peter S. Y. Lee Stroke Research Fund, the Stroke Research Fund, and the Fund for Brain Research. Recipient: Sharon Poisson, MD University of California San Francisco, San Francisco, CA AAN Foundation Practice Research Training Fellowship Funded by the American Academy of Neurology and the AAN Foundation. Recipient: Farrah Mateen, MD Johns Hopkins University, Baltimore, MD Funded by an endowment created by matching funds from the A. B. Baker Family Trust and Novartis Pharmaceuticals. AAN Foundation Robert Katzman, MD, Clinical Research Training Fellowship in Alzheimer’s Research Recipient: Ralph F. Józefowicz, MD, FAAN / Rochester, NY Presentation: The Globalization of Neurologic Education Date and Time: Monday, April 12, 9:00 a.m. Supported by the AAN Foundation and the Alzheimer’s Association. Recipient: Winston Chiong, MD University of California San Francisco, San Francisco, CA AAN Foundation Clinical Research Training Fellowships AAN Foundation/Myasthenia Gravis Foundation of America Clinician-Scientist Development Award Funded by the American Academy of Neurology and the AAN Foundation. Recipients: Vikram Khurana, MD, PhD Massachusetts General Hospital, Cambridge, MA Suzanne Goh, MD Columbia University Medical Center, New York, NY Jackie Whitesell, MD University of Utah, Salt Lake City, UT Khalid A. Hanafy, MD, PhD Columbia University Medical Center, New York, NY Michael Kruer, MD Oregon Health and Science University, Portland, OR Eugenia Ho, MD Children’s Hospital Boston, Boston, MA These fellowships are supported by the American Academy of Neurology, the AAN Foundation, and the AAN Foundation Corporate Roundtable Kevin Sheth, MD University of Maryland School of Medicine, Baltimore, MD Nicte Mejia, MD Massachusetts General Hospital, Cambridge, MA 20 AAN Foundation Clinical Research Training Fellowship In Stroke Co-sponsored by The Myasthenia Gravis Foundation of America and AAN Foundation. Recipient: Jeffrey Guptill, MD Duke University Medical Center, Raleigh, NC AAN Foundation/Consortium of Multiple Sclerosis Centers John F. Kurtzke, MD, FAAN Clinician-Scientist Development Three-Year Award Supported by the American Academy of Neurology, the AAN Foundation, the Consortium of MS Centers, and donations from Bayer Healthcare Pharmaceuticals, EMD Serono, Inc., and Questcor Pharmaceuticals, Inc. Recipient: Gabriele De Luca, MD, PhD Mayo Clinic College of Medicine, Rochester, MN AAN Foundation/National MS Society Clinician Development Award Funded by the AAN Foundation and the National Multiple Sclerosis Society. Recipient: Zongqi Xia, MD, PhD Brigham and Women’s Hospital, Boston, MA AAN Award For Creative Expression of Human Values in Neurology Sponsored by the Ethics, Law and Humanities Committee. Recipient: Mitchell S. V. Elkind, MD, MS, FAAN / New York, NY Title: “If I Had Time” Dreifuss-Penry Epilepsy Award Sponsored by the American Academy of Neurology and endowed by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma. Recipient: Martin Gallagher, MD, PhD / Nashville, TN Presentation: Awards Plenary Session Date and Time: Thursday, April 15, 4:30 p.m., Exhibit Hall FG John Dystel Prize for Multiple Sclerosis Research Presented by the American Academy of Neurology and the National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society. Recipient: David Hafler, MD, MSc / New Haven, CT Presentation: Awards Plenary Session Date and Time: Thursday, April 15, 5:30 p.m., Exhibit Hall FG Sheila Essey Award: An Award for ALS Research Presented by the American Academy of Neurology and the ALS Association and supported through the philanthropy of the Essey Family Fund and the ALS Association. Recipient: Clive Svendsen, PhD / Madison, WI Presentation: Awards Plenary Session Date and Time: Thursday, April 15, 4:00 p.m., Exhibit Hall FG American Academy of Neurology Foundation Chair’s Award Sponsored by the AAN Foundation. Recipient: TBD Norman Geschwind Prize in Behavioral Neurology Sponsored by the American Academy of Neurology and the AAN Behavioral Neurology Section and endowed through Dr. Geschwnd’s family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology. Recipient: Keith Josephs, MD, MST, MS / Rochester, MN Presentation: S08: Behavioral Neurology: From Genetics to Brain Function to Behavior Date and Time: Tuesday, April 13, 1:45 p.m., Room 714A Jon Stolk Award in Movement Disorders for Young Investigators Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, Dr. Dennis Gillings, and Vela Pharma. Recipient: E. Ray Dorsey, MD / Rochester, NY Presentation: S13: Movement Disorders: Huntington’s Disease: Pathophysiology and Clinical Assessment Date and Time: Tuesday, April 13, 4:00 p.m., Room 718AB Association of Indian Neurologists in America (AINA) Lifetime Achievement Award Endowed by the Association of Indian Neurologists in America (AINA). Recipient: Sudhansu Chokroverty, MD, FAAN / Edison, NJ Presentation: AINA Annual Meeting - Radisson Admiral Hotel Date and Time: Monday, April 12, 6:30 p.m. International Scholarship Award Sponsored by the American Academy of Neurology International Subcommittee. Recipients: Mariya Ivanova Petrova, MD Sofia, Bulgaria Hamid Suhail New Delhi, India Jelena Nikodinovic, MD Belgrade, Serbia Renato Oliveira dos Santos Campinas, Sao Paulo, Brazil Daniel Kaganovich, PhD Rehovot, Israel Emmanuel Olatunde Sanya, MB MBChB Kwara, Nigeria Xin Cheng, MD, PhD Shanghai, China Qi Li Chongqing, China Marina Coelho Gonsales, PhD Campinas, Sao Paulo, Brazil Hacer Durmus, MD Istanbul, Turkey Andre Carvalho Felicio Sao Paulo, Brazil Clarissa Yasuda, MD, PhD Campinas, Sao Paulo, Brazil 21 2010 Award Recipients Lawrence C. McHenry Award: An Award for the History of Neurology Sponsored by the American Academy of Neurology. Recipient: Elan Louis, MD, MS / New York, NY Presentation: S09: History of Neurology Date and Time: Tuesday, April 13, 1:45 p.m., Room 717AB Title: “The Coming of Age of Neurology: The Conceptualization and Organization of the First International Neurological Congress (1931)” Medical Student Essay Awards Sponsored by the American Academy of Neurology. xx Extended Neuroscience Award Recipient: Amanda Rowlands / Hershey, PA Presentation: Poster Session IV Date and Time: Wednesday, April 14, 3:00 p.m., Room 808 Title: “Immunological Aspects of Cell Transplantation in Parkinson’s Disease” xx G. Milton Shy Award in Clinical Neurology Recipient: Deanna Cettomai / Baltimore, MD Presentation: Poster Session IV Date and Time: Wednesday, April 14, 3:00 p.m., Room 808 Title: “Utility of Quantitative Sensory Testing and Neuropathy Screening Tools in Identifying HIV-Associated Peripheral Neurology in Western Kenya: A Pilot Testing” xx Roland P. Mackay Award in Historical Aspects Recipient: Lauren Bowen / Gainesville, FL Presentation: Poster Session IV Date and Time: Wednesday, April 14, 3:00 p.m., Room 808 Title: “Elementary My Dear Dr. Allen: the Case of Barium Toxicity and Pa Ping” xx Saul R. Korey Award in Experimental Neurology Recipient: Benjamin Kwan / Windsor, ON, Canada Presentation: Poster Session IV Date and Time: Wednesday, April 14, 3:00 p.m., Room 808 Title: “Neurogenetics: Parent of Origin Effects in Autistic Copy Number Variation, a Possible Mechanism for Autism Pathogenesis” Movement Disorders Research Award Sponsored by the American Academy of Neurology, the Parkinson’s Disease Foundation, and the AAN Movement Disorders Section and endowed by the Parkinson’s Disease Foundation. Recipient: David Eidelberg, MD / Manhasset, NY Presentation: S03: Movement Disorders: Epidemiology of Parkinson’s Disease Date and Time: Tuesday, April 13, 1:45 p.m., Room 718AB 22 2010 Award Recipients Neuroscience Research Prize Preuss Award in Clinical Neuro-oncology Recipients: Jan Gong / Garden City, NY Anouva Kalra-Lall / Roslyn, NY Theresa Tharakan / Bronx, NY Recipient: Antonio Omuro, MD / New York, NY Presentation: Neuro-oncology Section Meeting Date and Time: Thursday, April 15, 12:15 p.m. Sponsored by the American Academy of Neurology, American Academy of Neurology Foundation, and the Child Neurology Society. Child Neurology Neuroscience Research Prize Sponsored by the American Academy of Neurology, American Academy of Neurology Foundation, and the Child Neurology Society. Recipient: Pragya Kakani / Jericho, NY Note: The recipient will attend the Child Neurology Society Annual Meeting, October 13–16, 2010, in Providence, RI. Palatucci Advocacy Leadership Forum Advocates of the Year. Sponsored by the AAN Government Relations Committee. Recipients: Teshamae Monteith, MD / San Francisco, CA Mamta Bhushan Singh, MBBS, MD, DM / New Delhi, India Michael S. Pessin Stroke Leadership Prize Sponsored by the American Academy of Neurology and endowed by Dr. Pessin’s family, friends, and colleagues. Recipient: Shelagh Coutts, MD / Calgary, AB, Canada Presentation: S52: Cerebrovascular Disease II Date and Time: Thursday, April 15, 2:45 p.m., Constitution Hall 106 Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Supported by the American Academy of Neurology and the AAN Neurooncology Section and awarded through a gift from Dr. Preuss’ family, friends, and colleagues. Research Award in Geriatric Neurology Sponsored by the American Academy of Neurology and the AAN Geriatric Neurology Section and supported by the American Geriatrics Society and the John J. Hartford Foundation. Recipient: Liana Apostolova, MD / Los Angeles, CA Presentation: Geriatric Neurology Section Meeting Date and Time: Wednesday, April 14, 1:00 p.m. Bruce S. Schoenberg International Award in Neuroepidemiology Endowed by GlaxoSmithKline, Inc. Recipient: Judith Kwasa, MD / Kisumu, Kenya Presentation: S29: Neuroepidemiology Date and Time: Wednesday, April 14, 2:00 p.m., Room 713AB Title: “Status of Bone Health in Pre-Menopaused Women Living with Epilepsy on Anticonvulsant Drug Therapy in Kenya” H. Richard Tyler Award Sponsored by the American Academy of Neurology and the AAN Archive Committee. Not given in 2010. Kenneth M. Viste, Jr., MD, Patient Advocate of the Year Award Endowed by gifts from Dr. Viste’s colleagues, friends, and patients. Recipient: Enawgaw Mehari, MD / Morehead, KY Presentation: Palatucci Advocacy Leadership Forum Graduate Reception Date and Time: Monday, April 12, 5:00 p.m., Intercontinental Toronto Centre Harold Wolff-John Graham: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals, Inc. Recipient: Ana Recober, MD / Iowa City, IA Presentation: S35: Headache II Date and Time: Wednesday, April 14, 4:15 p.m., Room 716A Sleep Science Award Sponsored by the American Academy of Neurology and the AAN Sleep Section and endowed by Cephalon, Inc. Recipient: Arthur Walters, MD / Nashville, TN Presentation: S04: Sleep Disorders Date and Time: Tuesday, April 13, 1:45 p.m., Constitution Hall 107 Sponsored by the American Academy of Neurology, the AAN Foundation, and funded through the philanthropy of the Potamkin Family. Recipients: Bruce L. Miller, MD / San Francisco, CA Lennart Mucke, MD / San Francisco, CA Presentation: Awards Plenary Session Date and Time: Thursday, April 15, 5:00 p.m., Exhibit Hall FG American Academy of Neurology President’s Award Sponsored by the American Academy of Neurology. Recipient: Isabelle Rapin, MD, FAAN / Bronx, NY Vote for Your Favorite Neuro Film Festival Entry by March 17 The entries for the 2010 Neuro Film Festival are in and public voting for “Fan Favorite” has begun. The event highlights compelling stories from patients and their families and caregivers about living with a neurologic condition. The winner of the Fan Favorite award will receive a $500 prize. Two other winners will also be awarded for their filmmaking skills and creativity, as decided by the festival’s jury. Eligible entries are now online available to be voted on at www.youtube.com/neurofilmfest. For more information, contact Andrew Halverson at [email protected] or (651) 695-2757. 23 Saturday, April 10 Highlights 2010 AAN Clerkship and Program Directors Academy Central Conference: Career Development and Resources Saturday, April 10–Friday, April 16 8:30 a.m.–4:00 p.m. Education is one of the most important elements of medical science. Fostering the teaching, assessment, feedback, and administrative skills of medical educators is important for a successful career. Medical educators also must learn to document and use their accomplishments in education for career advancement and promotion. The process of recognizing educational contribution and enhancing teaching skills of teachers at all levels will be discussed. In addition, areas of interest to the educational community such as duty hours for residents and CME requirements and their impact on medical student education will be discussed. Basic Science Resident Curriculum 9:00 a.m.–12:45 p.m. 2:15 p.m.–6:00 p.m. The resident neuroscience initiative is a three-year basic science curriculum for neurology residents offered at the Annual Meeting. The curriculum is primarily intended to help neurology residents learn the basic sciences on which clinical neurology is founded. Topics that will be covered over the three-year cycle include neuroanatomy, neurophysiology, neuropharmacology, neuropathology, development, and genetics. This curriculum will also help residents prepare for the AAN’s RITETM Exam (Residency In-service Training Examination). This year’s program topics include: 1AC.001 Resident Basic Science I: Neuropathology 1PC.001 Resident Basic Science II: Clinical Application of Neuropathology Registration is required. BRAINS Colloquium: Critical Thinking for Critical Issues 1:00 p.m.–5:00 p.m. The BRAINS Colloquium is intended to provide attendees with up-todate information on the “business” of neurology and an opportunity to further develop practice management skill sets. Faculty will address how to recruit and retain physicians, adding ancillary services to your practice, physician productivity and tracking, benchmarking, and current hot topics relevant to neurology practice management. Neurology Skills Pavilion: Health Information Technology for Neurology: The Electric Frontier Academy Central offers a variety of resources central to the career of any neurology professional. Explore science and education publications such as Neurology ® and Continuum: Lifelong Learning in Neurology ®. Learn about clinical guidelines and shop for tools that can make your practice more effective and efficient. Find out how social networking is revolutionizing health care, and why the Academy is advocating on your behalf in Washington, DC. Enjoy a range of speakers who will address a variety of topics. Watch for a list of events and speakers. Academy Central helps demonstrate how the Academy is delivering on its promise to be an indispensable part of your career, each step of the way. Changes to Syllabi Process—Download in Advance Obtaining your Education Program syllabi is quicker and easier than ever. All registered attendees will be able to download the full syllabi for their selected programs, starting in late March. All registered attendees will receive an email notification once syllabi are available. Printed syllabi will not be available. Printed slides will be available in program rooms. AAN Foundation Research Area Saturday, April 10–Friday, April 16 Learn about the AAN Foundation’s Clinical Research Training Fellowship program and how donations help fund the next generation of researchers in neurology. Visit with Foundation staff and learn more about fundraising initiatives including the Art for Research gallery, the Foundation Silent Auction, and the Buy a Brain program. Research Career Development Symposium: Transitioning from Residency to Research This new full day conference provides information to assist young researchers transition from residency to investigative independence in academic neurology. The morning sessions are for and open to everyone. The afternoon sessions are invitations only. For additional information contact Terry Heinz at (651) 695-2746 or [email protected]. Sponsored by American Academy of Neurology, the AAN Foundation, and NINDS. 2:15 p.m.–6:00 p.m. Brush up on or learn new skills in an interactive, hands-on environment. Participants in small groups will rotate through multiple learning stations and participate in skills demonstrations. Most programs will begin at 2:15 p.m. and end at 6:00 p.m. Friday’s Neurology Skills Pavilion begins at 1:15 p.m. and ends at 5:00 p.m. to allow time to attend the Scientific Program Highlights Plenary Session. 25 Sunday, April 11 Highlights AUPN Clerkship Directors’ Boot Camp Celebration for Research 8:00 a.m.–11:00 a.m. 6:00 p.m.–11:00 p.m. This three-hour session is designed to be an interactive meeting for Neurology Clerkship Directors, both those new to the position and veterans. Also welcome are any Residents, Fellows, or Faculty interested in improving teaching and curriculum writing skills. To register visit www.aupn.org. Join us for an exciting evening filled with music, dancing, laughter, and more! Enjoy a buffet of Toronto favorites with your friends and colleagues. Extra tickets are available through registration. Proceeds from the evening are dedicated to AAN Foundation initiatives, including Clinical Research Training Fellowships. Patient Safety Colloquium: Diagnostic Errors in Neurology Neurobowl® 9:00 a.m.–12:00 p.m. There is no better way to begin the 62nd Annual Meeting than by attending Neurobowl. AAN former president Thomas R. Swift, MD, FAAN, hosts another year of competition by the best and brightest in neurology for the enviable Neurobowl title. This popular quiz show focuses on the process of neurological diagnosis with common and rare neurologic case histories, video clips, investigations, and movie segments. Seating is limited and is available on a first-come, first-served basis. The objective of this colloquium is to improve patient safety by reducing the likelihood of diagnostic errors in neurology. Faculty will cover the breadth of diagnostic errors in neurology and strategies for preventing misdiagnosis and misdiagnosis-related harm. Future opportunities in simulation and diagnostic technology will be introduced to promote diagnostic clarity. 6:00 p.m.–8:00 p.m. Practice Colloquium: Dialogue with the Insurer Medical Directors: A Conversation You Don’t Have Every Day Sponsored by UCB, Inc. 1:30 p.m.–4:30 p.m. 8:30 p.m.–10:30 p.m. Attendees will have a chance to dialogue with medical directors from major insurers at this free session. Attendees will gain a better understanding of what insurers are contemplating, so they are a step ahead of everyone else with new programs, and will understand how to take advantage of insurer programs that can increase their reimbursement and reduce administrative hassle. Attendees will have an opportunity to ask questions and provide feedback. Billy McLaughlin is recognized internationally as an innovative world-class acoustic guitarist, composer, and producer. He is a five-time Minnesota Music Award winner with 12 CD releases and a history on the Billboard Top Ten Chart. Recently diagnosed with focal dystonia, he has launched a remarkable comeback as a left-handed performer, a story recently featured with a one-hour documentary on PBS. Neurology Skills Pavilion: Neuromuscular Bedside Rounds Toronto comedy troupe The Second City returns to the Annual Meeting! Laugh out loud at this two-hour show tailored for neurology. The Second City’s alumni have gone on to become stars of movies and television, and garner awards galore. Notable grads include: Dan Aykroyd, Gilda Radner, Bill Murray, Mike Myers, Tina Fey, Steve Carell, and Stephen Colbert. This is sure to be a laugh riot—but seating is limited and is available on a first-come, firstserved basis—so get there early! 2:15 p.m.–6:00 p.m. Brush up on or learn new skills in an interactive, hands-on environment. Participants in small groups will rotate through multiple learning stations and participate in skills demonstrations. Most programs will begin at 2:15 p.m. and end at 6:00 p.m. Friday’s Neurology Skills Pavilion begins at 1:15 p.m. and ends at 5:00 p.m. to allow time to attend the Scientific Program Highlights Plenary Session. 26 Integrated Neuroscience Session: Emerging Concepts in Genetics Main Stage: The Second City and Billy McLaughlin Sponsored by Teva Neuroscience, Inc. NEW! Neuro Film Festival NEW! Specialists in Focus: Child Neurology 8:30 p.m.–10:30 p.m. This special, intensive program offers an in-depth look into child neurology focused topics. While primarily intended for child neurology specialists, generalists will also find useful information. This Sunday to Monday program includes: Join us for the “best of the fest,” a collection of inspirational stories revealing why brain research is so important. xx 2AC.006 Advanced Topics in Pediatric Neurology I: Neurodegenerative Diseases (Registration Required) xx Integrated Neuroscience Program: Pediatric Demyelinating Disorders xx 3AC.001 Advanced Topics in Pediatric Neurology II: Neuro-oncology (Registration Required) Neuro Hop Sunday, April 11 | 8:00 a.m.–12:00 p.m. Coordinators: Massimo Pandolfo, MD and Natalia Rost, MD Platform Session / 8:00 a.m.–9:30 a.m. / Reception Hall 104A–D 8:00 a.m. Introduction to INS: Concepts and Evolving Science 8:15 a.m. IN1-1.001 rAAV5 Mediated Delivery of Dysferlin as a Therapeutic Strategy for LGMD2B and Miyoshi Myopathy Louise RodinoKlapac, Kimberly Shontz, Chrystal Montgomery, Vinod Malik, Nancy Davis, Paul Janssen, K. Reed Clark, Robert Brown, Jerry Mendell 8:30 a.m. IN1-1.002 Meta-Analysis of MS Genome Scans V2.0 Implicates New Susceptibility Genes Involved in Proliferation and Differentiation Philip De Jager, Nikolaos Patsopoulos, Joachim Reischl, Stephan Lehr, David Bauer, Committees of BENEFIT, BEYOND, LTF, CCR1 Studies, Juergen Heubach, Rupert Sandbrink, Christoph Pohl, Paul De Bakker, David Hafler 8:45 a.m. IN1-1.003 Frequency and Phenotypic Characteristics of PRKN, LRRK2, GBA, PINK1 and DJ1 Mutation Carriers in Early Onset PD: The CORE-PD Study Roy Alcalay, Elise Caccappolo, Helen Mejia-Santana, Ming Tang, Llency Rosado, Miguel Verbitsky, Barbara Ross, Sergey Kisselev, Elan Louis, Cynthia Comella, Amy Colcher, Danna Jennings, Martha Nance, Susan Bressman, William Scott, Caroline Tanner, Susan Mickel, Howard Andrews, Cheryl Waters, Stanley Fahn, Lucien Cote, Steven Frucht, Blair Ford, Michael Rezak, Kevin Novak, Joseph Friedman, Ronald Pfeiffer, Laura Marsh, Bradley Hiner, Andrew Siderowf, Ruth Ottman, Karen Marder, Lorraine Clark 9:00 a.m. IN1-1.004 Single Nucleotide Polymorphisms of the ADRB2 Gene Modulate Migraine Phenotypes Bettina Bayerer, Volker Limmroth, Hans-Christopher Diener 9:15 a.m. IN1-1.005 Cigarette Smoking, CYP2A6 Genetic Variants, and Parkinson Disease: A Case-Control Study Maurizio Facheris, Timothy Lesnick, Julie Cunningham, Walter Rocca, Demetrius Maraganore Poster Session / Poster Rounds / 9:30 a.m.–10:30 a.m. / Reception Hall 104A–D IN1-2.001 Mutant LRRK2 and Cell Death-Signaling Complex Formation: Implications for Neurodegeneration in Parkinson’s Disease Hardy Rideout, Nasia Antoniou, Polena Valkimadi, William Dauer IN1-2.002 Gene Therapy for Mitochondrial Disease John Guy, Rajeshwari Koilkonda, Vittorio Porciatti, William Hauswirth, Hong Yu IN1-2.003 The 6p12.2-p21.1 Migraine Locus Is Associated with Migraine with and without Aura in General Pedigrees Agustin Oterino Duran, María Toriello, Nuria Ruiz-Lavilla, Ana Alonso-Arranz, Jesús Castillo, Pablo Sanchez-Velasco, Julio Pascual IN1-2.004 Sirtuin and Mitochondrial Uncoupling Protein Polymorphisms in Subclinical Carotid Atherosclerosis David Della-Morte, Chuanhui Dong, Mark McClendon, Ashley Beecham, Liyong Wang, Susan Blanton, Ralph Sacco, Tatjana Rundek IN1-2.005 Gene Identification Via Exome Sequencing in Hereditary Spastic Paraplegia Families Jia Huang, Eric Powell, Cherylyn Almonte, Gladys Montenegro, Stuart Young, Daniel Burges, Mike Schmidt, Benjamin Boese, Ed Szekeres, Xinmin Zhang, Jeffery Vance, Margaret Pericak-Vance, Eden Martin, Tim Harkins, Dale Hedges, Stephan Zuchner IN1-2.007 Dynamic Transcriptomes during Neural Differentiation of Human Embryonic Stem Cells Revealed by Short, Long, and Paired-End Sequencing Anna Szekely, Jia Qian Wu, Lukas Habegger, Parinya Noisa, Caihong Qiu, Stephen Hutchison, Debasish Raha, Michael Egholm, Haifan Lin, Sherman Weissman, Wei Cui, Mark Gerstein, Michael Snyder IN1-2.008 Association of Brain Derived Neurotrophic Factor SNPs and Imaging Phenotypes of Alzheimer’s Disease in the ADNI Cohort Robyn Honea, Amith Harsha, Eric Vidoni, Carlos Cruchaga, Russell Swerdlow, Andrew Saykin, Alison Goate, Jeffrey Burns IN1-2.009 Genome-Wide Association Study in Musician’s Dystonia Katja Lohmann, Alexander Schmidt, Claudia Hemmelmann, Hans-Christian Jabusch, Susen Winkler, Stefan Schreiber, Eckart Altenmüller, Andreas Ziegler, Christine Klein IN1-2.010 Development of Biomarkers for HDAC Inhibitor Treatment of Friedreich’s Ataxia Massimo Pandolfo, Heather Plasterer, Myriam Rai, Sushil Sharma, Carly Therkelsen, Andrew Cooper, Jennifer Farmer, David Lynch, James Rusche IN1-2.006 Autistic Copy Number Variations: Parent of Origin and Child Gender Effects Benjamin Kwan, Brett Abrahams, Daniel Geschwind Invited Speaker Session* / Time 10:30 a.m.–12:00 p.m. / Reception Hall 104A–D 10:30 a.m.–10:50 a.m. Genetic Basis of Neurological Disease Margaret Pericak-Vance, PhD 10:50 a.m.–11:10 a.m. Recent Discoveries in Neurogenetics Bryan Traynor, MD 11:10 a.m.–11:15 a.m. Questions and Answers 11:15 a.m.–11:35 a.m. Genes and Fuction: the Rewriting of our Textbooks of Pathology David Hafler, MD 11:35 a.m.–11:55 a.m. Epigenetics: A New Science Underlying Gene-Environmental Interactions, Regenerative Medicine and Multigenerational Inheritance Mark Mehler, MD 11:55 a.m.–12:00 p.m. Questions and Answers Sponsored by PSAV ® Presentation Services 8:30 p.m.–11:00 p.m. Dance the night away to classic hits from today and yesteryear. DJ Kyle spins the tunes. You provide the wild dance moves! *Current as of February 1, 2010 27 Integrated Neuroscience Session: Pediatric Demyelinating Disorders Sunday, April 11 | 1:00 p.m.–5:00 p.m. Monday, April 12 Highlights Morning Reports Coordinators: Brenda Banwell, MD and Ann Yeh, MD Invited Speaker Session* / 1:00 p.m.–2:45 p.m. / Reception Hall 104A–D 7:00 a.m–8:30 a.m. 1:00 p.m.–1:15 p.m. Directors present a case study in this new interactive program to elicit questions and answers from participants. All Morning Report programs will use the interactive audience response system. Morning Report programs will begin at 7:00 a.m. and run until 8:30 a.m. on select days. Introduction Ann Yeh, MD 1:15 p.m.–1:40 p.m. Pediatric Multiple Sclerosis: Diagnosis and Management in 2010 Jayne Ness, MD 1:40 p.m.–2:05 p.m. ADEM & NMO: Approach Diagnosis and Distinct Aspects of Care Tim Lotze, MD 2:05 p.m.–2:25 p.m. Environmental Exposures: Vitamin D, Microbial Infection, and Environmental Pollution and Risk of MS in Children Marc Tardieu, MD 2:25 p.m.–2:45 p.m. Controversies and Considerations in Childhood Demyelination: Age, Maturation, and the Developing Immune and CNS Systems Amit Bar-Or, MD Poster Session / 2:45 p.m.–3:45 p.m. / Reception Hall 104A–D IN2-1.001 Clinical and MRI Distinctions between Tumefactive Demyelination and Brain Tumors in Children Eppie Yiu, Suzanne Laughlin, Leonard Verhey, Sandra Magalhaes, Sridar Narayanan, Amit Bar-Or, Dessa Sadovnick, Douglas Arnold, Brenda Banwell IN2-1.002 Increasing the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric MS (NBPMS) with Regression-Based Normalization Audrey Smerbeck, Joy Parrish, Marietta Hoogs, Bianca Weinstock-Guttman, E. Ann Yeh, Ralph Benedict 7:00 a.m–9:30 a.m. IN2-1.003 Executive Functioning in Children and Adolescents with Multiple Sclerosis Ameeta Dudani, Rezwan Ghassemi, Sridar Narayanan, Douglas Arnold, John Sled, Brenda Banwell, Christine Till IN2-1.006 Recurrent Demyelinating Episodes in Pediatric Patients with Acute Disseminated Encephalomyelitis (ADEM) Thitiwan Simasathien, Khurram Bashir, John Rinker, Jayne Ness IN2-1.004 Quality of Life, Cognitive Function, and Mood in Young Adults with Pediatric-Onset Multiple Sclerosis Kristen Krysko, Paul O’Connor IN2-1.007 Lower Risk for Developing Neutralizing Antibodies to Interferon in Children with MS on Interferon Treatment E. Ann Yeh, Murali Ramanathan, Rachael Heim, Bianca Weinstock-Guttman IN2-1.005 Screening for Depression in Pediatric Clinically Isolated Syndrome and Multiple Sclerosis Populations; Patient and Parent Report David Rintell, Natalie Baruch, Brian Healy, Ellen O’Donnell, Mark Gorman, Tanuja Chitnis IN2-1.008 Effector B Cell Responses in Pediatric Multiple Sclerosis Lama Fawaz, Viviane Poupon, Brenda Banwell, Ciro Piccirillo, Anne Griffiths, M. Silverberg, Upton Allen, Amit Bar-Or IN2-1.009 Biomarkers in Pediatric MS: Predicting Recurrent Disease at Time of the First Demyelinating Episode Sandra Magalhaes, Sunita Venkateswaran, Chahrazed Belabani, Nadia Ouamara, Douglas Arnold, Dessa Sadovnick, Viviane Poupon, Brenda Banwell, Amit Bar-Or Platform Sessions / 3:45 p.m.–5:00 p.m. / Reception Hall 104A–D 3:45 p.m. IN2-2.001 Severity and Recovery of Exacerbations in Early Pediatric Multiple Sclerosis Alex Fay, Ellen Mowry, Dorothee Chabas-Chanezon, Jonathan Strober, Emmanuelle Waubant 4:00 p.m. IN2-2.002 Anti-Myelin Oligodendrocyte (MOG) Autoantibodies in Childhood Demyelination: Comparison of Assays and Longitudinal Analysis Anne-Katrin Proebstel, Klaus Dornmair, Constanze Breithaupt, Robert Weissert, Uwe Jacob, Amit Bar-Or, Brenda Banwell, Russell Dale, Fabienne Brilot-Turville, Esther Tantsis, Mohsen Khademi, Tomas Olsson, Daniela Pohl, Kevin Rostasy, Astrid Blaschek , Tania Kuempfel, Frank Weber, Hartmut Wekerle, Reinhard Hohlfeld, Edgar Meinl, Tobias Derfuss State Society Leadership Roundtable 4:15 p.m. IN2-2.003 Gestational Vitamin D and the Risk of Multiple Sclerosis in the Offspring Fariba Mirzaei, Karin Michels, Kassandra Munger, Eilis O’Reilly, Tanuja Chitnis, Edward Giovannucci, Alberto Ascherio 4:30 p.m. IN2-2.004 Lower Vitamin D Levels Are Associated with a Higher Rate of Subsequent Relapse in Pediatric-Onset Multiple Sclerosis Ellen Mowry, Lauren Krupp, Maria Milazzo, Dorothee Chabas, Jonathan Strober, Anita Belman, Jamie McDonald, Jorge Oksenberg, Peter Bacchetti, Emmanuelle Waubant 4:45 p.m. IN2-2.005 Cognitive and Behavioural Outcomes in Individuals with a History of Childhood Acute Disseminated Encephalomyelitis (ADEM) Bravina Bala, Brenda Banwell, Christine Till Leadership representatives of state neurological societies are invited to discuss challenges, strategies, and practices related to state society creation and maintenance. Discussion will be facilitated by Academy staff. Participants will learn from the experiences of established societies and be introduced to the resources available from the Academy. Education Colloquium: International Education 8:30 a.m.–12:00 p.m. The world grows smaller and more interconnected every day. It is global, multicultural, multilingual, and digitally connected. Neurologists need knowledge about other countries, regions, cultures, and global systems to foster the development of health care systems to service patients with neurological disease throughout the world. In an increasingly interdependent world, it is essential to foster global and cross-cultural knowledge and understanding. This colloquium will provide attendees with a greater understanding of the challenges, successes and opportunities providing neurology training in India, Africa, and Latin America. Attendees will have a greater understanding of the role of the World Federation of Neurology. Attendees will understand the challenges and opportunities of Canadian neurology residency and fellowship programs in providing training for foreign nationals. International Attendee Summit 12:00 p.m.–1:00 p.m. This exclusive, free event for international meeting attendees provides an excellent opportunity to socialize and network with your international colleagues, make your voice heard on matters most important to you, and get answers to your most pressing AAN-related questions. Reserve your space today by contacting Lynee Koester at [email protected] or (651) 695-2739. Kenneth M. Viste, Jr., MD, Neurology Public Policy Fellowship Information Session 12:00 p.m.–1:00 p.m. The Kenneth M. Viste, Jr., MD, Neurology Public Policy Fellowship provides an excellent opportunity to gain hands-on experience in federal policy and develop political relationships that help promote the interests of neurology. Meet with past fellows and selection committee members to learn more about the yearlong paid fellowship in Washington, DC, offered by the AAN Professional Association, the American Neurological Association, and the Child Neurology Society. Web Wonders: The Must-Have Technologies for Neurologists in 2010 2:30 p.m.–5:30 p.m. Web Wonders will feature six member presentations highlighting products and technologies that simplify office workflow, improve physician/patient communication, and prepare members for federally mandated changes and incentives with health information technology and reimbursement issues. The presentations will include: revenue cycle management, registries for quality reporting, social networking in your medical practice, “meaningful use”, incentives, patient portals and e-prescribing. Best Care Expo: Guidelines, Government Relations, and Getting Paid 3:00 p.m.–5:00 p.m. Attend the 2010 “Best Care Expo” where your colleagues will discuss ways the Academy helps you use the latest research, technology and tools to streamline your practice and provide the best possible care to your patients. Joel M. Kaufman, MD, FAAN, chair of the Academy’s Payment Policy Subcommittee, speaks about Academy relationships with private insurance companies, and tips for developing relationships with those with whom you work most. Laurence Kinsella, MD, FAAN, co-chair of the Government Relations Committee, speaks about Academy activities on Capitol Hill, why it is important to get involved, resources and opportunities. Hans D. Katzberg, MD, lead author of “Assessment: Symptomatic Treatment for Muscle Cramps” shares his experience of developing an Academy guideline. Activities include: xx Debate the nuances of evaluation and management coding with colleagues xx Discuss recommendations with authors of recently published guidelines xx Network with members who have participated in Academy programs designed to help you become a better advocate for neurology and your patients’ care Free to all Annual Meeting Attendees. *Current as of February 1, 2010 28 29 Monday, April 12 Highlights ABPN Resident Informational Session 4:00 p.m.–5:00 p.m. This is an interactive opportunity for residents and fellows to meet members of the ABPN. The panel will discuss all aspects of the neurology boards and what is expected from candidates. Free and open to all interested persons. Consortium of Neurology Residents and Fellows (CNRF) Meeting 5:00 p.m.–6:00 p.m. Come and learn about the consortium, meet officers, and participate in discussions on a variety of topics related to residents and fellows. Student Interest Group in Neurology (SIGN) Meeting 5:00 p.m.–6:30 p.m. Student and faculty representatives from existing SIGN chapters and those interested in starting chapters will gather for presentations and discussions. Exhibit Hall Opening Reception 5:00 p.m.–7:00 p.m. MTCC, Exhibit Halls DE Attend the opening reception to mingle with fellow attendees and preview the latest products and services available in the neurologic industry. Light hors d’oeuvres and beverages will be served. The exhibits will be open at this time. Sponsored by EMD Serono, Inc. and Pfizer Inc Neuro Flash 6:30 p.m.–8:00 p.m. Neuro Flash is a new interactive program featuring quick updates in the evenings on pertinent issues about a clinical topic. Three half-hour, case-by-case talks will be followed by questions and answers. All Neuro Flash programs will utilize the audience response system. Neuro Flash programs start at 6:30 p.m. and end at 8:00 p.m. on select days. Residents and Fellows Career Forum and Reception 6:30 p.m.–9:00 p.m. This career night for residents and fellows features three panel rooms including fellowship, private practice, and academic/research, as well as a poster forum and reception that includes exhibits of private practice groups and opportunities to learn about potential positions from Dendrite™ Careers in Neurology advertisers. For more information email [email protected]. Integrated Neuroscience Session: Global Neurology: Toxins and Infections Monday, April 12 | 8:00 a.m.–12:00 p.m. Coordinators: Michael Dobbs, MD and Gustavo Roman, MD, FAAN Platform Session / 8:00 a.m–9:30 a.m. / Reception Hall 104A–D 8:00 a.m. IN3-1.001 Neurology of the H1N1 Pandemic in Singapore Asha Prerna, Natalie Tan, Jocelyn Lim, Chia-Yin Chong, Derrick Chan, Kevin Tan Panel Forums 6:30 p.m.–7:30 p.m. xx Fellowship Panel Find out how to search for a fellowship, how program directors select fellows, and how a fellowship could benefit your career. xx Academic/Research Panel Learn how to start a career in academics/research. xx Private Practice Panel Learn about beginning a career in private practice. Poster Forum and Reception 7:30 p.m.–9:00 p.m. Socialize with other residents and representatives from various neurology programs and address questions regarding fellowships, academic research, and private practice career opportunities. International Component Posters Neurology Residency Programs that feature an international element will have the opportunity to showcase their programs during the poster forum and reception, and to share information about their international outreach. Neurology Residency Programs that have a formal affiliation with foreign programs that encompass teaching and research are encouraged to submit a poster. For questions about the Residents and Fellows Career Forum and Reception, contact Cheryl Alementi at [email protected] or (651) 695-2737. 8:15 a.m. IN3-1.002 Progressive Multifocal Leukoencephalopathy in Transplant Recipients: A Multi-Center Study of Clinical Characteristics and Outcomes Farrah Mateen, RajaNandini Muralidharan, Daniel Harrison, David Clifford, Marco Carone, Eelco Wijdicks, Avindra Nath 8:30 a.m. IN3-1.003 Stroke in Asymptomatic Trypanosome cruzi Infected Patients Francisco Javier Carod-Artal, Antonio Pedro Vargas, Thiago Falcao 8:45 a.m. IN3-1.004 African Dust-Laden Atmospheric Conditions Activate the Trigeminovascular System Hayrunnisa Bolay, Hacer Doganay, Didem Akcali, Tayfun Goktas, Kayhan Caglar, Deniz Erbas, Cemal Saydam 9:00 a.m. IN3-1.005 Longitudinal Evaluation of Diffusion Tensor Imaging from Acute Carbon Monoxide Poisoning to Delayed Encephalopathy Hiroshi Kuroda, Kazuo Fujihara, Shuichi Higano, Yotaro Shinozawa, Yasuto Itoyama 9:15 a.m. IN3-1.006 Intracranial Complications of Sinusitis in Children Caitlin Hicks, Joseph Weber, Manikum Moodley Poster Session / Poster Rounds / 9:30 a.m–10:30 a.m. / Reception Hall 104A–D IN3-2.001 Utility of Quantitative Sensory Testing in Characterizing HIVAssociated Peripheral Neuropathy in Western Kenya: Pilot Testing Deanna Cettomai, Judith Kwasa, Caroline Kendi, Gretchen Birbeck, Richard Price, Elizabeth Bukusi, Craig Cohen, AnaClaire Meyer IN3-2.002 Acute Cerebellitis Associated with Novel H1N1 Infection Diana Castro, Benjamin Greenberg IN3-2.003 Adipokines and Metabolic Abnormalities in HIV Patients on Nucleoside Reverse Transcriptase Inhibitor Containing Regimens Sivakumar Rajappa IN3-2.004 Neurocysticercosis. FiveYear Experience at Loyola University Medical Center Adolfo RamirezZamora, Esteban Golombievski IN3-2.005 Primary Amebic Encephalitis by Naegleria fowleri: Chimaera of Bacterial Meningitis Herbert Manosalva, Cesar Ponce, Ilmic Davelaar, Ana Waalkens, Richard Pladdet IN3-2.006 Neurological Complications of Influenza Viruses: The Role of Dysregulation of Immune System Sidney Houff, Joseph Berger IN3-2.007 Headache in Residents and Workers Exposed to World Trade Center (WTC) Dust, Gas, and Fumes Presenting for Medical Care Sara Crystal, Joan Reibman, Mengling Liu, Kristen Babinski, Alexandra Milin, Katherine Henry IN3-2.009 Chronic Neurological Symptoms and Disorders Occasionally Associated with Seafood Poisonings Occuring in French Polynesia: A FiveCase Exploration Clémence Mahana iti Gatti, Laurent Maurs, Stéphane Rihet, Anne-Marie Legrand IN3-2.008 Brain Blood Regional Flow Measured by 99Tc EDC SPECT in ’PACO’ Abusers Hugo Videla, David Huanambal, Juan Ollari, Monica Diez, Hector D’Onofrio, Juan Maegli, Jorge Ure IN3-2.010 HTLV-1 Proviral Load as a Surrogate Marker for Neurological Deterioration in HTLV-1-Infected Individuals: 10 Years of FollowUp Abelardo Araujo, Isa Martins, Cecília Longo, Raquel de Oliveira, Suzana Greffin, Maria José AndradaSerpa, Marcus Tulius Silva Invited Speaker Session* / 10:30 a.m–12:00 p.m. / Reception Hall 104A–D 10:30 a.m.–11:00 a.m. PML-IRIS: Diagnostic and Therapeutic Challenges Avindra Nath, MBBS, FAAN 11:00 a.m.–11:30 a.m. Immunoneurotoxicology in Carbon Monoxide Exposure Sidney Houff, MD, PhD 11:30 a.m.–12:00 p.m. Neurological Complications of Influenza Sidney Houff, MD, PhD *Current as of February 1, 2010 30 31 Integrated Neuroscience Session: Current Concepts in Cognitive Neuroscience: Implications for Neurological Disease Monday, April 12 | 2:00 p.m.–6:00 p.m. 2:00 p.m.–2:30 p.m. Network Approach to Spatial Attention M. Marsel Mesulam, MD, FAAN 2:30 p.m.–3:00 p.m. Network-Based Neurodegeneration William Seeley, MD 3:00 p.m.–3:30 p.m. The Effect of Focal Lesions on Cortical Networks Mark D’Esposito, MD Poster Session / 3:30 p.m.–4:30 p.m. / Reception Hall 104A–D IN4-1.002 Theory of Mind Deficits in Patients with Frontal and Parietal Lobe Syndromes Brianna Morgan, Rachel Gross, Paul Eslinger, Ashley Boller, Murray Grossman IN4-1.005 Imaging Cognitive Reserve: Fronto-Parietal Connectivity Increases with PIB Retention in Healthy Elderly Subjects Michael Greicius, Elizabeth Mormino, William Jagust IN4-1.006 Effect of Propranolol on Eye Contact in Autism Sepctrum Disorder David Beversdorf, Sanjida Saklayen, Ananth Narayanan, Katherine Higgins, Shawn Christ IN4-1.007 In ADHD Children, Motor Subtle Signs Correlate with Reduced Motor Cortex Inhibition Donald Gilbert, Kelly Isaacs, Priya Xavier, Lindsay MacNeil, Amanda Lewis, Martha Denckla, Stewart Mostofsky IN4-1.003 Post-Stroke Spatial Bias and Spatial Neglect in Near and Far Space Anna Barrett, Elizabeth Murray, Siby Varughese, Jenny Masmela, Karen Kelly, Shpresa Ahmeti IN4-1.008 Connected Speech Production in Three Variants of Primary Progressive Aphasia: Linguistic Features and Neuroanatomical Correlates Stephen Wilson, Maya Henry, Max Besbris, Jennifer Ogar, Bruce Miller, Maria Gorno-Tempini Bus service to and from the race site will be provided. For registration and details, visit www.aan.com/view/runwalk or contact Andrew Halverson at [email protected] or (651) 695-2757. IN4-1.009 Ego and Allocentric Hypometric Computations in Parkinson Disease Tigran Kesayan, Anahid Kabasakalian, John Williamson, Frank Skidmore, Kenneth Heilman 7:30 a.m.–9:30 a.m. Now a tradition, the Action Planning Roundtable returns to provide Donald M. Palatucci Advocacy Leadership Forum graduates a chance to share with their peers the challenges and successes they’ve encountered while implementing their action plans. Graduates from all years are encouraged to attend. 9:00 a.m.–12:00 p.m. MTCC, Exhibit Hall FG Platform Session / 4:30 p.m.–6:00 p.m. / Reception Hall 104A–D 5:00 p.m. IN4-2.003 Fractionating Episodic Memory: Dissociable Neuroanatomic Correlates of Impairment of Specific Memory Processes in AD, a Perspective from ADNI David Wolk, Bradford Dickerson 4:45 p.m. IN4-2.002 Motor Extinction in Distinct Reference Frames: Double Dissociations and Associated Cortical Lesions Jennifer Heidler-Gary, Cameron Davis, Melissa Newhart, John Molitoris, Argye Hillis 5:15 p.m. IN4-2.004 Drug-Induced Deactivation of Inhibitory Networks Predicts Pathological Gambling in PD Thilo van Eimeren, Giovanna Pellecchia, Roberto Cilia, Bénédicte Ballanger, Thomas Steeves, Sylvain Houle, Janis Miyasaki, Mateusz Zurowski, Anthony Lang, Antonio Strafella 5:30 p.m. IN4-2.005 The Human Dopaminergic VTAHippocampal Loop Evidenced by the Effect of BDNF Genotype Joseph Masdeu, Philip Kohn, Erica Baller, Joel Bronstein, Shau-Ming Wei, Angela Ianni, Andreas Meyer-Lindenberg, Bhaskar Kolachana, Jasmine Czarapata, Daniel Weinberger, Karen Berman Pediatric Stroke: Recent Insights From an Emerging Field 5:45 p.m. IN4-2.006 Shared Neural Substrates of Reading and Spelling in Left Fusiform Gyrus: Converging Evidence from LesionDeficit and Functional Imaging Studies Steven Rapcsak, Esther Kim, Maya Henry, Hyesuk Cho, Sarah Andersen, Pelagie Beeson Gabrielle A. DeVeber, MD Hospital for Sick Children, Toronto, ON, Canada George C. Cotzias Lecture Endowed by Roche Pharmaceuticals, Inc. Deciphering the Molecular Mechanisms of Alzheimer’s Disease Predicts Novel Therapies Dennis J. Selkoe, MD, FAAN Brigham & Women’s Hospital, Boston, MA Palatucci Advocacy Action Planning Roundtable Presidential Plenary Session 4:30 p.m. IN4-2.001 Lesions to the Ventromedial Frontal Lobe Impair the Ability To Make Preference Judgments Alexandre Henri-Bhargava, Alison Simioni, Lesley Fellows Sidney Carter Award in Child Neurology Endowed by an anonymous donor. Support research in neurology and join us for a 5k run or one mile walk in downtown Toronto along the scenic waterfront. Whether you’re an occasional or seasoned runner, or just enjoy a walk, you’ll enjoy this beautiful trek—for a good cause. All proceeds go to support Clinical Research Training Fellowships in neurology. The race is open to all meeting attendees and their families. Water and refreshments will be available following the race. The registration fee is $25. Invited Speaker Session* / 2:00 p.m.–3:30 p.m. / Reception Hall 104A–D IN4-1.004 Cognitive Impairment in ARCA-1, a Newly Discovered Pure Cerebellar Ataxia Syndrome Robert Laforce, James Buteau, Jean-Pierre Bouchard, Guy Rouleau, Lefebvre Bernard, Rémi Bouchard, Nicolas Dupré Run/Walk For Brain Research 6:30 a.m.–8:30 a.m. Coordinators: Anjan Chatterjee, MD, FAAN and Mark D’Esposito, MD IN4-1.001 Visual Search in Dementia: Evidence for Paradoxical Facilitation of Binding Processes in Semantic Dementia Adam Boxer, Indre Viskontas, Alisa Matlin, John Fesenko, Bruce Miller Tuesday, April 13 Highlights Moderator: Stefan M. Pulst, MD, FAAN, Chair, Science Committee and Scientific Program Subcommittee The Presidential Plenary Session features the Academy’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2010. The session concludes with the annual AAN Business Meeting. Lectures include: Presidential Lecture Stem and Progenitor Cell-Based Treatment of Neurological Disease Steven A. Goldman, MD, PhD University of Rochester, Rochester, NY Get Involved in Your Academy and Professional Association Stay for the annual AAN/AAN Professional Association Business Meeting immediately following the final lecture to find out the latest on Academy business and information. Meeting will take place in Exhibit Hall FG of the Metro Toronto Convention Centre. Exhibits 11:30 a.m.–5:00 p.m. Complimentary Luncheon 12:00 p.m.–2:00 p.m. MTCC, Exhibit Hall DE See the latest in pharmaceutical products, medical equipment, publications, and products to assist with practice management, teaching methods, and research activities. Ethics Colloquium 12:30 p.m.–2:00 p.m. Participants will have the opportunity to identify emerging ethical issues affecting the practice of neurology that they would like the Ethics, Law, and Humanities Committee (ELHC) to consider for future reports or policies. Attendees will be encouraged to submit topics, along with related articles, opinions, or guidelines, in advance of the Colloquium. Robert Wartenberg Lecture Midlife Risk Profile and Later Life Cognitive Decline and Dementia Philip A. Wolf, MD, FAAN Boston University School of Medicine, Boston, MA *Current as of February 1, 2010 32 33 Tuesday, April 13 Highlights Poster Discussion Session Hot Topics Plenary Session 7:30 a.m.–12:00 p.m. (Author stand by poster from 7:30 a.m.–9:00 a.m.) 5:30 p.m.–6:30 p.m. 3:00 p.m.–7:30 p.m. (Author stand by poster from 6:00 p.m.–7:30 p.m.) Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. NIH Sponsored Clinical Trials in Neurology: What’s Going On? How to Participate? How Can We Do Better? 1:00 p.m.–3:00 p.m. The National Institutes of Health is the world’s largest funding agency for medical research. In the amount of research dollars going to major areas, neuroscience research is second only to cancer. The final goal of the taxpayer’s investment in neuroscience research is clinical trials that test new therapies. Many trials are performed by industry based upon NIH funded neuroscience discoveries, but many are funded by the NIH. The program will review NIH clinical trials currently in progress or just completed. A major new emphasis has been placed on obtaining evidence to inform medical decision-making, so called comparative effectiveness research. The focus will be on how the results of these trials might impact practice and also to obtain feedback from practitioners on what are the major questions that need to be addressed by future trials. Free to all attendees. New! Platform Session Times 1:45 p.m.–3:45 p.m. 4:00 p.m.–5:15 p.m. New time slots this year allow registrants to attend the Highlights in the Field program of their choice while still being able to attend the evening’s Hot Topics Plenary Session. 34 Poster Session Floor Plan Metro Toronto Convention Centre, Room 808 242 243 244 245 246 247 248 249 250 251 MTCC, Exhibit Hall FG Moderator: Raymond P. Roos, MD, FAAN, Member, Science Committee This session highlights important and interesting abstracts presented at subspecialty meetings leading up to the Annual Meeting that are not on the program but should be heard by a wide audience at the Annual Meeting. Topics are selected by the AAN Science Committee and AAN Scientific Program Subcommittee. Topic: Whole Exome Sequencing Jeffrey M. Vance, MD, PhD University of Miami, Miami, FL 257 258 269 270 281 282 293 294 241 256 259 268 271 280 283 292 295 240 255 260 267 272 279 284 291 296 239 254 261 266 273 278 285 290 297 238 253 262 265 274 277 286 289 298 237 252 263 264 275 276 287 288 299 70 71 90 91 110 111 130 131 186 187 206 207 226 227 69 72 89 92 109 112 129 132 149 150 167 168 185 188 205 208 225 228 68 73 88 93 108 113 128 133 148 151 166 169 184 189 204 209 224 229 67 74 87 94 107 114 127 134 147 152 165 170 183 190 203 210 223 230 66 75 86 95 106 115 126 135 146 153 164 171 182 191 202 211 222 231 65 76 85 96 105 116 125 136 145 154 163 172 181 192 201 212 221 232 64 77 84 97 104 117 124 137 144 155 162 173 180 193 200 213 220 233 63 78 83 98 103 118 123 138 143 156 161 174 179 194 199 214 219 234 Corporate Therapeutic Updates 62 79 82 99 102 119 122 139 142 157 160 175 178 195 198 215 218 235 Sheraton Centre Toronto Hotel 61 80 81 100 101 120 121 140 141 158 159 176 177 196 197 216 217 236 Topic: CREST Trial Thomas G. Brott, MD, FAAN Mayo Clinic-Jacksonville, Jacksonville, FL Title: “Devices for Epilepsy” Gregory A. Worrell, MD May Clinic-Rochester, Rochester, MN Title: “Comparative Effectiveness Research” S. Claiborne Johnston, MD, PhD University of San Francisco, San Francisco, CA Tuesday, April 13 Poster Session I 7:30 a.m.–12:00 p.m. . 7:30 a.m.–9:00 a.m.* Poster Session II 3:00 p.m.–7:30 p.m.. 6:00 p.m.–7:30 p.m.* Wednesday, April 14 Poster Session III 7:30 a.m.–12:00 p.m.. 7:30 a.m.–9:00 a.m.* Poster Session IV 3:00 p.m.–7:30 p.m.. 6:00 p.m.–7:30 p.m.* Thursday, April 15 Poster Session V 7:30 a.m.–12:00 p.m.. 7:30 a.m.–9:00 a.m.* Poster Session VI 3:00 p.m.–7:30 p.m.. 6:00 p.m.–7:30 p.m.* *Authors stand by posters. 7:30 p.m.–10:00 p.m. Industry-sponsored, non-CME programs will be offered and are open to attendees at no charge. They will provide an opportunity for pharmaceutical companies, device companies, or other neurologic related organizations to share information regarding their current therapies and projects in the pipeline in accordance with standards set for industry by the FDA. See page 88 for more details. 10 11 30 31 50 51 9 12 29 32 49 52 8 13 28 33 48 53 7 14 27 34 47 54 6 15 26 35 46 55 5 16 25 36 45 56 4 17 24 37 44 57 3 18 23 38 43 58 2 19 22 39 42 59 1 20 21 40 41 60 35 Poster Session I Tuesday, April 13 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 Poster Discussion Session: Aging and Dementia: Risk Factors Location: 800 Level Moderator: Andrea Bozoki, MD Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. PD1.001 Subjective Memory Complaints Are Associated with Impending Cognitive Decline Isabel Hernandez Ruiz, Pablo Martinez-Lage, Monserrat Alegret Llorens, Sergi Valero Ventura, James Becker, Oscar Lopez, Lluis Tarraga Mestre, Merce Boada Rovira PD1.003 Effect of Age, Gender, Marital Status, and Education on Behavioral Symptoms in Mild Cognitive Impairment and Mild Alzheimer’s Disease Subjects Liana Apostolova, Chi-Hong Tseng, Lynn Fairbanks, David Elashoff, Jeffrey Cummings PD1.002 White Matter Hyperintensities Volume Is a Stronger Predictor of Dementia Than Silent Infarcts. A Population-Based Cohort Study: The 3C-Dijon MRI Study Christophe Tzourio, Yi-Cheng Zhu, Aicha Soumaré, Ophelia Godin, Bernard Mazoyer, Olivier Rouaud, Hugues Chabriat, Carole Dufouil PD1.004 Anxiety Affects Executive Functioning Differently in Asymptomatic APOEe4 Homozygotes and Noncarriers Cynthia Stonnington, Richard Caselli, Dona Locke, Amylou Dueck PD1.007 A Simple Risk Model Based on Age at Diagnosis, MMSE, and Gender for the Prediction of Survival in Persons with Alzheimer’s Disease: “Tell Me Doc, How Long Do I Have?” Gregory Jicha, Peter Nelson, Erin Abner, Marta Mendiondo, Frederick Schmitt, William Markesbery, Richard Kryscio PD1.005 Education Mitigates Effects of Frontal Inhibitory Network Atrophy To Maintain Executive Function in Normal Elders Jacob Mirsky, Hilary Heuer, Aria Jafari, Joel Kramer, Indre Viskontas, Bruce Miller, Adam Boxer PD1.008 Apoliprotein E Status Modulates the Clinical and Neuroanatomic Phenotype of Alzheimer’s Disease: Data from ADNI David Wolk, Bradford Dickerson Neurologic Education: Resident and Student Education Neurologic Education: Stroke Education P01.001 What Is the Effect of Logging Abnormal Clinical Signs on Medical Student Knowledge Acquisition during the Neurology Clerkship? David Tabby P01.009 Development, Implementation, and Evaluation of a Training Video To Instruct Healthcare Providers on a Formal Bedside Dysphagia Assessment for Stroke Patients Cathy Sila, Gina Nicastro, Natalie Rudd, Margaret Stecker, Erin Supan, LeighAnn McCartney P01.015 Median Nerve Ultrasonography in Carpal Tunnel Syndrome: A Blinded Case-Control Study Andrea Leep Hunderfund, Andrea Boon, Eric Sorenson P01.002 Effectiveness of a WebBased Essential Neurologic Exam Video Tutorial in Combination with a Didactic Lecture vs. Didactic Lecture Alone: A Randomized Trial Shelly Miller, Chuanhui Dong, Richard Isaacson P01.003 Neurology Residents as Teachers: A Medical Student Perspective Jennifer Elbaum, Stephen Krieger, Martin Goldstein P01.004 Neurology Residents’ Perceptions of Peer-Driven Neurology Board Review Sessions Esteban ChengChing, Lama Chahine, MaryAnn Mays P01.005 Potential Utility of Scenario Based Simulations for Teaching Neurology Residents Interpersonal/Communication Skills and System Based Practice Dreama Brar, Loretta Schnepel, Balena Adkins, Scott Silliman P01.006 Teaching Cranial Nerve Examination Using a Virtual Patient and the Nintendo Wiimote®: Preliminary Evaluation Chandni Kalaria, Chen Lin, Kyle Johnsen, David Lind, Aaron Kotranza, Candelario Laserna, Tia Aryal, Hevil Shah, Jerry Pruitt, Bayard Miller, Juan Cendan, Benjamin Lok P01.007 Review of Neurology Education Uses of Web 2.0 Jeff Kraakevik P01.008 Survey of Skin Preparation Technique before Neuraxial Procedures Christopher Grunseich, Shawn Sumida, Ejaz Shamim 36 PD1.006 Hypertension and Its Association with Prevalent Dementia in the Oldest-Old Maria Corrada, Daniel Berlau, Carrie Peltz, Claudia Kawas P01.010 Evaluation of a Stroke Alert Protocol Coupled with an Education Program in the Emergency Department Carl Hoegerl, Frederick Goldstein, Seeniann John P01.011 Chairmen Perspective on Current State of Vascular and Interventional Neurology Osama Zaidat, Junaid Kalia, Matthew Lochen, Anthony Furlan, Safwan Jaradeh, David Kaufman, Henry Kaminski, Carlos Kase, Lawrence Wechsler, Dileep Yavagal, Tudor Jovin, Rishi Gupta, Jose Biller P01.012 Program Directors’ Perspective on Education in Interventional Neurology Junaid Kalia, Wendy Peltier, David Preston, Douglas Woo, Osama Zaidat Clinical Neurophysiology: Electrodiagnosis and Clinical Peripheral Nerve Disease P01.013 Conduction Jump Measure on Motor Fibers To Improve the Electrodiagnosis of Carpal Tunnel Syndrome Philippe Lebrun-Grandié, Luc Letenneur P01.014 Peripheral Neuropathy in Wegener Granulomatosis: Clinical and Neurophysiological Features Elizabeth Soto-Cabrera, Horacio Senties-Madrid, Iris Gonzalez-Orizaga, Francisco GutierrezManjarrez, Bruno Estanol P01.016 Peripheral (PCT) and Central (CCT) Conduction Time to Quadriceps Muscle Alessia Di Sapio, Francesca Sperli, Simona Malucchi, Marco Capobianco, Antonio Bertolotto, Walter Troni P01.017 A Prospective Study on the Electrodiagnosis of Ulnar Neuropathy at the Elbow (UNE) Based on Bayesian Principles Raissa Villanueva, Paul Twydell, Bennett Myers, Marlene Downs, David Herrmann, Eric Logigian P01.018 Peripheral Neuropathy Associated to Progressive Systemic Sclerosis: Clinical and Neurophysiological Features Elizabeth Soto-Cabrera, Horacio Senties-Madrid, Lydia Lopez, Francisco Gutierrez-Manjarrez, Iris Gonzalez-Orizaga, Jose Gien-Lopez, Bruno Estanol P01.019 Decline in Nerve Conduction Velocity (NCV) with Age Occurs in Proximal Nerve Segments among the Healthy Elderly John Engstrom, Christopher Songster, Amy Lee, Carol Piunti, Ari Green P01.020 Pregabalin in Post-Traumatic Peripheral Neuropathic Pain: Efficient Assessment of Efficacy in a Randomized, Double-Blind, Placebo-Controlled Crossover Study Timothy Jenkins, Trevor Smart, Frances Hackman, Carol Cooke, Keith Tan, Raymond Cheung PD1.009 Diagnostic Norms for Subjects Aged between 50 and 89 Years with Mild Dementia: Single or Adjusted Cut-Off? Gilles Chopard, Geraldine Vanholsbeeck, Sabrina Ferreira, Elloi Magnin, Lucien Rumbach, Jean Galmiche PD1.010 Peripheral Insulin Predicts Rates of Brain Atrophy and Cognitive Decline in Early Alzheimer’s Disease Jeffrey Burns, Eric Vidoni, Robyn Honea, Heather Anderson, Russell Swerdlow, William Brooks P01.028 Ocular Vestibular Evoked Myogenic Potentials in Patients with Migraine Eren Gozke, Nursel Erdal, Haluk Ozkarakas P01.040 Treatment with Bcl-220-34 after CCI Provides Protection Against Mitochondrial and Synaptic Loss Roi Ann Wallis, Kimberly Panizzon, Suni Allen P01.029 Age-Dependent Pattern of Oxygen Metabolism Response to Continuous Visual Deprivation Andrei Vlassenko, Melissa Rundle, Mark Mintun P01.041 Computed Tomography Perfusion Findings To Identify Acute Ischemic Stroke Patients for Acute Thrombolysis Haralabos Zacharatos, Ameer Hassan, Mushtaq Qureshi, Gabriela Vazquez, Robert Taylor, Mustapha Ezzeddine, Adnan Qureshi P01.030 Frequency and Yield of Repeat Audio-Visual Electroencephalography in a Comprehensive Epilepsy Center Huijun Wang, Rohit Marawar, Anthony Ritaccio P01.031 Prevalence of Seizures and Epileptiform Activity in the Acute Setting of Cerebral Hemorrhage Jeffrey Politsky, Igor Ugorec Clinical Neurophysiology: Transcranial Magnetic Stimulation and Evoked Potentials P01.032 Repetitive Transcranial Magnetic Stimulation in Children with Attention Deficit Hyperactivity Disorder Lazaro Gomez P01.021 Latency Skin Sympathetic Reflex Is Shorter Palms and Fingers Compared to Wrist When Elicited by Electrical Stimulus Iris GonzalezOrizaga, Elizabeth Soto-Cabrera, Horacio Senties-Madrid, Cesar Callejas, Francisco Gutierrez-Manjarrez, Bruno Estanol P01.022 Simultaneous Recording of the H Reflexes of the Flexor Carpi Radialis and Biceps Brachii Miguel Padilla, Bruno Estanol, Guillermo Garcia-Ramos, Horacio Senties-Madrid Clinical Neurophysiology: EEG/ Epilepsy P01.023 Treatment of Hospital Onset Seizures: A Comparison between Two Hospitals Madeline Fields, Daniel Labovitz, Jacqueline French P01.024 Safety and Efficacy of Pregabalin in Patients with Central Post-Stroke Pain Raymond Cheung, Kevin Murphy, Guy Bashford, Andrew Martin, Jong Kim P01.025 Comparison of Detection Rates of Non-Convulsive Status Epilepticus and Non-Convulsive Seizure in Critically Ill Patients Using Routine EEG and Continuous EEG in a Busy County and a Private Hospital Shahram Izadyar, David Friedman, Vitor Pacheco, Richard Hrachovy P01.026 Quantitative EEG during Nocturnal Polysomnography before and after Treatment with Sodium Oxybate Victor Rosenfeld, John Stern, Dinh Ngyuen P01.027 Source Localization of Sleep Spindles by High Resolution EEG/MEG Recordings Eun Hye Jeong, Jooman Han, Songi Kim, June Sik Kim, Chun Kee Chung, Hyang Woon Lee Poster Session I Tuesday, April 13 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P01.033 Changes in Somatosensory Evoked Potentials to Fluctuations in Mean Arterial Pressure during Endoscopic Endonasal Approach to Skull Base Surgery Parthasarthy Thirumala, Miguel Habeych, Jeffery Balzer, Donald Crammond P01.034 withdrawn P01.035 TMS-Related Metabolic Changes in Limbic System and Default Network in Patients with Tinnitus Andrei Vlassenko, Lars Couture, Keith Garcia, Jay Piccirillo, Mark Mintun P01.036 Local Non-Synaptic Mechanisms Underlying Very Fast Oscillations in Rasmussen’s Encephalitis Anita Roopun, Venkateswaran Ramesh, Mark Baker, Alistair Jenkins, Ming Lai, Ian Schofield, Roger Whittaker, Roger Traub, Miles Whittington, Mark Cunningham Critical Care/Emergency Neurology/Trauma I P01.037 High Rate of Myopathy in Aneurysmal Subarachnoid Hemorrhage Patients Gaurav Parikh, Thomas Wolfe, Kaiz Asif, Denise Miller-Niklasch, Safwan Jaradeh, John Lynch, Michel Torbey P01.038 Imaging, Interventions, and Neurologic Outcomes in 8 ICU Patients with Severe Hyperammonemia Prem Kandiah, Dhruvil Pandya, Adriana Kori-Graf, Rahul Nanchal P01.039 Clinical, Electrophysiologic, and Pathologic Outcomes in a Large Animal Model of Limb Ischemia Nathan Sumner, Gabriel Burkhardt, John Sladky, Todd Rasmussen, Jerry Spencer, Jerry Cowart, Lyell Jones P01.042 A Malignant Case of Acute Promyelocytic Leukemia with Occlusion of Carotid Artery by Tumor Thrombus Selena Nicholas-Bublick, Gretchen Tietjen, John Irlam P01.043 Mortality, Impairment, and Disability of Patients with Acute Traumatic Spinal Cord Injury: Does Blood Alcohol Concentration Matter? Julio Furlan, Michael Fehlings P01.044 Predictors of EndotracheaI Intubation in Patients Presenting with Seizure Tenbit Emiru, Nauman Tariq, Robert Taylor, Adnan Qureshi, Mustapha Ezzeddine P01.045 The FOUR Score Is a Predictor of Outcome in Comatose Patients after Cardiac Arrest Eelco Wijdicks, Jennifer Fugate, Daniel Claassen, Alejandro Rabinstein P01.046 The Impact of Rebleeding on Delayed Cerebral Ischemia (DCI) after Aneurysmal Subarachnoid Hemorrhage Aaron Lord, Luis Fernandez, J. Michael Schmidt, Sachin Agarwal, Stephan Mayer, Kiwon Lee, Jan Claassen, E. Sander Connolly, Neeraj Badjatia P01.047 Clinical Interest of Long Latency Somatosensory Evoked Potentials (N60) in Postanoxic Coma Mathieu Bataille, Charlotte Quentin, Cedric Daubin, Gilles-Louis Defer, Olivier Etard P01.048 Neuron Specific Enolase as a Predictor in Therapeutic Hypothermia after Cardiac Arrest Jennifer Fugate, Eelco Wijdicks, Daniel Claassen, Alejandro Rabinstein P01.049 Predictive Value of Prevalent Aneurysmal Subarachnoid Hemorrhage Grading Scales for Clinical Outcomes Sachin Agarwal, Matthew Vibbert, Luis Fernandez, J. Schmidt, Jan Claassen, Stephan Mayer, Kiwon Lee, Neeraj Badjatia P01.050 The Effect of Motivation on Clinical Reaction Time Assessment in College Athletes Katherine Bohard, James Eckner, Jeffrey Kutcher P01.051 Gender and Racial Disparity in Survival after Cardiac Arrest Richard Dubinsky, Sue Lai P01.052 Prognosis after Therapeutic Hypothermia in Anoxic Brain Injury Patients Based on EEG Grading Scale Anahita Adeli, Mouhammad Jumaa, Gena Ghearing, Frank Guyette, Clifton Callaway, Jon Rittenberger Cerebrovascular Disease: Stroke Prevention Cerebrovascular Disease: Epidemiology I P01.053 Transcranial Doppler with Contrast for the Diagnosis of Vascular Lesions in Adult Patients with Sickle Cell Disease Abelardo Araujo, Orlando Velloso, Ana Claudia Leite, Raquel Oliveira, Paulo Valle Bahia P01.064 Change in Trends in the Occurrence of Young Stroke over the Last Two Decades—A Study from a Tertiary Care University Hospital, New Delhi (India) Manmohan Mehndiratta, Rohit Garg P01.054 Usefulness of Echocardiography in the Routine Evaluation of Patients with Ischemic Stroke/TIA Liqun Zhang, J. Harrison, Larry Goldstein P01.065 Prehospital Delay and Related Factors in Patients with Acute Ischemic Stroke or TIA: Change over Recent 4 Years in a Community Based Hospital Sucjoo Kim, Ji-Young Park, Byung-Kun Kim, Ohyun Kwon, Jong-Moo Park, JungJu Lee, Ja-Seong Koo P01.055 Pharmacokinetics of Extended-Release Dipyridamole Following Administration through Gastrostomy Tube David Greer, Leonardo Batista, David Crandell P01.056 Risk Profile of Subjects Enrolled in the Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) Trial over the First Six Years of Enrollment David Thaler, Diane Book, John Carroll, Larry Goldstein, Helmi Lutsep, Jeffrey Saver, Richard Smalling, David Tirschwell, Brian Van Dorn P01.057 A Model for Delivery of Community-Based Secondary Prevention Care for First-Time Stroke Survivors Kenneth Gaines, Duncan Howe, Andrew Kurtzman, Franklin Carlisle, Alisa Roberson, Monique Brown, Candice Munnerlyn P01.058 Percutaneous Closure of Patent Foramen Ovale: Guidelines, Selection Criteria, and Follow-Up of a Clinical Cohort Dario Giobbe, Alessandro Balducci, Gabriella Paglia, Paolo Scacciatella, Mauro Giorgi, Sebastiano Marra P01.059 Endarterectomy for “Hemodynamically Insignificant” Symptomatic Carotid Stenosis Rebekah Ahmed, John Harris, Craig Anderson, Virginia Makeham, Michael Halmagyi P01.060 Angioplasty with Stent for Radiation-Induced Extra-Cranial Stenosis Thomas Leung, Simon Yu, Yannie Soo, Alexander Lau, Anne Chan, Lawrence Wong P01.061 Mechanism of Ischemic Stroke in Takayasu Arteritis Jaechun Hwang, Gyeong-Moon Kim, Young Bang Oh, Chin-Sang Chung, Kwang Ho Lee, Dukkyung Kim P01.062 Lack of Impact of Local and National Stroke Awareness Campaigns on TIA Referrals to a UK District General Hospital David Collas P01.063 A Retrospective Cohort Study of Substance Abuse and Length of Hospital Stay in Ischemic Stroke Patients Lien Diep, John Kwagyan, Roger Weir, Alice Adams, Raza Khan, Zakiya Wynn, Sherita Chapman, Alok Dabi, S. Fatima, Annapurni Jayam-Trouth P01.066 Pregnancy Related Stroke in Developing Asian Countries: Risk Factors, Subtypes, Presentation, and Outcome Mohammad Wasay, Shahzad Ahmed, Kauser Mehmood, Subhash Kaul, Bindu Menon, Mohammad Saadatnia, Abdul Malik, Padma Gunaratne, Manmohan Mehndiratta P01.067 Neurofluctuations in Patients with Subcortical Ischemic Strokes (NISS) Study Indrani Acosta, Nusrat Harun, Hen Hallevi, Sean Savitz P01.068 Motor Function Impairment among Elderly Population with History of Stroke Afshin Divani, Gabriela Vazquez, Kyle Brandy, Anna Barrett, Andreas Luft P01.069 Cerebral Venous Sinus Thrombosis in Males: Is It Uncommon or Under-Reported? Rohit Garg, Man Mehndiratta, Sanjay Pandey, Awadh Pandit P01.070 Urinary Incontinence among Elderly Stroke Survivors Gabriela Vazquez, Rachel Meyer, Andreas Luft, Afshin Divani P01.071 Racial Disparities in Health Care Costs in Stroke Patients with or without Diabetes Majaz Moonis, Baqar Husaini P01.072 Investigating the Relationship between Cholesterol Level with Increased Risk of ICH in Different Races Bahareh Hassanzadeh, Florence Chukwuneke, Mohammad Moussavi, Vahid Tohidi, Ugo Paolucci, Martin Gizzi, Jawad Kirmani P01.073 Strokes in a Developing Country: Does Gender Matter? Jayanthi Arulneyam, Fahmi Al-Senani P01.074 Disparities in Acute Stroke Care: Role of Race and Insurance Status Jose Romero, Helena Lau, Michael Winter, Viken Babikian, Aleksandra Pikula, Andrew Morrison, Thanh Nguyen, Jason Viereck, Carlos Kase P01.075 Stroke Subtypes in Hawaii: Gender, Age and Ethnicity Douglas Valenta, Cherylee Chang, Susan Asai, Douglas Franz, Muhammad Suri P01.076 Trends in Hospital CaseMortality Rate for Ischemic Stroke: Does Hospital Size Matter? Manuel Seijo-Martinez, Javier Paz-Esquete, Ramon Ares-Rico, Angeles Bouzas Rodriguez 37 Poster Session I P01.077 Correlation of Ischemic Stroke and Coronary Artery Calcium Burden: A Retrospective Analysis Paul Lleva, Stephen Marks, Ramandeep Sahni, Brij Singh Ahluwalia, Oceanis Vaou, Sonia Lal, Maheep Singh P01.089 Epidemiological and Neurophysiological Characteristics of Epilepsy in African American Population with HIV Infection Mohankumar Kurukumbi, Rajesh Gupta, Annapurni Jayam-Trouth P01.078 Inverse Association of Atheromatous Aortic Arch Disease and Atrial Fibrillation in Patients with Ischemic Stroke and Transient Ischemic Attack Andrés Suarez, Patricia Riccio, Francisco Klein, Luciano Sposato P01.090 Predictors of Refractoriness in Patients with Post-Stroke Epilepsy Kandan Kulandaivel, Jyoti Pillai, Andrea Rosso, Jamie Swanson, Barbara Jobst P01.079 Prevalence and Risk Factors for Stroke in Rural Communities of Middle Belt Nigeria Emmanuel Sanya, Feyi Adepoju, Sunday Aderibigbe, Olabode Olaosebikan, Timothy Olarewaju P01.080 Known Versus De Novo Atrial Fibrillation in Patients with Acute Ischemic Stroke and Transient Ischemic Attack Juan Ressia Gómez, Patricia Riccio, Francisco Klein, Agustín Jáuregui, Marisol Ferrúa, Rafael Zamora, Luciano Sposato P01.081 Differences in Risk Factor Profiles between Asymptomatic Carotid Disease and Ischemic Stroke or Transient Ischemic Attack of Non-Carotid Etiology Juan Ressia Gómez, Patricia Riccio, Francisco Klein, Luciano Sposato P01.082 Risk Factors and Management of Ischemic Stroke in Korean Young Adults under 49 Years Old Do Kyung Lee, Dae-Il Chang, Jung Hwa Kim, Key Chung Park, Tae-Beom Ahn, Sung Sang Yoon, Kyung Cheon Chung P01.083 Outcomes after Spontaneous Intracerebral Hemorrhage in South Asians: The Race Factor Syed Abbas, Ugo Paolucci, Mohammed Alsumrain, Mohammad Moussavi, Martin Gizzi, Jawad Kirmani P01.084 Prevalence of Transthoracic Echocardiographic Abnormalities in Stroke Paul Eugene Lleva, Stephen Marks, Wilbert Aronow, Raveen Deol, Kaushang Gandhi, Brij Singh Ahluwalia Epilepsy: Epidemiology P01.085 Incident Epilepsy/Seizure Disorder in US Nursing Homes by Predisposing Conditions, 2003– 2007 Lynn Eberly, Ilo Leppik, Kenneth Svendsen, Shuzhen Li, Susan Harms, Judith Garrard, Beth Virnig P01.086 A Population-Based Study of Health-Related Quality-of-Life in Migraine and Epilepsy Compared to Asthma and Diabetes Nathalie Jette, Jody Pow, Jane McChesney, Scott Patten, Jeanne Williams, Sam Wiebe P01.087 Admission for Status Epilepticus over Eight Years in Tennessee: Effect of Race and Age Amir Arain, Pradumna Singh, Yanna Song, Van Cain, Baqar Husaini P01.088 Women with Epilepsy and Folic Acid Supplementation Prior to Pregnancy Kristi McIntosh, Autumn Klein 38 Tuesday, April 13 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P01.091 Analysis of 621 Death Certificates Issued during 1998–2007 in Curitiba, Brazil, Mentioning Epilepsy or Epileptic Seizures Renata Ducci, Raphael Cirino, Ramon de Oliveira, Carlos Twardowschy, Eliane Chomatas, Pedro Kowacs Child Neurology/Developmental Neurobiology: Epidemiology P01.092 Trends in Outcomes and Hospitalization Costs among Pediatric Spinal Cord Injury Patients in the United States Mahta Samizadeh, Khosro Farhad, Lubna Mehyar, Hafiz Khan, Nizar Souayah P01.093 Trends in Outcomes and Hospitalization Costs of Infantile Botulism in United States Lubna Mehyar, Hafiz Khan, Zaid Abed Al-Qudah, Shahanara Islam, Nizar Souayah P01.094 Idiopathic Inflammatory Myopathies in Childhood: Analysis of 27 Cases Paulo Lorenzoni, Rosana Scola, Claudia Kay, Lineu Werneck P01.095 Healthcare Transitions for Adolescents with Chronic Life-Limiting Neurological Illnesses: Identifying Research Priorities Lynn Straatman P01.096 Paroxysmal Kinesigenic Dyskinesia: The Cleveland Clinic Experience and Literature Review Krishe Menezes, David Rothner P01.097 Prognostic Factors for Outcome of Neonatal Seizures in Term Infants Jarred Garfinkle, Michael Shevell P01.098 Motor Stereotypies: Normal Childhood Behavior or a Disorder? Rebecca Gologorsky, Farhad Sahebkar P01.099 The Stereotypical Behavior of Parents Whose Children Have Stereotypies Farhad Sahebkar, Onica Kuch, Rebecca Gologorsky P01.100 Temporal Trends in Presentation Time to the Emergency Department (ED) for Pediatric Stroke Patients: A Population-Based Study Laura Lehman, Jane Khoury, Kathleen Alwell, Charles Moomaw, Pooja Khatri, Brett Kissela, Daniel Woo, Matthew Flaherty, Opeolu Adeoye, Simona Ferioli, Joseph Broderick P01.101 Spectrum of Disorders Seen at a Pediatric Movement Disorders and Spasticity Clinic Lama Chahine, Manuel Buitrago Blanco, Debabrata Ghosh Aging and Dementia: Epidemiology P01.102 Differential Risk Factors for Amnestic MCI and Dementia Amy Borenstein, James Mortimer, Ding Ding, Qian-hua Zhao, Qi-hao Guo, Douglas Galasko, David Salmon, Ronald Petersen, Zhen Hong P01.103 Cortical and Subcortical Gray Matter Volumes and Walking Speed in Elderly Subjects: The Three-City Study Julien Dumurgier, Fabrice Crivello, Bernard Mazoyer, Pauline Maillard, Béatrice Tavernier, Nathalie TzourioMazoyer, Christophe Tzourio, Alexis Elbaz P01.104 Terminal Decline in Specific Cognitive Domains in DementiaFree Elderly, Using Change Point Analysis Hiroko Dodge, Chung-Chou Chang, Mary Ganguli P01.105 Interaction of High Homocysteine Level and MTHFR Polymorphism on Dementia Risk. The 3C-Dijon Study Carole Dufouil, Ophelia Godin, Jean-Sebastien Vidal, Olivier Rouaud, Annick Alperovitch, Christophe Tzourio P01.106 Gender Differences in the Risk Profile and Male Predominance of Silent Brain Infarction in Japanese Elderly Subjects: The Sefuri Brain MRI Study Takahiro Mori, Yoshikazu Miwa, Yuki Takashima, Manabu Hashimoto, Akira Uchino, Takefumi Yuzuriha, Toshiyuki Sasaguri, Hiroshi Yao P01.107 Apathy in the Very Old and the Incidence of Dementia: The Monzino 80-Plus Population-Based Study Giancarlo Logroscino, Mauro Tettamanti, Angela Recchia, Maria Teresa Garrì, Emma Riva, Carlotta Franchi, Luca Pasina, Alessandro Nobili, Ugo Lucca P01.108 Association of Clinical Dementia Rating (CDR) and Episodic Memory (EM) Measures to Medial Temporal Atrophy (MTA) Scores among Different Ethnic Groups Maria Greig, David Loewenstein, Elizabeth Potter, Warren Barker, John Schinka, Balaibal Ashok Raj, Yougui Wu, Daniel Varon, Ranjan Duara P01.109 Cognitive Impairment Is a Major Risk Factor for the Incidence of Disability in the Oldest-Old Daniel Berlau, Maria Corrada, Carrie Peltz, Claudia Kawas P01.110 Clinical Trials of Alzheimer’s Drugs in Patients with Mild Cognitive Impairment: Enrichment of True Alzheimer’s Cases through Disease Markers Giovanni Frisoni, Marco Lorenzi, Donata Paternic≥, Cristina Scarpazza, Elaine Irving, Olivier Blin, Susanne Ostrowitzki P01.111 Macro- and Micro-Structural Brain Imaging Characteristics of Adults Who Have Maintained Cognitive Function Very Late in Life Caterina Rosano, Howard Aizenstein, Alexandra Fiocco, Anne Newman, Yan Du, Vijay Venkatraman, Tamara Harris, Jingzhong Ding, Suzanne Satterfield, Kristine Yaffe Neuroepidemiology/ Health Services and Outcomes Research: Stroke Neuroepidemiology/Health Services Research P01.112 JCAHO Primary Stroke Center Core Measures: Influence of Concurrent Data Collection Anand Vaishnav, Nicole Yarber, Megan Mason, Kara Kennedy, Lisa Bellamy P01.121 Correlations between Stroke Severity and Different Types of Antihyperglycemic Medication M. Ziad Darkhabani, Bijal Mehta, Tareq Kass-Hout, Omar Kass-Hout, Maxim Mokin, Vladan Radovic, Marilou Ching P01.122 Should Provision of Angioplasty for Cerebral Vasospasm Be a Mandatory Component for Hospitals Treating Patients with Subarachnoid Hemorrhage? Rakesh Khatri, Nauman Tariq, Gabriela Vazquez, M. Fareed Suri, Mustapha Ezzeddine, Adnan Qureshi Neuroepidemiology/Health Services and Outcomes Research P01.113 Impact of In-Patient Stroke Rehabilitation Units on Length of Hospital Stay: A Statewide Study Silvina Tonarelli, Gabriela Vazquez, Mushtaq Qureshi, Michael Tibbs, Adnan Qureshi P01.123 Health-Related Quality of Life across the Breadth of Neurologic Diseases Seen in the Ambulatory Setting Irene Katzan, Kay Bielawski, Michael Speck, John Urchek, Eric Novak, Nancy Obuchowski, Charles Bae, Lara Jehi, Elizabeth Ricksecker, Chris Dopler P01.114 Distribution of Certified Stroke Centers in the United States Ken Uchino, Kazuto Kobayashi P01.124 Neurohospitalist Experience in the UK Aisling Fitzpatrick, Peter McColgan, Mark McCarron P01.115 Endovascular and Neurosurgical Treatment of Cerebral Aneurysms among Octogenarians: Nationwide Inpatient Sample 2002– 2006 Gustavo Rodriguez, Rakesh Khatri, Gabriela Vazquez, Nauman Tariq, Yousef Mohammad, Mustapha Ezzeddine, M. Fareed Suri, Adnan Qureshi P01.125 Neurology In-Hospital Fall Risk Assessment: A Role for the Physician Andrea Leep Hunderfund, Cynthia Sweeney, LeAnn Johnson, Jeffrey Britton P01.116 Level of Evidence in Current American Stroke Association Guidelines Swaroop Pawar, M. Fareed Suri, Kamakshi Lakshminarayan, Adnan Qureshi, Mustapha Ezzeddine P01.117 Endpoint for Clinical Trials Involving Patients with Intracerebral Hemorrhage: Modified Rankin Scale as a Dichotomized or Ordinal Outcome Jill Novitzke, Yuko Palesch, Renee Martin, Adnan Qureshi, ATACH Investigators P01.118 Transcranial Doppler Ultrasound for Detecting Intracranial Stenosis in Elderly Population. Results from the Ultrasound Screening in Adults for Intracranial Disease (USAID) Study M. Fareed Suri, Nauman Tariq, Alexandros Georgiadis, Mushtaq Qureshi, Gabriela Vazquez, M. Naeem Qureshi, Adnan Qureshi P01.119 Anxiety Disorder among Stroke Caregivers Is Associated with the Presence of Depressive Symptoms in Stroke Survivors Francisco Javier Carod-Artal, Luciane Ferreira Coral, Daniele Stieven Trizotto, Clarissa Menezes Moreira P01.120 Subpar Utilization of Dental Care among Americans with a History of Stroke Nerses Sanossian, Nicole Gatto, Bruce Ovbiagele Poster Session I Tuesday, April 13 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P01.126 Multiple Sclerosis and Vitamin D Fredric Cantor, Nancy Richert, Irene Cortese, Joan Ohayon, Fenton Kaylan, Henry McFarland P01.127 Survey of Outside Physician Calls to University-Based Neurologists Kevin Walker, L. Dewitt, Jeffrey Wagner, Mark Bromberg, Richard Nelson, Jennifer Majersik P01.128 Prevalence of Neurological Illness and Associated Mortality on Ugandan Neurology Ward Jason Sico, Jeffrey Bigelow, Elly Katabira, Ivan Kimuli, Huned Patwa P01.129 Routine Collection of Health Status Measures in the Neurologic Population— Is It Feasible? Irene Katzan, Chris Dopler, Kay Bielawski, Michael Speck, Eric Novak, Cheryl Dunphy, Charles Bae, Lara Jehi, Nancy Obuchowski, John Urchek P01.130 National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Common Data Element (CDE) Project: Developing General and DiseaseSpecific CDEs Stacie Trollinger, Joanne Odenkirchen, Kristy Miller, Alexandra Stout, Katherine McDowell, Lisa Hunegs, Selma Kunitz P01.131 Long-Term Community Exposure to Drift Containing Organophosphate Pesticides (OP)— Are There Neurobehavioral Effects after Three Decades? Yoram Finkelstein, Michael Aschner, Amit Ophir, Elihu Richter P01.132 Putting AAN-TTA Guidelines on Botulinum Toxin into Clinical Practice Patrick Grogan, Maria Alvarez P01.133 Increased Use of Potentially Inappropriate Medications in Patients with Parkinson’s Disease Alexis Elbaz, Henri Leleu, Jean Houssinot, Jean-Louis Mazurie, Jean-Luc Dupupet, Marcel Goldberg, Ellen Imbernon, Christophe Tzourio P01.134 Prediction Model of Parkinson’s Disease Using Antiparkinsonian Drug Claims Frédéric Moisan, Jean-Luc Dupupet, Jean-Louis Mazurie, Jean Houssinot, Marcel Goldberg, Ellen Imbernon, Christophe Tzourio, Alexis Elbaz P01.135 A Pharmacoepidemiological Evaluation of Cognitive Impairment: Prescribing Patterns of Dementia Drugs Raúl Arizaga, Luciano DiCesare, Ignacio Demey, Galeno Rojas, Valeria Baccro, Maria Barbieri, Claudia Bavec, Jorge Campos, Luciano Codevilla, Maria Fernández, Silvina Frontera, Vicoria Grisolia, Diego Sarasola P01.136 Mild Parkinsonian Signs (MPS) Are Associated with Mild Cognitive Impairment (MCI) but Not Predictive of Progression to Alzheimer’s Disease (AD) in a Door-to-Door Study of an Elderly Arab Population Simon Israeli-Korn, Magdalena Massarwa, Edna Schechtman, Amin Abuful, Rosa Strugatsky, Lindsay Farrer, Robert Friedland, Rivka Inzelberg P01.137 Dependence Levels and Risk of Nursing Home Placement or Death in Patients with Alzheimer’s Disease Daniel Murman, Mary Charlton, Robin High, Trent McLaughlin P01.138 Increasing Use of Disease Modifying Drugs for MS in Canada Dalia Rotstein, Paul O’Connor P01.139 Tolerability, Satisfaction, and Discontinuation of Antiepileptic Drugs from the National Survey of Epilepsy, Comorbidities and Health Outcomes (EPIC) George Wan, Michael Reed, Ruth Ottman P01.140 Epilepsy and Mortality in Latin America: A Systematic Review Alejandro Escalaya, Jorge Burneo P01.141 Epilepsy Care in Developing World— Should the Brazilian Surgery Program Be Replicated to Other Countries? Francisco Arruda, Paulo Ragazzo, Sebastião Melo-Souza Anterior Horn: Epidemiology P01.142 National ALS Registry: Lessons from a Pilot Project in the State of Georgia Sharon Usher, Kevin Ward, Joanne Wuu, Michael Benatar P01.143 ALS Clinical Phenotypes: A Population-Based Study in Italy Adriano Chio, Andrea Calvo, Letizia Mazzini, Edo Bottacchi, Cristina Moglia, Michele Balma, Sara Gallo, Antonio Canosa, Roberto Mutani, Gabriele Mora P01.144 Rate of Familial Amyotrophic Lateral Sclerosis— A Systematic Review and Meta-Analysis Susan Byrne, Orla Hardiman P01.145 Beneficial Vascular Risk Profile Is Associated with ALS Susceptibility Leonard van den Berg, Nadia Sutedja, Marc Huisman, Jan Veldink P01.146 Platform for Managing Distributed Biological Samples with Ad Hoc Searches from Heterogeneous Data Sources Alexander Sherman, Mathew Jaffa, Karen Wallace, Marianne Kearney, Merit Cudkowicz P01.147 KIFAP3 Has No Effect on Survival in a Population-Based Cohort of ALS Patients Andrea Calvo, Shiao-Lin Lai, Gabriele Mora, Cristina Moglia, Antonio Canosa, Gabriella Restagno, Jennifer Schymick, Mark Cookson, Sampath Arepalli, Andrew Singleton, Brian Traynor, Adriano Chio P01.148 Dysregulation of Angiogenin in Amyotrophic Lateral Sclerosis Russell McLaughlin, Julie Phukan, Agnieska Slowik, David Lynch, Will McCormack, Matthew Greenway, Simon Cronin, Jean Saunders, Barbara Tomik, Peter Andersen, Phil Jakeman, Orla Hardiman P01.149 Epidemiology of Amyotrophic Lateral Sclerosis (ALS) in the State of Ceará, Brazil Marcio Erick Vanderlei, William Alves, Ineusi Araúo, Francisco Bezerra da Cunha, Maria Bitu Alencar, Carlos Maurício Castro Costa, Francisco Gondim P01.150 Association of Blood Lead with Risk of Amyotrophic Lateral Sclerosis (ALS) Fang Fang, Lydia Kwee, Kelli Allen, Weimin Ye, David Umbach, Mary Watson, Jean Keller, Eugene Oddone, Dale Sandler, Silke Schmidt, Freya Kamel P01.151 Benign Fasciculation Syndrome: Data from a Neuromuscular Center Chafic Karam, Weiyi Gao, Daniel MacGowan, Stephen Scelsa Movement Disorders: Parkinson's Disease: Epidemiology and Quality of Life P01.152 How Does Direct Care of the Parkinson’s Disease Patient Differ between Mid- and Late-Stage Disease? Teresa Mangin, Karen Lyons, Julie Carter P01.153 Prevalence and Clinical Correlates of Micrographia in Parkinson’s Disease Aparna Wagle Shukla, Song Ounprasueth, Vickie Gray, John Schwankhaus, Walter Steve Metzer P01.154 Real-Life Driving Outcomes in Mild-Moderate Parkinson’s Disease Ergun Uc, Matthew Rizzo, Elizabeth Dastrup, Dawei Liu, Steven Anderson, Jeffrey Dawson P01.155 The Effect of Medicare Part D on Parkinson’s Disease Patients Marcy Tarrants, Terrence Shea, Michel Denarie, Jane Castelli-Haley P01.156 Is There an Increased Risk of Hip Fracture in Parkinson Disease (PD)? Analysis of the Nationwide Inpatient Sample (NIS) Richard Dubinsky, Rajid Bhattacharya, Sue Lai, Hilary Dubinsky P01.157 Relationship of Brain Organochlorine Levels with Lewy Pathology: The Honolulu-Asia Aging Study Web Ross, John Duda, Helen Petrovitch, Edo Pellizzari, Qimei He, Diane Miller, James O’Callaghan, Caroline Tanner, Robert Abbott, Joseph Noorigian, Lon White P01.158 Risk Factors for Parkinson Disease Are Different in Men and Women: A Recursive Partitioning Analysis Rodolfo Savica, Brandon Grossardt, James Bower, J. Ahlskog, Walter Rocca P01.159 Predicting Health Status in Parkinson’s Disease: What Matters Most? Claire Hinnell, Catherine Hurt, Michael Samuel, Sabine Landau, Richard Brown P01.160 Using Telemedicine to Increase Access to Specialty Care for Individuals with Movement Disorders Lisa Deuel, E. Ray Dorsey, Benjamin George, Jason Reminick, Nicholas Scoglio, Anthony Joseph, Kevin Biglan P01.161 Effect of Handedness and Side of Onset on Survival in Parkinson’s Disease Renato Munhoz, Alberto Espay, Francesca Morgante, Irene Litvan, Jie-Yuan Li, Helio Teive, Emily Dunn, Eliza Gallin P01.162 Incidence and Prevalence of Parkinson's Disease in Buenos Aires City, Argentina Diego Bauso, Juan Tartari, Carla Stefani, Juan Rojas, Giunta Diego, Edgardo Cristiano P01.163 Follow-Up of Persons with Neurologic Diseases (FOUND): Remote Follow-Up— A Practical Approach To Maintain Continuous Contact Caroline Tanner, Cheryl Meng, Ira Shoulson, Bernard Ravina, Anthony Lang, Roger Kurlan, Kenneth Marek, David Oakes, John Seibyl, Emily Flagg, Lisa Gauger, Christopher Goetz, Karl Kieburtz, Diane DiEuliis, Stanley Fahn, Robin Elliott P01.164 High Prevalence of Hypovitamininosis D Status in Patients with Early Parkinson’s Disease from the DATATOP Study Marian Evatt, Mahlon DeLong, Peggy Auinger, Michael McDermott, Vin Tangpricha, Parkinson’s Study Group-PSG DATATOP Investigators P01.165 Longitudinal Changes in UPSIT Scores Erika Driver-Dunckley, Joseph Hentz, Holly Shill, John Caviness, Marwan Sabbagh, Linda Vedders, Charles Adler Multiple Sclerosis and Related Diseases: Clinical Research/ Epidemiology P01.166 Real Life Use of Natalizumab: Results of the Austrian Nationwide Registry Karl Vass 39 Poster Session I P01.167 Assessing the Risk of Malignancy in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon beta-1a Magnhild SandbergWollheim, Gabrielle Kornmann, Margaretha Stam Moraga, Montserrat Miret, Enrica Alteri P01.168 The Oregon Multiple Sclerosis Registry (OMSR)— Preliminary Results Stanley Cohan, Chiayi Chen, Ruyun Jin, Tamela Stuchiner, Garry Grunkemeier P01.169 Rising Incidence of Multiple Sclerosis in Females along with Urbanization Theodora Panou, Dimitra Kotzamani, Irene Tzanaki, Vasileios Mastorodemos, Minas Tzagournisakis, Gregory Chlouverakis, Cleanth Spanaki, Andreas Plaitakis P01.170 Acute Leukemia in Multiple Sclerosis Patients Treated with Mitoxantrone in the Postmarketing Setting: The EMD Serono Experience Ahmad AL-Sabbagh, Daryl Dawson, Randy Bennett, Fernando Dangond P01.171 Cardiovascular Adverse Events with Mitoxantrone: Results from the Registry To Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) Study Fernando Dangond, Daryl Dawson, Jacquie Beagan, Daena Bock, Peter Chang, Yuhong Yang, Randy Bennett, Ahmad AL-Sabbagh P01.172 Increased Risk of Multiple Sclerosis among Women with Migraine in the Nurses’ Health Study II Ilya Kister, Kassandra Munger, Joseph Herbert, Alberto Ascherio P01.173 Individual Based Analysis of Disease Activity in Progressive Multiple Sclerosis Rotem Orbach, Jim Zhao, Gilmore O’Neill, Diego Cadavid P01.174 Sample Size Estimates for Trials of Neuroprotection in Acute Optic Neuritis Andrew Henderson, Daniel Altmann, Anand Trip, Patricio Schlottmann, David Garway-Heath, Gordon Plant, David Miller P01.175 Effects of Oral Fingolimod (FTY720) on Pulmonary Function Tests in Patients with Moderate Asthma Alan Slade, Craig Boulton, Olivier David, Thomas Dumortier, Robert Schmouder P01.176 Multiple Sclerosis Is Increasingly Becoming a Female Disease George Kraft, Nesanet Mitiku, Alyssa Bamer, Kara McMullen P01.177 Diagnostic Accuracy of the Emergency Department in the Multiple Sclerosis Population (Data from the Mount Sinai Resource Utilization in MS Project [RESUMS]) Megan Alcauskas, Stephen Krieger, Svenja Oynhausen, Christine Hannigan, Yadira Bencosme, Fred Lublin P01.178 Hospital-Based Prevalence and Incidence of Multiple Sclerosis in Chile Violeta Diaz, Juan Antinao, Raimundo Quezada, Jorge Barahona 40 Tuesday, April 13 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P01.179 Prevalence and Incidence of Multiple Sclerosis in Campobasso (Molise Region, Southern Italy) Paolo Bellantonio, Gerardo Iuliano, Francesca Di Biasio, Stefano Ruggieri P01.180 Multiple Sclerosis: Clinical Features and Ethnic Variation in a Multi-Ethnic Community in Northern Sudan Tag-Eldin Sokrab, Mohamed Nagib Idris, Eetidal Ibrahim, Hasab-El Rasoul Ali, Maha El Zubair, Rasha Osman, Muaz Abdallatif P01.181 Late-Onset Multiple Sclerosis: A Cross-Sectional, PopulationBased Study of 1035 Consecutive Patients Jette Frederiksen, Erica Høegh P01.182 Emergency Medical Care of Multiple Sclerosis Patients (Data from the Mount Sinai Resource Utilization in MS Project [RESUMS]) Svenja Oynhausen, Stephen Krieger, Megan Alcauskas, Christine Hannigan, Yadira Bencosme, Marcus Müller, Fred Lublin P01.183 Early Prediction of Long -Term Evolution in Multiple Sclerosis: Application of the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) Juan Rojas, Liliana Patrucco, Edgardo Cristiano P01.184 Impact of Natalizumab on Economic and Clinical Outcomes in MS Patients in the Real-World Setting Qian Cai, Hiangkiat Tan, Sonalee Agarwal, Siddhesh Kamat P01.185 Preliminary Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry Lynda Cristiano, Carmen Bozic, Mariska Kooijmans-Coutinho Multiple Sclerosis and Related Diseases: Clinical Research P01.186 Safety and Impact on Disease Outcomes of Natalizumab in Patients with Relapsing-Remitting MS in Clinical Practice Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Heinz Wiendl, Fabio Pellegrini, Shibeshih Belachew, Amy Pace, Daniel Desgrandchamps P01.187 Prognostic Factors for Conversion to Clinically Definite Multiple Sclerosis in an Italian Cohort of Subjects with Clinically Isolated Syndromes Emilio Portaccio, Vito Lepore, Bahia Hakiki, Valentina Zipoli, Razzolini Lorenzo, Giancarlo Comi, Maria Trojano, Maria Pia Amato P01.188 How Benign Is Benign Multiple Sclerosis? Jorge Correale, Isabel Peirano P01.189 Is the Multiple Sclerosis Severity Score at Initial Presentation to an MS Comprehensive Care Center a Helpful Predictor of Long-Term Outcome? Aaron Miller, Colleen Farrell, Stephen Krieger, Gary Cutter, Kaitlin Eng, Svetlana Zhovtis, Michelle Fabian, Amber Salter P01.190 Sexuality and Intimacy in MS Patients Cécile Donze, Bruno Lenne, Samantha Demaille, Patrick Hautecoeur P01.191 Sub-Clinical Multiple Sclerosis: Clinical, Neuropsychological, and MRI Follow-Up Bahia Hakiki, Benedetta Goretti, Emilio Portaccio, Valentina Zipoli, Lorenzo Razzolini, Marco Roscio, Maria Laura Stromillo, Francesca Rossi, Maria Bartolozzi, Elisa Giunti, Leonello Guidi, Nicola De Stefano, Angelo Ghezzi, Maria Pia Amato P01.192 Gender Differences in Sexual Dysfunction of a MS Population Shalom Haggiag, Guido Ricci, Giovanni Bolla, Esmeralda Quartuccio, Orietta Picconi, Maria Rosaria Fele, Claudio Gasperini, Simonetta Galgani P01.193 Should Primary Multiple Sclerosis Treatment Regimen Be Changed after a Relapse? Brian Healy, Bonnie Glanz, James Stankiewicz, Guy Buckle, Howard Weiner, Tanuja Chitnis P01.194 Motor Disability in Progressive Multiple Sclerosis Is Independently Worsened by Relapses before and after Progression Junger Tang, Nuhad Abou Zeid, Nilufer Kale, Elizabeth Atkinson, Daniel Crusan, Orhun Kantarci P01.195 One-Year Prospective Study on Headache Occurrence in Multiple Sclerosis (MS) Patients Treated with Natalizumab Dacia Dalla Libera, Bruno Colombo, Bucello Sebastiano, Pietro Annovazzi, De Feo Donatella, Martinelli Vittorio, Giancarlo Comi P01.196 Vitamin D Insufficiency in Patients with MS in Southeastern Michigan and Its Relation with Age and Race Asfa Shad, Vladimir Shvarts, Lonni Schultz, Mirela Cerghet P01.197 Utilization of Diagnostic Tests and Procedures for Treated and Untreated Patients with Multiple Sclerosis (MS) Kavita Nair, John Corboy, Nikita Patel, Kristijan Kahler, Richard Allen, Robert McQueen, Vahram Ghushchyan, Jacci Bainbridge P01.198 Prediction of Disease Progression in Primary Progressive Multiple Sclerosis Liliana Patrucco, Juan Rojas, Edgardo Cristiano P01.199 Sudden Onset Sensorineural Hearing Loss in Multiple Sclerosis: Diagnosis and Prognosis Mark Hellmann, Ronit Mosberg-Galili, Israel Steiner P01.200 Validation of an Instrumented Gait Measure, the iTUG, in Multiple Sclerosis Rebecca Spain, Fay Horak, Dennis Bourdette P01.201 Relating Structural Brain Damage and Functional Cortical Reorganization in Patients with Benign MS Antonio Giorgio, Emilio Portaccio, Maria Laura Stromillo, Silvia Marino, Valentina Zipoli, Gianfranco Siracusa, Marco Battaglini, Maria Letizia Bartolozzi, Anita Blandino, Leonello Guidi, Sandro Sorbi, Antonio Federico, Maria Pia Amato, Nicola De Stefano P01.202 Assessing Baseline Health and Functional Status of Patients with Multiple Sclerosis: A Pilot Study Using Novel Information Technology Deborah Miller, Elizabeth Ricksecker, Eric Novak, Jeffrey Cohen, Robert Fox, Jennifer Hartman, Kathleen Schwetz, Richard Rudick P01.203 Vibration Sensation Thresholds Are Associated with the Sensory Functional System Score of the EDSS in Multiple Sclerosis Scott Newsome, Joseph Wang, Peter Calabresi, Kathy Zackowski P01.204 Impact of Medication Adherence to Disease-Modifying Drugs on Severe Relapse, and Direct and Indirect Costs among Employees with Multiple Sclerosis Amy Phillips, Jasmina Ivanova, Rachel Bergman, Howard Birnbaum, Michelle Stewart, Dennis Meletiche P01.205 Health Resource Utilization in the CLARITY Study Shehzad Ali, Stuart Cook, Gavin Giovannoni, Giancarlo Comi, Steven Greenberg, Alexandre Joyeux, Kottil Rammohan, Noman Paracha, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Bruno Musch Movement Disorders in Clinical Practice P01.206 Clinical Description of Patients Diagnosed with Clinically Probable Psychogenic Movement Disorders in a Movement Disorders Clinic Laura Jawidzik, Sue Leurgans, Bichun Ouyang, Aikaterini Kompoliti P01.212 Neuropsychological Differences Between Parkinson’s Disease Patients with Very Mild and Mild Dementia Mariya Petrova, Margarita Raycheva, Latchezar Traykov P01.213 The Pupil as a Measure of Emotion-Modulated Arousal in Parkinson’s Disease Jenna Dietz, Margaret Bradley, Lizabeth Jordan, Tara Braun, Michael Okun, Dawn Bowers P01.214 Is There the Delayed Gastric Emptying of Untreated Patients with Early-Stage Parkinson’s Disease? An Analysis Using the 13C-Acetate Breath Test Yuji Tanaka, Hiroshi Nishida, Megumi Yamada, Akihiro Kohmura, Takeo Sakurai, Yuichi Hayashi, Akio Kimura, Isao Hozumi, Masahito Nagaki, Tomohiro Kato, Hisataka Moriwaki, Takashi Inuzuka P01.215 Toys and Gadgets: Construct Validity of Apathy in Parkinson Disease Beata Ferencz, Lindsey Kirsch Darrow, Milana Bogorodskaya, Michael Okun, Dawn Bowers P01.216 Hallucinations in PD: Ten-Year Prospective Longitudinal Assessment Christopher Goetz, Bichun Ouyang, Alice Negron, Glenn Stebbins P01.217 Autonomic Insufficiency in Pupillary and Cardiovascular Systems in Parkinson Disease Samay Jain, Greg Siegle, Stuart Steinhauer, J. Jennings, Stephanie Studenski, J. Greenamyre P01.207 A Brief Structured Questionnaire To Discriminate Between Psychogenic and Neurogenic Movement Disorders David Glosser, Krystle Karoscik, Tsao-Wei Liang, Daniel Kremens P01.218 Parkinson’s Disease (PD) Increases Risk for Mild Cognitive Impairment (MCI) Charles Adler, Joseph Hentz, Holly Shill, Marwan Sabbagh, Donald Connor, Virgilio Gerald Evidente, Erika Driver-Dunckley, Caroline Tanner, Walter Kukull, Linda Vedders, Sandra Jacobson, John Caviness, Thomas Beach P01.208 Psychogenic Non-Epileptic Spells and Movement Disorders in Men Greg Thaera, Katherine Noe, Cynthia Stonnington, Dona Locke, Erika DriverDunckley P01.219 Nonmotor Symptoms in Parkinson’s Disease with Special Reference to Anxiety and Depression Manmohan Mehndiratta, Rohit Garg, Sanjay Pandey P01.209 Are Disparities in Parkinsonism Diagnoses Due to Underreporting of Symptoms? Nabila Dahodwala, Andrew Siderowf, Jason Karlawish, John Duda, David Mandell P01.220 Symptoms of Depression More Than Apathy Exhibit Better Neural Reflections of Conflict Processing in Parkinson’s Disease (PD) Christopher Sozda, Laura Zahodne, Dawn Bowers, William Perlstein, Hubert Fernandez P01.210 Quantitative Gait Changes in Probable-RBD Patients in the Mayo Clinic Study of Aging Eric McDade, Bradley Boeve, Teresa Christianson, David Knopman, Rosebud Roberts, Tanis Ferman, Ronald Petersen Movement Disorders: Parkinson's Disease: Non-Motor Symptoms P01.211 Muted Emotional Enhancement of Memory in Parkinson’s Disease Lizabeth Jordan, Jenna Dietz, Alexandra Clark, Heather McKently, Michael Okun, Hubert Fernandez, Dawn Bowers Poster Session I Tuesday, April 13 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P01.221 Gray Matter Changes Associated with Early Hallucinations in Parkinson’s Disease Javier Pagonabarraga, Gisela Llebaria, Carles Soriano-Mas, Berta Pascual-Sedano, Marina López-Solà, Alexandre Gironell, Jesús Pujol, Jaime Kulisevsky P01.222 Predictors of Impulse Control Disorders in MMPI-2 in Patients Suffering from Parkinson’s Disease: A Pilot Study Katerina Farnikova, Radko Obereigneru, Petr Kanovsky P01.223 Depression and Autonomic Nerve Dysfunction in Early Parkinson’s Disease and Essential Tremor Cheng-jie Mao, Ju-ping Chen, Wei-dong Hu, Dongqin Chen, Chun-feng Liu P01.224 The Addenbrooke’s Cognitive Examination (ACE) Detects Cognitive Impairment in Advanced Parkinson Disease (PD) but Not in Early Parkinson Disease Anabel Chade, María Roca, Teresa Torralva, Ezequiel Gleichgerrcht, Nicolás Fabbro, Gonzalo Gómez Arévalo, Oscar Gershanik, Facundo Manes P01.225 The Iowa Gambling Task and Wisconsin Card Sorting Test Performance Was Modulated by the Presence/Absence of Apathy in Non-Depressed Parkinson’s Disease Patients Saül Martínez-Horta, Merce Martinez-Corral, Gisela Llebaria, Javier Pagonabarraga, Carmen GarciaSanchez, Alexandre Gironell, Ramon Fernandez-Bobadilla, Jaime Kulisevsky P01.226 Depressive Symptoms in Parkinson’s Disease May Not Uniformly Respond to Pharmacologic Treatment Logan Schneider, Laura Zahodne, LaTasha Moore, Charles Jacobson, Hubert Fernandez, Michael Okun, Ramon Rodriguez, Irene Malaty P01.227 Rhinorrhea: A Common Non-Dopaminergic Feature of Parkinson Disease Kelvin Chou, Robert Koeppe, Nicolaas Bohnen P01.228 The PARS Study: Evaluating PreClinical Parkinsonian Features in a Healthy Hyposmic Cohort Danna Jennings, Matt Stern, Andrew Siderowf, Ken Marek P01.229 Dimensions of Apathy in Parkinson Disease: Apathy Scale Revisited Daniel Kay, Lindsey KirschDarrow, Laura Zahodne, Michael Okun, Hubert Fernandez, Dawn Bowers P01.230 Divergent Trajectories of Apathy and Depression Over Two Years in Medically-Managed, Idiopathic Parkinson’s Disease Laura Zahodne, Lindsey Kirsch Darrow, Hubert Fernandez, Michael Okun, Dawn Bowers P01.231 Ropinirole Prolonged Release Improves Mood in Patients with Advanced Parkinson’s Disease Not Optimally Controlled with L-Dopa Alan Lipschitz, Carol Rockett, Katie Rolfe P01.232 Assessment of Sleep Duration and Nocturnal Awakenings in Patients with Advanced Parkinson’s Disease Treated with Adjunctive Ropinirole Prolonged Release Pablo Martinez-Martin, Katie Rolfe, Alan Lipschitz, K. Ray Chaudhuri P01.233 Prevalence of DopamineRelated Behaviour Disorders in Parkinsonian Patients Treated with Continuous Subcutaneous Infusion of Apomorphine Alexandre Eusebio, Christine Brefel-Courbon, Caroline Moreau, Christine Tranchant, David Devos, François Viallet, Tatiana Witjas, Luc Defebvre, JeanPhilippe Azulay, ADDAPO Study Group P01.234 Mood and Autonomic Symptom Clusters in Parkinson’s Disease Jennifer Goetz, Dawn Bowers, Laura Zahodne, Ramon Rodriguez, Irene Malaty, Michael Okun, Hubert Fernandez P01.235 The Quantitative Pull Test: A Method To Measure Parkinsonian Postural Instability Robert McGovern, Anne Wilson, Ashwini Rao, Paul Greene, Guy McKhann, Pietro Mazzoni Movement Disorders: Parkinson's Disease: Pathophysiology P01.236 A Comparison of Prevalence of Non-Motor Symptoms in Movement Disorders Shoaib Malik, Mustafa Siddiqui, Michael Cartwright, Ihtsham Haq P01.246 Amiloride Accelerates MPTP-Induced Cell Death in the Human Dopaminergic SHSY-5Y Cells Overexpressed with Acid-Sensitive Ion Channel (ASIC)1a Kwok-Keung Tai, Daniel Truong P01.237 Parkinson Movement Tests Performance: Feasibility and Reliability of Video Feature Extraction for Quantization of Standard Test Movements Xiao-ke Gao, Kenneth Bonnet P01.247 Role of Dynein Dysfunction in Autophagic Stress and Neurodeneration In Vivo and Vitro Involved in Parkinson’s Disease Ji-jun Shi, Zeng-lin Cai, Ya-ping Yang, Chun-feng Liu P01.238 Neurophysiological Correlates of Over-Inhibition in Apathetic Parkinson’s Disease Patients Saül Martínez-Horta, Merce Martinez-Corral, Javier Pagonabarraga, Gisela Llebaria, Carmen Garcia-Sanchez, Alexandre Gironell, Jaime Kulisevsky P01.248 Interaction of Parkinson’s Disease and Age in PreSupplementary Motor Area Cortical Thickness Thomas Jubault, Jean-Francois Gagnon, Alain Ptito, Anne Lafontaine, Sylvain Chouinard, Alan Evans, Oury Monchi P01.239 Who Responds Best to Pharmacologic Treatment of Depressive Symptoms in Parkinson’s Disease? Logan Schneider, Laura Zahodne, Akash Patel, Charles Jacobson, Michael Okun, Ramon Rodriguez, Irene Malaty, Hubert Fernandez P01.240 Effect of Rotigotine on Sleep Quality and Control of Early Morning Motor Function in Subjects with Idiopathic Parkinson’s Disease Bryan Kies, K. Ray Chaudhuri, Tim Anderson, Jennifer Fine, Dennis Hill, Monika Rudzinska, Erwin Surmann, John Whitesides, Babak Boroojerdi, Claudia Trenkwalder, on Behalf of the RECOVER Study Group P01.241 Tracking Cognitive Change on the MMSE and MoCA in Parkinson’s Disease Stephanie Lessig, Steve Edland, Jody Goldstein, Jody Corey-Bloom P01.242 Digital Voice Analysis in Patients with Parkinson’s Disease (PD) Eduard Linetsky, Alex Lossos P01.243 Binge Eating in Parkinson Disease: Prevalence, Correlates and the Contribution of Deep Brain Stimulation Laura Zahodne, Frandy Susatia, Dawn Bowers, Tiara Ong, Charles Jacobson IV, Michael Okun, Ramon Rodriguez, Irene Malaty, Kelly Foote, Hubert Fernandez P01.244 Which Nonmotor Signs Can Best Discriminate Early Parkinson’s Disease? A Case-Control Study Nico Diederich, Géraldine Hipp, Vannina Pieri, Michel Vaillant P01.245 Mood and Neurocognitive Contributions to a Dementia Screening Scale in Patients with Parkinson’s Disease Michelle Prosje, Jenna Dietz, Barry Skoblar, Catherine Price, Russell Bauer, Michael Okun, Hubert Fernandez, Dawn Bowers P01.249 Brainstem Myoinositol as a Biomarker of Disease Severity in MSA-C: A 3 T 1H-MRS Study Yuhei Takado, Hironaka Igarashi, Kenshi Terajima, Takayoshi Shimohata, Tetsutaro Ozawa, Kouichirou Okamoto, Masatoyo Nishizawa, Tsutomu Nakada P01.250 The Hematopoietic Growth Factor G-CSF Enhances Recovery in the MPTP Mouse Model of PD Juan SanchezRamos, Vasyl Sava, Amanda Rowe, Kunyu Li, Theresa Zesiewicz, Takashi Mori, Shijie Song P01.251 Ubiquitin Proteasome System Impairment Mouse Model of Parkinson’s Disease Xuping Li, Chao Li, Wenjie Xie, Joseph Jankovic, Weidong Le P01.252 Development and Evaluation of Allosteric Modulators of Dopamine D2 Receptors in PreClinical Rat Models: Implications for the Treatment of Parkinson’s Disease and Drug-Induced Dyskinesia Dipannita Basu, Niran Argintaru, Ritesh Daya, Spencer Heffernen, Bailee Dyck, Ram Mishra, Rodney Johnson P01.253 Next-Generation Sequencing Allows for Comprehensive Detection of Mitochondrial Variation in Brain Tissue Stephan Zuchner, Sion Williams, Jia Huang, Alicia Pickrell, Lloye Dillon, Carlos Moraes, Jeffery Vance P01.254 Detection of Polyglutamine Protein Oligomers in Living Cells Using Protein-Fragment Complementation Assays Masayoshi Tada, Tom Kerppola, Stuart Decker, Sokol Todi, Matthew Scaglione, Maria do Carmo Costa, Henry Paulson P01.255 Reduced Dopamine Transporter Density in the Ventral Striatum of Patients with Parkinson’s Disease and Impulse Control Disorders: A Voxel-Wise Analysis Roberto Cilia, Ji Hyun Ko, Sang Soo Cho, Thilo van Eimeren, Giorgio Marotta, Giovanna Pellecchia, Gianni Pezzoli, Angelo Antonini, Antonio Strafella 41 Poster Session I P01.256 Selective Metabotropic Glutamate Receptor 5 (mGlu5) Antagonism Reduces L-DOPA-Induced Dyskinesia in MPTP-Lesioned Primates at the Expense of Anti-Parkinsonian Benefit Tom Johnston, Susan Fox, Matthew Piggott, Jonathan Brotchie P01.265 An Open-Label, Safety and Immunogenicity Study of Myobloc® (RimabotulinumtoxinB; BoNT-B) in Patients with Cervical Dystonia— (351) Mark Lew, Robert Chinnapongse, Fernando Pagan, Sharon Reinhard, William Birmingham P01.257 Ratings of “Mental Rigidity” Reflect Cholinergic Rather Than Dopaminergic Denervation in Parkinson Disease Kelvin Chou, Martijn Muller, Robert Koeppe, Michael Kilbourn, Kirk Frey, Roger Albin, Nicolaas Bohnen P01.266 A Seven-Year Open-Label Safety and Immunogenicity Study of Myobloc® (RimabotulinumtoxinB; BoNT-B) in Patients with Cervical Dystonia— (401CD-NA) Robert Chinnapongse, Mark Lew, Fernando Pagan, Sharon Reinhard, William Birmingham P01.258 Critical Alterations in the Basal Ganglia Pathophysiology in Parkinson’s Disease. A Computational Model Approach Georgios Tsirogiannis, Georgios Tagaris, Clementine Karageorgiou, Konstantina Nikita P01.259 Glycine Receptor Antibodies in Immune-Mediated Movement Disorders: Progressive Encephalomyelitis with Rigidity and Myoclonus, OpsoclonusMyoclonus Syndrome, and Ocular Flutter Syndrome Takahiro Iizuka, Yoshiaki Urano, Saori Miyakawa, Junichi Hamada, Maria Leite, Angela Vincent, Fumihiko Sakai, Hideki Mochizuki P01.260 Two Parkinson’s Disease Patients with α-Synuclein Gene Duplication and Rapid Cognitive Decline Chae Won Shin, Sung Sup Park, Beom Seok Jeon P01.261 Evaluation of SNCA CpG Island Methylation Level in Post-Mortem Brain of Parkinson’s Disease and Dementia with Lewy Bodies Lumine Matsumoto, Atsushi Iwata, Hisatomo Kowa, Yu Nagashima, Hiroshi Takuma, Akira Tamaoka, Hiroshi Kurisaki, Shoji Tsuji Movement Disorders: Dystonia I P01.262 CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) - A Multicenter, Observational Study of Repeated OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients— Preliminary Baseline Data Joseph Jankovic, Charles Adler, David Charles, Cynthia Comella, Mark Stacy, Matthias Kurth, Mitchell Brin, Lisa Misell, Lee Boo P01.263 Why Do Cervical Dystonia Patients Leave Academic Movement Disorders Clinics? Chandler Gill, Neil Manus, Michael Pelster, Jason Cook, Wallace Title, P. Charles P01.264 An Open-Label Safety and Immunogenicity Study of NeuroBloc® (MYOBLOC®; RimabotulinumtoxinB; BoNT-B) in Patients with Cervical Dystonia (CD) (401CD-EU) Sharon Reinhard, Fernando Pagan, William Birmingham, Mark Lew, Robert Chinnapongse, Joaquim Ferreira Integrated Neuroscience Session: Proteins, Genes, Neurodegeneration, and the Clinical Presentations Tuesday, April 13 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P01.267 Quantification of Cervical Dystonia and Response to Botulinum Toxin Using Electrical Impedance Myography Codrin Lungu, Andrew Tarulli, Daniel Tarsy, Phillip Mongiovi, Veronica VanderHorst, Seward Rutkove P01.268 Efficacy of NT 201 (Botulinum Neurotoxin Type A Free from Complexing Proteins) in the Treatment of Patients with Focal Dystonia Susanne Grafe, Angelika Hanschmann Movement Disorders: Dystonia II and Tardive Dyskinesia P01.269 Immunogenicity Analysis from a Randomized, Double-Blind Study To Compare the Efficacy and Safety of NeuroBloc® (Myobloc/ RimabotulinumtoxinB;BoNT-B) with OnabotulinumtoxinA (Botox®; BoNT-A) in Patients with Cervical Dystonia (CD) Who Have Never Previously Received a Botulinum Toxin Product (402CDEU) William Birmingham, Robert Chinnapongse, Mark Lew, Fernando Pagan, Sharon Reinhard, Joaquim Ferreira P01.270 Safety and Efficacy of Repeated NT 201 (Botulinum Neurotoxin Type A Free from Complexing Proteins) Injections of Patients with Cervical Dystonia: A First Long-Term Safety Analysis Susanne Grafe, Angelika Hanschmann P01.271 Presence of Neutralizing Antibodies in a Patient Population with Cervical Dystonia Prior to Clinical Study Entry Petra Minnasch P01.272 The Utility of Visual, Tactile, and Mixed Tasks in the Determination of Temporal Discrimination Thresholds in Adult-Onset Primary Torsion Dystonia David Bradley, Robert Whelan, Nicola Mulrooney, Richard Walsh, Richard Reilly, Siobhan Hutchinson, Fiona Molloy, Michael Hutchinson P01.273 Clinical Subtypes of Disproportionate Anterocollis in Parkinsonian Syndromes Gonzalo Revuelta, Stewart Factor P01.274 Seroconversion in Cervical Dystonia Patients After Treatment with Abobotulinumtoxin A Chandra Coleman, Jean Hubble, Joseph Schwab, Jean-Luc Beffy, Philippe Picaut, Carles Morte P01.275 Efficacy of AbobotulinumtoxinA for the Treatment of Cervical Dystonia: Analysis by Patient Subpopulation Jean Hubble, Chandra Coleman, Joseph Schwab, Jean-Luc Beffy, Philippe Picaut P01.276 CD-PROBE (Cervical Dystonia Patient Registry for Observation of BOTOX® Efficacy) - A Multicenter, Observational Study of OnabotulinumtoxinA Injections in Cervical Dystonia (CD) Patients–Interim Patient Reported Outcome Data Joseph Jankovic, Charles Adler, David Charles, Cynthia Comella, Mark Stacy, Matthias Kurth, Mitchell Brin, Lisa Misell, Lee Boo P01.277 The Blink Reflex Recovery Cycle Differs Between Patients with Benign Essential Blepharospasm and Patients with Atypical (Presumed Psychogenic) Blepharospasm Mark Edwards, Petra Schwingenschuh, Petra Katschnig, James Teo, Laxmi Korlipara, John Rothwell, Kailash Bhatia P01.278 Asian Over Representation Among Patients with Hemifacial Spasm Compared to Cranial Dystonia Yuncheng Wu, Anthony Davidson, Maosheng Huang, Tianhong Pan, Joseph Jankovic P01.279 Swallowing Induced Laryngo-Pharyngeal Movement— A New Variant of Focal PKD? Hrishikesh Kumar, Stephanie Somers, Mandar Jog P01.280 Curcumin Prevents the Development of Vacuous Chewing Movements in a Preclinical Animal Model of Human Tardive Dyskinesia and Proteomic Array Reveals a Possible Role of Target Proteins in the Mechanism of Action Christal Sookram, Mattea Tan, Ritesh Daya, Spencer Heffernan, Bailee Dyck, Ram Mishra Muscle Disease/Neuromuscular Junction: Neuromuscular Junction Disorders P01.281 Increasing Incidence of Seropositive Myasthenia Gravis in British Columbia, Canada: A 25- Year, Population -Based Study Zahra Pakzad, Tariq Aziz, Joel Oger P01.282 Cardiomyopathy in Myasthenia Gravis: The Frequency and Characteristics Jun Tsugawa, Yoshio Tsuboi, Hirosato Inoue, Shigeaki Suzuki, Tatsuo Yamada P01.283 Clinical Course of Patients with Myasthenia Gravis in a Regional Hospital in Hong Kong: A Retrospective Review Sze Wai Yeung, Chi Nam Lee, Richard Li, Sonny F. K. Hon, Man Auyeung, Chun Ming Cheung, Tak Hong Tsoi P01.285 Striated Muscle Antibodies: Clinical Features and Utility in Myasthenia Gravis Hugh McMillan, Jayashri Srinivasan, Gyorgy Abel, Royden Jones P01.286 MuSK-Antibody Positive Myasthenia Gravis and Their Clinical Features in North India Hamid Suhail, Vivekanandhan Subbiah, Sumit Singh, Madhuri Behari P01.287 Muscle Specific Tyrosine Kinase Antibody Positivity: Prevalence and Clinical Characteristics in Western Canada Jennifer Brealy, Tariq Aziz, Sara Zangeneh, Joel Oger P01.288 Novel Acetylcholinesterase Inhibitors in Myasthenia Patients: FourYear Follow-Up Carlos Navarrete, Vera Bril, Mireya Balart P01.289 Benefits from SustainedRelease Pyridostigmine Bromide in Myasthenia Gravis. Results of a Prospective Multicenter Open-Label Trial Jorn Sieb, Wolfgang Köhler P01.290 Rituximab in Generalized Myasthenia Gravis Samiullah Kundi, Mazen Dimachkie, Mamatha Pasnoor, April McVey, Laura Herbelin, Richard Barohn P01.291 Response of Patients with Refractory Myasthenia Gravis Treated with Ritxuimab Richard Nowak, Nazlee Zebardast, Jonathan Goldstein P01.292 Multi-Target Treatment for Refractory Myasthenia Gravis Claudio Mazia, Valeria Salutto P01.293 Trends in Outcomes and Hospitalization Cost of Adult Patients with Botulism in the United States Bilal Saulat, Lubna Mehyar, Hafiz Khan, Rania Abou Elenein, Nizar Souayah Tuesday, April 13 | 1:00 p.m.–5:00 p.m. Coordinators: Bradley Boeve, MD and Neill Graff-Radford, MD, FAAN Invited Speaker Session* / 1:00 p.m.–3:00 p.m. / Reception Hall 104A–D 1:00 p.m.–1:30 p.m. Theme 1: Frontotemporal Dementia and Parkinson’s Disease; Corticobasal Syndrome and Progressive Supranuclear Palsy and Primary Progressive Aphasia Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD 1:30 p.m.–2:00 p.m. Theme 2: ALS Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD 2:00 p.m.–2:30 p.m. Theme 3: Alzheimer’s Disease Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD 2:30 pm.–3:00 p.m. Theme 4: Lewy Body Disease, Parkinson’s Disease, and Multiple System Atrophy Bradley Boeve, MD, Neill Graff-Radford, MD, FAAN, Ian Mackenzie, MD, FRCP, and Rosa Rademakers, PhD Poster Session / 3:00 p.m.–3:30 p.m. / Reception Hall 104A–D IN5-1.001 Gerstmann-SträusslerScheinker Disease Due to a Novel Structural Mutation in the Prion Protein Gene Claire Hinnell, Michael Coulthart, Gerard Jansen, Neil Cashman, Julie Lauzon, Arthur Clark, Fiona Costello, Christopher White, Rajiv Midha, Samuel Wiebe, Sarah Furtado IN5-1.002 Basophilic Inclusion Body Disease (BIBD) Is a FUSopathy David Munoz, Manuela Neumann, Hirofumi Kusaka, Osamu Yokota, Kenji Ishihara, Seishi Terada, Shigetoshi Kuroda, Ian Mackenzie IN5-1.003 Clinical Features in Corticobasal Syndrome Predictive of Underlying Alpha-Synuclein Pathology Rachel Gross, Sarah Kranick, John Duda, John Trojanowski, Murray Grossman IN5-1.004 Proteomic Analysis of Cerebrospinal Fluid in Presymptomatic and Affected Persons Carrying Familial Alzheimer’s Disease Mutations John Ringman, Howard Schulman, Christopher Becker, Ted Jones, Yuchen Bai, Fred Immermann, Gregory Cole, Karen Gylys, Daniel Geschwind, Jeffrey Cummings, Hong Wan IN5-1.005 Clinically Useful Plasma Biomarkers in ALS Stacey Clardy, Ryan Mitchell, Helen Stephens, Zachary Simmons, James Connor IN5-1.006 Different Roles of the Proteasome and Autophagy Pathways in the Degradation of α-Synuclein Yaping Yang, Fang Yang, Cheng-jie Mao, Zeng-lin Cai, Jin-zhong Huang, Chunfeng Liu IN5-1.007 Uncommon Clinical Phenotype in Italian Patients with FUS/TLS Mutations Nicola Ticozzi, Cinzia Gellera, Stefano Messina, Luca Maderna, Claudia Morelli, Barbara Poletti, Antonia Ratti, Franco Taroni, Robert Brown, John Landers, Vincenzo Silani IN5-1.008 The Plasma Communicome in Persons at Various Levels of Genetic Risk for Alzheimer’s Disease John Ringman, Daniel Geschwind, Karen Gylys, Cathy Lee, David Elashoff, Jeffrey Cummings, Greg Cole IN5-1.009 Common Genetic Variants at 7p21 Show Strong Association with Frontotemporal Lobar Degeneration with TDP-43 Inclusions Alice ChenPlotkin, Vivianna Van Deerlin, Patrick Sleiman, Maria Martinez-Lage, Li-San Wang, Gerard Schellenberg, Hakon Hakonarson, John Trojanowski, Virginia Lee, International FTLD Collaboration IN5-1.010 TAR DNA-Binding Protein-43 (TDP-43) Aggregation in Von Economo Neurons in Early Behavioral Variant Frontotemporal Dementia Stephanie Gaus, Druthi Ghanta, Manu Sidhu, Bruce Miller, Stephen DeArmond, William Seeley Platform Session / 3:30 p.m.–5:00 p.m. / Reception Hall 104A–D 3:30 p.m. IN5-2.001 Relation of the Alzheimer’s Disesase Susceptibility Allele at the CR1 Locus to Cognitive Decline and Alzheimer’s Disease Neuropathology in Older Persons Philip De Jager, Lori Chibnik, Neelum Aggarwal, Joshua Shulman, Julie Schneider, Denis Evans, David Bennett 3:45 p.m. IN5-2.002 A Non-Coding Penta-Nucleotide Repeat Insertion Containing (TGGAA) n Is Associated with Spinocerebellar Ataxia Type 31 (SCA31) Nozomu Sato, Takeshi Amino, Kinya Ishikawa, Shuichi Asakawa, Taro Ishiguro, Makoto Takahashi, Nobuyoshi Shimizu, Shoji Tsuji, Hidehiro Mizusawa 4:00 p.m. IN5-2.003 Proteomic Biomarker Pattern Analysis in Cerebrospinal Fluid (CSF) from Patients with Amyotrophic Lateral Sclerosis (ALS) Nils von Neuhoff, Thomas Wolf, Katja Kollewe, Peter Bewerunge, Tonio Oumeraci, Boris Neumann, Benedict Brors, Marc Zapatka, Ulrich Wurster, Brigitte Schlegelberger, Reinhard Dengler, Susanne Petri 4:15 p.m. IN5-2.004 CSF Biomarkers for Alzheimer’s Disease and Frontotemporal Lobar Degeneration William Hu, Alice Chen-Plotkin, Steven Arnold, Murray Grossman, Christopher Clark, Les Shaw, Leo McCluskey, Lauren Elman, Jason Karlawish, Howard Hurtig, Andrew Siderowf, Holly Soares, Virginia Lee, John Trojanowski 4:30 p.m. IN5-2.005 Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration Alice ChenPlotkin, Patrick Sleiman, William Hu, Maria Martinez-Lage, Robert Greene, Shaoxu Bing, Murray Grossman, John Trojanowski, Virginia Lee, Vivianna Van Deerlin, International FTLD Collaboration 4:45 p.m. IN5-2.006 TDP-43 Mutant Transgenic Mice Develop Features of ALS and Frontotemporal Lobar Degeneration Iga Wegorzewska, Shaughn Bell, Nigel Cairns, Timothy Miller, Robert Baloh P01.284 Differences in Clinical and Immunological Profiles Between Early and Late-Onset Myasthenia Gravis in Japan Shigeaki Suzuki, Kimiaki Utsugisawa, Yuriko Nagane, Takashi Satoh, Masataka Kuwana, Norihiro Suzuki *Current as of February 1, 2010 42 43 Scientific Sessions S01 Multiple Sclerosis: Clinical Research I Theatre 102 Constitution Hall 106 1:45 p.m. S01.001 Polysomnographic Investigation of Frequency of Sleep Disorders in Consecutive Unselected Fatigued and Non-Fatigued Multiple Sclerosis Patients Christian Veauthier, Helena Radbruch, Gunnar Gäde, Carsten Pfüller, Jan Dörr, Judith Bellmann-Strobel, Jörn Sieb, Frauke Zipp, Paul Friedemann 1:45 p.m. S02.001 Physical Activity and Risk of Stroke. The Framingham Study Aleksandra Pikula, Philip Wolf, Alexa Beiser, Jayandra Himali, Margaret KellyHayes, Carlos Kase, Ramachandran Vasan, Sudha Seshadri 2:00 p.m. S01.002 Color Vision and High-Resolution OCT Are Highly Sensitive for Detecting Anterior Visual Pathway Abnormalities in Multiple Sclerosis Ari Green, Jeffrey Gelfand, Ami Cuneo, Pablo Villoslada 2:15 p.m. S01.003 Characteristics of Walking Speed Improvement Observed in Three WellControlled Studies of Sustained Release Fampridine 10 mg Bid in Patients with Multiple Sclerosis Andrew Goodman, Ted Brown, Keith Edwards, Randall Schapiro, Lawrence Marinucci, Ron Cohen, Andrew Blight 2:30 p.m. S01.004 Use of Natalizumab in Pediatric MS Patients: A Pediatric Network Experience E. Ann Yeh, Lauren Krupp, Nancy Kuntz, Jayne Ness, Dorothee Chabas-Chanezon, Tanuja Chitnis, Anita Belman, Moses Rodriguez, Emmanuelle Waubant, Mark Gorman, Khurram Bashir, Network Pediatric MS Centers of Excellence, Bianca Weinstock-Guttman 2:45 p.m. S01.005 Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in RelapsingRemitting Multiple Sclerosis Anthony Traboulsee, Bernard Uitdehaag, Ludwig Kappos, Magnhild SandbergWollheim, David Li, Peter Jongen, Cris Constantinescu, Elisabetta Verdun, Peter Cornelisse 3:00 p.m. S01.006 Clinical and NeuroImaging Predictors of Responsiveness to Immunomodulating Therapies in a Large Single-Center Cohort of Patients with RelapsingRemitting Multiple Sclerosis (RRMS) Giancarlo Comi, Marzia Romeo, Fiilippo Martinelli Boneschi, Vittorio Martinelli, Giuseppe Liberatore, Mariaemma Rodegher 3:15 p.m. S01.007 Mitoxantrone Treatment in Neuromyelitis Optica (NMO) Masaru Matsui, Kiyoe Ohta, Keiko Tanaka, Masayuki Tahara, Mitsuhiro Ohta, Masami Tanaka 3:30 p.m. S01.008 Interim Analysis of Open-Label Extension Studies of Sustained Release Fampridine in Patients with Multiple Sclerosis Andrew Goodman, Ted Brown, Keith Edwards, Randall Schapiro, Lawrence Marinucci, Ron Cohen, Andrew Blight, MS-F203, MS-F204, MSF203EXT, and MS-F204EXT Study 44 S02 Cerebrovascular Disease: Stroke Epidemiology I 2:00 p.m. S02.002 Impact of Healthy Lifestyle Practices on Mortality after Stroke in the United States Amytis Towfighi, Bruce Ovbiagele 2:15 p.m. S02.003 Serum Levels of Soluble Receptor for Advanced Glycation End-Products Are Associated with Subclinical Cerebrovascular Disease Among Hispanics and Blacks Barry Hudson, Yeseon Park Moon, Anastasia Kalea, Minesh Khatri, Chensy Marquez, Ann Marie Schmidt, Myunghee Paik, Ralph Sacco, Charles DeCarli, Clinton Wright, Mitchell Elkind Tuesday, April 13 | 1:45 p.m.–3:45 p.m. Metro Toronto Convention Centre S03 Movement Disorders: Epidemiology of Parkinson's Disease Room 718AB 1:45 p.m. Presentation of the Movement Disorders Research Award Recipient: David Eidelberg, MD Manhasset, NY 2:15 p.m. S03.003 Use of Non-Steroidal AntiInflammatory Drugs and Risk of Parkinson’s Disease: A Prospective Study and MetaAnalysis Xiang Gao, Honglei Chen, Michael Schwarzschild, Alberto Ascherio 2:30 p.m. S03.004 Late-Life Hemoglobin and the Incidence of Parkinson’s Disease: The Honolulu-Asia Aging Study Helen Petrovitch, Robert Abbott, Webster Ross, Caroline Tanner, Julie Andersen, Kamal Masaki, Lon White 2:30 p.m. S02.004 Disparities in Stroke Type and Vascular Risk Factors Between Two Hispanics Populations in Miami and Mexico City Antonio Arauz, Jose Romano, Juan Manuel Marquez, Carol Artigas, Sebastian Koch, Tatjana Rundek, Channui Dong, Diogo Haussen, Michael Katsnelson, Clinton Wright, Ralph Sacco 2:45 p.m. S03.005 Parkinson’s Disease Risk Is Increased in Discordant Twins Exposed to Specific Solvents Samuel Goldman, Caroline Tanner, Cheryl Meng, Grace Bhudhikanok, Patricia Quinlan, Kathleen Comyns, Monica Korell, Benjamin Priestley, J. William Langston 2:45 p.m. S02.005 New Ischemic Lesions on Magnetic Resonance Imaging After Endovascular Procedures in Patients with Cerebrovascular Diseases: A Systematic Review Yousef Mohammad, Mushtaq Qureshi, Laura Vaught, M. Fareed Suri, Marwan Kattan, Abhijin Das, Adnan Qureshi 3:00 p.m. S03.006 Reduced Sympathetically Induced Heart Rate Variability During Sleep in Parkinson’s Disease: A Polysomnographic Case-Control Study Nicolas Sauvageot, Michel Vaillant, Nico Diederich 3:00 p.m. S02.006 Stroke-Associated Pneumonia (SAP): Risk Factors for Its Development and Affect on Stroke Outcome Olga Finlayson, Moira Kapral, Ruth Hall, Eriola Asllani, Daniel Selchen, Gustavo Saposnik 3:15 p.m. S02.007 Are Certified Stroke Centers Adequately Placed To Meet the Population Needs of United States? Gabriela Vazquez, Silvina Tornelli, Michael Tibbs, Jill Novitzke, M. Fareed Suri, Adnan Qureshi 3:30 p.m. S02.008 Immediate Effect of New Jersey State Stroke Center Designation Act on Quality Stroke Coverage for New Jersey: A Model for Other States? Jawad Kirmani, Syed Abbas, Mohammad Moussavi, Spozhmy Panazi, Florence Chukwuneke, Martin Gizzi 3:15 p.m. S03.007 What Predicts Mortality in Parkinson’s Disease? A Long-Term Population Based Study Elin Forsaa, Jan Petter Larsen, Tore Wentzel-Larsen, Guido Alves 3:30 p.m. S03.008 Prevalence of Parkinson Disease in Patients and Obligate Carriers of Gaucher Disease Joanna Becker, Gregory Pastores, Marissa Ferraris, Jerome Graber, E. Kolodny, Swati Sathe S04 Sleep Disorders Constitution Hall 107 1:45 p.m. Presentation of the Sleep Science Award Recipient: Arthur Walters, MD Nashville, TN 2:00 p.m. S04.002 Plasma Biomarkers of Inflammation and Endothelial Dysfunction in Acute Stroke Patients with and without Sleep Apnea Alexander Kunz, Jörg Kraus, Patrick Oschmann, Stefanie Berger, Kerstin Retzlaff, Rainer Dziewas 2:15 p.m. S04.003 Relationship of Day/Night and Sleep/ Wake Patterns to Seizure Semiology and Epilepsy Localization Marcin Zarowski, Tobias Loddenkemper, Martina Vendrame, Andreas Alexopoulos, Sanjeev Kothare 2:30 p.m. S04.004 Analysis of Subjective Sleepiness in Patients with Multiple System Atrophy Takayoshi Shimohata, Hideaki Nakayama, Masahiko Tomita, Tetsutaro Ozawa, Masatoyo Nishizawa 2:45 p.m. S04.005 Cardiac Autonomic Dysfunction in Idiopathic REM Sleep Behavior Disorder Ronald Postuma, Paola Lanfranchi, Helene Blais, Jean-Francois Gagnon, Jacques Montplaisir 3:00 p.m. S04.006 Long-Term Safety and Efficacy of Rotigotine in Patients with Idiopathic RLS: Five-Year Results from a Prospective Multinational Open-Label Follow-Up Study Birgit Hogl, Claudia Trenkwalder, Diego Garcia-Borreguero, Ralf Kohnen, Werner Poewe, Karin Stiasny-Kolster, Lars Bauer, Andreas Fichtner, Erwin Schollmayer, Wolgang Oertel, for the SP710 study group 3:15 p.m. S04.007 Hypoxia Inducible Factor Pathway Activation in Restless Legs Syndrome Patients Stephanie Patton, Padmavathi Ponnuru, Amanda Snyder, Gerald Podskalny, James Connor 3:30 p.m. S04.008 Postmortem and Imaging Based Analyses Reveal CNS Hypomyelination in Restless Legs Syndrome James Connor, Padmavathi Ponnuru, Byeong-Yeul Lee, Qing Yang, Gerald Podskalny, Shoaib Alam, Richard Allen, Christopher Earley S05 Epilepsy: Clinical Epilepsy S06 Neuromuscular Junction and Muscle Disorders S07 Headache I Room 701A Constitution Hall 105 Room 701B 1:45 p.m. S05.001 Depiction of Seizure First Aid Managment in Medical Television Dramas Andrew Moeller, Jeremy Moeller, Susan Rahey, R. Mark Sadler 1:45 p.m. S06.001 Muscle Pathology in Biopsy of MuSK-Ab Positive Myasthenic Patients Shows Mitochondrial Abnormalities Corrado Angelini, Giovanna Cenacchi, Elisa Albertini, Marina Fanin, Sara Martignago 1:45 p.m. S07.001 Prevalence and Epidemiologic Profile for Adolescent Chronic Migraine (CM): Results of a U.S. National Survey of Chronic Daily Headache Richard Lipton, Aubrey Manack, Judith Ricci, Elsbeth Chee, Catherine Turkel, Paul Winner 2:00 p.m. S05.002 ‘WESTCOPS’—A Scoring System To Differentiate NonEpileptic from Epileptic Motor Seizures Kanishk Makhija, Arun Antony, Lina Lander, Sanjay Singh 2:15 p.m. S05.003 Serotonin Reuptake Inhibitors Reduce Ictal Hypoxemia in Medically Refractory Partial Epilepsy Lisa Bateman, ChinShang Li, Tzu-Chun Lin, Masud Seyal 2:30 p.m. S05.004 Autoimmune Epilepsy: A Case Series from the EMU Matthew Hoerth, Katherine Noe, Joseph Sirven, Dean Wingerchuk, Jonathan Carter, Joseph Drazkowski 2:45 p.m. S05.005 Catamenial Epilepsy and Mood in Hispanic Women with Epilepsy Adrienne Keener, Laura Kalayjian, Kristen Fowler, Andrew Herzog, the NIH Progesterone Trial Study Group 3:00 p.m. S05.006 Low Bone Mineral Density but Normal Microarchitecture in Premenopausal Women with Epilepsy Alison Pack, Adi Cohen, Robert Pelgrift, Chiyuan Zhang, Don McMahon, Elizabeth Shane 3:15 p.m. S05.007 Epilepsy: When To Think Surgery! Nathalie Jette, José Téllez Zenteno, Walter Hader, Sophie Macrodimitris, Jorge Burneo, Fred Andermann, Hude Quan, Elisabeth Sherman, Lorie Hamiwka, Amy Metcalfe, Lizbeth Hernandez-Ronquillo, Peter Camfield, Lionel Carmant, Elaine Wirrell, Donald Gross, Jeptha Davenport, Richard Huntsman, R. Mark Sadler, Churl-Su Kwon, Carter Snead, David Steven, Matt Wheatley, Jean-Pierre Farmer, Samuel Wiebe 3:30 p.m. S05.008 Iatrogenic Pathological Findings Related to Invasive EEG Monitoring for Medically Intractable Epilepsy (MIE) Joanna Fong, William Bingaman, Andreas Alexopoulos, Richard Prayson Scientific Sessions Tuesday, April 13 | 1:45 p.m.–3:45 p.m. 2:00 p.m. S06.002 Congenital Myasthenic Syndrome (CMS) Caused by Mutations in Choline Acetyltransferase (CHAT). Clinical Features, Genetic Analysis and Expression Studies in 11 Patients Xin-Ming Shen, Joan Brengman, Gyula Acsadi, Thomas Crawford, Susan Iannaccone, Emin Karaca, Chaouki Khoury, Jean Mah, Simon Edvardson, David Rodgers, Andrew Engel 2:15 p.m. S06.003 Fatal Muscular Dystrophy, Congenital Myasthenic Syndrome (CMS), and Epidermolysis Bullosa Simplex (EBS) Due to Plectin Deficiency Vern Juel, Lisa HobsonWebb, Edward Smith, David Stickler, Duygu Selcen, Andrew Engel 2:30 p.m. S06.004 Using Anthropometric Measures To Monitor Efficacy of Pulse Intravenous Methylprednisolone Versus Oral Corticosteroid Therapy in the Treatment of Juvenile Dermatomyositis Asim Haque, Linda Ray, Veda Vedanarayanan 2:45 p.m. S06.005 Mexiletine Trial in Non-Dystrophic Myotonias (NDM): Feasibility of the Interactive Voice Response (IVR) as a Patient-Reported Outcome Measure Yunxia Wang, Brian Bundy, Laura Herbelin, Mazen Dimachkie, Richard Barohn, The CINCH Study Group 3:00 p.m. S06.006 Patient Identification of the HighestImpact Symptoms and Issues in Facioscapulohumeral Muscular Dystrophy (FSHD) Nicholas Johnson, Nancy Chin, Robert Holloway, Rabi Tawil, Richard Moxley, Christine Quinn, Barbara Vickrey, Chad Heatwole 3:15 p.m. S06.007 A Cooperative International Neuromuscular Research Group (CINRG) Study of the Relationship Between Impairment, Activity Limitation, Participation, and Quality of Life in Persons with Confirmed Dystrophinopathies: One-Year Follow-Up of Skeletal Muscle Strength and Timed Motor Performance Erik Henricson, Craig McDonald, Richard Abresch, Jay Han, Robert Leshner, Eric Hoffman, Diana Escolar, Avital Cnaan, Fengming Hu, Angela Zimmerman, Tina Duong, Julaine Florence, Adrienne Arrieta, CINRG Investigators 3:30 p.m. S06.008 Transient Expression of a Therapeutic Dystrophin Transgene in Duchenne Muscular Dystrophy Revealed by T Cell Mediated Immunity Jerry Mendell, Katherine Campbell, Louise Rodino-Klapac, Zarife Sahenk, Christopher Shilling, Sarah Lewis, Dawn Bowles, Steven Gray, Chengwen Li, Gloria Galloway, Vinod Malik, Brian Coley, Reed Clark, Juan Li, Xiao Xiao , Jade Samulski, Scott McPhee, R. Samulski, Christopher Walker 2:00 p.m. S07.002 Migraine and White Matter Hyperintensity Volume: The EVA MRI Cohort Tobias Kurth, Shajahal Mohamed, Pauline Maillard, Bernard Mazoyer, Carole Dufouil, Christophe Tzourio 2:15 p.m. S07.003 Hypothalamic Volume Decrease in Hypnic Headache Dagny Holle, Steffen Naegel, Sarah Krebs, Charly Gaul, Elke Gizewski, Zaza Katsarava, Mark Obermann 2:30 p.m. S07.004 Cortical Spreading Depression Activates Trigeminovascular Neurons in Lamina I of the Spinal Trigeminal Nucleus Xi Chun Zhang, Dan Levy, Rami Burstein 2:45 p.m. S07.005 Frequent Headaches in the Preadolescent Pediatric Population—A PopulationBased Study Marco Arruda, Vincenzo Guidetti, Federica Galli, Regina Albuquerque, Marcelo Bigal 3:00 p.m. S07.006 Voxel-Wise Assessment of White and Gray Matter Damage in Patients with Migraine and Different Disease Phenotypes: A Combined TBSS and VBM Study Martina Absinta, Maria Rocca, Bruno Colombo, Andrea Falini, Giancarlo Comi, Massimo Filippi 3:15 p.m. S07.007 Depression: A Risk Factor for Migraine Chronification: Results from the American Migraine Prevalence and Prevention (AMPP) Study Sait Ashina, Dawn Buse, Aubrey Manack, Daniel Serrano, Morris Maizels, Catherine Turkel, Richard Lipton 3:30 p.m. S07.008 The Plasmatic Vascular Endothelial Growth Factor Level Is Decreased in Migraine Patients Maria Toriello, Agustin Oterino, Jesus Castillo, Ana ALonso-Arranz, Montserrat Gago, Julio Pascual S08 Behavioral Neurology: From Genetics to Brain Function to Behavior S09 History of Neurology Room 714A Room 717AB 1:45 p.m. Presentation of the Norman Geschwind Prize in Behavioral Neurology Recipient: Keith Josephs, MD, MST, MS Rochester, MN 2:00 p.m. S08.002 Changes in Gray and White Matter Perfusion During Retrieval of Spatial Memory in the Freely Moving Rat S. Stewart, J. Yang, T. Givard, S. Frances, Z. Wang, J. M. Maarek, D. Holschneider 2:15 p.m. S08.003 Is Motor System Long-Term Potentiation Normal in Tourette Syndrome? Steve Wu, Kelly Isaacs, Donald Gilbert 2:30 p.m. S08.004 Catechol-O-Methyl Transferase (COMT) Gene Polymorphism Associated with Hallucinations and Interpersonal Coldness Carmela Tartaglia, Anna Karydas, Tricia See, Adam Boxer, Bruce Miller, Katherine Rankin 2:45 p.m. S08.005 Depression Among Carriers and NonCarriers of Parkin Mutations Anil Srivastava, Ming Tang, Elan Louis, Helen Mejia-Santana, Ruth Ottman, Llency Rosado, Karen Marder, Cynthia Comella, Susan Bressman, Martha Nance, Andrew Siderowf, Danna Jennings, Amy Colcher, Danna Jennings, William Scott, Cheryl Waters, Lucien Cote, Howard Andrews, Caroline Tanner, Susan Mickel, Stanley Fahn, Barbara Ross, Steven Frucht, Miguel Verbitsky, Blair Ford, Sergey Kisselev, Roy Alcalay, Michael Rezak, Kevin Novak, Greg Neils, Joseph Friedman, Ronald Pfeiffer, Laura Marsh, Bradley Hiner, Lorraine Clark, Elise Caccappolo 3:00 p.m. S08.006 Depression/Dysphoria and Anxiety Are Early Symptoms in Dementia with Lewy Bodies Carolyn Orr, Bradley Boeve, Tanis Ferman, Glenn Smith, Yonas Geda, J. Ahlskog, David Knopman 3:15 p.m. S08.007 Persistent Neuropsychiatric Symptoms Predict Worse Cognitive and Functional Outcome in Alzheimer’s Disease Stephane Poulin, Bradford Dickerson, Alzheimer’s Disease Neuroimaging Initiative 3:30 p.m. S08.008 Pre-Frontal Neural Dysfunction to Emotional Stimuli: An fMRI Study of Executive Function in Non-Demented ALS Patients Martin Goldstein, Michael Silverman, Dale Lange, Mark Sivak, Ji-yeoun Yoo, Thomas Naidich 1:45 p.m. Presentation of the Lawrence C. McHenry Award: An Award for the History of Neurology Recipient: Elan Louis, MD, MS New York, NY 2:15 p.m. S09.003 Unethical Person-to-Person Transmission Experiments in Subjects with Neurological Vitamin Deficiency Disorders Douglas Lanska 2:30 p.m. S09.004 Shaking Up the Salpêtriíre: JeanMartin Charcot and Mercury Intoxications Christopher Goetz 2:45 p.m. S09.005 William W. Keen’s Contributions to Treatment of Traumatic Neuropathy Edward Fine, Raya Wehbeh 3:00 p.m. S09.006 The Coming of Age of Neurology: The Conceptualization and Organization of the First International Neurological Congress (1931) Elan Louis 3:15 p.m. S09.007 Echoencephalography and the Importance of Negative Findings in Research Jonathan Lau 3:30 p.m. S09.008 The NIH Yellow Berets: Legacy of the U.S. Doctor Draft Sandeep Khot, Buhm Soon Park, W. T. Longstreth S10 Multiple Sclerosis: MRI I Room 713AB 1:45 p.m. S10.001 Assessment of Deep Grey Matter Atrophy in Clinically Isolated Syndrome (CIS) Using 7 Tesla MR Imaging Su-Yin Lim, Ali Al-Radaideh, Christopher Tench, Penny Gowland, Cris Constantinescu 2:00 p.m. S10.002 Deep Gray Matter Atrophy in a Large Sample of Clinically Isolated Syndrome and Early RelapsingRemitting Multiple Sclerosis Patients Niels Bergsland, Michael Dwyer, Dana Horakova, Ondrej Dolezal, Eva Havrdova, Robert Zivadinov 2:15 p.m. S10.003 Patterns of Regional Gray Matter Atrophy and Cognitive Impairment in Multiple Sclerosis Patients with Different Disease Phenotypes Gianna Riccitelli, Maria Rocca, Cristina Forn, Andrea Falini, Elisabetta Pagani, Mariaemma Rodegher, Monica Falautano, Paolo Rossi, Giancarlo Comi, Massimo Filippi 2:30 p.m. S10.004 Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis Ashish Arora, Mohit Neema, Shahamat Tauhid, Daniel Goldberg-Zimring, Brian Healy, James Stankiewicz, Christian Chavarro-Nieto, Antonia Ceccarelli, Elisa Dell’Oglio, Charles Guttmann, Rohit Bakshi 2:45 p.m. S10.005 Magnetization Transfer Ratio Imaging Is Feasible in Large Multicenter MS Trials Douglas Arnold, Catherine Dalton, Sridar Narayanan, Mishkin Derakhshan, Daniel Tozer, Kelvin Hunter, Robert Fox, Ralf Gold, Minhua Yang, Katherine Dawson, David Miller 3:00 p.m. S10.006 Rapid Semi-Automatic Segmentation of the Spinal Cord from Magnetic Resonance Images in Multiple Sclerosis Mohit Neema, Mark Horsfield, Stefania Sala, Martina Absinta, Anshika Bakshi, Maria Sormani, Maria Rocca, Rohit Bakshi, Massimo Filippi 3:15 p.m. S10.007 Asymptomatic Spinal Cord Lesions Predict Clinical Progression in Radiologically Isolated Syndrome (RIS) Subjects Darin T. Okuda, Elizabeth Crabtree, Ellen Mowry, Bruce Cree, Ari Green, Dorothee Chabas-Chanezon, Scott Zamvil, Emmanuelle Waubant, Douglas Goodin, Daniel Pelletier 3:30 p.m. S10.008 Presence of Gadolinium Enhancement in MS Is Largely a Phenomenon of Age Omar Khan, Fen Bao, Megha Shah, Jai Perumal, Aaron Boster, Stephanie Hreha, Anza Memon, Christina Caon, Imad Zak, Alexandros Tselis 45 Poster Session II Tuesday, April 13 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 Poster Discussion Session: Epilepsy Location: 800 Level Moderators: Joseph Drazkowski, MD and Massimo Pandolfo, MD Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. PD2.001 Expression Analysis of Some Candidate Genes Involved in Neurotransmission and Neurogenesis in Human Hippocampal Sclerosis Nerses Bebek, Müge Sayitogu, Özkan Özdemir, Betül Baykan, Gur Özbek, Aykut Karasu, Altay Sencer, Ibrahim Izin, Candan Gürses, Özden Hatirnaz, Sinem Akat, Murat Imer, Gülcan Pulur, Ali Canbolat, Aysen Gökyigit PD2.002 Pathogenic Mechanism of SCN1B Mutation Affecting the β1b Splice Variant as a Cause of Familial Epilepsy Gustavo Patino, William Brackenbury, Patrick Cossette, Ronald Lafreniíre, Guy Rouleau, Lori Isom PD2.003 Association of Interleukin1beta and Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis Renato Santos, Mariana Saragiotto da Silva, Rodrigo Secolin, Clarissa Yasuda, Tonicarlo Velasco, Américo Sakamoto, Fernando Cendes, Íscia Lopes-Cendes, Cláudia Maurer-Morelli PD2.004 CNS-Related Comorbidities in Individuals with Self-Reported Epilepsy from the National Survey of Epilepsy, Comorbidities and Health Outcomes (EPIC) Ruth Ottman, Richard Lipton, Alan Ettinger, Joyce Cramer, Michael Reed, George Wan PD2.005 Patterns of Epilepsy and Associated Neurological Impairements among Patients Attending the Pediatric Neurology Clinic at the National Referral Hospital, Uganda Christine MugashaGahiire, Richard Idro, Sarah Kiguli, Justus Byarugaba History of Neurology P02.001 The Contributions of Two Presidents of Israel to the Development of Copaxone Kenneth Johnson, Pippa Loupe P02.002 Seasonal Patterns of Nutritional Night Blindness in the U.S. Army during the Civil War Douglas Lanska P02.003 A Continuum of Ideas of Hughlings-Jackson and Wilder Penfield about Epilepsy and Brain Function Edward English, Robert Hogan P02.004 Nutritional Night Blindness and Keratomalacia Among Malnourished Civilians during WWI Douglas Lanska P02.005 Migraine in Dr. Faustus by Thomas Mann Stephen Reich P02.006 A Biology of the Mind: Phrenology in Medicine in Antebellum America Daniel Schneider P02.007 Surreptitious Documentation of Thiamin-Deficiency Disorders by Allied POWs during WWII Douglas Lanska P02.008 “Elementary My Dear Dr. Allen”: The Case of Barium Toxicity and Pa Ping Lauren Bowen, S. Subramony, Jing Cheng, Samuel Wu, Michael Okun P02.009 Pathogenesis and Treatment of Infantile Beriberi in the Philippines, 1910–1912 Douglas Lanska P02.010 The Dorsal Columns, beyond Proprioception and Vibration Sense a Historical Review Ingrid Park P02.011 Pellagra Was the First Neurodegenerative and Redox Disorder To Be Cured: Can We Be Sure It Was Eliminated? Adrian Williams 46 P02.012 Neurology and the Old Testament Stephen Mathew, Jeyaraj Pandian P02.013 Descriptions of Parkinson’s Disease in Ancient Indian Medical Literature Ovallath Thazha Sujith P02.014 Abraham Levinson (A.L.)— His Contributions to Child Neurology Daniel Elefant, David Rothner P02.015 Decreased Creativity after Stroke— Christoph Willibald Gluck Tomislav Breitenfeld, Vesna Vargek Solter, Darko Breitenfeld, Vida Demarin P02.016 “Dystrophica Myotonica” and the Legacy of Hans Steinert Shrikant Mishra, Parampreet Singh P02.017 Neuro-Expressionism in Christfried Jakob Contributions from Lake Jakob to Visceral Brain Ana Isabel Fumagalli P02.018 Medical and Neurological Maladies of Sir George Everest Shrikant Mishra, Parampreet Singh P02.019 Charcot’s Son, Commander Jean-Baptiste Charcot: From Neurology to “ Pourquoi Pas?” Renato Munhoz, Helio Teive, Jefferson Simões, Lineu Werneck P02.020 A Brief History of Endovascular Neurology and Procedures Bijal Mehta, Edward Fine P02.021 Early Contributions to the Understanding of Frontotemporal Lobar Degeneration from Argentina Joaquín Barutta, John Hodges, Ezequiel Gleichgerrcht, Teresa Torralva, Mariangeles Pose, Agustín Ibáñez, Facundo Manes PD2.006 Uncinate Fasciculus Integrity and Impaired Problem Solving and Memory in Complex Partial Seizures Mario Dulay, Christof Karmonik, Amit Verma, Kimberly Raghubar, Adriana Strutt, Michele York, Robert Grossman PD2.007 Frequency of Thyroid Abnormalities in Patients with Epilepsy and Their Relationship with the Use of Antiepileptic Drugs Iris Martínez-Juárez, Liliana Romero-Ocampo, Erandi BravoArmenta, Ma. de los Ángeles FernándezAguilar PD2.008 Intra-Individual Variability of Carbamazepine and Valproic Acid Serum Concentrations in Elderly Nursing Home Residents Ilo Leppik, Jeannine Conway, Melissa Strege, Angela Birnbaum P02.035 Impact of Early Goal-Directed Hemodynamic Optimization on Clinical Management and Outcome After Subarachnoid Hemorrhage: A Prospective Controlled Study Tatsushi Mutoh, Tatsuya Ishikawa, Taizen Nakase, Akifumi Suzuki, Nobuyuki Yasui PD2.009 A Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Victor Biton, Gregory Krauss, Francesco Bibbiani, Allison Mann, Carlos Perdomo, Milind Narurkar P02.036 Extravascular Lung Water and Pulmonary Permeability Dynamics in Patients with Neurogenic Pulmonary Edema after Subarachnoid Hemorrhage Tatsushi Mutoh, Tatsuya Ishikawa, Taizen Nakase, Akifumi Suzuki, Nobuyuki Yasui PD2.010 An Evaluation of the Effect of Eslicarbazepine Acetate on Metabolic Parameters: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies Mark Friedman, Mark Versavel, Jacqueline French, Luis Almeida, Elinor Ben-Menachem, Kenneth Tripp, Christian Elger, Patricio Soares-da-Silva P02.037 Cell Proliferation in Chronic Subdural Hematomas: A Potential Mechanism of Expansion and Recurrence J. Goodman, Shankar Gopinath, Claudia Robertson P02.038 Peripheral Leukocyte Count and Matrix Metalloproteinase-2 in Cerebral Vasospasm Following Subarachnoid Hemorrhage Sherry Chou, MingMing Ning, Rachael Konigsberg, Eric Loesch, Gülhan Alpargu, Steven Feske, Eng Lo P02.039 Vasospasm in Aneurysmal SAH and Intracranial Calcification Haitham Hussein, Steve Cordina, Haralabos Zacharatos, Adnan Qureshi, Mustapha Ezzeddine P02.022 Epilepsy at the Theater: Underrepresentation and Misrepresentation of Epilepsy in 100 Years of International Cinematography Martina Vendrame Critical Care/Emergency Neurology/Trauma II P02.023 Trends in Outcomes and Hospitalization Costs among Spinal Cord Injury Adult Patients in the United States Khosro Farhad, Khan Hafiz, Abu Nsar, Nizar Souayah P02.024 Post-Traumatic Cerebral Atrophy: Relationship with Diffusion Tensor Imaging Measures of Traumatic Axonal Injury Matthew Warner, Alvin Chandra, Tommy Davis, Carlos Marquez De La Plata, Jun Yi Wang, Carol Moore, Caryn Harper, Christopher Madden, Ramon Diaz-Arrastia P02.025 Trends in Outcomes and Hospitalization Costs Among Traumatic Brain Injury in Pediatric Patients in the United States Khosro Farhad, Hafiz Khan, Shahanara Islam, Nizar Souayah P02.026 Use of Diffusion-Weighted Imaging To Assess Cytotoxic and Interstitial Edema after Traumatic Brain Injury Mena Milad, Nabila Choudhury, Lifang Peng, Carol Moore, Caryn Harper, Christopher Madden, Ramon Diaz-Arrastia P02.027 Regional Selectivity of Post-Traumatic Cerebral Atrophy Alvin Chandra, Matthew Warner, Tommy Davis, Carol Moore, Caryn Harper, Christopher Madden, Ramon Diaz-Arrastia P02.028 Trends in Outcomes and Hospitalization Costs Among Traumatic Brain Injury in Adult Patients in the United States Nizar Souayah, Abu Nasar, Khosro Farhad, Hussam Yacoub, Rania Abou Elenein, Pavel Tishuk P02.029 Can a Clinical Measure of Reaction Time Predict a Functional SportProtective Response? Implications for Sport Concussion Management James Eckner, David Lipps, Hogene Kim, James Richardson, James Ashton-Miller P02.030 Wild Bootstrap Analysis Detects Subject-Specific Changes in DTI Indices after Concussion Jeffrey Bazarian, Brian Blyth, Tong Zhu, Jianhui Zhong P02.031 Outcome After Mild Traumatic Brain Injury: The Role of Gender Jeffrey Bazarian, Brian Blyth P02.032 Traumatic Brain Injury— ”Kids in Transition” Daune MacGregor, Alastair Hodinott, Arbelle Manicat-Emo, Susan Stinson-Lypka, Tonya Flaming, Cindy Bruce-Barrett P02.033 Dual Intraventricular Catheter Use in Severe Intraventricular Hemorrhage Holly Hinson, Eric Melnychuk, John Muschelli, Daniel Hanley, Wendy Ziai P02.034 Predictors and Impact of Hematoma Resorption in Medically Treated Patients with Intracerebral Hemorrhage Nauman Tariq, Haitham Hussein, Remy Wong, Gabriela Vazquez, Yuko Palesch, Renee Martin, Jill Novitzke, M. Fareed Suri, Adnan Qureshi, ATACH Investigators Poster Session II Tuesday, April 13 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P02.040 Predictors and Outcome of Pneumonia in Patients with Spontaneous Intracerebral Hemorrhage Mohammad Alsumrain, Charles Probeni, Bahareh Hassanzadeh, Vahid Tohidi, Daniel Korya, Mohammad Moussavi, Nicholas Melillo, Jawad Kirmani P02.041 Correlation of External Cardiac Output Monitoring to Hemodynamic Parameters and Central Venous Pressure Readings in Critically Ill Neurological Patients Aarti Sarwal, J. Javier Provencio Aging and Dementia: Frontotemporal Dementia Tauopathies P02.042 Semantic Dementia Associated with Motor Neuron Disease: Clinicopathological Correlation Nicolas Gaspard, Patrick Féry, Hichem Slama, Martin Kavec, Jean-Pierre Brion, JeanChristophe Bier P02.043 Frontotemporal Dementia Associated with Primary Lateral Sclerosis in the Antemortem Suvendrini Lena, David Tang-Wai P02.044 Divergent Network Connectivity Changes in Behavioral Variant FTD and Alzheimer’s Disease Juan Zhou, Michael Greicius, Efstathios Gennatas, Matthew Growdon, Jung Jang, Joel Kramer, Michael Weiner, Bruce Miller, William Seeley P02.045 An Anatomopathological Classification of Frontotemporal Lobar Degeneration Jonathan Rohrer, Tammaryn Lashley, Simon Mead, Nick Fox, Janice Holton, Tamas Revesz, Martin Rossor, Jason Warren P02.046 Correlates of Alzheimer’s Pathology in Corticobasal Syndrome Suzee Lee, William Seeley, Stephen Wilson, Matthew Growdon, Jung Jang, Katherine Rankin, William Jagust, Michael Weiner, Maria-Luisa GornoTempini, Bruce Miller, Gil Rabinovici P02.047 Pre- and Post-Memantine FDG-PET Imaging in Frontotemporal Dementia Tiffany Chow, Ariel GraffGuerrero, Morris Freedman, David TangWai, Sandra Black, Bruce Pollock P02.048 Prediction of Underlying Alzheimer’s Disease in Corticobasal Syndrome Rachel Gross, William Hu, Corey McMillan, Delani Gunawardena, Virginia Lee, John Trojanowski, Murray Grossman P02.049 Functional Profile of Patients with Early Frontotemporal Dementia and Its Relation with Executive Functions Julieta Camino de la Llosa, Ezequiel Gleichgerrcht, María Luz Di Giacomo, Teresa Torralva, María Roca, Mariangeles Pose, Facundo Manes P02.050 Anosognosia and Behavioral Manifestations of Dementia Leopold Liss P02.051 Personality in Frontotemporal Dementia Mariangeles Pose, Guido Catagnola, Ezequiel Gleichgerrcht, Teresa Torralva, Pablo Lopez, Fernando Torrente, Federico Quaglia, Santiago O’Neill, Marcelo Cetkovich, Facundo Manes Aging and Dementia: Mild Cognitive Impairment P02.052 Neuropsychological Performance in MCI at Baseline: Effect of Apolipoprotein E ε4 Allele and Other Candidate Genetic Variants Ana Pozueta, Isabel Sala, Belén Sánchez Saudinós, Ignacio Mateo, Jose Vazquez-Higuera, Eloy Rodriguez-Rodriguez, Pascual SanchezJuan, Jon Infante, Jordi Clarimon, Alberto Lleo, Onofre Combarros P02.053 Self Administered Gerocognitive Examination (SAGE) and Mini-Mental State Examination (MMSE) Score Changes over Time in Worried Well, Mild Cognitive Impairment (MCI), and Dementia Converter Patients Douglas Scharre, Shu-Ing Chang, Maria Kataki, Haikady Nagaraja P02.054 Impact of Mild Cognitive Impairment (MCI) on Patients and Their Caregivers Trent McLaughlin, Lisa Mucha, Gerald Crans, Enchi Liu, Michael Grundman, Ronald Black P02.055 Learning, Retrieval, and Recognition Are Compromised in aMCI and Mild AD: Are Distinct Memory Processses Mediated by the Same Anatomical Structures? Marcio Balthazar, Clarissa Yasuda, Fernando Cendes, Benito Damasceno P02.065 Frequency of Sensory Symptoms and Abnormal Nerve Conduction Studies in a SCJD Cohort Catherine Lomen-Hoerth, Katherine Wong, Amy Kuo, Aissatou Haman, Stephen DeArmond, Michael Geschwind P02.056 PreMCI and MCI: Comparative Neuropsychological, Clinical and Imaging Features and Progression Rates Ranjan Duara, David Loewenstein, Maria Greig-Custo, Elizabeth Potter, Balaibal Raj, John Schinka, Amy Borenstein, Sunil Saxena, Michael Schoenberg, Warren Barker, Yougui Wu, Jessica Banko, Huntington Potter P02.066 Evaluation of Episodic Memory in Illiterate and Low-Educated Patients Catherine Belin, Didier Maillet, Anne-Marie Ergis, Herve Le Clesiau, Frederic Dessi, Antoine Carpentier P02.057 Hippocampal Atrophy Mediates the Associations between APOE-ε4 and Amnestic MCI and Verbal Memory James Mortimer, Amy Borenstein, Charles DeCarli, Ding Ding, Shugang Chu, Qian-hua Zhao, Qi-hao Guo, Douglas Galasko, David Salmon, Ronald Petersen, Zhen Hong P02.058 Prevalence of Mild Cognitive Impairment by Multiple Classifications: A Population-Based Study Mary Ganguli, Chung-Chou Chang, Beth Snitz, Judith Saxton, Joni Vander Bilt P02.059 Amnestic and NonAmnestic Mild Cognitive Impairment and Cardiovascular Risk Factors in The 90+ Study Carrie Peltz, Maria Corrada, Daniel Berlau, Claudia Kawas P02.060 Dementia = (MC)2: A FourItem Screening Test for Mild Cognitive Impairment and Dementia Vanja Douglas, John Neuhaus, Julene Johnson, Caroline Racine, Bruce Miller, S. Josephson P02.061 Home-Based Activity Changes Associated with MCI Jeffrey Kaye, Stuart Hagler, Hiroko Dodge, Nora Mattek, Daniel Austin, Teresa Buracchio, Michael Pavel, Tamara Hayes Aging and Dementia: Clinical P02.062 Dyslipidemia in Alzheimer’s Disease Is Associated with Blood-Brain Barrier Impairment Gene Bowman, Jeffery Kaye, Joseph Quinn P02.063 Comparison of the Montreal Cognitive Assessment (MoCA) with the Mini-Mental State Examination in Cognitively Impaired and Cognitively Normal Subjects as Assessed by Neuropsychological Testing Anne Damian, Sandra Jacobson, Christine Belden, Holly Shill, Marwan Sabbagh, Linda Vedders, Joseph Hentz, John Caviness, Charles Adler P02.064 Anxiety as a Possible Diagnosis Criteria for Logopenic Primary Progressive Aphasia and Pure Progressive Amnesia Eloi Magnin, Sabrina Ferreira, Geraldine Vanholsbeeck, Elfriede Dariel, Ilham Ryff, Lucien Rumbach, Pierre Vandel, Jean Galmiche P02.067 Alzheimer’s Disease CSF Biomarker Levels Correlate with Baseline Cognitive Performance and Post-Shunt Cognitive Outcomes in Normal Pressure Hydrocephalus Sunil Patel, Anica Law, Edward Lee, Eric Jackson, Joanna Lopinto, Steven Arnold, Christopher Clark, Anuj Basil, Leslie Shaw, Sharon Xie, M. Sean Grady, John Trojanowski, Roy Hamilton P02.068 Obsessive Compulsive Symptom Profile in Patients with Behavioral Variant Frontotemporal Dementia Guido Castagnola, Mariangeles Pose, Teresa Torralva, Marcelo Cetkovich, María Gonzalez Toledo, Facundo Manes P02.069 The Boston Driving Screen— Validation of a Clinical Tool for Assessing Driving Problems in the Elderly Anil Nair, Apar Gupta, Anna Hohler, Samuel Frank, Margaret Brickley, Georgia Montouris, Brian McGeeney, Jamie Frederick, Alan Kurland P02.070 Free Will, Decision-Making, and the Frontal Lobes: Unique Legal and Ethical Aspects in the Early Stages of the Behavioral Variant Frontotemporal Dementia Facundo Manes, Ezequiel Gleichgerrcht, María Roca, Guido Castagnola, Teresa Torralva P02.071 Clinical Phenotype of Dementia after Traumatic Brain Injury (TBI) Nasreen Sayed, Ramon Diaz-Arrastia Cerebrovascular Disease: Clinical Aspects of Cerebrovascular Disease P02.072 Cervical Artery Dissection: A Five-Year Experience of a Tertiary Care Center Shadi Yaghi, Nancy Maalouf, Islam Abujubara, Salah Keyrouz P02.073 Brain Stem and Cerebellar Strokes Are Less Cardioembolic and Less Severe Than Hemispheric Strokes. Prospective Data from the National Acute Stroke Israeli Surveys (NASIS) Israel Steiner, Michal Benderly, Isabelle KornLubetzki P02.074 Does National Institutes of Health Stroke Scale Score Provide Additional Predictive Value in Good Grade Patients with Intracerebral Hemorrhage? Results from the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) Study Adnan Qureshi, Yuko Palesch, Renee Martin, Jill Novitzke, Salvador Flores, As’ad Ehtisham, Mustapha Ezzeddine, Joshua Goldstein, Jawad Kirmani, Haitham Hussein, M. Fareed Suri, Nauman Tariq, ATACH Investigators 47 Poster Session II P02.075 Epidemiology and Outcomes of Fever Burden Among Patients with Acute Ischemic Stroke Michael Phipps, Rani Desai, Charles Wira III, Dawn Bravata P02.076 Admitted Transient Ischemic Attack Patients Have a Lower Two-Day Risk of Ischemic Stroke Than Predicted by the ABCD2 Score Rajesh Gupta, Yousef Mohammad, Vivien Lee, Shyam Prabhakaran P02.077 Incidence of Falling among Elderly with History of Stroke: Health and Retirement Study Survey 2002– 2006 Anna Barrett, Gabriela Vasquez, Rachel Meyer, Andreas Luft, Afshin Divani P02.078 Antecedent Chiropractic Manipulation May Be More Frequently Associated with Posterior Circulation Territory Strokes Nerses Sanossian, Jeffrey Saver, David Liebeskind, Sidney Starkman, Doojin Kim, Latisha Ali, Bruce Ovbiagele P02.079 The NIH Score: Predicting the Need for In-Patient Hospitalization (NIH) of TIA Patients Indrani Acosta, Hen Hallevi, Sean Savitz P02.080 Factors Influencing Early Cognitive Impairment After Stroke Maria Zurru, Laura Brescacin, Claudia Alonzo, Fabiana Ortega, Marina Romano, Silvina Brienza, Luis Camera, Gabriel Waisman, Edgardo Cristiano, Bruce Obviagele P02.081 Alcohol Consumption and Other Vascular Risk Factors Associated with White Matter Subcortical Lesions in Non-Demented Non-Stroke Maria Zurru, Claudia Alonzo, Laura Brescacin, Daniela Gil, Julieta Montecchia, Marcelo Schapira, Luis Camera, Gabriel Waisman, Edgardo Cristiano, Bruce Obviagele P02.082 Clinical and Radiological Predictors of Neurological Deterioration in Spontaneous Cervico-Carotid Dissections Gustavo Rodriguez, Ameer Hassan, M. Fareed Suri, Sudeepta Dandapat, Rehan Zahid, Yousef Mohammad, Nauman Tariq, Gabriela Vazquez, Ramachandra Tummala, Robert Taylor, Adnan Qureshi P02.083 Transcranial Doppler (TCD) and Neurological Manifestations in Brazilian Pediatric Patients with SCD Ana Claudia Leite, Celia Silva, Renata Azevedo, Patricia Moura, Raquel Oliveira, Clarisse Lobo P02.084 The Interval of Stenotic Index of TCD and Middle Cerebral Artery Stenosis Lianyuan Feng P02.085 Frequency of Emergency Physician and Neurologist Agreement in the Diagnosis of TIA Carlene Kingston, Osman Mir, George Leach, Michael Ross, Jacquelyn Abney, Lauren Ayala, Fadi Nahab P02.086 Clinical and Radiological Features of Reversible Cerebral Vasoconstriction Syndrome Javier Moschini, Francisco Meli, Maria Goicochea, Macarena de la Fuente, Sebastian Ameriso 48 Tuesday, April 13 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P02.087 Characterization of Ischemic Strokes and Transient Ischemic Attacks after Cardiovascular Procedures in a HighVolume Center Gabriela Bressán, Patricia Riccio, Francisco Klein, Luciano Sposato P02.088 Preparation for Accreditation and State Designation of a Comprehensive Stroke Center Improves Stroke Case Volume, Evaluation, and Treatment Response Times Bahareh Hassanzadeh, Appaji Rayi, Madhu Gupta, Jawad Kirmani, Martin Gizzi P02.089 Characterization of Large Hemispheric Infarction Seo Hyun Kim, Hyun-Chan Jang, Do Han Kim, Ji-Yong Lee, Sung-Soo Lee P02.090 Vitamin D Deficiency and Stroke Severity Peterkin Lee Kwen, Mateen Rahman, Michael Merrill, John Baker P02.091 Safety, Feasibility, and Advantages of Tapering Antihypertensive Agents in Older Adults Preparing for Enrollment in a Cognitive Clinical Trial Siu-Hin Wan, Meaghan Hart, Ihab Hajjar P02.092 Effect of Early Decompressive Hemicraniectomy in Patients with Malignant Middle Cerebral Artery Infarction Joyce Lee-Iannotti, Ryan Armour, Rishi Gupta, Shaye Moskowitz P02.093 Current Diagnosis and Management of Cerebral Venous Thrombosis in Buenos Aires, Argentina Marcos Fernández Suárez, María Gaitan, Javier Moschini, Sebastian Ameriso P02.094 A Study of Reflex and Voluntary Cough after Acute Ischemic Stroke Katie Ward, Kerrie Mills, Michael Polkey, John Moxham, Lalit Kalra P02.095 The Role of Indoleamine 2,3-Dioxygenase Activation in the Etiology of Post-Stroke Depression Amy Wong, Nathan Herrmann, Gayla Tennen, Abby Li, Allison Gold, Philip Francis, Robert Mitchell, Krista Lanctot P02.096 Leukocyte-Platelet Complex Formation as a Predictor of Clinical Outcome in the Acute and Convalescent Phases of Ischemic Stroke Maria Lukasik, Grzegorz Dworacki, Joanna Kufel, Cezary Watala, Bartosz Brzezicha, Wojciech Kozubski P02.097 Basilar Artery Occlusion in Young Adults Julie Khoury, Dan Capampangan, Nadine Lendzion, David Dodick, Terri Kiernan, Timothy Ingall, Bart Demaerschalk, Maria Aguilar P02.098 Complications in Acute Stroke (CAST): An Indian Multicentred Study Jeyaraj Pandian, Arshpreet Kaur, Rashmi Jyotsna, P. N. Sylaja, Vijaya PV, K. V. Venkateswaralu, Sajith Sukumaran, Kurupath Radhakrishnan, Robert Mathew, Yashpal Singh P02.099 Sneddon’s Syndrome Without Antiphospholipid Antibodies: A Report of 26 Cases with Cerebral Angiography El Mostafa El Alaoui Faris, Mounia Rahmani, Mouna Maamar, Fatima Boutbib, My Rachid El Hassani, Mohamed Jiddane, Chafiq Hicham, Maria Benabdeljlil, Saadia Aidi P02.100 Outcomes and Predictive Prognostic Factors in Patients with Cerebral Venous and Dural Sinus Thrombosis: Experience from a Tertiary Care Hospital in India Mathew Alexander P02.101 Antihypertensive Medication Management in Acute Ischemic Stroke: Evidence from Observational Data Michael Phipps, Jason Sico, Rani Desai, Dawn Bravata P02.102 Ipsilateral Ptosis and Astasia with Thalamic Infarct: A Case Report Deepali Jain, Nader Antonios P02.103 Prevalence and Clinicoradiological Hallmarks of Vertebrobasilar Dolichoectasia in Acute Stroke Patients Ken Ikeda, Hirono Ito, Yoshikazu Nakamura, Takehisa Hirayama, Riya Nagata, Konosuke Iwamoto, Ryuta Sato, Kiyoko Murata, Osamu Kano, Kiyokazu Kawabe, Yasuo Iwasaki P02.104 Predictors of Stroke Mortality in a Nigerian Teaching Hospital Bertha Ekeh P02.105 Factors Which Influence the Speed of Diagnosis of Cerebral Venous Sinus Thrombosis Keith Sanders, Lisa Johnston, Todd Ostrow P02.106 Correlation between Two Methods of Measuring Transcranial Doppler Cerebral Vasomotor Reactivity Michael Katsnelson, Jose Romano, Iszet Campo-Bustillo, Yosdely Echevarria, Gustavo Ortiz, Sebastian Koch P02.107 The Effects of Uric Acid on Severity and Early Prognosis in Ischemic Stroke Junhyun Kim, Dae-Il Chang, Sung Hyuk Heo, Kyung Cheon Chung, Sung Sang Yoon, Tae-Beom Ahn, Key Chung Park P02.108 Thalamic Infarction Causing Astasia-Abasia, Ataxia, and Asterixis: Clinical and Radiological Features of Two Cases Yazan Alderazi, James Frey P02.109 Is Pulmonary Shunting a Risk Factor for Ischemic Stroke? Case Series Ahmad Bayrlee, Karen Furie P02.110 Importance of Hormonal Medication in Young Women with Ischemic Stroke Preeti Puntambekar, Pratik Bhattacharya, Ramesh Madhavan, Seemant Chaturvedi Cerebrovascular Disease: Hemorrhagic Stroke P02.111 Predictors for Tracheostomy in ICH Shadi Yaghi, Bappaditya Ray, Salah Keyrouz P02.112 Misdiagnosis of Cerebellar Hemorrhage: Frequency of PseudoGastroenteritis Clinical Presentations to the Emergency Department Seung-Han Lee, Victoria Stanton, Richard Rothman, Barbara Crain, Robert Wityk, David Newman-Toker P02.113 Factor VII for Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis Ayman Daoud, Aninda Acharya, Randall Edgell, Eliahu Feen, Paisith Piriyawat, Nirav Vora, Salvador Cruz-Flores P02.114 An Unusual Acute Development of Superficial Siderosis Andrew Gomez-Vargas, Chidam Yegappan P02.115 Enlargement of a Distal Part of the Optic Nerve Sheath in Hyperacute Stage of Intracerebral Hemorrhage Roman Herzig, David Skoloudik, Tana Fadrna, Michal Bar, Pavel Hradilek, Martin Roubec, Monika Jelinkova, Daniel Sanak, Michal Kral, Jana Chmelova, Miroslav Herman, Katerina Langova, Petr Kanovsky P02.116 Risk Factors and Intra Cerebral Hemorrhage in African American Population Rajesh Gupta, Mohankumar Kurukumbi, Annapurni Jayam-Trouth P02.117 Does Variance in Blood Pressure Parameters Within 24 Hours Predict Early Mortality in Patients with Intracerebral Hemorrhage? Latha Stead, Minal Jain, Neeraja Yerragondu, Anunaya Jain, Dipti Agarwal, Balavani Palamari, Veena Manivannan, Babak Jahromi, Wyatt Decker P02.118 The MCA Arrow Sign in Subarachnoid Hemorrhage Jay Joshi, Manisha Gupte, Sayona John, Shyam Prabhakaran, Vivien Lee P02.119 Does Transfer Time to a Tertiary Care Center Play a Role in Predicting Mortality in Intracranial Hemorrhage? Ahmed Hassan, Ivan Rocha Ferreria da Silva, Bichun Ouyang, Richard Temes, Vivien Lee, Shyam Prabhakaran, Sayona John P02.120 Early Blood Pressure Hemodynamics and Their Association with Intra-Ventricular Extension of Intracerebral Hemorrhage Minal Jain, Anunaya Jain, Neeraja Yerragondu, Dipti Agarwal, Veena Manivannan, Balavani Palamari, Babak Jahromi, Wyatt Decker, Latha Stead P02.121 Spontaneous ICH in Chronic Daily Alcohol Users Gayle Pletsch, Sheryl Martin-Schild P02.122 Systemic Blood Pressure and Occurrence of Intracerebral Hemorrhage in Patients with Cerebral Venous Thrombosis Gaurav Guliani, Muna Irfan, Haitham Hussein, M. Fareed Suri, Adnan Qureshi Poster Session II Tuesday, April 13 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. Neural Repair and Rehabilitation: Clinical P02.123 Diabetic Mean Fasting Plasma Glucose Levels and Stroke Rehabilitation Outcome Susanna Shepper, Rolf Martin, Mery Elashvili, Mike Reding P02.124 Quantifying Neural Cell Birth in the Pediatric Spinal Cord Daniel Becker, Yun Qu, John McDonald P02.125 A New Marker for Neuroinflammation in Acute Adult Traumatic Brain Injury Pavel Tishuk, Timothy Cunningham, Hafiz Khan, Nizar Souayah P02.126 Importance of Raising Awareness about Head Injuries in Recreational Sports Sandra Morovic, Valentina Matijevic, Vida Demarin P02.127 Cognitive Training and Long -Term Follow-Up in Patients with Mild Cognitive Impairment Veronica Villar, Galeno Rojas, Paula Harris, Cecilia Serrano, Carol Dillon, Monica Iturry, Leonardo Bartoloni, Ricardo Allegri P02.128 Sensorimotor Cortical Changes after Botulinum Toxin Therapy for Cervical Dystonia: A Functional MRI Study Petr Hluštík, Robert Opavský, Pavel Otruba, Roman Herzig, Petr Kanovský P02.129 Effectiveness of Virtual Reality Using Wii Gaming Technology in STroke Rehabilitation (EVREST): Results from a Randomized Clinical Trial Gustavo Saposnik, Mark Bayley, Muhammad Mamdani, Judith Hall, Kevin Thorpe, Jackeline Willems, Donna Cheung, Bill McIlroy, Robert Teasell, Leonardo Cohen P02.130 Fibrocartilaginous Embolism: Clinical Features and Outcomes Priya Monrad, Farrah Mateen, Andrea Leep Hunderfund, Eric Sorenson P02.131 The Adverse Effect of Post-Stroke Spasticity on Three-Month Functional Outcomes Samir Belagaje, Christopher Lindsell, Kathy Alwell, Charles Moomaw, Kari Dunning, Dawn Kleindorfer, Daniel Woo, Matthew Flaherty, Opeolu Adeoye, Pooja Khatri, Joseph Broderick, Brett Kissela P02.132 Combat Veterans with Mild TBI Due to Explosions Have Persisting Neurological Deficits Robert Ruff, Suzanne Ruff, Xiao-Feng Wang P02.133 Frequency of Visual Field Defects in Neuro-Rehabilitation Seema Khurana, Iszet Campo-Bustillo, Jose Romano P02.134 Efficacy of NT 201 (Botulinum Neurotoxin Type A, Free from Complexing Proteins) in the Treatment of Patients with Upper Limb Spasticity Petr Kanovsky, Michael Barnes, Irena Pulte, Petra Minnasch, Susanne Grafe P02.135 Diagnosing Adult Polyglucosan Body Disease: A Case Report and Review of the Literature Eduardo Garcia, Marybeth Toran, Karen Dudich, Shakti Ramkissoon, Sandro Santagata, Avraham Almozlino P02.136 Efficacy and Safety of Repeated NT 201 (Botulinum Neurotoxin Type A Free from Complexing Proteins) Treatments for up to 89 Weeks in Upper Limb Post-Stroke Spasticity Petr Kanovsky, Irena Pulte, Georg Comes, Susanne Grafe P02.137 Falls in People with Multiple Sclerosis: Frequent and Correlated with Balance Confidence and Disease Severity Michelle Cameron, Dennis Bourdette P02.138 Scopolamine and Ketamine Modelling of Neurocognitive Deficits: Clinical Trials Applications Denise Milovan, Myroslava Romach, Edward Sellers Multiple Sclerosis and Related Diseases: Clinical Research/ Biomarkers P02.139 Angiotensin II Type 1 Receptor Antibodies in Multiple Sclerosis: A New Biomarker for Disease Activity? Alexandra Schröder, Harald Heidecke, De-Hyung Lee, Dominik Muller, Johannes Stegbauer, Ralf Gold, Ralf Linker P02.140 Immunological Factors That Condition an Aggressive Multiple Sclerosis Course Luisa Villar, Mercedes Espiño, Ernesto Roldan, Maria Sadaba, Gonzalez-Porque Pedro, Jose AlvarezCermeño P02.141 Predictors of Response to First-Line Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis Tamara Castillo-Trivino, Alberto Gajofatto, Peter Bacchetti, Emmanuelle Waubant P02.142 Functional Bioenergetic Measure of CD4 +-Cellular Immunocompetence in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy Aiden Haghikia, Bartosz Pula, Moritz Perrech, Sabrina Ruhrmann, Anja Potthoff, Norbert Brockmeyer, Susan Goelz, Hans Lindå, Tor-Bjorn Käll, Tomas Olsson, Ralf Gold, Andrew Chan P02.143 Lower Serum Creatinine Levels Correlate with Blood-Brain Barrier Dysfunction in Multiple Sclerosis Patients Gordana Toncev, Evica Dincic, Slavco Toncev P02.144 The North-South MS Prevalence Gradient in Ireland in Relation to Vitamin D Status Roisin Lonergan, Katie Kinsella, Patricia Fitzpatrick, Marguerite Duggan, Sinead Jordan, Ciaran Dunne, Richard Hagan, Jennifer Brady, Barbara Murray, Malachi McKenna, Michael Hutchinson, Niall Tubridy P02.145 T-Cell Responses to Aquaporin-4 in Neuromyelitis Optica (NMO) Livnat Brill, Dimitrios Karussis, Panayiota Petrou, Adi Vaknin-Dembinsky P02.146 Frequency and Prognostic Value of NMO-IgG Seropositivity in Isolated Optic Neuritis Marcelo Matiello, Andrew McKeon, Sean Pittock, Brian Weinshenker Multiple Sclerosis and Related Diseases: Clinical Research/ Quality of Life P02.158 Attitudes about PhysicianAssisted Suicide in Patients with Multiple Sclerosis Louisa Lavy, Alyssa Bamer, James Bowen, George Kraft P02.147 Rituximab in Secondary Progressive Multiple Sclerosis— OneYear Follow-Up Carolina Ionete, Biljana Beretich, Peter Riskind P02.159 Developing an Instrument To Assess Caregiver Quality of Life in Multiple Sclerosis (CAREQOL-MS) Julián Benito-León, Jesús Rivera-Navarro, Angel Luis Guerrero, Virginia De las Heras, José Balseiro, Elena Rodríguez, Mireia Belló P02.148 Clinical Markers of Therapeutic Response and the Long-Term Impact of Glatiramer Acetate on RelapseInduced Disability Adriana Carrá, Patricia Onaha, Galeno Rojas, Gastón ImhoffJullier, Carlos Vrech P02.160 Quality of Life in Multiple Sclerosis: Exploring Transcultural Differences Efthymia Gavala, Lampros Samartzis, Thomas Thomaides, Julie Webster, Helen Willis, Achilleas Aspiotis, Yannis Zoukos P02.149 Potential Factors Influencing Vitamin D Metabolism in Multiple Sclerosis Patients Jodie Burton P02.161 Longitudinal Changes in Depression, Fatigue, Quality of Life, and Social Functioning in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a in the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) Study Francesco Patti, Maria Amato, Maria Trojano, S. Bastianello, Maria Tola, Orietta Picconi, Sabina Cilia, Diego Centonze, Claudio Gasperini, Salvatore Cottone, Luigi Grimaldi P02.150 Autoimmune Brainstem and Cerebellar Encephalitis with New Auto Antibody Emma Burbank, Michael Kruer, Edward Kim, Grazyna Adamus, Michele Mass P02.151 Serum Levels of the Phosphorylated Neurofilament Heavy Chain Biomarker of Axonal Injury is Reduced Five Years after Treatment by Intravenous Methylprednisolone in the Optic Neuritis Treatment Trial Joshua Pasol, William Feuer, Gerry Shaw, John Guy P02.152 CSF Oligoclonal Bands in Multiple Sclerosis Patients: Worse Prognosis? Liliana Patrucco, Liliana Patrucco, Juan Rojas, Edgardo Cristiano P02.153 Prior Suggestive Symptoms in Third of Patients Consulting for a “First” Demyelinating Event Olivier Gout, Christine Lebrun Frenay, Pierre Labauge, Emmanuelle Le Page, Pierre Clavelou, Sylvie Allouche P02.154 Severe Multiple Sclerosis Exacerbation during the Third Trimester of Pregnancy Presenting with Tumefactive MRI Lesions Zeenat Jaisani, David Hojnacki, Bianca Guttman P02.155 The Cellular Immune Response Against Epstein-Barr Virus in Multiple Sclerosis and Cross-Reactivity with Brain Antigens J. Lindsey, Landon Hatfield P02.156 IL-23/IL-1b Ratio as a Biomarker of Disease Activity in Multiple Sclerosis Mathieu Vokaer, Francoise Villee, Kaoutar El Hafsi, Patrick Stordeur P02.157 Overlapping Molecular Mechanisms of Protection during Pregnancy and Disease-Modifying Therapies in Patients with Multiple Sclerosis Antonio Bertolotto, Nicole Navone, Simona Malucchi, Paola Valentino, Alessia di Sapio, Simona Perga, Marco Capobianco, Annalisa Pulizzi, Fabiana Marnetto, Marzia Caldano, Francesca Gilli P02.162 Establishing a Quality of Life Scale Related to Relapses in Multiple Sclerosis Antoine Baroin, Gilles Chopard, Hassna Mokadym, Annick Lavier, Eric Berger, Lucien Rumbach, Nathalie Rude P02.163 Effects of Meditation on Pain and Quality of Life in Multiple Sclerosis and Polyneuropathy: A Controlled Study Jinny Tavee, Mary Rensel, Sarah Pope Planchon, Lael Stone P02.164 Effect of Natalizumab on Disease-Specific Quality of Life after One Year of Natalizumab Treatment Siddhesh Kamat, Likun Hou, Sonalee Agarwal, Krithika Rajagopalan, Judith Stephenson P02.165 Quality of Life in Benign Multiple Sclerosis Line Hviid, Bonnie Glanz, Brian Healy, David Rintell, Tanuja Chitnis, Howard Weiner P02.166 Improvement in HealthRelated Quality of Life in Multiple Sclerosis Patients Receiving Natalizumab in the United States Likun Hou, Judith Stephenson, Krithika Rajagopalan, Sonalee Agarwal, Siddhesh Kamat P02.167 Comorbidity Is Associated with Greater Decrements in Quality of Life over Two Years in MS Ruth-Ann Marrie, Ralph Horwitz, Gary Cutter, Tuula Tyry, Timothy Vollmer 49 Poster Session II Multiple Sclerosis and Related Diseases: Clinical Research/Quality of Life and Neuropsychology Multiple Sclerosis and Related Diseases: Neuromyelitis Optica, Multiple Sclerosis Differential Diagnosis and Clinical Research P02.168 Perceived Cognitive Impairment in Multiple Sclerosis Predicts Quality of Life Independently of Depression Lampros Samartzis, Efthymia Gavala, Yannis Zoukos, Julie Webster, Helen Willis, Achilleas Aspiotis, Thomas Thomaides P02.178 Increased CSF Levels of B Cells Activating Factor (BAFF) in Neuromyelitis Optica (NMO) Adi VakninDebinsky, Livnat Brill, Oded Abramsky, Dimitrios Karussis P02.169 Improvement in EDSS Corresponds with Improvement in Quality of Life in Patients with Multiple Sclerosis Fredrick Munschauer, Gavin Giovannoni, Deborah Miller, Richard Rudick, Paul O’Connor, Chris Polman, Amy Pace, Richard Kim P02.170 Longitudinal MRI Assessment of Quality of Life and Disability in Early Treated Relapsing- Remitting Multiple Sclerosis Mikael Cohen, Christine Lebrun Frenay, Dominique Aufauvre, Stephane Chanalet, Christelle Filleau, William Camu, Pierre Thomas, Gregoire Malandain, Pierre Clavelou P02.171 Cognitive Resilience in Relapsing-Remitting Multiple Sclerosis Anat Achiron, Yermi Harel, Mor Lavie, Ely Simon, Glen Doniger P02.172 Specific Impairments in the Recognition of Emotional Facial Expressions in Multiple Sclerosis (MS) Bruno Lenne, Jean-Louis Nandrino, Henrique Sequeira, Philippe Gallois, Patrick Hautecoeur P02.173 Physical Comorbidities Are Associated with an Increased Risk of Depression in Multiple Sclerosis RuthAnn Marrie, Gary Cutter, Tuula Tyry, Timothy Vollmer P02.174 Relationship between Cognitive Performance and Neurological Disability in Early MS Pasquale Calabrese, Iris Katharina Penner, Mark Freedman, Chris Polman, Gilles Edan, Hans-Peter Hartung, David Miller, Xavier Montalban, Frederik Barkhof, Vivian Lanius, Rupert Sandbrink, Christoph Pohl, Brigitte Stemper, Ludwig Kappos P02.175 Quantifying the Effects of Acute Relapses on Neuropsychological Status in Multiple Sclerosis Patients Sarah Morrow, Stephanie Jurgensen, Dominick Paes, Christophe Hotermans, Ralph Benedict P02.176 Higher Cognitively Functioning Relapsing-Remitting Multiple Sclerosis Patients Have a More Specific Pattern of Impairment on Neuropsychological Testing Sandeep Vaishnavi, John Barkenbus, C. Gualtieri P02.177 Predicting Cognitive Decline in Multiple Sclerosis: Implications for Clinical Trial Design Stephen Rao, Jar-Chi Lee, Lauren Strober, Jack Simon, Elizabeth Fisher, Richard Rudick 50 Tuesday, April 13 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P02.179 Intractable Vomiting as the Initial Presentation of Autoimmune Aquaporin-4 Water Channelopathy Metha Apiwattanakul, Marcelo Matiello, Brian Weinshenker, Claudia Lucchinetti, Andrew McKeon, Vanda Lennon, Adam Carpenter, Sean Pittock P02.180 Effects of Aquaporin4 Antibody in Primary Human Astrocytes in Culture: A Living Cell Imaging Analysis Shuhei Nishiyama, Tatsuro Misu, Rina Takano, Toshiyuki Takahashi, Ichiro Nakashima, Kazuo Fujihara, Yasuto Itoyama P02.181 Is NMO a Paraneoplastic Marker? Daniel Ontaneda, Welf Saupe, Robert Fox P02.182 Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroid (CLIPPERS) Mark Keegan, Jan Debruyne, Karl Krecke, Caterina Giannini, Jelle van den Ameele, Veerle De Herdt, Andrew McKeon, Robert Fealey, Brian Weinshenker, Allen Aksamit, Elizabeth Shuster, Bruce Krueger, Sean Pittock P02.183 Can the Increase of T-Helper 17 Lymphocyte Percentage in Peripheral Blood Anticipate a Relapse in Relapsing Remitting Multiple Sclerosis? Luca Durelli, Marinella Clerico, Simona Rolla, Giulia Contessa, Stefania De Mercanti, Antonio Uccelli, Mauro Zaffaroni, Paola Cavalla, Luciano Rinaldi, Cristoforo Comi, Roberto Cavallo, Luisa Sosso, Francesco Novelli P02.184 IL-27 Mediates Glatiramer Acetate Effect on Antigen Presenting Cells in Multiple Sclerosis Reuben Valenzuela, Kouichi Ito, Suhayl Jalbut P02.185 Differential Diagnosis of Adult Leucoencephalopathies: Validation of MR Criteria in a Series of 75 Patients Léorah Freeman, Ayman Tourbah, Damien Galanaud, Caroline Papeix, Benjamin Granger, Hugues Chabriat, Pierre Labauge, Frederic Sedel P02.186 Consistent Efficacy of Cladribine Tablets Across Multiple Sclerosis and Patient Characteristics, in the Double-Blind, 96-Week CLARITY Study Kottil Rammohan, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Rehan Verjee, Bruno Musch, Steven Greenberg P02.187 Mitochondrial Disease Manifesting as Multiple Sclerosis: A Report of Two Patients with Optic Neuropathy, Brain White Matter Abnormalities, Cerebrospinal Fluid Oligoclonal Bands, and Novel POLG1 Variations Andoni Echaniz-Laguna, M. Chassagne, Michel Mohr, P. Clerc-Renaud, Christine Tranchant, Benedicte Mousson de Camaret Multiple Sclerosis and Related Diseases: Neuromyelitis Optica P02.188 Increased Serum Matrix Metalloproteinase-9 in Neuromyelitis Optica; Implication of Disruption of BloodBrain Barrier Takafumi Hosokawa, Hideto Nakajima, Yoshimitsu Doi, Masakazu Sugino, Fumiharu Kimura, Toshiaki Hanafusa, Toshiyuki Takahashi P02.189 Neuromyelitis Optica in France: A Multicenter Study of 125 Patients Nicolas Collongues, Romain Marignier, Helene Zephir, Anne Caroline Papeix, Frederic Blanc, Cecile Ritleng, Maia Tchikviladze, Olivier Outteryck, Sandra Vukusic, Marie Fleury, Bertrand Fontaine, David Brassat, Michel Clanet, Mathieu Milh, Jean Pelletier , Bertrand Audoin, Aurelie Ruet, Christine Lebrun Frenay, Eric Thouvenot, William Camu, Marc Debouverie, Alain Creange, Thibault Moreau, Pierre Labauge, Giovanni Castelnovo, Gilles Edan, Emmanuelle Le Page, Gilles Defer, Bruno Barroso, Olivier Heinzlef , Olivier Gout, Diana Rodriguez, Sandrine Wiertlewski, David Laplaud, Florent Borgel, Patricia Tourniaire, Jerome Grimaud, Bruno Brochet, Patrick Vermersch, Christian Confavreux, Jerome De Seze P02.190 Predictive Role of Neuromyelitis Optica (NMO)-IgG in Isolated Optic Neuritis and Isolated Myelitis in the Diagnosis of NMO Carla Tortorella, Elisabetta Di Monte, Maddalena Ruggieri, Maria Pia Amato, Angelo Ghezzi, Alessandra Lugaresi, Francesco Patti, Patrizia Sola, Giovanni Bosco Zimatore, Vita Direnzo, Pietro Iaffaldano, Mariangela Mastrapasqua, Paolo Livrea, Maria Trojano P02.191 Anti-Aquaporin 4 Antibodies Increase Transiently After Rituximab Treatment in Neuromyelitis Optica with an Association of B Cell Activating Factor Ichiro Nakashima, Toshiyuki Takahashi, Bruce Cree, Chihiro Suzuki, Kazuo Fujihara, Yasuto Itoyama, Amit BarOr P02.192 Unconventional Spinal Cord and Brain MRI in Neuromyelitis Optica Jerome de Seze, Nicolas Collongues, Jeremy Jeantroux, Francois Rousseau, Lin Xiu, Frederic Blanc, Marie Fleury, Jean Paul Armspach, Izzie Namer, Stephane Kremer P02.193 Painful Tonic Spasm in Neuromyelitis Optica Yoshiki Takai, Ichiro Nakashima, Tatsuro Misu, Kazuo Fujihara, Yasuto Itoyama P02.194 Interferon-β1b Increases Th2 Response in Neuromyelitis Optica Hideto Nakajima, Takafumi Hosokawa, Masakazu Sugino, Fumiharu Kimura, Toshiaki Hanafusa, Toshiyuki Takahashi P02.195 Chitinase Effects on Immune Cell Responses in Multiple Sclerosis and Neuromyelitis Optica Jorge Correale, Marcela Fiol P02.196 Neuropsychiatric Presentation of Neuromyelitis Optica Spectrum Disorders Etsuji Saji, Yasuko Toyoshima, Kaori Yanagawa, Masatoyo Nishizawa, Izumi Kawachi P02.197 Comparison of Type I Interferon Activity in Patients with Systemic Lupus and Neuromyelitis Optica Xuan Feng, Mounica Yanamandala, Addie Hill, Timothy Niewold, Anthony Reder, Adil Javed P02.198 Tumefactive Supraspinal Variant of Severe Neuromyelitis Optica De-Hyung Lee, Ralf Linker, Carsten Lukas, Imke Metz, Achim Berthele, Brueck Wolfgang, Christine Stadelmann, Ralf Gold, Alexandra Schroeder P02.199 Mithocondrial DNA Signature in Chronic Inflammatory Diseases of the Central Nervous System Valentina Durastanti, Filippo Menolascina, Brunella Caronti, Francesco Marincola, Ena Wang, Lorenzo Uccellini, Enrico Millefiorini, Antonio Cortese, Alessandro Monaco P02.200 Hiccup, Nausea, and Vomiting: Neuromyelitis Optica in a Teenage Girl Joanne Riphagen, Piet Modderman, Aad Verrips P02.201 Coexistence of Anti-NMO IgG and Anti-GFAP in Neuromyelitis Optica Ioanna Chatzi, Haralambos Alexopoulos, Athanasia Alexoudi, Dimitrios Tzortzis, Georgia Dokou, Panagiota Filippakopoulou, Marinos Dalakas, Clementine Karageorgiou P02.202 Evaluation of Health-Related Quality of Life, Fatigue and Depression in Neuromyelitis Optica Jean-Baptiste Chanson, Hélíne Zéphir, Nicolas Collongues, Olivier Outteryck, Frédéric Blanc, Marie Fleury, Patrick Vermersch, Jérôme de Seze P02.203 Early Diagnostic Biomarker in Patients with First Neurological Manifestation Suggestive of Multiple Sclerosis or Neuromyelitis Optica Rita Vadalà, Antonio Cortese, Brunella Caronti, Mauro De Angelis, Alberto Pierallini, Enrico Millefiorini, Elisabetta Giugni, Valentina Durastanti P02.204 Severe Relapse Despite B-Cell Depletion in Neuromyelitis Optica Claire Riley, Mark Tullman P02.205 Fulminant Neuromyelitis Optica Associated with Human Papilloma Virus Vaccination Til Menge, Bruce Cree, Andreas Saleh, Orhan Aktas, Hans-Peter Hartung, Axel Methner, Bernd Kieseier Poster Session II Tuesday, April 13 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P02.206 Case-Report: High-Dose Immunoablation with Autologous Stem Cells Transplantation in Neuromyelitis Optica Eva Krasulova, David Pohlreich, Blanka Vackova, Marek Trneny, Manuela Vaneckova, Zdenek Seidl, Petra Nytrova, Helena Mareckova, Dana Horakova, Eva Havrdova P02.207 Antiaquaporin 4 Antibodies Detection in Neuromyelitis Optica (NMO) Patients Andres Villa, Pablo Mannucci, Luciana Melamud, Orlando Garcea Clinical Epilepsy P02.208 Coverage of Epilepsy and Driving in US Newspapers Srijana Zarkou, Joseph Drazkowski, Katherine Noe, Matthew Hoerth, Joseph Sirven P02.209 Perceptions of Epilepsy at Mulago Hospital in Kampala, Uganda Jeffrey Bigelow P02.210 Treatment Continuation Patterns, Resource Use, and Costs Among Patients with Epilepsy in a Medicaid Population Jamie Forlenza, Stephen Johnston, Laurie Costa, Greg Lenhart, Emily Durden, Steve Ascher, Augusto Grinspan P02.211 The Epilepsy Treatment Gap in the Ecuadorian Amazon Patricio Espinosa, Aaron Berkowitz, Nicole Falcone, Denise Dvorquez, Kathleen Principe, William Principe, Melissa Murphy, Christopher Shanahan, Ann Kao, Dominic Fee, Karin Swartz, Blanca Vasquez, Sydney Cash P02.212 Assessing the Value of a Medical Home for Children and Youth with Epilepsy in Medically Underserved and Rural Populations Paul Levisohn, Deborah McGruder P02.213 A Study on the Change of Quality of Life in People with Epilepsy after Two-Year Follow-Up Zhen Hong, Dehao Zhao, Peimin Yu, Guoxing Zhu P02.214 Do Mood Instability Symptoms in Epilepsy Represent Formal Bipolar Disorder? Connie Lau, Alan Ettinger, Sandra Hamberger, Kristina Fanning, Michael Reed P02.215 Health Anxiety and Somatic Vigilance in Epilepsy and Non-Epileptic Behavioral Spells Danielle Koby, Cindy Nelson, Max Trenerry, Gregory Worrell P02.216 Oro-Dental and Maxillofacial Trauma in Epilepsy: Our Experience at a Tertiary Hospital in Lagos Francis Ojini, Richard Adewole, Mustapha Danesi P02.217 Spinal Cord Compression: A Potential Risk in Individuals with Mental Retardation and Epilepsy Sonia Lal, Raveen Deol, Venkat Ramani P02.218 Rapid Screening for Anxiety and Major Depressive Disorders and Suicidal Risk in an Outpatient Neurology Clinic Andres Kanner, Erica Sanchez, Hilary Kanner P02.219 Cognitive Function Assessment in Patients with Epilepsy Using Community Screening Interview for Dementia Taofiki Sunmonu, Olubunmi Ogunrin, Morenikeji Komolafe, Adesola Ogunniyi P02.220 Fatigue in People with Epilepsy. The Validation of the Fatigue Symptom Inventory, the Fatigue Assessment Instrument, and the Fatigue Severity Scale in Patients with Epilepsy Jose Tellez Zenteno, Lizbeth Hernandez-Ronquillo, Moien-Afshari Farzad, Britz Jan, Knox Katherine P02.221 MERRF: Clinical Features, Muscle Biopsy, and Molecular Genetics Paulo Lorenzoni, Rosana Scola, Claudia Kay, Raquel Arndt, Carlos Silvado, Lineu Werneck P02.222 Frequency and Correlates of Perceived Stigma in a Nigerian Epilepsy Population Michael Fawale, Mayowa Owolabi, Adesola Ogunniyi P02.223 Early Seizures after Discharge from a Seizure Monitoring Unit Sunil Goli, Suzanne Miller, Edward Faught P02.224 Effect of Pregnancy on Seizure Frequency in Women with Epilepsy Angela La Neve, Marzia Plantamura, Giovanni Boero, Teresa Francavilla, Giuseppe Pontrelli, Paolo Lamberti, Giancarlo Logroscino P02.225 Inadequate Vitamin D Levels in Pediatric Patients with Epilepsy Leon Weinstock, Raya Wehbeh, Barbara Teter, Bianca Weinstock-Guttman P02.226 Recurrent Status Epilepticus as the Primary Neurological Manifestation of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL): A Case Report Catherine Ikard, James Schmidley, Naim Haddad P02.227 Mycophenolate Mofetil Responsive Anti-Glutamic Acid Decarboxylase Antibody Associated Limbic Encephalitis Shiv Saidha, Sinead Murphy, Aoife Ronayne, Peter McCarthy, Michael Hennessy, Timothy Counihan Anterior Horn: Clinical Studies P02.228 Computerized Dynamic Posturography (CDP) Identifies an Early Subclinical Balance Disorder in Amyotrophic Lateral Sclerosis (ALS) Patients Not Diagnosed by Clinical Balance Assessment Mohammed Sanjak, Mark Hirsch, Kimberly Lang, Kerry Duffy, Amber Ward, Jordan Lyerly, Jaime Shue, Priscilla Russo, Urvi Desai, Elena Bravver, Benjamin Brooks P02.229 Detecting Disordered Sleep in Patients with ALS: Results of a 10-Minute Targeted Sleep Questionnaire Hans Katzberg, Adam Seligman, Nancy Yuan, Charles Cho, Jonathan Katz, Robert Miller, Yuen So P02.230 Validation of a Shorter ALSSpecific Quality of Life Instrument: The ALSSQOL-R Zachary Simmons, Stephanie Felgoise, Jamie Rodriguez, Susan Walsh, Barbara Bremer, Helen Stephens P02.241 Baseline and Longitudinal Perspectives on Motor Cortex Grey and White Matter in ALS Kevin Yang, Christopher Hanstock, Myrlene Gee, Sanjay Kalra P02.231 Prospective Study of Depression, ALS-Related Symptoms, and Research Enrollment Nazem Atassi, Merit Cudkowicz P02.242 Slow Saccades in BulbarOnset Amyotrophic Lateral Sclerosis (ALS) Colette Donaghy, Ralph Pinnock, Raeburn Forbes, Chris Cardwell, Orla Hardiman, Victor Patterson, R. McGivern, J. Gibson P02.232 Utility of Forced Expiratory Volume in Six Seconds for Assessment of Respiratory Function in Patients with Amyotrophic Lateral Sclerosis Margaret Walker, Susan Gronka, Sharon Usher, Nazem Atassi, Joanne Wuu, Mary Lou Watson, Jeremy Shefner, Merit Cudkowicz, Michael Benatar P02.233 Plasma Levels of Neurofilament Heavy Subunit (NF-H) Are Increased in ALS Patients; Correlation with Site of Onset and Survival in Patients at Two Centers in Evaluation of Plasma NF-H as a Potential ALS Biomarker Kevin Boylan, Jonathan Glass, Cui Yang, Julia Crook, Michael Heckman, Kelly Crystal, Meraida Polak, Gerry Shaw P02.234 Effects of Noninvasive Ventilation on Sleep Outcomes in Patients with Amyotrophic Lateral Sclerosis Hans Katzberg, Adam Seligman, Nancy Yuan, Charles Cho, Jonathan Katz, Robert Miller, Yuen So P02.235 Muscle Ultrasound Quantifies Reduction of Muscle Thickness over Time in ALS Patients Christopher Lee, Amanda Peltier, Peter Donofrio P02.236 Using Eye Movements to Distinguish Amyotrophic Lateral Sclerosis (ALS) from Its Variants and Mimics Colette Donaghy, Matthew Thurtell, Erik Pioro, R. Leigh P02.237 The Prevalence and Effect of Diabetes on the Course of Amyotrophic Lateral Sclerosis Zaid Al-Qudah, Lubna Mehyar, Natalia Krivitskaya, Khan Hafiz, Shahanara Islam, Nazsa Baker, Nizar Souayah P02.238 Evidence for a Decreased Activity of the Resting State Motor Network in Patients with ALS Massimo Filippi, Martina Absinta, Federica Agosta, Maria Rocca, Paola Valsasina, Stefania Sala, Nilo Riva, Alessandro Prelle, Domenico Caputo, Michele Perini, Raffaella Fazio, Giancarlo Comi P02.239 Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels in ALS Patients Isabella Simone, Maddalena Ruggieri, Rosanna Tortelli, Eustachio D’Errico, Antonio Leo, Mariangela Mastrapasqua, Rosaria Leante, Rosa Capozzo, Paolo Livrea, Giancarlo Logroscino P02.240 15-30 Hz Intermuscular Coherence: A Novel Biomarker of Upper Motor Neurone Dysfunction in Amyotrophic Lateral Sclerosis Karen Fisher, Mark Baker, Boubker Zaaimi, Stephan Jaiser, Tim Williams, Stuart Baker P02.243 Assessment of CSF Biomarkers in a Pilot Study of Memantine in ALS Todd Levine, Robert Bowser, Nicole Hank, David Saperstein P02.244 Nutritional Prognostic Factors in Amyotrophic Lateral Sclerosis Johannes Dorst, Albert Ludolph, Corinna Hendrich, Peter Kuehnlein, AnneDorte Sperfeld P02.245 Shoulder Pain in ALS Doreen Ho, Robin Ruthazer, James Russell P02.246 Oral Secretion Scale (OSS) Score in Amyotrophic Lateral Sclerosis (ALS) Patients Is Associated with Tolerance of Noninvasive Positive Pressure Ventilation (NPPV), Need for Hospice or Transition to Tracheal Positive Pressure Ventilation (TPPV) and Survival Pamela Cazzolli, Benjamin Brooks, Joseph Lewarski, Douglas McKim, Robert Chatburn Muscle Disease/Neuromuscular Junction: Mitochondrial Disorders: Clinical P02.247 Maternally Inherited LimbGirdle Myopathy with Neck Extensor and Cardiopulmonary Involvement Resulting from a Mitochondrial tRNA Leu3302 Point Mutation Annabel Wang, Mariella Simon, Douglas Wallace, Tahseen Mozaffar P02.248 A Novel Mitochondrial tRNAIle Mutation Uniquely Affecting the Variable Loop in a Patient with Chronic Progressive External Ophthalmoplegia (CPEO) Andres Berardo, Jorida çoku, Bulent Kurt, Salvatore Di Mauro, Michio Hirano P02.249 Clinical and Molecular Characterization of the MERRF Mutation A8344G in a Family without CNS Involvement Veronica Crugnola, Lorenzo Peverelli, Andreina Bordoni, Patrizia Ciscato, Diego Spagnoli, Nereo Bresolin, Giacomo Comi, Maurizio Moggio, Monica Sciacco P02.250 Diverse Clinical Presentations in Adults with Carnitine Deficiency Yitao Ma, Douglas Laske, Daniel Brown, Jin Luo P02.251 Mitoshondrial Myopathy, a Rare or a Common Human Disease? Based on Nationwide MELAS Cohort Study Yasutoshi Koga, Shu-ichi Yastuga, Nataliya Povalko, Toyojiro Mastuishi P02.252 Cardiofaciocutaneous Syndrome Due to BRAF Mutation Causes CoQ10 Myopathy Paul Golumbek, Alan Pestronk, Robert Heuckeroth 51 Poster Session II P02.253 Relapsing Encephalopathy Associated with Coenzyme Q10 Deficiency R. Brian Sommerville, Anne Cross, Alan Pestronk P02.254 A Prospective Randomized Double-Blind and Placebo-Controlled Phase II Trial— Effect of CoQ 10 on Statin-Induced Mitochondrial Dysfunction Naganand Sripathi, Kavita Grover, Lester Kobylak, Mei Lu, Lonni Schultz, Christine Geauvreau, Georgirene Vladutiu P02.255 Acquired and Environmental Mitochondrial Toxicity in Patients with Adult-Onset Chronic Progressive External Ophthalmoplegia Gerald Pfeffer, Sandra Sirrs, Michelle Mezei P02.256 “Incidental” Mitochondrial Myopathy Veronica Crugnola, Valeria Lucchini, Dario Ronchi, Maria Grazia D’Angelo, Andreina Bordoni, Gigliola Fagiolari, Lorenzo Peverelli, Stefano Jann, Nereo Bresolin, Giacomo Comi, Maurizio Moggio, Monica Sciacco Muscle Disease/Neuromuscular Junction: Myopathy: Clinical Studies P02.257 Genetic Markers for CK Outliers in Army Recruits; Relationship to Exertional Rhabdomyolysis? Kimbra Kenney, Rodney Gonzalez, Carmen Contreras-Sesvold, Andre Blokhin, Nyamkhishig Sambuughin, Patricia Deuster, Laurie Hoover, Sheila Muldoon, William Campbell P02.258 Clinicopathological Features of Patients with Dermatomyositis with Subcutaneous Edema Akihiro Sugai, Tetsuya Takahashi, Takayoshi Shimohata, Masatoyo Nishizawa P02.259 Autoimmune Myopathy without Inflammation (AMWI); Clinical and Laboratory Features Nizar Chahin P02.260 Sporadic Inclusion Body Myositis: Evaluation of 116 Cases Matthew Wicklund, William Arnold, John Kissel P02.261 Amyloid Myopathy: A Diagnostic Dilemma Isaac Annan, Kymberly Gyure, Ludwig Gutmann P02.262 Electromyography in Dropped Head Syndrome Following Remote Radiation Shahram Gharibshahi, William Arnold, Bakri Elsheikh, John Kissel P02.263 Prevalence and Risk Factors of Muscular Complications among Patients Using Statins Khalid El-Salem, Bashar Ababneh, Ahmed Malkawi, Yousef Khader, Ali Alrefai P02.264 Myopathy Developed during Clevudine Therapy Myung-Goo Ji, Nam Hee Kim P02.265 Acetazolamide-Induced Recurrent Paralysis Yessar Hussain, Deborah Bradshaw 52 Tuesday, April 13 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P02.266 Characterization of Electrophysiological Findings in 55 Patients with Biopsy-Proven Critical Illness Myopathy Andrew Godbey, Muhammad Al-Lozi P02.267 Psychometric Evaluation of the Short Form 36 and Individualized Neuromuscular Quality of Life (INQoL) Questionnaire Domains in Patients with Muscle Disease and Myasthenia Gravis (MG) Reza Sadjadi, Michael Rose Ethics, Pain, and Palliative Care P02.268 Ethical and Social Challenges in Healthcare for Adolescents and Young Adults with Cerebral Palsy Danae Lariviere-Bastien, Eric Racine P02.269 Experience and Attitudes of Healthcare Professionals Regarding Ethics Issues and End-of-Life Decision Making in Patients Suffering from Chronic Disorders of Consciousness Catherine Rodrigue, Eric Racine, Richard Riopelle, James Bernat P02.270 Hope and Patient Expectation in Deep Brain Stimulation (DBS): Healthcare Provider Perspectives and Approaches Emily Bell, Bruce Maxwell, Mary Pat McAndrews, Eric Racine P02.271 Euthanasia in Patients Suffering from Dementia: PatientOriented Ethical Approach Patrick Cras, Willem Van Ijperen, Ellen Peeters P02.272 Quantitative Assessment of the Pain Disability in Individuals with Nervous System Disorders Due to Polytrauma, According to the AMA Guides to Evaluation of Permanent Impairment Fifth Edition Armando Miciano P02.273 Worsening of Fibromyalgia Symptoms Following Abrupt Discontinuation of Milnacipran: Results from a Randomized, Double-Blind, Placebo-Controlled Trial Philippe Saxe, Lesley Arnold, R. Michael Gendreau, Allan Spera, Judy Gendreau, Yong Wang P02.274 The Efficacy and Tolerability of Milnacipran 100 mg/day Monotherapy for the Management of Fibromyalgia: A Randomized, Double-Blind, PlaceboControlled Trial Lesley Arnold, R. Michael Gendreau, Allan Spera, Judy Gendreau, Yong Wang P02.275 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Trial of Intradermal Onabotulinumtoxin A Injections in the Treatment of Post Herpetic Neuralgia (PHN) Michael Tuchman, Patrick Kesslak, Wayne Lam, Rozalina Dimitrova, Amanda Vandenburgh, Mitchell Brin, Susan Abu-Shakra P02.276 Efficacy and Safety of LongTerm Lidocaine Trigger Point Injections in Patients with Chronic Musculoskeletal Pain Mihaela Hangan, Neetu Dhadwal, Frances Dyro, Jin Li P02.277 Ethical Challenges Encountered in an Experimental Research Protocol for Rabies Encephalitis Aarti Sarwal, Joshua Botdorf, David Fleming P02.278 Palliative Care in Neurological Catastrophes: Guidelines for System-Specific Supportive Care Amy Sullivan, Keith Swetz P02.279 The Enigma of a Chronic Pain Syndrome-A High Level of Diagnostic Suspicion, Vigilance, and Close Follow-Up Sometimes Results in an Alternative Diagnosis (Acute Intermittent Porphyria) Jay Rosenberg, Andrew Blumenfeld Sleep Disorders: Restless Legs Syndrome Treatment P02.280 A Randomized, Crossover Polysomnography Study of Gabapentin Enacarbil in Subjects with Moderate-toSevere Primary Restless Legs Syndrome and Associated Sleep Disturbance John Hudson, Markus Schmidt, Richard Bogan, John Winkelman, Sarah DeRossett, Christina Hill-Zabala P02.281 An Open-Label, 52-Week Extension Study to Assess the Long-Term Tolerability and Efficacy of Gabapentin Enacarbil in Subjects with Moderateto-Severe Primary Restless Legs Syndrome Aaron Ellenbogen, Stephen Thein, David Winslow, Philip Becker, Jerry Tolson, Heather Conklin, Marie-Liesse Lassauzet, Dan Chen P02.282 Population Pharmacokinetics and Pharmacodynamics of Gabapentin after Administration of Gabapentin Enacarbil in Subjects with Primary Restless Legs Syndrome Ritu Lal, Juthamas Sukbuntherng, Kenneth Cundy P02.283 Gabapentin Enacarbil Improves RLS Symptoms and Subjective Measures of Sleep in Subjects with Primary Restless Legs Syndrome with and without Severe Sleep Disturbance: Secondary Analyses from Two Studies Richard Bogan, Aaron Ellenbogen, Philip Becker, Eric Ball, William Ondo, Clete Kushida, Nicola Williams, Christine Caivano P02.284 Gabapentin Enacarbil Relieves the Pain Associated with Restless Legs Syndrome Ronald Ziman, Daniel Lee, A. Thomas Perkins, J. Steven Poceta, Arthur Walters, Ronald Barrett P02.285 An Examination of Mood, Quality of Life, and Function in Subjects with Primary Restless Legs Syndrome (RLS) Treated with Gabapentin Enacarbil Compared with Placebo Ronald Ziman, Daniel Lee, A. Thomas Perkins, J. Steven Poceta, Arthur Walters, Ronald Barrett P02.286 Evaluating Maintenance of Improvements in Sleep and Quality of Life in Subjects with Restless Legs Syndrome Treated with Gabapentin Enacarbil for up to 36 Weeks Richard Bogan, Michel Cramer Bornemann, Clete Kushida, Ronald Barrett P02.287 An Evaluation of Gabapentin Enacarbil and Restless Legs Syndrome Symptom Augmentation in Subjects Treated for 12 Weeks: Secondary Analyses from Two Studies Aaron Ellenbogen, Richard Bogan, Eric Ball, William Ondo, Clete Kushida, Nicola Williams, Christine Caivano P02.288 Augmentation during Treatment with Ropinirole in Restless Legs Syndrome. Results From a Prospective, Multicentric Study Over 66 Weeks Diego Garcia-Borreguero, Birgit Högl, Luigi Ferini-Strambi, John Winkelman, Christina Hill-Zabala, Richard Allen Sleep Disorders: Restless Legs Syndrome Pathology and Pathophysiology P02.289 Neuroanatomical Aspect of the Diencephalospinal Dopaminergic Pathway in the Non-Human Primate: Potential Implications for Restless Legs Syndrome Quentin Barraud, Incarnation Aubert, Ibrahim Obeid, Francois Tison, Erwan Bezard, Ghorayeb Imad P02.290 Proteomic Analysis of the Cerebrospinal Fluid of Patients with Restless Legs Syndrome Stephanie Patton, Thomas Clardy, Yong-Won Cho, Richard Allen, Christopher Earley, James Connor P02.291 A New Locus for Familial Restless Legs Syndrome on Chromosome 21 in a Large Utah Kindred Jacinda Sampson, Lisa Baird, Brith Otterud, Mark Leppert Guidelines, Government Relations, and Getting Paid A thriving neurology practice needs a blueprint for success. Your Academy helps you use the latest research, technology, and tools to enhance your practice and provide the best possible care to your patients. Get expert advice and share experiences: • Discuss evaluation and management (E/M) coding with colleagues • Speak with guidelines authors • Network with peers who have participated in Academy advocacy programs • Learn how to use quality and performance measures Free to all Annual Meeting attendees. Monday, April 12, 3:00 p.m.–5:00 p.m. | InterContinental Toronto Centre, Ballroom B Learn more at www.aan.com/view/bce Scientific Sessions S11 Multiple Sclerosis: Clinical Trials I Theatre 102 Constitution Hall 106 4:00 p.m. S11.001 Optimal Design and Analysis of Phase I/II Clinical Trials in Multiple Sclerosis with Gadolinium Enhancing Lesions as the Endpoint Brian Healy, David Ikle, Gary Cutter 4:00 p.m. S12.001 Safety of Full Dose Intravenous rt-PA Followed by Intra-Arterial Therapy for Acute Cerebral Infarction Raul Nogueira, Shihab Masrur, Leonardo Batista, Reza Hakimelahi, Albert Yoo, Lee Schwamm 4:15 p.m. S11.002 Twice Weekly Versus Daily Glatiramer Acetate: Results of a Randomized, Rater-Blinded Prospective Clinical Trial Clinical and MRI Study in RelapsingRemitting MS Christina Caon, Jai Perumal, Alexandros Tselis, Wendy Ching, Fen Bao, Zahid Latif, Imad Zak, Omar Khan 4:30 p.m. S11.003 A Randomized, Controlled Trial of Neuroprotection with Lamotrigine in Secondary Progressive Multiple Sclerosis Raju Kapoor, Julian Furby, Thomas Hayton, Kenneth Smith, Daniel Altmann, Robert Brenner, Jeremy Chataway, Richard Hughes, David Miller 4:45 p.m. S11.004 Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-Month Clinical Efficacy Results from a Randomized, DoubleBlind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS) Ludwig Kappos, Paul O’Connor, Chris Polman, Reinhard Hohlfeld, Ernst-Wilhelm Radue, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin ZhangAuberson, on Behalf of the FREEDOMS Study Group 5:00 p.m. S11.005 Oral Fingolimod (FTY720) Reduces Inflammatory Activity vs Placebo in RelapsingRemitting Multiple Sclerosis: 24-Month MRI Results from a Randomized, DoubleBlind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS) Ernst-Wilhelm Radue, Paul O’Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Lixin Zhang-Auberson, Malgorzata Leyk, Ludwig Kappos, on Behalf of the FREEDOMS Study Group 54 S12 Cerebrovascular Disease: Acute Stroke Therapy 4:15 p.m. S12.002 Risk of Thrombolysis in Older Patients: Analysis of a Large Database Afshin Mohammadi, Salvador Cruz-Flores, Randall Edgell, Nirav Vora, Amer Alshekhlee 4:30 p.m. S12.003 Gaze Paralysis in the Baseline NIH Stroke Scale (NIHSS) Exam Is an Independent Predictor of Hemorrhagic Complications After Ischemic Stroke Sherman Chen, Enrique Leira, Patricia Davis, James Torner, Jason Day, Harold Adams 4:45 p.m. S12.004 Increasing IV rt-PA Use Using Modern Eligibility Criteria. The Simplified Management of Acute Stroke Using Revised Treatment (SMART) Criteria Study: Feasibility, Safety, and Efficacy David Tong, Nobl Barazangi, Jack Rose, Shirley Chen, Jeff Thomas, Daniel McDermitt, Ann Bedenk, Jackie Phan 5:00 p.m. S12.005 Effect of Admission Blood Glucose on tPA -Induced Arterial Recanalization in Acute Ischemic Stroke: A MultiCenter Transcranial Doppler Study Joseph Sebastian, Carol Derksen, Mohammad Ibrahim, Georgios Tsivgoulis, Andrei Alexandrov, Vijay Sharma, Ken Uchino, Andrew Demchuk, Ashfaq Shuaib, Maher Saqqur Tuesday, April 13 | 4:00 p.m.–5:15 p.m. Metro Toronto Convention Centre S13 Movement Disorders: Huntington's Disease: Pathophysiology and Clinical Assessment Room 718AB 4:00 p.m. Presentation of the Jon Stolk Award in Movement Disorders for Young Investigators Recipient: E. Ray Dorsey, MD Rochester, NY 4:15 p.m. S13.002 Using the Mattis Dementia Rating Scale (DRS) To Track Cognitive Change in Huntington’s Disease (HD) Jody Corey-Bloom, Steven Edland, Jody Goldstein, Guerry Peavy, Mark Jacobson, Stephanie Lessig 4:30 p.m. S13.003 A New Factor To Reduce Levels of Aggregates Formed by Mutant Huntingtin, Ataxin-3 and SOD1: The Cytosolic Aminopeptidase PSA Raphael Hourez, Alfred Goldberg 4:45 p.m. S13.004 GH Response to Arginine Test Differentiates Two Subgroups of Huntington’s Disease Patients Elena Salvatore, Carlo Rinaldi, Tecla Tucci, Luigi Di Maio, Carolina Di Somma, Silvia Savastano, Gaetano Lombardi, Alessandro Filla, Annamaria Colao, Giuseppe De Michele 5:00 p.m. S13.005 Identification and Validation of an Abnormal Metabolic Network Associated with Phenoconversion of Preclinical Huntington’s Disease Chengke Tang, Andrew Feigin, Matthew Bussa, Yilong Ma, Shichun Peng, Mark Guttman, Jane Paulsen, Vijay Dhawan, David Eidelberg S14 Aging and Dementia: Epidemiology S15 Epilepsy: Clinical Neurophysiology and Imaging S16 Anterior Horn: Clinical Studies Constitution Hall 107 Room 701A Constitution Hall 105 4:00 p.m. S14.001 Diabetes Mellitus and Its Treatments Predict Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging Rosebud Roberts, Yonas Geda, David Knopman, Ruth Cha, V. Pankratz, Bradley Boeve, Robert Ivnik, Ronald Petersen, Walter Rocca 4:00 p.m. S15.001 Spontaneous Seizures Recorded Intraoperatively on Hippocampal Electrocorticography (IH-ECoG) and Hippocampal Pathology Aashit Shah, Darren Fuerst, Ian Zitron, Marie Atkinson, William Kupsky, Sandeep Mittal 4:00 p.m. S16.001 Lithium Carbonate in ALS: A Treatment Failure Adriano Chio, Gabriele Mora, Massimo Corbo, Claudia Caponnetto, Jessica Mandrioli, Fabrizio Salvi, Gianni Sorar∙, Letizia Mazzini, Vincenzo Silani, Maria Rosaria Tola, Fabio Giannini, Mario Sabatelli, Maria Monsurr≥, Giuseppe Borghero, Isabella Simone , Michele Perini, Francesco Patti, Norina Marcello, Vladimiro Pietrini, Fabrizio Pisani, Elisabetta Pupillo, Andrea Calvo, Cristina Moglia, Giancarlo Logroscino, Ettore Beghi 4:15 p.m. S14.002 Incident Dementia in Mild Cognitive Impairment Varies According to Cognitive Domains David Knopman, Rosebud Roberts, Walter Rocca, Vernon Pankratz, Ruth Cha, Ronald Petersen 4:30 p.m. S14.003 Physical Activity Over the Life Course and Its Association with Cognitive Impairment in Old Age Laura Middleton, Deborah Barnes, Li-Yung Lui, Kristine Yaffe 4:45 p.m. S14.004 Mediterranean Diet (MeDi) and Subclinical Cerebrovascular Disease Adam Brickman, Jose Luchsinger, Truman Brown, Charlie DeCarli, Yaakov Stern, Yian Gu, Nikolaos Scarmeas 5:00 p.m. S14.005 Higher Incidence of Amnestic Than Non-Amnestic Mild Cognitive Impairment: The Mayo Clinic Study of Aging Rosebud Roberts, Yonas Geda, David Knopman, Bradley Boeve, Ruth Cha, V. Pankratz, Robert Ivnik, Walter Rocca, Ronald Petersen 4:15 p.m. S15.002 Gray Voxel-Based Morphometry (VBM) and Clinical Findings of Three Patterns of Drug Response in Mesial Temporal Lobe Epilepsy (MTLE) Elizabeth Bilevicius, Clarissa Yasuda, Mariana Silva, Carlos Guerreiro, Iscia Lopes-Cendes, Fernando Cendes 4:30 p.m. S15.003 Correlation of MRI Involvement with Clinical and EEG Data in Sturge-Weber Syndrome Georg Evers, András Fogarasi, Cecilia Mellado, Ingrid Tuxhorn, Péter Halász, Péter Barsi, György Rásonyi, Csilla Gyimesi, Zsuzsanna Siegler, József Janszky, Rita Jakus, Dean Sarco, Richard Burgess, Mustafa Sahin, Friedrich G. Woermann , Tobias Loddenkemper 4:45 p.m. S15.004 SPECT Perfusion Patterns in Temporal Lobe Epilepsy— Correlation with Ictal EEG, MRI, and Surgical Outcome Sita Sattaluri, Pushpalatha Sudhakar, Manas Panigrahi, Sundaram Challa 5:00 p.m. S15.005 Left Temporal PET Hypometabolism Predicts fMRI Language Laterality William Gaillard, Elizabeth Duke, Edythe Wiggs, Andrey Finegersh, Clarissa Liew, Irene Dustin, Sabina Miranda, Susumu Sato, William Theodore Scientific Sessions Tuesday, April 13 | 4:00 p.m.–5:15 p.m. 4:15 p.m. S16.002 Phase II Controlled Trial of Lithium Carbonate in Patients with Amyotrophic Lateral Sclerosis Robert Miller, Dallas Forshew, Jonathan Katz, Dan Moore, Mark Spitalny, Michael Valan, Richard Barohn, Mark Bromberg, Kimberly Goslin, Michael Graves, Leo McCluskey, April McVey, Tahseen Mozaffar, Alan Pestronk, Mark Ross, Ericka Simpson 4:30 p.m. S16.003 Cognitive Impairment Is a Negative Prognostic Indicator in ALS: A Population -Based Study Marwa Elamin, Julie Phukan, Susan Byrne, Norah Jordan, Nail Pender, Orla Hardiman 4:45 p.m. S16.004 Examination of SOD1 Protein Levels in the CSF of ALS Patients Seung-Joo Chun, Matthew Jaffa, Leah Winer, Merit Cudkowicz, Timothy Miller 5:00 p.m. S16.005 Cerebrospinal Fluid Biomarkers Panel in Amyotrophic Lateral Sclerosis James Connor, Ryan Mitchell, Zachary Simmons S17 Critical Care, Trauma, and Inpatient Neurology Room 701B 4:00 p.m. Presentation of the Founders Award Recipient: Farrah Mateen, MD Baltimore, MD 4:15 p.m. S17.002 The Effect of Concussion on Clinically Measured Reaction Time in NCAA Division I Collegiate Athletes: A Pilot Study James Eckner, Jeffrey Kutcher, James Richardson 4:30 p.m. S17.003 Effect of Serum Glucose Concentrations during Acute Hospitalization on Hematoma Expansion, Perihematomal Edema, and Three-Month Outcome among Patients with Intracerebral Hemorrhage. Results from the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) Study Adnan Qureshi, Yuko Palesch, Renee Martin, Jill Novitzke, Salvador Flores, Asad Ehtisham, Mustapha Ezzeddine, Joshua Goldstein, Jawad Kirmani, Haitham Hussein, M. Fareed Suri, Nauman Tariq, Yaun Liu, ATACH Investigators 4:45 p.m. S17.004 Neurohospitalists Reduce Length of Stay for Acute Ischemic Stroke Patients Steven Dawson, Kevin Barret, Carol Raper, William Freeman 5:00 p.m. S17.005 Validation of CT Classification Scale for Clinical Trials of Traumatic Brain Injury Victoria Pan, Caryn Harper, Carol Moore, Christopher Madden, Ramon Diaz-Arrastia S18 Interventional Neurology S19 Movement Disorders: Dystonia S20 Neurologic Education Room 714A Room 717AB Room 713AB 4:00 p.m. S18.001 Intracranial Angioplasty and/or Stent Placement in Octogenarians Is Associated with a Threefold Greater Risk of Periprocedural Stroke or Death Robert Taylor, Nauman Tariq, M. Fareed Suri, Farhan Siddiq, Gabriela Vazquez, Ramachandra Tummala, Joan Wojak, John Chaloupka, Adnan Qureshi 4:00 p.m. S19.001 Botulinum Toxin Injections Reduce Excessive Cortical Plasticity in Patients with Cervical Dystonia Maja Kojovic, Antonio Caronni, Matteo Bologna, Kailash Bhatia, John Rothwell, Mark Edwards 4:00 p.m. S20.001 Assessing Core Competencies in Clinical Neurophysiology: A Vignette-Based Tool Devon Rubin, Eric Sorenson, Joseph Drazkowski, Barbara Westmoreland 4:15 p.m. S18.002 Safety of Elective Coiling of Cerebral Aneurysms Equal or Less Than 7mm: A Multicenter Analysis Osama Zaidat, Junaid Kalia, Leonardo Batista, Sabareesh Natarajan, Mahmoud Rayes, Vahid Etezadi, Johynny Pryor, Raul Nogueira, Elad Levy, Andrew Xavier, Rishi Gupta, Italo Linfante, Thanh Nguyen, Sandra Narayanan, Albert Schuette, Randall Edgell 4:30 p.m. S18.003 A Review of Periprocedural Stroke and Death Rates in 18,205 Patients Undergoing Carotid Angioplasty and Stent Placement Alberto Maud, Silvina Tonarelli, Gabriela Vazquez, M. Fareed Suri, Adnan Qureshi 4:45 p.m. S18.004 Natural History of Asymptomatic Restenosis Following Endovascular Treatment of Symptomatic Intracranial Stenosis. A Multicenter Study Haitham Hussein, Nauman Tariq, Stanley Kim, Ameer Hassan, M. Fareed Suri, Ramachandra Tummala, Robert Taylor, Mohammad Abdelmoula, Adnan Qureshi 4:15 p.m. S19.002 De Novo and Recurrent Mutations in ATP1A3 Are Common in Rapid-Onset Dystonia-Parkinsonism Allison Brashear, Debbie Hill, Beverly Snively, Kathleen Sweadner, Laurie Ozelius 4:30 p.m. S19.003 Are the Yips a Form of Golfer’s Cramp or Focal, Task-Specific Dystonia Charles Adler, Debra Crews, Kanav Kahol, Marco Santello, Brie Noble, John Caviness 4:45 p.m. S19.004 Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Patients with Primary Cranial Cervical Dystonia Jill Ostrem, Jamie Grace, Graham Glass, Caroline Racine, Monica Volz, Susan Heath, Philip Starr 5:00 p.m. S19.005 New Triggers in Rapid-Onset Dystonia-Parkinsonism (RDP) Allison Brashear, Debbie Hill, Beverly Snively, Kathleen Sweadner, Laurie Ozelius 4:15 p.m. S20.002 Effects on Knowledge Retention Produced by Repeated Testing with Standardized Patients in Neurological Education Douglas Larsen, Amy Lawson, Andrew Butler, Henry Roediger III 4:30 p.m. S20.003 The Standardized Patient Outcomes Trial (SPOT) in Neurology: Assessing the Effectiveness of the Standardized Patient Session at Teaching the Cranial Nerve Exam Andrew Lin, Yoon Kang, Juliet Aizer, Joseph Safdieh 4:45 p.m. S20.004 Is Team-Based Learning Effective in Undergraduate Neurology Education? Kevin Tan, Nagaendran Kandiah, Nigel Tan 5:00 p.m. S20.005 Evaluating Medical Student Professionalism in a Neurology Clinic From the Patient Perspective Larry Davis, Molly King 5:00 p.m. S18.005 Comparison between Thrombolytic Bridging Therapy and Primary Endovascular Treatment in Acute Ischemic Stroke: A Multicenter Study Jefferson Miley, Gabriela Vazquez, Muhammad Zeeshan Memon, Haitham Hussein, M. Fareed Suri, Gustavo Rodriguez, Ramachandra Tummala, Robert Taylor, Adnan Qureshi 55 Wednesday, April 14 Highlights Poster Discussion Session Exhibits 7:30 a.m.–12:00 p.m. (Author stand by poster from 7:30 a.m.–9:00 a.m.) 11:30 a.m. 5:00 p.m. 3:00 p.m.–7:30 p.m. (Author stand by poster from 6:00 p.m.–7:30 p.m.) MTCC, Exhibit Hall DE Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. Contemporary Clinical Issues and Case Studies Plenary Session 9:00 a.m.–12:00 p.m. MTCC, Exhibit Hall FG Moderator: Carlayne E. Jackson, MD, FAAN, Member, Science Committee This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. In addition to the Contemporary Clinical Issues discussion, a case study format addresses topics of interest. David B. Clifford, MD, FAAN Washington University School of Medicine/Saint Louis, MO Discussant: Kenneth L. Tyler, MD, FAAN/Denver, CO David W. Dodick, MD Mayo Clinic-Phoenix/Phoenix, AZ Discussant: Anne Louise Oaklander, MD, PhD, FAAN/Lincoln, MA Hans-Christoph Diener, MD, PhD, FAHA, FAAN University Duisburg-Essen/Essen Germany Discussant: Robert G. Hart, MD/San Antonio, TX In addition to the Contemporary Clinical Issues discussion, a case study format will be presented by the following presenters: Title: “Sports Concussion” Jeffrey S. Kutcher, MD University of Michigan Hospital/Ann Arbor, MI Title: “Spinal Muscular Atrophy: A Story of Rags to Riches” John T. Kissel, MD, FAAN Ohio State University/Columbus, OH Topic: CDC and H1N1 James J. Sejvar, MD Centers for Disease Control and Prevention/Decatur, GA Complimentary Luncheon: 12:00 p.m.–2:00 p.m. See the latest in pharmaceutical products, medical equipment, publications, and products to assist with practice management, teaching methods, and research activities. American Academy of Neurology and American Academy of Neurology Foundation Awards Luncheon 12:00 p.m.–1:30 p.m. MTCC, Exhibit Hall B Join AAN leaders as they honor the recipients of the 2010 AAN Awards. From enterprising high school students to world-renowned researchers, this program recognizes some of the top accomplishments in neuroscience research. Past keynote speakers on the importance of neurologic diseases include Tedy Bruschi, NFL player and stroke survivor; Dame Julie Andrews, Academy Award-winning actress and supporter for Huntington’s Chorea and the Hereditary Disease Foundation; Cuba Gooding, Jr., actor and supporter for MS research; Leeza Gibbons, television and radio journalist and advocate for people with Alzheimer’s disease; the famed concert pianist and conductor Maestro Leon Fleischer, who continues to play the piano despite dystonia; Mayo Clinic researcher Anthony Windebank, MD; and advocate for Parkinson’s disease research Michael J. Fox. Tickets are available for $50. Buy a ticket and show your support for award recipients. Student and Junior members of the AAN may attend this event at no cost by requesting a ticket. Reserve a Department Table and Be Recognized Bring your department together and gain exposure for your team at the Awards Luncheon by reserving a department table. Give your residents and fellows the chance to sit together with department faculty and chairs in a place of honor among the top minds in the neurology/neuroscience academic community. To reserve a department table, download the reservation form at www.aan.com/am. If you have questions about reserving a department table, contact Sarah Glover at [email protected]. NEW! Platform Session Times 2:00 p.m.–4:00 p.m. 4:15 p.m.–5:30 p.m. New time slots this year allow registrants to attend the Highlights in the Field program of their choice. Current Practice Issues in Neurology: Health Care Reform 5:30 p.m.–7:00 p.m. With health care reform in the news and on everyone’s mind, this free event will explain how reform initiatives impact neurologists and their patients. 56 Poster Session III Wednesday, April 14 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 Anterior Horn: Imaging Poster Discussion Session: Anterior Horn: Therapeutics Location: 800 Level Moderator: Bryan Traynor, MD Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. PD3.001 Power Wheelchair Utilization Benchmarks for Patients with Amyotrophic Lateral Sclerosis: Selection, Timing, Satisfaction, and Cost Amber Ward, Mohammed Sanjak, Kerry Duffy, Nicole Williams, Mindy Nichols, Elena Bravver, Benjamin Brooks PD3.002 Repetitive Rhythmic Exercise (RRE) Mediated by Supported Treadmill Ambulation Training (STAT) Pilot Trial: RRE-STAT Is Feasible, Safe, Tolerable with 21-34 Percent Positive Treatment Effect Size over Eight Weeks and Improves on Treadmill and Over Ground Gait in Amyotrophic Lateral Sclerosis (ALS) Patients Sanjak Mohammed, Kerry Duffy, Amber Ward, Jordan Lyerly, Priscilla Russo, Jaime Shue, Urvi Desai, Elena Bravver, Benjamin Brooks Infections/AIDS/Prion Disease P03.001 Neuropathological Studies of Patients with Non-Herpetic Acute Limbic Encephalitis Koichi Okamoto, Fukio Fujita, Yuichi Tashiro, Masamitsu Takatama P03.002 Surveillance for Progressive Multifocal Leukoencephalopathy: Possible Approaches James Sejvar, Avindra Nath, Eugene Major P03.003 The Prevalence of Human Polyomavirus DNA in Cerebrospinal Fluid of Patients with Varied Neurological Diseases Yung-Yee Chang, Cheng-Hui Peng, Min-Yu Lan, Yin-Fa Chen, Jia-Shou Liu P03.004 Clinical Manifestations in Two Spanish Families with CreutzfeldtJakob Disease Margarita Pondal, Teodoro Del Ser, Felix Bermejo-Pareja, Alberto Rabano P03.005 Pruritus in CreutzfeldtJakob Disease Joab Chapman, Oren Cohen, Hedok Lee, Zeev Nitzan, Hanna Rosenmann, Shmuel Appel, Isak Prohovnik P03.006 How To Interpret a Blood Contaminated Traumatic Spinal Tap? Farzad Afshari, Alexander Rajput P03.007 A Simple Method To Reduce Infection of Ventriculoperitoneal Shunts Vikas Gupta, Tausif Rehman, Atiq Rehman, Hasaan Bashir P03.008 Therapeutic Challenge of Neurotuberculosis: An Observational Case Study Abhijit Chaudhuri 58 PD3.003 Systemic Transplantation of C-Kit+ Cells Exerts a Therapeutic Effect in a Model of Amyotrophic Lateral Sclerosis Stefania Corti, Monica Nizzardo, Martina Nardini, Chiara Donadoni, Sabrina Salani, Chiara Simone, Marianna Falcone, Nicoletta Mezzina, Francesca Gianni, Giulietta Riboldi, Nereo Bresolin, Giacomo Comi PD3.004 A Decrease in Body Mass Index Is Associated with Faster Progression of Motor Symptoms and Shorter Survival in ALS Ali Jawaid, Santosh Murthy, Andrew Wilson, Salah Qureshi, Moath Amro, Michael Wheaton, Ericka Simpson, Yadollah Harati, Adriana Strutt, Michele York, Paul Schulz PD3.005 NonInvasive Ventilation in Admitted Amyotrophic Lateral Sclerosis Patients with Acute Respiratory Failure Virginia Pujol Lereis, Gisella Gargiulo Monachelli, Gabriel Rodriguez, Martin Sivori, Andres Villa, Raul Rey PD3.006 Riluzole and Antioxidants: Effects in a Preclinical Model System Utilizing Homocysteine, a Known Modulator of Sporadic Amyotrophic Lateral Sclerosis (ALS) Pathogenesis Richelle Hemendinger, Edward Armstrong III, Benjamin Brooks PD3.009 Elevated Urinary Coproporphyrin III (CoproIII) Identifies Clinically Significant Mercury (Hg) and Arsenic (As) Intoxication in Unselected Motor Neuron Disease (MND) Patients Zhifang Li, Elena Bravver, Benjamin Brooks PD3.007 Update on ALSUntangled; a Global Scientific Effort To Investigate Alternative and Off-Label Treatment Options for Patients with ALS Richard Bedlack PD3.010 The Effect of Riluzole on Cellular Injury in ALS: Insights from a Multi-Modal Non-Conventional MRI Study Stephanie Hreha, Megan Mackinzie, Megha Shah, Fen Bao, Ronald Bailey, Michael McCaffrey, Agnes Acsadi, Richard Lewis, Omar Khan PD3.008 Oligomers That Redirect AMPA Splicing To Reduce Excitotoxicity as Potential Therapeutics for ALS Terry Heiman-Patterson, Nicole Lykens, Jyotti Reddi, Christina Ferrer, Jeffrey Deitch, Melanie Tallent, Gordon Lutz P03.017 Trends in Outcomes and Hospitalization Costs Among Patients with Tetanus in the United States Mahta Samizadeh, Khosro Farhad, Hafiz Khan, Abu Nasar, Nizar Souayah P03.010 Tuberculosis, an Uncommon Cause of Cerebral Venous Thrombosis in Children Abderrahim Bougteba, Assia Basir Aging and Dementia: Imaging: Other P03.011 Bartonella Cat Scratch Disease Presenting as Neuroretinitis and Headache without Lymphadenopathy Joanna Gan, Alan Mandell, James Otis, Michael Perloff P03.012 Meningoencephalitis Caused by Rickettsia Conori Abderrahim Bougteba, Assia Basir P03.013 The Role of Dexamethasone in Cryptococcus gattii Meningitis Madeleine Sharp, Kristine Chapman P03.014 Neurocysticercosis: A Not so Rare Parasitic Infection in Geneva, Switzerland Verónica Castillo, Pierre R. Burkhard P03.015 Admission Surveillance Cultures for Methicillin-Resistant Staphylococcus Aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE) in a Neurocritical Care Unit Wendy Ziai, Paras Minhas, Alex Shangraw P03.016 Cladophialophora bantiana Cerebral Abscesses in an Immunocompetent Host Laura Mason P03.028 Brain Cortex Thinning in Motor and Extra-Motor Areas in Amyotrophic Lateral Sclerosis Domenico Mezzapesa, Carla Tortorella, Franca Dicuonzo, Aristide Carella, Maria De Caro, Maria Barulli, Rosanna Tortelli, Francesco Federico, Paolo Livrea, Isabella Simone P03.029 Clinical Features and Natural History in ALS Patients with Upper Motor Neuron Abnormalities on Conventional Brain MRI Genevieve Matte, Erik Pioro P03.030 Fibre Tractography of the Corticospinal Tract in Recent Onset Motor Neuron Disease: A Longitudinal Study Maaike van der Graaff, Matthan Caan, Caroline Sage, Erik Akkerman, Cristina Lavini, Charles Majoie, Aart Nederveen, Aeilko Zwinderman, Frans Vos, Stefan Sunaert, Frans Brugman, Leonard Van den Berg, Maarten de Rijk, Pieter Van Doorn, Marianne De Visser P03.031 Proton MRS of Thalamus and Basal Ganglia in Amyotrophic Lateral Sclerosis Khema Sharma, Varan Govind, Sulaiman Sheriff, Andrew Maudsley P03.032 DTI and MRS of the Cervical Spinal Cord in ALS Michael Benatar, Govind Nair, Nader Metwalli, Sharon Usher, Xiaoping Hu, John Carew P03.009 Development of CNS Complications After Initiation of Antituberculosis Treatment Maria Alejandra Gonzalez Duarte, Jesus Higuera Calleja, Guillermo García-Ramos P03.018 Brain MRI in Sporadic Jakob-Creutzfeldt Disease Is Often Misread Michael Geschwind, Chiara Kuryan, Tatiana Cattaruzza, Paolo Vitali, Stephen DeArmond, Katherine Wong P03.019 Distinct Patterns of Cerebral Blood Flow in Frontotemporal Lobar Degeneration and Alzheimer’s Disease William Hu, Ze Wang, John Detre, Virginia Lee, John Trojanowski, Murray Grossman P03.020 The Value of FDG-PET Imaging in the Diagnosis of Atypical/ Unclear Dementias: A Retrospective Memory Clinic Study Robert Laforce, James P. Buteau, Nancy Paquet, Louis Verret, Michíle Houde, Rémi W. Bouchard P03.021 Hippocampal Gray Matter Volume Declines at a Faster Rate in Cognitively Normal APOE e4 Carriers Leslie Baxter, Seban Liu, Kewei Chen, Richard Caselli P03.022 Mapping Amygdalar Structural Differences in Alzheimer’s Patients with 3T MRI Marina Boccardi, Enrica Cavedo, Alberto Beltramello, Carlo Caltagirone, Paul Thompson, Giovanni Frisoni P03.023 Mapping Cortical Thickness in Autosomal Dominant Alzheimer’s Disease Carriers Liana Apostolova, Kristy Hwang, Luis Medina, Amity Green, Rebecca Dutton, Jeffrey Lai, Daniel Geschwind, Jeffrey Cummings, Paul Thompson, John Ringman P03.024 Survey of Protocols for Manual Hippocampal Volumetry: Preparatory Steps for an EADC-ADNI Harmonized Protocol Giovanni Frisoni, Marina Boccardi, Rossana Ganzola, Simon Duchesne, Nicolas Robitaille, Alberto Redolfi, George Bartzokis Bartzokis, John Csernansky, Mony de Leon, Ronald Killiany, Stéfane Lehéricy, Nikolai Malykhin, Johannes Pantel, Jens Pruessner, Hilkka Soininen, Clifford Jack P03.025 Predictive Value of an Index of Cholinergic Damage (ICD) for Cognitive Performance in Alzheimer Disease Christopher Ahuja, Fuqiang Gao, Sandra Black P03.026 Hypothalamic Atrophy and Decline in Physical Activity Are Associated with Bone Loss in a Study of Non-Demented Aging and Early Alzheimer’s Disease Natalia Loskutova, Robyn Honea, Eric Vidoni, Jeffrey Burns P03.027 Seriation of Cortical Atrophy in the Degenerative Dementias John Listerud, David Libon, Peachie Moore, Murray Grossman Poster Session III Wednesday, April 14 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P03.033 The Utilization of 3 Tesla Neuroimaging as a Biomarker for Cognitive Impairment in Amyotrophic Lateral Sclerosis Peter Bede, Colin Doherty, Arun Bokde, Michael Ewers, Harald Hampel, Orla Hardiman P03.034 Nuclear Magnetic Resonance (NMR)-Based Metabolomic Analysis of Cerebrospinal Fluid (CSF) in Amyotrophic Lateral Sclerosis (ALS) Patients Helene Blasco, Philippe Corcia, Ségolíne Veau, Patrick Vourc’h, David Devos, Caroline Moreau, Julien Praline, Lydie NadalDesbarats, Christian R. Andres P03.035 Assessing Motor Neuron Loss in the ALS Rat with Electrical Impedance Myography Seward Rutkove, Lucy Wang, Jia Li P03.036 Clinical and MRI Predictors of Long-Term Evolution in Amyotrophic Lateral Sclerosis: A 3.4-Year FollowUp Study Federica Agosta, Elisabetta Pagani, Melissa Petrolini, Maria Sormani, Domenico Caputo, Michele Perini, Alessandro Prelle, Fabrizio Salvi, Massimo Filippi P03.037 Degeneration of the Mid Cingulate Cortex in Amyotrophic Lateral Sclerosis Detected In Vivo with MR Spectroscopy Namratha Sudharshan, Chris Hanstock, Benjamin Hui, Timothy Pyra, Wendy Jonhston, Sanjay Kalra P03.038 Upper Motor Neuron and Extramotor White Matter Involvement in Phenotypes of Recent Onset Motor Neuron Disease; a Longitudinal Diffusion Tensor Study Using Voxel-Based Analyses Caroline Sage, Maaike van der Graaff, Matthan Caan, Ronald Peeters, Wim Van Hecke, Erik Akkerman, Cristina Lavini, Charles Majoie, Leonard Van den Berg, Frans Brugman, Marianne De Visser, Wim Robberecht, Stefan Sunaert Muscle Disease/Neuromuscular Junction: Muscular Dystrophies P03.039 Outcome Measures Validation Study for Mesoangioblasts Transplantation in Children Affected by Duchenne Muscular Dystrophy Serena Bonfiglio, Alberto Lerario, Andrea Tettamanti, Sarah Marktel, Sara Napolitano, Stefano Previtali, Marina Scarlato, Maria Grazia Natali Sora, Nereo Bresolin, Giancarlo Comi, Roberto Gatti, Fabio Ciceri, Giulio Cossu, Yvan Torrente P03.040 The Six-Minute Walk Test in Duchenne Muscular Dystrophy: Longitudinal Observations Craig McDonald, Erik Henricson, Richard Abresch, Jay Han, Alina Nicorici, Erica Goude, Gary Elfring, Allen Reha, Samit Hirawat, Langdon Miller P03.041 Pulmonary Function Characteristics of Boys with Duchenne and Becker Muscular Dystrophy by Age Groups and Steroid Use: One-Year Data from the CINRG Longitudinal Study Project R. Abresch, Craig McDonald, Jay Han, Robert Leshner, Diana Escolar, Avital Cnaan, Eric Hoffman, Adrienne Arrieta, Tina Duong, Fenming Hu, Julaine Florence, CINRG Investigators P03.042 Functional Motor Performance Characteristics of Boys with Duchenne Muscular Dystrophy by Age Groups and Steroid Use: One-Year Data from the CINRG Longitudinal Study Project Craig McDonald, Erik Henricson, Richard Abresch, Jay Han, Robert Leshner, Diana Escolar, Eric Hoffman, Avital Cnaan, Addrienne Arrietta, Fenming Hu, Angela Zimmerman, Tina Duong, Julaine Florence, CINRG Investigators P03.043 Risk Factors for Fractures in the Muscular Dystrophy Surveillance, Tracking, and Research Network Cohort Lisa Miller, Kathy James, Katherine Mathews, Shree Pandya, Susan Apkon, Chris Cunniff P03.044 Preclinical Safety of AVI4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Being Developed To Skip Exon 51 in Duchenne Muscular Dystrophy Peter Sazani, Stephen Shrewsbury P03.045 Should All Patients with FSHD Be Screened for Retinal Telangiectasias? Constantine Farmakidis, Mina Chung, Rabi Tawil P03.046 Muscle Imaging in Oculopharyngeal Muscular Dystrophy Celedonio Marquez, Carmen Paradas, Montse Olive, Juan Bautista, Jose Manuel Morales, Antonio Cano, Fernando Castellanos, Laura Gonzalez, Ricard Rojas, Raul Garcia P03.047 Are Brain White Matter Changes and Muscle Involvement Related in DM1? Elena Pegoraro, Vincenzo Romeo, Marina Fanin, Renzo Manara, Mario Ermani, Chiara Ferrati, Corrado Angelini P03.048 Brain Morphometry and Psychological Evaluation in Myotonic Dystrophy Type 1 (DM1) Helena Mendonça, Clarissa Yasuda, Marcondes França Júnior, Fabiano Reis, Veronica Zanardi, Carlos Guerreiro, Fernando Cendes, Anamarli Nucci Cerebrovascular Disease: Genetics/Clinical Aspects of Cerebrovascular Disease P03.049 The Correlation between GPIa C807T SNPs and Young Ischemic Stroke in Shanghai Chinese of Han Population Dongya Huang, Jingang Zhang P03.050 Using Latent Semantic Analysis To Measure the Association of KCNN4 and ACTA2 Genes and Ischemic Stroke Ramin Zand, Vida Abedi, Mohammed Yeasin P03.051 A Novel Heteroplasmic Cytochrome b Mutation in the Mitochondrial DNA Is Associated with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes) Lauren Hyams, Genevieve Langley, Lauren Mylacraine, John Shoffner P03.052 Genome-Wide Association Studies of MRI-Defined Brain Infarcts: Meta-Analysis from the CHARGE Consortium Stephanie Debette, Josh Bis, Myriam Fornage, Helena Schmidt, M. Ikram, Sigurdur Sigurdsson, Gerardo Heiss, Maksim Struchalin, Albert Smith, Aad van der Lugt, Charles DeCarli, Thomas Lumley, David Knopman, Christian Enzinger, Gudny Eiriksdottir, Peter Koudstaal, Anita DeStefano, Bruce Psaty, Carole Dufouil, Diane Catellier, Franz Fazekas, Thor Aspelund, Yurii Aulchenko, Alexa Beiser, Jerome Rotter, Christophe Tzourio, Dean Shibata, Maria Tscherner, Tamara Harris, Fernando Rivadeneira , Larry Atwood, Kenneth Rice, Rebecca Gottesman, Mark van Buchem, Andre Uitterlinden, Margaret Kelly-Hayes, Mary Cushman, Yicheng Zhu, Eric Boerwinkle, Vilmundur Gudnason, Albert Hofman, Jose Romero, Oscar Lopez, Cornelia van Duijn, Rhoda Au, Susan Heckbert, Philip Wolf, Thomas Mosley, Sudha Seshadri, Monique Breteler, Reinhold Schmidt, Lenore Launer, Will Longstreth, Jr P03.054 Utility of Measuring Distal Motor Function in the NIHSS: Correlation with Motor Arm Function Kathryn Kirchoff, Stephanie Shaftman, Victor Zach, David Tanne, Barbara Tilley, Mark Gorman, Steven Levine P03.055 Brain Arteriovenous Malformations: Outcome after Interventional Versus Conservative Management. Prospective Study of 302 Patients Carlos Cantú, Alberto Mimenza, Marco Zenteno, Juan Sánchez, Guillermo García P03.056 Non-Convulsive Status Epilepticus after Acute Ischemic Stroke Andrés Rodríguez, Darío Scocco, Analía Calle, Agustín Jáureui, Patricia Riccio, Alfredo Thomson, Francisco Klein, Luciano Sposato P03.057 Young Women’s Stroke Etiology Differs from Young Men: An Analysis of 511 Patients Emily Nakagawa, Michael Hoffmann P03.058 Short-Term Stroke Outcomes in the Oldest Old: A Buenos Aires Heath System Study Claudia Alonzo, Laura Brescacin, Maria Zurrú, Marina Romano, Silvina Brienza, Fabiana Ortega, Luis Camera, Gabriel Waisman, Edgardo Cristiano, Bruce Obviagele Cerebrovascular Disease: Stroke Imaging P03.059 The No Smoking Sign: Insular Infarction Hebah Hefzy, Rachel Wulf Silver, Brian Silver P03.060 Whole-Brain CT Perfusion (CTP) Using a Novel Volume Helical Shuttle (VHS) Technique on a Conventional 64-Slice CT Scanner: Utility in Routine Stroke Evaluation Nobl Barazangi, Albert Lu, Jack Rose, Shirley Chen, Derk Purcell, Amy Huang, Jerry Barakos, David Tong P03.061 Frequency and Characterization of MR Diffusion Lesions in Acute Spontaneous Intracerebral Hemorrhage Jonathan Kleinman, Nancy Fischbein, Alisa Gean, Ryan Snider, Michael Mlynash, Rashmi Narayana, Irina Eyngorn, Chitra Venkatasubramanian, Jean-Marc Olivot, Gregory Albers, Christine Wijman P03.062 Detecting Infarcted Tissue with Perfusion-Based Measures on MRI Richard Leigh, Argye Hillis, Peter Barker P03.063 Diagnostic and Prognostic Value of Magnetic Resonance Imaging in Spinal Dural Arteriovenous Fistula RajaNandini Muralidharan, Andrea Saladino, Giuseppe Lanzino, John Atkinson, Alejandro Rabinstein P03.053 Evidence for a Heritable Contribution to Death from Ischemic Stroke Jennifer Majersik, Lisa CannonAlbright 59 Poster Session III P03.064 Imaging More with Less: Whole Brain 64-Slice Stroke CT Imaging Using Currently Available Volume Shuttle (VS) and Novel Volume Helical Shuttle (VHS) Brain Perfusion Does Not Increase Radiation Exposure Jack Rose, Qui Luong, Nobl Barazangi, Derk Purcell, Amy Huang, Shirley Chen, Jerome Barakos, David Tong, Kirk Moon P03.065 How Accurate Is 3D Rotational Angiography in Evaluating Intracranial Stenosis in Patients with Stroke? Qi Li, Jialun Li, Fajin Lv, Tianyou Luo, Peng Xie P03.066 3D CT Angiography for Detection of Intracranial Aneurysms: Comparison with 3D Rotational Angiography Qi Li, Jialun Li, Fajin Lv, Peng Xie P03.067 Computational Fluid Dynamics of Retrograde Leptomeningeal Collateral Flow in Acute Ischemic Stroke: Unique Insight on Essential Hemodynamics David Liebeskind, Fabien Scalzo, Yiemeng Hoi, Qing Hao, Xiao Hu, David Steinman P03.068 Volume of Infarction on Diffusion Weighted Imaging Predicts Poor Neurologic Outcome in Children Following an Acute Ischemic Stroke Nassim Zecavati, Rani Singh, Jennifer Pettiford, Cara Olsen, Nadja Kadom P03.069 A Combined Power M-Mode and Spectrogram TCD Microemboli Signal Criteria for Improving Emboli Detection and Reliability Youngbin Choi, Maher Saqqur, Albert Jin, Eileen Stewart, Caroline Stephenson, Mohamed Ibrahim, Jean-Martin Boulanger, Shelagh Coutts, Andrew Demchuk, Talip Asil P03.070 Microbleed Detection in Traumatic Brain Injury by 7T MRI Kathryn Hammond-Rosenbluth, Janine Lupo, Esther Yuh, Adam Kincaid, Hana Lee, Duan Xu, Srivathsa Veeraraghavan, Geoffrey Manley, Sarah Nelson, Pratik Mukherjee P03.071 Yield of Diagnostic Tests in Evaluating Syncopal Episodes in the Emergency Room Shafiuddin Ahmed, David Marks P03.072 Is Admission and Diagnostic Testing Needed To Evaluate Syncope? Shafiuddin Ahmed, David Marks P03.073 An Unusual Case of Bilateral Carotid Artery Webs and Stroke May Kim, Matthew Tenser, Latisha Ali, Satoshi Tateshima, Jeffrey Saver P03.074 Comparison of NASCET and ECST Ratio with Absolute Methods of Measurement for Grading Carotid Artery Stenosis with Noninvasive Imaging Modalities Chiara Zavanone, Sandrine Deltour, Emma Ragone, Aurelie Drier, Sophie Crozier, Fabien Koskas, Yves Samson 60 P03.075 Transcranial Doppler Ultrasonography (TDU) Is Useful in Guiding Treatment of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage (SAH) Fabienne Perren, Bawarjan Schatlo, Marc Kotowski, Philippe Bijlenga, Vitor Pereira-Mendes, Yvan Gasche, Karl Schaller P03.076 MRI Diffusion-Weighted Imaging for Predicting Poor Outcome Following Cardiac Arrest David Greer, Patricia Scripko, James Bartscher, Erica Camargo, John Sims, Aneesh Singhal, Karen Furie P03.077 Distal Hyperintense Vessels in Acute Ischemic Stroke Beyond Three Hours Dileep Yavagal, Diogo Haussen P03.078 Hyperglycemia and Perfusion in Acute MCA Occlusion David Liebeskind, Radoslav Raychev, Qing Hao, Xiao Hu, Monica Sapo, Farzad Buxey, Jeffry Alger, Jeffrey Saver, UCLA Stroke Investigators P03.079 Variability in Determining Acute Stroke Lesion Volumes from ADC Maps Richard Leigh, Argye Hillis, Peter Barker P03.080 Use of Transcranial Doppler for the Detection of Severe Carotid Stenosis Sanjeev Sivakumar, Deepak Arjundas, Sivakumar Rajappa P03.081 Dual Energy CT Scan and Pathological Analysis of Ex-Vivo Carotid Plaque Venkata Dandamudi, Christine Thomas, Ibrahim Bechwati, Claudia Fitzgerald, Kinan Hreib P03.082 Prevalence of Asymptomatic Intracranial Stenosis in US Elderly Population: Results from the Ultrasound Screening in Adults for Intracranial Disease (USAID) Study M. Fareed Suri, Nauman Tariq, Alexandros Georgiadis, Mushtaq Qureshi, Gabriela Vazquez, M. Naeem Qureshi, Adnan Qureshi P03.083 MRI (DWI, T2, Flair Sequences) Findings of an Acute Ischemic Stroke in a 61-Year-Old Patient Taken at Least 30 Minutes Before Symptom Onset: A Case Report Remia Paduga, Gary Gronseth P03.084 Carotid Intima Media Thickness Does Not Correlate with Coronary Artery Atherosclerosis in Pakistani Population Ismail Khatri, Faika Usman, Syed Mumtaz Shah, Waqas Ahmed, Ayesha Vohra, Ali Alam P03.085 CT Perfusion Imaging in Spectacular Shrinking Deficit Vivien Lee, Sayona John, Yousef Mohammad, Shyam Prabhakaran P03.086 Transcranial Doppler FollowUp after Intracranial Stenting Jose Romano, Dileep Yavagal, Frank Cabrera, Yosdely Echevarria, Sebastian Koch Wednesday, April 14 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P03.087 Association of Interleukin 1b and Volume of Acute Ischemic Infarct on Magnetic Resonance Imaging Minal Jain, Anunaya Jain, Neeraja Yerragondu, Dipti Agarwal, Balavani Palamari, Veena Manivannan, Babak Jahromi, Wyatt Decker, Latha Stead P03.088 Abnormal White Matter Structure Is Present in Regions of Vascular Steal Phenomenon in Patients with Arterial Steno-Occlusive Disease John Conklin, Jorn Fierstra, Adrian Crawley, Jay Han, Julien Poublanc, Daniel Mandell, Frank Silver, Tymianksi Michael, Joseph Fisher, David Mikulis P03.089 The Predictive Value of Early Regional Changes of Cerebral Blood Flow for Ischemic Tissue Damage in an Embolic Rat Stroke Model Maureen Walberer, Heiko Backes, Maria Dennin, Bernd Neumaier, Heike Endepols, Mathias Hoehn, Gereon Fink, Rudolf Graf, Michael Schroeter Child Neurology/Developmental Neurobiology: Imaging P03.090 Metabolic and Diffusion Abnormalities of the Thalamus and Their Cognitive Correlates in Unilateral Sturge-Weber Syndrome Balint Alkonyi, Harry Chugani, Michael Behen, Stacey Halverson, Emily Helder, Malek Makki, Csaba Juhasz P03.091 Are “Screening” MRIs for Asymptomatic NF-1 Patients Necessary or Cost Effective? Sahithya Wintrich, Manikum Moodley, Erika Schneider, Paul Ruggieri, Jack Lake, David Rothner P03.092 Cerebrovascular Reactivity in Children with Hematological Disorders Including Sickle Cell Disease Nomazulu Dlamini, Suzan Williams, Melanie Kirby, Ivanna Yau, Daune Macgregor, Gabrielle deVeber, William Logan P03.093 Headaches (HA) in Children and Adolescents (C/A) with Neurofibromatosis Type 1 (NF-I) D. Elefant, A. Rothner P03.094 Childhood Stroke in Saudi Arabia: Etiology, Course and Recurrence Rates Mohammed Aldosari, Mohammad Al-Muhaizea, Aood Almuslamani, Aziza Chedrawi, Hesham Al-Dhalaan P03.095 Familial Pediatric Cavernous Malformation in a New Mexican CohortClinical, Radiological, and Pathologic Correlate Vikas Gupta, Leslie Morrison, Howard Yonas, Rafael Medina-Flores Epilepsy: Imaging P03.096 White Matter Reorganization in a Rat Model of Temporal Lobe Epilepsy Observed Using Enhanced MRI Mansi Parekh, William Triplett, Paul Carney, Thomas Mareci P03.097 MRI Structural Analysis of the Hippocampus in Families with Mesial Temporal Lobe Epilepsy Marcia Morita, Luiz Betting, Clarissa Yasuda, Claudia Maurer-Morelli, Iscia Lopes-Cendes, Fernando Cendes P03.098 DTI Voxel-Based Analysis of Patients with Idiopathic Generalized Epilepsy Luiz Betting, Marcia Morita, Clarissa Yasuda, Li Li, Iscia Lopes-Cendes, Marilisa Guerreiro, Carlos Guerreiro, Fernando Cendes P03.108 Are Periventricular Lesions Specific for Multiple Sclerosis? Gianna Casini, Mary Yurashevich, Rohini Vanga, Subasini Dash, Suhayl Dhib-Jalbut, Brian Gerhardstein, Matilde Inglese, Win Toe, Konstantin Balashov P03.099 Voxel Based Morphometry Reveals Association Between Gray Matter Loss and Dysfunctional Odor Identification in MTLE Patients Maria Natalicio, Clarissa Yasuda, Maria Da Silva, Fernando Cendes P03.109 A Five-Year Serial Longitudinal Study of Deep Gray Matter Atrophy in Patients with Multiple Sclerosis Niels Bergsland, Dana Horakova, Michael Dwyer, Deepa Ramasamy, Eva Havrdova, Zdenek Seidl, Ondrej Dolezal, Sara Hussein, Ellen Carl, Manuela Vaneckova, Robert Zivadinov P03.100 fMRI Validation of Novel MEG Expressive Language Tasks Elizabeth Donner, Frank Wang, Marion Malone, Elizabeth Pang P03.101 Receptive Language Localization with Magnetic Source Imaging in Correlation with Electrical Cortical Stimulation Wenbo Zhang, Gail Risse, Joel Landsteiner, Brian Owens, Laura Petersen, Mary Dunn, Frank Ritter, Michael Frost, Jason Doescher, Patricia Penovich, Robert Doss, El-Hadi Mouderres, Deanna Dickens P03.102 Relationship between MEG Spike Sources and fMRI Language Patterns in Children with Epilepsy Omer Bar-Yosef, Hiroshi Otsubo, Chaung Sylvester, Drew Morris, William Logan, Elizabeth Donner P03.103 Conflicting Neuropsychological and Amytal Test Results: Outcomes in Temporal Lobectomies Christina Cheung, Brent Hayman-Abello, Rick McLachlan, David Steven, Jorge Burneo P03.104 Surgical Failure in Refractory MTLE Is Associated with Progression of Atrophy in Contralateral Hippocampus Clarissa Yasuda, Jarbas Neto, Amanda Pereira, Marcia Morita, Alberto Costa, Tânia Cardoso, Helder Tedeschi, Evandro Oliveira, Marilisa Guerreiro, Carlos Guerreiro, Fernando Cendes P03.105 Alterations of Intracerebral GABA Levels by Titration with Levetiracetam in Patients with Focal Epilepsies Thilo Hammen, Marc Doelken, Angelika Mennecke, Arndt Doerfler, Hermann Stefan Multiple Sclerosis and Related Diseases: MRI Diverse P03.106 Corpus Callosum “Silent” Atrophy in Relapsing-Remitting Multiple Sclerosis Patients: A Seven-Year Prospective Study Fernando Figueira, Gustavo Figueira P03.107 Functional and MRI Studies of Corpus Callosum (CC) in Relapsing-Remitting Multiple Sclerosis (RRMS) Bruno Lenne, Jean-Louis Nandrino, Henrique Sequeira, Philippe Gallois, Patrick Hautecoeur Poster Session III Wednesday, April 14 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P03.110 Brain Atrophy Predicts the Conversion From a Clinically Isolated Syndrome to Multiple Sclerosis Daniel Goldberg-Zimring, Christian ChavarroNieto, Brian Healy, Anat Achiron, Simon Warfield, Mohit Neema, Ashish Arora, Rohit Bakshi P03.111 A 3T MRI Investigation of the Topography of Whole Spinal Cord Atrophy in Multiple Sclerosis Joshua Klein, Ashish Arora, Mohit Neema, Brian Healy, Shahamat Tauhid, Daniel Goldberg-Zimring, Christian ChavarroNieto, James Stankiewicz, Adam Cohen, Antonia Ceccarelli, Elisa Dell’Oglio, Charles Guttmann, Rohit Bakshi P03.112 Whole Brain and Tract-Specific Diffusion Tensor and Magnetization Transfer Imaging Values Correlate with Quantified Brain Atrophy Daniel Harrison, John Ratchford, Sheena Farrell, Peter Calabresi, Daniel Reich P03.113 The Relationship Between Spinal Cord Atrophy, Brain Atrophy, and Disability in Multiple Sclerosis Adam Cohen, Mohit Neema, Ashish Arora, Elisa Dell’Oglio, Ralph Benedict, Shahamat Tauhid, Daniel Goldberg-Zimring, Christian Chavarro-Nieto, Antonia Ceccarelli, Joshua Klein, James Stankiewicz, Charles Guttmann, Rohit Bakshi P03.114 Benefits of Alemtuzumab Are Evident Even in Relapsing-Remitting Multiple Sclerosis Patients Who Experience Autoimmune Adverse Events Vesna Brinar, N. A. on Behalf of the CAMMS223 Study Group P03.115 Natalizumab and Risk of Melanoma: A Prospective Follow-Up of Patients Treated by Natalizumab for Multiple Sclerosis Emeline Castela, Christine Lebrun Frenay, Muriel Laffon, Fanny Rocher, Thierry Passeron Multiple Sclerosis and Related Diseases: MRI/Technique and PET P03.116 Measurement of Yearly Change in RRMS Brain Volume Using 3T MRI Scans Stuart Cook, Leo Wolansky, Jojy Cheriyan, Diego Cadavid P03.117 Quantitative MRI Reveals Abnormality of Fornix and Cingulum in MS Stephanie Syc, John Ratchford, Sheena Farrell, Jonathan Grynspan, Peter Calabresi, Daniel Reich P03.118 Low Contrast Visual Stimuli Yield Differential Volumes of Functional MRI Activation in Affected and Unaffected Eyes Following Recovery from Optic Neuritis Robert Bermel, Jeffrey Cohen, Lael Stone, Blessy Mathew, Michael Phillips, Mark Lowe P03.119 Cerebral White and Grey Matter MRI Segmentation with Lesion InPainting in Multiple Sclerosis Jonathan Jackson, Declan Chard, Elisa Dell’Oglio, Brian Healy, Mohit Neema, Rohit Bakshi, David Miller, Claudia Wheeler-Kingshott P03.120 3 Tesla Imaging of the Brain in Multiple Sclerosis Patients with Nystagmus—A New Diagnostic Tool Parameswaran Iyer, Andrew Fagan, Aliz Takacs, James Meaney, Niall Colgan, Stephen Meredith, Kathleen Curran, Janice Redmond P03.121 Imaging CNS Myelin by PET in Multiple Sclerosis Using the Thioflafin Derivative [11C]-PIB Bruno Stankoff, Leorah Bosqué-Freeman, Maris-Stephane Aigrot, Frederic Dolle, Catherine Lubetzki, Bernard Zalc, Michel Bottlaender P03.122 Cerebral Activation Patterns Associated with Increased Working Memory Load in Multiple Sclerosis Lindsay Barker, Bonnie Glanz, Elisabeth Moes, Bradford Dickerson, Charles Guttmann, Guy Buckle P03.123 Assessment of Neuronal Pathology in the Cerebral Grey Matter of Patients with MS: Added Value of PET with [11C]-Flumazenil Léorah Freeman, Claire Leroy, Damien Galanaud, Rana Assouad, Ayman Tourbah, Caroline Papeix, Claude Comtat, Catherine Lubetzki, Jacques Delforge, Michel Bottlaender, Bruno Stankoff P03.124 Focal Cerebral Increases of α-[11C]Methyl-L-Tryptophan Uptake Suggest Activation of the Kynurenine Pathway in Multiple Sclerosis: A PET Study Balint Alkonyi, James Garbern, Diane Chugani, Otto Muzik, Pulak Chakraborty, Csaba Juhasz P03.125 24-Month Efficacy and Safety Outcomes From the TRANSFORMS Extension Study of Oral Fingolimod (FTY720) in Patients with RelapsingRemitting Multiple Sclerosis Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Xavier Montalban, Jean Pelletier, Tracy Stites, Stacy Wu, Frederick Holdbrook, Jeffrey Cohen, on Behalf of the TRANSFORMS Study Group Multiple Sclerosis and Related Diseases: MRI/Technique P03.126 Chronic Cerebrospinal Venous Insufficiency and Iron Deposition on Susceptibility-Weighted Imaging in Patients with Multiple Sclerosis Michael Dwyer, Paolo Zamboni, Mark Haacke, Erica Menegatti, Bianca Weinstock-Guttman, Claudiu Schirda, Anna Malagoni, David Hojnacki, Cheryl Kennedy, Ellen Carl, Niels Bergsland, Sara Hussein, Mari HeininenBrown, Ilaria Bartolomei, Fabrizio Salvi, Robert Zivadinov P03.127 Triple Stimulation in Patients with Clinical Isolated Syndromes: Sensitivity To Detect Clinically Silent Lesions in Comparison to Transcranial Magnetic Stimulation and Visual/ Somatosensory Evoked Potentials Ulrich Hofstadt-van Oy, Christoph Klawe, Dirk Hagenburger, Michael Strotzer, Stefan Lieser, Patrick Oschmann P03.128 Hypoperfusion of Brain Parenchyma Is Strongly Associated with the Severity of Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis Paolo Zamboni, Eric Menegatti, Bianca Weinstock-Guttman, Michael Dwyer, Claudiu Schirda, Anna Maria Malagoni, David Hojnacki, Cheryl Kennedy, Ellen Carl, Niels Bergsland, Christopher Magnano, Ilaria Bartolomei, Fabrizio Salvi, Robert Zivadinov P03.129 A Comparison of MS and Ischemic Lesions as Visualized Using 7 Tesla T2* Phase Imaging Ian Donaldson, Emma Tallantyre, Jennifer Dixon, Samuel Wharton, Penny Gowland, Peter Morris, Nikos Evangelou P03.130 Impaired Motor Performance in MS Is Associated with Increased GABA Level in Sensorimotor Cortex Pallab Bhattacharyya, Michael Phillips, Lael Stone, Mark Lowe P03.131 The Need for Standardization of Lesion Activity Analysis Categorization in the Multiple Sclerosis Clinical Trials David Wack, Michael Dwyer, Niels Bergsland, Robert Zivadinov P03.132 Assessing Brain Tissue Damage in Subjects with Radiologically Isolated Syndrome Francesca Rossi, Maria Laura Stromillo, Bahia Hakiki, Marco Battaglini, Antonio Giorgio, Emilio Portaccio, Gian Michele Malentacchi, Maria Letizia Bartolozzi, Antonio Federico, Sandro Sorbi, Maria Pia Amato, Nicola De Stefano P03.133 Cine Cerebrospinal Fluid Imaging in Multiple Sclerosis. A CaseControl Study Christopher Magnano, Claudiu Schirda, Bianca WeinstockGuttman, David Hojnacki, Niels Bergsland, Cheryl Kennedy, Justine Reuther, Christina Brooks, Michael Dwyer, Robert Zivadinov P03.134 DTI Correlates of Cognitive Dysfunction in Patients with Benign MS and with Clinically Isolated Syndrome Matilde Inglese, Gunja Parikh, Maxim Bester, James Babb, Joseph Herbert, Robert Grossman, Mariana Lazar P03.135 Detecting Multiple Sclerosis Cortical Lesions Post-Mortem Using 3, and 7 Tesla Magnetic Resonance Imaging Bing Yao, Peter van Geldern, Christina Chen, Vasiliki Ikonomidou, Hellmut Merkle, Marshall Davis, Fredric Cantor, Jeff Duyn, Henry McFarland, Francesca Bagnato Multiple Sclerosis and Related Diseases: Clinical Research Sleep and Genetics P03.136 Multiple Sclerosis (MS) Patients, with and without Restless Legs Syndrome (RLS), Have Frequent Sleep Disturbances on Polysomnographic Studies Joelle Proulx-Therrien, Steven Brass, Pierre Duquette P03.137 Quality of Life in Multiple Sclerosis Patients Is Associated with Poor Sleep as Assessed by Polysomnography Daria Trojan, Marta Kaminska, Amit Bar-Or, Deborah Da Costa, Andrea Benedetti, Yves Lapierre, Douglas Arnold, Ann Robinson, Deborah Weiss, Kevin Schwartzman, Adriana Venturini, R. John Kimoff P03.138 Clinical Pathway for the Differential Diagnosis of Daytime Sleepiness in MS Using Self-Administered Scales Stefan Braune P03.139 Gene Expression Profiling of Post-Mortem Multiple Sclerosis Derived Normal Appearing White Matter and Active Lesion Tissue Ka Ka Ting, Simon Hawke P03.140 HLA Allele Interactions Associated with Multiple Sclerosis Activity, Severity, and Progression Maria Liguori, Brian Healy, Dong Tran, Bonnie Glanz, Cara Wolfish, Samia Khoury, Howard Weiner, Philip De Jager, Charles Guttmann P03.141 Familial Multiple Sclerosis, Does Consanguinity Has a Role? Mohammed Al Jumah, Suliman Kojan, Ibrahim AlAbdulkaream, Mohammed Al Blawi P03.142 NQO1 Inborn Gene Polymorphism and Susceprtibility in Multiple Sclerosis Athanasia Alexoudi, Ioanna Chatzi, Sofia Zachaki, Christiana Stavropoulou, Asimina Athanasouli, Thomas Tsolis, Constantina Sambani, Clementine Karageorgiou Behavioral Neurology: Imaging, Genetics, and Other P03.143 XYY Syndrome: A Possible Model for Autism Spectrum Disorder (ASD) David Roeltgen, Judith Ross 61 Poster Session III P03.144 Polymorphism in Progranulin Gene Associated with Structural Differences in Brains of Normal Controls Carmela Tartaglia, Victor Laluz, Marc Sollberger, Rosa Rademakers, Anna Karydas, Matt Baker, Tricia See, Kate Rankin, Bruce Miller P03.145 Presenilin 1 S170P Mutation with a Limbic Encephalitis Like Presentation Tobias Langheinrich, Charles Romanowski, Stephen Wharton, Marios Hadjivassiliou P03.146 Clinical Correlations of Asymmetric Temporal and Parietal Lobe Glucose Hypometabolism Daniel Claassen, Ioana Stoian, Keith Josephs, Patrick Peller P03.147 Glucose Metabolism in Progressive Non-Fluent Aphasia Patients with Versus without Parkinsonism Jee Hoon Roh, Sang Won Seo, Kim Geon Ha, Duk L. Na P03.148 Shape Analysis of the Neostriatum in Frontotemporal Lobar Degeneration, Alzheimer’s Disease, and Healthy Controls— Regional and Functionally Significant Atrophy Jeffrey Looi, Mark Walterfang, Martin Styner, Leif Svensson, Olof Lindberg, Per Ostberg, Eva Orndahl, Dennis Velakoulis, Rajeev Kumar, Lars-Olof Wahlund Movement Disorders: Neuroimaging P03.157 Olfactory Tract and Substantia Nigra Diffusion Tensor Imaging and Olfactory Function Testing in De Novo Parkinson’s Disease Tyler Rolheiser, Heather Fulton, Kim Good, Ron Leslie, John Fisk, Roger McKelvey, Kerri Schoffer, Naeem Khan, Harry Robertson P03.158 Clinical and DAT Imaging Characteristics of Parkinson’s Disease Patients According to Their Smell Test Result Andre Felicio, Clecio GodeiroJunior, Ming Shih, Vanderci Borges, Sonia Silva, Rodrigo Bressan, Luiz Andrade, Henrique Ferraz P03.159 Volumetric MRI as an Image Biomarker for the Early Diagnosis of Parkinson’s Disease Mya Schiess, Timothy Ellmore, Richard Castriotta, Diane Bick, Marie-Francoise Doursout, Erin Stimming, Roger Bick P03.149 Spatial Localization of Densely Ischemic Regions Associated with Motor Extinction in Acute Stroke Mikolaj Pawlak, Jennifer HeidlerGary, Edward Herskovits, Argye Hillis P03.160 Volumetric Imaging Markers of Early Dementia in Older Patients with Parkinson’s Disease Richard Camicioli, Jennifer Sabino, Myrlene Gee, Chris Hanstock, Derek Emery, Wayne Martin P03.150 Investigating the Relation Between Basal Ganglia Volume and Intelligence Penny MacDonald, Sherif Karama, Hooman Ganjavi, Alan Evans P03.161 Functional MRI in De Novo Patients with Parkinson’s Disease during a Self-Paced Simple Motor Task Claudio Lucetti, Filippo Baldacci, Carlo Tessa, Paolo Del Dotto, Chiara Logi, Caterina Berti, Stefano Diciotti, Lorenzo Paoli, Paolo Cecchi, Andrea Ginestroni, Mario Mascalchi, Ubaldo Bonuccelli P03.151 Léger de Main: The Thalamus and the Automatic Limb Darrell Newman, David Burkholder, Richard Elias P03.152 Primal Neuroanthropology— The Study of Archetypal Postures, Movements, and Behavior in Sports and Related Activity That Connect Us to Our Evolution, Infancy, Neurodegeneration, and Primordial Selves Kenneth Gross Behavioral Neurology: Other P03.153 Filial Catamenial Phantosmia Alan Hirsch, Jhanvi Menon, Jhoette Dumlao P03.154 Surgical Resection of Hypothalamic Hamartomas for Severe Behavioral Symptoms Eric Hastriter, John Kerrigan, Harold Rekate, Yu-tze Ng P03.155 Early Exposure to Anti Convulsants and the Development of Autism in Epilepsy Samiah Al-Zaidy, Hayley Wood, Wendy Roberts, Shelly Weiss 62 P03.156 Visuo-Motor Deficits and Damage to White Matter Tracts in a Posterior Cortical Atrophy Patient Raffaella Migliaccio, Federica Agosta, Monica Toba, Fabian Corlier, Leonardo Cruz De Souza, Stephane Lehericy, Marie Sarazin, Dalila Samri, Bruno Dubois, Massimo Filippi, Paolo Bartolomeo P03.162 A Novel Set Shifting fMRI Task Identifies Differences in Brain Activation in Parkinson’s Disease and Healthy Controls Michele York, Christof Karmonik, Phillip Burton, Doug Richards, Ekta Kakkar, Robert Grossman, Joseph Jankovic P03.163 The Topographical Distribution of White Matter Damage in Parkinson’s Disease and Progressive Supranuclear Palsy Sebastiano Galantucci, Federica Agosta, Igor Petrovic, Vladana Spica, Milica Jecmenica, Giulia Longoni, Vladimir Kostic, Massimo Filippi P03.164 The In-Vivo Topographical Distribution of Brain Tissue Loss Associated with Depression in Parkinson’s Disease: A Voxel-Based Morphometry Study Vladimir Kostic, Federica Agosta, Igor Petrovic, Sebastiano Galantucci, Vladana Spica, Milica Jecmenica, Massimo Filippi Wednesday, April 14 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P03.165 Pattern of Global and Regional Brain Volume in Progressive Supranuclear Palsy Identified by MRI Using “Freesurfer” Post Processing Software Rita Vadala, Giuseppe Bomboi, Alberto Pierallini, Elisabetta Giugni P03.166 Comparison of Clinical Features and [18F]FP-CIT PET Findings between Drug-Induced Parkinsonism with and without Underlying Parkinson’s Disease Youngshin Yoon, Jae Seung Kim, Kyung A. Kim, Chong Sik Lee P03.167 Aging Effects of [18F]FP-CIT PET Measures in the Striatum of Drug Naïve, De Novo PD Patients: Comparison with Normal Subjects Chong Lee, Chang You, Kyung Kim, Jae Kim P03.168 Baroreflex Sensitivity and Power Spectral Analysis during Autonomic Testing in Different Extrapyramidal Syndromes Heinz Reichmann, Daniela Berg, Ludger Schoels, Tjalf Ziemssen P03.169 Bulbar Function Is Correlated with Neuroimaging Outcomes in Parkinson’s Disease Catherine Gallagher, Sterling Johnson, Moo Chung, Benjamin Brooks, James Abbs, Selami Dogan, Barbara Bendlin, Robert Nickles, W. Brown P03.170 Symptomatic Correlation of [18F]FP-CIT PET Measures in PD Patients Chang You, Chong Lee Movement Disorders: Ataxia and Cerebellar Disease P03.171 Identifying Drugs for the Treatment of Spinocerebellar Ataxia Type 2 (SCA2) Daniel Scoles, Lance Pflieger, Stefan Pulst P03.172 WITHDRAWN P03.173 Effects of Erythropoietin Single Dose Treatment in Patients with Friedreich Ataxia Sylvia Boesch, Wolfgang Nachbauer, Sascha Hering, Markus Seifert, Hannes Steinkellner, Markus Reindl, Brigitte Sturm, Guenther Weiss, Barbara Scheiber-Mojdehkar, Werner Poewe P03.174 The Emerging Role of Spinocerebellar Ataxia 17 in a Canadian Movement Disorders Clinic Katie Wiltshire, Sarah Furtado, Scott Kraft, Jillian Parboosingh, Oksana Suchowersky P03.175 Case Report: Human Immunodeficiency Virus Type 2 (HIV 2) and Ataxia Raam Sambandam, Zhigao Huang P03.176 Retrospective Analysis of the Use of Varenicline (Chantix®) in Ataxia Israt Jahan, Abinaya Chari, Clifton Gooch, Kelly Sullivan, Laurie Dempsey, Juan Sanchez-Ramos, Theresa Zesiewicz P03.177 Case Report: Bilateral Ballism Following Postinfectious Meningoencephalitis with Demyelinating Polyneuropathy, Ophthalmoplegia, Bulbar Dysfunction, Areflexia, and Negative Anti-GQ1B Antibody Riley Bove, Ruchira Jha, Daniel Weisholtz, Tommy Thomas, Richard Woolf, Galen Henderson P03.178 A Case of Subacute Encephalopathy, Ataxia, and Myoclonus Due to Amantadine Toxicity in Chronic Renal Insufficiency Angela Hardwick, Michael Devereaux, Benjamin Walter P03.179 SCA-17 Presenting with an Unusually Mild Phenotype Sarah Wahlster, Phyllis Grable-Esposito, Herminia Rosas, Jeremy Schmahmann, Richard Myers, Gillis Tammy, Jayalakshmi Mysore, Marcy McDonald, Diane Lucente, Jang-Ho Cha P03.180 Efficacy and Safety of Idebenone in a Six-Month US Phase III Clinical Study of Idebenone in Children with Friedreich’s Ataxia David Lynch, Susan Perlman, William Andrews, Thomas Meier Movement Disorders: Parkinson's Disease: Genetics P03.181 Parkin and Pink1 Promote DRP1-Mediated Mitochondrial Fusion in Cellular Models Maria Damiano, Lori Buhlman, Giulia Bertolin, Rosa Ferrando Miguel, Amandine Roux, Alexis Brice, Olga Corti P03.182 Neuropathological and Biochemical Report of a Patient with a Parkin Mutation Hugh Kearney, Helene Plun-Favreau, John Hardy, Francesca Brett, Tim Lynch P03.183 LRRK2 G2019S Mutation in an Argentinean Cohort of Patients with Parkinson’s Disease Emilia Gatto, Daniela Converso, José Martí-Massó, Coro Paisán Ruiz, Gabriel Persi, Jose Etcheverry, Virginia Parisi, Fernando Leiguarda, María Carreras, Juan Poderoso P03.189 Olfactory Loss in LRRK2 Related Parkinsonism Laura SilveiraMoriyama, Renato Munhoz, Margarete Carvalho, Salmo Raskin, Ekaterina Rogaeva, Tais Moriyama, Patricia Aguiar, Rodrigo Bressan, Andre Felicio, Orlando Barsottini, Luis Augusto Andrade, Hsin Chien, Vicenzo Bonifati, Egberto Barbosa, Helio Teive , Andrew Lees P03.200 Lafora Disease: An Experience of 10 Years in the National Institute of Neurology and Neurosurgery, Mexico Liliana Romero-Ocampo, Erandi Bravo-Armenta, Steven Vargas, Luis Ruano-Calderon, Francisca FernandezValverde, Adriana Morales-Ochoa, Ma. Elisa Alonso-Vilatela, Rosalba VegaOrozco, Iris Martínez-Juárez P03.190 Mitochondrial Impairment in Manifesting LRRK2-G2019S Carriers Oliver Bandmann, Krisztina Johansen, Jan Aasly, Heather Mortiboys P03.201 Investigation of Bromodomain-Containing Protein 2 (BRD2) Gene Mutations in Photosensitive Epilepsy Betul Baykal, Ebru Nur VanliYavuz, Ozkan Ozdemir, Suzin Catal, Nerses Bebek, Ugur Ozbek P03.191 Olfactory Dysfunction Associated with LRRK2 G2019S Mutations Kaili Stanley, Vicki Shanker, Deborah Raymond, Paul Soto, Richard Lipton, Susan Bressman, Rachel SaundersPullman P03.192 Parkinsonism and Progressive External Ophthalmoplegia with Multiple Mitochondrial DNA Deletions: Report of Two New Cases Brandon Barton, Sandra Jackson, Nico Diederich P03.193 New Mutations Identified in the SYNE1 Gene in ARCA-1 Patients Anne Noreau, Pierre Provencher, Cynthia Bourassa, Patrick Dion, Nicolas Dupre, Alexis Brice, Guy Rouleau P03.194 Systematic Integration of GWAS Data into Ongoing MetaAnalyses of Parkinson’s Disease Genetic Association Studies Christina Lill, Johannes Roehr, Sachin Bagade, BritMaren Schjeide, Matthew McQueen, Lars Bertram Epilepsy: Basic Science, Genetics, and Epidemiology P03.184 PINK1 Mediates the Stress-Induced Degradation of Parkin Aleksandar Rakovic, Anne Grunewald, Alfredo Ramirez, Slobodanka Orolicki, Katja Lohmann, Christine Klein P03.195 Microglia Contribute to Synaptic Stripping During Epileptogenesis: Animal and Human Evidence Martina Vendrame, Delia Talos, Frances Jensen P03.185 Mutations in the LRRK2 (G2019S) and the Glucocerebrosidase Genes Can Influence the Clinical Course and Pre Morbid Behavior of Patients with Parkinson’s Disease Tanya Gurevich, Anat Mirelman, Avner Thaler, Shiran Levy, Elissa Ash, Avi Orr-Urtreger, Nir Giladi P03.196 Ca2+ Channel Promiscuity of Small Conductance Ca2+-Activated K+ channels (SK) in Hippocampal Pyramidal Neurons Felix Benninger, Shmuel Chen, Yoel Yaari P03.186 Genetic Risk Factors for Cognitive Impairment in the DATATOP Cohort Karen Marder, Lorraine Clark, Michael McDermott, Ergun Uc, PSG DATATOP Investigators P03.187 Functional Polymorphisms of Human Dopamine Pathway Genes COMT, DBH and MAOB: A Pilot SNP Study of Single Gene Locus and Gene-Gene Interaction in Parkinson Disease Tao Xie, Allan Levey, Yilang Tang, Joseph Cubells, Wenzhen Duan P03.188 Progression of Motor Features in Elderly LRRK2 G2019S NonManifesting Carriers Marta San Luciano, Richard Lipton, Cuiling Wang, Laurie Ozelius, Mindy Katz, Susan Bressman, Amy Sanders, Rachel Saunders-Pullman Poster Session III Wednesday, April 14 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P03.197 Differential Cellular Distribution of Acetyl CoA Synthetases in the Rat Brain: Implications for Ketogenic Diet Mediated Neuroprotection Aryan Namboodiri, John Moffet, Prasanth Ariannur, Peethambaran Arun, Chikkathur Madhavarao, Batool Kirmani P03.198 Using SCN1A Gene Mutation Screening in Clinical Practice Marina Gonsales, Paula Preto, Marilisa Guerreiro, Iscia Lopes-Cendes P03.199 Familial Cortical Myoclonic Tremor with Epilepsy (FCMTE): Mapping the Third Gene to 5p in a Large French Family: FCMTE 3 Eloi Magnin, Christel Depienne, Delphine Bouteiller, Giovanni Stevanin, Cécile Saint-Martin, Marie Vidailhet, Emmanuelle Apartis, Eric LeGuern, Pierre Labauge, Lucien Rumbach P03.202 Decreasing Presentations of Seizures to Emergency Departments in a Large Australian Population Dennis Cordato, Peter Thomas, Ghia Darshan, Taneja Sanjeev, John Worthington, Alan McDougall, Suzanne Hodgkinson, Hanna Ibrahim, Neil Griffith, Cecilia CappelenSmith, Roy Beran P03.203 Characteristics and Outcome of Post-Hypoxic Status Epilepticus Neena Jamwal, Imran Ali, Siddharth Sehgal, Shekhar Raj, L. Greenfield P03.204 Risk Factors for the Development of Prolonged Status Epilepticus Francisco Gutierrez Manjarrez, Iris Gonzalez Orizaga, Elizabeth Soto Cabrera, Horacio Senties Madrid, Guillermo Garcia Ramos, Hector Barragan Campos, Bruno Estanol Vidal Peripheral Nerve: Inherited Neuropathies: Clinical and Genetic Insights P03.205 Clinical Neurophysiologic and Genetic Presentation in Patients with Axonal Charcot-Marie-Tooth Disease Jelena Nikodinovic, Vedrana Milic Rasic, Slobodanka Todorovic, Vidosava Rakocevic Stojanovic, Jelena Mladenovic P03.206 Increased Activity of Mutant TRPV4 Channels Is a Commom Feature in Both Scapuloperoneal Spinal Muscular Atrophy and Hereditary Motor and Sensory Neuropathy Type IIC Faisal Fecto, Yong Shi, Han-Xiang Deng, Jianhua Yan, Haujie Yau, Marco Martina, Teepu Siddique P03.207 Development of the Pediatric Charcot-Marie-Tooth Disease Quality of Life Instrument (pCMT-QOL): An Outcome Measure for Clinical Trials Sindhu Ramchandren, Joshua Burns, Michael Shy P03.208 Development and Validation of the Charcot-Marie-Tooth Disease Pediatric (CMTPed) Scale Joshua Burns, Rosemary Shy, Tim Estilow, Gyula Acsadi, Allan Glanzman, Robert Ouvrier, Francesco Muntoni, Mary Reilly, Michael Shy, Richard Finkel P03.209 Axonal Deformities in a Mouse Model of Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) Mario Saporta, Istvan Katona, Yunhong Bai, Michael Shy, Jun Li P03.210 Novel Mutation in First Codon of Connexin 32 Causing CMT-X Dreama Brar, Sat Dev Batish, Michael Pulley P03.211 Ethambutol Toxicity Exacerbating the Phenotype of CMT2A2 Ekokobe Fonkem, Elaine Binkley, Monica Skordil, John Kissel, Victoria Lawson P03.212 Phenotypic Characteristics of Hereditary Motor and Sensory Neuropathy Type VI (HMSN VI) Hye Yang, Kee Duk Park, Kyoung-Gyu Choi, Byung-Ok Choi P03.213 Phenotypical Features of 14 Moroccan Families with Autosomal Recessive Charcot-Marie-Tooth Disease Associated with Mutations in the GDAP1 Gene Nazha Birouk, Ahmed Bouhouche, Halima Belaïdi, Hamid Azzeddine, Odile Dubourg, Ali Benomar, Thierry Maisonobe, Mohamed Yahyaoui, Eric Le Guern, Reda Ouazzani P03.214 Distribution of CharcotMarie-Tooth Disease Subtypes and Frequency of Positive Genetic Testing Results Carly Siskind, Stephanie Sottile, Shawna Feely, Lindsey Miller, Michael Shy Neurogenetics and Gene Therapy P03.215 Allele-Specific Expression Changes in SNCA and GAK in Parkinson Disease Brain Tissue Nathan Pankratz, William Nichols, Xiaoling Xuei, Diane Kissell, Michael Pauciulo, Salvatore Spina, Yunlong Liu, Mingxiang Teng, Bernardino Ghetti, Howard Edenberg, Tatiana Foroud P03.216 Impact of Mutations in Parkin on Mitochondrial Function and Morphology Anne Grünewald, Lisa Voges, Aleksandar Rakovic, Meike Kasten, Norman Kock, Anthony Schapira, Slobodanka Orolicki, Christine Klein P03.217 Spinocerebellar Ataxia Type 31 (SCA31) Is a Common Late-Onset Purely Cerebellar Ataxia Kinya Ishikawa, Yusuke Niimi, Nozomu Sato, Takeshi Amino, Hitomi Matsuo, Taro Ishiguro, Makoto Takahashi, Masato Obayashi, Hidehiro Mizusawa P03.218 Cytochrome Oxidase Gene Variations and Their Potential Functional Consequences Russell Swerdlow, Jane Lu, Mariana Rodova, Isaac Onyango, E. Lezi, Raquel Esteves P03.219 Variation Databases for Neurodegenerative Disorders Shoji Tsuji, Makiko Yoshida, Yuji Takahashi, Asako Koike, Yoko Fukuda, Jun Goto P03.220 Changes in MicroRNA Expression Profile in Mesial Temporal Sclerosis Danyella Dogini, Tiago Pereira, Cristiane Rocha, Clarissa Yassuda, Helder Tedeschi, Evandro de Oliveira, Claudia Maurer-Morelli, Fernando Cendes, Iscia Lopes-Cendes P03.221 Spinal Cord Atrophy Correlates with Clinical Disability in Friedreich Ataxia Marcondes Franca, Jr, Felipe Bergo, Anelyssa D’Abreu, Luciana Bonadia, Marilza Silva, Iscia LopesCendes, Fernando Cendes P03.222 Hematopoietic Stem Cell Transplantation for Adult-Onset Krabbe Disease: First Report in the Literature Madeleine Sharp, Corree Laule, Sandra Sirrs P03.223 Altered GABA Receptor Expression and Function in Fragile X Knockout Mice Daniel Adusei, Laura Pacey, David Hampson P03.224 Isolated Hexosaminidase B Deficiency in a Family with Late Onset Spinocerebellar Degeneration Dina Amrom, Frederick Andermann, Serge Melançon, Eva Andermann P03.225 Superior Cerebellar Peduncle Atrophy in Friedreich’s Ataxia Correlates with Disease Symptoms Hamed Akhlaghi, Louise Corben, Johnson Bradshaw, Nellie Georgiou-Karistianis, Martin Delatycki, Gary Egan, Elsdon Storey P03.226 Neuroprotective Potential of DJ-1 in Neurodegenerative Diseases Nirit Lev, Daniel Offen, Eldad Melamed P03.227 Protein Analysis in Cells with Oxidative Phosphorylation Deficiency Celia Tengan, Andresa Rodrigues, Katia Oliveira, Beatriz Kiyomoto P03.228 Phenotypes of 117 Korean Patients with Mitochondrial Disorders Eun Hye Jeong, Ji Soo Shin, Eun Kyung Park, Su Jin Hwang, Sun Young Cho, Ki Wha Chung, Byung-Ok Choi P03.229 Maternally Inherited Spastic Paraplegia Due to a Mitochondrial DNA Mutation Christophe Verny, Adriana Prundean, Naïg Gueguen, Valérie Desquiret, Frederic Dubas, Arnaud Chevrollier, Patrizia Amati-Bonneau, Dominique Bonneau, Pascal Reynier, Vincent Procaccio P03.230 Electrophysiological Evidence of Subclinical Multi-System Involvement in Pure OPA1 Autosomal Dominant Optic Atrophy Mark Baker, Karen Fisher, Roger Whittaker, Stuart Baker, Patrick Yu-WaiMan, Patrick Chinnery P03.231 The “Ear of the Lynx” MRI Sign in Spastic Paraparesis with SPG 11 Mutations Belen Pascual, Mario Riverol, Joseph Masdeu P03.232 Regional Brain Energy Deficit in a Preclinical Model of Huntington Disease: Presymptomatic Compensatory Mechanisms Fanny Mochel, Brandon Durant, Raphael Schiffmann, Alexandra Durr P03.233 Phenotype-Genotype Correlation of Four Novel Senataxin Gene Mutations in Hungarian Patients Zsuzsanna Pal, Klara Pentelenyi, Anikó Gal, Viktoria Remenyi, Arndt Rolfs, Maria Molnar 63 Poster Session III P03.234 Genetic Epidemiological and Clinicopathological Study of Familial and Sporadic Amyotrophic Lateral Sclerosis with FUS Mutations in the Japanese Population Yuji Takahashi, Jun Goto, Masahiko Watanabe, Shuji Kishida, Yuichi Maruki, Shigeo Murayama, Shoji Tsuji P03.235 Application of a MicroarrayBased Whole Mitochondrial DNA Sequence Analysis for Molecular Diagnosis of Mitochondrial Diseases Hiroyuki Ishiura, Yuji Takahashi, Shinobu Fukumura, Yoshiko Nomura, Ritsuko Hanajima, Yasuo Terao, Akihiro Yugeta, Jun Shimizu, Jun Goto, Shoji Tsuji P03.236 TIMM8A 3`UTR Mutations in Subjects with Deafness and Dystonia May Affect TIMM8A Expression Russell Swerdlow, Joseph Fontes, Mariana Rodova P03.237 The Phenotype of CADASIL in a Family with Hemozygous and Heterozygous Same R1231C Notch3 Mutation Saeed Bohlega, Najeeb Qadi, Mohammad Alhamed, Brian Meyer P03.238 Genetic Testing of Oxidative Phosphorylation Diseases: Comparison of Next Generation Sequencing with Capillary Sequencing Approaches John Shoffner, Genevieve Langley, Lauren Mylacraine, Lauren Hyams P03.239 Lithium Reduces Cell Death in an In Vitro Model of Machado-Joseph Disease Camila Lopes, Tiago Pereira, Rovilson Gilioli, Iscia Lopes-Cendes P03.240 Vitamin D Receptor Gene Confers Genetic Risks for Parkinson Disease Guney Bademci, Jeffery Vance, Todd Edwards, Amber Burt, Stephan Zuchner, William Scott, Eden Martin, Liyong Wang P03.241 The PhenX Toolkit: Providing Standard Measures of Neurological Traits for Genome-Wide Association Studies Jeffery Vance, Lindsay Farrer, Maiese Deborah, Wayne Huggins, Erin Ramos, Tracey Grant, Carol Hamilton Aging and Dementia: Genetics P03.242 PICALM and ApoE Polymorphisms in Italian Patients with Alzheimer’s Disease Benedetta Nacmias, Silvia Bagnoli, Irene Piaceri, Andrea Tedde, Valentina Bessi, Laura Bracco, Biancamaria Guarnieri, Sandro Sorbi P03.243 First Report of Frontotemporal Dementia-Like Phenotype in an Argentine Family with Presenilin-1 M146V Alzheimer’s Disease with Pick Bodies Ricardo Allegri, Leonardo Bartoloni, Cecilia Serrano, Galeno Rojas, Miguel Riudavets, Gustavo Sevlever, Analia Taratuto, Peter St George-Hyslop P03.244 Histone Deacetylases Suppress CGG Repeat Induced Neurodegeneration in Drosophila Model of FXTAS Peter Todd, J. Taylor, Henry Paulson 64 P03.245 Apolipoprotein E Polymorphism and Age of Onset for Alzheimer’s Disease in a Quadriethnic Sample Oh Dae Kwon, Aisha Khaleeq, Hye Guk Ryu P03.246 CALHM1 P86L Polymorphism Is Associated with Late-Onset Alzheimer’s Disease under a Recessive Model Merce Boada Rovira, Carmen Antunez Almagro, Jesus Lopez-Arrieta, Jose Jorge Galan, Francisco Moron, Isabel Hernandez Ruiz, Juan Marin, Pablo Martinez-Lage, Jose Carrasco, Luis Real, Antonio GonzalezPerez, Lluis Tarraga Mestre, Agustin Ruiz P03.247 Genetic Variability in Cholesteryl Ester Transfer Protein (CETP) Is Independently Associated with Protection from Incident Dementia Amy Sanders, Cuiling Wang, Mindy Katz, Carol Derby, Nir Barzilai, Laurie Ozelius, Richard Lipton P03.248 Incidence of a Positive Family History in Genetic Prion Disease: Data from a Large Cohort Julie Thai, Tricia See, David Johnson, Amy Kuo, Katherine Wong, Stephen DeArmond, Jill Goldman, Bruce Miller, Michael Geschwind P03.249 KIBRA: A Candidate Gene for Alzheimer’s Disease with Implications for Memory Jeremy Burgess, Otto Pedraza, Meron Hirpa, Thuy Nguyen, Ma Li, Zou Fanggeng, Steven Younkin, Julia Crook, Vernon Pankratz, Ronald Petersen, Neill Graff-Radford, Nilufer Ertekin-Taner Aging and Dementia: Therapeutics P03.250 Dimebon (Latrepirdine) Does Not Enhance Cognition by Actions on Acetylcholinesterase or NMDA Receptor Modulation Marco Giorgetti, Sebastián Bernales, Iván Alfaro, Christophe Drieu La Rochelle, Thomas Cremers, C. Anthony Altar, Robert Wronski, Andrew Protter P03.251 Safety and Tolerability of a Once-Daily, Extended-Release Memantine Formulation (28 mg) in Patients with Moderate to Severe Alzheimer’s Disease: Results of a 52Week Open-Label Trial Barnett Meyers, Min Lin, Stephen Graham P03.252 Predictors of Adherence among Alzheimer’s Disease Patients Receiving Oral Therapy: Results of a Retrospective Database Analysis Bijan Borah, Patricia Sacco, Victoria Zarotsky P03.253 Effectiveness of Memantine in Patients with Moderate to Severe Alzheimer’s Disease as Measured by the Caregiver Perceived Burden Questionnaire (CPBQ) Teresa Wilcox, Wen-Hung Chen, Sean O’Quinn, Juliana Setyawan, Judith Saxton, M. Haim Erder P03.254 Donepezil’s Effect on Cognition in Severe Alzheimer’s Disease: A Pooled Data Analysis Jeffrey Cummings, Joan Mackell, Sharon Richardson Wednesday, April 14 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P03.255 Evaluating Cognitive Effects of Oral Rivastigmine Using Subscales and Items of the ADAS-Cog in Patients with Mild to Moderate Parkinson’s Disease Dementia Frederick Schmitt, Dag Aarsland, Kolbjorn Brønnick, Jason Olin, Xiangyi Meng P03.256 Effects of Rivastigmine Transdermal Patch on Cognitive Ability in Patients with Mild to Moderately Severe Alzheimer’s Disease George Grossberg, Frederick Schmitt, Jason Olin, Xiangyi Meng P03.257 Effects of Oral Rivastigmine on Specific Cognitive Abilities in Patients with Mild to Moderately Severe Alzheimer’s Disease: A Pooled Analysis Martin Farlow, Jeffrey Cummings, Jason Olin, Xiangyi Meng P03.258 Benefits of ExtendedRelease Memantine (28 mg, Once Daily) on Caregiver Distress: Results of a Multinational, Double-Blind, PlaceboControlled Trial in Moderate to Severe Alzheimer’s Disease George Grossberg, Facundo Manes, Ricardo Allegri, Luis Miguel Gutierrez Robledo, Sergio Gloger, Lei Xie, Xinwei Daniel Jia, James Perhach, Michael Tocco, Stephen Graham P03.259 Dimebon (Latrepirdine) Promotes Neurite Outgrowth and Prevents Loss of Mitochondrial Membrane Potential in Cultured Hippocampal Neurons Sebastián Bernales, Iván Alfaro, Andrew Protter P03.260 Dimebon (Latrepirdine) Is Well-Tolerated in Patients with Alzheimer’s Disease Receiving Memantine or Memantine Plus Donepezil Anton Porsteinsson, Bryan Selby, Fong Wang, Pierre Tariot P03.261 The Effects of Cholinesterase Inhibitors of Developing Dementia from Mild Cognitive Impairment Pablo Martinez-Lage, Isabel Hernandez Ruiz, Montserrat Alegret Llorens, Sergi Valero Ventura, James Becker, Oscar Lopez, Lluis Tarraga Mestre, Merce Boada Rovira Child Neurology/Developmental Neurobiology: Genetics/ Therapeutics P03.262 Recognition and Therapy of Tetrahydrobiopterin Deficiency (BH4) in Childhood Dystonia, a Spectrum of Dopa Responsive Disorders Bennett Lavenstein, Uta Kozecki-Lichter, Kenneth Rosenbaum P03.263 Partial Trisomy 2p13.3-P16.3: Report of a Patient with Developmental Delay and Polymicrogyria, and Review of the Literature; a Shared Locus for Bilateral Perisylvian Polymicrogyria Narrowed to 2p16.1-P16.3 Dina Amrom, Bernard Dan, Nicolas Deconinck, Daniel Brasseur, Catherine Christophe, Bruno Pichon, Christopher Walsh, Eva Andermann P03.264 A Novel Congenital Disorder of Glycosylation Caused by Deficiency in ALG11 (ALG11-CDG) Luc Regal, Wendy Vleugels, Valerie Race, François Foulquier, Linda De Meirleir, Katrien Jansen, Jaak Jaeken, Gert Matthijs P03.265 L-Dopa Therapy in Angelman Syndrome of Childhood Bennett Lavenstein, Andrea Gropman P03.266 Pyruvate Therapy on Leigh Syndrome Due to a Novel Mutation in PDH E1a Gene Nataliya Povalko, Toyojiro Matsuishi, Etsuo Naito, Masashi Tanaka, Yasutoshi Koga P03.267 Lacosamide as Add-On Therapy in Pediatric Epilepsy: Retrospective Clinical Experience Michael Chez P03.268 Idebenone as a Potential Therapy for Ataxia with Oculomotor Apraxia Type I— Results of a OneYear N-of-1 Trial Grace Yoon, Robyn Westmacott, Brenda Banwell P03.269 Treatment of Pediatric Status Migrainosus: Can We Prevent the “Bounce Back”? Genevieve Legault, Harley Eisman, Michael Shevell P03.270 Mapping of Loci for Autistic Spectrum Disorder on Chromosomes 7q31.31-31.33 and 9q21.33-q22.2 Mohammed Aldosari, Latifa Al-Sharif, Dania Khalil, Jameela Shinwari, Ahood Almuslamani, Nada Al Tassan, Michael Nester Poster Session III Wednesday, April 14 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P03.276 Effect of Healthy Subjects’ Age on Systemic Exposure to Armodafinil Mona Darwish, Mary Kirby, Edward Hellriegel, Ronghua Yang, Philmore Robertson, Jr P03.277 Outcomes of Sodium Oxybate Therapy for Narcolepsy in an Out Patient Sleep Clinic Population Jo Anne Turner, Richard Bogan P03.278 Narcolepsy Risk in Relation to Alcohol and Caffeinated Beverage Consumption Among Genetically Susceptible Individuals: A PopulationBased Case-Control Study Thanh Ton, Nathaniel Watson, W. T. Longstreth P03.279 Daytime Sleepiness Is Associated with Reduced Baroreflex Sensitivity in OSAS and Not in Narcolepsy Daniela Grimaldi, Alessandro Silvani, Giorgio Barletta, Christian Franceschini, Stefano Vandi, Giuseppe Plazzi, Pasquale Montagna, Pietro Cortelli P03.280 A Multicenter, Randomized, Double-Blind, Placebo-Controlled fMRI Study of the Effect of Armodafinil on Prefrontal Cortical Activation in Patients with Residual Excessive Sleepiness Associated with CPAP-Treated OSA Gregory Rippon, Douglas Greve, Stephen Duntley, Linda Larson-Prior, Andrew Krystal, Bruce Fischl, Stephen Thein, Ronghua Yang, Jeffrey Dayno, Clete Kushida, Robert Thomas P03.281 Myotonic Dystrophy and Sleep-Disordered Breathing: Emergence of Severe Central Sleep Apnea After Initiation of Non Invasive Positive Airway Pressure Raam Sambandam, John Decerce P03.282 Respiratory-Related Rhythmic Movements of Sleep (RRMS) Divya Gupta, Irving Smith, Sushanth Bhat Sleep Disorders: Neurological Issues and Disorders in Sleep P03.283 Circadian Rhythm of Core Body Temperature in an Animal Model of Chronic Epilepsy Sachin Talathi, Junli Zhou, William Ditto, Paul Carney P03.284 Use of Sleep Medications Prior to Presentation to Sleep Clinic in Patients with Epilepsy and Insomnia: A Retrospective Study Mausumi Khaund, Alcibiades Rodriguez P03.290 Sleep-Related Falling Out of Bed in Parkinson’s Disease Douglas Wallace, Henry Moore-Quiroga, Fatta Nahab, Salim Dib, Cenk Sengun, Carlos Singer, Alberto Ramos P03.285 Sleep Disorders in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) Recorded Over Night by Video-Polysomnography Rosalia SilvestriHobson, Antonella Gagliano, Irene Arico’, Tiziana Calarese, Rosaria Condurso P03.291 Sleep Abnormalities in the Pallido-Ponto-Nigral Degeneration Kindred Andrew Spector, Zbigniew Wszolek, Brittany Dugger, Ryan Uitti, Paul Fredrickson, Joseph Kaplan, Bradley Boeve, Dennis Dickson, Audrey Strongosky, Siong-Chi Lin P03.286 Potential Mechanisms Underlying Spatial Learning and Memory Impairment Following Sleep Deprivation in Early Development Rama Maganti, Do Young Kim, Heather Milligan, Julianne Wilke, Tom Bautista, Jong Rho P03.287 Shifting Demographics in REM Sleep Behavior Disorder: Sex Ratio, Antidepressants, and Autoimmunity YoEl Ju, Linda Larson-Prior, Stephen Duntley P03.288 Self- Perceived Personality Changes in Healthy Adults Reporting Dream Enactment Behavior Scott Findley, Dona Locke, Charlene Snyder, Richard Caselli P03.289 Sleep Disturbance, Dreams, Mood, and Impulsive-Compulsive Behaviours in Parkinson’s Disease Sean O’Sullivan, Clare Loane, Andrew Lawrence, Andrew Evans, Paola Piccini, Andrew Lees P03.292 Improvement in Multiple Symptoms of Fibromyalgia with Sodium Oxybate Treatment: Results from a US Phase III Randomized, Controlled Trial Todd Swick, Victor Rosenfeld, Sarah Alvarez-Horine, Y. Grace Wang, Diane Guinta, I. Jon Russell P03.293 Sodium Oxybate Reduces Pain and Improves Function and PGIC in Fibromyalgia: Results from an International, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Todd Swick, Michael Spaeth, Ernest Choy, Sarah Alvarez-Horine, Y. Grace Wang, Beverly Benson, Robert Bennett P03.271 Psychiatric Comorbidity and Management in Patients with Tuberous Sclerosis Complex Thomas Chung, Cheryl Fiser, Daniel Nelson, David Franz, Darcy Krueger Sleep Disorders: General Sleep, Narcolepsy, and Sleep Related Breathing Disorders P03.272 Serotonergic Modulation of Eye Movements in Sleep Assessed by Automated Detection Mark Boulos, Karthikeyan Umapathy, Peyman Shokrollahi, Kristiina McConville, Tess Sudenis, Dana Jewell, Sridhar Krishnan, Brian Murray P03.273 Slow Eye Movements in Light Sleep on the Maintenance of Wakefulness Test as a Marker of Sleepiness Mark Boulos, Karthikeyan Umapathy, Peyman Shokrollahi, Kristiina McConville, Tess Sudenis, Dana Jewell, Sridhar Krishnan, Brian Murray P03.274 Race-Ethnic Variation of Sleep Symptoms in an Urban MultiEthnic Cohort: The Northern Manhattan Study Alberto Ramos, Chuanhui Dong, Sandino Cespedes, William Wohlgemuth, Bernadette Boden-Albala, Mitchell Elkind, Clinton Wright, Ralph Sacco, Tatjana Rundek P03.275 Epworth Sleepiness Scale (ESS) and SleepMed Insomnia Index (SMI) as Outcome Measures in Treated Narcolepsy Jo Anne Turner, Richard Bogan 65 Integrated Neuroscience Session: Emerging Treatments in Neuromuscular Disease Integrated Neuroscience Session: Multiple Sclerosis Imaging Wednesday, April 14 | 2:00 p.m.–6:00 p.m. Wednesday, April 14 | 2:00 p.m.–6:00 p.m. Coordinators: Daniel Reich, MD, PhD and Nancy Sicotte, MD, FAAN Coordinators: Nicholas Maragakis, MD and Charles Thornton, MD, FAAN Platform Sessions / 2:00 p.m.–3:30 p.m. / Constitution Hall 105 Platform Session / 2:00 p.m.–3:15 p.m. / Reception Hall 104A–D 2:00 p.m. IN6-1.001 Preliminary Results with AVI-4658 of Dystrophin Expression, Safety and Pharmacokinetics from the First Systemic Administration Study in Boys with Duchenne Muscular Dystrophy (DMD), with a Phosphorodiamidate Morpholino Oligomer (PMO) to Skip Exon 51 Francesco Muntoni, Kate Bushby, Sebahattin Cirak, Michela Guglieri, Shirley Leow, Stephen Shrewsbury 2:15 p.m. IN6-1.002 A Phase I/IIa Systemic Study on Antisense Oligonucleotide Compound PRO051 in Patients with Duchenne Muscular Dystrophy Nathalie Goemans, Mar Tulinius, Gunnar Buyse, Sjef de Kimpe, Judith van Deutekom 2:30 p.m. IN6-1.003 Clinical Trial Testing Lithium Carbonate and Riluzole in Patients with ALS Terminates Early for Futility Swati Aggarwal, Lorne Zinman, David Schoenfeld, Robin Conwit, Jeremy Shefner, Merit Cudkowicz 2:45 p.m. IN6-1.004 ACE-031 Significantly Increases Lean Body Mass and Muscle Volume in Healthy Postmenopausal Volunteers Following a Single Subcutaneous Dose Niels Borgstein, Yijun Yang, Carolyn Condon, Dawn Wilson, Eric Haltom, Jennifer Lackey, Jasbir Seehra, Mathew Sherman 3:00 p.m. IN6-1.005 Adult Murine Derived Mesoangioblasts Successfully Recovered Dysferlin Expression in a Murine Model of Dysferlinopathy Jordi Díaz-Manera, Thierry Touvier, Rossana Tonlorenzi, Laura Perani, Arianna Dellavalle, Graziella Messina, Patrizia Pessina, Eduard Gallardo, Isabel Illa, Yvan Torrente, Giulio Cossu IN6-2.004 Pulsed Electromagnetic Fields To Reduce Diabetic Neuropathic Pain and Stimulate Neuronal Repair: A Randomized Controlled Trial Michael Weintraub, David Herrmann, A. Smith, Misha Backonja, Steven Cole IN6-2.006 Initial Efficacy and Safety Evaluation in Cynomolgus Monkeys of AVI-5038, a Peptide Conjugated Phosphorodiamidate Morpholino Oligomer (PPMO) Being Developed to Skip Exon 50 in Duchenne Muscular Dystrophy Peter Sazani, Stephen Shrewsbury 2:00 p.m. IN7-1.001 Correlation of Retinal Nerve Fiber Layer Thickness in Optical Coherence Tomography with Visual Cortex MR Spectroscopy and Brain Atrophy in Multiple Sclerosis Caspar Pfueller, Alexander Brandt, Jens Wuerfel, Florian Schubert, Bernadeta Walaszek, Helmar Waiczies, Markus Bock, Frauke Zipp, Friedemann Paul, Bernd Ittermann 2:15 p.m. IN7-1.002 The Role of CD 4 T-Cells and Epitope Specific CD8 T-Cells in the Formation of T1 Hypointense Lesions in a Murine Model of MS Istvan Pirko, Jeremiah McDole, Yi Chen, Anne Lohrey, Scott Dunn, Aaron Johnson 2:30 p.m. IN7-1.003 Quantitative Venous Vasculature Assessment on SusceptibilityWeighted Imaging Reflects Presence of Severe Chronic Venous Insufficiency in the Brain Parenchyma of Multiple Sclerosis Patients. A Case-Control Study Guy Poloni, Paolo Zamboni, Mark Haacke, Stefano Bastianello, Michael Dwyer, Niels Bergsland, Claudiu Schirda, David Wack, Christopher Magnano, Bianca Weinstock-Guttman, Fabrizio Salvi, David Hojnacki, Robert Zivadinov 2:45 p.m. IN7-1.004 7 Tesla MR Imaging Marker Distinguishes Between MS and Ischemic Brain Lesions Emma Tallantyre, Jennifer Dixon, Ian Donaldson, Paul Morgan, Peter Morris, Nikos Evangelou 3:15 p.m. IN7-1.006 Contribution of Cortical Lesion Types to Cortical Thinning in MS: A Combined 3T-7T MRI Study> 3:00 p.m. IN7-1.005 Cortical Thickness in MS as Long -Term Predictor of Physical Impairment: Results From a Longitudinal and Observational Large Study Mehul Sampat, Christopher Nguyen, Darin Okuda, Roland Henry, Daniel Pelletier Poster Session / 3:15 p.m.–4:30 p.m. / Reception Hall 104A–D IN6-2.001 Single, High Doses of Epoetin alfa Increase Frataxin in Patients with Friedreich’s Ataxia Francesco Sacca, Raffaele Piro, Giuseppe De Michele, Fabio Acquaviva, Antonella Antenora, Guido Carlomagno, Sergio Cocozza, Alessandra Denaro, Anna Guacci, Angela Marsili, Gaetano Perrotta, Giorgia Puorro, Antonio Cittadini, Alessandro Filla IN6-2.002 Intrathecal Delivery of Autologous Mesenchymal Stem Cells in Patients with Amyotrophic Lateral Sclerosis Clementine Karageorgiou, Ioanna Chatzi, Athanasia Alexoudi, Andreas Papasavvas, Georgios Gortzolidis, Elissaios Karageorgiou, Eleni Papageorgiou, Georgios Tagaris, Aikaterini Stavropoulou-Gioka IN6-2.003 Prolonged Administration of High- Dose Ascorbic Acid Impairs Rat Sciatic Nerve Functional Recovery After Crush Injury Itzik Wirguin, Marina Bersudsky IN6-2.005 Tafamidis (Fx-1006A): A First-In-Class Disease-Modifying Therapy for Transthyretin Type Familial Amyloid Polyneuropathy Teresa Coelho, Luis Maia, Ana Martins da Silva, Marcia Waddington Cruz, Violane Plante-Bordeneuve, Pierre Lozeron, Ole Suhr, Josep Campistol, Isabel Conceicao, Hartmut Schmidt, Pedro Trigo, Jeff Packman, Donna Grogan Invited Speaker Session* / 4:30 p.m.–5:00 p.m. / Reception Hall 104A–D 4:30 p.m.–5:00 p.m. Gene Therapy for Muscular Dystrophy: Progress and Lessons Learned Jerry Mendell, MD Platform Session / 5:00 p.m.-6:00 p.m. / Reception Hall 104A–D 5:00 PM IN6-3.001 Complete Rescue of SMA Mouse Model by Systemic Delivery of scAAV9 Mediating SMN Replacement Chiara Valori, Ke Ning., Matthew Wyles, Mimoun Azzouz *Current as of February 1, 2010 66 5:20 PM IN6-3.002 Antisense Therapeutics for the Treatment of Neurodegenerative Disorders: Preclinical Studies Richard Smith, Robert Fey, Richard Geary, Robert Boyd, Scott Henry, John Grundy, Daniel Norris, Ed Wancewicz, Holly Kordasiewcz, Don Cleveland 5:40 PM IN6-3.003 Pharmacokinetics of IV Immunoglobulin and Outcome in Guillain-Barré Syndrome Krista Kuitwaard, Jenny de Gelder, Anne Tio-Gillen, Wim Hop, Teun van Gelder, Albert van Toorenenbergen, Pieter van Doorn, Bart Jacobs IN6-2.007 Proof-of-Concept for a Novel Small Molecule Hsp90 Inhibitor for Spinal and Bulbar Muscular Atrophy (SBMA) Allan Rubenstein, Udai Pandey, Zahara Jaffer, Ruihong Chen, Sophia Barluenga, Nicolas Winssinger, J. Taylor Poster Session / 3:30 p.m.–4:30 p.m. / Constitution Hall 105 IN7-2.001 Ganglion Cell Layer Volume by Spectralis Optical Coherence Tomography (OCT) in Multiple Sclerosis Emma Davies, Lauren Talman, Dina Jacobs, James Wilson, Clyde Markowitz, Steven Galetta, Elliot Frohman, Peter Calabresi, Laura Balcer IN7-2.004 Relation between Thalamic Atrophy and Long-Term Disability Progression in Multiple Sclerosis: An Eight-Year Follow-Up Study Maria Rocca, Sarlota Mesaros, Elisabetta Pagani, Maria Pia Sormani, Giancarlo Comi, Vittorio Martinelli, Massilmo Filippi IN7-2.002 Cortical Microglial Activation Is Associated with Disability in Secondary Progressive Multiple Sclerosis: An In Vivo Imaging Study Marios Politis, Paolo Giannetti, Paul Su, Federico Turkheimer, Shiva Keihaninejad, Kit Wu, Adam Waldman, Richard Reynolds, Richard Nicholas, Paola Piccini IN7-2.005 Long-Term Evolution of Chronic Black Holes in T1Weighted MRIs of Multiple Sclerosis Patients Raghavan Gopalakrishnan, Jar-Chi Lee, Richard Rudick, Elizabeth Fisher IN7-2.003 3T MRI Frequency of MS Cortical Lesions and Their Relationship with Cognitive Performance Andrea Mike, Bonnie Glanz, Peter Hildenbrand, Dominik Meier, Khalima Bolden, Elisa Dell’Oglio, Brian Healy, Maria Liguori, Rohit Bakshi, Charles Guttmann IN7-2.006 Objective Quantification of Cerebrospinal Fluid (CSF) Flow Rate in Cerebral Aqueduct in Patients with Multiple Sclerosis Claudiu Schirda, Paolo Zamboni, Christopher Magnano, Eric Lindzen, David Wack, Bianca Weinstock-Guttman, Deepa Ramasamy, Ellen Carl, David Hojnacki, Cheryl Kennedy, Michael Dwyer, Niels Bergsland, Jennifer Cox, Fabrizion Salvi, Robert Zivadinov IN7-2.007 Increased Conspicuity of Cervical Spinal Cord Lesions in Multiple Sclerosis on Multiple-Echo Recalled Gradient Echo (MERGE) Images at 3T Iordanis Evangelou, Nancy Richert, Steven Jacobson, Bibiana Bielekova, Daniel Reich IN7-2.008 Relaxometry—A New MR Marker of Neurodegeneration in Multiple Sclerosis? Jan Krasensky, Manuela Vaneckova, Eva Havrdova, Andrea Burgetova, Dana Horakova, Zdenek Seidl IN7-2.009 Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study Mohit Neema, Jennifer Moodie, Brian Healy, Guy Buckle, Susan Gauthier, Bonnie Glanz, Tanuja Chitnis, Samia Khoury, Charles Guttmann, Howard Weiner, Rohit Bakshi IN7-2.010 Identifying the Start of Multiple Sclerosis Inflammation: A Serial DTI Study Daniel Ontaneda, Ken Sakaie, Jian Lin, Xiaofeng Wang, Mark Lowe, Michael Phillips, Robert Fox Invited Speaker Session* / 4:30 p.m.–6:00 p.m. / Constitution Hall 105 4:30 p.m.–4:50 p.m. Microvascular Changes Associated with MS Lesion Formation William Rooney, PhD 4:50 p.m.–5:10 p.m. Whole-Brain Relaxometry and Myelin Water Imaging: Techniques and Applications to MS and Other Neurological Disorders Sean Deoni, PhD 5:10 p.m.–5:30 p.m. Typical Presentations of Sinovenous Stenosis and Thrombosis: Lessons From Neuroradiologic Evaluation Ari Blitz, MD 5:30 p.m.–5:50 p.m. Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: A Paradigm Shift in the Physiology of Cerebral Venous Return Paolo Zamboni, MD 5:50 p.m.–6:00 p.m. Panel Discussion *Current as of February 1, 2010 67 Scientific Sessions S21 Multiple Sclerosis: Clinical Trials II S23 Movement Disorders: Parkinson's Disease / NonMotor Symptoms S24 Aging and Dementia: Imaging S25 Epilepsy: Antiepileptic Drug Therapy Scientific Sessions Wednesday, April 14 | 2:00 p.m.–4:00 p.m. S26 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy S27 Infections S28 Neuro-ophthalmology/ Neuro-otology Theatre 102 Constitution Hall 106 Room 718AB Constitution Hall 107 Room 716A Room 701B Room 701A Room 714B 2:00 p.m. S21.001 Oral Teriflunomide or Placebo Added to Glatiramer Acetate for Six Months in Patients with Relapsing Multiple Sclerosis: Safety and Efficacy Results Mark Freedman, Jerry Wolinsky, Gérald Frangin, Christian Confavreux, Giancarlo Comi, William Byrnes, Ludwig Kappos, Tomas Olsson, Aaron Miller, Paul O’Connor 2:00 p.m. S22.001 Levels of Matrix Metalloproteinase-9 (MMP9) Are Associated with Inflammation and Severity in Acute Ischemic Stroke Lauren Nentwich, Fabricio Lima, Gisele Silva, Leonardo Batista, Matthew Maas, Shahmir Kamalian, Alona Muzikansky, Ken Arai, Sophia Hartdegen, Steven Feske, Ron Walls, Eng Lo, Karen Furie 2:00 p.m. S23.001 Depression and Anxiety Phenotypes in Parkinson’s Disease Richard Brown, David Burn, John Hindle, Catherine Hurt, Sabine Landau, Mike Samuel, Ken Wilson 2:00 p.m. S24.001 Histopathological Validation of Amyloid Imaging with Florbetapir F 18 (18F-AV-45) PET in an Ongoing Phase III Prospective Clinical Study of Subjects at the End of Life Adam Fleisher, Julie Schneider, Thomas Beach, Barry Bedell, Simone Zehntner, Jose Gamez, Franco Sicuro, Meenaskshi Patel, Marwan Sabbagh, Christopher Clark, Michael Krautkramer, Michael Pontecorvo, Abhinay Joshi, Mark Mintun, Matthew Flitter , Franz Hefti, Daniel Skovronsky 2:00 p.m. S25.001 Investigating the Role of Interleukin1Beta in Temporal Lobe Epilepsy in the Pilocarpine Rat Model Using RNA Interference Vinicius Pascoal, Rafael Marchesini, Tiago Pereira, Rovilson Gilioli, Jaqueline Malheiros, Roberson Polli, Hilde Buzzá, Alberto Tannús, Luciene Covolan, Ésper Cavalheiro, Fernando Cendes, Iscia Lopes-Cendes 2:00 p.m. S26.001 Randomized Controlled Trial of Immunoglobulin Intravenous 10% (NewGam, Octapharma AG) in CIDP (POINT Trial) David Cornblath, Richard Hughes, Marinos Dalakas, Norman Latov, Pieter Van Doorn, Hans Hartung, Stefan Haag, Stefan Wietek 2:00 p.m. S27.001 Herpes Simplex Virus (HSV) Infections in Cancer Patients: The Memorial Sloan Kettering Cancer Center (MSKCC) Experience Jerome Graber, Lisa DeAngelis 2:00 p.m. S28.001 Large Genomic Deletions in CACNA1A Causing Episodic Ataxia Type 2 Ji-Jun Wan, Hafsa Mamsa, Janine Johnston, Elizabeth Spriggs, Harvey Singer, David Zee, Alhamza AlBayati, Robert Baloh, Joanna Jen 2:15 p.m. S25.002 Polymorphisms in Drug-Transporter Genes Are Significantly Associated with Response to Antiepileptic Drugs in Mesial Temporal Lobe Epilepsy Mariana Silva, Elisabeth Bilevicius, Renato Santos, Rodrigo Secolin, Claudia Maurer-Morelli, Fernando Cendes, Iscia Lopes-Cendes 2:15 p.m. S26.002 Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies Laurent Magy, Raphaél Kaboré, Christiane Caudie, Gaël Gallouedec, Jean-Michel Vallat 2:15 p.m. S27.002 Evaluation of Rabies Virus Infection of Adult Mouse Dorsal Root Ganglia Neurons: Role of Oxidative Stress Alan Jackson, Wafa Kammouni, Elena Zherebitskaya, Paul Fernyhough 2:15 p.m. S28.002 Retinal Nerve Fiber Layer (RNFL) Thickness by Optical Coherence Tomography (OCT) in Multiple Sclerosis (MS): Relation to Visual Function Using Current vs. HighResolution Technologies Jennifer Graves, Lauren Talman, Amy Conger, Stephanie Syc, Dina Jacobs, Clyde Markowitz, Yang Dai, Gui-shuang Ying, Steven Galetta, Elliot Frohman, Peter Calabresi, Laura Balcer 2:15 p.m. S21.002 Double-Blind, Placebo-Controlled, Randomized Phase II Serial MRI, Safety and Tolerability Study of Two Doses of CDP323 in Subjects with Relapsing Forms of Multiple Sclerosis over 24 Weeks Chris Polman, James Bowen, Frederik Barkhof, David Bates, Daniel Wynn, Evert Sanders, Christian Wolf, Tony Morris, Petra Duda, Birgit Weinkauf, Frances Lynn, Barbara Bennett 2:30 p.m. S21.003 Recombinant T Cell Receptor Ligand (RTL) for the Treatment of Multiple Sclerosis: Report of a Phase I Clinical Trial Vijayshree Yadav, Dennis Bourdette, James Bowen, Sharon Lynch, David Mattson, Jana Preiningerova, Clive Rose, Richard Stead, Adolph Ferro, Andrew Goldstein, Gregory Burrows, Halina Offner, Arthur Vandenbark 2:45 p.m. S21.004 A Multi-Center Randomized Clinical Trial of Donepezil to Treat Memory Impairment in Multiple Sclerosis Lauren Krupp, Christopher Christodoulou, Patricia Melville, William Scherl, Ling-Yu Pai, Ralph Benedict, Andrew Goodman, Syed Rizvi, Steven Schwid, Bianca Weinstock-Guttman, Holly Westervelt, Heather Wishart 3:00 p.m. S21.005 Atorvastatin Reduces the Risk of New Brain MRI Lesions in Patients with Clinically Isolated Syndrome (CIS) Compared to Placebo Emmanuelle Waubant, Daniel Pelletier, Michele Mass, Jeffrey Cohen, Mariko Kita, Anne Cross, Amit Bar-Or, Timothy Vollmer, Michael Racke, Olaf Stuve, Steven Schwid, Andrew Goodman, Norman Kachuck, Jana Preiningerova, Bianca Weinstock-Guttman , Peter Calabresi, Aaron Miller, Masoud Mokhtarani, David Iklé, Stacey Murphy, Linna Ding, Ellen Rosenberg, ITN020AI Study Management Team, Collin Spencer, Scott Zamvil 3:15 p.m. S21.006 Pilot Phase I/II Clinical Trial with Autologous Mesenchymal Stem Cells in Patients with Multiple Sclerosis and Amyotrophic Lateral Sclerosis Dimitrios Karussis, Clementine Karageorgiou, Basan Gowda-Kurkalli, Adi Vaknin-Dembinsky, John Gomori, Ibrahim Kassis, Panayiota Petrou, Jeff Bulte, Shimon Slavin 3:30 p.m. S21.007 Omega-3 Fatty Acids as an Adjunct Therapy for Depression in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Lynne Shinto, Gail Marracci, Lauren Stuber, Dennis Bourdette 3:45 p.m. S21.008 Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Rehan Verjee, Bruno Musch, Steven Greenberg 68 S22 Cerebrovascular Disease I Wednesday, April 14 | 2:00 p.m.–4:00 p.m. Metro Toronto Convention Centre 2:15 p.m. S22.002 Spinal Cord Infarcts: LongTerm Outcome and Prognostic Predictors Carrie Robertson, Alejandro Rabinstein 2:30 p.m. S22.003 Risk Factors for Readmission after Hospitalized Stroke Yu-wei Chen, Mei-Chiun Tseng, HueyJuan Lin 2:45 p.m. S22.004 The NIHSS-Mapped Rankin Score: A Novel Index of Pretreatment Disability and Treatment-Induced Improvement in Disability in Acute Stroke Trials Jeffrey Saver, Sidney Starkman 3:00 p.m. S22.005 The Very Long-Term Risk and Prognosis of Post-Stroke Epilepsy in Patients with a Previous Young Stroke FrankErik de Leeuw, Loes Jacobs, Noortje Maaijwee, Renate Arntz, Henny Schoonderwaldt, Lucille Dorresteijn 3:15 p.m. S22.006 Cognitive Dysfunction in Children and Adolescents with Sickle Cell Disease without Evidence of Stroke: Preliminary Results Ana Claudia Leite, Janete Silva, Heber Maia Filho, Ursula Thome, Patricia Moura, Clarisse Lobo 3:30 p.m. S22.007 Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients with Acute Ischemic Stroke Qiang Dong, Ya Lin Chen 3:45 p.m. S22.008 The Impact of Diabetes on the Extent of Pial Collaterals in Ischemic Stroke Patients Marc Lazzaro, Michael Chen, Gregory Christoforidis, Shyam Prabhakaran, Yousef Mohammad 2:15 p.m. S23.002 Imaging Gambling Severity in Patients with Parkinson’s Disease: Evidence of Fronto-Striatal Disconnection Roberto Cilia, Sang Soo Cho, Thilo van Eimeren, Giorgio Marotta, Chiara Siri, Ji Hyun Ko, Giovanna Pellecchia, Gianni Pezzoli, Angelo Antonini, Antonio Strafella 2:30 p.m. S23.003 Fatigue in Parkinson’s Disease Is Associated with Reduced Brain Serotonin and Dopamine Innervation Nicola Pavese, Vinod Metta, Subrata Bose, K. Chaudhuri, David Brooks 2:45 p.m. S23.004 A Multi-Center, PlaceboControlled, Double-Blind Trial To Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson’s Disease Joseph Friedman, Bernard Ravina, Roger Mills, Hilde Williams, Daun Bahr, Perry Peters, Francois Tison, David Burn 3:00 p.m. S23.005 Severity of REM Atonia Loss in Idiopathic REM Sleep Behavior Disorder Predicts Parkinson Disease Ronald Postuma, JeanFrancois Gagnon, Sylvie Rompre, Jacques Montplaisir 3:15 p.m. S23.006 Effect of Rotigotine on Non-Motor Symptoms in Subjects with Idiopathic Parkinson’s Disease K. Ray Chaudhuri, Monika Rudzinska, Bryan Kies, Jennifer Fine, Dennis Hill, Tim Anderson, Edwin Surmann, John Whitesides, Babak Boroojerdi, Claudia Trenkwalder, on Behalf of the RECOVER Study Group 3:30 p.m. S23.007 Clinical Validation of Diagnostic Procedures for Parkinson’s Disease Dementia (PD-D) Brandon Barton, David Grabli, Bryan Bernard, Virginie Czernecki, Jennifer Goldman, Glenn Stebbins, Bruno Dubois, Christopher Goetz 3:45 p.m. S23.008 Can Motor Features of Parkinson’s Disease Be Used To Predict Occurrence of Non-Motor Symptoms of the Disease? Renato Munhoz, Helio Teive, Hariklia Eleftherohorinou, Lachlan Coin, Andrew Lees, Lineu Werneck, Laura Silveira-Moriyama 2:15 p.m. S24.002 Effect of Minimal Atrophy of the Hippocampus (HPC) and Entorhinal Cortex (ERC) on Memory and Functional Ability Daniel Varon, Elizabeth Potter, Miriam Rodriguez, David Loewenstein, Warren Barker, Balaibal Ashok Raj, John Schinka, Maria Greig, Yougui Wu, Ranjan Duara 2:30 p.m. S24.003 Distinct Clinical and Metabolic Deficits in Alzheimer’s Disease and Posterior Cortical Atrophy Are Not Related to Amyloid Distribution Michael Rosenbloom, Adi Alkalay, Neha Agarwal, Suzanne Baker, James O’Neill, Mustafa Janabi, Irene Yen, Matthew Growdon, Jung Jang, Cindee Madison, Bruce Miller, William Jagust, Gil Rabinovici 2:45 p.m. S24.004 Mapping Cortical Atrophy in Parkinson’s Disease Patients with Cognitive Impairment and Dementia Kristy Hwang, Mona Beyer, Amity Green, Paul Thompson, Carmen Janvin, Jan Larsen, Jeffrey Cummings, Dag Aarsland, Liana Apostolova 3:00 p.m. S24.005 The Impact of Atrophy to Mechanical Structure Measurements in Brain Kaspar-Josche Streitberger, Dagmar Krefting, Ingolf Sack, Jürgen Braun, Friedemann Paul 3:15 p.m. S24.006 MRI Predictors of Cognitive Change in a Diverse and Carefully Characterized Elderly Population Owen Carmichael, Dan Mungas, Laurel Beckett, Danielle Harvey, Sarah Farias, Bruce Reed, John Olichney, Joshua Miller, Charles DeCarli 3:30 p.m. S24.007 Degenerative Dementia as the Failure of a Large-Scale Distributed Network John Listerud, David Libon, Peachie Moore, Murray Grossman 3:45 p.m. S24.008 Abnormal Modular Organization of Structural Cortical Network in Alzheimer’s Disease Zhang Chen, Yong He, Gaolang Gong, Rosa-neto Pedro, Lingzhong Fan, Alan Evans 2:30 p.m. S25.003 Comparing Bioequivalence of Generic Antiepilepsy Drugs (AEDs) Gregory Krauss, Barbara Davit, Brian Caffo, Yi-Ting Chang, Craig Hendrix, Anitha Palamakula 2:30 p.m. S26.003 Motor Neuropathies and Serum IgM Binding to NS6S Heparin Disaccharide or GM1 Ganglioside Alan Pestronk, Miguel Chuquilin Arista, Rati Choksi 2:45 p.m. S25.004 Neurologist-Patient Dialogue about Mood/Behavior and Adverse Effects of Antiepileptic Drugs: Results of a Phase II Communication Study John Stern, Patricia Penovich, Gregory Holmes, Corey Eagan, Meaghan Onofrey, Eileen Kois, David Labiner, Frank Gilliam 2:45 p.m. S26.004 Reliability and Validity of In-Vivo Corneal Confocal Microscopy as a Novel Small-Fiber Test for Diabetic Polyneuropathy Bruce Perkins, Paul Hertz, Andrej Orszag, Eduardo Ng, Patti Nwe, Vera Bril 3:00 p.m. S25.005 Retigabine 600, 900, or 1200 mg/ Day Provides Effective Adjunctive Therapy in Adults with Refractory Epilepsy with Baseline Total Partial-Seizure Frequency of ≤8 or >8 Seizures Per 28 Days Jacqueline French, Bassel Abou-Khalil, Martin Brodie, Susan Hall, Kevin Nanry 3:00 p.m. S26.005 Clinical Utility of LDI Compared with QTT for Small Fibre Neuropathy Vera Bril, Eduardo Ng, Patti Nwe, MyLan Ngo, Rita Leung, Slavcho Todorochko, Andrej Orzag, Bruce Perkins 3:15 p.m. S25.006 Safety, Tolerability, Efficacy and? Dosing of Rufinamide in Pediatric Epilepsy: A Single Center Experience Vasu Gooty, Tobias Loddenkemper, Martina Vendrame, Masanori Takeoka, Ann Bergin, Yaman Eksioglu, Frank Duffy, Alexander Rotenberg, Annapurna Poduri, Mark Libenson, Blaise Bourgeois, Sanjeev Kothare 3:30 p.m. S25.007 Effects of Breastfeeding in Children of Women on Antiepileptic Drugs Kimford Meador, Gus Baker, Nancy Browning, Jill Clayton-Smith, Deborah Coombs-Cantrell, Morris Cohen, Laura Kalayjian, Andres Kanner, Joyce Liporace, Page Pennell, Michael Privitera, David Loring 3:45 p.m. S25.008 HLA B*1502 as a Genetic Marker for Carbamazepine Induced Stevens Johnson Syndrome Sivakumar Rajappa, Srinivasan Venkatesan 3:15 p.m. S26.006 Upper and Lower Limb Aδ Fiber Conduction Velocities by Contact Heat Evoked Potential Stimulation (CHEPS) Benn Smith, Mark Ross 3:30 p.m. S26.007 Declines in Compound Motor Action Potential Amplitudes (CMAPs) in Peripheral Nerve Conduction Studies (NCS) Associated with Age May Be Related to Inflammation and Glucose Metabolism Ari Green, Christopher Songster, Amy Lee, Carol Piunti, John Engstrom 3:45 p.m. S26.008 The Effect of Lifestyle Intervention on Nerve Regeneration in Metabolic Syndrome A. Smith, Robin Marcus, Colin Arsenault, Charles Latner, Michael Porzio, Haimei Wang, Sheldon Smith, Arwen Fuller, J. Singleton 2:30 p.m. S27.003 Neurologic Complications Associated with 2009 Pandemic Influenza A (H1N1) Virus Infection, 2009–2010 James Sejvar 2:45 p.m. S27.004 Preliminary Evidence for Selective Orbitofrontal Dysfunction in Patients with HIV Infection Evan Wong, Ami Tsuchida, Marie-Josee Brouillette, Richard Lalonde, Lesley Fellows 3:00 p.m. S27.005 The Neuradapt Study: Volumetric and Metabolic Changes in Basal Ganglia of Patients with HIVAssociated Neurocognitive Disorders Matteo Vassallo, Alexandra Harvey-Langton, Christine Lebrun-Frenay, Stephane Chanalet, Gregoire Malandain, Jacques Durant, Christian Pradier, Philippe Robert, Jacqueline Cottalorda, Michel Ticchioni, Pierre Dellamonica 3:15 p.m. S27.006 A Comparison of Rating Scales and an Evaluation of Progression of HIVAssociated Neurocognitive Disorder Nishiena Gandhi, Richard Moxley IV, Jason Creighton, Heidi VornbrockRossa, Richard Skolasky, Ola Selnes, Justin McArthur, Ned Sacktor 3:30 p.m. S27.007 Insulin Receptor as a Biomarker for HAND in a Cohort of HIVInfected Women Valerie Wojna, Yamil Gerena, Richard Skolasky, Raul Mayo, Avindra Nath 3:45 p.m. S27.008 Clinico-Pathologic Study of Prion Disease Mimics Numthip Chitravas, Richard Jung, R. Leigh, Diane Kofskey, Mark Cohen 2:30 p.m. S28.003 Weight Gain and Recurrence in Idiopathic Intracranial Hypertension: An Expanded Case-Control Study Melissa Ko, Sally Chang, Maysa Ridha, Tabassum Ali, Luis Mejico, Nicholas Volpe, Steven Galetta, Laura Balcer, Grant Liu 2:45 p.m. S28.004 Non-Mydriatic Fundus Photography in the Diagnosis of Acute Neuro-Ophthalmic Disease in the Emergency Department (ED) Beau Bruce, Cedric Lamirel, David Wright, Antoinette Ward, Nancy Newman, Valerie Biousse 3:00 p.m. S28.005 Optical Coherence Tomography (OCT) Measurements and Visual Function Tests in a Secondary Progressive MS Trial of the Compound Dirucotide Kristin Galetta, Lauren Talman, Kim Cello, Tony Verco, Sally Jones, Peter Calabresi, Steven Galetta, Jack Werner, John Keltner, Laura Balcer, Clyde Markowitz 3:15 p.m. S28.006 Photophobia: Is the Central Visual System Necessary? Sarah Dolgonos, Craig Evinger 3:30 p.m. S28.007 Contribution of Structural and Functional Visual Outcomes to Work Capacity and Employment Status in Multiple Sclerosis David Sackel, Lauren Talman, Dina Jacobs, Amy Conger, James Wilson, Clyde Markowitz, Peter Calabresi, Elliot Frohman, Steven Galetta, Ralph Benedict, Sarah Morrow, Laura Balcer 3:45 p.m. S28.008 Increased Resting State Activity of the Visual Cortex in Patients with Leber Hereditary Optic Neuropathy Maria Rocca, Paola Valsasina, Stefania Bianchi-Marzoli, Melissa Petrolini, Jacopo Milesi, Andrea Falini, Giancarlo Comi, Massimo Filippi S29 Neuroepidemiology Room 713AB 2:00 p.m. Presentation of the Bruce S. Schoenberg International Award in Neuroepidemiology Recipient: Judith Kwasa, MD Kisumu, Kenya 2:30 p.m. S29.003 The Frequency, Outcome, and Causes of Post-Operative Cognitive Decline in Older People Emma Jones, David Green, Katja Kossakowski, Nathan Gauge, Eirini Katsaiti, Jennifer Stevens, Clive Ballard 2:45 p.m. S29.004 Does Baseline Self-Efficacy for Managing Parkinson’s Disease Predict Outcomes? Lisa Shulman, Ann Gruber-Baldini, Karen Anderson, Paul Fishman, Brad Robottom, William Weiner, Stephen Reich 3:00 p.m. S29.005 Restless Legs Syndrome (RLS) Diagnosis in an Integrated Health Delivery System, and Concordance with Four RLS Criteria Questions Stephen Van Den Eeden, Kathleen Albers, Julie Davidson, Rita Popat, Amethyst Leimpeter, Caroline Tanner, Michael Irizarry, Charles Quesenberry, Lorene Nelson 3:15 p.m. S29.006 Quality Indicators for Multiple Sclerosis Eric Cheng, Carolyn Crandall, Barbara Giesser, Jodie Haselkorn, Chris Bever, Paul Shekelle, Ron Hays, Barbara Vickrey 3:30 p.m. S29.007 A Multi-Center Study Assessing the Impact of Seizures in Mortality After Ischemic Stroke Jorge Burneo, Jiming Fang, Gustavo Saposnik 3:45 p.m. S29.008 First Stroke, Acute Symptomatic Seizures, and Early Mortality: A Prospective Cohort Study. The EPISTROKE Group (*) Ettore Beghi, Roberto D’Alessandro, Laureta Delaj, Flavia Mattana S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis Room 717AB 2:00 p.m. S30.001 Alzheimer’s Disease Risk Alleles in PCDH11X and SORL1 Are Associated with the Rate of Cognitive Decline in Subjects with Multiple Sclerosis Zongqi Xia, Lori Chibnik, Joshua Shulman, Cristin Aubin, Dong Tran, Bonnie Glanz, Charles Guttmann, Samia Khoury, Tanuja Chitnis, Howard Weiner, Philip De Jager 2:15 p.m. S30.002 IL12A, MPHOSPH9/CDK2AP1, and RGS1 Are Novel Multiple Sclerosis Susceptibility Loci International MS Genetics Consortium (IMSGC), Federica Esposito, Nikolaos Patsopoulos, Barbara Stranger, Filippo Martinelli Boneschi, Giancarlo Comi, David Hafler, Paul de Bakker, Philip De Jager 2:30 p.m. S30.003 The MSGene Database—Systematic Meta-Analyses and Field Synopsis of Genetic Association Studies in Multiple Sclerosis Christina Lill, Matthew McQueen, Johannes Roehr, Brit-Maren Schjeide, Ute Zauft, Sachin Bagade, Frauke Zipp, Lars Bertram 2:45 p.m. S30.004 mRNA-Expression Patterns of Intracellular TRADD, FADD, cFlip, TRAF2 and Caspase 8 in RelapsingRemitting Multiple Sclerosis Regina Budde, Tobias Thomas, Martin Berghoff 3:00 p.m. S30.005 Influence of Glial Factors on B Cell Biology: Implication in Multiple Sclerosis Pathogenesis Nathalie Lebeurrier, Ichiro Nakashima, Aja Rieger, Philippe Saikali, Antonia Kobert, Jack Antel, Yasuto Itoyama, Amit Bar-Or 3:15 p.m. S30.006 The Effect of Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in Interferon Treated Multiple Sclerosis Patients Barbara Green, Edward Fox, Andrew Goodman, Clyde Markowitz, Ronald Murray 3:30 p.m. S30.007 New Genetic Factors in MS: TRAPS and TNFRSF1A R92Q Mutation in Argentina Marcelo Kauffman, Dolores Gonzalez Moron, Orlando Garcea, Andres Villa 3:45 p.m. S30.008 A Link Between Autoimmunity and Neurodegeneration in Multiple Sclerosis Sangmin Lee, Lijing Xu, Yoojin Shin, Lidia Gardner, Anastasia Hertzes, Michele Roberts, F. Curtis Dohan, Cedric Raine, Ramin Homayouni, Michael Levin 69 Poster Session IV Wednesday, April 14 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 Poster Discussion Session: Movement Disorders: Parkinson's Disease: Treatment Behavioral Neurology: Memory Location: 800 Level Moderators: TBD Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. PD4.001 A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial of the Adenosine 2a Antagonist SYN115 in Parkinson Disease Kevin Black, Meghan Campbell, Wesley Dickerson, Mary Creech, Jonathan Koller, St. Clare Chung, Stephen Bandak PD4.002 The Natural Progression of Clinical Symptoms in Parkinson’s Disease May Not Be Faster in the Earlier Stages: Results from the ADAGIO Delayed-Start Study Olivier Rascol PD4.003 Overnight Conversion From Immediate-Release to Extended-Release Pramipexole for Adjunctive Treatment of Advanced Parkinson’s Disease Anthony Schapira, Paolo Barone, Robert Hauser, Youshikuni Mizuno, Werner Poewe, Olivier Rascol, Michael Busse, Laurence Salin, Mandy Sohr, in the Name of the Pramipexole ER Studies Group Headache and Facial Pain P04.001 Reversible Hypohidrosis with Topiramate Therapy for Chronic Migraine Shira Markowitz, Matthew Robbins, Clair Cascella, Huma Sheikh, Brian Grosberg P04.002 Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL): Could It Be an Autoimmune Disease? Gülsen AkmanDemir, Erdem Tüzün, Dilaver Kaya, Burçak Vural, Elif Ugurel, Sema Içöz, Mefküre Eraksoy, Angela Vincent, Mustafa Ertas, Murat Kürtüncü P04.003 Application of the Kano Methodology for Evaluating Migraine Treatment Expectations Among Neurologists in Spain. The MIGREXX Study Jorge Matias-Guiu, Gonzalo Nocea, Teresa Caloto P04.004 High Migraine Frequency May Be Associated with Increased Interictal Platelet Activation in Episodic Migraine Jill Jesurum, Cindy Fuller, Sylvia Lucas, Natalia Murinova, Lisa Hales, Elisa McGee P04.005 Response of SUNCT (Short-Lasting Unilateral Neuralgiform Headaches with Conjunctival Injection and Tearing), SUNA (Short-Lasting Unilateral Neuralgiform Headaches with Autonomic Symptoms) and Primary Stabbing Headaches to Occipital Nerve Stimulation (ONS) Juana Marin, Peter Goadsby P04.006 Lifetime Anxiety Symptoms in Migrainous Vertigo Gulden Akdal, Birgul Balci, Aysegül Ozer, Elif Onur 70 PD4.004 Efficacy of the Adenosine A 2A Receptor Antagonist BIIB014 in Parkinson’s Disease (PD) Patients with Motor Fluctuations Spyridon (Spyros) Papapetropoulos, Rupam Borgohain, Mark Kellett, Nir Giladi, Davorka Tomic, Alex Coppell, John Barnard, Ying Zhu, Gilmore O’Neill PD4.005 Safety and Tolerability Profile of the Adenosine A 2A Receptor Antagonist BIIB014 as an Adjunct Treatment in Parkinson’s Disease (PD) Patients with Motor Fluctuations Spyridon (Spyros) Papapetropoulos, Rupam Borgohain, Mark Kellett, Nir Giladi, Davorka Tomic, Alex Coppell, John Barnard, Ying Zhu, Gilmore O’Neill PD4.006 Initial Diagnosis and Treatment Patterns in Parkinson’s Disease Maureen Lage, Marcy Tarrants, Jane Castelli-Haley PD4.007 Long-Term Study on Clinical Benefits and Quality of Life of Intraduodenal Levodopa in Routine Care for a Cohort of Treatment-Naïve Patients with Advanced Parkinson’s Disease S. Pälhagen, N. Dizdar, T. Hauge, B. Holmberg, R. Jansson, J. Linder, H. Widner, A. Johansson PD4.008 Synthesis and Evaluation of Novel Compounds for the Treatment of Parkinson’s Disease Niran Argintaru, Dipannita Basu, Bailee Dyck, Ram Mishra, Rodney Johnson Wednesday, April 14 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. PD4.009 Controlled Study of Intermittent Theta-Burst Transcranial Magnetic Stimulation for the Treatment of Parkinson’s Disease David Benninger, Brian Berman, Elise Houdayer, Natassja Pal, Dave Luckenbaugh, Logan Schneider, Sabina Miranda, Mark Hallett PD4.010 Effect of Safinamide on Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease Mohit Bhatt, Dana Chirileanu, Chandrashekhar Meshram, Paolo Stanzione, Emma Forrest, Valentina Lucini, on Behalf of the Study 016 Investigators P04.030 Double Dissociation of Semantic and Episodic Memory Impairment in Temporal Variant Frontotemporal Dementia and Alzheimer’s Disease Kimiko Domoto-Reilly, Lucille Pellerin, Alyson Negreira, Michael Brickhouse, Daisy Sapolsky, Bradford Dickerson P04.031 False Recognition of Unfamiliar Faces in Frontotemporal Dementia Steven Rapcsak, Emily Edmonds, Maya Henry, G. Hishaw, Bryan Woodruff P04.032 Loss of Future Oriented Behavior in a Patient with Behavioral Variant Frontotemporal Dementia Jee Hoon Roh, Mee kyung Seo, Ji Hye Yoon, Duk L. Na P04.033 MRI Features Mimicking Limbic Encephalitis and CJD in Hashimoto’s Encephalopathy Without Paraneoplastic Antibodies Asa Cordle, Matthew Ostrander, Daniel Kaufer P04.034 Profiles of Performance in Verbal Serial List Learning in Alzheimer’s Disease and Semantic Dementia Ashley Boller, Brianna Morgan, David Libon, Murray Grossman P04.007 Evaluation of Efficacy and Safety of MAP0004 in Reversing Central Sensitization and Treating Migraine in Established Allodynic Patients Stewart Tepper, Shashidhar Kori, Scott Borland, Min Wang, Bin Hu, Stephen Silberstein P04.008 The Timing of Gastric Stasis in an Acute Migraine and Its Impact on Treatment Shashidhar Kori, Sheena Aurora P04.009 Occipital Neuralgia as an Isolated Symptom of Bone Metastasis Caused by Hepatocellular Carcinoma Myung-Goo Ji, Nam Hee Kim P04.014 Spinal Subdural Collection in the Setting of a Spontaneous Cerebrospinal Fluid Leak Vera Fridman P04.022 Atypical Presentation of Cerebellar Mutism in an Adult Tina Lin, May Kim P04.015 The Headache UnderResponse to Treatment (HURT) Index: An Instrument Developed by the “Lifting the Burden” Campaign To Improve Management of Headache, Especially in Primary Care Dawn Buse, Timothy Steiner, Daniel Serrano, Michael Reed, Richard Lipton P04.023 Effect of Education on Severity of Language Dysfunction After Stroke Marlis Gonzalez-Fernandez, Cameron Davis, John Molitoris, Argye Hillis P04.016 Scleral Buckle as a Unique Cause of Facial Pain Babak Movassaghi, David Watson P04.010 Posttraumatic and Postsurgical Nummular Headache Brian Grosberg, Jelena Pavlovic, Matthew Robbins, Uri Napchan, Seymour Solomon, Richard Lipton P04.017 Determinants of MigraineRelated Disability Richard Lipton, Andrew Blumenfeld, Jack Ishak, Sepideh Varon, Ariane Kawata, Aubrey Manack, Dawn Buse, Peter Goadsby P04.011 Clinical Phenotypes and Morphological Changes of the Circle of Willis in Migraineurs Ken Ikeda, Hirono Ito, Konosuke Iwamoto, Kiyoko Murata, Yuji Kawase, Osamu Kano, Kiyokazu Kawabe, Hiroaki Iguchi, Yasuo Iwasaki P04.018 Magnetic Resonance Perfusion Imaging in Hemiplegic Migraine Sirinan Tazen, C. Haynes Ralsten, Margaret Jaynes, David Watson P04.012 Syncopal Migraine: Migraine as a Cause of Syncope David Curfman, Michael Chilungu, Robert Daroff, Amer Alshekhlee, Gisela Chelimsky, Thomas Chelimsky P04.013 Putative Clinical, Mechanical and Local Paracrine Mechanisms of Pituitary Adenoma-Attributed Headache Christoph Schankin, Markus Krumbholz, Anna Kristin Reifferscheid, Jennifer Linn, Walter Rachinger, Petra Sostak, Thomas Arzberger, Andreas Straube P04.019 Migrainous Vertigo Presenting in the Perimenopause Jan Brandes, Susan Roberson, Mark Bennett, David Haynes Behavioral Neurology: Language and Praxis P04.020 Spatial Vision, Intellectual Loss, and Neuroimaging Variables as Predictors of Constructional Apraxia in Patients with Cerebrovascular Disease Daniel Capruso, Patrick Pullicino, Kerry Hamsher P04.021 Spatially Adherent Graphemic Perseveration Waldo Guerrero, Kenneth Heilman, Abhay Kumar, Anuali Khaku P04.024 Narrative Discourse in Parkinson Disease Sharon Ash, Rachel Goldmann Gross, Brianna Morgan, Ashley Boller, Andrew Siderowf, Murray Grossman P04.025 You Don’t Say: A New Variant of PPA? Kirk Daffner, Scott McGinnis, Daisy Sapolsky, Bradford Dickerson P04.026 Quantifier Comprehension in Corticobasal Syndrome and Frontotemporal Degeneration Brianna Morgan, Rachel Goldmann Gross, Corey McMillan, Ashley Boller, Murray Grossman P04.027 Extrapyramidal Signs in Primary Progressive Aphasia Sarah Kremen, Mario Mendez, Po-Heng Tsai, Edmond Teng P04.028 Impaired Decision-Making Strategies for Pronoun Resolution in Behavioral-Variant Frontotemporal Dementia (bvFTD) Megan Reilly, Corey McMillan, Robin Clark, Murray Grossman P04.029 Language Circuits Investigated with Semantic Decision/ Tone Decision fMRI Task and Independent Component Analysis (ICA) Kwang Ki Kim, Prasanna Karunanayaka, Michael Privitera, Christi Banks, Scott Holland, Jerzy Szaflarski P04.035 Patterns of Memory Deficit Modify the Rate of Conversion to Dementia in a Large Sample of Patients with Mild Cognitive Impairment Pablo Martinez-Lage, Isabel Hernandez, Merce Boada Rovira, Montserrat Alegret, Ana Espinosa, Georgina Vinyes, Ana Mauleon, Asuncion Lafuente, Maitee Rosende, Susana Ruiz, James Becker, Lluis Tarraga P04.036 Graphabulation, a New Form of Confabulation J. Hoon Roh, Duk L. Na P04.037 Vitamin D, Fall Frequency, and Cognitive Function in Free-Living Elders Amie Peterson, Nora Mattek, Aaron Clemons, Gene Bowman, Teresa Buracchio, Jeffrey Kaye, Joseph Quinn P04.038 Prospective Evaluation of 32 Patients with Symptoms of Transient Global Amnesia (TGA) in a Community Hospital of Argentina Maria Fernandez, Juan Rojas, Angel Golimstok, Edgardo Cristiano P04.039 Hyposmia, Central Cholinergic Integrity, and Cognitive Impairment in Parkinson Disease Without Dementia Nicolaas Bohnen, Martijn Muller, Vikas Kotagal, Robert Koeppe, Michael Kilbourn, Roger Albin, Kirk Frey P04.040 Dissociation Between Two Routes to Action in Gesture Imitation Eric Roy, Timour Al-Khindi, Mark Gravely, Loch MacDonald, Sandra Black, Tom Schweizer Behavioral Neurology: Executive and Motor Functions P04.041 Gait Disorders, an Interesting Marker of Frontotemporal Dementia Gilles Allali, Bruno Dubois, Frederic Assal, Elise Lallart, Leonardo de Souza, Maxime Bertoux, Cedric Annweiler, Francois Herrmann, Richard Levy, Olivier Beauchet P04.042 Validation of a Simple Bedside Antisaccade Task in Neurodegenerative Dementia Joanna Hellmuth, Alisa Matlin, Mary Widmeyer, Ashley Berhel, Aria Jafari, Joel Kramer, Bruce Miller, Adam Boxer P04.043 Reckless Driving Associated with Dopamine Agonist Use: A Case Series Alida Griffith, Pinky Agarwal, Marilyn Borromeo-Westner P04.044 Right Inferior Frontal Gyrus Is Necessary for Interference Suppression, but Not Error Correction, in the Eriksen Flanker Task Maiya Geddes, Ami Tsuchida, Mandana Modirrousta, Adam Aron, Lesley Fellows P04.045 Executive Functions and Cognition in Amyotrophic Lateral Sclerosis Natalia Sierra, Alberto Dubrovsky, Ana Gamba, Teresa Torralva, María Roca, Facundo Manes P04.046 Insight of Involuntary Movements in Early Huntington’s Disease: A Simple Explanation Damian Justo, Perrine Charles, Valerie Hahn-Barma, Lionel Naccache, Sophie Tezenas Du Montcel, Celine Jauffret, Cecilia Marelli, Marcela Gargiulo, Alexandra Durr P04.047 Relationship Between Cognition and Spatiotemporal Gait Parameters in Parkinson Disease without Dementia Nicolaas Bohnen, Martijn Muller, Kirk Frey, Roger Albin P04.048 Quantification of Increased Mirror Overflow in ADHD: Laterality and Gender Effects Stewart Mostofsky, Priya Xavier, Lindsey MacNeil, Kelly Isaacs, Amanda Lewis, Martha Denckla, Donald Gilbert P04.049 Excessive Hoarding in Parkinson’s Disease Sean O’Sullivan, Atbin Djamshidian, Andrew Evans, Clare Loane, Andrew Lees, Andrew Lawrence P04.050 Neuropsychological Profile of Adult Patients with Duchenne Muscular Dystrophy Natalia Sierra, Lilia Mesa, Alberto Dubrovsky, Pablo Sojo, Teresa Torralva, María Roca, Fernando Chloaca, Laura Pirra, Facundo Manes Anterior Horn: Spinal Muscular Atrophy P04.051 Trends in Outcomes and Hospitalization Costs among Patients with Warding’s Hoffman Disease in the United States Khan Hafiz, Lubna Mehyar, Bilal Saulat, Shahanara Islam, Nizar Souayah Poster Session IV P04.052 The Role of Ulnar Compound Muscle Action Potential (U-CMAP) as a Surrogate Outcome Measure in Ambulatory Adults with Spinal Muscular Atrophy (AA-SMA) Bakri Elsheikh, Kathryn Swoboda, Charles Scott, Wendy King, Elizabeth Bollman, Kristin Krosschell, Bernard LaSalle, Stephen Kolb, John Kissel P04.053 Beta-Lactam Antibiotics Offer Neuroprotection in a Spinal Muscular Atrophy Mouse Model by Multiple Mechanisms Monica Nizzardo, Martina Nardini, Dario Ronchi, Sabrina Salani, Chiara Simone, Marianna Falcone, Chiara Donadoni, Nicoletta Mezzina, Francesca Gianni, Nereo Bresolin, Giacomo Comi, Stefania Corti P04.054 Salbutamol Increases SMN mRNA in Spinal Muscular Atrophy Patients (SMA): Relevance for Clinical Trial Design Francesco Tiziano, Rosa Lomastro, Anna Pinto, Sonia Messina, Adele D’Amico, Stefania Fiori, Carla Angelozzi, Marika Pane, Eugenio Mercuri, Enrico Bertini, Giovanni Neri, Christina Brahe P04.055 Further Progress in Defining UBE-1 Mutations and Downstream Effects Underlying X-Linked Lethal Infantile SMA (XL-SMA) Lisa Baumbach, Mary Ellen Ahearn, Juliane Ramser, Kemal Yariz, Thomas Prior, Zafar Nawaz, Antonio Barrientos, Alfons Meindl P04.056 Hand Held Dynamometry and Fixed Maximal Voluntary Isometric Contraction Strength Testing in Ambulatory Adults with Spinal Muscular Atrophy Wendy King, Bakri Elsheikh, Chuck Scott, Bernard LaSalle, Kristin Krochell, John Kissel P04.057 Biomarker Study for Spinal Muscular Atrophy: Study Design and Preliminary Results Richard Finkel, Thomas Crawford, Kathryn Swoboda, Petra Kaufmann, Margaret Bell, Rebecca Li, Felicia Trachtenberg, Thomas Plasterer, Peter Juhasz, Xiaohong Li, Karen Chen, Rory Olson, Jenny Shu, Sergey Paushkin, Dione Kobayashi, Cynthia Joyce, Suzanne Forrest P04.058 Videofluorography in Spinal and Bulbar Muscular Atrophy (SBMA) Haruhiko Banno, Masahisa Katsuno, Keisuke Suzuki, Seiya Tanaka, Motoshi Kawashima, Noriaki Suga, Atsushi Hashizume, Yasushi Fujimoto, Gen Sobue P04.059 Reliability of the Six-Minute Walk Test in Ambulatory Patients with Spinal Muscular Atrophy W. Arnold, Bakri Elsheikh, Kathryn Swoboda, Charles Scott, Wendy King, Elizabeth Bollman, Bernard LaSalle, Kristin Krosschell, John Kissel P04.060 Fatigue Related Spatiotemporal Gait Changes During the Six-Minute Walk Test in Spinal Muscular Atrophy (SMA) Jacqueline Montes, Sally Dunaway, Megan Montgomery, Douglas Sproule, Petra Kaufmann, Darryl De Vivo, Ashwini Rao Anterior Horn: Genetics P04.061 A Novel BSCL2/Seipin Variant Associated with Atypical Silver Syndrome Mimicking ALS Jennifer Michaels, Thomas Winder P04.062 Studies of Sequence Changes of the Dynactin p150 Gene In Vitro Marianne Stockmann, Marie MeyerOhlendorf, Corinna Hendrich, Tobias Böckers, Albert Ludolph, Stefan Liebau P04.063 FUS Mutations in a Large Series of Sporadic and Familial ALS Cristina Moglia, Andrea Calvo, ShiaoLin Lai, Yevgeniya Abramzon, Jennifer Schymick, Rita Guerreiro, Dietrich Stephan, Travis Dunckley, Roberto Mutani, Gabriele Mora, Sara Gallo, Fabio Giannini, Stefania Battistini, Fabrizio Salvi, Ilaria Bartolomei , Cecilia Carlesi, Gabriele Siciliano, Jessica Mandrioli, Patrizia Sola, Claudia Caponnetto, Giovanni Mancardi, Kalliopi Marinou, Maura Brunetti, Amelia Conte, Mario Sabatelli, Francesca Valentino, Vincenzo La Bella, Gioacchino Tedeschi, Maria Rosaria Monsurr≥, Gabriella Restagno , Brian J. Traynor, Adriano Chio P04.064 Fronto-Temporal Dementia in 3 ALS Families with TARDBP Missense Mutation Andrea Calvo, Cristina Moglia, Michele Balma, Gabriella Restagno, Irene Ossola, Maura Brunetti, Anna Montuschi, Anna Cistaro, Anna Picca, Bryan Traynor, Jennifer Schymick, Roberto Mutani, Giovanna Marrosu, Maria Murru, Giuseppe Borghero , Adriano Chio P04.065 The Mutational Spectrum of Adult Onset Dominant-Inherited Familial Amyotrophic Lateral Sclerosis in Chinese Population on Taiwan Yi-Chung Lee, BingWen Soong, Ching-Piao Tsai Peripheral Nerve: Progress in Amyloid Neuropathies P04.066 Initial Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)—A Global Web-Based Registry Violane Plante-Bordeneuve, Teresa Coelho, Bo-Goran Ericzon, Rodney Falk, Sh√-ichi Ikeda, Mat Mauer, Ole Suhr, Pedro Trigo, Donna Grogan P04.067 Skin Denervation in Amyloid Neuropathy with a Hot-Spot Mutation of Transthyretin (Ala97Ser) in Taiwan SungTsang Hsieh, Ming-Jen Lee, Chi-Chao Chao P04.068 Outcome Measures for Transthyretin Type Familial Amyloid Polyneuropathy Teresa Coehlo, Ingemar Merkies, Aaron Vinik, Etta Vinik, Jason Chan, Jeff Packman, Donna Grogan P04.069 Post-Liver Transplant ATTR Val30Met Patients: CNS Clinical Phenotype Luis Maia, Sara Cavaco, Manuel Pires, Joel Freitas, Daniel Dias, Helena Miranda, Rui Magalhães, Manuel Correia, Teresa Coelho 71 Poster Session IV P04.070 Transthyretin Familial Amyloid Polyneuropathy: Does a Mitochondrial Polymorphism Entirely Explain the Parent-of-Origin Difference in Penetrance? Violaine Plante-Bordeneuve, Malin Olsson, Urban Hellman, Ole Suhr, Catherine Bonaiti-Pellié, Bernard Bonaiti Aging and Dementia: Amyloid and Gray Matter Imaging P04.071 Patterns of Amyloid Deposition in Individual Patients with Mild Cognitive Impairment: An 11C-PIB PET Study Najlaa Ahmad Nazri, Sofia Sofia Rodriguez Martinez De Llano, Aren Okello, Paul Edison, Jaana Koivunen, Noora Scheinin, Juha Rinne, David Brooks, Nicola Pavese P04.072 Cortical Thickness Change in Alzheimer’s Disease Over Six Months: Data from ADNI James Paskavitz, Yong He, Kristina Deduck, Barry Bedell, Alan Evans, Alex Zijdenbos P04.073 Can We Use Pons as a Reference Region for the Analysis of [11C] PIB PET? Paul Edison, Rainer Hinz, Anil Ramalackansingh, John Thomas, Federico Turkheimer, David Brooks P04.074 Florbetaben β-Amyloid Brain PET— Correlation with Cognition Parameters in Alzheimer Disease Osama Sabri, Julia Luthardt, Marianne Patt, Eva Hammerstein, Kristin Hartwig, Georg Becker, Andreas Schildan, Ulrich Hegerl, Beate Rohde, Cornelia Reininger, Hermann-Josef Gertz, Henryk Barthel P04.075 Voxel-Based Longitudinal Changes of Gray Matter Density in Incipient Alzheimer’s Disease Marco Lorenzi, Giovanni Frisoni P04.076 In Cognitively Healthy and Mildly Impaired Individuals Florbetapir F 18 PET Measures of Amyloid Deposition Correlate with the Degree of Functional Impairment Assessed Six Months Later P. Murali Doraiswamy, R. Edward Coleman, Jeffrey Petrella, Forrest Sheldon, Michael Pontecorvo, Franz Hefti, Alan Carpenter, Daniel Skovronsky, Christopher Clark P04.077 FDG-PET Pattern in Patients with White Matter Changes with and without Dementia: Differentiation from Alzheimer Disease Belen Pascual, Elena Prieto, Josep Marti-Climent, Javier Arbizu, Joseph Masdeu P04.078 Hippocampal Activation during Episodic Memory Processing in Healthy Adult Apolipoprotein E ε4 Carriers Is Significantly Influenced by Age Lisa Nichols, Joseph Masdeu, Venkata Mattay, Philip Kohn, Fabio Sambataro, Matthew Emery, Bhaskar Kolachana, J. Shane Kippenhan, Daniel Weinberger, Karen Berman P04.079 The Changes of Cortical Gray Matter in Alzheimer’s Disease According to Clinical Dementia Rating: Voxel- Based Morphometric Study Young Chul Youn, Jae won Jang 72 P04.080 Progression of Prodromal AD Associated with Amyloid Deposition Using PIB PET Imaging Shizuo Hatashita, Hidetomo Yamasaki Aging and Dementia: Other P04.081 Immunosignature of Alzheimer’s Disease Lucas Restrepo, Phillip Stafford, Mitch Magee, Stephen Johnston P04.082 Capgras Syndrome and the Cognitive Neuroscience of Attachment Anthony Jack, Rochelle Hudson, Georges Naasan, Regina Cesaro, Zimbul Albo, Alan Lerner P04.083 Diagnostic Serendipity in Evaluating Normal-Pressure Hydrocephalus Aleksandra Stark, Daniel Kaufer, Elizabeth Joran P04.084 Verbal Memory Decline in Alzheimer’s Disease Is Associated with an Impairment of Frontal Executive Control Novraj Dhanjal, Jane Warren, Richard Wise P04.085 Evidence That Cognitive Activities During Adulthood Modify the Reserve-Building Effects of Education Bruce Reed, Dan Mungas, Maritza Dowling, Joshua Sonnen, Sarah Tomaszewski Farias, Milton Strauss, Eddie Billingslea, David Bennett P04.086 The Cognitive Reserve Reflected in Sex Differences Is Not Altered by APOE Genotype Leslie Baxter, Kara Dassel, Amylou Dueck, Richard Caselli P04.087 Micronutrients and Neuropsychologic Function in Patients with Mild Cognitive Impairment and Alzheimer’s Disease Gereon Nelles, Wilhelm Stahl, Ludger Pientka, Maria Polidori, Helen Griffith P04.088 Development of a Caregiver Burden Assessment in Alzheimer’s Disease Diane Ito, Jonathan Stokes, Elizabeth Piault-Louis, Josephine LiMcLeod P04.089 Assessing Differences in CoMorbidities, Utilization, and Expenditures for Alzheimer’s Medicare Beneficiaries Compared to the NonAlzheimer’s Medicare Population Kara Suter, Amanda Forys, Susanne Machacz, Joel Bobula, Trent McLaughlin P04.090 Clinically Confirmed Normal Pressure Hydrocephalus Usually Has Alzheimer’s Disease Pathology at Autopsy Danielle Cabral, Thomas Beach, Linda Vedders, Lucia Sue, Sandra Jacobson, Kent Myers, Marwan Sabbagh P04.091 Intranasal Insulin Modulates Hippocampal Activation According to APOE-ε4 Genotype in Early Alzheimer’s Disease George Thomas, William Brooks, Cary Savage, Jeffrey Burns Wednesday, April 14 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 Cerebrovascular Disease: Other P04.105 Are Stroke Prevention Measures Better Utilized in Primary Stroke Centers? Kumar Rajamani, Scott Millis, Flicia Mada, Leeza Salowich-Palm, Sabrina Hinton, Panayiotis Mitsias, Diane Vaphiadis, Sam Watson, Seemant Chaturvedi P04.093 Diagnostic Value of Presenting Symptoms and Physical Signs in Spinal Dural Arteriovenous Fistula RajaNandini Muralidharan, Andrea Saladino, Giuseppe Lanzino, John Atkinson, Alejandro Rabinstein P04.106 Free-Floating Thrombus of the Carotid Artery Detected on Carotid Ultrasound in Patients with Cerebral Infarcts: A 10-Year Study Sheila Srinivasan, Hoe Chin Chua, Boon Choon Teo, Ziqun Phua, Johnny Eng P04.094 The Northern Manhattan Study Global Vascular Risk Score Is Associated with Cognitive Performance Jessica Loring, Chuanhui Dong, Norbelina Disla, Tatjana Rundek, Mitchell Elkind, Ralph Sacco, Yaakov Stern, Clinton Wright P04.107 Sex Differences in Acute Ischemic Stroke in the Young Adult Population Johanna Morton, Esteban Cheng-Ching, Irene Katzan P04.092 Age-Related Changes in Processing Syntactically Ambiguous Sentences: Evidence from fMRI Delani Gunawardena, Corey McMillan, Vanessa Troiani, Murray Grossman P04.095 Augmented Treatment Efficacy - A Repeated Measures Analysis of NINDS rt-PA Study Wuwei Feng, Gabriela Vasquez, Muhammad Suri, Kamakshi Lakshminarayan, Qureshi Qureshi P04.096 Increased Expression of the Endocannabinoid Receptor 1 in Acute Human Stroke Marcello Naccarato, Paola Caruso, Nelly Redolfi, Veronica Macchi, Andrea Porzionato, Raffaele De Caro, Giorgio Stanta, Gilberto Pizzolato P04.097 Ischemic Lesion Pattern Was Different According to Antithrombotic Treatment Status in Acute Cardioembolic Stroke Hyo-Jin Kim, Hye-Jin Kim, Ju-Hun Lee, Kang-Yeol Park, Kyung-Hee Cho, A-Hyun Cho, Sang-Won Ha, Kyung-Bok Lee, Jee-Hyun Kwon, Dong-Eog Kim, JaeKwan Cha, Hahn-Young Kim, Dong-Wha Kang, Jong S Kim, Sun U. Kwon P04.098 Comparison of 10 mg and 5 mg Warfarin Loading Regimen as the Initiation of Anticoagulation for Acute Ischemic Stroke Patients Jun-Sang Sunwoo, Yong-Seok Lee, Hyung-Min Kwon P04.099 Withdrawn P04.100 Cephalocervical Aneurysms Associated with Fibromuscular Dysplasia Sol Cavanagh, Patricio Brand, Martin Nogués, Javier Moschini, Sebastian Ameriso P04.101 Awareness of Stroke by Nigerians at High Risk Kolawole Wahab, Bode Kayode, Omotosho Musa P04.102 Modafinil in Post Stroke Fatigue Iftekhar Ahmed, Natasha Ahmed, Ann Sly P04.103 The Clinical Features of LateOnset Poststroke Seizures Shiho Okuda, Shin Takano, Masao Ueno, Youji Tomota, Hirotoshi Hamaguchi, Fumio Kanda P04.104 Cocaine Strokes: Are Large Vessel Atherosclerosis and Small Vessel Disease More Prevalent Than Vasospasm? Sharief Taraman, Pratik Bhattacharya, Seemant Chaturvedi, Ramesh Madhavan P04.108 Stroke Registry Definitions Lack Consensus Across the US Karen Albright, Sheryl Martin-Schild, M. Sline, H. Bockholt, Sean Savitz P04.109 Factors Predictive of Length of Stay in Acute Ischemic Stroke Patients Devon Conway, Nishant Ranawat P04.110 Incidence of Stroke and Stroke-Related Mortality on Ugandan Neurology Ward Jason Sico, Jeffrey Bigelow, Ivan Kimuli, Elly Katabira, Huned Patwa P04.111 Barriers to Thrombolysis in Acute Ischiemic Stroke Sapna Erat Sreedharan, William Jeffries, Janakan Ravindran P04.112 Concomitant Anterior Circulation Infarction and Age Correlate with Clinical Outcome in Posterior Circulation Strokes Jacob Kitchener, Austin Hake, Nirav Vora, Randall Edgell, Salvador Cruz-Flores, Paisith Piriyawat, Eliahu Feen, Aninda Acharya, John Chibnall, Tagann Chaisam, Sushant Kale, Saengduan Mayotarn, Ayman Daoud, Eve Holzemer, Janet Severine P04.113 Currently Used Stroke Registry Definitions Have Poor Inter Rater Reliability When Compared with ACC Guidelines Karen Albright, H. Bockholt, Sheryl Martin-Schild, M. Sline, Sean Savitz P04.114 Ischemic Stroke Due to Paradoxical Embolisms in the Hereditary Hemorrhagic Telangiectasia Disease: New Evidence for Repeated Screening and Early Treatment of Pulmonary Arteriovenous Malformations (PAVM). Study of Two Cases and a Literature Review Espartaco Ribeiro, Julien Cogez, Emmanuel Babin, Fausto Viader, Gilles Defer P04.115 Aspirin Failure in Noncardioembolic Ischemic Stroke: A Retrospective Cohort Study on Its Incidence, Choice of Antiplatelet Treatment, and Clinical Outcome Alan Tse, Raymond Cheung Poster Session IV Wednesday, April 14 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P04.116 Heart Rate Variability Changes Occur with MCA Stroke, Related to the Extent of Insular Ischemia Karen Orjuela, Xiao Hu, Qing Hao, Nils Borgstrom, Jeffry Alger, Noriko Salamon, Pablo Villablanca, Latisha Ali, Bruce Ovbiagele, Doojin Kim, Sidney Starkman, Jeffrey Saver, David Liebeskind P04.117 TGF beta 1 and Acute Ischemic Stroke: The Protective Effect for Stroke Occurrence Suroto Setijorumekso, Sutedjo Widjojo, Suratno Sastrosukarno, Agus Soedomo, O. S. Hartanto, Risono Risono, Diah Mirawati P04.118 A Systems Approach to Stroke Care: The University Hospitals Cleveland Experience Cathy Sila, Leigh McCartney, Nancy Tinsley, Erin Supan, Robert Tarr, Warren Selman, Anthony Furlan P04.119 Acute Anticoagulation with Intravenous Un-Fractionated Heparin Reduces Early Recurrences in Cardio Embolic Stroke Spyros Zafeiris, Mastorodemos Vasileios, Mavrides Mihalis, Tzagournisakis Minas, Spilioti Marhta, Plaitakis Andreas Movement Disorders: Essential Tremor P04.120 Subclinical Tremor in Normal Controls with vs. without a Family History of Essential Tremor: Data from the United States and Turkey Elan Louis, Okan Dogu, Ruth Ottman P04.121 Increased Number of Heterotopic Purkinje Cells in Essential Tremor Sheng-Han Kuo, Cordelia EricksonDavis, Arthur Gillman, Phyllis Faust, Jean Paul Vonsattel, Elan Louis P04.122 Holmes’ Tremor: Etiology and Outcome—A Case Series of 37 Patients from the Mayo Clinic Kathrin Czarnecki, Joseph Matsumoto P04.123 Embarrassment in Essential Tremor: Discrepancies Between Patients and Neurologist-Experts Rebecca Traub, Elan Louis P04.124 Specificity of Purkinje Cell Loss in Essential Tremor Ali Rajput, Christopher Robinson, Michele Rajput, Alex Rajput P04.125 Depressive Symptoms in Essential Tremor Patients Roberto Prado, Lis Ferreira, Ana Gabriela Prado, Vivian Andrade P04.126 Validity and Reliability of Computerized Tremor Spirography as Outcome Measure for Clinical Trials in Essential Tremor Dietrich Haubenberger, Daniel Kalowitz, Fatta Nahab, Camilo Toro, Dominic Ippolito, Loretta Wittevrongel, Mark Hallett Movement Disorders: Parkinson's Disease: Treatment P04.127 Long-Term Safety and Efficacy of Pramipexole Extended-Release in Early Parkinson’s Disease Robert Hauser, Paolo Barone, Youshikuni Mizuno, Werner Poewe, Olivier Rascol, Anthony Schapira, Jaana Harjula, Mandy Sohr, Laurence Salin, in the Name of the Pramipexole ER Studies Group P04.128 Long-Term Efficacy and Safety of Pramipexole Extended-Release in Advanced Parkinson’s Disease: An Open-Label Trial Anthony Schapira, Paolo Barone, Robert Hauser, Youshikuni Mizuno, Olivier Rascol, Michael Busse, Laurence Salin, Mandy Sohr, Werner Poewe, in the Name of the Pramipexole ER Studies Group P04.129 Comparison of IPX066, a Novel Extended-Release Oral CarbidopaLevodopa Formulation, to ImmediateRelease Carbidopa-Levodopa in Patients with Advanced Parkinson’s Disease (PD) Ann Hsu, Leonard Verhagen Metman, Aaron Ellenbogen, Martin O’Connell, Nishit Modi, Sherron Kell, Suneel Gupta P04.130 Carbidopa/Levodopa Pharmacy Errors in Parkinson’s Disease Nasim Khadem, Melissa Nirenberg P04.131 Long-Term Treatment of Advanced Parkinson’s Disease with Rotigotine Peter LeWitt, Babak Boroojerdi, Werner Poewe, on Behalf of the SP516 and SP715 Study Groups P04.132 Three-Year Efficacy and Safety Data for Ropinirole Prolonged Release in Patients with Early Parkinson’s Disease Mark Lew, Katie Rolfe, Kenneth Shulman P04.133 Open-Label Extension Trial Assessing the Effects of Long-Term Treatment with Rotigotine in Subjects with Early-Stage, Idiopathic Parkinson’s Disease: Results from up to Seven Years Ray Watts, Babak Boroojerdi, Joseph Jankovic, on Behalf of the SP702 Study Group P04.134 3,4-Dihydroxyphenylacetaldehyde Research Supports Rasagiline Neuroprotection Found in ADAGIO Study William Burke, Michael Panneton, Vijay Kumar, James Galvin P04.135 A Five Year Prospective Assessment of Advanced Parkinson’s Disease Patients Treated with Subcutaneous Apomorphine Infusion or Subthalamic Nucleus Deep Brain Stimulation Angelo Antonini, Ioannis Isaias, Roberto Cilia, Andrea Landi, Claudio Mariani, Francesca Natuzzi, Francesco Vergani, Erik Sganzerla, Roberto Piolti, Carlo Ferrarese, Gianni Pezzoli P04.136 Adverse Events and Patient Satisfaction Associated with Dopamine Agonist and Levodopa Use for RLS Richard Allen, Eric Ball, Ranjani Manjunath, Rachel Higbie, Mechele Lee, Michael Calloway, Paul Nisbet, William Ondo P04.137 Parkinson’s Disease and Idiopathic Restless Leg Syndrome Elizabeth Dragan, William Ondo P04.138 Quantitative Assessment of Acute L-Dopa Effects on Parkinsonian Dysphagia with Videofluoroscopy Francois Viallet, Martine Baudo, Bernard Teston, Dominique Gayraud, Marie-Noelle Sert P04.139 Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson’s Disease: Results from a Double-Blind, Sham-Controlled, Randomized, Controlled Trial Hubert Fernandez, Dawn Bowers, William Triggs, William Perlstein, Chris Hass, Laura Zahodne, Michael Okun, Ramon Rodriguez, Irene Malaty, Samuel Wu P04.140 Improvements in Awake Time Spent “On” Throughout the Day in Patients with Advanced Parkinson’s Disease Treated with Adjunctive Ropinirole Prolonged Release James Cooper, Katie Rolfe, Alan Lipschitz, K. Ray Chaudhuri P04.141 Utilizing Intensive-Amplitude Specific Therapeutic Approaches as an Effective Strategy for Improving Functional Mobility in Patients Diagnosed with Parkinson’s Disease Roxanne Julius, Mike Sandmann, Jawad Bajwa, Penny Tatman, Amy Fehrer P04.142 Parkinson Movement Tests Performance: Effects of Acute Medication Challenge on Quantitative Measures in Standard Movement Tests Xiao-ke Gao, Kenneth Bonnet P04.143 Can Large Amplitude Exercise (ThinkBIG) and Nintendo Wii® Game Exercise Offer Parkinson Disease Neuroprotection? Maria Alvarez, Patrick Grogan, Melinda Rodriguez P04.144 Parkinson’s Disease Patients: “Owls” or “ Larks” Aleksandar Videnovic, Charleston Noble, Richard Ginnetti, Angelica Marconi, Teresa Kuhta, Tanya Simuni, Cindy Zadikoff, Phyllis Zee P04.145 Differential Response of Speed, Amplitude, and Rhythm to Dopaminergic Medications in Parkinson’s Disease Alberto Espay, Dustin Heldman, Robert Chen, Sang-jin Kim, Jennifer Vaughan, Emily Dunn, Andrew Duker, Joseph Giuffrida P04.146 Higher Proportion of Responders on the Clinical Global Impression – Improvement Scale with Ropinirole Prolonged Release Compared with Ropinirole Immediate Release in Patients with Advanced Parkinson’s Disease Kenneth Shulman, Katie Rolfe, Fabrizio Stocchi P04.147 Improvements in Nocturnal Symptoms with Ropinirole Prolonged Release in Patients with Advanced Parkinson’s Disease and with Significant Nocturnal Symptoms Not Optimally Controlled with L-Dopa K. Ray Chaudhuri, James Cooper, Katie Rolfe, Alan Lipschitz, Pablo Martinez-Martin Movement Disorders: Parkinson's Disease: Surgical Treatment P04.148 Visuo-Motor Function in Patients with Parkinson’s Disease Does Not Improve with Subthalamic Stimulation Simon Israeli-Korn, Shraga Hocherman, Sharon Hassin, Oren Cohen, Edna Schechtman, Rivka Inzelberg P04.149 The National Deep Brain Stimulation Brain Tissue Network (DBSBTN): Preliminary Results Vinata VedamMai, Nolie Krock, Michael Ullman, William Shain, Karen Smith, Anthony Yachnis, Dennis Steindler, Brent Reynolds, Fernando Pagan, Stacy Merritt, Jill Marjama-Lyons, Penelope Hogarth, Andrew Resnick, Michael Okun P04.150 Brain Micro-Structural Features of Parkinsonian Signs in Very Old Persons: A Diffusion Tensor Imaging Study of the Health Aging and Body Composition (Health ABC) Cohort Caterina Rosano, Howard Aizenstein, Vijay Venkatraman, David Bennett, Christopher Taylor, Kristine Yaffe, Tamara Harris, Stephen Kritchevsky, Anne Newman P04.151 Cortico-Striatal Activity Patterns During a Finger-Movement fMRI Task in Parkinson’s Disease Patients On and Off Medication Kristina Martinu, Clotilde Degroot, Antonio Strafella, Oury Monchi P04.152 Deep Brain Stimulation Effects on Cardiovagal Responses in Patients with Parkinson’s Disease JyhGong Hou, Laura Jui-Chen Wu, Eugene Lai P04.153 ADC Value of Substantia Nigra in Idiopathic Parkinson’s Disease with Unilateral Motor Symptom KyungWook Kang, Byeong-Chae Kim, Tai-Seung Nam, Joon Tae Kim, Seong-Min Choi, Seung Han Lee, Man-Seok Park, Myeong Kyu Kim, Ki Hyun Cho P04.154 Pallidal Stimulation in Advanced Parkinson’s Patients with Contraindications for Subthalamic Stimulation Tiphaine Rouaud, Thibaut Dondaine, Sophie Drapier, Claire Haegelen, François Lallement, Julie Péron, Sylvie Raoul, Paul Sauleau, Marc Verin 73 Poster Session IV P04.155 Recognition Mismatch of Non-Motor Symptoms in DBS Candidates Among Parkinson Patients and Caregivers May Be Scale Driven Nelson Hwynn, Ihtsham Haq, Irene Malaty, Andrew Resnick, Yunfeng Dai, Michael Okun, Danica Carew, Kelly Foote, Samuel Wu, Atchar Sudhyadhom, Ramon Rodriguez, Charles Jacobson IV, Hubert Fernandez P04.156 Lesion Rather Than Stimulation: Laterality of Microlesion Impacts Postoperative Verbal Fluency Decline in Subthalamic Deep Brain Stimulation Surgery Lars Wojtecki, Lars Timmermann, Ute Habel, Christiane Reck, Volker Sturm, Frank Schneider, Alfons Schnitzler P04.157 Pediatric Deep Brain Stimulation at Cook Children’s Medical Center: 22 Consecutive Cases Warren Marks, John Honeycutt, Fernando Acosta, Jr, Mary Ann Reed Movement Disorders: Atypical Parkinsonism and Wilson's Disease P04.158 The Unified Multiple System Atrophy Rating Scale (UMSARS) Is Also Suitable To Reveal the Progression of Chinese Multiple System Atrophy Patients Jun Xu, Yong Chen, Xuexu Zhao P04.159 Autopsy-Proven Progressive Supranuclear Palsy Presenting as Behavioral Variant Frontotemporal Dementia Anhar Hassan, Joseph Parisi, Keith Josephs P04.160 A Novel Mutation of CP Genes Inhibits Its Secretion and Causes Aceruloplasminemia Hisatomo Kowa, Ayumi Hida, Atushi Iwata, Shin Kwak, Jun Shimizu, Shoji Tsuji P04.161 Concordance for Wilson’s Disease Phenotype Among Siblings Anna Czlonkowska, Grzegorz Chabik, Stanislaw Wolanin, Grazyna Gromadzka P04.162 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins: A Preliminary Report Peter Novak, Paula Ravin, Bernadette White, Arlene Williams, Vera Novak P04.163 The Determinants of Disability in Corticobasal Syndrome Sandra Ruby, Bradley Robottom, Jason Hawley, Karen Anderson, Julie Medalie, Paul Fishman, Stephen Reich, William Weiner, Lisa Shulman P04.164 Jaw-Opening Oromandibular Dystonia Secondary to Wilson’s Disease—A Preliminary Report of Five Cases after Use of Botulinum Toxin Type A Renato Munhoz, Helio Teive, Leandro Kuppel, Nilson Becker, Paulo Muller, Lineu Werneck 74 P04.165 Methyltetrahydrofolate Reductase Gene Polymorphism: A Novel Genetic Factor That Modifies Phenotypic Effects of Copper Toxicity in Wilson’s Disease Anna Czlonkowska, G. Gromadzka, Magdalena Rudnicka, Grzegorz Chabik Movement Disorders: Parkinson's Disease: Neurochemistry P04.166 Aminopyridines Correct Presymptomatic Neuronal Dysfunction and Improve Late Behavioral and Cellular Phenotype in a Mouse Model of Spinocerebellar Ataxia Type 1 (SCA1) Raphael Hourez, Laurent Servais, David Gall, Massimo Pandolfo, Serge Schiffmann P04.167 Zona Incerta Lesions Affect Striatal Neurochemistry and Behavioural Asymmetry in 6OHDA-Lesioned Rats Georgia Davies, Rick Koch, Andrew Haack, Cindy Moore, Charles Meshul, Ruth Walker P04.168 Distinct Roles of GABAergic Interneurons in the Regulation of Striatal Output Pathways Alexandra Nelson, Aryn Gittis, Anatol Kreitzer P04.169 Reduced Expression of Catecholamine Regulated Protein (CRP40) in Pre Clinical Animal Models and Human Striatum Post-Mortem Samples Obtained from Subjects with Parkinson’s Disease (PD) Ram Mishra, Bailee Dyck, Venu Nair, Joseph Gabriele, Zdenek Pristupa, Mattea Tan, Nancy Thomas P04.170 Post-Mortem Neurochemical Evidence for Decreased Putamen Aldehyde Dehydrogenase in Parkinson Disease David Goldstein, Patricia Sullivan, Courtney Holmes, Irwin Kopin, Margaret Basile, Deborah Mash P04.171 SEP-228791, a Novel Dopamine and Norepinephrine Re-Uptake Inhibitor, Has Anti-Parkinsonian Actions, without Eliciting Dyskinesia, in the MPTPLesioned Primate Model of Parkinson’s Disease Tom Johnston, Susan Fox, Jianguo Ma, Liming Shao, Una Campbell, Jonathan Brotchie P04.172 Neurodegenerative Markers in CSF in Patients Suffering from Parkinson’s Disease Hana Prikrylová Vranová, Martin Nevrlý, Jan Mareš, David Stejskal, Petr Kanovský Wednesday, April 14 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P04.175 A Novel Computerized Word-Naming Test Shows That CrossedHemisphere Processing Speed Is Slowed in Multiple Sclerosis Patients Joshua Bacon, Tamar Bacon, Ilya Kister, Joseph Herbert P04.176 Cognitive and Psychosocial Evaluation of Patients with “Benign Multiple Sclerosis” Ana-Luiza Sayao, Anna-Marie Bueno, Virginia Devonshire, Helen Tremlett P04.177 Ten-Year Trends by Patient-Report Metrics in Multiple Sclerosis Functional and Psychosocial Limitations Barbara Teter, Cornelia Mihai, Brian Apatoff, Patricia Coyle, Alfred Frontera, Andrew Goodman, Malcolm Gottesman, Joseph Herbert, Richard Holub, Burk Jubelt, Lauren Krupp, Michael Lenihan, Fred Lublin, Aaron Miller, Fredrick Munschauer, Paulette Niewczyk, Allan Perel, David Snyder, Mark Tullman, Robert Zivadinov, Bianca Weinstock-Guttman P04.178 Depression and Fatigue in Clinically Definite Multiple Sclerosis (CDMS, McDonald Criteria)— Results from the Oregon Multiple Sclerosis Registry (OMSR) Stanley Cohan, Chiayi Chen, Ruyun Jin, Adam Bodie, Tamela Stuchiner, Garry Grunkemeier P04.179 Multiple Sclerosis: EDSS and Disease Duration: Effects on Cognition in a Community Based Study Myassar Zarif, Mark Gudesblatt, Barbara Bumstead, Max Gutman, Lori Fafard, Laura Graffitti, Carol Seidel, Lourdes Cruz, Joan Bohuslaw, Serina Fahie, Chris Burke, Jocelyn Caputo, Susan Riley, Ely Simon, Glen Doniger P04.180 Cognitive Impairment in Patients with Clinically Isolated Syndrome: A Reappraisal After Eight Years Rana Assouad, Anne Claire Viret, Caroline Bensa, Antoine Gueguen, Pierre Lecanuet, Antoine Moulignier, Bruno Stankoff, Clotilde Arnaud, Olivier Gout P04.181 Group Psychotherapy in Patients with Multiple Sclerosis: A SixMonth Study in Groups with Different Disability Scores Sara Collorone, Simona Pontecorvo, Stefano Pascucci, Massimiliano Prencipe, Ada Francia Multiple Sclerosis and Related Diseases: Clinical Research / Neuropsychology P04.182 Longitudinal Changes on Self-Report of Cognitive Symptoms on the Perceived Deficits Questionnaire in MS: Correlations with Changes in Neuropsychologic Tests and Depression Jesus Lovera, Jorge Melara, Elliot Frohman, Theodore Brown, Daniel Bandari, Katherine Wild, Ruth Whitham, Dennis Bourdette P04.173 Apathy in Multiple Sclerosis and Its Association with Depression, Fatigue, and Cognitive Impairment Regina Berkovich, Bryan Spann Multiple Sclerosis and Related Diseases: Clinical Research and Pathology P04.174 Episodic Memory in a Cohort of 395 Multiple Sclerosis Patients Hélíne Brissart, Elodie Morele, Marc Debouverie P04.183 Estimating the Probability of Employment Status Transitions and Exploration of Influential Factors Amber Salter, Rachel Moreau, Tuula Tyry, RuthAnn Marrie, Timothy Vollmer, Gary Cutter P04.184 Hand Function, Mobility, and Employment Status in the NARCOMS Registry Rachel Moreau, Amber Salter, Tuula Tyry, Ruth-Ann Marrie, Timothy Vollmer, Gary Cutter P04.185 Ipsilateral Motor Cortex Activity in RRMS: Compensation or Not? Nancy Sicotte, Kyle Kern, Joseph Sarcona, Michael Montag, Barbara Giesser P04.186 Pregnancy Outcomes from the AVONEX® (Interferon beta-1a) Pregnancy Exposure Registry Pamela Foulds, Sandra Richman, Gabrielle Glick, Timna Onigman P04.187 An Assessment of Bone Health Lifestyle Factors in MS Patients Nancy Hammond, Nicholas Levine, Sharon Lynch P04.188 Lack of Congruence in the Ratings of Patients’ Health Status by Patients with Multiple Sclerosis and Their Physicians Marcelo Kremenchutzky, Len Walt P04.189 Impact of Treatment Adherence on Clinical and Economic Outcomes among Multiple Sclerosis Patients Receiving Disease-Modifying Therapies Hiangkiat Tan, Qian Cai, Sonalee Agarwal, Siddhesh Kamat P04.190 Headache in Multiple Sclerosis. Clinical and Therapeutical Correlations Chiara Monaldini, Jay Guido Capone, Maria Luisa Caniatti, Ilaria Casetta, Susanna Guttmann, Enrico Granieri, Maria Rosaria Tola P04.191 Spectrum of Clinical Symptoms in Early MS with Pathologically Confirmed Cortical Demyelination Reem Bunyan, Brendan Kelley, Richard Ransohoff, Kristine Thomsen, Bernd Scheithauer, Joseph Parisi, Caterina Giannini, Linda Linbo, S. Roemer, Claudia Lucchinetti P04.192 Increasing Macroscopic Pathological Damage in Multiple Sclerosis (MS) Is Associated with More Severe Disease Milestones Richard Nicholas, Bishan Radotra, Federico Roncaroli, Richard Reynolds Multiple Sclerosis and Related Diseases: Drug Mechanisms I P04.193 Changes in Circulating Tregs Parallel Reductions in Activated T Cells during Daclizumab Treatment of MS James Sheridan, Ying Zhang, Katherine Riester, Gilmore O’Neill, Valdimir Vexler, Jacob Elkins P04.194 Hypereosinophilia with Natalizumab Fanny Rocher, Muriel Laffon, Mickael Cohen, Christine Lebrun Frenay P04.195 In MS Patients, When Should MxA mRNA Be Measured after Interferon-beta Injections? Regina Lam, Joel Oger Poster Session IV Wednesday, April 14 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P04.196 Differential Effects of a Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator (CS-0777) on Circulating Lymphocyte Subsets in Multiple Sclerosis Patients Hamim Zahir, James Moberly, Daniel Ford, Kenneth Truitt, Amit Bar-Or, Timothy Vollmer P04.207 Pharmacokinetics of Oral BG-12 Alone Compared with BG-12 and Interferon β-1a or Glatiramer Acetate Administered Together, Studied in Healthy Volunteers James Woodworth, Zhenming Zhao, Scott Stecher, Liyu Yang, Katherine Dawson P04.197 Interferon Beta-1a Modulation of B Cells: Implications for Relapsing Multiple Sclerosis Hui Huang, Sumandeep Sumandeep, Kouichi Ito, Suhayl Dhib-Jalbut P04.208 Laquinimod In Vitro HighThroughput Gene Analysis Reveals Orchestrated Th2 Shift in RelapsingRemitting Multiple Sclerosis Michael Gurevich, Rotem Orbach, Tamir Tuller, Anna Feldman, Anat Achiron P04.198 Effects of Glatiramer Acetate on Proliferation and Differentiation of OLN-93 Cells and Its Interaction with FGF2 Alvaro Barrera-Ocampo, Martin Berghoff, Mario Giraldo Velásquez P04.199 Unusual Development of Progressive Multifocal Leukoencephalopathy with High JC Virus Titer in a Patient with Multiple Sclerosis after Two Years of Natalizumab Therapy Tjalf Ziemssen, Henning Bagelmann, Jochen Machetanz P04.200 In Vitro Whole Blood Monitoring of Biological Response to Type I Interferon Therapy in Multiple Sclerosis Mathieu Vokaer, Francoise Villee, Kaoutar El Hafsi, Patrick Stordeur P04.201 Intravenous Immunoglobulin (IVIG) in Treatment of Central Pontine and Extrapontine Myelinolysis Shahram Izadyar, Shumaila Sultan, Joseph Kass, Corey Goldsmith P04.202 An IL-2 Paradox; Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells Jayne Martin, Neha Jakhete, Xiang Wang, Bibiana Bielekova P04.203 P2X7 Purinergic Receptor on Monocytes of Patients with Multiple Sclerosis: Effects of Glatiramer Acetate Immune Modulation Carlo Avolio, Mariantonietta Caragnano, Paola Tortorella, Anna Lia, Roberta Grasso, Maddalena Ruggieri, Paolo Livrea, Luigi Specchio, Maria Trojano P04.204 Treatment Effects of IFNB-1b on Cognitive Performance in Patients with a First Event Suggestive of MS Iris Katharina Penner, Pasquale Calabrese, Mark Freedman, Chris Polman, Gilles Edan, Hans Hartung, David Miller, Xavier Montalban, Frederik Barkhof, Vivian Lanius, Rupert Sandbrink, Christoph Pohl, Brigitte Stemper, Ludwig Kappos P04.205 CD161/CCR6 (IL-17 Associated) Expression in Relapsing MS: Effect of Glatiramer Acetate on Immune Regulation Lloyd Kasper, Alan Bergeron, John Delong, Kathleen Smith, Kathleen Ryan, Jacqueline Channon P04.206 Systematic Assessment of JC Virus in Multiple Sclerosis Patients Treated with Natalizumab Iuliana Slesari, Olivier Heinzlef, Jean-Dominique Poveda P04.209 Omega-3 Fatty Acids Treatment in Relapsing-Remitting Multiple Sclerosis Kjell-Morten Myhr, Sjur Reinertsen, Antonie Beiske, Harald Hovdal, Rune Midgard, Frøydis Dalene, Jan Schepel, Grete Kleveland, Halfdan Kierulf, Randi Eikeland, Alla Bru, Olaf Henriksen, Terje Kristensen, Astrid Edland, Ingrid Bjørnä, Søren Bakke, Tom Pedersen, Finn Lilleäs, Bärd Bjørnarä, Inge Christoffer Olsen, Rita Nilsen, Kristian Bjerve P04.210 Duration Following Severe Attacks of CNS Demyelinating Disease to Plasma Exchange Initiation: How Long Is Too Long? Setty Magana, Stephen Weigand, Kristine Thomsen, Jayawant Mandrekar, Claudia Lucchinetti, Mark Keegan P04.211 Safety and Efficacy of Autologous T-Cell Immunotherapy (Tovaxin) in Patients with Active Relapsing-Remitting Multiple Sclerosis Dawn McGuire, Edward Fox, Clyde Markowitz, Stanley Cohan, Daniel Wynn, Donna Rill, Mary Riser, Shannon Inman P04.212 Synergistic Mechanisms of Fumarate Treatment in CNS Autommunity: Augmenting Axon Protective Effects in Combination Therapies Christiane Reick, Gisa Ellrichmann, De-Hyung Lee, Ralf Gold, Ralf Linker P04.213 Alemtuzumab Reduces Disease Progression in RRMS: Long-Term Results of the CAMMS223 Trial Omar Khan, N. A. on Behalf of the CAMMS223 Study Group P04.214 Prediction and Characterization of CD56bright NK Cell Expansion during Daclizumab Treatment for Multiple Sclerosis James Sheridan, Ying Zhang, Katherine Riester, Gilmore O’Neill, Meina Tang, Jacob Elkins P04.215 Multiple Sclerosis and Other CNS Demyelination after Treatment with Tumor Necrosis Factor alpha Blockers George Hutton, Mirla Avila, Pilar Guillermo Prieto, Jose Avila, Victor Rivera P04.216 Copolymer-1 Shows Neuroprotective Effects Via Peripheral Immunomodulation Rather Than Direct Actions on Neurons Sven Meuth, Alexander Herrmann, Kerstin Göbel, Nico Melzer, Ole Simon, Stefan Bittner, Heinz Wiendl P04.217 Cellular and Humoral Influenza Vaccine-Specific Immune Responses in Patients with Multiple Sclerosis Treated with FTY720 or Interferon-beta Matthias Mehling, Stefanie Fritz, Patricia Hilbert, Raija Lindberg, Jens Kuhle, Ludwig Kappos, Christoph Hess P04.227 Validation of a Novel Computerized Performance-Based Functional Assessment for HIV Associated Neurocognitive Disorders Liana Rosenthal, Richard Skolasky, Richard Moxley IV, Heidi Vornbrock Roosa, Ola Selnes, Amy Eschman, Justin McArthur, Ned Sacktor P04.218 Production of Neurotrophic Factors in MS Patients Treated with Disease Modifying Therapies Yang MaoDraayer, Julia Knight, John Soltys, Hillel Panitch P04.228 Clinical and Cognitive Associations with Midsagittal Corpus Callosum Area in HIV Infected Patients Rola Khedraki, Mehul Sampat, Jared Price, Daniel McCaffrey, Daniel Branson, Bradford Navia, David Tate P04.219 Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS) Per Soelberg Sørensen, Peter Rieckmann, Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Kottil Rammohan, Patrick Vermersch, Daena Bock, Anthony Hamlett, Téa Fevr, Bruno Musch, Steven Greenberg P04.220 Plasmacytoid Denditic Cells (pDC) in Multiple Sclerosis: IFN-β Treatment Inhibits pDC Secretion of Chemokines Specific for CCR5-Positive Th1 Cells Latt Aung, Suhayl Dhib-Jalbut, Konstantin Balashov P04.221 Decreased Chemokine Directed Migration of Effector Memory T Cells in Fingolimod-Treated Patients Trina Johnson, Amit Bar-Or, Jack Antel P04.222 The Activation of Microglia and Macrophages Is Attenuated by Laquinimod Janet Wang, Claudia Silva, Scott Sloka, V. Wee Yong P04.223 Glatiramer Acetate-Reactive T Lymphocytes Regulate Oligodendrocyte Progenitor Cell Number In Vitro Yueting Zhang, Farzaneh Jalili, Nadia Oumara, Andleeb Zameer, Gregory Cosentino, Liat Hayardeny, Jack Antel, Amit Bar-Or, Gareth John AIDS P04.224 Predictors of Ventricular Volume in HIV Disease James Becker, Bruce Cohen, Eileen Martin, Eric Miller, Joanne Mullen, Ann Ragin, Ned Sacktor, Ola Selnes, Owen Carmichael P04.225 Dual Infection with HIV and HCV Has Worse Effects on Cognition Than Infection with HIV Alone Inna Kleyman, Jennifer Manly, Jason Lazar, Mardge Cohen, Elizabeth Golub, Chenglong Liu, Leigh Pearce, Victor Valcour, Kathryn Anastos, Howard Crystal P04.226 Utility of HIV-Associated Neuropathy Screening Tools in Western Kenya: Pilot Testing Deanna Cettomai, Judith Kwasa, Caroline Kendi, Gretchen Birbeck, Richard Price, Elizabeth Bukusi, Craig Cohen, Ana-Claire Meyer P04.229 Treatment of Mice with HIV Encephalitis with a Novel Interferon-alpha Blocker William Tyor, Cari Fritz-French, Rajeth Koneru, Ligia Padilla, Hee Young Hwang, Leonard Maroun, Jennifer Ward, Markus Dettenhofer P04.230 Matrix Metalloproteinase-1 Protects Against HIV-1 Tat-Induced Neurotoxicity by Cleavage-Dependent and Cleavage-Independent Mechanisms Jeffrey Rumbaugh, Muznabanu Bachani, Avindra Nath P04.231 Atrophy in the Medial Temporal Lobes of HIV Patients Is Correlated to ADC Stage Nosheen Jawaid Rafique, Henrietta Afari, Daniel McCaffrey, Jared Price, Daniel Branson, Bradford Navia, David Tate P04.232 Gray Matter Volume Loss in HIV Associated Dementia Matthias Maschke, Michael Kueper, Kasja Rabe, Stefan Esser, Elke Gizewski, Ingo Husstedt, Mark Obermann P04.233 Mechanisms of Neurotoxicity Induced by Morphine in the HIV-1 Transgenic Rat Walter Royal III, Sanjit Roy, Huifen Li, Odell Jones, Joseph Bryant Infections/AIDS P04.234 Utility of a Diagnostic Tool for HIV-Associated Cognitive Impairment in Western Kenya: Pilot Testing Judith Kwasa, Deanna Cettomai, Edwin Lwanya, Dennis Osiemo, Patrick Oyaro, Gretchen Birbeck, Richard Price, Elizabeth Bukusi, Craig Cohen, Ana-Claire Meyer P04.235 Pattern of Neuropsychological Performance Among HIV-Positive Patients in Kenya Judith Kwasa, Edwin Lwanya, Deanna Cettomai, Dennis Osiemo, Patrick Oyaro, Gretchen Birbeck, Richard Price, Elizabeth Bukusi, Craig Cohen, Ana-Claire Meyer P04.236 Prevalence of Seizures in HIV Patients Measured in the Outpatient Setting Kristi Nord, Stuart Tomko, Deborah Forst, Liliana Robles, David Friedman, Joseph Kass P04.237 CNS Immune Reconstitution Inflammatory Syndrome (IRIS) in an HIV-Infected Patient with a Stable CD4 Cell Count and Undetectable Viral Load Michele Mass 75 Poster Session IV P04.238 Prevalence of HTLV-1 Among Selected Cases of Progressive Spastic Non-Compressive Myelopathy in North Eastern Nigeria Abdullahi Ibrahim, Yakub Nyandaiti P04.252 Psychogenic Non-Epileptic Seizures in Postural Orthostatic Tachycardia Syndrome Katherine Noe, Joseph Drazkowski, Joseph Sirven, Brent Goodman P04.263 Menstrual Exacerbation in Irritable Bowel Syndrome, Fibromyalgia, and Interstitial Cystitis Thomas Chelimsky, Shruti Madan, Umit Ulas, Gisela Chelimsky, Kevin McNeeley P04.239 Progression of Nerve Conduction and EMG Abnormalities in Acute West Nile Virus Infection Logan McDaneld, Edward Kim, Jau-Shin Lou Autonomic Disorders: Testing Methods and Treatments P04.253 Low Iron Storage and Anemia in Adolescents with Postural Tachycardia Syndrome (POTS) Imad Jarjour, Laila Jarjour P04.264 Prospective Elderly Human Blood-CNS Biodistribution and Neurocognitive Studies of a Quaternary Amine Antimuscarinic Agent for Overactive Bladder (OAB): The SMART Trial Michael Oefelein, Gary Kay, David Staskin, Howard Goldman P04.254 What Is the Optimal Duration of a Tilt Table Test? Iyavut Thaipisuttikul, Aninda Acharya, Laurence Kinsella Neuro-Ophthalmology/NeuroOtology P04.240 Factors Governing Herpes Simplex Virus Type 1 (HSV-1) Infection of Brain Tissues in Organotypic Cultures Israel Steiner, Meytal Cohen, Efrat Braun, Amos Panet P04.241 Encephalitis Associated with Pandemic H1N1-2009: Case Report and Review Adam Edwards, Kathleen Currey P04.242 Novel H1N1 Encephalomyelitis Kristen Smith, Ryan Smith, Alessandro Serra, Bashar Katirji Autonomic Disorders: Comorbidities and Clinical Connections P04.243 High Cervical Cord Injury with Posterior Reversible Leukoencephalopathy Syndrome: Case Report Yessar Hussain, Terrence Li, Ma Jiaxin P04.244 Focal Hyperhidrosis Due to Irritative Effect of Nerve Root and Spinal Cord Mass Lesions Robert Fealey, J. D. Bartleson, Eduardo Benarroch, Paola Sandroni P04.245 Underlying Autonomic Dysfunction in Cough Syncope William Cheshire P04.246 Comorbid Health Conditions in Women with Syncope Umit Ulas, Thomas Chelimsky, Giesla Chelimsky, Kevin McNeely, Alshekhlee Amer P04.247 Can Sex Hormone Dysregulation Cause Autonomic Storm? Umit Ulas, Baha Arafah, Kevin McNeeley, Di Zhang, Gisela Chelimsky, Thomas Chelimsky P04.248 The Identification and Characterization of Autonomic Dysfunction in Migraineurs with and without Auras Mark Stillman, Fetnat Fouad-Terazi, Lan Zhou, Stewart Tepper, Neil Cherian P04.249 Orthostatic and NonOrthostatic Headache in Postural Tachycardia Syndrome (POTS) Ramesh Khurana, Lindsay Eisenberg P04.250 Menstrual Symptom Alteration in Orthostatic Intolerance, Syncope, and Migraine Thomas Chelimsky, Devraj Sukul, Umit Ulas, Shruti Madan, Di Zhang, Kevin McNeeley, Gisela Chelimsky P04.251 Pregnancy in Postural Tachycardia Syndrome: Clinical Course and Maternal and Fetal Outcomes Hasti Poya, Glenna Bett, Svetlana Blitshteyn 76 Wednesday, April 14 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P04.255 Cardiac Metaiodobenzylguanidine (cMIBG) Scintigraphy Is a Useful Tool To Access Subclinical Autonomic Involvement in Peripheral Neuropathies Osvaldo Nascimento, Marco Antonio Leite, Marcos Freitas, Wilson Marques Junior, Camila Pupe P04.256 Catecholaminergic Denervation in the Brain and Heart in Parkinson Disease: Associations with Non-Motor Manifestations David Goldstein P04.257 A Modification to the Quantitative Direct and Indirect Axon Reflex Sudomotor Test (QDIRT) Enhances Test Utility Ben Illigens, Christopher Gibbons, Roy Freeman P04.258 Treatment Induced Diabetic Neuropathy—An Acute Reversible Painful Autonomic Neuropathy Christopher Gibbons, Roy Freeman P04.259 Contamination of the Norepinephrine Pro-Drug Droxidopa by Dihydroxyphenylacetaldehyde Courtney Holmes, David Goldstein P04.260 Pleasant Olfactory Stimulation Enhances Cardiovagal Modulation in Mild Traumatic Brain Injury Patients Max Hilz, Harald Marthol, Tim Schroeder, Anja Roámeiál, Thomas Hummel, Steven Flanagan, Philip De Fina, Stefan Schwab, Christoph Lang, Eva Heuberger, Theresa Rameder P04.261 Hematopoietic Cell Transplantation for AdolescentOnset Cerebral X-Linked Adrenoleukodystrophy Takashi Matsukawa, Tomotaka Yamamoto, Keiki Kumano, Tsuyoshi Takahashi, Sachiko Seo, Yuji Takahashi, Jun Goto, Mineo Kurokawa, Shoji Tsuji Autonomic Disorders: Bowel and Bladder Disorders P04.262 Prevalence of Somatic and Autonomic Small Fiber Neuropathy in a Cohort of Patients with Inflammatory Bowel Disease (IBD) Liana Melo Coelho, Gisele Oliveira, Allyne Mayane Costa, Patricia Aquino, Lucia Libanez Campelo Braga, Marcellus Henrique Ponte de Souza, Francisco Rola, José Correia, Francisco de Assis Gondim P04.265 Self-Complementary AAV Induces Rapid and Highly Efficient Allotopic Expression of the Human ND4 Complex I Subunit in the Mouse Visual System Rajeshwari Koilkonda, Tsung-Han Chou, Vittorio Porciatti, William Hauswirth, John Guy P04.266 Idiopathic Intracranial Hypertension at a Canadian Tertiary Care Centre Mary-Magdalene Dodd, Vivek Patel, Carlos Torres, David Zackon, Miguel Bussiere P04.267 Neuroretinitis with Bartonella Henselae and EBV Co-Infection: Direct Infection or Immunomodulated Reaction? Hossein Ansari, Paola Pergami, Kathryn Moffett, Michael McAllister P04.268 Obstructive Sleep Apnea (OSA) in Idiopathic Intracranial Hypertension (IIH): A Prospective Study Matthew Thurtell, Beau Bruce, David Rye, Nancy Newman, Valerie Biousse P04.269 Neuro-Ophthalmological Implications of CADASIL Federighi Pamela, Alessandra Rufa, Maria Dotti, Elena Pretegiani, Francesca Rosini, Silvia Bianchi, Antonio Federico P04.270 Short Term Adaptation of Visual Search Strategies in Simulated Hemianopia Sara Simpson, Mathias Abegg, Jason Barton P04.271 Region-Specific Patters of White Matter Diffusivity Changes in Leber’s Hereditary Optic Neuropathy: A Tract-Based Spatial Statistics Study Jacopo Milesi, Maria Rocca, Stefania Bianchi-Marzoli, Melissa Petrolini, Lisa Melzi, Andrea Falini, Giancarlo Comi, Massimo Filippi P04.272 Retinal Nerve Fibre Layer Thickness and Brain Volume in Acute Optic Neuritis Klaus Kallenbach, Birgit Sander, Michael Larsen, Henrik Larsson, Jette Frederiksen P04.273 Anemia-Dependent Transient Cortical Visual Loss Heralding Acute Myelogenous Leukemia in a Woman with Basilar Stenosis Marc Dinkin, Jacqueline Winterkorn P04.274 Optical Coherence Tomography as Measure of the Effects of Glatiramer Acetate on Axonal Loss in Patients with Acute Optic Neuritis (AON) Mark Kupersmith, Peter Calabresi, Gary Cutter, Robert Sergott, Ron Neumann P04.286 The m.3244G>A Mutation in mtDNA Is Another Cause of Progressive External Ophthalmoplegia Evangelia Sotiriou, Jorida Coku, Kurenai Tanji, Hua-bin Huang, Michio Hirano, Salvatore DiMauro P04.275 Is Down Slower Than Up? Vertical Saccades in Progressive Supranuclear Palsy (PSP) Athena Chen, David Riley, Anand Joshi, Ke Liao, Alessandro Serra, R. Leigh P04.287 Saccadic Abnormalities in Ocular Myasthenia Reflect Morphological Differences between Neuromuscular Junctions of Extraocular Muscle-Fiber Types Alessandro Serra, Richard Jung, Numthip Chitravas, Henry Kaminski, R. Leigh P04.276 The Usefulness of Bedside Neuro-Otological Examination in Differentiating Central and Peripheral Causes of Isolated Vertigo in Emergency Room Ji-Young Park, Byung-Kun Kim, Sucjoo Kim, Jaseong Koo, Ohyun Kwon, Jong-Moo Park, Jung Ju Lee P04.277 Vestibular Evoked Neurogenic Potentials Using Air-Conducted Sound: The Discovery of a New Scalp Recorded Potential (N6) That Probably Originates from the Midbrain Eleftherios Papathanasiou, Athena Lemesiou, Stavros Hadjiloizou, Panayiota Myrianthopoulou, Marios Pantzaris, Savvas Papacostas Poster Session IV Wednesday, April 14 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P04.288 Prevalence of Clinical NeuroOphthalmic Abnormalities in an ALS Cohort Heather Moss, Steven Galetta, Laura Balcer, Lauren Talman, Murray Grossman, Lauren Elman, Leo McCluskey, Grant Liu P04.289 Ocular Myositis in Crohn’s Disease with MRI Imaging Mimicking Thyroid Ophthalmopathy Shan Chen, Mohammad Fouladvand P04.290 Saccade Related Gamma Oscillations Recorded from the Human Basal Ganglia and Thalamus Originate from Ocular Muscles Arun Sundaram, James Sharpe, Robert Chen, William Hutchison Medical Student Essay Award Recipients P04.291 Immunological Aspects of Cell Transplantation in Parkinson’s Disease Amanda Rowlands P04.292 Utility of Quantitative Sensory Testing and Neuropathy Screening Tools in Identifying HIVAssociated Peripheral Neuropathy in Western Kenya: a Pilot Testing Deanna Cettomai P04.293 Elementary My Dear Dr. Allen: the Care of Barium Toxicity and Pa Ping Lauren Bowen P04.294 Neurogenetics: Parent of Origin Effects in Autistic Copy Number Variation, a Possible Mechanism for Autism Pathogenesis Benjamin Kwan P04.278 Vestibular Dysfuctions in Migrainous Vertigo Evaluated by Rotatory Chair Ji-yun Park, Tae-Kyeong Lee, Sun-Ah Park, Ki-Bum Sung, Jong-Ho Park P04.279 Horizontal Conjugate Gaze Deviation in the Acute Vestibular Syndrome Jorge Kattah, John Pula, David Newman-Toker P04.280 Bilateral Synergistic Convergence with Horizontal Gaze Palsy and Scoliosis. Is the Mechanism Supranuclear? Berker Bakbak, Joanna Jen, Tulay Kansu P04.281 The Video Head Impulse Test: Diagnostic Accuracy in Peripheral Vestibulopathy Konrad Weber, Hamish MacDougall, Leigh McGarvie, G. Halmagyi, Ian Curthoys P04.282 Acute Encephalopathy, Multiple Ocular Motor Deficits and Bilateral Ptosis Following Embolization of Branches of the External Carotid Artery Feeding a Carotid Body Tumor Ahmed El-Dokla, Amar Swarnkar, Philip Cherian, Luis Mejico P04.283 Prosaccade and Antisaccade Performances in Spinocerebellar Ataxia Type 2 and Other Genetic Ataxias Pamela Federighi, Francesca Rosini, Giacomo Veneri, Elena Pretegiani, Maria Dotti, Antonio Federico, Alessandra Rufa P04.284 Cerebral Hemispheric Eye Movement Disorders Are Different in Parkin-Linked and Idiopathic Parkinson’s Disease Wolfgang Heide, Bjorn Machner, Andreas Sprenger, Philipp Baumbach, Peter Pramstaller, Christine Klein, Christoph Helmchen P04.285 Recurrence of Symptoms after Successful Carotid Cavernous Fistula Endovascular Treatment Aimee Szewka, Gioconda Mojica, Janet Rucker, Thomas Mizen, Victor Aletich, Demetrius Lopes, Susan Ksiaszek The NEW 2010 Exhibit Hall: For Your Professional—and Personal—Interests. Visit the 2010 AAN Annual Meeting Exhibit Hall to discover and watch live presentations on the latest products and services designed to help you excel in your profession and provide the best care for neurology patients. Then visit the Exhibit Hall’s new MarketPlace where non-neurology related companies and organizations will showcase exciting offerings of personal interest. Monday, April 12 / 5:00 p.m.–7:00 p.m. Tuesday, April 13–Wednesday, 14 / 11:30 a.m.–5:00 p.m. / special luncheon 12:00 p.m.–2:00 p.m. Thursday, April 15 / 11:30 a.m.–4:00 p.m. / special luncheon 12:00 p.m.–2:00 p.m. Visit www.aan.com/view/exhibit for more information. 77 Scientific Sessions S31 Multiple Sclerosis: Biomarkers S33 Current and Future Treatment of Parkinson's Disease S34 Aging and Dementia: Recognition and Treatment Theatre 102 Constitution Hall 106 Room 718AB Constitution Hall 107 4:15 p.m. S31.001 Evaluation of New Immunological Targets in Neuromyelitis Optica JeanBaptiste Chanson, Ilaria Paolini, Nicolas Collongues, MariaClaudia Alcaro, Frédéric Blanc, Francesca Barbetti, Marie Fleury, Elisa Peroni, Paolo Rovero, Gabrielle Rudolf, Francesco Lolli, Elisabeth Trifilieff, Anna-Maria Papini, Jérôme de Seze 4:15 p.m. S32.001 Blood-Brain-Barrier Permeability Derangements in Posterior Circulation Ischemia: Frequency, Clinical Correlates, and Relation to Hemorrhagic Transformation Meng Lee, Jeffrey Saver, Jeffry Alger, Qing Hao, Sidney Starkman, Latisha Ali, Doojin Kim, Bruce Ovbiagele, Paul Vespa, Michael Froehler, Matthew Tenser, Noriko Salamon, J. Pablo Villablanca, Reza Jahan, Gary Duckwiler , Satoshi Tateshima, Nestor Gonzalez, Fernando Vinuela, David Liebeskind 4:15 p.m. S33.001 Plasma and Brain Levels of PYM50028 (Cogane™) Associated with Neurorestorative Efficacy in Rodent and Primate Models of Parkinson’s Disease: Translation to Once Daily Dosing in Humans Susan Fox, Tom Johnston, James Koprich, Philippe Huot, Caroline Ward, Nick Meyers, Patrick Howson, Jonathan Brotchie 4:15 p.m. S34.001 Safety and Tolerability of Extended-Release Memantine (Once Daily, 28 mg) in Patients with Moderate to Severe Alzheimer’s Disease: An OpenLabel Extension Study Gustavo Alva, George Grossberg, Facundo Manes, Ricardo Allegri, Luis Miguel Guttierez Robledo, Sergio Gloger, Lei Xie, Xinwei Daniel Jia, James Perhach, Stephen Graham 4:30 p.m. S31.002 Effects of Natalizumab Treatment on the Presence of JC Virus DNA in Blood or Urine in Multiple Sclerosis Patients Richard Rudick, Paul O’Connor, Chris Polman, Andrew Goodman, Soma Ray, Stephanie Jurgensen, Susan Goelz, Fiona Forrestal, Leonid Gorelik, Alfred Sandrock 4:45 p.m. S31.003 Evaluation of the Incidence of Anti-JCV Antibodies in a Cohort of Natalizumab-Treated MS Patients Leonid Gorelik, Sarah Bixler, Michaela Lerner, Ewa Wilson, Anne Cheung, Ling Ling Chen, Melissa Berman, Mary Crossman, Ken Simon, Brian Schlain, Susan Goelz, Meena Subramanyam 5:00 p.m. S31.004 Anti-GAGA4 IgM Antibodies (gMS[®Dx Test) Differentiate Newly Diagnosed Relapsing -Remitting Multiple Sclerosis Patients From Other Inflammatory Demyelinating Disease Patients Within One Year from Diagnosis Jennifer Yarden, Hollie Schmidt, Jette Frederiksen, Hayrettin Tumani, Johannes Brettschneider, Sana Abdul, Sven Jarius, Brigitte Wildemann, Diego Franciotta, Larissa Spector, Ella Fire, Nir Dotan 5:15 p.m. S31.005 MS Immunopattern Heterogeneity Persists in Active Lesions throughout Duration of Disease: Relation to Plaque Type and Clinical Course Claudia Lucchinetti, Josa Frischer, Joseph Parisi, Stephen Weigand, Kristine Thomsen, Wolfgang Brueck, Hans Lassmann, Jayawant Mandrekar 78 S32 Cerebrovascular Disease: Stroke Imaging Wednesday, April 14 | 4:15 p.m.–5:30 p.m. Metro Toronto Convention Centre 4:30 p.m. S32.002 HIV-Vasculopathy and VZVVasculitis as Cause of Stroke in HIV-Infected Patients Jose Gutierrez, Sebastian Koch, Jose Romano, Michael Katsnelson, Roberto Sanchez, Gustavo Ortiz 4:45 p.m. S32.003 Loss of Consciousness at the Onset of Subarachnoid Hemorrhage Is Highly Predictive of Aneurysmal Rupture Stefan Dupont, Eelco Wijdicks, Alejandro Rabinstein 5:00 p.m. S32.004 Extra- or Intra-Cranial Dissection Involving Multiple Arteries: A Distinct Clinical and Angiographic Syndrome? Marc Lazzaro, Ameer Hassan, Rehan Zahid, Sudeepta Dandapat, Gabriela Vazquez, Gustavo Rodriguez, Mustafa Ezzedine, M. Fareed Suri, Ramachandra Tummula, Robert Taylor, Adnan Qureshi, Yousef Mohammad 5:15 p.m. S32.005 Block-Design Versus EventRelated fMRI for Language Evaluation in Post-Stroke Aphasia Jane Allendorfer, Christi Banks, Jennifer Vannest, Angel Ball, Stephen Page, Brett Kissela, Kenneth Eaton, Scott Holland, Jerzy Szaflarski 4:30 p.m. S33.002 ADX10059 a Negative Allosteric Modulator of the Metabotropic Glutamate 5 Receptor (mGlur5) Effectively Controls Chorea and Dystonia in a Primate Model of Levodopa Induced Dyskinesia Charlotte Keywood, Erwan Bezard, Francoise Girard, Vincent Mutel 4:45 p.m. S33.003 24-Hour Symptom Control with Ropinirole Prolonged Release in Patients with Advanced Parkinson’s Disease Not Optimally Controlled with L-Dopa Fabrizio Stocchi, Katie Rolfe, James Cooper, Alan Lipschitz 5:00 p.m. S33.004 UWA-0121, a Novel Dopamine and Serotonin Re-Uptake Inhibitor, Increases Quality and Duration of L-DOPA AntiParkinsonian Actions in the MPTP-Lesioned Primate Model of Parkinson’s Disease Philippe Huot, Tom Johnston, M. Gabriela Reyes, Katie Lewis, Susan Fox, Matthew Piggott, Jonathan Brotchie 5:15 p.m. S33.005 Perfusion MRI in Parkinson Disease Reveals Pharmacodynamics of the Adenosine A2a Antagonist SYN115 Kevin Black, Jonathan Koller, Meghan Campbell, Stephen Bandak 4:30 p.m. S34.002 A Randomized, Double-Blind, Controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic CJD Michael Geschwind, Amy Kuo, Benjamin Raudabaugh, Aissatou Haman, Gillian Devereux, David Johnson, Charles Torres-Chae, Julie Thai, Katherine Wong, Stanley Prusiner, John Neuhaus, Stephen DeArmond, Bruce Miller 4:45 p.m. S34.003 Vitamin D Deficiency and Cognitive Impairment in Older Women: A Multicentric Cross- Sectional Study Cédric Annweiler, Gilles Allali, AnneMarie Schott, Didier Le Gall, François Herrmann, Olivier Beauchet 5:00 p.m. S34.004 An Evaluation of the Prodromal Alzheimer’s Disease Diagnostic Criteria within the ADNI Cohort Study Howard Feldman, Jian Han, Stephen Kaplita, Robert Berman, Vlad Coric, Bongin Yoo, Thomas Kelleher, Leah Burns, Charles Albright, Pablo Lapuerta 5:15 p.m. S34.005 Neuropsychological Outcomes Following 18-Months of Uninterrupted Intravenous Immunoglobulin (IVIg) Treatment in Patients with Alzheimer’s Disease (AD) Diamanto Tsakanikas, Norman Relkin S35 Headache II Room 716A 4:15 p.m. Presentation of the Harold Wolff-John Graham: An Award for Headache/Facial Pain Research Recipient: Ana Recober, MD Iowa City, IA 4:30 p.m. S35.002 Evaluation of Safety and Efficacy of MAP0004 in Treating Acute Menstrual Migraine Curt Schreiber, Shashidhar Kori, Sylvia Lucas, Scott Borland, Min Wang, Bin Hu, Jan Brandes 4:45 p.m. S35.003 OnabotulinumtoxinA Treatment Improves Health-Related Quality of Life and Reduces the Impact of Chronic Migraine: 56-Week Results from the PREEMPT Clinical Program Richard Lipton, Sepideh Varon, Peter Goadsby, Ronald DeGryse, Catherine Turkel 5:00 p.m. S35.004 Efficacy of Telcagepant in Subgroups: Pooled Analysis of Data from Phase III Studies Tony Ho, Kathryn Connor, Andrew Ho, James Kost, Xiaoyin Fan, David Dodick, Stephen Silberstein, Christopher Lines, Christopher Assaid 5:15 p.m. S35.005 OnabotulinumtoxinA for Treatment of Chronic Migraine: 56-Week Analysis of the PREEMPT Chronic Migraine Subgroup with Baseline Acute Headache Medication Overuse Stephen Silberstein, Joel Saper, Michael Stein, Ronald DeGryse, Catherine Turkel Scientific Sessions Wednesday, April 14 | 4:15 p.m.–5:30 p.m. S36 Anterior Horn: Spinal Muscular Atrophy S37 Neurologic Manifestations: Imaging and Therapeutics Room 701B Room 701A 4:15 p.m. S36.001 Maximum Ulnar Compound Motor Action Potential (CMAP) Is Related to Motor Function in Children with Spinal Muscular Atrophy: Report from the SMA CARNI-VAL Clinical Trial Aga Lewelt, Kristin Krosschell, Charles Scott, John Kissel, Thomas Crawford, Gyula Acsadi, Guy D’Anjou, Bakri Elsheik, Sandra Reyna, Bernie Lasalle, Mary Schroth, Louise Simard, Jo Anne Maczulski, Kathryn Swoboda 4:15 p.m. S37.001 The Effects of High Dose Interferon-β1a on Plasma Endothelial Microparticles: Correlation with MRI Parameters Mary LoweryNordberg, Erin Eaton, J. Alexander, Eduardo GonzalezToledo, Meghan Harris, Kathrine Chalamidas, Jeanie McGee, Alireza Minagar 4:30 p.m. S36.002 SMN Transcript Quantification as a Surrogate Outcome Measure in Spinal Muscular Atrophy (SMA) Clinical Trials: Towards a Validated International Standard Operating Procedure (SOP) Louise Simard, F. Danilo Tiziano, Rosa Lomastro, Elzbieta Slominski, Giovanni Neri, Christina Brahe 4:45 p.m. S36.003 Segmental Thigh Muscle Volumes Estimated by Magnetic Resonance Imaging (MRI) Remain Stable over a Six-Month Interval in Spinal Muscular Atrophy (SMA): An Effective Early Biomarker? Megan Montgomery, Mark Punyanitya, Wei Shen, Stephen Dashnaw, Jacqueline Montes, Sally Dunaway, Petra Kaufmann, Darryl De Vivo, Douglas Sproule 5:00 p.m. S36.004 Dominantly Inherited Spinal Muscular Atrophy with Lower Limb Predominance Showing Linkage to 14q32 Matthew Harms, Peggy Allred, Robert Gardner, Jose Americo Fernandes-Filho, Julaine Florence, Alan Pestronk, Muhammad Al-Lozi, Robert Baloh 5:15 p.m. S36.005 Investigating the Cellular Site of Action of Survival Motor Neuron Protein Gyu Hwan Park, Yuka Maeno-Hikichi, Tomoyuki Awano, Katelyn Nelson, Lynn Landmesser, Umrao Monani 4:30 p.m. S37.002 Characterizing Cerebrovascular Disease in Idiopathic Hypereosinophilic Syndrome: A Systematic Review Kathryn Kirchoff, Sarah Cherian, Steven Levine 4:45 p.m. S37.003 Cognitive Functions and Cerebral Volume in Neuromyelitis Optica Frederic Blanc, Barbara Jung, Vincent Noblet, Nadine Longato, Catherine Kleitz, Nadjette Cremel, François Rousseau, Stephane Kremer, Jean-Paul Armspach, Jerome de Seze 5:00 p.m. S37.004 Presentations and Clinical Associations of Posterior Reversible Encephalopathy Syndrome Jennifer Fugate, Daniel Claassen, Osman Kozak, Harry Cloft, David Kallmes, Alejandro Rabinstein 5:15 p.m. S37.005 Neuroimaging Markers of Accelerated Brain Aging in Middle Aged Patients with Type-1 Diabetes (T1D) Howard Aizenstein, Vijay Venkatraman, Trevor Orchard, Anne Newman, Peter Gianaros, Elsa Strotmeyer, Christopher Ryan, Tamara Harris, Kristine Yaffe, Stephen Kritchevsky, Caterina Rosano S38 Neurogenetics: Basic Science and Therapeutics Room 714B 4:15 p.m. Presentation of the S. Weir Mitchell Award Recipient: Peter Todd, MD, PhD Ann Arbor, MI 4:30 p.m. S38.002 Gentamicin Treatment of Duchenne Muscular Dystrophy Reinforces the Potential for Mutation Suppression Therapy Vinod Malik, Louise Rodino-Klapac, Laurence Viollet, Cheryl Wall, Wendy King, Roula Al-Dahhak, Sarah Lewis, Christopher Shilling, Janaiah Kota, John Hayes, John Mahan, Katherine Campbell, Brenda Banwell, Majed Dasouki, Victoria Watts , Kumaraswamy Sivakumar, Ricardo Bien-Willner, Kevin Flanigan, Zarife Sahenk, Richard Barohn, Christopher Walker, Jerry Mendell 4:45 p.m. S38.003 Modification of Adenoassociated Virus (AAV) To Deliver DNA to Mitochondria Hong Yu, John Guy 5:00 p.m. S38.004 PGC-1alpha Is Involved in the Pathogenesis of the Blunted Antioxidant Response in Friedreich’s Ataxia and Is a Potential Therapeutic Target Massimo Pandolfo, Mario Manto, Daniele Marmolino 5:15 p.m. S38.005 New Rodent Model for Hereditary Spastic Paraplegia Odelia Ghodsizadeh, Mackenzie Schumer, Lesley Fisher, Michele Basso, Robert Hammer, Yaz Kisanuki S39 Neuro-oncology: Paraneoplastic Disorders S40 Multiple Sclerosis: Epidemiology Room 713AB Room 717AB 4:15 p.m. S39.001 Paraneoplastic Neurological Syndromes from the Euronetwork Database. A European Study from 20 Centres Bruno Giometto, Wolfgang Grisold, Roberta Vitaliani, Guido Bertolini, PNS Euronetwork 4:15 p.m. S40.001 Variations in the Gender Ratio of Multiple Sclerosis Linked to Converging Smoking Trends in Men and Women Natalia Palacios, Alvaro Alonso, Henrik Bronnum-Hansen, Alberto Ascherio 4:30 p.m. S39.002 Paraneoplastic Dysautonomia: 55 Cases from the PNS Euronetwork Database Roberta Vitaliani, Guido Bertolini, Bruno Giometto, PNS Euronetwork 4:45 p.m. S39.003 Autoantibodies to the GABAB Receptor Associate with Limbic Encephalitis and Seizures, and Alter GABAB Receptor Function Eric Lancaster, Meizan Lai, Ethan Hughes, Xiaoyu Peng, Stephen Moss, Rita BaliceGordon, Josep Dalmau 5:00 p.m. S39.004 Anti-NMDA Receptor Patient Antibodies Potentiate NMDA Receptor Currents in Cultured Hippocampal Neurons Leo Wang, Xiaoping Jiang, Amanda Taylor, Alan Pestronk, Krista Moulder 5:15 p.m. S39.005 Death of Purkinje, Granule, and Molecular Layer Neurons Following Uptake of Anti-Hu Antibodies in Organotypic Rat Cerebellar Cultures John Greenlee, Susan Clawson, Kenneth Hill, Noel Carlson 4:30 p.m. S40.002 Increase of Relapse Rate in Patients with Multiple Sclerosis after In-Vitro Fertilization Is Related to the Use of LHRH Agonists: A Multicenter Retrospective Study in France Laure Michel, Yohann Foucher, Jerome De Seze, Sandra Vukusic, Christian Confavreux, David Brassat, Pierre Clavelou, Jean Christophe Ouallet, Bruno Brochet, Jean Pelletier, Pierre Labauge, Christine Lebrun Frenay, Fabienne Lefrere, Marylíne Jacq, Sandrine Wiertlewsk , David Laplaud 4:45 p.m. S40.003 Breastfeeding Is Not Related with the Risk of Post Partum Relapses in Women with Multiple Sclerosis Emilio Portaccio, Angelo Ghezzi, Bahia Hakiki, Valentina Zipoli, Lorenzo Razzolini, Vittorio Martinelli, Lucia Moiola, Francesco Patti, Loredana La Mantia, Gianluigi Mancardi, Claudio Solaro, Maria Rosaria Tola, Carlo Pozzilli, Laura De Giglio, Rocco Totaro , Alessandra Lugaresi, Valeria Di Tommaso, Damiano Paolicelli, Maria Giovanna Marrosu, Giancarlo Comi, Maria Trojano, Maria Pia Amato 5:00 p.m. S40.004 The Curious Case of Vitamin D, Pregnancy, Breastfeeding, and Postpartum Multiple Sclerosis Relapses Annette Langer-Gould, Rohit Gupta, Stephen Van Den Eeden, Ronald Horst, Lorene Nelson, Bruce Hollis 5:15 p.m. S40.005 Subcutaneous Interferon beta1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis Magnhild Sandberg-Wollheim, Enrica Alteri, Margaretha Stam Moraga, Gabrielle Kornmann 79 Thursday, April 15 Highlights Frontiers in Clinical Neuroscience Plenary Session publications, and products to assist with practice management, teaching methods, and research activities. 9:00 a.m.–11:00 a.m. NEW! Platform Session Times 7:30 a.m.–12:00 p.m. (Author stand by poster from 7:30 a.m.–9:00 a.m.) MTCC, Exhibit Hall FG 1:15 p.m.–2:30 p.m. 2:45 p.m.–3:45 p.m. 3:00 p.m.–7:30 p.m. (Author stand by poster from 6:00 p.m.–7:30 p.m.) This session focuses on translational research related to clinical issues of importance. Four physician-scientists outline their recent research findings, along with the clinical implications. Moderator: Stefan M. Pulst, MD, FAAN Chair, Science Committee and Scientific Program Subcommittee ”Reflections on Memory: What Neurosurgical Patients Have Taught Us” Brenda Milner, PhD Montreal Neurological Institute, Montreal, QC, Canada ”Clinical Spectrum and Cellular Mechanisms of Autoimmunity to NMDA and Other Synaptic Receptors” Josep O. Dalmau, MD, PhD University of Pennsylvania, Philadelphia, PA ”Stroke and Alzheimer’s Disease: Fellow Travelers or Partners in Crime?” Vladimir Hachinski, MD, DSc, FAAN London Health Center, London, ON, Canada ”Neurologists Listening to Neurons: Intracortically Based Brain-Computer Interfaces” Leigh R. Hochberg, MD, PhD Massachusetts General Hospital and Brigham and Women’s Hospital; Harvard Medical School; Brown University; Providence VA Medical Center, Boston, MA Exhibits 11:30 a.m.–4:00 p.m. Complimentary Luncheon 12:00 p.m.–2:00 p.m. MTCC, Exhibit Hall DE See the latest in pharmaceutical products, medical equipment, 80 Thursday, April 15 Highlights NEW! AAN Awards Plenary Session 4:00 p.m.–6:00 p.m. MTCC, Exhibit Hall FG Moderator: Brenda Banwell, MD, Member, Science Committee The Awards Plenary Session highlights some of the best and brightest in the field today, featuring presentations by the recipients of four top 2010 awards. Sure to become a staple of future Annual Meetings, three of the lectures will become perennials: The Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases, the Sheila Essey Award—An Award for ALS Research, and the John Dystel Prize for Multiple Sclerosis Research, with the fourth lecture in rotation. In 2010 the rotating lecture will feature a presentation from the recipient of the Dreifuss-Penry Epilepsy Award. Sheila Essey Award–An Award for ALS Research Presented by the American Academy of Neurology and the ALS Association and supported through the philanthropy of the Essey Family Fund and the ALS Association. Recipient: Clive Svendsen, PhD/ Madison, WI Poster Discussion Session Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. NEW! Highlights in the Field These new sessions bring you all you need to know for your subspecialty or area of special interest. Get overviews in subspecialty topics from the past year featuring scientific and educational abstracts, journal articles, subspecialty society updates, tips, resources, and more. Look for highlights from the following AAN Sections: xx Autonomic Nervous System/Neuroendocrinology/Pain and Palliative Care Wednesday, April 14 12:00 p.m. to 1:30 p.m. xx Behavioral Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Child Neurology/Women’s Issues in Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Clinical Neurophysiology Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Critical Care and Emergency Neurology/Endovascular and Interventional Neurology/Stroke and Vascular Neurology Thursday, April 15 11:15 a.m. to 12:45 p.m. xx Epilepsy Monday, April 12 12:00 p.m. to 1:30 p.m. xx Ethics Thursday, April 15 11:15 a.m. to 12:45 p.m. Dreifuss-Penry Epilepsy Award Sponsored by the American Academy of Neurology and endowed by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma. Recipient: Martin Gallagher, MD, PhD/ Nashville, TN Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Sponsored by the American Academy of Neurology, the AAN Foundation, and funded through the philanthropy of the Potamkin Family. Recipients: Bruce L. Miller, MD/ San Francisco, CA Lennart Mucke, MD/ San Francisco, CA The following sections will conduct their regular business meetings as follows: xx A.B. Baker Section of Neurologic Educators Monday, April 12 12:00 p.m. to 1:00 p.m. xx Headache & Facial Pain Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx History Section Tuesday, April 13 1:00 p.m. to 2:00 p.m. xx Multiple Sclerosis Monday, April 12 4:00 p.m. to 5:30 p.m. xx Neurohospitalist Tuesday, April 13 12:00 pm.m-1:30 p.m. 2010 Corporate Roundtable Members* The AAN Foundation thanks its 2010 Corporate Roundtable Members for their demonstrated vision, commitment, and strong support of neurologic research. $40,000 Allergan, Inc. Eli Lilly and Company Forest Laboratories, Inc. Genentech, Inc./Roche Teva Neuroscience, Inc. John Dystel Prize for Multiple Sclerosis Research Presented by the American Academy of Neurology and the National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society. Recipient: David Hafler, MD, MSc/ New Haven, CT xx General Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Geriatric Neurology Wednesday, April 14 12:15 p.m. to 1:30 p.m. xx Government Service Neurologists Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Movement Disorders Wednesday, April 14 12:00 p.m. to 1:30 p.m. xx Multiple Sclerosis Thursday, April 15 11:15 p.m. to 12:15 p.m. xx Neural Repair and Rehabilitation/Spine Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Neuroepidemiology Thursday, April 15 11:15 a.m.to 12:45 p.m. xx Neurogenetics Wednesday, April 14, 12:00 p.m. to 1:30 p.m. xx Neuroimaging Thursday, April 15 11:15 a.m. to 12:45 p.m. xx Neuro-infectious Disease Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Neuromuscular Thursday, April 15 11:15 a.m. to 12:45 p.m. xx Neuro-oncology Thursday, April 15 11:15 a.m. to 12:45 p.m. xx Neuro-ophthalmology/Neuro-otology Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Sleep Medicine Tuesday, April 13 12:00 p.m. to 1:30 p.m. xx Sports Neurology Tuesday, April 13 12:00 p.m. to 1:30 p.m. Information is subject to change. *Current as of February 8, 2010 $30,000 Pfizer Inc Sepracor Inc. UCB Inc. $20,000 Acorda Therapeutics, Inc. Bayer Healthcare Pharmaceuticals, Inc. Biogen Idec Boehringer Ingelheim Pharmaceuticals, Inc. Endo Pharmaceuticals, Inc. Genzyme Corporation Medivation, Inc. Merz Pharmaceuticals Inc. Novartis Pharmaceuticals Corporation PhotoThera, Inc. Questcor Pharmaceuticals, Inc. Upsher-Smith Laboratories, Inc. 81 Poster Session V Thursday, April 15 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 Poster Discussion Session: Multiple Sclerosis and Related Diseases: Drug Mechanisms Location: 800 Level Moderator: Michael Racke, MD Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. PD5.001 Effect of Immunomodulatory Agents (IMAs) on Cortical Inflammatory Lesions (CLs) in Patients with RelapsingRemitting Multiple Sclerosis (RRMS): A 2-Year Longitudinal Comparison Study Paolo Gallo, Valentina Bernardi, Francesca Rinaldi, Alice Favaretto, Irene Mattisi, Paola Perini, Luciano Rinaldi, Massimiliano Calabrese PD5.002 Induction of Immune Tolerance in Multiple Sclerosis Patients by Epicutaneous Immunization with Myelin Peptides Agata Walczak, Maciej Jurynczyk, Krzysztof Selmaj PD5.003 Glatiramer Acetate Immunomodulates Pro-Inflammatory B Cell Function in Central Nervous System Autoimmune Disease Deetje Hertzenberg, Martina Betz, Klaus Lehmann-Horn, Scott Zamvil, Patrice Lalive D’Epinay, Bernhard Hemmer, Martin Weber Behavioral Neurology: Emotion and Insight P05.001 The Contribution of Neuropsychiatric Symptoms to the Cost of Frontotemporal, Alzheimer, and Vascular Dementia Care Galeno Rojas, Leonardo Bartoloni, Cecilia Serrano, Carol Dillon, Ricardo Allegri P05.002 Subgenual Cingulate Gyrus Deep Brain Stimulation for Refractory Major Depressive Disorder: PET Findings Sakina Rizvi, Jakub Konarski, Sidney Kennedy, Peter Giacobbe, Helen Mayberg, Andres Lozano P05.003 Psychiatric Comorbidities Are Frequent in Patients with Migraine, Epilepsy, and Multiple Sclerosis Andres Kanner, Alan Ettinger, Bichun Ouyang, Hilary Kanner, Sandra Hamberger, Connie Lau P05.004 The Effectiveness of the One -Item Interview “Are You Depressed?” in Multiple Sclerosis and Hereditary Spastic Paraplegia Katrin Gross-Paju, Liina Vahter, Mark Braschinsky, Sulev Haldre, Tiina Talvik P05.005 Structural Brain Differences Associated with Personality Dimitrios Kapogiannis, Angelina Sutin, Paul Costa, Susan Resnick P05.006 Laughter Induction in the NIH OCD DBS Cohort: A Potential Predictor of Therapeutic Response? Ihtsham Haq, Kelly Foote, Samuel Wu, Atchar Sudhyadhom, Wayne Goodman, Nicola Ricciutti, Dawn Bowers, Charles Jacobson, Herbert Ward, Michael Okun 82 PD5.004 Laquinimod Induces UpRegulation of BDNF in Serum of Patients with Relapsing-Remitting Multiple Sclerosis Jan Thöne, Silvia Seubert, Rebecca Conrad, Giancarlo Comi, Stefan Wiese, Liat Hayardeny, Ralf Gold, Ralf Linker PD5.006 Prolonged Reduction in Circulating Lymphocytes After Discontinuation of FTY720 (Fingolimod): Possible Relationship to Duration of Therapy Mark Keezer, Yves Lapierre, Igor Shames, David Haegert, Amit Bar-Or, Jack Antel PD5.005 Detection and Quantification of IFNB-1b-Induced NAbs Using Various Assays and Laboratories Hans Hartung, Bernd Kieseier, Douglas Goodin, Barry Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Douglas Jeffery, Ludwig Kappos, Paul O’Connor, Timon Bogumil, Volker Knappertz, Christoph Pohl, Rupert Sandbrink, Brigitte Stemper , Stephan Lehr, Joachim Reischl PD5.007 Interferon-beta Decreases Energetic Activity in CD4+-Lymphocytes: A Possible Mechanism of Action? Aiden Haghikia, Derek Pappas, Bartosz Pula, Sabrina Ruhrmann, Elahe Taherzadeh-Fard, Denis Akad, Larissa Arning, Susan Goelz, Ralf Gold, Sergio Baranzini, Andrew Chan P05.007 Traumatic Brain Injuries and Psychogenic Nonepileptic Seizures W. Curt LaFrance, Jr., Marie DeLuca P05.008 Tizanidine Improves Geriatric Depression Scale Scores in Stroke and Brain Injury Survivors with Spastic Hemiparesis: Post-Hoc Analysis from a Randomized, Double-Blind, PlaceboControlled Trial Stuart Yablon, David Simpson, Jean-Michel Gracies, Richard Barbano, Allison Brashear P05.009 Receptive Aprosodia and the Acquired Loss of Empathy Following Acute Stroke Shaan Khurshid, Argye Hillis P05.010 Metacognitive Sensitivity to Neuropsychological Impairment in Frontotemporal Degeneration and Alzheimer’s Disease Lauren Massimo, David Libon, Brianna Morgan, Ashley Boller, Peachie Moore, Murray Grossman Behavioral Neurology: Attention and Visual Functions P05.011 Line Bisection and “ Where” Perceptual-Attentional Spatial Bias: Aged Men Go Right Peii Chen, Kelly Goedert, Elizabeth Murray, Karen Kelly, Shpresa Ahmeti, Anna Barrett P05.012 Posterior Cortical Atrophy and Cholinesterase Inhibitors: Do They Help? Paul McMonagle P05.013 Superior Temporal Sulcus and Detection of Rare Events Petra Haitova, Milan Brazdil, Radek Marecek, Michal Mikl, Petr Krupa, Ivan Rektor PD5.009 Vitamin D Metabolites Are Linked to Clinical and MRI Outcomes in Multiple Sclerosis Patients Bianca Weinstock-Guttman, Robert Zivadinov, Jun Qu, Eunjin Bang, David Hojnacki, Frederick Munschauer, Niels Bergsland, Sarah Hussein, Laura Willis, Marya Cherneva, Murali Ramanathan PD5.010 Early Effects of Natalizumab on the Cognitive Functioning, Fatigue and Quality of Life of African American Patients with Multiple Sclerosis Judith Stephenson, Likun Hou, Sonalee Agarwal, Siddhesh Kamat, Krithika Rajagopalan P05.014 Drug-Induced Changes in Performance on the Divided Attention Task in Subjects with a History of Recreational Drug Use Naama LevyCooperman, Boris Danilov, Myroslava Romach, Edward Sellers P05.015 A Descriptive Study on Constructional Apraxia in Multiple Sclerosis Manuela de Stefano, Raffaella Migliaccio, Daniela Buonanno, Gioacchino Tedeschi, Ugo Nocentini, Patrizia Montella Movement Disorders: Huntington's Disease P05.021 Effect of Tetrabenazine (TBZ) on Motor Function in Patients with Huntington Disease (HD) Joseph Ferrara, Giovanni Mostile, Christine Hunter, Octavian Adam, Joseph Jankovic P05.016 The Clinical Presentation and Functional Neuroimaging Characteristics of Posterior Cortical Atrophy Po-Heng Tsai, Mario Mendez P05.022 Huntington Disease Prevalence in a Cohort from Argentina: Analysis of Normal CAG Repeats in Huntingtin Gene Among HD Patients and Control Individuals Virginia Parisi, Gabriel Persi, Viviana Varela, Jose Etcheverry, Fernando Leiguarda, Daniela Converso, Emilia Gatto P05.017 Late-Life Attention Deficit Hyperactivity Disorder (ADHD): A Neglected Condition in a Memory Clinic Ezequiel Gleichgerrcht, Teresa Torralva, Alicia Lischinsky, María Roca, Facundo Manes P05.023 Interaction of Normal and Mutant CAG Repeat Sizes and Age at Onset in a Huntington Disease Cohort from Argentina Emilia Gatto, Gabriel Persi, Virginia Parisi, Jose Etcheverry, Fernando Leiguarda, Viviana Varela P05.018 Disorders of Higher Cognitive Visual Functions in Pure Alexia Jagan Pillai, Steven Sparr P05.024 Clinical Correlates of Eye Movements in Huntington Disease Cameron Jeter, Ashley Hood, Alicia Palao, Saumil Patel, Joseph Jankovic, Anne Sereno P05.019 The Iowa Gambling Tasks and Its Relation with Fluid Intelligence María Roca, Teresa Torralva, Ezequiel Gleichgerrcht, John Duncan, Facundo Manes P05.020 Armodafinil and Modafinil Counteract the Attentional Dysfunction Associated with Sleep Deprivation: Implications for Treating Parkinson’s Dementia and Dementia with Lewy Bodies Gregory Rippon, Keith Wesnes P05.027 OFF Test for Patients Treated with Globus Pallidus Internus Deep Brain Stimulation for Huntington’s Disease Victoria Gonzalez-Martinez, Laura Cif, Brigitte Biolsi, Ana Maria Moura, Hassan El Fertit, Philippe Coubes P05.036 Long-Term Follow-Up of Immune Thrombocytopenia after Treatment of Multiple Sclerosis Patients with Alemtuzumab in CAMMS223 Edward Fox, N. A. on Behalf of the CAMMS223 Study Group P05.028 Upper Face Chorea in Huntington Disease Robert Fekete, Joseph Jankovic P05.037 Network Analysis of Transcriptional Regulation in Response to Interferon-β-1a Multiple Sclerosis Treatment Suggests a Molecular Basis for Adverse Effects Michael Hecker, Robert Goertsches, Christian Fatum, Dirk Koczan, Hans-Juergen Thiesen, Reinhard Guthke, Uwe Zettl P05.029 Impact of Caffeine Intake on Huntington’s Disease (HD) Course Cécile Duru, Clémence Simonin, Florence Richard, Pascale Hincker, Julia Salleron, Perrine Charles, Katia Youssov, Sylvie Burnouf, Jean-Philippe Azulay, Christophe Verny, Christine Tranchant, Cyril Goizet, Luc Defebvre, Bernard Sablonniíre, Monique Romon , Luc Buée, Philippe Amouyel, Olivier Godefroy, Alexandra Dürr, AnneCatherine Bachoud-lévi, David Blum, Pierre Krystkowiak P05.030 Increases of 8-Hydroxy-2Deoxyguanosine Plasma Levels in Patients with Huntington’s Disease Isaac Túnez, Inmaculada Tasset, Eduardo Agüera, Francisco Sánchez, Ricardo FernandezBolanos, Fernando Sánchez-Lopez PD5.008 Effect of Intramuscular Interferon beta-1a on Gray Matter Atrophy in Relapsing-Remitting Multiple Sclerosis Kunio Nakamura, Richard Rudick, Jar-Chi Lee, Pamela Foulds, Elizabeth Fisher P05.025 Impact of Placebo Treatment in Huntington’s Disease Esther Cubo, Miguel González, Inés Del Puerto, Olga Fernández Arconada, Justo Garcia de Yebenes P05.026 Evaluation of mGluR5 in Early Parkinson and Huntington Disease Using 18 F-FPEB PET Imaging Danna Jennings, Kenneth Marek, David Russell, Jeff Batis, Andre Koren, Olivier Barret, Gilles Tamagnan, John Seibyl Poster Session V Thursday, April 15 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P05.031 Rate of Change in Early Huntington’s Disease Patients Without Antipsychotics Christina Meyer, Bernhard Landwehrmeyer, Casten Schwenke, Adam Doble, Michael Orth, Albert Ludolph Multiple Sclerosis and Related Diseases: Drug Mechanisms II P05.032 Pharmacokinetics of Oral Teriflunomide, a Novel Oral DiseaseModifying Agent Under Investigation for the Treatment of Multiple Sclerosis Tharin Limsakun, Francoise Menguy-Vacheron P05.033 Teriflunomide Treatment Reduces Infiltration of Macrophages, T Cells and B Cells, and Increases Survival of Oligodendrocytes in the Spinal Cord of the Dark Agouti Rat Model of Experimental Allergic Encephalomyelitis Margaret Petty, Lan Lee, Xioayou Ying, Michelle Taurino, Julian Oliver, Kathleen McMonagle-Strucko, Cecilia Marta P05.034 25-OH Vitamin D3 Reduces Interferon Gamma and Interleukin-17 Release from CD4 + T-Cells Edward Knapp, Christopher Eckstein, Peter Calabresi P05.035 Continuous DownRegulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections Jörg Kraus, Katrin Oppermann, Peter Wipfler, Georg Pilz, Andrea Harrer, Shahrzad Afazel, Elisabeth Haschke-Becher, Alexander Kunz, Stefan Golaszewski, Wolfgang Staffen, Gunther Ladurner P05.038 Oral Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis: Baseline Patient Demographics and Disease Characteristics from a Two-Year Phase III Trial (FREEDOMS II) Peter Calabresi, Douglas Goodin, Douglas Jeffery, Fred Lublin, Kottil Rammohan, Anthony Reder, Timothy Vollmer, Tracy Stites, Bingbing Li, Rebecca Gottschalk, Manoj Malhotra, on Behalf of the FREEDOMS II Study Group P05.039 Serum from Interferonβ-1b Treated MS Patients Induced In Vitro Stabilization of the Blood-Brain Barrier Marcus Mueller, Achim Frese, Isabelle Nassenstein, Maike Hoppen, Martin Marziniak, E. Bernd Ringelstein, Kwang Kim, Wolf Schaebitz, Jörg Kraus P05.040 Pharmacological Changes Induced by Administration of PEGylated IFNb -1a in Healthy Volunteers Larisa Miller, Michaela Lerner, Mary Crossman, Stacy Hitchman, Gudarz Davar, Meena Subramanyam P05.041 Persistence of Neutralizing Antibodies Against Interferon Beta in Multiple Sclerosis Patients Switching to Natalizumab Malin Lundkvist, Ajith Sominanda, Jan Hillert, Anna FogdellHahn P05.042 Sustained Positive Effects of Alemtuzumab on Diverse Neurological Functions in Relapsing-Remitting Multiple Sclerosis Patients Edward Fox, N. A. on Behalf of the CAMMS223 Study Group P05.043 Plasma Exchanges in Severe and Acute Inflammatory Demyelinating Attacks of the Central Nervous System Sandrine Brunot, Sandra Vukusic, Agnís Fromont, Grégory Couvreur, Christiane Mousson, Maurice Giroud, Christian Confavreux, Thibault Moreau P05.044 Vitamin D and Cognitive Impairment in Multiple Sclerosis (MS) Sarah Morrow, Murali Ramanathan, Ralph Benedict, Jun Qu, Xiaotao Duan, Barbara Teter, David Hojnacki, Robert Zivadinov, Bianca Weinstock-Guttman P05.045 Effects of Pro-Inflammatory Cytokines on Cannabinoid CB1 and CB2 Receptors in Immune Cells of Normal Subjects and Patients with Multiple Sclerosis Lucie Jean-Gilles, Angela Fahey, Manjit Braitch, Laura Edwards, R. Adrian Robins, Louise Showe, M. Liaque Latif, Steve Alexander, Victoria Chapman, Dave Kendall, Cris Constantinescu P05.046 Morphea in a Multiple Sclerosis Patient Treated with Natalizumab Katayoun Alikhani, Marcelo Kremenchutzky P05.047 The Kinetics of CSF Lymphocyte Recovery after Cessation of Natalizumab in Patients with Multiple Sclerosis Adil Javed, Howard Rossman, Anthony Reder P05.048 Expanded Laboratory Surveillance for PML in a Large Cohort of Patients on Natalizumab for Multiple Sclerosis Lilyana Amezcua, Regina Berkovich, Margaret Burnett, Jose Aparicio, Norman Kachuck P05.049 Glatiramer Acetate Reduces Th17 Inflammation and Induces Regulatory T-Cells in the CNS of Mice with Relapsing-Remitting and Chronic Experimental Autoimmune Encephalomyelitis Rina Aharoni, Raya Eilam, Ariel Stock, Anya Vainshtein, Elias Shezen, Ruth Arnon P05.050 Amelanotic Lentigo Maligna Melanoma Associated with Long-Term Natalizumab Treatment for Multiple Sclerosis Jonathan Carter, Suzanne Connolly P05.051 Rapid Onset of Natalizumab Effect Regardless of Baseline Disease Activity in Multiple Sclerosis Ludwig Kappos, Richard Rudick, Chris Polman, Paul O’Connor, Patrick Vermersch, Heinz Wiendl, Amy Pace, Daniel Desgrandchamps, Christophe Hotermans P05.052 BAF312, a Selective S1P1/ S1P5 Receptor Modulator, Effectively Reduces Absolute Lymphocyte Counts in Human Volunteers and Demonstrates the Relevance of S1P1 in Mediating a Transient Heart Rate Reduction Erik Wallström, Peter Gergely, Barbara Nuesslein-Hildesheim, Frédéric Zécri, Nigel Cooke, Christian Bruns, Olivier Luttringer, Tobias Sing, Andrea Groenewegen, Mitchell Rosenberg, Marc Saltzman P05.053 The Immunoregulatory Properties of Laquinimod on Human B Cells Shahar Nussbaum, Ayelet Snir, Liat Hayardeny, Doron Melamed, Ariel Miller, Elias Toubi P05.054 IFNB-1b Therapy Reduces vs. Glatiramer Acetate the Evolution of Permanent T1 Hypointensities (“Black Holes”) on Brain MRI in Treatment-Naïve RRMS Patients Massimo Filippi, Mara Rocca, Fabiano Camesasca, Stuart Cook, Giancarlo Comi, Douglas Goodin, Paul O’Connor, Douglas Jeffery, Hans-Peter Hartung, Barry Arnason, Ludwig Kappos, Jerry Wolinsky, Volker Knappertz, Christoph Pohl, Karola Beckmann , Catherine Brown, Douglas Arnold, Gary Cutter, Rupert Sandbrink, Timon Bogumil P05.055 Course of Multiple Sclerosis Associated Fatigue during Treatment with Glatiramer Acetate Maren Nowack, Dagmar Rinas, Volker Limmroth, Barbara Tettenborn, Norman Putzki P05.056 Time Dependent Ex Vivo RNA Expression Analysis of Monocytes Derived from Glatiramer Acetate Treated Multiple Sclerosis Patients Robert Goertsches, Michael Hecker, Madhan Thamilarasan, Dirk Koczan, Hans-Juergen Thiesen, Uwe Zettl P05.057 The Influence of Plasma Exchange Treatment on Cellular Immunity in Multiple Sclerosis Relapses Refractory to Steroid Therapy Mariusz Stasiolek, Alexandra Schroeder, Chris Meyer, De Hyung Lee, Ralf Gold, Ralf Linker P05.058 Oral Administration of the Small Molecule Lipoic Acid Leads to Elevation in cAMP Levels in Multiple Sclerosis Sonemany Salinthone, Vijayshree Yadav, Dennis Bourdette, Daniel Carr P05.059 Association of Th1/ Th2-Related Chemokine Receptors in Peripheral T Cells with Disease Activity and Immunomodulatory Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica Yuko Shimizu, Kohei Ota, Sachiko Kubo, Masaki Kobayashi, Shinichiro Uchiyama P05.060 Low-Contrast Letter Acuity Detects Visual Function Improvement in Phase III Relapsing MS Trials of Natalizumab Laura Balcer, Steven Galetta, Chris Polman, Richard Rudick, Fredrick Munschauer, Eric Eggenberger, Peter Calabresi, Annie Zhang, Richard Kim P05.061 Long -Term Treatment of Multiple Sclerosis with Glatiramer Acetate: Natural History of the Subtypes of Anti-Glatiramer Acetate Antibodies and Their Correlation with Clinical Efficacy Talma Brenner, Dvora Teitelbaum, Camille Sicsic, Dimitrios Karussis P05.062 A Treatment for LipoatrophyInduced Injection with Subcutaneous Glatiramer Acetate Christine Lebrun Frenay, Lydiane Mondot, Marc Bertagna, Pierre Thomas, Mikael Cohen Multiple Sclerosis and Related Diseases: Ocular Coherence Tomography P05.063 Ocular Coherence Tomography in a Three-Year-Old with Neuromyelitis Optica Christopher Eckstein, Stephanie Syc, Christina Warner, Peter Calabresi P05.064 Retinal Nerve Fibre Layer Thickness Is Associated with Cognitive Performance in Youth with Multiple Sclerosis Constantina Lafoyiannis, Christine Till, Mary Desrocher, R. Buncic, Brenda Banwell P05.065 Optical Coherence Tomography as a Clinical Trial Outcome Measure: Implications of Treating On-Study Relapses with Intravenous Methylprednisolone Robert Bermel, Peter Imrey, Jeffrey Cohen 83 Poster Session V P05.066 Improving Optical Coherence Tomography Sensitivity and Specificity in Multiple Sclerosis by Analysis of Retinal Nerve Fiber Layer Shape Alexander Brandt, Markus Bock, Sebastian Bischoff, Sebastian Mansow-Model, Friedemann Paul P05.067 Maximizing the Reliability of Serial Stratus OCT Testing in Multiple Sclerosis Patients Mark Morrow P05.068 Retinal Nerve Fiber Layer Thickness Correlates with Gray and White Matter Volume in MS John Ratchford, Sheena Farrell, Navid Shiee, Christina Warner, Stephanie Syc, Scott Newsome, Daniel Harrison, Elliot Frohman, Laura Balcer, Dzung Pham, Daniel Reich, Peter Calabresi P05.069 Visual Function in Neuromyelitis Optica: From Retina to Optic Tracts Jerome de Seze, Marie Bouyon, Jeremy Jeantroux, Nicolas Collongues, Frederic Blanc, Marie Fleury, Laurent Ballonzoli, Claude Speeg, Stephane Kremer P05.070 Trend Towards Lowering of Multiple Sclerosis Severity Scores Among More Recent Enrollees Into the New York State Multiple Sclerosis Consortium Joseph Herbert, Eric Chamot, Joshua Bacon, Brian Apatoff, Karen Blitz, Patricia Coyle, Andrew Goodman, Malcolm Gottesman, Keith Edwards, Alfred Frontera, Richard Holub, Burk Jubelt, Mustafa Khan, Lauren Krupp, Michael Lenihan , Fred Lublin, Cornelia Mihai, Aaron Miller, Frederick Munschauer, Allan Perel, David Snyder, Barbara Teter, Mark Tullman, Bianca Weinstock-Guttman, Robert Zivadinov, Ilya Kister P05.071 Comparability of Randomized Controlled Versus Observational Studies: Findings from the Toronto Observational Study of Natalizumab in Multiple Sclerosis Kristen Krysko, Paul O’Connor P05.072 Demographic and Clinical Characteristics of Patients Treated with Natalizumab in Post-Marketing Setting. A Prospective Multicenter Observational Study of 1000 Patients Laure Dagrassa, Patrick Vermersch, Jerome De seze, Bruno Brochet, Lucien Rumbach, Christine Lebrun, Marc Debouverie, David Laplaud, Philippe Cabre, Christian Confavreux, Jean Pelletier, Gilles Defer, William Camu, Ayman Tourbah, Pierre Labauge , Pierre Clavelou, Olivier Casez, Patrick Hautecoeur, Caroline Papeix, Gilles Edan, Didier Ferriby, Roland Liblau, Michel Clanet, David Brassat Multiple Sclerosis and Related Diseases: Human Basic Research P05.073 Circulating Perforin+CD8+ and T-Bet+CD8+ Lymphocytes in Relapsing Remitting, Secondary Progressive and Primary Progressive Multiple Sclerosis Patients Giovanni Frisullo, Viviana Nociti, Raffaele Iorio, Domenico Plantone, Agata Katia Patanella, Pietro Tonali, Anna Paola Batocchi 84 P05.074 Response of Human Oligodendrocyte Progenitors to Growth Factors and Axon Signals Qiao Ling Cui, Gabriella Fragoso, Veronique Miron, Guillermina Almazan, Jack Antel P05.075 Mesenchymal Stem Cell Therapy as a Control of Pro-Inflammatory Th1 and Th17 Responses in Multiple Sclerosis Peter Darlington, Marie-Noelle Boivin, Christel Renoux, Jeffrey Cohen, Luis Solchaga, Amit Bar-Or P05.076 Intrathecal Anti-MOG Antibody Production Is Elevated in Multiple Sclerosis Eric Klawiter, Laura Piccio, Jeri-Anne Lyons, Kevin O’Connor, Anne Cross P05.077 Bio Assays for the Investigation of Sub Lethal Neurobiological Injury in Multiple Sclerosis Gregoire Morisse, Sandeep Vanamala, Isabel Rambaldi, Sathyanath Rajasekharan, Amit Bar-Or P05.078 IL-11 Producing Cells Are a New T-Cell Subset That Promotes Th17Differentiation in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Xin Zhang, Yazhong Tao, Jianping Jin, Yunan Tang, Silva MarkovicPlese P05.079 Immune-Mediate Changes to the Astrocyte Cytoskeleton as Seen in Multiple Sclerosis Peter Darlington, Jack Antel, Amit Bar-Or Aging and Dementia: Risk Factors P05.080 Cerebral Atrophy Is Correlated with White Matter Hyperintensity, but Not with Brain Microbleeds Yusuke Yakushiji, Megumi Hara, Yusuke Nanri, Makoto Eriguchi, Tomoyuki Noguchi, Masashi Nishihara, Masanori Nishiyama, Hideo Hara P05.081 Cerebrovascular Risk Factors Influence Age-Related Memory Decline in APOE E4 Carriers Richard Caselli, Amylou Dueck, Dona Locke, Marwan Sabbagh, Geoffrey Ahern, Steven Rapcsak, Leslie Baxter, Roy Yaari, Bryan Woodruff, Charlene Snyder, Scott Findley, Eric Reiman P05.082 Hemodynamic Correlates of Vascular Risk Factors in Patients with Alzheimer’s Disease Takashi Yamazaki, Daiki Takano, Ken Nagata P05.083 Cerebrovascular Reactivity in Patients with Alzheimer’s Disease: Correlation with Cognition and White Matter Lesions Yong Soo Shim, A-Hyun Cho, Dong Suk Shim, Dong-Won Yang P05.084 Association of Vascular Risk Factors and White Matter Hyperintensities with Regional Cerebral Atrophy in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Cohort Lindsay Horton, Kyle Womack, Ramon Diaz-Arrastia Thursday, April 15 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P05.085 Clinical Correlating Factors and Cognitive Function in CommunityDwelling Healthy Subjects with Cerebral Microbleeds (MBs) Yuki Takashima, Takahiro Mori, Manabu Hashimoto, Akira Uchino, Takefumi Yuzuriha, Hiroshi Yao P05.086 Language and Behavior Domains Enhance the Value of the Clinical Dementia Rating Scale David Knopman, Sandra Weintraub, V. Pankratz P05.087 NCAT: A Visual-Based Cognitive Assessment Tool for Use in a Multiracial Multilingual Population Nagaendran Kandiah, Lynn Wiryasaputra, Esther Chua P05.088 Utility of an Abbreviated Version of the Executive and Social Cognition Battery in the Detection of Executive Deficits in Early Behavioral Variant Frontotemporal Dementia Patients Ezequiel Gleichgerrcht, Teresa Torralva, María Roca, Facundo Manes P05.089 Cardiorespiratory Fitness Is Associated with Brain Atrophy in Early Alzheimer Disease Robyn Honea, Eric Vidoni, Heather Anderson, William Brooks, Russell Swerdlow, Jeffrey Burns Aging and Dementia: Lewy Body Disorders P05.090 Does REM Sleep Behavior Disorder Improve the Diagnostic Accuracy of Dementia with Lewy Bodies? Validation with an Autopsy Sample Tanis Ferman, Bradley Boeve, Ryan Uitti, Zbigniew Wszolek, Jay Van Gerpen, Neill GraffRadford, V. Shane Pankratz, Ronald Petersen, David Knopman, Joseph Parisi, Dennis Dickson, Glenn Smith P05.091 Probable REM Sleep Behavior Disorder Is Associated with Decreased Olfaction in Cognitively Normal Subjects: The Mayo Clinic Study of Aging Brendon Boot, Bradley Boeve, Rosebud Roberts, Yonas Geda, David Knopman, Eric Tangalos, Glenn Smith, Robert Ivnik, Vernon Pankratz, Teresa Christianson, Michael Silber, Tanis Ferman, Ronald Petersen P05.092 Validation of the Mayo Fluctuations Scale in an Autopsy Confirmed Sample of DLB, AD and Normal Controls Winnie Pao, Tanis Ferman, Bradley Boeve, Glenn Smith, Dennis Dickson, Joseph Paris, Ryan Uitti, Jay Van Gerpen, Zbigniew Wszolek, Neill GraffRadford, David Knopman, Ronald Petersen P05.093 Risk of One Year Decline in Functional Activities in Dementia with Lewy Bodies and Alzheimer Disease Dawn Gill, Thomas Koepsell, Rebecca Hubbard, Walter Kukull P05.094 The Evaluation of Alzheimer’s Disease (AD) and Lewy Body Disease (LBD) Using Clinical and Semiquantitative MRI Measures Miriam Rodriguez, Elizabeth Potter, Qian Shen, Warren Barker, Maria Grieg-Custo, Joscelyn Agron, David Loewenstein, Ranjan Duara P05.095 Visual Hallucinations, Visuospatial Dysfunction and Brain SPECT Perfusion in Dementia with Lewy Bodies Michael Misch, Elizabeth Hollingdrake, Sandra Black, Mario Masellis P05.096 Screening for REM Sleep Behavior Disorder in the CommunityDwelling Elderly: Validation of the Mayo Sleep Questionnaire in the Mayo Clinic Study of Aging Bradley Boeve, Jennifer Molano, Tanis Ferman, Glenn Smith, Kevin Bieniek, Maja Tippmann-Peikert, David Knopman, V. Shane Pankratz, Yonas Geda, Rosebud Roberts, Eric Tangalos, Michael Silber, Ronald Petersen P05.097 Sensitivity of the Clock Drawing Test in Parkinson’s Disease Patients with Mild Cognitive Impairment Evelyne Matteau, Martine Simard, Melanie Langlois, Nicolas Dupre P05.098 Excessive Daytime Somnolence Is Objectively Demonstrated in Early Dementia with Lewy Bodies but Is Not a Feature of Early Alzheimer’s Disease Bradley Boeve, Tanis Ferman, Michael Silber, Siong-Chi Lin, Glenn Smith, Ryan Uitti, Jay Van Gerpen, Zbigniew Wszolek, Neill Graff-Radford, David Knopman, Ronald Petersen P05.099 Probable REM Sleep Behavior Disorder in Cognitively Normal Elderly Subjects and Risk of Cognitive Impairment and/or Parkinsonism: The Mayo Clinic Study of Aging Brendon Boot, Bradley Boeve, Teresa Christianson, Rosebud Roberts, Yonas Geda, David Knopman, Eric Tangalos, Robert Ivnik, Vernon Pankratz, Michael Silber, Tanis Ferman, Ronald Petersen Aging and Dementia: Basic Science P05.100 Phytic Acid as a Potential Therapy for Alzheimer’s Disease Thimmappa Anekonda, Teri Wadsworth, Randy Woltjer, Christopher Harris, Babett Petriko, Joseph Quinn P05.101 Alzheimer’s Impairs Responses to Speed Changes in Simulated Self-Movement: A Visual Motion Evoked Potentials Study Roberto Fernandez, Charles Duffy P05.102 Differential Activation of Tumor Necrosis Factor Receptors Distinguishes Between Brains From Alzheimer’s Disease and Non-Demented Patients Xin Cheng, Libang Yang, Ping He, Rena Li, Yong Shen P05.103 Aging-Related DownRegulation of Dynein Causes Accumulation of α-Synuclein Zeng-lin Cai, Ji-jun Shi, Ya-ping Yang, Wei-dong Hu, Chun-feng Liu P05.104 Production and Characterization of High Affinity Rabbit Monoclonal Antibodies to Amyloid β 40 (Aβ40) and Amyloid β 42 (Aβ42) Peptides Pankaj Mehta, Marc Barshatzky, Anna Potempska, Bruce Patrick, Sangita Mehta, David Miller Poster Session V Thursday, April 15 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P05.105 Prolonged Disease Duration Is Associated with Lower Neuritic Amyloid Plaque Burden in Alzheimer’s Disease Gregory Jicha, Peter Nelson, Erin Abner, Marta Mendiondo, Frederick Schmitt, William Markesbery, Richard Kryscio P05.106 Intracerebroventricular Injection of Tumor Necrosis Factor-α Monoclonal Antibody (Infliximab) Reduces Cerebral Amyloid Plaques and Neurofibrillary Tangles Rapidly in Aged APP/PS1 Double Transgenic Mice Jun Xu, Jianquan Shi, Wei Shen, Yingdong Zhang, Jun Chen, Haiqing Zhu, Qiaoquan Zhang, Yao Chen, Lingling Zhong, Yong Chen, Yinwei Zhu P05.107 Dimensions of AD Neuropathology: Differential Relationships with Age and ApoE Dan Mungas, Rochelle Tractenberg, Paul Crane, Julie Schneider, David Bennett P05.116 Peripheral Nerve Inflammation and Muscle Denervation in mSOD1 Transgenic Mice: Which Comes First? Osamu Kano, David Beers, Jenny Henkel, Weihua Zhao, Bing Liao, Stanley Appel P05.117 Purification of Motor Neurons Derived from Embryonic Stem Cells Cultures Stephanie Milazi, Andrea Price, Benjamin Brooks, Jean-Luc Mougeot P05.118 Treatment with a Soluble Activin Receptor Type IlB Attenuates Loss of Lean Tissue and Grip Strength in SODG93A Mice Niels Borgstein, Jennifer Lachey, Vicki Wong, Jeffrey Ucran, Jas Seehra Muscle Disease/Neuromuscular Junction: Myopathy: Basic Science P05.108 Splicing Isoforms of SORCS1 and APP Processing Shinya Tokuhiro, Peter St George-Hyslop, Ekaterina Rogaeva P05.119 Killing Two Birds with One Botox Dose: The Anti-Inflammatory Effects of C. botulinum Toxin Type A Andrew Gomez-Vargas, Dinesh Kumbhare P05.109 Deficits in Covert Orienting of Visual Attention in Alzheimer’s Disease: Relationship to HMPAO SPECT Measures of Cortical Hypoperfusion Brandon Vasquez, Brian Buck, Sandra Black, Farrell Leibovitch, Nancy Lobaugh, Curtis Caldwell, Marlene Behrmann P05.120 Expression of Heat Shock Proteins in Skeletal Muscle From Idiopathic Inflammatory Myopathy and Duchenne Muscular Dystrophy Patients Jan De Bleecker, Kim Creus, Jean-Jacques Martin, Joachim Weis, Boel De Paepe Anterior Horn: Basic Science P05.121 The Dysferlin Interactome Bilal Azakir, Sabrina Di Fulvio, Christian Therrien, Michael Sinnreich P05.110 Alteration of snRNAs in Amyotrophic Lateral Sclerosis Tomohiko Ishihara, Atsushi Shiga, Akiyoshi Kakita, Akio Yokoseki, Masatoyo Nishizawa, Hitoshi Takahashi, Osamu Onodera P05.111 CD4 +CD25 + Regulatory T-Cells Suppress Microglial Activation in a Mouse Model of ALS Weihua Zhao, David Beers, Jenny Henkel, Bing Liao, Stanley Appel P05.112 Growth Inhibitory Factor Inhibits the Progression of Amyotrophic Lateral Sclerosis Model Mice Kazunori Hashimoto, Yuichi Hayashi, Takashi Inuzuka, Isao Hozumi P05.113 Familial ALS-Linked Mutant SOD1 Impairs a Network of RNA-Binding Proteins That Regulate VEGF and Other Cell Survival Factors Liang Lu, Lei Zheng, Shin Oh, Peter King P05.114 Oxidative Stress as Target for Neuroprotection in Experimental Models of Amyotrophic Lateral Sclerosis (ALS) Aikaterini Nanou, Adrian Higginbottom, Chiara Valori, Matthew Wyles, Ke Ning, Pamela Shaw, Mimoun Azzouz P05.115 Effects of Cholesterol β-D-Glucoside (CβG) on Respiration and Reactive Oxygen Species (ROS) Generation in Rat Brain Mitochondria Alexander Panov, Jeremy Presson, Nataliya Kubalik, Benjamin Brooks, Christopher Shaw P05.122 Increased Transcript of the Non-Coding β-Site of Amyloid-β Precursor Protein Cleaving Enzyme (BACE1-Antisense) and BACE1-mRNA in Sporadic Inclusion Body Myositis (s-IBM) Muscle Fibers and in an IBM Model Anna Nogalska, W. King Engel, Valerie Askanas P05.123 Experimentally Induced Endoplasmic Reticulum Stress (ERS) Decreases VMA21 and Impairs the Autophagosomal-Lysosomal-System (A-L-S) in Cultured Human Muscle Fibers (CHMFs): Relevance to Sporadic Inclusion Body Myositis (s-IBM) Anna Nogalska, Carla D’Agostino, W. King Engel, Valerie Askanas P05.124 Altered Pre-mRNA Processing Is a Common Feature of Muscle Cells in Senescence and Myotonic Dystrophy Type 2 (DM2) Giovanni Meola, Manuela Malatesta, Federica Perdoni, Rosanna Cardani, Enrico Bugiardini, Marzia Giagnacovo, Carlo Pellicciari P05.125 Treatment of CoQ10 Deficiency Fibroblasts with Ubiquinone Analogs and Vitamin C: Time Dependent Effect on Bioenergetic and Oxidative Stress Status Luis López, Catarina Quinzii Hirano, Estela Area, Ali Naini, Shamina Rahaman, Markus Schuelke, Leonardo Salviati, Salvatore Di Mauro, Michio Hirano P05.126 ROS Production, Oxidative Stress, and Cell Death Correlate with the Level of CoQ10 in Fibroblast Models of CoQ10 Deficiency Catarina Quinzii, Luis Lopez, Robert Gilkerson, Beatriz Dorado, Jorida Coku, Ali Naini, Clotilde LagierTourenne, Meriem Tazir, Markus Sckuelke, Rosalba Carrozzo, Filippo Santorelli, Shamina Rahman, Leonardo Salviati, Michel Koenig, Salvatore Di Mauro , Michio Hirano P05.127 Clinical and Laboratory Features in a Family with an ANT1 (SLC25A4) Gene Mutation: Effects on Monomeric OXPHOS Enzyme Assembly and Supercomplex Formation Lauren Hyams, Genevieve Langley, Lauren Mylacraine, John Shoffner P05.128 SURF1 Mutation: Effects on Supercomplex Formation and Monomeric Enzyme Assembly Lauren Mylacraine, Genevieve Langley, Lauren Hyams, John Shoffner P05.129 Complex V (ATP Synthase) Mutations: Diverse Effects on Supercomplex Formation and Oxidative Phosphorylation Function Lauren Mylacraine, Genevieve Langley, Lauren Hyams, John Shoffner P05.130 Effects of a Novel Complex III (Cytochrome b Subunit) Mutation on Supercomplex Formation in a Patient with Mitochondrial Myopathy Genevieve Langley, Lauren Mylacraine, Lauren Hyams, John Shoffner P05.131 Quantitative Oxidative Phosphorylation Enzyme Subunit Western Blot: Role of Testing in a Multifaceted Approach for Diagnosis of Mitochondrial Disease Genevieve Langley, Lauren Mylacraine, Lauren Hyams, John Shoffner Child Neurology/Developmental Neurobiology: Basic Science/ Neuroimmunology P05.132 Neuronal Voltage-Gated Potassium Channel Autoimmunity in Children Radhika Dhamija, Deborah Renaud, Sean Pittock, Andrew McKeon, Elaine Wirrell, Nancy Kuntz, Vanda Lennon P05.133 Reduced GLE1 Protein Levels Cause Axonal Growth Defects in Zebrafish Motor Neurons Adil Seytanoglu, Chiara Valori, Tennore Ramesh, Basil Sharrack, Mimoun Azzouz P05.134 Autoimmune Limbic Encephalitis in a Paediatric Patient Blathnaid Mc Coy, Tomoyuki Akiyama, Elysa Widjaja, Cristina Go P05.135 Transient Mutism in Para Infectious Encephalopathy Johan Berghuis, Aad Verrips P05.136 Severe Central and Peripheral Neuro-Lupus: Role of CSF B Cells and Chemokines Brajesh Agrawal, Jane Taylor, Hossam AbdelSalam, Zeng Wang, Gurpreet Mandar, Michael Pranzatelli P05.137 Increased Susceptibility of the Glut-1 Knockout Mouse to Postnatal Hypoxia Michael Rotstein, Paivi Ullner, Hong Yang, Vadim Ten, Darryl De Vivo P05.138 Menstrual Migraine in Adolescents Ashley Nemes, A. David Rothner P05.139 Do Children Learn New Motor Skills Differently From Adults? Toni Pearson, Christine Kim, John Krakauer, Pietro Mazzoni Neural Repair and Rehabilitation: Basic Science, Therapeutics, and Outcomes Measures P05.140 Lithium Promotes Survival and Proliferation of Transplanted NestinExpressing Cells Isolated From Neonatal Blood In Vitro and Vivo Tsutomu Iseda, Masayuki Hashimoto, Dongming Sun, Yasuhiro Maeda, Wise Young P05.141 Effect of Mesenchymal Stem Cell-Derived Neural Progenitors on Demyelination and Immune Cell Infiltration in Mice with Experimental Autoimmune Encephalomyelitis Sadia Sahabi, Qijiang Yan, Violaine Harris, Xin-he Liu, Tamara Vyshkina, Saud Sadiq P05.142 Postconcussion Syndrome after Blast Injuries in OEF and OIF Veterans Mario Mendez, Deidre O’Neill, Eliot Licht, Dominique Peppers P05.143 HIF-1α-Mediated Neuroprotection on MPP+-Induced Apoptosis in SH-SY5Y Cells Tianhong Pan, Yuncheng Wu, Wenjie Xie, Weidong Le, Joseph Jankovic P05.144 Efficacy of Dietary Agmatine Sulfate in Herniated Lumbar DiscAssociated Radiculopathy. A Randomized, Double-Blind, Placebo-Controlled Study Gad Gilad, Ory Keynan, Yigal Mirovsky, Samuel Dekel, Varda Gilad P05.145 Is Confrontation Testing Adequate To Detect Visual Field Defects? Iszet Bustillo, Seema Khurana, Jose Romano P05.146 Arbaclofen Placarbil Is Efficacious and Safe in a Study of the Treatment of Spasticity Due to Spinal Cord Injury F. Jacob Huff, Patricia Nance, Alberto Martinez-Arizala, Ziyad Ayyoub, Dan Chen, Sheryl Baldwin, Amy Bian, David Stamler Cerebrovascular Disease: Basic Science P05.147 High Triglyceride in Leukoaraiosis-Free Small Vessel Occlusive Stroke Yu-Ri Jeong, Jong-Moo Park, Byung-Kun Kim, Jaseong Koo, JungJu Lee, Ohyun Kwon P05.148 The Role of Akt/Protein Kinase B and P38-alpha in Retinal Ischemic Post-Conditioning Ajay Sampat, John Dreixler, Afzhal Shaikh, Marcus Marcet, Steven Roth 85 Poster Session V P05.149 Are Levels of the Neuromodulator Adenosine Depressed During Hyperoxia? Tobias Kulik, German Echeverry, Richard Winn P05.150 Increased TGF-β Signaling Underlies the Pathogenesis of Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL) Hiroaki Nozaki, Atushi Shiga, Hirotoshi Kawata, Kunimasa Arima, Kenju Hara, Toshio Fukutake, Akio Yokoseki, Akihide Koyama, Toshiaki Takahashi, Mari Ikeda, Akira Tanaka, Imaharu Nakano, Shu-ichi Ikeda, Tadashi Yamamoto, Takeshi Ikeuchi , Masatoyo Nishizawa, Shoji Tsuji, Osamu Onodera P05.151 Serum Levels of Chemokine CCL2 in Patients with Intracerebral Hemorrhage Jacek Losy, Jaroslaw Zaremba, Alicja Kalinowska P05.152 Tissue Plasminogen Activator Gene Expression in Ischemic Stroke Glen Jickling, Bradley Ander, Xinhua Zhan, Paul Lapchak, Frank Sharp P05.153 Circulating Levels of ProInflammatory Cytokines After Acute Ischemic Stroke as Markers of Stroke Severity Neeraja Yerragondu, Minal Jain, Anunaya Jain, Dipti Agarwal, Balavani Palamari, Veena Manivannan, Babak Jahromi, Wyatt Decker, Latha Stead P05.154 Serum Il-6 as a Marker of Functional Outcome after Acute Ischemic Stroke Anunaya Jain, Minal Jain, Neeraja Yerragondu, Dipti Agarwal, Balavani Palamari, Veena Manivannan, Babak Jahromi, Wyatt Decker, Latha Stead Cerebrovascular Disease: Acute Stroke Therapy P05.155 Intravenous Fibrinolysis 3 to 4.5 Hours After Acute Ischemic Stroke Onset: A Single Institution Experience Yazan Alderazi, Julian Yang, Mohamed Teleb, Jason Chang, Alwala Awad, James Frey, Lucas Restrepo P05.156 Successful Intra-Arterial Altepase (IA t-PA) Intervention in Two Pediatric Patients Matthew Smith, Paola Pergami, Margaret Jaynes, Jeffrey Carpenter, Ansaar Rai P05.157 Using IV TPA To Treat 106 Patients with or without IA Interventions in 104 Weeks, the Outcome and Mortality Analysis at Discharge David Wang, Arun Talkad, Maureen Mathews, Jan Jahnel, Judi Beck, Clayton McNeil, Bradley Gleason, Huaguan Zheng P05.158 Selection of Antiplatelet at Discharge after Aspirin and Clopidogrel Loading for Acute Ischemic Stroke Gayle Pletsch, Lester Leung, Joe Tarsia, Karen Albright, Sheryl Martin-Schild P05.159 Outcomes Differences by Mechanism in Stroke Treated with IV tPA: An Unrecognized Pattern? Julian Yang, Yazan Alderazi, Jason Chang, Mohamed Teleb, Gunjan Parikh, Al Wala Awad, James Frey, Lucas Restrepo 86 Thursday, April 15 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P05.160 Evaluation of Optimal Blood Pressure Level in Acute Lacunar Stroke Patients Using Ambulatory Blood Pressure Monitoring Yasumasa Yamamoto, Tomoyuki Ohara P05.170 Dravet Syndrome and Deep Brain Stimulation: Seizure Control After 10 Years of Treatment Danielle Andrade, Clement Hamani, Andres Lozano, Richard Wennberg P05.161 Acute Ischemic Stroke Caused by an Acute Internal Carotid Artery Occlusion: Factors Predicting Better Clinical Outcome in Patients Undergoing Emergent Carotid Endarterectomy Roman Herzig, David Skoloudik, Michal Kral, Daniel Sanak, Martin Roubec, Ondrej Skoda, Petr Bachleda, Petr Utikal, Petr Havranek, Toman Hrbac, Milan Fucik, Jana Zapletalova, Tomas Veverka, Andrea Bartkova, Jan Mares, Petr Hlustik, Michal Bar, Petr Kanovsky P05.171 A Clinical Trial of Adjunct Carvedilol-CR as a P-Glycoprotein (P-Gp) Inhibitor for Medically Intractible Epilepsy Derek Chong, Emily Cohen, Frank Gilliam P05.162 A Pivotal Study Evaluating the Ischemic Stroke System (ISS*) for Treatment of Acute Ischemic Stroke up to 24 Hours from Stroke Onset Thomas Devlin P05.163 Oxygen Use for Suspected Acute Ischemic Stroke in Pre-Hospital and Emergency Department Settings Yu-Feng Chan, Lynne Richardson, Maya Katz, Ari Moskowitz, Aneesh Singhal, Kevin Chason, Tavis Allison, Daniel Lakoff, Annie Yang, Steven Levine P05.164 Erythropoietin May Have Neuroprotective Role in Ischemic Stroke Patients with Advanced Renal Disease Vahid Tohidi, Bahareh Hassanzadeh, Mohammad Moussavi, Charles Porbeni, Spozhmy Panazi, Martin Gizzi, Jawad Kirmani Epilepsy: Refractory Epilepsy Therapy P05.165 Outcome of Surgery for Temporal Lobe Epilepsy Evaluated with Non-Invasive Protocol Sita Sattaluri, Manas Panigrahi, Pushpalatha Sudhakar, Sundaram Challa, Sailaja Sarva, Shanmukhi Somayajula P05.166 Survival Analyses between Surgical and Clinical Treatments for Refractory MTLE: A Prospective Study with Five Years of Follow-Up Clarissa Yasuda, Marcia Morita, TΓnia Cardoso, Alberto Costa, Carlos Guerreiro, Marilisa Guerreiro, Helder Tedeschi, Evandro Oliveira, Fernando Cendes P05.167 Preference-Based Quality of Life Measures for Neocortical Epilepsy Surgery Health Outcomes Jitesh Kar, Frank Gilliam, Nita Limdi, Meredith Kilgore, Robert Knowlton P05.168 Timing of Surgical Resection of Cavernous Malformation and Seizure Outcome Steve Chung, Kris Smith P05.169 Seizure Response to Vagus Nerve Stimulation: Three-Year Follow-Up and Effects of Syndromic Classification Thaddeus Walczak, Edward Walczak, James White, Jeanne Beattie, Lizbeth DePadua, Ilo Leppik P05.172 Lacosamide in Refractory Status Epilepticus: A Report of Four Patients Luis Mayor- Romero, Mohamad Koubeissi P05.173 Biopsy-Proven Rasmussen’s Encephalitis: Seizure Suppression and Partial Reversal of Deficits with Antiepileptic Medications and Tacrolimus Carmel Armon, Sivakumar Natanasabapathy, Dennis Oh, Luis Moral, Barbara Greco, William House P05.174 The Approach of the Harvard Epilepsy Botanical Program to the Study of Herbal Therapies for Epilepsy Dana Ekstein, H. White, James Stables, Steven Schachter Epilepsy Therapy: Antiepileptic Drugs P05.175 Retention Rate MetaAnalysis and Computational Modeling Results of Second Generation Antiepileptic Drugs in Epilepsy Patients with Partial Onset Seizures Gregory Holmes, Joyce Cramer, Josemir Sander, Nancy Zhang, D. Russell Wada, Frank Wiegand P05.176 Clinical Experience with Generic Levetiracetam in a Tertiary Care Epilepsy Clinic Siresha Chaluvadi, Larry Tran, Corey Goldsmith, David Friedman P05.177 Rapid Titration of Lacosamide with Simultaneous Reduction in Concomitant AEDs Is Well-Tolerated and Effective in Reducing Seizures in Patients with Drug-Resistant PartialOnset Epilepsy Alison Griffiths, Gregory Krauss, Ashela Bean, Stephanie Swords, Amanda Cole P05.178 A Multicenter, Open-Label Trial To Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Maintenance as Adjunctive Therapy in Subjects with Partial-Onset Seizures: An Interim Report Nathan Fountain, Gregory Krauss, Jouko Isojarvi, Deanne Dilley, Pamela Doty, G. David Rudd P05.179 Long-Term Efficacy of Lacosamide for Partial-Onset Seizures: An Interim Evaluation of Completer Cohorts Exposed to Lacosamide for up to 36 Months Elinor Ben-Menachem, Jacqueline French, Jouko Isojarvi, David Hebert, Pamela Doty P05.180 Outcome of Infants with Prenatal Exposure to Lacosamide During the Clinical Development Program Jouko Isojarvi, Christina Williams, Pamela Doty P05.181 Long-Term Safety and Tolerability of Lacosamide for PartialOnset Seizures: An Interim Evaluation of Patients Exposed to Lacosamide in Double-Blind and Open-Label Trials William Rosenfeld, Felix Rosenow, Jouko Isojarvi, David Hebert, Pamela Doty P05.192 Retigabine 600, 900, or 1200 mg/Day as Adjunctive Therapy in Adult Patients with Refractory Epilepsy with Partial-Onset Seizures Robert Leroy, Jacqueline French, Antonio Gil-Nagel, Susan Hall, Kevan VanLandingham P05.182 Pharmacokinetic Evaluation of Intravenous Lacosamide as Short-Term Replacement for Oral Lacosamide in Partial-Onset Seizures Willi Cawello, Gregory Krauss, Melissa Brock, Andrea Eggert-Formella P05.193 Long-Term Maintenance of Efficacy with Retigabine 600-1200 mg/ Day in Adult Patients with Refractory Epilepsy: Extension Study of RESTORE 1 Robert Leroy, William Rosenfeld, Susan Hall, Kevan VanLandingham, Narinder Lotay P05.183 Effect of Carisbamate, a Novel Antiepileptic Drug, on Cognition in Three Placebo-Controlled, Healthy Volunteer, Multiple-Dose Studies H. Robert Brashear, Gerald Novak, Frank Wiegand, Kimford Meador P05.194 Long-Term Maintenance of Efficacy with Retigabine 600-1200 mg/ day in Adult Patients with Refractory Epilepsy: Extension Study of RESTORE 2 Holger Lerche, Robert Leroy, Susan Hall, Kevan VanLandingham, Narinder Lotay P05.184 A Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Victor Biton P05.195 Work Loss and Associated Costs in U.S. Employees with Epilepsy Receiving Multiple Antiepileptic Drugs Jamie Forlenza, Emily Durden, Stephen Johnston, Steve Ascher, George Wan P05.185 An Investigation of the Effects of Eslicarbazepine Acetate on Hyponatremia: A Pooled Analysis of Three Double-Blind Phase III Clinical Studies Mark Versavel, Elinor BenMenachem, Kenneth Tripp, Christian Elger, Luis Almeida, Patricio Soares-da-Silva P05.186 Lacosamide Efficacy in Partial-Onset Seizures with and without Secondary Generalization: A Pooled Analysis of Three Phase II/III Trials Jouko Isojarvi, Felix Rosenow, R. E. Faught, David Hebert, Pamela Doty P05.187 Improvement in PatientReported Outcomes Seen in Patients Responding to Lacosamide: Pooled QOLIE-31, SSQ and PGIC Data From 3 Phase II/III Clinical Trials Joyce Cramer, Christine De La Loge, Simon Borghs, Knut Mueller, Andrea Eggert-Formella, Pamela Doty P05.188 Lacosamide Add-On Treatment: Results of Open Label 6 Months Follow-Up Hermann Stefan, Frank Kerling, Bernhard Steinhoff P05.189 Efficacy of Retigabine 6001200mg/day in Patients with Refractory Epilepsy with Partial-Onset Seizure: Integrated Analysis of Three Randomized Studies Roger Porter, Jacqueline French, Martin Brodie, Kevan VanLandingham, Kevin Nanry, Susan Hall P05.190 Retigabine Provides Effective Adjunctive Therapy in Adults with Refractory Epilepsy with Partial-Onset Seizures, Irrespective of Gender, Race, and Age Elza Targas Yacubian, Bassel Abou-Khalil, Christian Elger, Sue Hall, Kevan VanLandingham P05.191 The Effects of Retigabine on the Pharmacokinetics of Concomitantly Administered Antiepileptic Drugs Debra Tompson, Kevan VanLandingham Poster Session V Thursday, April 15 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P05.204 UCB Antiepileptic Drug Pregnancy Registry Cynthia Harden, Shilpa Alekar, Ilo Leppik, Georgia Montouris, Angela Scheuerle Epilepsy: Clinical Neurophysiology P05.205 Electroclinical Features and Results of Intracranial Recordings in Atypical Cases of Mesial Temporal Lobe Epilepsy (mTLE): “A Pseudo-Extratemporal Epilepsy”? Kanjana Unnwongse, Imad Najm, William Bingaman, Andreas Alexopoulos P05.206 Computer Modeling of the Cause and Treatment of Epilepsy in the Dentate Gyrus Thomas Cronin, Faysal Altahawi, Bradley Gill, Manu Raam P05.207 A Video-EEG Analysis Study of Dialeptic Seizures: In 100 Patients with Generalized and Focal Epilepsies Betul Baykal, Ebru Altindag, Berend Feddersen, Sevda Ozel, Nazmi Arslan, Soheyl Noachtar P05.196 The Effects of Antiepileptic Drugs in Oral Health Cecilia Aragon, Jorge Burneo, Andrea Cornacchio P05.208 Unilateral Opercular Lesion and Eating-Induced Epileptic Spasms Siresha Chaluvadi, Doris Kung, David Friedman, Michael Newmark P05.197 Epilepsy in Pregnancy in a Minority Population Adel Olshansky, Alhamza Al-Bayati, Alice Stek, Larisa Yedigarova, Laura Kalayjian P05.209 Ictal Lip-Smacking in Temporal Lobe Epilepsy Has a Stereotyped Electrographic Signature Amy Wasterlain, Josef Parvizi P05.198 Carbamazepine Co Administration with an Oral Contraceptive: Effects on Steroid Pharmacokinetics, Bleeding, and Ovulation Anne Davis, Carolyn Westhoff, Frank Stanczyk P05.210 Helpless Romantics: Ictal Kissing (IK) as a Release Phenomenon in Non-Dominant Temporal Lobe Epilepsy Razi Rashid, Katherine Eder, Michael Macken, Stephan Schuele P05.199 Levetiracetam in the Treatment of Idiopathic Generalized Epilepsies: A Long-Term Observational Study Ioannis Tsiropoulos, Katerina Tsatsou, Nozomi Akanuma, Michail Koutroumanidis P05.200 Levetiracetam Induced Thrombocytopenia Kinshuk Sahaya, Munish Goyal, Aarti Sarwal, Niranjan Singh P05.201 An Investigation of the Effect of Eslicarbazepine Acetate on Cardiac Repolarization: A Pooled Analysis of Over-Read Electrocardiograms From Three Double-Blind Phase III Clinical Studies Mark Versavel, Kenneth Tripp, Luis Almeida, Patricio Soares-da-Silva P05.202 Effect of Eslicarbazepine Acetate on the SteadyState Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects Jacqueline Zummo, Manuel Vaz-da-Silva, Luis Almeida, Amilcar Falcao, Mark Versavel, Eva Soares, Joana Maia, Teresa Nunes, Patricio Soares-da-Silva P05.203 Pregabalin vs Placebo for the Treatment of Partial Onset Seizures in Patients Taking Concomitant Antiepileptic Drugs: An Analysis of Combined Clinical Trials Torbjörn Tomson, Suzanne Giordano, Mary Almas P05.211 Utility of Interictal Heart Rate Variability in Lateralizing Epileptogenic Foci Shan Chen, Michale Rosenberg, Eli Neiman, Kavitha Velicheti, Taly Agha, Joseph Drazkowski, Brent Goodman P05.212 Periictal Heart Rate Changes in Patients with Localization-Related Epilepsy Eun Hye Jeong, Won Sup Kim, Kyoung-Gyu Choi, Kee-Duk Park, Hyang Woon Lee P05.213 A Descriptive Analysis of Prognostic Indicators in Patients with Non-Convulsive Status Epilepticus in a Tertiary Hospital Population Chantelle Hrazdil, Raed Alroughani, Manouchehr Javidan P05.214 Aphasic Status Epilepticus: Electroclinical Correlation Eric Ericson, Michael Macken, Stephan Schuele Child Neurology/Developmental Neurobiology: Clinical Neurophysiology/Epilepsy P05.215 Electroclinical Correlates of Postictal Psychosis in a Child Manpreet Kaur, Rohit Marawar, Karen Powers, Anthony Ritaccio P05.216 Status Epilepticus, Both Convulsive and Non-Convulsive, in the Elderly: A Tertiary-Care Hospital-Based Study in South India Jagarlapudi Murthy, Devdutt Deshmukh, Amrit Saxena, Gautam Tripathy P05.217 Maturational Changes of SSVEPs Elicited by Intermittent Photic Stimulation Ala Birca, Lionel Carmant, Anne Lortie, Phetsamone Vannasing, Hannelore Sauerwein, Manon Robert, Louise Lemay, Dominique Piper, Valentina Donici, Maryse Lassonde P05.228 A Randomized, PlaceboControlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Post-Herpetic Neuralgia Richard Rauck, R. Norman Harden, Theresa Jimenez, Carrie McClung, Ole Graff P05.218 Infantile Spasms: Retrospective Review of Epilepsy Outcome Patricia Krief, Tanya Sweeney, Robin Smith, Joseph Maytal P05.229 Onset of Treatment Response to NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Postherpetic Neuralgia Gordon Irving, Miroslav Backonja, Richard Rauck, Jeffrey Tobias, Geertrui Vanhove P05.219 Association Between Clinical, Morphological, and Biochemical Findings and Central and Peripheral Nerve Conduction in Late Infantile Metachromatic Leukodystrophy C. i Dali, M. Dunoe, N. Barton, R. Mensah, J. Griffin, C. Krarup P05.220 Intraoperative MEP and SEP Monitoring in Spinal Surgery for Predicting Postoperative Minor Motor Deficits Bo-mi Kim, Eun Mi Lee, Joong Koo Kang P05.221 “Simple Febrile Seizures Plus (SFS+)”: It Is Okay To Have More Than One Seizure Within a 24 Hour Period Marie Grill, Yu-tze Ng P05.222 Clinical Features of Children with Refractory Epilepsy and MRI Evident Versus MRI Occult Malformations of Cortical Development Rohit Das, Dana Marafie, Annapurna Poduri Peripheral Nerve: Noninvasive Measures, and Neuropathic Pain P05.223 In-Vivo Confocal Microscopy of Meissner Corpuscles as a Measure of Early HIV Neuropathy David Herrmann, Michael McDermott, Michele Ferguson, Christi Alessi-Fox, Giovanni Schifitto P05.224 Sweat Gland Duct Density with Optical Coherence Tomography in Peripheral Neuropathy Mayank Mathur, Krystle Karoscik, Thomas Leist, Eduardo De Sousa P05.225 A Quantitative Device To Test Touch Sensitivity on the Finger Pad William Kennedy, Gwen Crabb, James Hodges, Mona Selim, Thaddeus Brink, Donald Simone P05.226 Peripheral Nerve Function in HIV-Infection: Electrophysiological and Quantitative Sensory Test Results in the CHARTER Study Muhammad Al-Lozi, Ronald Ellis, Florin Vaida, Chelsea FitzSimons, Ann Collier, J. Allen McCutchan, Justin McArthur, Susan Morgello, David Simpson, Christina Marra, Benjamin Gelman, David Clifford, Scott Letendre, Igor Grant P05.227 Pathophysiology of Painful Neuropathy: Correlations of Contact Heat Evoked Potential with Skin Innervation and Features of Neuropathic Pain ChiChao Chao, Ming-Tsung Tseng, Sung-Tsang Hsieh P05.230 The Neuromuscular Spectrum of Herpes Zoster Infection in the Upper Limb Edward Tay, Bashar Katirji, Amer Alshekhlee, Marek Buczek, Saef Ahmad P05.231 Epidermal Nerve Fiber Density as a Potential Marker for Central Pain Syndromes Devanshi Gupta, John Harney P05.232 Multi-Microcramps (MMC) Syndrome: A New Pathogenic Concept of Subtle Lower Motor Neuron (LMN) Lability Causing Very Disturbing, Continuing Muscle Pains, Sometimes Gratifyingly Treatable–But Often Misinterpreted as Mysterious “Fibromyalgia” or “Psychogenic” W. King Engel Neurologic Manifestations of Systemic Disease I P05.233 Renal Cell Carcinoma Presenting with Sensory Ataxia Due to Acute Inflammatory Demyelinating Polyneuropathy Arnaldo Da Silva, Radoslav Raychev, Jeffrey Frank, Scott Eggener, Kourosh Rezania P05.234 Sacral Polyradiculitis Due to HSV2 (Elsberg Syndrome): A Report of Two Cases Bernadette Schoneburg, Steven Lewis P05.235 The Occurrence of Central Nervous System Demyelination in Diabetes Lubna Mehyar, Natalia Krivitskaya, Hafiz Khan, Shahanara Islam, Abu Nasar, Huey-Jen Lee, Hussam Yacoub, Nizar Souayah P05.236 A Case of Mistaken Identity: Anti-NMDA Receptor Encephalitis in a Young Woman JingTian Wang, Jay Desai, May Kim P05.237 Thiamine Deficiency Presenting with Encephalopathy and Optic Neuropathy after Chemoradiation for Tongue Cancer Rimas Lukas, Juan Piantino, Jeffrey Nichols, Ezra Cohen, Daniel Haraf, Kourosh Rezania P05.238 Evaluation of Central Effects of Diabetes Mellitus by Multimodal Evoked Potentials and Brain Magnetic Imaging Tests Mohammed EL-Sherif, Sabry Elmogy, Seyam Salem, Mohamed Elkhateeb, Maha Belal, Saleh Attia 87 Poster Session V P05.239 Silent Brain Infarctions in Diabetes Mellitus Patients: The Multimodal Evoked Potential Tests Sensitivity and Specificity Mohammed EL-Sherif, Mohamed Elkhateeb, Nabil Awad Alla, Saleh Attia P05.240 Neuro Psychiatric Manifestations of Systemic Lupus Erythematosus: A Monocentric Retrospective Study of 96 Patients Nathalie Philippi, Etienne Dahan, Vincent Poindron, Stéphane Vinzio, Benjamin Cretin, Laurent Balonzoli, AnneSophie Korganow, Andoni Echaniz-Laguna, Valerie Wolf, Bruno Moulin, Jean-Louis Dietemann, Pierre Vidailhet, Christine Tranchant, Emmanuel Andres, Michel Fischbach, Dan Lipsker, Thierry Martin, Jean-Louis Pasquali, Jean Sibilia, Jerome De Seze P05.241 Lower Extemity Amyotrophic Diplegia (LAD): Prevalence and Pattern of Weakness Iryna Muzyka, Mazen Dimachkie, Richard Barohn, Jonathan Katz, Carlayne Jackson, Yunxia Wang, April McVey, Mamatha Pasnoor, Tahsen Mozaffar, Arthur Dick, Jeffrey Rosenfeld P05.242 Light Sensitivity Due to Erythropoietic Protoporphyria Responds to Oral Prednisone Paul Golumbek, Soe Mar P05.243 ANCA-Negative Wegener’s Granulomatosis Presenting as a Cavernous Sinus Syndrome Lisa Costelloe, Orla Tuohy, Paul Brennan, Francesca Brett, Michael Farrell, Joan Moroney P05.244 Treatment of Adult Spasticity with Myobloc® (RimabotulinumtoxinB; BoNT-B) in Clinical Practice: A Multicenter Retrospective Chart Review Robert Chinnapongse, Meg Corliss P05.245 Serotonin Syndrome After Administration of Milnacipran for Fibromyalgia Roula Ainchaybah, Hussam Yacoub, Nizar Souayah P05.246 Effect of Apocynin, a NADPH Oxidase Inhibitor, on Cerebral Miocroglia in Sabra Rat Model of Hypertension Bella Gross, Olga Azrilin, Hector Cohen, Shifra Sela, Eilam Palzur P05.247 Neurological Manifestations of Behçet Disease: Epidemiology, Clinical Characteristics, and Management in a Series of Hospitalized Patients Ignacio Casanova, Manuel Bartolome, Maria Jose Catalan, Teresa Lapeña, Rocio García-Cobos, Daniella Di capua, Arturo Sampedro, Cesar García, Jesus PortaEtessam P05.248 MELAS Syndrome Presenting as Pure Word Deafness and Wernicke’s Aphasia Georges Naasan, Michael DeGeorgia P05.249 Selective Cerebellar Degeneration Following Carbon Monoxide Poisoning: A Case Report Hui-Jun Yang, Jin-Hwan Cho, Beom-Seok Jeon 88 P05.250 A Case of Low -Dose Oral Methotrexate-Induced Reversible Neurotoxicity Bandhu Paudyal, Ryan Viets, Maryna Skliut P05.251 Association between Stroke Severity and the Intensity of Periodontitis Joanna Slowik, Marcin Wnuk, Kinga Grzech, Anna Jurczak, Maria Chomyszyn-Gajewska, Agnieszka Slowik P05.252 Autoimmune MuSK-Positive Myasthenia Gravis in Two Sisters Stanley Iyadurai, Muhammad Al-Lozi P05.253 P-ANCA-Related Neurological Syndromes: Two Cases with Atypical Presentation Masaki Kobayashi, Yuko Shimizu, Masahiro Iguchi, Yuri Inose, Shinichiro Uchiyama P05.254 Atypical Case of Posterior Reversible Encephalopathy Syndrome in an HIV-Seropositive Patient Hebah Hefzy, Sasha Zivkovic, Walter Bartynski P05.255 Facial Onset Sensorimotor Neuronopathy: A Case Series Dobrin Dobrev, Richard Barohn, Saud Khan, April McVey, Laura Herbelin, Mazen Dimachkie P05.256 Intracerebral Hemorrhage, CNS Vasculitis, and Sjogren’s Syndrome in a 57-Year-Old Female: A Case Report Marvin Sih, Nadera Sweiss, Kourosh Rezania P05.257 Supplement-Associated Hyperammonia after c(K)achetic Episode (SHAKE) Syndrome Michael Perloff, Emily Welsh, Jan Kucera P05.258 A Case of Reversible Brainstem Hypertensive Encephalopathy Orla Tuohy, Lisa Costelloe, Albi Chalissery, Joan Moroney P05.259 Atypical Presentation of Posterior Reversible Leukoencephalopathy in a Sickle Cell Patient Anjana Nair, Fernando Testai P05.260 Acute Combined Degeneration Associated with B12 Deficiency and Nitrous Oxide Anesthesia Ales Hlubocky, Troy Wiedenbeck, Jonathan McKinnon, Amy Almaraz, Jonathan Carter, Virgilio Gerald Evidente P05.261 Churg Strauss Syndrome Associated with Asymmetric Neuropathy and Multiple Effusions Bernadette Calabek, Peter Hitzenberger, Otto Berger, Hermann Moser, Ludwig Erlacher, Sonja Brandstätter, Wolfgang Grisold Interventional Neurology P05.262 Intrasinus Thrombolysis of Deep Cerebral Sinus Thrombosis Resulting in Reversible Thalamic Infarcts Nidhi Sood, Arun Talkad P05.263 Is Thrombolysis a Safe Option in Patients with an Unruptured Aneurysms? Remy Wong, Nauman Tariq, Robert Taylor, M. Fareed Suri, Mustapha Ezzeddine, Adnan Qureshi Thursday, April 15 | 7:30 a.m.–12:00 p.m. Metro Toronto Convention Centre / Room 808 P05.264 Prominent Loss of Clinical Benefit Among Patients with Acute Ischemic Stroke Treated with Endovascular Treatment After Six Hours of Symptom Onset Jefferson Miley, Gabriela Vazquez, Muhammad Zeeshan Memon, Haitham Hussein, Mushtaq Qureshi, M. Fareed Suri, Robert Taylor, Ramachandra Tummala, Adnan Qureshi P05.274 Low Risk of Intracranial and Systemic Hemorrhages in Patients Treated with Dual Antiplatelets Beyond One-Month after Neurovascular Angioplasty and Stent Placement Ameer Hassan, Gabriela Vazquez, Amy Puchta, Gustavo Rodriguez, M. Fareed Suri, Ramachandra Tummala, Robert Taylor, Adnan Qureshi P05.265 Acute Stroke Interventions Based on the Radiographic Time Window for Those Who Present Beyond the Current Therapeutic Time Window Adham Kamel, Tara Ramachangran, Ravi Patel, Amar Swrankar, Juliuse-Gene Latorre, Yahia Lodi P05.275 Long Term Clinical- Outcome of Patients Undergoing Intracranial Stent in the Setting of Acute Ischemic Stroke Ambooj Tiwari, Amit Kansara, Paritosh Pandey, Seemant Chaturvedi, Andrew Xavier P05.266 Use of Intravenous Heparin Prior to CEA in Acute Internal Carotid Ischemic Syndrome: A Preliminary Demonstration of Safety and Possible Efficacy Wei Liu, Chakorn Chansakul, Murray Flaster P05.267 Anesthesia Patterns for Endovascular Therapy in Acute Ischemic Stroke Junaid Kalia, DaiWai Olson, Rishi Gupta, Alex Abou-Chebl, Osama Zaidat, David McDonagh P05.268 Intravenous Thrombolysis with rt-PA Even within the First-Three Hours Is Not Effective for Large Artery Stroke Rajiv Padmanabhan, Kevin Kane, Marc Fisher, Majaz Moonis P05.269 Role of Vertebral Dominance Pattern in Ischemic Stroke Subtype Ugo Paolucci, Mohammad Moussavi, Spozhmy Panazi, Martin Gizzi, Jawad Kirmani P05.270 Reversible Arterial Vasoconstriction in Sturge Weber Syndrome Presenting with Postcoital Headache and Transient Hemiplegia Matthew Grantz, Elaine Skalabrin, Michael Wilder, L. DeWitt, Benjamin Lewis, Jennifer Majersik, Juliann Allred, Amer Malik, Pegah Afra P05.271 Evaluating Rates of Recanalization and Outcomes in Patients Receiving Full Dose of IV tPA Followed by IA Thrombolytics Versus Followed by Mechanical Intervention Ugo Paolucci, Mohammad Moussavi, Spozhmy Panazi, Martin Gizzi, Jawad Kirmani P05.272 Risk of Contrast Induced Nephropathy in Patients Undergoing Endovascular Treatment of Acute Ischemic Stroke Ashish Nanda, Sonal Mehta, Daniel Hsu P05.273 Long-Term Clinical and Angiographic Outcomes in Patients with Spontaneous Cervico-Cranial Dissections Treated with Stent Placement Ameer Hassan, Gustavo Rodriguez, Nauman Tariq, Gabriela Vazquez, M. Fareed Suri, Adnan Qureshi P05.276 Patients with Arteriovenous Malformations of the Brain Demonstrate Impaired Cognitive Status at the Time of Diagnosis Leo Galvin, Niall Pender, John Thornton, Paul Brennan, Joan Moroney P05.277 Effect of Hypertension on Hematoma Volume in an Experimental Model of Intracerebral Hemorrhage Afshin Divani, Blake Siljander, Vance Fredrickson, Ming Lin, Laina Bretzke, Ryan Chamberlain P05.278 Diagnosing Ischemic and Hemorrhagic Complication Post Neuro Intervention Using a Conebeam CT: A Sensitivity and Specificity Analysis Junaid Kalia, Michael Abraham, Kaiz Asif, Osama Zaidat P05.279 Intravascular Ultrasound (IVUS) Guided Angioplasty of a Carotid Dissection in a Patient with Fibromuscular Dysplasia Esteban Cheng-Ching, Muhammad Hussain, Heather Gornik, Rishi Gupta Thursday, April 15 | 7:30 a.m.–12:00 p.m. First Authors Stand by Poster from 7:30 a.m.–9:00 a.m. P05.285 Giant Cell Arteritis Diagnosed by a Cerebellar Infarction: A Case Report Chiara Zavanone, Sandrine Deltour, David Saadoun, Frederique Charlotte, Sophie Crozier, Antoine Chevrel, Yves Samson P05.286 Acute Stroke Intervention Using Penumbra Device Intervention Versus Multi-Device Intervention: Effect on Clinical Efficacy and Recanalization Time Junaid Kalia, Aamir Badruddin, John Lynch, Brian-Fred Fitzsimmons, Osama Zaidat Neuroscience Research Prize Recipients P05.287 High Glucose Levels Alter Morphine Signaling Systems: A Novel Pathway for Sugar Addiction Jan Gong P05.288 Relationship Between Cellular Dopamine and Morphine Concentrations Suggests Supplemental Treatment for Parkinson’s Disease Addiction Anauva Kalra-Lall Poster Session V Neural Repair/Rehabilitation: Imaging P05.290 Evidence of Regional Cortical Atrophy in Patients with Cerebrotendinous Xanthomatosis Silvia Guerrera, Maria Laura Stromillo, Andrea Mignarri, Marco Battaglini, Placido Bramanti, Silvia Marino, Carol Di Perri, Antonio Federico, Maria Teresa Dotti, Nicola De Stefano Neurologic Manifestations of Systemic Disease: Other P05.291 Effect of Hyperglycemia after the Correction of Glucose Level or Decreased Body Temperature on the Prognosis of Patients with Hypoglycemic Coma Tetsuhiko Ikeda, Tetsuya Takahashi, Masato Kanazawa, Masatoyo Nishizawa, Takayoshi Shimohata P05.289 Calcium Signaling and Glutamate Receptor Trafficking in the Retina Theresa Tharakan RED: 10AM Run/Walk Ad Useage: To be placed in the Abstract Listing Specs: 8.25” x 5.5625” (full bleed +.125”): B+W P05.280 Evaluating Rate of Recanalization and Outcomes in Patients Receiving Full Dose of IV tPA Bridged to IA Therapy Compared to IA Therapy Alone Jawad Kirmani, Ugo Paolucci, Mohammad Moussavi, Spozhmy Panezai, Martin Gizzi P05.281 Immediate Technical Outcome of Elective Symptomatic Carotid Stenting with Embolic Protective Devices Performed by Interventional Neurologists Kaiz Asif, Junaid Kalia, Khaled Asi, Ayman Gheith, John Lynch, Brian-Fred Fitzsimmons, Osama Zaidat P05.282 Obesity and Intracranial Stent Thrombosis David Rose, Sebastian Koch, Yolanda Reyes-Iglesias, Dileep Yavagal P05.283 Exploratory Analysis of Time Delays in Administrating Endovascular Therapy for Acute Ischemic Stroke Amit Kansara, Ambooj Tiwari, Sandra Narayanan, Andrew Xavier P05.284 Manometery-Guided Endovascular Management of Dural Sinus Stenosis Via Balloon Angioplasty and Stenting Junaid Kalia, John Lynch, BrianFred Fitzsimmons, Bernd Remler, Osama Zaidat Raise funds for brain research. One step at a time. Get moving to support new fellowships. Register for the 2010 Run/Walk for Brain Research on page 113, then set up your pledge sponsorships at www.aan.com/view/runwalk. 89 Integrated Neuroscience Session: Deep Brain Stimulation: Where Are We and Where Do We Go From Here? Thursday, April 15 | 12:00 p.m.–4:00 p.m. Coordinators: Andres Lozano, MD and Jerrold Vitek, MD, PhD Invited Speaker Session* / 12:00 p.m.–1:30 p.m. / Reception Hall 104A–D 12:00 p.m.–12:25 p.m. How Does Deep Brain Stimulation Work Jerrold Vitek, MD, PhD 12:25 p.m.–12:45 p.m. GPi Versus STN Deep Brain Stimulation for Parkinson’s Disease TBD 12:45 pm.–1:05 p.m. Deep Brain Stimulation for Dystonia Marie Vidhailet, MD 1:05 p.m.–1:30 p.m. Emerging Indications for Deep Brain Stimulation Andres Lozano, MD Poster Session / 1:30 p.m.–2:30 p.m. / Reception Hall 104A–D IN8-1.001 Ethics of Control in DBS: Consent and Control Centered in Patients’ Values Paul Ford, Cynthia Kubu IN8-1.002 Deep Brain Stimulation with Individualized Gamma Frequencies of the Human Subthalamic Nucleus Is as Effective as High Frequency Stimulation for Parkinson’s Disease Eric Tsang, Clement Hamani, Elena Moro, Filomena Mazzella, Utpal Saha, Andres Lozano, Mojgan Hodaie, Rosalind Chuang, Shen-Yang Lim, Thomas Steeves, Bogdan Neagu, Robert Chen IN8-1.003 Steady or Not Following Thalamic Deep Brain Stimulation for Essential Tremor Nelson Hwynn, Chris Hass, Pamela Zeilman, Janet Romrell, Yunfeng Dai, Samuel Wu, Kelly Foote, S. Subramony, Oyama Genko, Frances Velez-Lago, Hubert Fernandez, Ramon Rodriguez, Irene Malaty, Michael Okun IN8-1.004 Unilateral STN DBS Improves Sleep in Parkinson’s Disease Amy Amara, Harrison Walker, Stephanie Guthrie, Gary Cutter, David Standaert, Ray Watts IN8-1.005 Comparing Microelectrode Recording Versus Imaging Targeting During Pallidal Deep Brain Stimulation for Parkinson’s Disease Kristine Ziemba, Virgilio Gerald Evidente, Mark Lyons IN8-1.008 Apathy After STN DBS: Are Patients with Impulse Control Disorders at Risk? Tatiana Witjas, Alexandre Eusebio, Marie Delfini, Jean Regis, Jean Claude Peragut, Jean Philippe Azulay IN8-1.006 Automated Optimization of Deep Brain Stimulation Settings Across Multiple Parkinson’s Disease Motor Symptoms Joseph Giuffrida, Jay Alberts, Jerrold Vitek, Thomas Mera IN8-1.009 An Open-Label, Exploratory Study of the Efficacy and Safety of Repetitive Transcranial Magnetic Coil Stimulation (rTMS) in Aphasia in Alzheimer’s Disease Gayatri Devi, Elizabeth Shin, Linda Heier, Henning Voss, James Halper, Sandlin Lowe, Vanessa Lo IN8-1.007 Adjuvant Medication Reduces Post-DBS Impulsivity: A Saccade Study in Parkinson Disease Ashley Hood, Mya Schiess, Anne Sereno IN8-1.010 Deep Brain Stimulation Can Suppress Pathological Synchronization in Parkinsonian Patients Alexandre Eusebio, Wesley Thevathasan, Louise Doyle Gaynor, Alek Pogosyan, Ed Bye, Thomas Foltynie, Luvic Zrinzo, Keyoumars Ashkan, Tipu Aziz, Peter Brown Platform Session / 2:30 p.m.-4:00 p.m. / Reception Hall 104A–D 2:30 p.m. IN8-2.001 Anatomical Location of Deep Brain Stimulation Electrodes in Chronic Cluster Headache Denys Fontaine, Michel Lanteri-Minet, Yves Lazorthes, Gilles Geraud, Nelly Fabre, Patrick Mertens, Malou Navez, Serge Blond, Christian Lucas, Francois Dubois, Lemlih Ouchchane, Jean-Jacques Lemaire 2:45 p.m. IN8-2.002 Benefits and Risks of Deep Brain Stimulation for People with Parkionson’s Disease (PD SURG Collaborative Group) Keith Wheatley, Adrian Williams, Natalie Ives, Caroline Rick, Smitaa Patel 3:00 p.m. IN8-2.003 Unilateral Pedunculopontine Nucleus Deep Brain Stimulation in Progressive Supranuclear Palsy: A Pilot Study Mark Simpson, Andres Lozano, Yu-Yan Poon, Clement Hamani, Cindy Zadikoff, Jonathan Dostrovsky, William Hutchison, Elena Moro 3:15 p.m. IN8-2.004 Responsive Brain Stimulation for Treatment of Medically Intractable Mesial Temporal Epilepsy in Adults: Results of a Subset Analysis from the RNS™ System Pivotal Investigation in Epilepsy Vicenta Salanova, Martha Morrell 3:30 p.m. IN8-2.005 Does Subthalamic DBS Directly Impact Levodopa-Induced Dyskinesias? Joseph Rudolph, Sabrina Ahmmad, Ronald Alterman, Michele Tagliati 3:45 p.m. IN8-2.006 Effects of Deep Brain Stimulation at Individually Established Frequencies on the Motor Signs of Parkinson’s Disease and Essential Tremor Patients Bogdan Neagu, Eric Tsang, Utpal Saha, Sang Kim, Filomena Mazzella, Clement Hamani, Elena Moro, Mojgan Hodaie, Andres Lozano, Robert Chen *Current as of February 1, 2010 91 Scientific Sessions S41 Multiple Sclerosis: Clinical Immunology S42 Cerebrovascular Disease: Stroke Prevention S43 Movement Disorders: Essential Tremor and Ataxia S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology S45 Child Neurology: Developmental Neurobiology Scientific Sessions Thursday, April 15 | 1:15 p.m.–2:30 p.m. S46 Peripheral Nerve: Molecular Mechanisms of Peripheral Neuropathy S47 Neurologic Manifestations: Clinical Neurophysiology and Epidemiology S48 Autonomic Disorders: Frontiers of Autonomic Neurology S49 Cerebrovascular Disease: Hemorrhagic Stroke S50 Multiple Sclerosis: EAE/Animal Models Theatre 102 Constitution Hall 106 Room 718AB Constitution Hall 107 Room 701B Constitution Hall 105 Room 713AB Room 717AB Room 714A Room 701A 1:15 p.m. S41.001 TLR9 Processing in Multiple Sclerosis: A New Immunomodulatory Effect of Interferon-beta Konstantin Balashov, Suhayl Dhib-Jalbut, Latt Latt Aung 1:15 p.m. S42.001 De Novo Atrial Fibrillation After Carotid Endarterectomy Andrés Suarez, Andrés Rodríguez, Matias Altounian, Mauro Andreoli, Gabriela Bressán, Juan Ressia Gómez, Agustín Jáuregui, Patricia Riccio, Luciano Sposato 1:15 p.m. S43.001 Replication of the LINGO1 Gene Association with Essential Tremor in a North American Population Lorraine Clark, Naeun Park, Sergey Kisselev, Joseph Lee, Elan Louis 1:15 p.m. S44.001 Frontoinsular von Economo Neuron and Forked Cell Degeneration in Behavioral Variant Frontotemporal Dementia Eun-Joo Kim, Manu Sidhu, Stephanie Gaus, Marcelo Macedo, Eric Huang, Bruce Miller, Stephen DeArmond, William Seeley 1:15 p.m. S45.001 Effect of Timing of Glucocorticoid Administration on Cerebellar Growth in Preterm Newborns Emily Tam, Vann Chau, Colin Studholme, Kenneth Poskitt, A. James Barkovich, Donna Ferriero, Steven Miller 1:15 p.m. S46.001 Oral Curcumin Treatment Partially Mitigates the Phenotype of the R98C Knock-In Mouse Model of CMT1B Agnes Patzko, Istvan Katona, Mario Saporta, Agnes Jani-Acsadi, Michael Shy 1:15 p.m. S47.001 NMDA Receptor Autoimmunity in the Absence of Malignancy: A Case Series Ged O’ Connor, Sajid Farid, Iqbal Mudassir, Colin Doherty, Daniel Healy, Orla Hardiman 1:15 p.m. S48.001 Up-Regulation of Catecholaminergic Innervation to Sweat Glands in Early Diabetic Neuropathy Ningshan Wang, Christopher Gibbons, Christopher Brown, Roy Freeman 1:15 p.m. S50.001 Reduction of Microglia Activity in a Model of Multiple Sclerosis by Dipyridamole V. Wee Yong, Scott Sloka, Hollie Mowbray, Janet Wang, Brooke Verhaeghe, Yan Fan, Luanne Metz 1:30 p.m. S45.002 Location of Early Brain Lesions Impacts Integration of Cognitive and Emotional Information Tal Shany-Ur, Amichai Brezner, Katherine Rankin, Simone Shamay-Tsoory 1:30 p.m. S46.002 Spontaneous Demyelinating Autoimmune Neuropathy in ICAM-1 Deficient NOD Mice Gerd Meyer zu Horste, Houda El-Haddad, Anne Mausberg, Stefan Martin, HansPeter Hartung, Bernd Kieseier 1:30 p.m. S47.002 Central and Peripheral Demyelination as a Side Effect of Infliximab: A Case Series Kenkichi Nozaki, Marc Judson 1:30 p.m. S48.002 Familial Dysautonomia: A Genetic Disease with Afferent Baroreflex Failure Lucy NorcliffeKaufmann, Felicia Axelrod, Horacio Kaufmann 1:15 p.m. S49.001 Female Gender Is an Independent Predictor of Poor Outcome After Spontaneous Intra Cerebral Hemorrhage Neeraja Yerragondu, Minal Jain, Anunaya Jain, Veena Manivannan, Dipti Agarwal, Balavani Palamari, Babak Jahromi, Wyatt Decker, Latha Stead 1:45 p.m. S47.003 Sjögren’s Syndrome Associated Polyneuropathy: Clinical and Immunological Profiles Pantelis Pavlakis, Haralampos Alexopoulos, Michael Kosmidis, Eleftherios Stamboulis, Athanasios Tzioufas, Haralampos Moutsopoulos, Marinos Dalakas 1:45 p.m. S48.003 Hypovitaminosis D (HVD) in Postural Tachycardia Syndrome (POTS) in Adolescents Imad Jarjour, Laila Jarjour 1:30 p.m. S41.002 Th17 Cells Enter Inflamed CNS Parenchyma Independently of VLA-4 Blockade Rothhammer Veit, Franziska Petermann, Malte Claussen, Bernhard Hemmer, Thomas Korn 1:45 p.m. S41.003 Neuroprotective Activity of Methylthioadenosine for the Treatment of Multiple Sclerosis and Other Neurological Diseases Pablo Villoslada, Alessandra di Penta, Martin Kerschensteiner, Hannah Pellkofer, Carlos Matute, María Victoria Sánchez-Gómez, María Domercq, Miroslav Gottlieb, Valentin Ceña, Iciar Lopez, Jordi Aberch, Albert Giralt, Jack Parent, Helen Zang, Alan Chu , Jordi Serra, Beatriz Moreno 2:00 p.m. S41.004 Novel Neuroprotective Outcomes of Vitamin D in Models of Multiple Sclerosis Scott Sloka, Claudia Silva, Janet Wang, Yan Fan, Luanne Metz, Peter Stys, Wee Yong 2:15 p.m. S41.005 Effect of Laquinimod on Monocyte Subsets Tal Birnberg, Steffen Jung 1:30 p.m. S42.002 Does Aspirin Failure Increase the Chances of Recurrent Stroke and/or Death Among Patients with Ischemic Stroke: A Pooled Analysis of Two Prospective Trials Steve Cordina, Gabriela Vazquez, M. Fareed Suri, Kamakshi Lakhsminarayan, Harold Adams, Jr, Adnan Qureshi 1:45 p.m. S42.003 Cerebral Ischemic and Hemorrhagic Events in Patients with Atrial Fibrillation on Warfarin: A Prospective MultiCentre Study Maurizio Paciaroni, Giancarlo Agnelli, Walter Ageno, Valeria Caso, Francesco Corea, Alessia Lanari, Andrea Alberti, Paolo Previdi, Marta Fedele, Giorgia Manina, Cristina Vedovati, Michele Venti, Antonia Billeci, Maurizio Batta, Giorgio Silvestrelli 2:00 p.m. S42.004 Factors Associated with Dimensions of Poor Sleep in a Stroke and TIA Cohort: The Stroke Warning Information and Faster Treatment (SWIFT) Study Bernadette Boden-Albala, Laura Evensen, Joshua Stillman, Joshua Willey, Margaret Doyle, Myunghee Paik 2:15 p.m. S42.005 Headache as a Risk Factor for Neurovascular Events in Pediatric Brain Tumor Patients Sarah Kranick, Cynthia Campen, Scott Kasner, Sudha Kessler, Rebecca Ichord, Daniel Licht, Sabrina Smith, Lauren Beslow, Michael Fisher 92 Thursday, April 15 | 1:15 p.m.–2:30 p.m. Metro Toronto Convention Centre 1:30 p.m. S43.002 Faster Rate of Cognitive Decline in Essential Tremor Patients Than Controls: A PopulationBased Prospective Study Elan Louis, Julian Benito-Leon, Saturio Vega-Quiroga, Felix BermejoPareja 1:45 p.m. S43.003 Depolarization Block of Purkinje Neurons in a Mouse Model of Spinocerebellar Ataxia Type 3 Vikram Shakkottai, James Dell’Orco, Henry Paulson 2:00 p.m. S43.004 “Hairy Baskets” Associated with Degenerative Purkinje Cell Changes: A New Pathological Finding in Essential Tremor Cordelia Erickson-Davis, Phyllis Faust, Jean Paul Vonsattel, Elan Louis 2:15 p.m. S43.005 Effects of Erythropoietin on Endothelial Progenitor Cells, Frataxin Levels, and Oxidative Metabolism in the Skeletal Muscle of Friedreich Ataxia Patients Wolfgang Nachbauer, Julia Wanschitz, Markus Reindl, Barbara Scheiber-Mojdehkar, Werner Poewe, Sylvia Boesch 1:30 p.m. S44.002 Quantitative Analysis of the Neuroanatomic Distribution and Progression of Cerebral Amyloid Angiopathy Across the Cognitive Continuum Nicolas Badre, William Markesbery, Gregory Jicha 1:45 p.m. S44.003 Declines of Metabotropic Glutamate Receptor in Patients with Early AD: In Vivo Evidence of a Novel Biomarker for Hippocampal Dysfunction Pedro Rosa Neto, Jared Rowley, Dorothee Shoemaker, Betteke Van Noort, Ludymila Kandratavicius, Luciano Minuzzi, Serge Gauthier 2:00 p.m. S44.004 Physical Exercise, Cognitive Activity, Caloric Intake, and Mild Cognitive Impairment: The Mayo Clinic Study of Aging Yonas Geda, Rosebud Roberts, David Knopman, Teresa Christianson, Vernon Pankratz, Bradley Boeve, Robert Ivnik, Eric Tangalos, Walter Rocca, Ronald Petersen 2:15 p.m. S44.005 Cardiorespiratory Fitness Change and Dementia Progression in Early Alzheimer’s Disease Eric Vidoni, Robyn Honea, Heather Anderson, Jeffrey Burns 1:45 p.m. S45.003 PTEN Depletion Rescues the á-Actin Deficit in Axonal Growth Cones in Motoneurons from a Mouse Model of Spinal Muscular Atrophy Ke Ning, Carsten Drepper, Azza Ismail, Chiara Valori, Matthew Wyles, Adrian Higginbottom, Thomas Herrmann, Pamela Shaw, Basil Sharrack, Michael Sendtner, Mimoun Azzouz 2:00 p.m. S45.004 Arcuate Fasciculus FiberTracking Identification and Speech Development in Patients with Congenital Bilateral Perisylvian Malformations Anita Dias Saporta, Ajay Kumar, Rajkumar Govindan, Senthil Sundaram, Harry Chugani 2:15 p.m. S45.005 Glial Fibrillary Acidic Protein (GFAP) Mutations, Age of Onset and Clinical Presentation in Alexander Disease Morgan Prust, Albee Messing, Tom Hartka, Alex Sokohl, Raphael Schiffmann, Heather GordishDressman, Rafael Gorospe, Adeline Vanderver 1:45 p.m. S46.003 Unfolded Protein Response (UPR) Activation in a Mouse Model of Early-Onset CMT 1B Mario Saporta, Yunhong Bai, Brian Shy, Agnes Patzko, Maria Pennuto, Cherie Southwood, Alexander Gow, Cinzia Ferri, Maria Feltri, Michelle Crowther, Daniel Kirschner, Lawrence Wrabetz, Michael Shy 2:00 p.m. S46.004 Distinct Pathogenic Processes between Fig4-Deficient Sensory and Motor Neurons Istvan Katona, Xuebao Zhang, Yunhong Bai, Michael Shy, Quing Yan, Jun Li 2:15 p.m. S46.005 NT-3 Gene Therapy Improves Compound Muscle Action Potential (CMAP) and Function in Mouse Model for Charcot-MarieTooth (CMT) Neuropathy Zarife Sahenk, Gloria Galloway, Chris Edwards, Jerry Mendell, Kelly Clark 2:00 p.m. S47.004 Cross-Sectional Survey of Neurologic Dysfunction and Headaches in North American Patients with Behcet’s Disease Ilya Kister, Maria Filopoulos, Monalyn De Los Reyes Labitigan, Sara Crystal, Matthew Robbins, Joseph Herbert, Yusuf Yazici 2:15 p.m. S47.005 Long Term Cognitive and Neurological Outcomes Following Successful Cardiac Defibrillation for Out-of-Hospital Cardiac Arrest: A PopulationBased Study Farrah Mateen, Keith Josephs, Max Trenerry, M. Donna Felmlee Devine, Amy Weaver, Roger White 2:00 p.m. S48.004 Improved Orthostatic Responses in Fabry Patients After Enzyme Replacement Therapy Max Hilz, Harald Marthol, Stefan Schwab, Edwin Kolodny, Miroslaw Brys, Brigitte Stemper 2:15 p.m. S48.005 Autoimmune Autonomic Ganglionopathy: A Reversible Cortical Dementia Christopher Gibbons, Justin Centi, Roy Freeman 1:30 p.m. S49.002 Predictors of Hemorrhage Volume in Hypertensive Intracerebral Hemorrhage Mohammad Wasay, Ammar Masud, Adnan Yousuf, Darshan Lal, Safia Awan 1:45 p.m. S49.003 The Impact of Weekend Admission on In-Hospital Mortality in Intracerebral Hemorrhage Jay Joshi, Manisha Gupte, Bichun Ouyang, Sayona John, Shyam Prabhakaran, Vivien Lee 2:00 p.m. S49.004 Troponin I Levels Are Associated with In-Hospital Mortality in Subarachnoid Hemorrhage Manisha Gupte, Jay Joshi, Sayona John, Shyam Prabhakaran, Vivien Lee 2:15 p.m. S49.005 Elevated Troponin Is Predictive of Disability but Not Mortality in the Acute Intracerebral Hemorrhage Nina Tsakadze, Pedro Hernandez-Frau, Karen Wilson, Reza Behrouz 1:30 p.m. S50.002 Protective Effect of TLR7-Deficiency in Experimental Autoimmune Encephalomyelitis Patrice Lalive, Mahdia Benkoucha, Marie-Laure Santiago-Raber 1:45 p.m. S50.003 Age-Associated Susceptibility to Central Nervous System Autoimmune Disease Is Associated with Cerebral MHCII Expression by CD19+ B Cells, CD8+DC and Gr-1 Monocytes Petra Cravens, Bernd Kieseier, Martin Weber, Christiane Knobbe, Rehana Hussain, Li-hong Ben, Oliver Neuhaus, Carsten Korth, HansPeter Hartung, Michael Racke, Jan Cohen Tervaert, Scott Zamvil, Olaf Stuve 2:00 p.m. S50.004 Pharmacological PrP-Silencing Accelerates CNS Autoimmune Disease Via TCR Signaling Sima Zein, Wei Hu, Stefan Nessler, Bernhard Hemmer, Todd Eagar, Lawrence Kane, S. Rutger Leliveld, Anne Gocke, Amy LovettRacke, Li Hong Ben, Rehana Hussain, Jeffrey Elliot, Krishna Puttaparthi, Petra Cravens, Benjamin Petsch , Katherine Deming, Lothar Stitz, Michael Racke, Carsten Korth, Olaf Stuve 2:15 p.m. S50.005 Molecular Imaging in Experimental Autoimmune Encephalomyelitis Dorothea Buck, Annette Foerschler, Thomas Korn, Stefan Nessler, Patrick Vollmar, Hortenzia Jacobi, Sybille Reder, Constantin Lapa, Christine Stadelmann, Alexander Drzezga, Claus Zimmer, Bernhard Hemmer 93 Scientific Sessions S51 Multiple Sclerosis: Clinical Research II Theatre 102 2:45 p.m. S51.001 Multiple Sclerosis: Quality of Life and Perceived DeficitRelationship to Cognition in a Community-Based Study Mark Gudesblatt, Myassar Zarif, Barbara Bumstead, Max Gutman, Lori Fafard, Laura Graffitti, Carol Seidel, Lourdes Cruz, Serina Fahie, Joan Bohuslaw, Chris Burke, Jocelyn Caputo, Susan Riley, Ely Simon, Glen Doniger 3:00 p.m. S51.002 Multiple Sclerosis: Fatigue and Depression: Effects on Cognition in a CommunityBased Study Mark Gudesblatt, Myassar Zarif, Barbara Bumstead, Max Gutman, Lori Fafard, Laura Graffitti, Carol Seidel, Lourdes Cruz, Serina Fahie, Joan Bohuslaw, Chris Burke, Jocelyn Caputo, Susan Riley, Ely Simon, Glen Doniger 3:15 p.m. S51.003 CSF Identification of Novel Initiating Targets and Putative Prognostic Markers of Multiple Sclerosis in Pediatric-Onset CNS Demyelination Ajit Singh Dhaunchak, Brenda Banwell, Douglas Arnold, Dessa Sadovnick, Christopher Becker, Howard Schulman, David Colman, Amit Bar-Or 3:30 p.m. S51.004 The Self IgG Repertoire Directed Against CNS Antigens Discriminates NMO From MS and Healthy Subjects Hélíne Zéphir, Didier Lefranc, Nicolas Collongues, Frédéric Blanc, Patricia Dussart, Sylvain Dubucquoi, Marie Fleury, F. Viallet, Alain Créange, Jean-François Pélissier, Lionel Prin, Jérôme de Síze, Patrick Vermersch 94 S52 Cerebrovascular Disease II Constitution Hall 106 2:45 p.m. Presentation of Michael S. Pessin Stroke Leadership Award Recipient: Shelagh Coutts, MD Calgary, AB, Canada 3:00 p.m. S52.002 Optimal Timing of Anticoagulation after Central Nervous System Hemorrhage in Patients with High Thromboembolic Risk: A Systematic Review of the Literature Julio Furlan, Gregory Hawryluk, James Austin, Jang Lee, Cian O’Kelly, Michael Fehlings 3:15 p.m. S52.003 The Possible Risk of Intra Operative Hypothermia for Strokes Complicating Cardiac Surgery Isabelle Korn-Lubetzki, Israel Steiner, Avraham Oren, Rachel Tauber, Bettina Steiner Birmanns, Daniel Bitran 3:30 p.m. S52.004 Stroke in Patients with a Left Ventricular Assist Device: One Institution’s Experience Crystal Tung, Natalie Hoffman, Tudor Jovin, Robert Kormos, Mouhammad Jumaa Thursday, April 15 | 2:45 p.m.–3:45 p.m. Metro Toronto Convention Centre S53 Movement Disorders: Parkinson's Disease and Atypical Parkinsonism S54 Aging and Dementia: Genetics S55 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials Scientific Sessions Thursday, April 15 | 2:45 p.m.–3:45 p.m. S56 Anterior Horn: Basic Science S57 Neural Repair and Neurorehabilitation S58 Behavioral Neurology: Language, Action, and Memory S59 Ethics S60 Multiple Sclerosis: MRI II Room 718AB Constitution Hall 107 Room 701B Constitution Hall 105 Room 713AB Room 717AB Room 714A Room 701A 2:45 p.m. S53.001 Autosomal Dominant Late-Onset Parkinsonism with Dementia— Association with a Novel PD Gene Norbert Brüggemann, Wiebe Külper, Johann Hagenah, Vera Tadic, Holger Tönnies, Peter Bauer, Olaf Riess, Arnd Rolfs, Reiner Siebert, Peter Vieregge, Katja Lohmann, Christine Klein 2:45 p.m. S54.001 Enhancing Power for Gene Discovery in Alzheimer’s Disease: Intermediate Phenotypes and Functional Validation in Drosophila Joshua Shulman, Cristin Aubin, Dong Tran, Patricia Kramer, Mel Feany, David Bennett, Philip De Jager 2:45 p.m. S55.001 Intraoperative Neurophysiologic Monitoring in the Endovascular and Surgical Treatment of Pediatric Arteriovenous Malformations Viet Nguyen, Sungho Cho, Steven Chang, Gary Steinberg, Michael Marks, Huy Do, Jaime Lopez 2:45 p.m. S56.001 Cytoplasmic C-Terminus TDP-43 Aggregate Leads to Increased Phosphorylation of Full-Length TDP-43 in Culture Cell Yuko Ariizumi, Tomohiko Ishihara, Mariko Yokoo, Atsushi Shiga, Akio Yokoseki, Osamu Onodera, Masatoyo Nishizawa 2:45 p.m. S57.001 Serial Investigation of Neuronal Reorganisation in Acute Stroke Patients Using fMRI Techniques Lalit Kalra, Fernando Zelaya, Steve Williams 2:45 p.m. S58.001 Sounds of Silence: Pauses in the Speech of Progressive Non-Fluent Aphasics Sharon Ash, David Adamowicz, Corey McMillan, Murray Grossman 3:00 p.m. S54.002 Telomere Shortening Is a Biomarker for Biological Aging Min Kang, Nicole Schupf, Joseph Lee, Lawrence Honig 3:00 p.m. S55.002 Interhemispheric Inhibition and Facilitation in Patients with Callosal Infarction Jie-Yuan Li, Ping-Hong Lai, Robert Chen 3:15 p.m. S55.003 Multimodal Visual, Motor and Somatosensory Evoked Potentials (EP) as Markers and Predictors of the Disease Course in Patients with Early Relapsing Remitting Multiple Sclerosis (RRMS)—A Prospective Three Year Study Regina Schlager, Marcus D’souza, Leticia Grize, Christian Schindler, Ludwig Kappos, Peter Fuhr 3:00 p.m. S58.002 Factors Associated with Impulse Control Disorders in Parkinson’s Disease: A Case-Control Study of 564 Subjects Valerie Voon, Juergen Koester, Anthony Lang, Marc Potenza, Andrew Siderowf, Jacquie Whetteckey, Daniel Weintraub, Glen Wunderlich, Mark Stacy 2:45 p.m. S60.001 Corpus Callosum Area and Thalamic Volume as Predictors of Cognitive Impairment in Children and Adolescents with MS Christine Till, Berengere Broche, Rezwan Ghassemi, Sridar Narayanan, Louis Collins, John Sled, Douglas Arnold, Brenda Banwell 3:15 p.m. S54.003 Estrogen Receptor Alpha Gene Variants Are Associated with Alzheimer’s Disease in the Spanish Population Mercí Boada Rovira, Carmen Antunez Almagro, Jesús López-Arrieta, Antonio Caruz, Concha Moreno-Rey, Reposo Ramírez-Lorca, Francisco Jesús Morón, Isabel Hernández Ruiz, Ana Mauleon, Maitée Rosende-Roca, Pablo MartínezLage, Juan Marin, Lluís Tárraga, Montserrat Alegret, José Rafael Pedrajas, Nuria Urda, José Luis Royo, Maria Eugenia Saez, Javier Gayan, Antonio González-Pérez, Luis Miguel Real, Agustín Ruiz, Jose Jorge Galán 3:00 p.m. S56.002 Microglial Transformation From a Motoneuron Protective to a Toxic Phenotype in a Mouse Model of ALS Bing Liao, Weihua Zhao, David R. Beers, Jenny S. Henkel, Stanley Appel 3:00 p.m. S57.002 Combining Visual Rehabilitation and Noninvasive Brain Stimulation To Enhance Function in Patients with Hemianopia Ela Plow, Souzana Obretenova, Mark Halko, Patricia Schulz, Lais Oliveira, Nurhan Torun, Mary Lou Jackson, Alvaro Pascual-Leone, Lotfi Merabet 2:45 p.m. S59.001 Significant Pain Relief in Treatment Resistant Neuropathic Pain. Results from the First Multicenter, Randomized Trial with Intravenous Immunoglobulin (IGD 001 Trial, Eudract 2007007007-32) Stefano Jann, Maria Fruguglietti, Ada Francia, Roberto Sterzi 3:15 p.m. S56.003 Prion-Like Propagation of SOD1 Misfolding In Vitro Neil Cashman, Leslie Grad, Anat Yanai, William Guest, Megan O’Neill, Edward Pokrishevsky, Masoud Yousefi, Steven Plotkin 3:15 p.m. S57.003 Integrity of Intra- and InterHemispheric Motor Fibers Predicts Recovery Potential in Chronic Stroke Patients Robert Lindenberg, Lin Zhu, Gottfried Schlaug 3:30 p.m. S56.004 CD4+ T-Cells Induce Alternatively Activated (M2) Microglia in the ALS Mouse Jenny Henkel, David Beers, Weihua Zhao, Bing Liao, Stanley Appel 3:30 p.m. S57.004 Measuring Regional Cerebral Blood Flow Changes Induced by Non Invasive BrainStimulation Xin Zheng, David Alsop, Robert Lindenberg, Gottfried Schlaug 3:15 p.m. S58.003 Accuracy-Certainty Memory Profiles Enhance Discrimination among Alzheimer’s Disease, Mild Cognitive Impairment, and Normal Elderly Controls Daniel Kaufer, Feng Liu, Elizabeth Snitz, James Becker, Judith Saxton, Steven DeKosky, Oscar Lopez 3:00 p.m. S53.002 Early Clinical Features Differentiate Cerebellar Variant of Multiple System Atrophy and Sporadic Ataxia Alexandra Lloyd-Smith, Michael Schulzer, Sian Spacey 3:15 p.m. S53.003 Freezing of Gait in Parkinson Disease Is Associated with Reduced Dopaminergic Innervation of the Dorsal Caudate Nucleus Roger Albin, Martijn Muller, Robert Koeppe, Michael Kilbourn, Kirk Frey, Nicolaas Bohnen 3:30 p.m. S53.004 White Matter Lesions Augment Motor Impairments of Nigrostriatal Dopaminergic Denervation in Parkinson Disease Roger Albin, Martijn Muller, Christopher Bogan, Robert Koeppe, Michael Kilbourn, Kirk Frey, Nicolaas Bohnen 3:30 p.m. S54.004 Olfactory Receptor Cluster Copy Number Is Associated with Age at Onset of Alzheimer Disease Yanchun Li, Chad Shaw, Kinga Szigeti 3:30 p.m. S55.004 Microvascular Decompression for Hemifacial Spasm: Evaluating the Prognostic Value of Intra Operative Lateral Spread Response Monitoring and Clinical Characteristics in 293 Patients Aalap Shah, Tara Nikonow, Miguel Habeych, Parthasarthy Thirumala, Yue-Fang Chang, Michael Horowitz 3:30 p.m. S58.004 Hypoperfusion in the Left Inferior Parietal Lobule Correlates with Severity of Apraxia in Corticobasal Syndrome Mario Masellis, Wendy Galpern, Philip Francis, Isabelle Guimont, Farrell Leibovitch, Anthony Lang, Sandra Black 3:00 p.m. S59.002 Evaluation of Neurogenic Intermittent Claudication in Lumbar Spinal Stenosis John Markman, Maria Frazer, Ross Hanson, Nicole Murray 3:15 p.m. S59.003 Functional Connectivity in Patients with Chronic Neuropathic Pain Meredith Barad, Justin Brown, Elena Sherman, Neil Chaterjee, Sean Mackey 3:30 p.m. S59.004 Functional Polymorphisms of Catechol-O-Methyl Transferase (COMT) and Dopamine BetaHydroxylase (DBH) and Chronic Pain in the Elderly Richard Lipton, Lucas McCarthy, Mindy Katz, Laurie Ozelius 3:00 p.m. S60.002 Subregional Hippocampal Atrophy Is Linked to Depressive Symptoms in Multiple Sclerosis Stefan Gold, Kyle Kern, Mary-Frances O’Connor, Michael Montag, Aileen Kim, Ye Yoo, Barbara Giesser, Nancy Sicotte 3:15 p.m. S60.003 Definition of Regional Distribution of Gray Matter Loss in MS Patients with Fatigue: A Voxel-Based Morphometry Study Gianna Riccitelli, Maria Rocca, Cristina Forn, Bruno Colombo, Giancarlo Comi, Massimo Filippi 3:30 p.m. S60.004 Magnetic Resonance Evidence of the Involvement of the Striatal-Thalamic-Frontal Cortex System in Determining Fatigue in Multiple Sclerosis Paolo Gallo, Francesca Rinaldi, Paola Grossi, Alice Favaretto, Massimiliano Calabrese 95 Poster Session VI Thursday, April 15 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 Cerebrovascular Disease: Acute Stroke Therapy Location: 800 Level Moderators: Pooja Khatri, MD and Walter Koroshetz, MD, FAAN Ten posters in six neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will facilitate questions and answers with attendees and poster authors during the 90-minute author standby time. Thursday, April 15, 2010 3:00 p.m.–7:30 p.m. PD6.001 The Impact of NIH Stroke Scale on Functional Outcome Varies by the Hemisphere of Involvement in Major Ischemic Stroke Leonardo Batista, Fabricio Lima, Raul Nogueira, Ramon Gonzalez, Walter Koroshetz, William Dillon, Wade Smith, Karen Furie, Michael Lev, Albert Yoo PD6.002 Early Recurrence of Cerebral Ischemia in Patients with Symptomatic Carotid Artery Stenosis Henning Mast, Jay Mohr, Claudia Elste, Andreas Hartmann, Christian Stapf Cerebrovascular Disease: Epidemiology II P06.001 Acute Kidney Injury Is Associated with Hospital Mortality after Acute Ischemic Stroke, but Not Intracerebral Hemorrhage Minesh Khatri, Derk Adams, Kyra Becker, Christine Logar, W. T. Longstreth, David Tirschwell P06.002 Depressive Symptoms and Incidence of First Stroke: Does Stroke Risk Decline after Depressive Symptoms Resolve? M. Maria Glymour P06.003 Incidence of Cerebral Venous Thrombosis in United States: 2002–2006. A National Analysis Yousef Mohammad, M. Fareed Suri, Gabriela Vazquez, Tariq Nauman, Marwan Kattan, Gaurav Guliani, Adnan Qureshi P06.004 Endocarditis Is a Common Stroke Mechanism in Hemodialysis Patients Mesha Gay Brown, Mark Weiner, Sidney Kobrin, Scott Kasner, Steven Messe PD6.003 Safety and Feasibility of Intravenous Autologous Bone Marrow Derived Stem Cell Therapy for Patients with Acute Ischaemic Stroke: An OpenLabel, Phase I Trial Kameshwar Prasad, Rohit Bhatia, Sujata Mohanty, MV Padma Srivastava, Ajay Garg, Achal Srivastava, Vinay Goyal, Manjari Tripathi, Amit Kumar, Arti Vij, NK Misra, C. S. Bal PD6.004 Utilization of Helicopter Transport for Patients with Suspected Acute Ischemic Stroke Mark MacKenzie, Craig Domke, Thomas Jeerakathil PD6.005 The Safety of Clopidogrel Loading in the Treatment of Acute Ischemic Stroke and Transient Ischemic Attacks Lester Leung, Joe Tarsia, Gayle Pletsch, Karen Albright, Sheryl MartinSchild P06.008 Load of Myocardial Infarction and Risk of Brain Infarction: The AGESReykjavik Study Jean-Sebastien Vidal, Sigurdur Sigurdsson, Thor Aspelund, Tamara Harris, Vilmundur Gudnason, Andrew Arai, Lenore Launer P06.009 The Northern Manhattan Study Global Vascular Risk Score Is Associated with Leukoaraiosis Clinton Wright, Chuanhui Dong, Joanna Guzman, Mitchell Elkind, Tatjana Rundek, Charles DeCarli, Ralph Sacco P06.010 Newly Diagnosed Diabetes Portends a Poor Outcome for Acute Stroke Patients Regardless of the Subtype Mohammad Moussavi, Bahareh Hassanzadeh, Madhu Gupta, Florence Chukwuneke, Mohammad Alsumrian, Charles Porbeni, Martin Gizzi, Jawad Kirmani P06.011 Chocolate Consumption and Risk of Stroke Sarah Sahib, Joel Ray, Gustavo Saposnik P06.005 Low Rates of Blood Pressure Goal Achievement among Minorities with Stroke and Coronary Artery Disease Are Not Due to Less Aggressive Treatment Nerses Sanossian, Sharmineh Shams, Adrian Burgos, Gene Sung P06.012 Seasonal Variation of Stroke in Relation to Influenza Infection S. Kohake, J. Khoury, C. J. Moomaw, K. Alwell, BM Kissela, D. Woo, M. L. Flaherty, O. Adeoye, P. Khatri, S. Ferioli, D. Kleindorfer P06.006 Physical Activity and Functional Outcome from Stroke Pamela Rist, I-Min Lee, Tobias Kurth P06.013 Trends in Outcome and Hospitalization Cost Among Adult Patients with Acute Ischemic Stroke in the United States Hafiz Khan, Hussam Yacoub, Khosro Farhad, Lubna Mehyar, Shahanara Islam, Bilal Saulat, Rania Abou Elenein, Nizar Souayah P06.007 Should ICH Outcome Prediction Models Be Modified in African Americans? Pratik Bhattacharya, Wazim Mohamed, Lakshmi Shankar, Denise Rhoney, Seemant Chaturvedi, Ramesh Madhavan PD6.006 Are You Ever Too Old for Thrombolysis? Intravenous Recombinant Tissue Plasminogen Activator in Patients Age 80 and Older Shirley Chen, Nobl Barazangi, Jack Rose, Ann Bedenk, Jackie Phan, David Tong PD6.007 Use of Perfusion CT to Guide Stroke Thrombolysis Between Three and Six Hours Is Safe and Effective Laszlo Sztriha, Jozef Jarosz, Lalit Kalra, Dulka Manawadu PD6.008 Stroke Mimics Treated with IVTPA: A Retrospective Analysis Mohamed Teleb, Julian Yang, Jason Chang, Yazan Alderazi, Alwala Awad, Gunjan Parikh, Lucas Restrepo, James Frey P06.014 Accuracy of the New ICD-9 Code for “Drip-and-Ship” Thrombolytic Treatment in Patients with Acute Ischemic Stroke Silvina Tonarelli, Michael Tibbs, M. Naeem Qureshi, Gustavo Rodriguez, Kamakshi Lakshminarayan, Adnan Qureshi, Gabriela Vazquez P06.015 Racial and Geographic Differences in Fish Consumption: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study Fadi Nahab, Anh Le, Suzanne Judd, Michael Frankel, Jamy Ard, P. Newby, Virginia Howard P06.016 Stroke-Associated Pneumonia (SAP): Do Academic and Community Hospitals Have Similar Incident Risk and Outcomes? Olga Finlayson, Moira Kapral, Ruth Hall, Eriola Asllani, Daniel Selchen, Gustavo Saposnik P06.017 Prevalence of Thyroid Abnormalities and Associations with Cerebrovascular Disease in a Nationwide Survey May Kim, Nerses Sanossian P06.018 Pronounced Association of Elevated Serum Homocysteine with Stroke in Subgroups of Individuals: A Nationwide Study Amytis Towfighi, Bruce Ovbiagele P06.019 Impact of Microalbuminuria on Incident Stroke Risk: A MetaAnalysis Meng Lee, Shen-Chih Chang, Jeffrey Saver, Kuo-Hsuan Chang, HungWei Liao, Bruce Ovbiagele P06.020 Incidence of First Stroke in a Total Population Study Agust Hilmarsson, Olafur Kjartansson, Elias Olafsson PD6.009 Thrombolysis for Acute Ischaemic Stroke in Patients Over 80 Years of Age: A Perspective from Clinical Practice Laszlo Sztriha, Dulka Manawadu, Jozef Jarosz, Lalit Kalra PD6.010 Borderline Elevation of International Normalized Ratio and Use of Intravenous Recombinant Tissue Plasminogen Activator Harsh Aggarwal, Ameer Hassan, Gustavo Rodriguez, M. Fareed Suri, Kamakshi Lakshminarayan, Robert Taylor, Mustapha Ezzeddine, Adnan Qureshi Muscle Disease/Neuromuscular Junction: Inherited Myopathy P06.021 Distal Myopathies: A Retrospective Study of 28 Cases Jerome Franques, Emmanuelle Campana-Salort, Shahram Attarian, Annie Verschueren, Bruno Eymard, Carla Fernandez, Andre Maues De Paula, Dominique FigarellaBranger, Nicolas Levy, Pascale Richard, Nicole Monnier, Carina WallgrenPettersson, Bjarne Udd, Jean-Francois Pellissier, Jean Pouget P06.022 Progressive Dysphagia in Limb Girdle Muscular Dystrophy Type 2B: An Extension of the Clinical Phenotype Richard Walsh, Fiona Hill, Francesca Brett, Richard Charlton, Rita Barresi, Dominick McCabe P06.023 Oculopharyngodistal Myopathy Is a Distinct Entity— Clinical and Genetic Characterization of 40 Turkish OPDM Patients Hacer Durmus, Steve Laval, Feza Deymeer, Yesim Parman, Esen Kiyan, Munevver Gokyigit, Cumhur Ertekin, Straub Volker, Ibrahim Ercan, Kate Busby, Hanns Lochmüller, Piraye Piraye Serdaroglu-Oflazer P06.026 Non-GNE Related Quadriceps Sparing Myopathy: A Case Report Shrikant Mishra, Doris Cardenas, Aldobrando Broccolini, Yadira Ayoub, Chai Saechao, Daniel No, Daniel Darvish, Parampreet Singh P06.027 Scoliosis Surgery (ScSu) in Respiratorily-Compromised Congenital Neuromuscular Patients Can Fatally Worsen Ventilatory Function or Engender Nocturnal BiPAP Dependency, as Evidenced in Four Children with FocalLoss-of-Cross-Striations (FLCS) Shalini Mahajan, W. King Engel P06.028 Sparing of Myofiber Membranes in Infantile Pompe’s Disease: Dissociated Excitation-Contraction Coupling Ludwig Gutmann, Margaret Jaynes, Kymberly Gyure, Christopher Nance, Laurie Gutmann P06.038 The Pathological Characterization of Peripheral Neuropathy in Copper Deficiency Sean Taylor, Neeraj Kumar, James Dyck P06.051 Timed Vibration Predicts Progression to Symptomatic Neuropathy in Diabetic Subjects J. Singleton, Collin Arsenault, A. Smith P06.039 Statin Toxicity for Sensory Neurons In Vitro: Mechanism of Action Distinct from Cholesterol Synthesis Beth Murinson, Zachary Sender Peripheral Nerve: Acute Immune Neuropathies P06.040 Sensori-Motor CMT “ Like” Neuropathy with Ataxia Ophtalmoplegia and Dysarthria in Moroccan Patient with Homozygote POLG Mutation Mohammed Abdoh Rafai, Fatima Zahra Boulaajaj, Bouchra El Moutawakil, Ilham Slassi P06.041 SCA3 Presenting as an Isolated Axonal Polyneuropathy Tracey Graves, Roberto Guiloff Peripheral Nerve: Diabetic Neuropathy P06.029 Clinical Methodology and Outcome of Enzyme Replacement Therapy in a Series of Late-Onset GSDII Patients Corrado Angelini, Claudio Semplicini, Chiara Ferrati, Paola Tonin, Massimiliano Filosto, Elena Pegoraro P06.042 Impaired Neurovascular Repair in Subjects with Diabetes Following Intracutaneous Axotomy Gigi Ebenezer, Ryan O’Donnell, Peter Hauer, Nicholas Cimino, Justin McArthur, Michael Polydefkis P06.030 Analysis of Cardiac Involvement in Children and Adults with Pompe Disease from the Pompe Registry Edward Cupler, Barry Byrne, Laura Case, Angela Genge, Priya Kishnani, Ying Zhang, Suyash Prasad P06.043 MNSI, Electrophysiologic and Epidermal Nerve Fiber Density Findings in Cryptogenic Sensory Polyneuropathy Compared to Diabetic Polyneuropathy and Normal Controls Mamatha Pasnoor, Yuvraj Nijjar, Laura Herbelin, Douglas Wright, Janelle Ryals, Mazen Dimachkie, Richard Barohn P06.031 Enzyme Replacement Therapy in Five Adults with Late-Onset Pompe Disease Carly Oboudiyat, Gregory Pastores, Marrisa Ferraris, Swati Sathe Peripheral Nerve: Nutritional, Metabolic, and Small Fiber Neuropathy P06.044 Is Clinically Diagnosed Diabetic Peripheral Neuropathy Predominantly Metabolic or Vascular in Origin? Mayowa Owolabi, Aarinola Ipadeola, Jokotade Adeleye P06.032 Characterization of NonLength-Dependent Small Fiber Sensory Neuropathy Sara Khan, Lan Zhou P06.045 Electrodiagnostic Features of CIDP in Diabetes Mellitus Hiroyuki Nodera, Russell Chin, Jennifer Langsdorf, Bridget Carey, Norman Latov P06.033 Natural History of Idiopathic Small and Large Fiber Polyneuropathy: A Retrospective Study Rami Assi, Victoria Lawson, John Kissel P06.046 Type 2 Diabetes Mellitus Exacerbates Neuropathy in Patients with CMT1a Sourabh Arora, Steven Baker P06.034 Sensory Neuropathy in Patients with Cryoglobulin Negative Hepatitis-C Infection Min-Suk Yoon, Mark Obermann, Christina Dockweiler, Roland Assert, Ali Canbay, Sebastian Haag, Guido Gerken, Hans-Christopher Diener, Zaza Katsarava P06.024 Dominant Cardiomyopathy and Very Distal Myopathy with Rod, Myofibrillar and AVSF Myopathology Stanley Iyadurai, Conrad Weihl, Alan Pestronk P06.035 Alcohol-Related Peripheral Neuropathy Is Not Caused by Nutritional Deficiency Michelle Mellion, VanAnh Nguyen, Ming Tong, Princess Mark, Jack Wands, Jame Gilchrist, Suzanne de la Monte P06.025 Hereditary Myopathy with Early Respiratory Failure (HMERF)—A Uniform Clinical Phenotype with Several Possible Genotypes Lars Edstrom, Bengt Isberg, Fengqing Xiang, Kathe Dahlbom, Thomas Sejersen, Bjarne Udd P06.036 Peripheral and Central Large Fiber Dysfunction in Idiopathic Hyperhomocysteinemia Ramin Ansari, Favio Bumanlag, Ruma Mukerjee, J. Robert Chang, Tania Giovannetti, Bassel E. Sawaya, Jin Jun Luo P06.037 Lower Extremity Weakness and Dysesthesias Associated with Zinc Deficiency Stanley Iyadurai, Taylor Bear, Glenn Lopate 96 Poster Session VI Thursday, April 15 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P06.047 Epidemiology of Peripheral Neuropathy (PN) in a Tertiary Neuromuscular Disease Clinic in Northeast Brazil Francisco de Assis Gondim, Paulo Marcelo Sales, Francisco Basilio, Gisele Oliveira, Carlos Augusto Teixeira, Carlos Castro Costa P06.048 Multi-Factorial Analysis of Risk Factors for the Development of Peripheral Neuropathy Kartik Sivaraaman, Hussain Wajid, Jin Luo P06.049 Dizziness and Loss of Balance in Diabetics: The Relative Contribution of Vestibular vs. Somatosensory Dysfunction; Implications for Therapeutic Intervention Mary Walch, Charles Maitland, Winston Ortiz P06.050 Effects of Brief Supervised Exercise Program on Diabetic Neuropathy Mamatha Pasnoor, Patricia Kluding, Rupali Rupali, Benjamin Tseng, Laura Herbelin, Kevin Farmer, Stephen Jernigan, Douglas Wright P06.052 Acute Motor Axonal Neuropathy Presenting with Ventral Horn and Proximal Root Involvement: A Case Report and Review of the Literature Mahmoud Rayes, Sindhu Ramchandren, Sulaiman Mohammad, Alexandros Tselis, Richard Lewis P06.053 Guillain-Barre Syndrome after Influenza Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990–2009) Hussam Yacoub, Hafiz Khan, Shahanara Islam, Nizar Souayah P06.054 Cerebrospinal Fluid Oligoclonal IgM Bands in Guillain-Barré Syndrome Diana Ferraro, Anna Maria Simone, Maria Grazia Venneri, Jessica Mandrioli, Roberta Bedin, Giuliana Galassi, Maria Chiara Malaguti, Paolo Frigio Nichelli, Patrizia Sola P06.055 Guillain-Barre Syndrome after Hepatitis Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990–2009) Hussam Yacoub, Hafiz Khan, Shahanara Islam, Khosro Farhad, Peter Michas-Martin, Bilal Saulat, Rania Aboualenein, Nizar Souayah P06.056 Guillain-Barre Syndrome after GARDASIL Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (2006–2009) Peter Michas-Martin, Hafiz Kahn, Shahanara Islam, Rania Abou Elenein, Khosro Farhad, Bilal Saulat, Nizar Souayah P06.057 Acute Motor Conduction Block Neuropathy (AMCBN): Review of 11Cases Julien Gallard, Shahram Attarian, Francoise Bouhour, Stephane Mathis, Emilien Delmont, Yon Andoni Echaniz Laguna, Karine Viala, Jean Pouget P06.058 Anti-Ganglioside Antibodies in Guillain-Barré Syndrome Patient Sera Activate Small GTPase RhoA Gang Zhang, Sowmia Manoharan, Kazim Sheikh P06.059 Preciding Infections, the Spectrum of Morbidity and Outcome of Guillain-Barré Syndrome in the Intensive Care Unit David Dolezil, Pavel Adam P06.060 Case of Recurrent Guillain-Barré Syndrome with Three Episodes David Dolezil, Libor Svoboda, Tomaš Peisker, Eva Medová, Pavel Adam, Radim Mazanec Peripheral Nerve: Chronic Relapsing Neuropathies P06.061 Rituximab in Polyneuropathies with Anti-MAG Antibodies: Efficacy, Tolerance, and Predictive Factors of Response to Treatment Claude Desnuelle, Pierre-Yves Jeandel, Charles Benaïm, Jean Gabriel Fuzibet, Emilien Delmont P06.062 Cauda Equina Hypertrophy with Abundant Onion Bulb Formation Presenting as a Lower Motor Neuron Syndrome Erin O’Ferrall, Daniel Gendron, Marie-Christine Guiot, Michael Sinnreich P06.063 Chronic Inflammatory Demyelinating Polyneuropathy Disease Activity Status (CDAS): Recommendations for Clinical Research Standards Kenneth Gorson, Ivo Van Schaik, Ingemar Merkies, Richard Lewis, Richard Barohn, Carol Koski, David Cornblath, Richard Hughes, Angelika Hahn P06.064 A Randomized Controlled Trial Comparing Two Different IV Immunoglobulins in CIDP (CICStudy) Krista Kuitwaard, Leonard van den Berg, Marinus Vermeulen, Esther Brusse, Elisabeth Cats, Anneke van der Kooi, Nicolette Notermans, W.-Ludo van der Pol, Ivo van Schaik, Sonja van Nes, Wim Hop, Pieter van Doorn P06.065 “Real World” Use of IVIg in CIDP: Assessment of Utilization Across the Scope of Practice Jonathan Katz, David Saperstein, Tahseen Mozaffar, Michelle Greer P06.066 Proteonomic Analysis of Amyloid-Like IgM Neuropathy in Waldenstrom’s Macroglobulinemia Juan Figueroa, P. James B. Dyck, Ahmet Dogan, Christopher Klein P06.067 Increased Frequency of HLA-DRB1*15 in Patients with Multifocal Motor Neuropathy Leonard Van den Berg, Nadia Sutedja, Elisabeth Cats, Sanne Piepers, Ludo Van der Pol P06.068 Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Juan Figueroa, P. James B. Dyck, Phillip Low P06.069 Non-Myeloblative Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Neuropathy (CIDP) Treatment Amilton Barreira, Wilson Junior, Jean Ramos, Doralina Brum, AnaBeatriz Stracieri, Maria-Carolina Oliveira, Daniela Moraes, Dannielle Godoi, Júlio Voltarelli P06.070 Interest of Intensive Intravenous Immunoglobulins (IVIG) Regimen in CIDP Partially IVIg Responders Pierre Lozeron, Marie Théaudin-Saliou, Catherine Lacroix, David Adams 97 Poster Session VI Peripheral Nerve: Focal and Multifocal Neuropathies P06.071 Clinical Characteristics and Potential Therapeutic Implications of Inflammatory Pseudotumor of Nerve Michelle Mauermann, Bernd Scheithauer, Robert Spinner, Kimberly Amrami, David Kline, Robert Tiel, Peter Dyck, Christopher Nance, JaNean Engelstad, P. James B. Dyck P06.072 Inflammatory Post-Surgical Neuropathy Nathan Staff, JaNean Engelstad, Peter Dyck, P. James B. Dyck P06.073 Anterior Interosseous Nerve Syndrome Following Procedures Thomas Brennan, Edward Cupler P06.074 Phrenic Nerve Pacemaker for Isolated Diaphragmatic Palsy in Neuralgic Amyotrophy Xinrong Lu, Ghazala Hayat, Diana Balsalobre, Peter Ward, Kenneth Smith P06.075 Phrenic Neuropathies: A Clinical and Electrodiagnostic Study Simon Podnar P06.076 The Timing and Distribution of Triggers among 268 Bouts of Neuralgic Amyotrophy Mark Ferrante P06.077 “Hold Your Arms High” Traction Lesions of the Brachial Plexus in Bodyflying Walter Haupt, Amande Pauls, Norbert Galldiks P06.078 High-Dose Intravenous Steroids in Definite or Suspected ImmuneMediated Neuropathies Eduardo NobileOrazio, Francesca Gallia, Fabrizia Terenghi P06.079 Predictors of Positive Nerve Biopsies in Presumed Vasculitis Christina Fournier, Stephanie Scala, Jayashri Srinivasan P06.080 Hereditary Neuropathy with Pressure Palsies: Analysis of 24 De Novo Unrelated Cases Christopher Scheiner, Anthony Amato, Matthew Wicklund Neuroepidemiology/Health Services and Outcomes Research: Peripheral Nervous System P06.081 Disparities in the Diagnosis of Duchenne and Becker Muscular Dystrophy: Data from the MDSTARnet, 1999–2007 Christopher Cunniff, Jennifer Andrews, Emma Ciafaloni, Deborah Fox, Caleb Holtzer, Zhenqiang Lu, Lisa Miller, John Meaney P06.082 Respiratory Care Trends for Duchenne and Becker Muscular Dystrophies (DBMD): Data From the MD STARnet, 2001–2007 Daniel Mandel, Daniel Sheehan, Shree Pandya, Christina Westfield, Deborah Fox, Sarah Nabukera, Katherine Mathews, Christopher Cunniff, Carolyn Constantin, David Birnkrant P06.083 Clinical and Electrophysiological Features in 58 Chilean Children with Guillain-Barré Syndrome Claudia Castiglioni, Alejandra Diaz, Maria Beytia, Lorena Pizarro, Eliana Rodillo 98 P06.084 Impact of Botulinum Toxin Type A (BoNTA) on Health Utility in Patients Receiving Treatment for Approved Therapeutic Indications: Interim Analysis of a Large Ongoing Phase IV Prospective Observational Cohort Study (MDs on BOTOX® Utility-Mobility) in Canada Theodore Wein, Mandar Jog, Richard Beauchamp, Robert Miller, Meetu Bhogal, Susan Simonyi P06.085 Evaluation of Quality of Life in Korean Charcot-Marie-Tooth Disease Patients Hye Yang, Jisoo Shin, Byung-Ok Choi P06.086 Caregiving Parents of Children with Neuromuscular Conditions: Experiences of Stress and Personal Growth Susan Cadell, Lynn Straatman P06.087 Baseline Characteristics of Patients Receiving Botulinum Toxin Type A for Approved Therapeutic Indications in a Large Ongoing Phase IV Prospective Observational Cohort Study (MDs on BOTOX® UTILITY— MOBILITY) in Canada Theodore Wein, Mandar Jog, Richard Beauchamp, Robert Miller, Meetu Bhogal, Susan Simonyi P06.088 Edge Motion Technology To Detect Abnormalities of Gait and Balance William Bauer, John Tsotsos, Evgueni Simine, Steven Benedict, Brendan Bauer, Daniel Lynch, Frank Bunn P06.089 Dual-Task Related Gait Changes and Risk of Falls: A Systematic Review Olivier Beauchet, Cédric Annweiler, Gilles Allali, Frederic Assal, François Herrmann Neuro-oncology: Primary and Metastatic Tumors P06.090 Incidence of Central Nervous System Tumors in Two Different Populations from Argentina Ignacio Casas-Parera, Mario Melcom, Manuel Fernández Pardal, Mariana Báez, Alejandra Báez, Juan Martín Cardozo Oliver, Erica Rojas Bilbao, Carlos Rugilo, Inés Tamer, Mario Halfon, Liliana Giménez, Cecilia Sánchez Retamal, Inés Aparisi, Verónica Baró, Mariel Bonaldo , René Boudot, Carlos Cabrera, Laura Clement, Mariano Díaz Java, Gustavo Di Rienzo, Marcelo Fellner, Fabiana Gandolfi, Cristina Giménez, Emilio Girardet, Aurora Grassi, Susana Ibáñez, Patricio Labal, Lorena Maraviglia, Carlos Lozano, Oscar Moreno , Mónica Moro, Graciela Oyarzo, Liliana Pérez, Ana Prieto, Eugenia Romero, Gastón Ruston, Hugo Solaligue, Pedro Villavicencio, Vivian Colombo, María Esther Domínguez, Laura Escur, Juan Gutiérrez, Silvia Hid, Pedro Ordoqui, Fernando Rodríguez Forgués , Néstor Torres P06.091 Pattern of Pediatric Brain Tumors in Province of Egypt, a Multidisciplinary Team Experience Hassan Salama, Hatem Badr, Mohammed Mansour, Ashraf Ezzeldeen, Hosam Maaty Thursday, April 15 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P06.092 Hemangiopericytoma Affecting the Central Nervous System Christian Grommes, Maame Dankwah, Phillip Gutin, Mark Bilsky, Jason Huse, Thomas Kaley, Marc Rosenblum, Lauren Abrey, Antonio Omuro P06.093 Esthesioneuroblastoma: Clinical and Survival Analysis at a Single Institution in Argentina Macarena de la Fuente, Ricardo Marengo, Martin Nogues, Blanca Diez, Naomi Arakaki, Alejandro Muggeri P06.094 Glioblastoma Multiforme, Adenoid-Type with Melanocytic Differentiation Erica Rojas-Bilbao, Juan Cardozo-Oliver, Ignacio Casas-Parera P06.095 Brain Metastases from Melanoma: Implications for Future Studies Samuel Goldlust, Andrew Lassman, Lindsay Jacks, Lisa DeAngelis, Edward Avila P06.096 A Retrospective Study of Central Nervous System Metastases in Esophageal Cancer Shivani Patel, Jennifer Serventi, Nimish Mohile P06.097 Incidence of Cerebral Metastasis: A Population-Based Study in an Island Community Agust Hilmarsson, Olafur Kjartansson, Helgi Isaksson, Aron Bjornsson, Jon Hrafnkelsson, Elias Olafsson P06.098 Upfront Association of Carboplatin and Pemetrexed in Patients with Brain Metastasis of a Non Small Cell Lung Cancer Olivier Bailon, Kader Chouahnia, Alexandre Augier, Iríne Coman, Catherine Belin, Sophie Bouvier, Laurent Zelek, Jean-François Morere, Antoine Carpentier P06.099 Bevacizumab as Treatment for Brain Metastasis of Lung Cancer Rima El-Abassi, Ivo Tremont-Lukats Neuro-oncology: Neurologic Complications of Cancer P06.100 Leptomeningeal Plasmacytosis as an Early Manifestation of Waldenstrom’s Macroglobulinemia—A Case Report Brian Scott, Vishal Patel, Matthew Tilem, Rabinowitz Arthur P06.101 Richter’s Syndrome of the Spinal Cord Tracey Graves, Graham Collins, Christian Hatton, Allyson Parry P06.102 Cranial Nerve Neuropathy as Initial Presentation of Recurrent Multiple Myeloma Rima El-Abassi, Ivo TremontLukats P06.103 A Unique Case of Hyperviscosity Syndrome in a Patient with Chronic Lymphocytic Leukemia Treated with Rituximab Fazeel Siddiqui, Brajesh Agrawal, Harirama Acharya, Rodger Elble P06.104 Acute Obstructive Hydrocephallus in Griscelli Syndrome Logan McDaneld, Thomas Koch P06.105 A Case of Intracranial Plasma Cell Granuloma Presenting as a Mass Lesion Preeti Puntambekar, Sunitha Santhakumar, Sandeep Mittal, William Kupsky, Alexandros Tselis P06.106 Subdural Hematoma in Cancer Patients Samuel Singer, Jordan Reichman, Babak Navi, Alan Segal, Lisa DeAngelis P06.107 Orofacial Dyskinesia: A Possible Paraneoplasic Disoder? Ruxandra Costa, Stephen Gancher, Jennifer Lycette, Vanda Lennon P06.108 Previous Biopsy History and Histopathological Outcome Affect Cognition and Quality of Life Following Breast Biopsy Bruno Giordani, Janet Osuch, Christina Cusumano, Stephanie Smith, Pam Haan, Ravi Khattree, Laura Symonds, Wei Xue, Adrian Blow, Michael Boivin P06.109 Coagulation State and Carotid Profile Assessment as a Cerebrovascular Complication in Central Nervous System Tumor Tiara Aninditha, Mursyid Bustami, Teguh Ranakusuma P06.110 Gemcitabine-Induced Myopathy Elena Pentsova, Anli Liu, Adilia Hormigo, Xi Chen Neurologic Manifestations of Systemic Disease II P06.111 Voltage Gated Potassium Channel Antibody Negative Neuromyotonia and Optic Neuritis Associated with Hodgkin Lymphoma: Paraneoplastic Neuromyotonia Plus Andrew Solomon, Michael Kruer, Crystal Fo, Alexander Landfield, Barry Oken, Dennis Bourdette P06.112 A Case of Mistaken Identity: Anti-NMDA Receptor Encephalitis in a Young Woman JingTian Wang, Jay Desai, May Kim P06.113 Steroid Responsive Encephalopathy Associated with Vestibular Symptoms and Sleep Disorders: Clinical, PSG, MSLT, ENG, CSF, and Brain MRI Correlates Bibhutibhushan Mishra, Leah Gaedeke, Richard Amdur, Leslie Williams, James Bicksel, Bernhard Samuel P06.114 Brain and Spinal Cord Infarction Secondary to Giant Cell Arteritis (GCA) after Intrathecal Ziconotide Melissa Cortez, L. DeWitt, Mark Bromberg P06.115 Rare Neurological Complications Associated with Intravenous Immunoglobulin Infusion Obinna Moneme, Andrew Slivka, William Arnold, Bakri Elsheikh P06.116 Striational Antibodies in a Paraneoplastic Context: A Case-Control Study Andrew McKeon, Sean Pittock, Vanda Lennon Poster Session VI Thursday, April 15 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P06.117 Cerebrotendinous Xanthomatosis: Clinical Manifestations in Long-Term Follow-Up Aad Verrips, Tijmen Balvers P06.130 Hypoglycemic Encephalopathy with Normal Brain MRI Munish Goyal, Gyanendra Kumar, Niranjan Singh P06.118 Cognitive Impairment in Moderate Chronic Kidney Disease Compared with Hemodialysis Patients: A Pilot Study Anne Murray, Ali Kolste, Sarah Pederson, David Zaun Multiple Sclerosis and Related Diseases: Clinical Trials P06.119 Summary of Cardiac Safety from a Randomized, Placebo-Controlled, Trial of Dextromethorphan/Quinidine (STAR) for Treatment of Pseudobulbar Affect Randall Kaye, Craig Pratt P06.120 Cognitive Dysfunctions in Primary Sjögren Syndrome Frederic Blanc, Nadine Longato, Catherine Kleitz, Barbara Jung, Laure Di Bitonto, Nadjette Cremel, Christelle Sordet, Marie Fleury, Jean Sibilia, Jerome de Seze P06.121 Auto Immune Encephalitis: Clinical, Radiological and Immunological Data Jérôme Aupy, Nicolas Collongues, Benjamin Cretin, Frederic Blanc, MarieCéline Fleury, Patrice Bourgin, Edouard Hirsh, Jérôme De Seze P06.122 Peripheral and Central Nervous System (PNS and CNS) Involvement in the Primary Carnitine Deficiency of Adult Jin Luo, Yitao Ma, Douglas Laske, Daniel Brown P06.123 Celiac Disease Presenting as a Disabling Myopathy Without Gastrointestinal Symptoms Charlene Hoffman Snyder, Mark Ross P06.124 Idiopathic Intracranial Hypertension Treatment Trial Michael Wall, Mark Kupersmith, James Corbett, Karl Kieburtz, Michael McDermott, Deborah Friedman, Steven Feldon, John Keltner P06.125 Auto-Immune Encephalitis and Striatal Hypermetabolism Frederique Fluchere, Alexandre Eusebio, Emmanuelle Bernit, Elsa Kaphan, Eric Guedj, JeanPhilippe Azulay P06.126 Hashimoto’s Encephalopathy and Idiopathic Thrombocytopenic Purpura Rohit Marawar, Huijun Wang, Barbara Changizi P06.127 Mononeuritis Multiplex as Result of Acute Hepatitis B-Related Vasculitis Mihaela Hangan, Jin Li P06.128 Safety and Tolerability of Dextromethorphan/Quinidine for Pseudobulbar Affect in a 12-Week, Open-Label Extension Study Erik Pioro, Benjamin Brooks, Jeffrey Cummings, Randolph Schiffer, Daniel Wynn, Adrian Hepner, Randall Kaye, on Behalf of the STAR Trial Investigators P06.129 Proton Magnetic Resonance Spectroscopy (1)H-MRS as a Tool in Neuroimmunological Disease Monitoring Simona Pontecorvo, Emanuele Tinelli, Manuela Morreale, Maria esmeralda Quartuccio, Massimiliano Prencipe, Ada Francia P06.131 Efficacy and Safety of Weekly Intramuscular Interferon Beta-1a in Patients More Than 50 Years of Age Christian Lampl, Regine Buffels, Wolfgang Mair, Xiaojun You, Volker Limmroth P06.132 Nocebo Responses in Disease-Modifying and Symptomatic Treatment Trials for Multiple Sclerosis: A Systematic Review Dimos Mitsikostas, Dimitrios Papadopoulos P06.133 Natalizumab Is Effective in RRMS Patients Who Do Not Respond to Sequential Therapy with Interferon beta and Glatiramer Acetate: Result of a Switching Study Anza Memon, Christina Caon, Jai Perumal, Aaron Boster, Alexandros Tselis, Stephanie Hreha, Fen Bao, Omar Khan P06.138 Short-Term Immunosuppression with Mitoxantrone Followed by Long-Term Glatiramer Acetate vs Glatiramer Acetate Alone: Results at 60 Months in Patients with Relapsing Multiple Sclerosis Timothy Vollmer, Amit Bar-Or, Denise Campagnolo, Hillel Panitch, Douglas Arnold P06.139 Surgical Procedures for Medically Intractable Multiple Sclerosis Associated Trigeminal Neuralgia Karen Truitt, Mark Keegan, James Watson, John Atkinson P06.140 Frequency of Mitoxantrone Related Heart Involvement in Patients Affected by Multiple Sclerosis Giovanni Savettieri, Paolo Aridon, Marco D’Amelio, Maria Antonietta Mazzola, Sabrina Realmuto, Leila Zummo, Giuseppe Salemi, Paolo Ragonese P06.141 Immunogenicity of PEGylated Interferon Beta-1a: Data from Preclinical and Phase I Clinical Studies Darren Baker, Michaela Lerner, Meena Subramanyam, Gudarz Davar, Susan Goelz, Miranda van Beers, Huub Schellekens P06.134 Phase II Double-Blind Controlled Clinical Trial with T-Cell Vaccination in Multiple Sclerosis Rivka Abulafia-Lapid, Massimo Filippi, Panayiota Petrou, Adi Vaknin-Dembinsky, Michal Mor, Oded Abramsky, Henry Atlan, Dimitrios Karussis P06.142 Evaluation of Natalizumab for the Relief of Multiple Sclerosis Associated Fatigue: The ENER-G Study Jeffrey Wilken, Robert Kane, Cynthia Sullivan, Mark Gudesblatt, Sylvia Lucas, Robert Fallis, Amy Pace, Richard Kim P06.135 Cancer Risk among Patients with Multiple Sclerosis During the Treatment Era: The CARIMS Study Update Christine Lebrun Frenay, Marc Debouverie, David Brassat, Patrick Vermersch, Gilles Defer, Jerome De Seze, Pierre Clavelou, Olivier Heinzlef, Lucien Rumbach, Sandrine Wiertlevski, Patricia Tourniaire, Frederic Berthier P06.143 Immunotherapy After Discontinuation of Natalizumab in Relapsing Multiple Sclerosis Neeta Garg, Kevin Kane P06.136 Response to Treatment with Sustained Release Fampridine in Patients with Multiple Sclerosis Is Independent of Baseline Patient Characteristics and Concomitant Immunomodulator Therapy Theodore Brown, Randall Schapiro, Keith Edwards, Andrew Goodman, Lawrence Marinucci, Ron Cohen, Andrew Blight, on Behalf of the MS-F202, MS-F203, and MS-F204 Study Groups P06.137 Oral Fingolimod (FTY720) Treatment Improves the Performance of Daily Activities Compared with Intramuscular Interferon β-1a: PatientReported Indices for Multiple Sclerosis (PRIMUS)-Activities Results from a Phase III Study (TRANSFORMS) Jeffrey Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Bhupendra Khatri, Xavier Montalban, Jean Pelletier, Tracy Stites, Stacy Wu, James Jin, Benjamin Eckert, on Behalf of the TRANSFORMS Study Group P06.144 Combined Transcranial and Extracranial Venous Doppler Evaluation (CTEVD Study). Description of the Design and Interim Results of an Epidemiological Study of the Prevalence of Chronic Cerebrospinal Venous Insufficiency in MS and Related Diseases Robert Zivadinov, Karen Marr, Murali Ramanathan, Paolo Zamboni, Ralph Benedict, Gary Cutter, Cheryl Kennedy, Makki Elfadil, David Hojnacki, Frederick Munschauer, Justine Reuther, Christina Brooks, Kristin Hunt, Michelle Andrews, Bianca WeinstockGuttman P06.145 Adherence to DiseaseModifying Therapies in Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project Estefania Arroyo, Cecilia Grau, Juan Parra, Olga Sanchez Solino P06.146 Utilization and Safety of Intramuscular Interferon Beta-1a in the Postmarketing Setting Pamela Foulds, Sandra Richman, Susan Friend P06.147 Effects of Glucosamine Sulfate on Multiple Sclerosis Progression: A Randomized, Placebo-Controlled Trial Vahid Shaygannejad, Fereshteh Ashtari, Mohsen Janghorbani P06.148 Objective and Subjective Efficacy of Natalizumab on Disability and Fatigue in Relapsing Remitting (RR) and Relapsing Progressive (RP) Multiple Sclerosis (MS) over a Two Year Period Ioannis Doumos, Vassiliki Kotsi, Elissaios Karageorgiou, Dimitrios Tzortzis, Moira Tzitzika, Panagiota Karanasou, Christos Giannoulis, Helen Papageorgiou, Sofia Tsiara, Clementine Karageorgiou P06.149 Baseline Characteristics of Patients in the DEFINE Trial: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Study of BG-12 in Relapsing-Remitting Multiple Sclerosis Ralf Gold, Douglas Arnold, Ludwig Kappos, Amit Bar-Or, Gavin Giovannoni, Krzysztof Selmaj, Minhua Yang, Katherine Dawson P06.150 ReaLiNat Study: A European Multicenter Study Investigating Benefits and Risks of Natalizumab in Real Life Joerg Kraus, Bruno Brochet, Uwe Zettl, Thomas Berger, Sebastian Humpert, Martin Marziniak, Wolfgang Kristoferitsch, Peter Schnabl, Franz Aichner, Hayrettin Tumani, Marcus Müller, Peter Wipfler, Julian Zimmermann, Irina Sapunova-Mayer, Hamid Assar , Joerg Weber, Helmut Rauschka, Lydia Bernhardt, Cristina Vouga, Gabriele Gillwaldt, Gunther Ladurner P06.151 Discontinuing DiseaseModifying Therapy in Progressive Multiple Sclerosis— Can We Stop What We Have Started? Roisin Lonergan, Katie Kinsella, Marguerite Duggan, Sinead Jordan, David Bradley, Michael Hutchinson, Niall Tubridy P06.152 Comparison of Adherence and Persistence Associated with FirstLine Disease-Modifying Therapies Among Patients with Multiple Sclerosis Rachel Halpern, Sonalee Agarwal, Leigh Borton, Tomislav Babic P06.153 Factors Related to Adherence in Spanish Patients with MS: Two Year Results of the GAP Study Juan Parra, Cecilia Grau, Estefania Arroyo, Olga Sanchez Solino P06.154 Baseline Characteristics of a Subpopulation of Indian Patients Enrolled in Two Phase Three Trials for Oral BG-12 in Relapsing-Remitting Multiple Sclerosis Madhuri Behari, Meena Kanikannan, Pahari Ghosh, Ralf Gold, Robert Fox, Douglas Arnold, David Miller, Minhua Yang, Katherine Dawson P06.155 Clinical Efficacy of Natalizumab and Immunological Effects in Progressive MS Patients with High Degrees of Disability Dimitrios Karussis, Oded Ambramsky, Panayiota Petrou, Tamir Ben Hur, Adi Vaknin-Dembinsky P06.156 Real-World Assessment of Adherence and Persistence to SecondLine Disease-Modifying Therapies Among Multiple Sclerosis Patients Rachel Halpern, Sonalee Agarwal, Leigh Borton, Tomislav Babic 99 Poster Session VI P06.157 GERONIMUS Study: Progression Rates to Multiple Sclerosis According to McDonald and Poser Criteria in Patients with Clinically Isolated Syndrome. On Behalf of the GERONIMUS Study Group Roberto D’Alessandro P06.158 Baseline Characteristics of Patients Enrolled in a Randomized, Multicenter, Placebo-Controlled and Active Comparator Trial Evaluating Efficacy and Safety of BG-12 in Relapsing-Remitting Multiple Sclerosis: The CONFIRM Trial Robert Fox, David Miller, Ted Phillips, Mariko Kita, Michael Hutchinson, Eva Havrdova, Minhua Yang, Katherine Dawson P06.159 Efficacy of Short Courses of Parenteral Cladribine in Patients with Aggressive Multiple Sclerosis Elizabeth Hartman, Rebecca Romero, Dusan Stefoski, Roumen Balabanov, Adil Javed P06.160 High Dose Cyclophosphamide Treatment in Marburg Variant of Multiple Sclerosis (MS): A Case Report Kenkichi Nozaki, Nada Abou Fayssal P06.161 Impact of Intramuscular Interferon Beta-1a on Multiple Sclerosis Disease Severity: Analysis of Patients from the MSCRG and ASSURANCE Studies Using the Multiple Sclerosis Severity Scale Joseph Herbert, Bianca WeinstockGuttman, Pamela Foulds, Xiaojun You P06.162 Characteristics of Switching From Interferon beta to Glatiramer Acetate in Non- Respondent- Relapsing Remitting Multiple Sclerosis Celia Oreja-Guevara, Pedro Bermejo-Velasco, Ambrosio Miralles, Exuperio Diez-Tejedor P06.163 Four Cases of Co-Morbid Multiple Sclerosis and Psoriasis: Sustained Remission of Both Conditions While on Natalizumab Regina Berkovich P06.164 Exploring Alemtuzumab’s Long Term Efficacy and Safety: Design of the CARE-MS Extension Study Christopher LaGanke, N. A. on Behalf of the CAMMS Study Groups P06.165 Efficacy of Natalizumab in a French Cohort of Multiple Sclerosis Patients Olivier Outteryck, Jean-Claude Ongagna, Hélíne Zéphir, M.-C. Fleury, Arnaud Lacour, Frédéric Blanc, Patrick Vermersch, Jérome de Síze P06.166 Central Demyelination Complicating the Use of Anti-TNFα in the Treatment of Inflammatory Bowel Disease (IBD): A Retrospective Study Carolina Ionete, Valentine Ebuh, Anupam Singh, Kevin Kane, Jane Lavallee, Peter Riskind, John Zawacki P06.167 Improvement in PatientReported Fatigue and Cognitive Function over Time with Natalizumab Treatment Judith Stephenson, Sonalee Agarwal, Likun Hou, Siddhesh Kamat, Krithika Rajagopalan P06.168 Motherhood and Natalizumab—Effects of Natalizumab Therapy on Pregnancy Outcome and Disease Activity during Pregnancy Kerstin Hellwig, Aiden Haghikia, Ralf Gold 100 P06.169 Dosing of Rituximab in Demyelinating Disease: How Much Is Enough? Benjamin Greenberg, Donna Graves, Jason Silversteen, Gina Remington, Elliot Frohman P06.170 Oral Fingolimod (FTY720) Reduces the Rate of Relapses That Require Steroid Intervention or Hospitalization Compared with Intramuscular Interferon β-1a: Results from a Phase III Study (TRANSFORMS) in Multiple Sclerosis Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Xavier Montalban, Jean Pelletier, Tracy Stites, Stacy Wu, Benjamin Eckert, Jeffrey Cohen, on Behalf of the TRANSFORMS Study Group Multiple Sclerosis and Related Diseases: Clinical Trials and Clinical Research P06.171 Oral Fingolimod (FTY720) vs Placebo in Relapsing-Remitting Multiple Sclerosis: 24-Month Safety and Tolerability Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study (FREEDOMS) Paul O’Connor, Chris Polman, Reinhard Hohlfeld, ErnstWilhelm Radue, Peter Calabresi, Krzysztof Selmaj, Lixin Zhang-Auberson, Catherine Agoropoulou, Malgorzata Leyk, Ludwig Kappos, on Behalf of the FREEDOMS Study Group P06.172 Leukocyte Dynamics Following Alemtuzumab Treatment of Relapsing-Remitting Multiple Sclerosis in a Phase II Study (CAMMS223) Alasdair Coles, N. A. on Behalf of the CAMMS223 Study Group P06.173 Efficacy and Safety of Natalizumab in the STRATA Study Chris Polman, Andrew Goodman, Ludwig Kappos, Fred Lublin, Paul O’Connor, Richard Rudick, Stephanie Jurgensen, Dominick Paes, Fiona Forrestal, Christophe Hotermans P06.174 Simvastatin Treatment Favours the Long-Term Outcome of Patients with ON Anna Tsakiri, Benedikte Wanscher, Jette Frederiksen P06.175 Efficacy of Natalizumab After Insufficient Response to Other DiseaseModifying Therapies for the Treatment of Relapsing- Remitting Multiple Sclerosis Norman Putzki P06.176 Natalizumab Treatment for Multiple Sclerosis in Clinical Practice Dinah Thyerlei, Lynda Hillman, Valerie Woolvett, Dora Krasucki, Annette Wundes P06.177 Use of Glatiramer Acetate During Pregnancy: Offering Women a Choice Aaron Miller, Jennifer Reardon P06.178 Immunological Response to Glatiramer Acetate in MS Patients after Different Pretreatments—The CopImmunoNet Study Nina Kleiner, Tjalf Ziemssen Thursday, April 15 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P06.179 Development and First Evaluation of the New Patient Management and Documentation System MSDS 3D for Patients with Multiple Sclerosis Tjalf Ziemssen, Fabian Kratzsch, Marco Eulitz, Raimar Kempcke, Nina Kleiner P06.190 Diffusion Tensor Imaging Reveals Differences in Normal Appearing Corpus Callosum in Childhood Onset Multiple Sclerosis and Monophasic Demyelinating Events Jan-Mendelt Tillema, Istvan Pirko P06.180 Intellectual Enrichment Lessens the Negative Impact of Brain Atrophy on Cognition in Multiple Sclerosis James Sumowski, Glenn Wylie, Nancy Chiaravalloti, John DeLuca P06.191 White Holes and Their Impact on Physical Disability in Patients with Multiple Sclerosis Francesca Bagnato, Vasiliki Ikonomidou, Peter van Gelderen, Sungyoung Auh, Marco Riva, Fernanda Tovar-Moll, Nancy Richert, Joan Ohayon, Fredric Cantor, Jeffrey Duyn, Henry McFarland P06.181 Multiple Sclerosis (MS) and Pregnancy: A Comparison Study Dessa Sadovnick, Magdalena Dybalski, Colleen Guimond, Irene Yee, Pierre Duquette Multiple Sclerosis and Related Diseases: Clinical Immunology P06.182 Inflammatory Cytokines and Chemokines in the Cerebrospinal Fluid of Multiple Sclerosis Patients Following Administration of Natalizumab Aaron Kithcart, Amy Lovett-Racke, Olaf Stüve, Nancy Monsoon, Caroline Whitacre, Michael Racke P06.183 PI3Kγ: A Sex-Specific and Novel Therapeutic Target in the Treatment of CNS Autoimmune Injury NaTosha Gatson, Hong Ji, Christian Rommel, Caroline Whitacre P06.184 Anti-Inflammatory and Pro-Metabolic Effects of BG-12 in Glial Cells Douglas Feinstein, Paul Polak, Lucia Lisa, Cinzia Dello Russo, Shao Xia Lin, Anthony Sharp Multiple Sclerosis and Related Diseases: Disease Prediction and Diagnosis P06.185 On Prediction Power of MRI for Future Development of Relapsing Remitting Form of Multiple Sclerosis Manuela Vaneckova, Jan Krasensky, Eva Havrdova, Dana Horakova, Zdenek Seidl P06.186 Relapsing Tumefactive Lesions Are Associated with a More Aggressive Course of Multiple Sclerosis Sibyl Wray, Adil Javed, Bruce Hughes P06.187 Diffusion Tensor Imaging as a Clinical Trial Outcome Metric: Sample Size Estimates Robert Fox, Ken Sakaie, Jian Lin, Thomas Cronin, Mark Lowe, Michael Phillips, Xiao-feng Wang P06.188 Memory Impairment in MS Correlates to Hemodynamic Response in Event-Related fMRI of Episodic Memory Lael Stone, Katherine Koenig, Blessy Mathew, Stephen Rao, Robert Bermel, Micheal Phillips, Mark Lowe P06.189 Early MS Activity on Subtraction MRI Predicts Lesion Accrual and Atrophy over Five Years Maria Liguori, Dominik Meier, Peter Hildenbrand, Brian Healy, Bastian Moraal, Rohit Bakshi, Tanuja Chitnis, Frederik Barkhof, Charles Guttmann P06.192 MRI-Only Conversion to MS Following a Clinically Isolated Syndrome Declan Chard, Catherine Dalton, Josephine Swanton, Leonora Fisniku, Katherine Miszkiel, Alan Thompson, Gordon Plant, David Miller P06.193 Post-Natalizumab Rebound: A CNS Immune Reconstitution Inflammatory Syndrome (CIRIS) Jai Perumal, Christina Caon, Stephanie Hreha, Fen Bao, Megha Shah, Zahid Latif, Imad Zak, Alexandros Tselis, Omar Khan P06.194 Diagnosing Multiple Sclerosis from Conventional MR Images Using Pattern Recognition Techniques Martin Weygandt, Hackmack Kerstin, Caspar Pfüller, Judith Bellmann-Strobel, Friedemann Paul, Frauke Zipp, John-Dylan Haynes Multiple Sclerosis and Related Diseases: Multiple Sclerosis Differential Diagnosis P06.195 Multiple Sclerosis and Systemic Sarcoidosis: A Double Diagnosis Aimee Szewka, Monica McAndrews, Michael Ko, Dusan Stefoski, Roumen Balabanov P06.196 Cerbral Amyloid Angiitis: Two Unique Case Presentations Rohit Marawar, Kelly Donnelly, Earl Zimmerman, Jiang Qian, Michael Gruenthal P06.197 An Unusual Case of a Rapidly Progressive Leucoencephalopathy Arjune Sen, Prem Ranji, Ute Pohl, Abhijit Chaudhuri P06.198 Development of Neurosarcoidosis During Exposure to AntiTNF-Alpha Medications for Rheumatoid Arthritis: Case Report Daniel Harrison, Carlos Pardo-Villamizar, Justin McArthur P06.199 Solitary Focal Demyelinating Lesion as a Cause of Progressive Myelopathy William Schmalstieg, Mark Keegan, Brian Weinshenker P06.200 Multiple Sclerosis in a Patient with Duchenne Muscular Dystrophy Adrienne Salomon, Negar Sodeifi, Babak Movassaghi, David Libell P06.201 Atypical Symptoms to ’Flag’ Non-Demyelinating Disease in Patients with Suspected MS Siobhan Kelly, Elijah Chaila, Niall Tubridy, Michael Hutchinson Poster Session VI Thursday, April 15 | 3:00 p.m.–7:30 p.m. First Authors Stand by Poster from 6:00 p.m.–7:30 p.m. P06.202 Association of Parkinsonian Syndrome with Multiple Sclerosis: A Report of 27 Cases Valerie Jaillon-Riviere, Karine Droulon, Jerome De Seze, Christine Lebrun, Jean Pelletier, Patrick Vermersch, Giovanni Castelnovo, Patrick Hautecoeur, Olivier Heinzlef, Lucien Rumbach, Gilles Defer P06.203 Long-Term Intrathecal Baclofen Therapy in Ambulatory Multiple Sclerosis Patients James Stark, Armistead Williams, Saud Sadiq P06.204 Therapeutic Considerations and Outcome of Steroid Refractory Neurosarcoidosis: Five-Year Single Centre Experience Sandipan Pati, Yazan Alderazi, Roberto Bomprezzi, Aman Deep, Timothy Vollmer Multiple Sclerosis and Related Diseases: EAE/Drugs P06.205 Ingested (Oral) Somatostatin (SST) Inhibits Acute EAE Staley Brod, Zachary Hood P06.206 Possible Neuroprotection and Th17 Modulation by a Red Wine Component, Resveratrol, in a Mouse Model for Multiple Sclerosis, Theiler’s Virus Infection Fumitaka Sato, John Rose, Noel Carlson, Alireza Minagar, Ikuo Tsunoda P06.207 Detailed Analysis of CD52 Expression and Cellular Depletion/ Repopulation after Alemtuzumab Treatment in HuCD52 Transgenic Mice Michael Turner, Michael LaMorte, Matthew Gale, Jacqueline Shields, Johanne Kaplan, Bruce Roberts, William Siders P06.208 Axonal Protection Effect of Laquinimod Appears Partially Independent of Its Inhibitory Effect on Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis Christiane Wegner, Christine Stadelmann, Emanuel Raymond, Bracha Timan, Liat Hayardeny, Wolfgang Brück P06.209 Protection from CD8+ T Cell-Mediated Experimental Autoimmune Encephalomyelitis by CD28 Superagonistor Glatiramer Acetate-Stimulated CD4 + T Cells Shin-Young Na, Niklas Beyersdorf, Rainer Apfel, Thomas Kerkau, Thomas Hünig P06.210 Intrathecal Methotrexate Reduces Astrogliosis in a Murine Model of Experimental Demyelination Adam Nassery, Xinhe Liu, Jesse Greenberg, Andre Mueller, Saud Sadiq P06.211 Effects of Acamprosate (Acamp) in Experimental Autoimmune Encephalomyelitis (EAE) Zohara Sternberg, Raymond Sobel, Bing Zhu, Fredrick Munschauer P06.212 Oral Treatment with Purified Polysaccharide A (PSA) of Human Commensal Bacteroides fragilis Protects Against Experimental CNS Demyelinating Disease Javier Ochoa-Repáraz, Yan Wang, Daniel Miecarz, Sakhina Begum-Haque, Dennis Kasper, Lloyd Kasper P06.222 Mouse Loci Influencing Inflammatory Demyelinating Disease: Shared Synteny Between Tmevd2/Eae3 and the MS Locus on Chr 1 Identified by Admixture Mapping Chase Petersen, Karren Spach, Elizabeth Blankenhorn, William Hickey, Cory Teuscher P06.213 Therapeutic Effects of Oral Fingolimod (FTY720) in an Animal Model of the Progressive Disability of Multiple Sclerosis Andrew Pachner, Priyanka Apte, Jennifer Brady, Libin Li P06.223 Sustained Release Fampridine Improves Walking Speed Across a Wide Range of Baseline Deficits: Pooled Data from Three Placebo-Controlled Studies in Patients with Multiple Sclerosis Keith Edwards, Theodore Brown, Randall Schapiro, Andrew Goodman, Lawrence Marinucci, Ron Cohen, Andrew Blight, on Behalf of the MS-F202, MS-F203, and MSF204 Study Groups P06.214 Effects of Glatiramer Acetate on T Cells in the Mouse Model Xin Ding, Rainer Apfel, Thomas Kerkau, Thomas Hünig, Niklas Beyersdorf Multiple Sclerosis and Related Diseases: EAE/Drugs and Disease Mechanisms and Imaging and Genetics P06.215 Beneficial Effect of IgG Glycans Hydrolysis by EndoS in Experimental Autoimmune Encephalitis Mahdia Benkhoucha, MarieLaure Santiago-Raber, Martin Weber, Mattias Collins, Patrice Lalive P06.216 Alteration of Osteopontin Cytokine Expression in Experimental Autoimmune Encephalomyelitis by Glatiramer Acetate Sakhina BegumHaque, Marc Christy, Eli Kasper, Islam Fayed, Javier Ochoa-Reparaz, Daniel Mielcarz, Jacqueline Smith, Azizul Haque, Lloyd Kasper P06.217 Lipoic Acid Confers Neuroprotection in Experimental Autoimmune Optic Neuritis Priya Chaudhary, Gail Marracci, Xiaolin Yu, Danielle Galipeau, Dennis Bourdette P06.218 A Cyclophilin D Inhibitor (Debio 025) Protects Axons in Experimental Autoimmune Encephlomyelitis: A New Therapeutic Target for Neuroprotecion in Multiple Sclerosis Dennis Bourdette, Gail Marracci, Priya Chaudhary, Jean-Maurice Dumont, Grégoire Vuagniaux, Michael Forte P06.219 Dietary Supplementation with N-3 Polyunsaturated Fatty Acids Restores Normal Emotional Behaviors in Autoimmune-Prone BAFF Transgenic Mice Rosalia Crupi, Linda Sparz, Edoardo Spina, Fortunato Battaglia P06.220 BAF312, a Potent and Selective S1P1/5 Receptor Modulator Reverses Ongoing Chronic EAE in Mice Barbara Nuesslein-Hildesheim, Frédéric Zécri, Christian Bruns, Nigel Cooke, Timothy Seabrook, Paul Smith P06.221 In Vivo Characterization of the Therapeutic Effect of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis by Magnetic Resonance Imaging (MRI) Rina Aharoni, Inbal Biton, Ruth Arnon P06.224 Does Benign Form of Neuromyelitis Optica Exist? Nicolas Collongues, Philippe Cabre, Romain Marignier, Helene Zephir, Anne Caroline Papeix, Bertrand Audoin, Christine Lebrun Frenay, Bertrand Fontaine, Patrick Vermersch, Christian Confavreux, Jerome De Seze Multiple Sclerosis and Related Diseases: EAE Disease Mechanisms P06.225 Identifying Factors That Determine Disease Susceptibility in C57BL/6 Mice for Adoptive Transfer of Experimental Autoimmune Encephalomyelitis Tresa Zacharias, LiHong Ben, Petra Cravens, Sima Zein, Todd Eagar, Rehana Hussain, Stefan Nessler, Scott Zamvil, Olaf Stuve P06.226 Central Motor Conduction Failure Examined with the Triple Stimulation Technique Correlates with Pyramidal Tract Dysfunction and Disability in Patients with Multiple Sclerosis Ulrich Hofstadt-van Oy, Christoph Klawe, Dirk Hagenburger, Reinhard Reuá, Patrick Oschmann P06.227 CMV Infection Modulates the Disease Course of TMEV Induced Demyelinating Disease in SJL/J Mice Istvan Pirko, Rhonda Cardin, Yi Chen, Anne Lohrey, Robert Zivadinov, Aaron Johnson P06.228 Cytochrome C Deficiency Ameliorates Neurodegeneration in Animal Models of Amyotrophic Lateral Sclerosis and Multiple Sclerosis Andrew Chan, Ulrich Schweizer, Bartosz Pula, Sabrina Ruhrmann, Ralf Gold, Michael Sendtner, Stefan Wiese, Aiden Haghikia P06.229 Serum Phosphorylated Neurofilament Heavy Chain Is a Marker of Axonal Loss in Experimental Optic Neuritis Tania Arguello, Gerry Shaw, Vittorio Porciatti, Rajeshwari Koilkonda, John Guy P06.230 Mercury Increases Th17 Polarization and Exacerbates Experimental Autoimmune Encephalomyelitis: Dependence on Matrix Metalloproteinase-9 Scott Sloka, Claudia Silva, Janet Wang, Yan Fan, Tiona Todoruk, Luanne Metz, Wee Yong P06.231 Etiology of Exaggerated Axon Loss in MAGKO Mice with EAE: Activated Microglia Laying in Wait? Melina Jones, Thien Nguyen, John Griffin, Peter Calabresi P06.232 Specific Regulation of CD4 T Cells During Autoimmune Demyelination by microRNA Marcin Mycko, Agnieszka Machlanska, Maria Cichalewska, Magdalena Marasiewicz, Bozena Szymanska, Hanna Cwiklinska, Krzysztof Selmaj P06.233 Estrogen Dependent Attenuation of EAE in a Transgenic Mouse Expressing the RNA Regulator, HuR, in Astrocytes Crystal Wheeler, Burt Nabors, Scott Barnum, Xianzhen Hu, Trenton Schoeb, Peter King P06.234 Therapeutic Effects of Lipoic Acid in Experimental Autoimmune Encephalomyelitis Depend on Expression of the Prostaglandin Receptor EP2 Gail Marracci, Priya Chaudhary, Brooke Morris, Sonemany Salinthone, Daniel Carr, Dennis Bourdette Aging and Dementia: Imaging Connectivity P06.235 Relationship between Microstructural Degeneration of the Corpus Callosum, White Matter Hyperintensities, and Executive Function in Cognitively Intact Elderly Lisa Silbert, Louie Perkins, Jeffrey Kaye P06.236 Aging and Gender Effects on the Cortical Anatomical Network Efficiency Gaolang Gong, Pedro RosaNeto, Felix Carbonell, John Chen, Yong He, Alan Evans P06.237 Distinct White Matter Tract Changes in Frontotemporal Dementia Associated with FTLD and Alzheimer’s Disease Pathology or CSF Biomarkers William Hu, Hui Zhang, Corey McMillan, Virginia Lee, John Trojanowski, Murray Grossman P06.238 Structural Correlates of Memory Performance with Diffusion Tensor Imaging Efrat Sasson, Glen Doniger, Ofer Pasternak, Ely Simon, Yaniv Assaf P06.239 The Effect of Memantine on the Activity of the Resting Working Memory Network in Alzheimer’s Disease D. Paternico’, M. Lorenzi, A. Beltramello, E. Canu, G. Zoccatelli, M. Cotelli, F. B. Pizzini, D. Costardi, F. Alessandrini, S. Rosini, G. B. Frisoni P06.240 Age Effect on Functional Connectivity David Jones, Prashanthi Vemuri, Mary Machulda, Kirk Welker, Bradley Boeve, David Knopman, Ronald Petersen, Clifford Jack P06.241 White Matter Integrity Accounts for Reaction Time in Older Adults Geoffrey Kerchner, Caroline Racine, Sandra Hale, Victor Laluz, Reva Wilheim, Stephen Hauser, Bruce Miller, Joel Kramer 101 Poster Session VI P06.242 Early and Late Onset Alzheimer’s Disease Patients Have Distinct Patterns of White Matter Damage Elisa Canu, Federica Agosta, Michela Pievani, Giovanni Frisoni, Massimo Filippi P06.243 Evidence for Brain White Matter Damage and Atrophy with Aging: A Diffusion Tensor MRI Tractography Study Federica Agosta, Stefania Sala, Elisabetta Pagani, Domenico Caputo, Massimo Filippi P06.244 Regional Relation of Gray Matter Atrophy with Corpus Callosum Alteration in Normal, MCI, and AD Dong Young Lee, Evan Fletcher, Oliver Martinez, Natalia Zozulya, Jane Kim, Jeannie Tran, Michael Buonocore, Owen Carmichael, Charles DeCarli Headache and Facial Pain P06.245 Telcagepant Does Not Reduce Exercise Tolerance in Patients with Exercise- Induced Myocardial Ischemia Andrew Ho, Bernard Chaitman, Martin Behm, Janice Rowe, John Palcza, Tine Laethem, Ingeborg Heirman, Deborah Panebianco, Valentin Moiseev, Sergey Martsevich, Almena Free, Tony Ho, Neville Bittar, Steven Chrysant, Zhanna Kobalava , Jeffrey Chodakewitz, M. Gail Murphy, Rebecca Blanchard P06.246 Cutaneous Allodynia as a Prognostic Factor in the Treatment of Migraine with Botulinum Toxin Paul Mathew, Fred Cutrer, Ivan Garza P06.247 Does Gender Affect Efficacy and Tolerability of SumaRT/Nap During the Early Intervention Treatment of Migraine? Shelly Lener, Jill Palchinsky, Nathalie Richard, April Thompson P06.248 Headache Prophylaxis Using Combination Therapy—A Statistical Modeling Study Bibhutibhushan Mishra, Leah Gaedeke, Richard Amdur, Bernhard Samuel P06.249 Experience with Botulinum Toxin Type A in the Treatment of Medically Intractable Pediatric Chronic Daily Headache Kamran Ahmed, Kimberly Oas, Kenneth Mack, Ivan Garza P06.250 OnabotulinumtoxinA for Treatment of Chronic Migraine: Analysis of the 56-Week PREEMPT 1 Trial Sheena Aurora, Ninan Mathew, Stephen Forner, Dennis Riff, Xiaofang Lei, Catherine Turkel P06.251 OnabotulinumtoxinA for Treatment of Chronic Migraine: Analysis of the 56-Week PREEMPT 2 Trial David Dodick, Marek Gawel, Reto Agosti, Tamara Ann Miller, Xiaofang Lei, Catherine Turkel P06.252 Intracranial Hypotension Mimicking Focal Spinal Amyotrophy Enrico Ferrante, Dante Facchetti, Ines Arpino, Alberto Citterio, Roberto Sterzi P06.253 OnabotulinumtoxinA for Chronic Migraine: PREEMPT Trials Establish a Safe and Effective Dose and Injection Paradigm Andrew Blumenfeld, Stephen Silberstein, David Dodick, Sheena Aurora, Catherine Turkel, William Binder 102 P06.254 Antialgic Effect of Low Intensity Laser in the Treatment of Cervicogenic Headaches Jose Speciali, Renata Pizzo, Fabiola Dach, Rosane Lizarelli P06.255 Acute Medication Use Patterns in Episodic Migraine: Results of the American Migraine Prevalence and Prevention Study (AMPP) Richard Lipton, Dawn Buse, Daniel Serrano, Wendy Golden, Ya-Ting Chen, Marcelo Bigal P06.268 Reversible Cerebral Vasoconstriction (RCVS) in Children and Adolescents (C/A): Its Role in Thunderclap Headaches Shalaka Indulkar, Catalina Cleves, S. Pinar Karakas, Sumit Parikh, A. David Rothner P06.269 Osmophobia Is Increased in Menstrually Associated Migraine Christine Matarese, F. Michael Cutrer P06.256 Spreading Depression: The Effects of Antiepileptic Drugs Used in Migraine Prophylaxis Joao Baptista De Moraes P06.270 Cardiac Autonomic Dysfunctions in Migraine Attack Dong-jin Shin, Sung-Hyouk Kim, Wook-Jin Chung, Seung-Won Seol P06.257 Is Telcagepant Effective in Migraineurs Who Previously Used Opioids? Andrew Ho, James Kost, Carl Dahlof, Stephen Silberstein, Samar Froman, Heather Leibensperger, Christopher Lines, Tony Ho P06.258 Fungal Sinusitis: A Surgically Treatable Cause of Chronic Daily Headache Pedro Kowacs, Renato Iachinski, Gustavo Nogueira, Ana Amélia Torres P06.259 Efficacy of Enalapril in Migraine Prophylaxis: Does It Work Through Endothelial Dysfunction Recovery? Seyed Ali Sonbolestan, Kiyan Heshmat, Shaghayegh Javanmard, Mohammad Saadatnia P06.260 Intravenous Valproate Sodium Aborts Migraine Headaches Rapidly Radi Shahien, Abdalla Bowirrat, Saad Abu Saleh P06.261 Acute Anti-Migraine Efficacy and Tolerability of Zelrix™, a Novel Iontophoretic Transdermal Patch of Sumatriptan Mark Pierce, Angel Angelov P06.262 Bilateral Masseter and Temporalis Hypertrophy: Case Report and Review of Literature Pinky Agarwal, Marilyn Borromeo-Wesner, Alida Griffith P06.263 Pulse IV Steroid and IV Valproate Combination Therapy for Sustained Relief of Chronic, Treatment Refractory Headaches in Patients with Psychiatric Disorders Hasan Askari, Muhammad Zaidi P06.264 Regression of Chronic Migraine and High Frequency Episodic Migraine to Low Frequency Migraine through Surgery Deborah Reed, Bahman Guyuron P06.265 Spontaneous Retinal Venous Pulsations as a Window to CSF Pressures—Are They Reliable? Paul McMonagle P06.266 A Case of Multiple Cranial Neuropathies from Perineural Spread of a Non-Melanoma Skin Cancer Ryan Walsh, David Capobianco P06.267 Serial Polysomnography in Hypnic Headache Shows No Association with REM Sleep Mark Obermann, Dagny Holle, Thomas Wessendorf, Sebastian Zaremba, Charly Gaul, Hans-Christoph Diener, Zaza Katsarava Friday, April 16 Highlights Thursday, April 15 | 3:00 p.m.–7:30 p.m. Metro Toronto Convention Centre / Room 808 P06.281 Natural History of Post -Traumatic Headache: Prevalence, Impact, and Clinical Characteristics Sylvia Lucas, Jeanne Hoffman, Sureyya Dikmen, Kathleen Bell Future of Neuroscience Conference: Frontiers in Neuroimaging: Coming Soon to a Scanner Near You P06.282 An Analysis of Practice Guidelines on Headache Published by American Academy of Neurology Arun Antony, Najib Murr This interactive day-long program focuses on neuroimaging, and will feature poster sessions, platform presentations, a series of case vignettes, and several invited speakers discussing new developments in the field. The presenters will combine high-level science with practical clinical application. Registration is required to attend this session, in addition to Annual Meeting registration fee. P06.283 New Daily Persistent Headaches (NDPH)—Follow Up and Outcome in Children and Adolescents (C/A) Sahithya Wintrich, David Rothner 9:00 a.m.–9:20 a.m. Brief History of Neuroimaging in Neurology 9:00 a.m.–5:00 p.m., Room 718A Walter Koroshetz, MD P06.271 A Tale of Two Systems: Cardiac Cephalalgia vs. Neurologic Cardiodynia Paul Mathew, Christopher Boes, Ivan Garza P06.284 Body Mass Index (BMI) and Migraine in the Korean Population Min Kyung Chu, Kyung Mi Oh, Byung-Gun Kim, Jae-Myun Chung, Kwang Soo Lee, Richard Lipton 9:20 a.m.–9:55 a.m. Imaging White Matter Connections: A Transforming MRI Technology P06.272 Onset and Potential Initiating Factors in New Daily-Persistent Headache Matthew Robbins, Brian Grosberg, Uri Napchan, Sara Crystal, Richard Lipton P06.285 Temporomandibular Disorders, Headache Status and Headache Frequency: A Population-Based Study Jose Speciali, Daniela Gonçalves, Cinara Camparis, Marcelo Bigal 9:55 a.m.–10:30 a.m. High Field Strength Structural MRI: What Becomes Visible With Increasing Teslas P06.273 Relationship between Headache Frequency and MigraineRelated Disability in the International Burden of Migraine Study (IBMS) Wilcox Teresa, Andrew Blumenfeld, Sepideh Varon, Krista Payne, Aubrey Manack, Dawn Buse, Peter Goadsby, Richard Lipton P06.286 Sex Hormone Receptor Gene Polymorphisms and Migraine: A Systematic Review and MetaAnalysis Markus Schuerks, Pamela Rist, Tobias Kurth P06.274 The Effect of Serum Glucose Level on Cerebrovascular Reactivity to CO2 in Women with Migraine without Aura: Transcranial Doppler Study Using Breath Holding Method Jeong-Ho Park, Sun-Ah Park, Tae-Kyeong Lee, Ki-Bum Sung P06.275 Impact of Nutritional Factors on the Prevalence of Headache or Migraine Catherine Buettner P06.276 Rates and Predictors of Remission from Chronic Migraine (CM) to Episodic Migraine (EM): Results from the American Migraine Prevalence and Prevention (AMPP) Study Aubrey Manack, Dawn Buse, Daniel Serrano, Catherine Turkel, Richard Lipton P06.277 Prevalence of Chronic Daily Headaches as a Function of Parental Headache Status—Results from the “Attention Brazil Project” Marco Arruda, Vincenzo Guidetti, Federica Galli, Regina Albuquerque, Marcelo Bigal P06.278 PTSD, Drug Abuse, and Migraine: New Findings from the National Comorbidity Survey Replication (NCS-R) B. Peterlin, Andrea Rosso, Fred Sheftell, David Libon, Jana Mossey, Kathleen Merikangas P06.279 Cutaneous Allodynia—A Predictor of Migraine Chronification: A Longitudinal Population-Based Study Sait Ashina, Dawn Buse, Marcelo Bigal, Daniel Serrano, Michael Reed, Richard Lipton P06.280 Results from an International Observational Study of Pregnancy Outcomes Following Exposure to Sumatriptan, Naratriptan, or the Fixed Dose Tablet Sumatriptan and Naproxen Sodium (SumaRT/Nap) Frederick Derosier, Marianne Cunnington P06.287 Relationship between Migraine Status and Functional Outcome from Stroke Pamela Rist, Julie Buring, Tobias Kurth P06.288 Acute Treatment of Migraine in Patients with Cardiovascular Disease or Risk Factors Wendy Golden, Marcelo Bigal, Junhua Yu, Henry Hu, Diana Brixner, Richard Lipton, Joanne LaFleur P06.289 5-HTTLPR Polymorphism in the Serotonin Transporter Gene and Migraine: A Systematic Review and MetaAnalysis Markus Schuerks, Pamela Rist, Tobias Kurth P06.290 Caffeine Intake in Adolescents Upon First Visit to Headache Specialty Center Chad Whyte, A. Rothner P06.291 Association between Socioeconomic Status and Migraine with and without Aura Anke Winter, Julie Buring, Tobias Kurth P06.292 Field Testing Chronic Migraine Criteria in the Population: Results of the German Headache Consortium (GHC) Study Zaza Katsarava, Aubrey Manack, Min-Suk Yoon, Mark Obermann, Dagny Holle, Peter Dommes, Catherine Turkel, Richard Lipton, Hans-Christoph Diener P06.293 Triptan Use as a Function of Cardiovascular Risk. A Population-Based Study Marcelo Bigal, Wendy Golden, Dawn Buse, Ya-Ting Chen, Richard Lipton P06.294 Prenatal Tabagism and Alcohol Intake Are Associated with Chronic Daily Headache at Childhood. A Population-Based Study Marco Arruda, Vincenzo Guidetti, Federica Galli, Regina Albuquerque, Marcelo Bigal Jeremy Schmahmann, MD, FAAN Jeff Duyn, PhD 10:30 a.m.–11:05 a.m. Imaging Brain Networks: Merging Structural and Functional MRI Michael Greicius, MD, MPH 11:05 a.m.–11:25 a.m. Break and Posters 11:25 a.m.–12:00 p.m. Quantitative Imaging as a Marker of Diagnosis and Progression of Neurodegenerative Diseases Bradford Dickerson, MD 12:00 p.m. SC01.001 Functional Networks in Chronic Migraine: A Resting State Functional Connectivity MRI Study Todd Schwedt, Soe Mar, Tracy Nolan, Tammie Benzinger, Bradley Schlaggar, Linda Larson-Prior 12:15 p.m. SC01.002 Adenosine A2A Receptor Availability in Parkinson’s Disease Patients with and without Levodopa Induced Dyskinesias Studied with [11C] SCH442416 PET Anil Ramlackhansingh, Subrata Bose, Imtiaz Ahmed, Federico Turkheimer, Nicola Pavese, David Brooks 1:30 p.m.–2:05 p.m. Functional Imaging of Targets in Psychiatric Disease Helen Mayberg, MD 2:05 p.m.–2:40 p.m. Quantitative Perfusion Imaging in Acute Stroke: Treatment Decisions Based on Imaging Ting-Yim Lee, PhD, FCCPM 2:40 p.m. SC01.003 21.1-Tesla Magnetic Resonance Microscopy (MRM) in Neurodegeneration Katherine Schweitzer, Parastou Foroutan, Dennis Dickson, Uwe Klose, Daniela Berg, Daniel Broderick, Zbigniew Wszolek, Samuel Grant 2:55 p.m. SC01.004 Hippocampal Neuropil Atrophy Visualized in Mild Alzheimer’s Disease Using 7-Tesla MRI Geoffrey Kerchner, Christopher Hess, Kathryn Hammond-Rosenbluth, Duan Xu, Douglas Kelley, Daniel Vigneron, Sarah Nelson, Bruce Miller 3:10 p.m.–3:30 p.m. Break and Posters 3:30 p.m.–4:05 p.m. MRI Focused Ultrasound: Turning Deep Brain Structures On and Off Ferenc Jolesz, MD 4:05 p.m.–4:40 p.m. The New PET: Imaging Molecular Targets in Neurological Disease Peter Herscovitch, MD 4:40 p.m.–5:00 p.m. Questions and Answers Poster Presentations Presentation Times: 11:05 a.m.–11:25 a.m., 3:10 p.m.–3:30 p.m. SC02.001 Correlation of directional diffusivity with Neurological Status in Leukodystrophies Soe Mar, Tammie Benzinger SC02.002 Serotonergic Terminals are Differentially Affected in Parkinson’s Disease: An in vivo 11C-DASB PET study Marios Politis, Kit Wu, Clare Loane, Lorenzo Kiferle, Sophie Molloy, David Brooks, Paola Piccini SC02.003 Reliable Detection of Specific Spatial Patterns of Cortical Thinning in Subtypes of Primary Progressive Aphasia: A Quantitative MRI-Based Imaging Biomarker Bradford Dickerson, Daisy Sapolsky, Alyson Negreira, Michael Brickhouse, Derin Cobia, Emily Rogalski, Sandra Weintraub, M. Mesulam SC02.004 Quantification of Age-Related Shape Changes in the Cerebral Cortex Using Fractal Dimension Richard King, Kristen Kennedy, Karen Rodrigue, Denise Park SC02.005 Using Multi-Modal Imaging to Tease Apart Atypical Dementia Cases Howard Chertkow, Jim Nikelski, Gabriel Leger, Leah Litwin, Victor Whitehead, Alan Evans SC02.007 Primary Outcome Analysis of the Multicentre Phase II Trial of 18F-Flutemetamol, a Pittsburgh Compound B Derivative for In Vivo Beta Amyloid Imaging Rik Vandenberghe, Koen Van Laere, Adrian Ivanoiu, Eric Salmon, Eric Triau, Gunhild Waldemar, Steen Hasselbalch, Ian Law, Allen Andersen, A. Korner, L. Minthon, Chris Buckley, Lennart Thurfjell, David Brooks SC02.008 Resting State Functional Connectivity is Disrupted after Traumatic Axonal Injury (TAI) Tianshi Wu, Shuvro De, An Nguyen, Carlos Marquez de la Plata, Carol Moore, Caryn Harper, Christopher Madden, Ramon Diaz-Arrastia SC02.009 Abnormal Interictal Resting State Activity in Episodic Migraine Till Sprenger, Christian Seifert, Michael Valet, Kathrin Staehle, Thomas Toelle, Annette Foerschler, Claus Zimmer, Peter Goadsby SC02.010 Network-Level Structural Covariance in the Developing Brain Brandon Zielinski, Efstathios Gennatas, Juan Zhou, William Seeley SC02.006 Functional MRI Suggests Iron Deposition in Pain Regulatory Nuclei in Episodic Migraine and Chronic Daily Headache Stewart Tepper, Kechung Liu, Stephen Jones, Micheal Phillips, Mark Stillman, Mary Horvat, Mark Lowe Richard King, MD, PhD 12:30 p.m.–1:30 p.m. Luncheon New! Clinical Trials Session 12:00 p.m.–1:30 p.m., MTCC Theatre 102 This midday seminar covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented with a question and answer period following. The session will cover several scientific topics. Scientific Program Highlights Plenary Session 5:15 p.m.–6:15 p.m., MTCC, Theatre 102 Moderator: Stefan M. Pulst, MD, FAAN, Chair, Science Committee and Scientific Program Subcommittee This plenary reviews the most critical new research from more than 2,000 studies presented throughout the 2010 Scientific Program. Education Programs will end at 5:00 p.m. Friday, allowing time for meeting participants to attend this session. 103 Integrated Neuroscience Session: Ischemic Stroke, Interventional, and Endovascular Therapies/Large Vessel Disease Integrated Neuroscience Session: Molecular Markers and Targets in Neuro-oncology Friday, April 16 | 8:00 a.m.–12:00 p.m. Friday, April 16 | 1:00 p.m.–5:00 p.m. Coordinators: Seemant Chaturvedi, MD, FAAN and Pierre Fayad, MD Coordinators: Tracy Batchelor, MD, MPH and Josep Dalmau, MD, PhD Invited Speaker Session* / 8:00 a.m–9:30 a.m. / Reception Hall 104A–D Platform Session / 1:00 p.m–2:30 p.m. / Reception Hall 104A–D 8:00 a.m.–8:20 a.m. Acute Occlusive Large Vessel Disease Raul Nogueira, MD 8:20 a.m.–8:40 a.m. Extracranial Large Vessel Disease and Carotid Revascularization Adnan Qureshi, MD, FAAN 8:40 a.m.–9:00 a.m. Non-Atherosclerotic Large Vessel Vasculopathy Cheryl Bushnell, MD, MHS 9:00 a.m.–9:20 a.m. Intracranial Atherosclerotic Large Vessel Disease Edward Feldmann, MD 9:20 a.m.–9:30 a.m. Questions and Answers 1:00 p.m. IN10-1.001 Radiation Sensitivity of Neural and Progenitor Stem Cells Nizar Souayah, Lubna Mehyar, Nazsa Baker, Steve Levison Poster Session / 9:30 a.m.–10:30 a.m. / Reception Hall 104A–D IN9-1.001 Occurrence of Subacute Recanalization and Collateral Formation in Patients with Cerebral Venous Thrombosis. A Serial Venographic Study Abeer Farraq, Muna Irfan, Gaurav Guliani, Yousef Mohammad, Jay Joshi, Robert Taylor, M. Fareed Suri, Adnan Qureshi IN9-1.002 Trends in Clinical Outcome, Recanalisation and Reocclusion with Different Stroke Subtypes: A Multi-Center Transcranial Doppler Study Joseph Sebastian, Georgios Tsivgoulis, Andrei Alexandrov, Vijay Sharma, Khurshid Khan, Mohammed Ibrahim, Ken Uchino, Ashfaq Shuaib, Andrew Demchuk, Maher Saqqur IN9-1.003 Intra-Arterial Thrombolytic Infusion after Six Hours of Symptom Onset in Patients with Anterior Circulation Ischemic Stroke: A Matched Case Control Study Mushtaq Qureshi, Jefferson Miley, Gabriela Vazquez, Muhammad Zeeshan Memon, Haitham Hussein, M. Fareed Suri, Ramachandra Tummala, Robert Taylor, Harold Adams, Adnan Qureshi IN9-1.004 Safety and Feasibility of Intracranial Stenting for Acute Ischemic Stroke Beyond Eight Hours of Symptom Onset Ambooj Tiwari, Natasha Purai, Amit Kansara, Andrew Xavier IN9-1.005 How Frequently Are Ischemic Stroke Patients Eligible for Decompressive Hemicraniectomy? A Population-Based Study Richard Curry, Ope Adeoye, Brett Kissela, Kathleen Alwell, Charles Moomaw, Matthew Flaherty, Pooja Khatri, Daniel Woo, Simona Ferioli, Joseph Broderick, Dawn Kleindorfer IN9-1.006 A National Study Comparing Carotid Artery Stent Placement with Carotid Endarterectomy in Octogenarians and Non-Octogenarian Population Rakesh Khatri, Gabriela Vazquez, M. Fareed Suri, Yousef Mohammad, Kamakshi Lakhsminarayan, Adnan Qureshi IN9-1.007 Endovascular Management of Symptomatic Extracranial Stenosis and Associated Secondary Tandem Stenosis Fazeel Siddiqui, Gabriela Vazquez, Ameer Hassan, Nauman Tariq, M. Fareed Suri, Robert Taylor, Adnan Qureshi IN9-1.009 Stenting and Angioplasty in Small, Distal Cerebral Arteries for Symptomatic Intracranial Atherosclerosis Using Wingspan Junaid Kalia, Kaiz Asif, John Lynch, Brian-Fred Fitzsimmons, Osama Zaidat IN9-1.008 Factors Associated with Neurological Complications Following Intracranial Angioplasty and/ or Stent Placement. A Multicentric Study Nauman Tariq, Ameer Hassan, Gabriela Vazquez, Haitham Hussein, M. Fareed Suri, Alexandros Georgiadis, Ramachandra Tummala, Robert Taylor, Adnan Qureshi IN9-1.010 Impact of Endovascular Treatment for Cerebral Vasospasm on Subarachnoid Hemorrhage Patient Outcomes in a Comprehensive Stroke Program Alberto Maud, Rakesh Khatri, Haralabos Zacharatos, Muhammad Zeeshan Memon, Ather Taqui, Mushtaq Qureshi, Gabriela Vazquez, M. Fareed Suri, Ramachandra Tummala, Robert Taylor, Mustapha Ezzeddine, Adnan Qureshi 1:15 p.m. IN10-1.002 Role of Perfusion MR Imaging in Differentiating Between TumorProgression and Pseudo-Progression in Recurrent Glioblastoma Multiforme Christel HeidemansHazelaar, Bas Van der Kallen, Antoinette Verbeek, Charles Vecht 1:30 p.m. IN10-1.003 Sunitinib as an Antitumor Substance in Human Meningioma Cells Christian Mawrin, Nadine Andrae, Elmar Kirches 2:00 p.m. IN10-1.005 Retrospective Review of Symptomatic Intracranial Hemorrhage (ICH) in Cancer Patients Treated with Bevacizumab; the Memorial SloanKettering (MSK) Experience Mustafa Khasraw, Samuel Goldlust, Andrew Lassman, Lisa DeAngelis 2:15 p.m. IN10-1.006 [18F]FACBC and [18F]FLT PET Imaging for Glioblastomas (GBM) Christian Grommes, Timothy Akhurst, Ronald Blasberg, Bradley Beattie, Mikhail Doubrovin, Jenna Monaster, Andrew Lassman IN10-2.002A Dramatic and Prolonged Response to Meningeal Gliomatosis Jeremy Rudnick, Rebecca Naor, Franklin Moser, Surasak Phuphanich IN10-2.004Multi-Parametric Imaging and Immunohistochemistry Studies of the Effects of YC-1 on Rat C6 Glioma Josée Bergeron, Antonio Aliaga, Barry Bedell IN10-2.006Late Relapse in Primary Central Nervous System Lymphoma Lakshmi Nayak, Marc Ladanyi, Cyrus Hedvat, Lauren Abrey, Lisa DeAngelis IN10-2.003Lacosamide in Brain Tumor Patients Lizbeth Robles-Irizarry, Kathy Lupica, Glen Stevens IN10-2.005Post-Therapy NonHemorrhagic T1 Hyperintensity on MRI in PCNSL Patients and Its Prognostic Implication Vineet Punia, Sasan Karimi, Antonio Omuro IN10-2.007Neurological Outcome of Childhood Brain Tumor Survivors Sari Pietilä, Anne Mäkipernaa, Hanna Lenko, Anna-Maija Koivisto, Raija Korpela 1:45 p.m. IN10-1.004 Efficacy of Bevacizumab Following Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor (VEGF-R) for Recurrent Glioblastoma (GBM) Samuel Goldlust, Robert Cavaliere, Antonio Omuro, Lisa DeAngelis, Lauren Abrey, Herbert Newton, Meier Hsu, Andrew Lassman Poster Session / 2:30 p.m–3:30 p.m. / Reception Hall 104A–D IN10-2.001Primary Central Nervous System EBV-Associated Lymphomatoid Granulomatosis: A Comprehensive Study of Three Cases Pamela New, Hidehero Takei, Chung-Che Chang, Youli Zu Invited Speaker Session* / 3:30 p.m–5:00 p.m. / Reception Hall 104A–D 3:30 p.m.–3:55 p.m. MGMT in the Management of Gliomas Warren Mason, MD 3:55 p.m.–4:15 p.m. Tumorigenic Glioma Stem Cells Santosh Kesari, MD, PhD 4:15 p.m.–4:35 p.m. Angiogenesis-Targeting Therapy for Malignant Gliomas Patrick Wen, MD, FAAN 4:35 p.m.–5:00 p.m. Targeted Therapies in Glioblastoma Alfred Yung, MD, FAAN Platform Session / 10:30 a.m.–12:00 p.m. / Reception Hall 104A–D 10:30 a.m. IN9-2.001 Ultra-Early Recanalization and Re Occlusion in Patients with Acute Ischemic Stroke: A Multimodal Serial Angiographic Study Mushtaq Qureshi, Alberto Maud, M. Fareed Suri, Ramachandra Tummala, Robert Taylor, Mustapha Ezzeddine, Adnan Qureshi 10:45 a.m. IN9-2.002 Building Radiological Support for Intra-Arterial Delivery by Gaining Efficiency—The BRIDGE Study Andrew Barreto, Sminil Mahajan, Shuichi Suzuki, Kathy Masters, Vivek Misra, Indrani Acosta, Sean Savitz, Roc Chen, Nicole Gonzales, Anitha Abraham, Terrell Evans, Clarence Johnson, Nusrat Harun, Digvijaya Navalkele, James Grotta 11:00 a.m. IN9-2.003 Hospital and Operator Characteristics Associated with Optimal Outcomes Following Carotid Artery Stenting Seemant Chaturvedi, William Gray, Jon Matsumura, Patrick Verta, Lei Peng 11:15 a.m. IN9-2.004 Evolving Technique in Vertebral Artery Origin Stenting Randall Edgell, Rishi Gupta, Linfante Italo, Andrew Xavier, Alex Abou-Chebl, Raul Nogueira, Siddhartha Varma, Junaid Kalia, Vahid Etezadi, Osama Zaidat, Research Consortium Society of Vascular and Interventional Neurology 11:30 a.m. IN9-2.005 Transcranial Laser Therapy for Acute Ischemic Stroke: A Pooled Analysis of NEST-1 and NEST-2 Andrew Stemer, Branko Huisa, Justin Zivin 11:45 a.m. IN9-2.006 Acute Intra-Carotid Delivery of Mesenchymal Stem Cells in Middle Cerebral Artery Occlusion Dileep Yavagal, Tienlong Pham, Baowan Lin, Sushrut Dharmadhikari, Philip Garza, Ian McNiece, Joshua Hare, Miguel Perez-Pinzo *Current as of February 1, 2010 104 *Current as of February 1, 2010 105 2010 Virtual Annual Meeting Products ordered on this order form will be mailed during the Annual Meeting. 2010 Syllabi on CD Enjoy quick and convenient access to complete syllabi from more than 175 education programs. 2010 Webcast-on-Demand Receive online access to the slides, audio, and video of more than 130 hours of education programs and presentations on the latest science, including all six plenary sessions. Owning both the Webcast-on-Demand and the Syllabi on CD provides a quick and convenient method to stay up-to-date on AAN education programming. 2010 Practice CD Convenient access to 15 AAN Regional Conference and Annual Meeting practice related syllabi conveniently located on a single disk. Attending the 2010 Annual Meeting? xx Order your copy of the Syllabi on CD, online access to Webcast-on-Demand, the MP3 On-Demand, and practice CD on the registration order form on page 113 under box C. xx Pick up your products at the Annual Meeting. If you do not pick up your CD at the meeting, there will be an additional $15.00 shipping and handling charge. Not Attending the 2010 Annual Meeting? If you are unable to attend the Annual Meeting, order your copy of the Syllabi on CD, online access to Webcast-on-Demand, MP3 DVD, and Practice CD and take advantage of the special pre-meeting pricing. Simply fill out and fax the completed order form located on this page to (651) 361-4800. Products ordered on this form will be mailed during or after the Annual Meeting. SPECIAL RATE ON SYLLABI ON CD FOR AAN JUNIOR MEMBERS Purchase the 2010 Annual Meeting Syllabi on CD at a discounted pre-meeting rate of $49. This rate is only available to AAN Junior members (one copy per Junior member). Note: the discounted rate is available until March 10, 2010. Orders received after March 10, 2010, will be charged the member meeting price. 2010 Virtual Annual Meeting Order Form Special Reduced Pricing Before March 10 After March 10 Quantity_ Total $49 $99 $149 $299 $299 $299 _______ _______ _______ �������� �������� �������� $99 $149 $199 $599 $599 $599 _______ _______ _______ �������� �������� �������� Syllabi oN CD Junior and Non-Neurologist Member (limit 1) Member Neurologist Nonmember WEBCAST-ON-DEMAND Junior and Non-Neurologist Member (limit 1) Member Neurologist Nonmember Virtual Annual Meeting Two-Pack (Syllabi on CD and Webcast on-Demand) Junior and Non-Neurologist Member (limit 1) Member Neurologist Nonmember $129 $199 $299 $849 $849 $849 _______ _______ _______ �������� �������� �������� $39 $49 $59 $99 $99 $99 _______ _______ _______ �������� �������� �������� MP3 On-Demand and DVD (available after AAN Annual Meeting) Junior and Non-Neurologist Member $99 $299 Member Neurologist $149 $299 Nonmember $199 $299 _______ _______ _______ �������� �������� �������� Practice CD Junior and Non-Neurologist Member Member Neurologist Nonmember Virtual Annual Meeting Three-Pack (Webcast, syllabi, and mp3) Junior and Non-Neurologist Member Member Neurologist Nonmember $199 $299 $499 US Shipping: $39.00 – $75.00������������������������������������������������������� $7.95 $75.01 – $120.00���������������������������������������������������� $9.95 $120.01 – $250.00������������������������������������������������ $12.95 $250.01 – $500.00������������������������������������������������ $14.95 For orders over $500 and international orders call AAN Member Services (see below). $1,099 $1,099 $1,099 Please send: Grand Total Shipping (see left) Total amount due _______ _______ _______ �������� �������� �������� $ $ $ Price includes applicable sales tax For questions, contact AAN Member Services at [email protected], (800) 879-1960, or (651) 695-2717 (International). Junior and Non-Neurologist Member Member Neurologist Nonmember Name ������������������������������������ Address (for shipping)������������������������� ���������������������������������������� Payment (must accompany form): Check (US funds only, do not send cash) Make Payable to American Academy of Neurology VISA Master Card American Express Address line 2 ������������������������������ Credit card number ���������������������������������������� ���������������������������������������� City/State ��������������������������������� Expiration Date ___ /___ ZIP/Postal code ����������������������������� Print name��������������������������������� Signature���������������������������������� Country����������������������������������� Phone������������������������������������ Mail or fax completed order form to: American Academy of Neurology / 1080 Montreal Avenue / St. Paul, MN 55116 / Fax: (651) 361-4800 Did You Know? Still available: 2009 Syllabi on CD, printed syllabi, Webcast-on-Demand, audio CDs, and MP3 downloads are still available from the 2009 Annual Meeting. Visit the AAN Store™ at www.aan.com/store for more information. 107 General Information Cme/Accreditation Unlabeled Use Disclosure Internet Center Cell Phones Accreditation The AAN requires all Annual Meeting presenters to disclose if a product is not labeled for the use being discussed or if the product is still investigational. Unlabeled use disclosures will be included in individual program materials. The AAN strives to offer the latest in technological products and services designed to make communicating between the office, colleagues, or family easier while attending the 62nd Annual Meeting. The Internet Center provides attendees with computer workstations, printers, and Internet access. Check email, enter course or session notes, or search the AAN website. Enhancements to the Internet Message Center allow faster access to messages and the ability to search for other attendees by name, company, or networking topics of interest. The AAN requests that attendees turn cellular phones and pagers to vibrate mode upon entering all Annual Meeting programs. Contact your service provider directly to inquire if service is available and/or the applicable rates. Wireless Connection Sponsored by Neurology® The Metro Toronto Convention Centre is a nonsmoking facility. For the health and comfort of everyone, smoking is prohibited at Annual Meeting functions, which include all education and scientific activities and social functions. Business Center Press Room Metro Toronto Convention Centre has a business center that offers administrative and office services, including copy machines, faxes, and shipping services. The business center is located in the North Building on the Third Floor. Only authorized media may use the Press Room at the Annual Meeting. Journalists must check in at the Press Room and provide proper credentials. For more information, contact Angela Babb at [email protected] or (651) 695-2789. First Aid Station Volunteer Opportunities A First Aid station is located in the North Building on the second floor of the Metro Toronto Convention Centre. The station is staffed by licensed medical professionals and fully equipped with supplies, including automatic external defibrillators (AED). The station is operational throughout the duration of the Annual Meeting. Education and Scientific Program Monitors The AAN is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education (CME) for physicians. CME: American Medical Association Physician’s Recognition Award™ The AAN designates select Annual Meeting activities for a specific number of AMA PRA Category 1 Credit™ hours towards the American Medical Association Physician’s Recognition Award. (See individual program description for specific number of credits per program.) Physicians should only claim credit commensurate with the extent of their participation in the activity. CME: Education Program AMA PRA Category 1 Credits are awarded for courses, seminars, workshops, morning reports, neuro flashes, neurology skills pavilions, luncheons, and kick-off programs. (See individual program description for specific number of credits per program). Confirmation of CME credits earned at the 2010 Annual Meeting will be available to attendees approximately four to six weeks after the Annual Meeting. Disclaimers/Disclosures Education/Scientific Disclaimer The primary purpose of the Annual Meeting is to offer education and scientific programs to attendees. Information presented—as well as publications, technologies, products, and/or services discussed—is intended to inform attendees about the knowledge, techniques, and experience of physicians willing to share that information with colleagues. A diversity of opinions exists in the medical field and the views of Annual Meeting physician participants do not represent those of the AAN or constitute endorsement by the AAN. The AAN disclaims any and all liability for all claims that may result from the use of information, publications, products, and/or services discussed at the Annual Meeting. Disclosure of Commercial Relationships According to AAN and ACCME policies, Annual Meeting presenters must disclose any significant financial or other relationship with industry. All presenters must sign an AAN Letter of Agreement stating explicitly they understand and will adhere to AAN and ACCME policies that require full disclosure of commercial relationships, unlabeled use of products, and identification of data sources. Full disclosure of presenters’ commercial relationships will be included in individual program materials. This policy is intended to provide attendees with information about faculty commercial relationships in order for attendees to evaluate material discussed during an education activity. 108 General Information Education Grants Some Annual Meeting education and scientific programs are supported in part by education grants from the AAN’s industry supporters. Support acknowledgment statements are included in individual program descriptions and materials. Although industry support is received, all programs are developed and implemented solely by the AAN Education Committee and its Annual Meeting Subcommittee, the Science Committee and its Scientific Program Subcommittee, and AAN staff. Industry supporters must sign an AAN Letter of Agreement stating they will not influence the faculty or directors and agreeing to no direct control or input. The AAN uses grant funds to support and enhance existing, as well as new, education programs. Services Child Care Information A variety of child care options is available in Toronto, Ontario. Check with the concierge at your hotel on or before your arrival to make your arrangements. Shuttle Services Complimentary shuttle bus service will be provided between designated official AAN hotels (see below) and the convention centre. Schedules will be available at the Metro Toronto Convention Centre and will also be posted in each hotel lobby that has shuttle service. Route 1 xx Sheraton Centre Toronto Hotel xx Hilton Toronto (will use Sheraton stop) Route 2 xx The Fairmont Royal York xx The Strathcona Hotel (will use Fairmont stop) Route 3 xx Radisson Admiral Hotel-Toronto Harbourfront xx The Westin Harbour Castle Route 4 xx Hyatt Regency Toronto Route 5 xx Toronto Marriott Downtown Eaton Centre Hotel xx Delta Chelsea Hotel xx Courtyard by Marriott Downtown Toronto Wireless Internet hotspots will be available at the Metro Toronto Convention Centre. Guidelines Photography and Recording of Programs The AAN strictly prohibits all unauthorized photography (flash, digital, or otherwise), audio and/or videotaping during the Annual Meeting. Equipment will be confiscated. Consent to Use of Photographic Images Registration and attendance at, or participation in, AAN/AAN Professional Association meetings and other related activities constitutes attendee’s authorization to AAN’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs, video recordings, electronic reproductions, and audio recordings of the events and activities. Language The official language of the Annual Meeting is English. No simultaneous translation is available. No Smoking Monitors are needed for all education program offerings and scientific platform sessions to distribute and collect evaluation materials and assist directors, faculty, session co-chairs, and staff as required. The AAN will waive all monitors’ Annual Meeting registration and education program fees as well as grant CME credit for the monitored program. Space is available on a first-come, first-served basis. For an application form or more information, contact Kyle Krause at [email protected] or (651) 695-2733. EMG Skills Workshop Volunteers Volunteers are needed to participate in the EMG Clinical Skills Workshops on Sunday, April 11, and Monday, April 12. Volunteers are also needed to participate in the Neurophysiologic Intraoperative Monitoring Skills Workshop on Wednesday, April 14. Skills workshop subjects will receive a waived meeting registration and workshop fee as well as payment of $40 per noninvasive session and $60 per invasive session. Space is available on a first-come, first-served basis. For more information, contact Elizabeth Busch at [email protected] or (651) 332-8685. Weather/Attire The climate in Toronto in early spring is generally cool and damp. In April, temperatures usually range from 42 degrees to 70 degrees Fahrenheit. It can be quite wet, so a waterproof coat and umbrella are a good idea, as are layered clothing and a good jacket. The AAN promotes business casual attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary. 109 Registration Online Registration Enjoy the convenience and efficiency of registering online at www.aan.com/abstractreg. Early Registration Deadline: March 10, 2010 Register early to avoid increased general registration and Education Program fees. Any registrations received after March 10, 2010, will be charged higher rates. On-site registration opens at 8:00 a.m. on Saturday, April 10, 2010, at the Metro Toronto Convention Centre. Underserved Countries If you are from one of the following countries, you are entitled to receive your general registration fee waived and access to lower cost hotels. In addition, you also qualify for two free education programs. To register online, enter an Invitation Code of “unmbr” if you are an AAN member or “unnon” if you are not an AAN member. US and Canadian registrants who submit their registration form before March 10, 2010, will receive Annual Meeting name badges and Education Program tickets by mail. Those who register after March 10, 2010, will pick up their badges and tickets on-site. Badges and tickets will be reprinted once at no cost. There will be a $100 administrative fee for each reprint thereafter. The countries are: Afghanistan, Bangladesh, Benin, Bolivia, Burkina Faso, Burundi, Cambodia, Cameroon, Central African Rep., Chad, Comoros, Congo Dem. Rep., Congo Rep., Cote d’lvoire, Eritrea, Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Kenya, Korea Dem. Rep. North, Kyrgyz Rep., Lao PDR, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Myanmar, Nepal, Nicaragua, Niger, Rwanda, Sao Tome and Principe, Senegal, Sierre Leone, Somalia, Sudan, Tajikistan, Tanzania, Togo, Uganda, Uzbekistan, Vietnam, Yemen Rep., Zambia, and Zimbabwe. Fees Scientific Program Presenters General Registration Fee The general registration fee is mandatory for all registrants and is determined by AAN member type. AAN Member Types Include: Medical Student/PhD Candidate Members: Medical Students and PhD candidates who are members of the AAN are not required to pay the general registration fee and pay non-neurologist rates for Education Programs. Junior Members: Non-neurologist rates are for Junior (resident, fellow, post-doctoral graduate) members of the AAN. Physicians in training who are not Junior members must pay nonmember rates. Business Administrator, Research Scientist, Non-Neurologist Clinician Members: These members pay non-neurologist member rates. Fellow, Active, Associate, Honorary, and Senior Members: AAN members must pay their current year’s dues to register at neurologist member rates. Honorary and Senior members are not required to pay the general registration fee. Many programs and events are FREE with your badge. See page 110 for details. Special Membership Considerations Nonmembers: Become an AAN member and receive significant discounts on Annual Meeting registration and Education Program fees. For an AAN membership application, contact AAN Member Services at (800) 879-1960 or (651) 695-2717. Medical Student/PhD Candidate nonmembers: To be eligible for the student rate as a nonmember, a student ID card or a letter from a professor must be submitted. The general Annual Meeting registration fee will be waived but nonmember rates must be paid for all Education Programs. For an AAN membership application, contact AAN Member Services at (800) 879-1960 or (651) 695-2717 (international). 110 Registration All platform and poster presenters must submit a registration form and pay the applicable registration fee. Note that fees after March 10 are significantly higher. Registration by March 10, 2010, is encouraged. Education Programs There is a fee for each selected offering within the Education Program. Enrollment is limited. Registration by March 10, 2010, is encouraged. Virtual Annual Meeting 2010 Virtual Annual Meeting Three-Pack—$299 Member Pre-Meeting Price ($1,099 List Price) Save $800 on the 2010 Webcasts-On-Demand and on DVD, 2010 Syllabi on CD, and 2010 MP3-On-Demand and on DVD. 2010 Webcasts-On-Demand and on DVD—Enjoy online access or disk archive of the slides, audio, and video of more than 130 hours of the latest science and education programs and presentations, including all six plenary sessions. (Purchase separately for $149 Member PreMeeting Price vs. $599 List Price.) 2010 Syllabi on CD—Quick and convenient access to complete syllabi from more than 175 education programs. (Purchase separately for $99 Member Pre-Meeting Price vs. $299 List Price.) 2010 MP3-On-Demand and on DVD—Audio files on today’s most significant scientific topics can be downloaded to your MP3 player or listened to on your disk player or computer. (Purchase separately for $149 Member Pre-Meeting Price vs. $299 List Price.) 2010 Virtual Annual Meeting Two-Pack—$199 Member Pre-Meeting Price ($849 List Price) Save $650 on the Webcasts-On-Demand and on DVD, plus the 2010 Syllabi on CD. 2010 Practice CD—$49 Member Pre-Meeting Price ($99 List Price) Enhance your practice and improve your bottom line with these 15 AAN Regional Conference and Annual Meeting practicerelated programs. Celebration for Research; Neurobowl®, Neuro Film Festival, Main Stage, Neuro Hop, and more! Each registered meeting attendee will receive one free ticket to these celebration events. Guest tickets are $50 each. See page 24. American Academy of Neurology and American Academy of Neurology Foundation Awards Luncheon Join the leaders of the AAN, the Science Committee, and the Lecture Awards Subcommittee in honoring recipients of the 2010 Scientific Awards Program on April 14, 2010. A limited number of seats are available for $50. Junior and Medical Student members may attend this event at no cost, but must obtain a ticket through registration. Group Registration Deadline: February 26, 2010 Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. No administrative fee is charged to register a group as long as housing is secured through the AAN’s official housing company, Convention Management Resources (CMR). Groups that have not secured housing through CMR can still register as a group; however, a $1,000 administrative fee will be charged. Contact CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 9792283 (international) to receive special registration instructions. See page 114 for housing information. Changes to Syllabi Process— Download in Advance Obtaining your Education Program syllabi is quicker and easier than ever. All registered attendees will be able to download the full syllabi for their selected programs, starting in late March. All registered attendees will receive an email notification once syllabi are available. Printed syllabi will not be available. Printed slides will be available in program rooms. Cancelled or Closed Programs Education programs may be canceled or closed due to capacity or insufficient enrollment. If any selections are canceled or closed and payment was made by credit card, the amount charged will include only the available programs. If paid by check, a full refund will be issued for affected programs. Allow four to six weeks after the Annual Meeting for processing refunds. Cancellations/Refunds of Registration Until March 10, 2010 Refund less $50 administrative fee March 11–April 2, 2010 Refund less $100 administrative fee After April 2, 2010 No refund xx All cancellations must be submitted in writing to [email protected] or fax to (415) 979-2260. xx No-shows will not receive a refund. xx Name substitutions are not permitted. xx No refunds will be processed for amounts of $20 or less. xx Programs are subject to cancellation if enrollment is insufficient. In the event of cancellation, registration for the cancelled course will be fully refunded. xx The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration cancellation. Special Needs Deadline: March 10 The Metro Toronto Convention Centre and the AAN are in compliance with the Americans with Disabilities Act or Human Rights Code and strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, contact Sarah Glover no later than March 10, 2010, at [email protected] or (651) 695-2804. Note: Kosher meals can be provided at any breakfast, lunch, or dinner seminar and should be arranged no later than March 10, 2010, by contacting Sarah Glover at [email protected] or (651) 695-2804. There is a $25 surcharge per meal. On-site requests cannot be accommodated. Exhibits Only To view the exhibits without registering for the Annual Meeting, a single-day pass is available at on-site registration for $100 per day. Changes in Education Programs Select education programs carefully. An administrative fee of $20 will be charged for each program change or cancellation. To assure correct mailing of your name badge and tickets, changes must be submitted in writing and received no later than March 10, 2010. After that date, changes must be made on-site and will be charged an administrative fee of $30 for each program change or cancellation. 111 What’s Free with Your Badge? The AAN Annual Meeting provides tremendous value to all registered attendees, with free access to a variety of programs and events included in your economical registration fee. Events of Interest to All Attendees Scientific Platform and Poster Sessions 60 Scientific Platform Sessions and 6 poster sessions throughout the meeting Plenary Sessions xx Presidential Plenary Session xx Hot Topics Plenary Session xx Frontiers in Clinical Neuroscience Plenary Session xx Contemporary Clinical Issues and Case Studies Plenary Session xx Awards Plenary Session xx Scientific Program Highlights Plenary Session Integrated Neuroscience Sessions xx Emerging Concepts in Genetics xx Pediatric Demyelinating Disorders xx Current Concepts in Cognitive Neuroscience: Implications for Neurological Disease xx Emerging Treatments in Neuromuscular Disease xx Global Neurology: Toxins and Infections xx Proteins, Genes, Neurodegeneration, and the Clinical Presentations xx Multiple Sclerosis Imaging xx Deep Brain Stimulation: Where Are We and Where Do We Go From Here? xx Ischemic Stroke, Interventional, and Endovascular Therapies/Large Vessel Disease xx Molecular Markers and Targets in Neuro-oncology Highlights in the Field Enjoy subspecialty highlights and networking with colleagues at meetings held throughout the meeting. Celebration for Research: Neurobowl®, Main Stage, Neuro Film Festival, and Neuro Hop Sunday, April 11 Exhibit Hall and Complimentary Luncheons xx Opening Reception: Monday, April 12, 5:00 p.m.–7:00 p.m. xx Hall Hours: Tuesday–Wednesday, 11:30 a.m.–5:00 p.m.; Thursday, 11:30 a.m.–4:00 p.m. xx Complimentary Luncheons: Tuesday–Thursday, 12:00 p.m.–2:00 p.m. 112 Of Interest to Practicing Neurologists xx BRAINS Colloquium: Critical Thinking for Critical Issues xx Patient Safety Colloquium: Diagnostic Errors in Neurology xx Practice Colloquium: Dialogue with the Insurer Medical Directors: A Conversation You Don’t Have Every Day xx Education Colloquium: International Education xx Web Wonders: The Must-Have Technologies for Neurologists in 2010 xx Best Care Expo: Guidelines, Government Relations, and Getting Paid xx ABPN MOC Informational Session xx Ethics Colloquium xx Corporate Therapeutic Updates xx Controversial Issues in Practice Session: Health Care Reform Of Interest to Neurology Advocates xx Best Care Expo: Guidelines, Government Relations, and Getting Paid xx Palatucci Advocacy Action Planning Roundtable Of Interest to Students, Residents, and Fellows Medical and graduate students and PhD candidates who present a student ID card or are AAN members receive free admission to the Annual Meeting. xx ABPN Resident Informational Session xx SIGN Meeting and Reception xx Consortium of Neurology Residents and Fellows Meeting xx Basic Science Resident Curriculum xx Residents and Fellows Career Forum and Reception xx Resident/Medical Student Rush Line Check in at the Information Booth each morning for tickets to available courses for that day. Two tickets will be held for each course, available on a first-come, first-served basis. Of Interest to International Attendees xx International Attendee Summit xx Integrated Neuroscience Session: Global Neurology: Toxins and Infections xx Education Colloquium: International Education xx International Component Posters at the Residents and Fellows Career Forum and Reception xx Members of underserved countries are entitled to receive their general registration fee waived and qualify for free Rush Line programs. How to Register The deadline for early registration is March 10, 2010. After this date, you must register on-site. Register quickly and easily at www.aan.com/abstractreg Step 1: Personal Information Box D: Additional Activities (optional): Register for special events, including: Remove the mailing label on the back of this book and affix it to the Personal Information box on the registration form. If the information on the label is incorrect, make corrections on the label or in the space provided. xx Celebration for Research xx AAN/AAN Foundation Awards Luncheon xx Run/Walk for Brain Research xx Buy a Brain Fundraiser Note: It is important that this information be current. A confirmation letter will be emailed or faxed. Name badge, tickets, and CME transcripts will be mailed to the address provided. Step 2: Education Program Step 5: Payment Shade the boxes corresponding to the Education Program type you wish to register and enter the program number on the line. Indicate method of payment. Full payment in US funds must accompany your registration form. Include credit card information or enclose a check made payable to the American Academy of Neurology. Note: Government credit cards are not accepted for advance registration, as they cannot be processed without the actual credit card. Government credit cards may be used on-site. Deadline: March 10 Registrations will be processed according to the date of receipt. Registrations received after March 10, 2010, will be processed at a higher rate. On-site registration opens Saturday, April 10, 2010, at 8:00 a.m. at the Metro Toronto Convention Centre. Box C: Virtual Annual Meeting (optional): Select a Syllabi on CD, Webcast-on-Demand, and/or Practice CD. Price includes applicable sales tax. If you do not pick up your CD at the AAN Store during the Annual Meeting, there will be an additional $15 shipping and handling charge. Questions: US/Canada International Email (800) 676-4226 (415) 979-2283 [email protected] Education Program Fee Schedule Use this table to calculate the fees for the number of registered programs. Tally the number of each type of program. Multiply the amount by the fee for your membership type. Transfer the total amount to Box B on the registration form. Note: Do not use this schedule for on-site registration. Neurologist member and nonmember fees increase $20.00 per program on-site. Program Type: AC/PC (Half-Day Course) AS (After-Dinner Seminar) BS (Breakfast Seminar) CS (Case Studies Program) DS (Dinner Seminar) EP* (Directors Conference) FC (Full-Day Course) KP (Kick-Off Program) LS (Luncheon Seminar) MR (Morning Report) NF (Neuro Flash) NP (Neurology Skills Pavilion) PW (PM Skills Workshop) SC** (Science Conference) SW (Skills Workshop) TP (Therapy Program) Junior and Non-Neurologist Member: Member Neurologist: x $45 = x $75 = x $70 = x $80 = x $110 = x $125 = x $90 = x $55 = x $70 = x $80 = x $110 = x $180 = x $180 = x $100 = x $350 = x $20 = Nonmember: (Honorary, Senior, Fellow, Active, Associate) (Junior, Research Scientist, Non-neurologist Clinician, Business Administrators, Students) x $110 = x $110 = x $95 = x $115 = x $160 = x $255 = x $210 = x $85 = x $95 = x $105 = x $160 = x $235 = x $235 = x $155 = x $460 = x $45 = x $140 = x $150 = x $125 = x $155 = x $185 = x $385 = x $265 = x $110 = x $125 = x $135 = x $185 = x $315 = x $315 = x $210 = x $615 = x $60 = *If you are attending the Clerkship and Program Directors’ Conference (1EP.001) only and no other Annual Meeting events, the cost increases $50. ** If you are attending the Future of Neuroscience Conference (7SC.001) only, and no other Annual Meeting events, the cost increases $70 ($170 on-site) and includes Thursday and Friday Scientific events. Medical students and PhD candidates may attend at no charge but MUST register and receive a ticket. 114 Primary Focus of Practice City/State/Country Fax Member Neurologist (Active, Associate, Fellow) $240 $355 Member Neurologist (Senior, Honorary) $0 $0 $545 $775 Nonmember BOX C: Virtual Annual Meeting Syllabi CD There is a fee for each selected Education Program. Calculate the total in the Education Program Fee Schedule on page 112 and enter in Box B in the Fees section. To register for a program, shade the box and enter the complete number of the program on the line. Saturday, April 10, 2010 1EP. 1AC. 2BS. 2AC. 2FC. 2DS. 2NP. Junior and Non-Neurologist Member $39 $99 Member Neurologist $49 $99 Nonmember $59 $99 MP3 ON-DEMAND and DVD (available after AAN Annual Meeting) 3AS. 3MR. 3NF. $849 $849 $849 $199 $299 $499 $1,099 $1,099 $1,099 BOX D: Additional Opportunities (check all that apply) Wednesday, April 14, 2010 Celebration for Research Guest Tickets (one free ticket per registrant) 5CS. 5SW. Thursday, April 15, 2010 6TP. 6CS. $50 ea. Run/Walk for Brain Research $25 ea. AAN and AAN Foundation Awards Luncheon (Junior Members and Students free upon request) $50 ea. Support Research, Buy a Brain $5 ea. TOTAL Friday, April 16, 2010 Registrations received after March 10, 2010, will be processed at higher rates 7SC. 7PC. 7PW. 7TP. 7NP. 7NF. Saturday, April 17, 2010 4. Exhibitors I would like to receive hard copy mailings, invitations, and emails from exhibitors. 5. Payment Check/Money Order Payment must accompany registration. Make check payable to American Academy of Neurology (US funds only). A $25 charge will apply to checks returned for insufficient funds. 8AC. Questions: $129 $199 $299 Junior and Non-Neurologist Member $99 $299 Member Neurologist $149 $299 Nonmember $199 $299 Virtual Annual Meeting Three-Pack (Webcast, Syllabi, and MP3) Junior and Non-Neurologist Member Member Neurologist Nonmember 4PC. 4NP. 6BS. 6PC. Junior and Non-Neurologist Member (limit 1) $99 $599 Member Neurologist $149 $599 Nonmember $199 $599 Virtual Annual Meeting Two-Pack (Syllabi on CD and Webcast ON-DEMAND) 2SW. 2LS. 2PC. Tuesday, April 13, 2010 5BS. 5PC. $299 $299 $299 Junior and Non-Neurologist Member (limit 1) Member Neurologist Nonmember Practice CD 3SW. 3PC. 3DS. 4BS. 4LS. $49 $99 $149 1KP. 1NP. Monday, April 12, 2010 3BS. 3AC. 3FC. Junior and Non-Neurologist Member (limit 1) Member Neurologist Nonmember Webcast ON-DEMAND 1FC. 1PC. Sunday, April 11, 2010 Register: $0 Calculated in program fee schedule on page 112 2. Education Program 8BS. After March 10 $0 BOX B: Education Program Fees Email 7BS. 7AC. 7FC. Before March 10 Student Junior and Non-Neurologist Member $90 $120 (Junior, Business Administrator, Non-Neurologist Clinician, Research Scientist) ZIP/Postal Code Telephone Total Program Fees (Enter in Box B on Registration Form): BOX A: General Registration Fee Address Registrant’s mailing and email addresses will be used for AANgenerated hard copy mailings and emails related to the Annual Meeting. Check the box if you would also like to receive hard copy mailings, invitations, and emails from third-party exhibitors. Box B: Education Program Fees: Calculate the total fees using the Education Program Fee Schedule. One form per registrant Name (last, first, middle) and degree (MD, DO, PhD, RN) Indicate your Primary Focus of Practice: Aging/Dementia, Behavioral Neurology, Cerebrovascular Disease, Chronic Pain, CNS Infectious Disease, Critical Care, EEG, EMG, Epilepsy, General Neurology, Headache, Interventional Neurology, Movement Disorders, Neuro-oncology, Neuro-ophthalmology, Neuropharmacology, Neurorehabilitation, Sleep Disorders, or currently not in practice. Box A: General Registration Fee: Select the appropriate fee. All attendees and Scientific Program presenters are required to pay this fee. See page 108 for fee inclusion details. 3. Fees 1. Personal Information AAN ID Number Step 4: Exhibitors Step 3: Fees AAN 62ND Annual Meeting Registration Form / Deadline: March 10, 2010 VISA Master Card Online: www.aan.com/abstractreg / Fax: (415) 979-2260 Mail: A AN Registration / CMR 33 New Montgomery, Suite 1100 San Francisco, CA 94105 Card number: Expiration date: [email protected] (800) 676-4226 US/Canada (415) 979-2283 International Signature American Express Diner’s Club / No government credit cards. I authorize the AAN to charge my credit card the amount determined by the AAN as registration fees. Fed ID# 41-0726167AAN 115 Hotel Reservations Save on Hotel Reservations Take advantage of the AAN’s special hotel rates to make your trip more affordable. Annual Meeting hotel accommodations are processed by Convention Management Resources (CMR). AAN Online Hotel Reservations www.aan.com/abstractreg The AAN makes it easy and convenient to book your hotel rooms for the 62nd Annual Meeting. Booking online allows you to: xx Take advantage of the AAN’s special hotel rates xx View room descriptions, photos, and availability xx Access maps of hotel proximity to Annual Meeting locations Mail, Fax, or Telephone Reservations All correspondence, questions, and inquiries should be directed to CMR at: Mail: AAN Housing c/o CMR 33 New Montgomery, Suite 1100 San Francisco, CA 94105 email: [email protected] Fax: Credit card reservations only (415) 979-2260 Phone: Credit card reservations only US/Canada (800) 676-4226 International (415) 979-2283 Hours: Monday–Friday 6:00 a.m.–6:00 p.m. (PST) Deposits xx All hotels require a credit card guarantee or a check deposit of $300 (US dollars) per room and $500 (US dollars) per suite. Deposits will be credited towards your first night’s room and tax. xx No hotel reservation will be processed without a credit card guarantee or a deposit. xx Deposits are refundable up to seven days prior to arrival, after which there will be no refunds. xx Credit cards will be charged for one night’s room and tax if you fail to arrive on the confirmed date of arrival or if you fail to cancel your reservation at least seven days prior to arrival. Hotel Reservations Form Confirmations, Changes, and Cancellations xx You will receive your hotel confirmation from CMR. This is the only confirmation you will receive. xx Contact CMR if your housing confirmation is not received within one week of mailing. xx Please check your arrival and departure dates carefully. xx After March 10, 2010, you may still submit your hotel form to CMR. After this date, however, rooms are subject to availability. Note: Some hotels may charge a penalty for changes made to your departure date after you have checked in. Group Accommodations Reservation Deadline: March 10, 2010 / Meeting Dates: April 10–April 17, 2010 1. Confirmation to: Please type or print clearly. One form per registrant. Confirmations sent by mail, fax, or email. Nonsmoking room Company name 6. Occupants: List all occupants, giving primary occupant first: Mailing address Additional Tax/Assessments Fax Booking your room through the official AAN housing company assures you are getting a room at the hotel that best fits your needs. You are also helping the AAN maintain consistent and competitive and registration fees. The reason is simple. When a city is selected as the site for the AAN Annual Meeting, contracts are signed with several hotels reserving a specific number of rooms to be available for meeting attendees. If these rooms are not sold, the AAN is liable financially. Penalties incurred affect the overall costs of the Annual Meeting and what the AAN charges for registration, exhibit space, and other services. Smoking room Note: Special requests are forwarded to the hotels for their consideration and are subject to availability. Blocks of 10 or more sleeping rooms are considered a group. Fax your written request to (415) 979-2260 or email to [email protected] and you will be contacted by an AAN Housing Consultant. Why Book a Hotel Room Through the AAN? Special Needs: Name (last, first, middle) City/State/Zip xx Rates do not include the 13.00% hotel tax. xx An $8 per night assessment fee is included to offset the expense of the meeting. NOTE: All hotel rates are listed in Canadian dollars and the amount due at the time of check out from your hotel will be based on current exchange rates. 5. Special Requests: 1. Country 2. 3. Telephone 4. 7. Payment: Email International attendees indicate country/city code: 2. Hotel Preference: Please indicate your choice (list ten hotels). Hotel rooms assigned on a first-come, first-served basis. 1. All AAN hotel reservations must be guaranteed with a credit card or check deposit of $300 per room, $500 per suite. No hotel reservations will be processed without a guarantee. Cancellation deadline is seven days prior to arrival date. Late cancellations subject to forfeit of room deposit or one night’s room plus tax charge. Check enclosed; Check no. Payable to: Convention Management Resources 2. 7. 3. 8. 4. 9. 5. 10. VISA American Express Diner’s Club Card number: Expiration date: Cardholder’s name: 6. 3. Accommodations: Master Card Signature: To register online visit www.aan.com/abstractreg Single: 1 person, 1 bed Double: 2 people, 1 bed Double/Double: 2 people, 2 beds Triple: 3 people, 2 beds Quad: 4 people, 2 beds Suite: 1 bedroom Suite: 2 bedrooms By mail: AAN Housing/CMR 33 New Montgomery, Suite 1100 San Francisco, CA 94105 Note: Suites are available on a limited basis. All persons requesting a suite will be contacted by an AAN Housing Consultant. By email: 4. Arrivals and Departures: By phone: Credit card reservations only Day and date of arrival: [email protected] Day and date of departure: US/Canada (800) 676-4226 International (415) 979-2283 Note: Some hotels may charge a penalty for departure date changes after check-in. By fax: Credit card reservations only (415) 979-2260 Hours: Monday–Friday 6:00 a.m.–6:00 p.m. (PST) Note: Rates are listed in Canadian dollars. The amount you pay when you check out will be based on the current exchange rates. 116 117 Travel Information Opportunities for Students, Residents, and Fellows Save on Travel Arrangements Direct Through Airlines Book your travel now to Toronto, ON, Canada and take advantage of special airline discounts available to meeting attendees and their companions. Airport You may also contact your preferred airline directly and receive a 2- to 10-percent discount off regularly published fares. You must reference the AAN Annual Meeting and provide the appropriate airline discount codes listed below. Toronto is served by the Toronto Pearson International Airport, located approximately 16 miles from the downtown area, and the Toronto City Centre Airport, located 8 minutes from downtown via ferry. Airline Discount Codes Phone Number Website United 586LT (800) 521-4041 www.united.com American 9940AC (800) 433-1790 www.aa.com Reservations and Discounts Delta NM483 (800) 328-1111 www.delta.com Porter NEURO10 (888) 619-8622 www.flyporter.com Carlson Wagonlit Travel Carlson Wagonlit Travel is the official travel agency for the Annual Meeting. For discounted airline tickets to the Annual Meeting and all of your pre- or post-meeting vacation plans including tours, event tickets, car rental, and more, contact Carlson Wagonlit Travel at: (City Centre Airport) Discounts are subject to availability—book well in advance. Normal mileage and status upgrades apply for all airline programs. A service fee may be charged for reservations made via phone. Travel Updates Phone: (866) 978-1071 Email: [email protected] Hours:Monday–Friday, 7:30 a.m.–5:00 p.m. CST Closed weekends and holidays A $52 international per ticket service charge will be assessed. For travel information updates, visit the AAN Annual Meeting website at www.aan.com/am. A valid passport is required for travel between the United States and Canada. The AAN Alliance offers a variety of tours during the AAN’s 62nd Annual Meeting in Toronto. Tours are open to all Annual Meeting attendees, their families, and guests. Tours are sponsored by the AAN Alliance and operated by the JPdL Destination Management tour company. Tour Registration Reservations for all tours are available by advance registration only and must be received by Thursday, March 18, 2010, by 5:00 p.m. EST, to guarantee space. To register, download the registration form at www.aan.com/go/about/alliance Submit printed form: xx By Fax to the AAN Tour Bureau at (416) 221-6372 (Visa, American Express & Master Card only) xx By Mail to AAN Tour Bureau, c/o JPdL Toronto, 2 Berkeley Street, Suite 500, Toronto, ON, Canada, M5A 4J5 (Money Order in Canadian Funds only), Visa, American Express & Master Card When registering, keep the following in mind: xx Credit card, check, and money order payments will be accepted until March 18, 2010. Registrations will be accepted based on availability. xx Advance registration is required. xx Prepaid tickets will be held in your name at the convention center’s Registration Desk. xx JPdL Destination Management tour company reserves the right to cancel tours when the minimum number of registrants is not met; pre-registered registrants will receive a full refund. xx All tour buses depart from and return to the Metro Toronto Convention Centre North. Please arrive 15 minutes prior to departure. xx A jacket and comfortable walking shoes are recommended for all tours. xx On-site registration will be subject to a $10.00 handling fee. Medical and graduate students and PhD candidates who present a student ID card or are AAN members receive free admission to the Annual Meeting. See page 112 for registration rates for residents and fellows. Basic Science Resident Curriculum A multi-year basic science curriculum, launched at the 2007 Annual Meeting, will help neurology residents prepare for Part I of the Neurology Boards, and the RITE ™. See page 23 for more details. Celebration for Research: Neurobowl®, Main Stage, Neuro Film Festival, and Neuro Hop Sunday, April 11/ 6:30 p.m.–11:00 p.m. See page 24 for details. Consortium of Neurology Residents and Fellows Meeting Monday, April 12 / 5:00 p.m.–6:00 p.m. AAN Alliance Tours Tours Available in the Toronto Area To help build careers in neurology, the AAN 62nd Annual Meeting offers a variety of opportunities to students, residents, and fellows. Annual Meeting registration for students, residents, and fellows includes scientific platform and poster sessions, Plenary Sessions, Colloquia, Awards Luncheon, Celebration for Research, and Exhibits. Medical students and residents also receive a reduced rate for Education Programs. Tour Information Sunday, April 11 2:00 p.m.-5:00 p.m. Discover Toronto City Tour Monday, April 12 9:00 a.m.-5:00 p.m. Niagara: The Wonder of It All Tuesday, April 13 12:00 p.m.-5:00 p.m. Historic Architectural City Tour with Visits to Bata Shoe Museum and Casa Loma Wednesday, April 14 1:00 p.m.-5:00 p.m. Two Unique Museums: Royal Ontario Museum and the Gardiner Museum of Ceramic Art Come and learn about the consortium, meet officers, and participate in discussions on a variety of topics related to residents and fellows. Residents and Fellows Career Forum and Reception Monday, April 12 / 6:30 p.m.–9:00 p.m. Learn how to search for a fellowship, how program directors select fellows, and how a fellowship could benefit your career. Find out how to start a career in academics/research and private practice. Socialize with other residents and fellows as well as representatives from various neurology programs and learn about potential positions from headhunters. Advertisers in Dendrite™ Careers in Neurology will also be on hand to discuss job opportunities. Programs that feature an international element will have the opportunity to showcase their programs. Free and open to all meeting registrants. See page 28 for more information. American Board of Psychiatry and Neurology Resident Informational Session Monday, April 12 / 4:00 p.m.–5:00 p.m. Meet members of the American Board of Psychiatry and Neurology (ABPN). The panel will discuss all aspects of the neurology boards and what is expected from candidates. Free and open to all meeting registrants. SIGN Meeting and Reception Monday, April 12 / 5:00 p.m.–6:30 p.m. Student and faculty representatives from existing Student Interest Groups in Neurology (SIGN) chapters and those interested in starting chapters will gather for presentations and discussions. This is free and open to all medical students. American Academy of Neurology and American Academy of Neurology Foundation Awards Luncheon Wednesday, April 14 / 12:00 p.m.–1:30 p.m. MTCC, Exhibit Hall B Join AAN leaders as they honor the recipients of the 2010 AAN Awards. From enterprising high school students to world renowned researchers, this program recognizes some of the top accomplishments in neuroscience research. See page 54 for more information. Resident/Medical Student Rush Line Check in at the Information Booth each morning for tickets to available courses for that day. Two tickets will be held for each course, available on a first-come, first-served basis. Eligible participants are limited to one free course per day, two free courses for the week unless there are unclaimed rush tickets ten minutes prior to a course starting. The program is available for half-day and full-day courses, case-study, kick-off, Neuro Flash, Neurology Skills Pavilion, Morning Report, and therapy programs. Seminars, workshops, and luncheons are not included. No CME will be provided. Thursday, April 15 1:00 p.m.-5:00 p.m. Truly Canadian! Opportunities to Save Money: Visit www.aan.com/go/about/alliance for more details. Discount on Virtual Annual Meeting products if ordered before Annual Meeting (see page 104). Education and Scientific Program Monitors, Skills Workshop Volunteers (see page 107) AAN Staff Contact Donna Honeyman [email protected] phone: (651) 695-2713 fax: (651) 361-4813 Note: All tour fees are Canadian currency. 118 119 Educational Programs and Scientific Sessions by Topic Aging/Dementia/Degenerative Disease 1KP.001 Assessment of Rapidly Progressive Dementias and Related Neurologic Conditions...............................................................7 2DS.001 Mild Cognitive Impairment: Implications for Clinicians...............................8 3MR.001 Morning Report: Behavioral Neurology........................................................8 3PC.003 Non-Alzheimer’s Dementia............................................................................9 3AS.001 Improving Accuracy of Dementia Diagnosis: Case Studies with Both Imaging and Neuropathology................................9 PD1 Aging and Dementia: Risk Factors Poster Discussion Session................ 34 P01 Poster Session I............................................................................................ 34 Presidential Plenary Session....................................................................... 31 IN5 Proteins, Genes, Neurodegeneration, and the Clinical Presentations Integrated Neuroscience Session.......................................41 P02 Poster Session II........................................................................................... 44 S14 Aging and Dementia: Epidemiology............................................................ 52 5BS.001 Anosognosia and Anosodiaphoria in Stroke and Dementia......................10 P03 Poster Session III.......................................................................................... 56 Geriatric Neurology Highlights in the Field................................................ 79 S24 Aging and Dementia:Imaging...................................................................... 66 P04 Poster Session IV......................................................................................... 68 S34 Aging and Dementia: Recognition and Treatment.................................... 76 5CS.001 Case Studies: Dementia...............................................................................11 6BS.001 Differential Diagnosis of Dementia: Linking Clinical Syndromes to Pathology...............................................................................11 P05 Poster Session V........................................................................................... 80 S44 Aging and Dementia: Cellular Anatomy and Exercise Physiology........... 90 S54 Aging and Dementia: Genetics................................................................... 92 P06 Poster Session VI......................................................................................... 94 7BS.001 Diagnosing Spells in Older Adults...............................................................12 7FC.002 Dementia Update..........................................................................................13 8BS.001 Vascular Cognitive Impairment and Dementia: Current Status and Future............................................................................13 Cerebrovascular Disease/Interventional Neurology 1KP.004 2FC.006 3AC.004 3LS.001 3PC.004 3DS.002 3NF.001 3AS.002 P01 4LS.001 S02 4PC.003 P02 S12 S18 4NP.001 P03 S22 5PC.005 P04 S32 P05 S42 120 Surviving Stroke Call: A Guide for Non-Vascular Neurologists..................7 Cerebrovascular Disease................................................................................7 Update on Endovascular Treatment of Cerebrovascular Diseases.............8 Primary and Comprehensive Stroke Centers: The Future of Stroke Care..............................................................................9 Stroke Prevention in 2010..............................................................................9 Stroke in Children and Neonates...................................................................9 Acute Stroke Management............................................................................9 Stroke Rehabilitation for Spatial Neglect: Win-Win Treatment Science..........................................................................9 Poster Session I............................................................................................ 34 Telemedicine Increases Options for Successful Stroke Treatment: Nuts and Bolts...............................................................10 Cerebrovascular Disease: Stroke Epidemiology I...................................... 42 Localization in Clinical Neurology................................................................10 Poster Session II........................................................................................... 44 Cerebrovascular Disease: Acute Stroke Therapy...................................... 52 Interventional Neurology............................................................................. 53 Neurology Skills Pavilion: Acute Stroke Alert............................................10 Hot Topics Plenary Session......................................................................... 32 Poster Session III.......................................................................................... 56 Contemporary Clinical Issues and Course Studies Plenary Session....... 54 Cerebrovascular Disease I........................................................................... 66 Perioperative Stroke: A Practical Approach to Risk Stratification and Modification During the Preoperative Evaluation...............................11 Poster Session IV......................................................................................... 68 Cerebrovascular Disease: Stroke Imaging................................................. 76 Frontiers in Clinical Neuroscience Plenary Session.................................. 78 Poster Session V........................................................................................... 80 Critical Care and Emergency Neurology/Endovascular and Interventional/Stroke and Vascular Neurology Highlights in the Field..................................................................................................... 79 Cerebrovascular Disease: Stroke Prevention............................................ 90 S49 S52 PD6 P06 6TP.003 7BS.004 IN9 7FC.001 7PC.004 8BS.005 8AC.002 Cerebrovascular Disease: Hemorrhagic Stroke......................................... 91 Cerebrovascular Disease II.......................................................................... 92 Cerebrovascular Disease: Acute Stroke Therapy Poster Discussion Session........................................................................... 94 Poster Session VI......................................................................................... 94 Therapy Program: Stroke..............................................................................12 Unruptured Intracranial Aneurysms and Intracranial Vascular Malformations: What a Practicing Neurologist Needs to Know..............12 Ischemic Stroke, Interventional, and Endovascular Therapies / Large Vessel Disease Integrated Neuroscience Session................................. 102 Genetics in Neurology..................................................................................13 Stroke In Young Adults.................................................................................13 Clinical Trials Session................................................................................ 101 Advances in the Care of Brain Injury After Resuscitation from Cardiac Arrest.......................................................................................13 Women’s Issues In Cerebrovascular Diseases...........................................13 Child Neurology/Developmental Neurobiology 1KP.003 2AC.006 IN2 3BS.003 3AC.001 3DS.002 3AS.004 P01 P03 5PC.002 P05 S45 7AC.006 7PC.004 7PC.006 7NF.001 Movement Disorder Emergencies: Adults and Children..............................7 Advanced Topics in Pediatric Neurology I: Neurodegenerative Diseases.........................................................................7 Pediatric Demyelinating Disorders Integrated Neuroscience Session................................................................................. 26 Blink and You Live: Coma Prognosis in Child Neurology..............................8 Advanced Topics in Pediatric Neurology II: Neuro-oncology......................8 Stroke in Children and Neonates...................................................................9 EEG In Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates................................9 Poster Session I............................................................................................ 34 Child Neurology / Woman’s Issues Highlights in the Field....................... 79 Presidential Plenary Session....................................................................... 31 Poster Session III.......................................................................................... 56 Diagnosis and Management of Movement Disorders in Children............11 Poster Session V........................................................................................... 80 Child Neurology: Developmental Neurobiology........................................ 90 Child Neurology I...........................................................................................13 Stroke In Young Adults.................................................................................13 Child Neurology II..........................................................................................13 Neuro Flash: Child Neurology.......................................................................13 Cognitive Neurology/Neurologic Disorders Presenting with Psychiatric Symptoms/Behavioral Neurology 2BS.001 2AC.001 3BS.001 3MR.001 IN4 3AC.003 4BS.001 S08 4PC.003 5BS.001 P03 5PC.001 P04 P05 6PC.001 S58 7PC.001 8BS.001 Attention Deficit Hyperactivity Disorder Across the Lifespan....................7 Structure Function Correlations in Behavioral Neurology...........................7 Can I Drive? Can I Fly?.....................................................................................8 Morning Report: Behavioral Neurology........................................................8 Current Concepts in Cognitive Neuroscience: Implications for Neurological Diseases Integrated Neuroscience Session....................... 30 Traumatic Brain Injury.....................................................................................8 The Neurology of Social Behavior.................................................................9 Behavioral Neurology Highlights in the Field............................................ 79 Behavioral Neurology: From Genetics to Brain Function to Behavior.................................................................................... 43 Localization in Clinical Neurology................................................................10 Anosognosia and Anosodiaphoria in Stroke and Dementia......................10 Poster Session III.......................................................................................... 56 Primer of Cognitive Neurology.....................................................................11 Poster Session IV......................................................................................... 68 Poster Session V........................................................................................... 80 Frontiers in Clinical Neuroscience Plenary Session.................................. 78 Psychiatry for the Neurologist.....................................................................12 Behavioral Neurology: Language, Action, and Memory........................... 93 Behavioral Neurology: Contemporary Topics: Vision................................13 Vascular Cognitive Impairment and Dementia: Current Status and Future............................................................................13 Critical Care/Emergency Neurology/Trauma 1KP.003 Movement Disorder Emergencies: Adults and Children..............................7 Educational Programs and Scientific Sessions by Topic 3PC.002 P01 P02 S17 5PC.003 6BS.002 6PC.002 7FC.004 7PC.002 8BS.005 Traumatic Spinal Cord Injury..........................................................................9 Poster Session I............................................................................................ 34 Poster Session II........................................................................................... 44 Critical Care, Trauma, and Inpatient Neurology........................................ 53 Emergency Neurology...................................................................................11 Critical Care Epilepsy/EEG...........................................................................11 Critical Care and Emergency Neurology/Endovascular and Interventional/Stroke and Vascular Neurology Highlights in the Field..................................................................................................... 79 Neurologic Consultations in the ICU...........................................................12 Neurologic Intensive Care............................................................................13 Emergency Room Neuro-ophthalmology....................................................13 Advances in the Care of Brain Injury After Resuscitation from Cardiac Arrest.......................................................................................13 Demyelinating Disorders/Multiple Sclerosis and Related Diseases 1KP.007 2AC.003 IN2 Multiple Sclerosis (Quint)Essentials..............................................................7 Update on Multiple Sclerosis I: Basic Science.............................................7 Pediatric Demyelinating Disorders Integrated Neuroscience Session................................................................................. 26 2PC.003 Update on Multiple Sclerosis II: Clinical.......................................................8 3MR.003 Morning Report: Multiple Sclerosis..............................................................8 3PC.001 Diagnostic Dilemmas in Multiple Sclerosis..................................................9 3NF.003 Neuro Flash: Multiple Sclerosis.....................................................................9 P01 Poster Session I............................................................................................ 34 S01 Multiple Sclerosis: Clinical Research I....................................................... 42 S10 Multiple Sclerosis: MRI I............................................................................. 43 P02 Poster Session II........................................................................................... 44 S11 Multiple Sclerosis: Clinical Trials I.............................................................. 52 P03 Poster Session III.......................................................................................... 56 S21 Multiple Sclerosis: Clinical Trials II............................................................. 66 S30 Multiple Sclerosis: Genetics and Human Immunopathogenesis............. 67 IN7 Multiple Sclerosis Imaging Integrated Neuroscience Session................ 65 P04 Poster Session IV......................................................................................... 68 S31 Multiple Sclerosis: Biomarkers................................................................... 76 S40 Multiple Sclerosis: Epidemiology............................................................... 77 5CS.004 Case Studies: Multiple Sclerosis.................................................................11 6BS.003 Criteria for Stopping and Starting Multiple Sclerosis Therapy.................11 PD5 Multiple Sclerosis and Related Diseases: Drug Mechanisms Poster Discussion Session........................................... 80 P05 Poster Session V........................................................................................... 80 Multiple Sclerosis Highlights in the Field.................................................. 79 S41 Multiple Sclerosis: Clinical Immunology.................................................... 90 S50 Multiple Sclerosis: EAE/Animal Models.................................................... 91 S51 Multiple Sclerosis: Clinical Research II...................................................... 92 S60 Multiple Sclerosis: MRI II............................................................................ 93 P06 Poster Session VI......................................................................................... 94 6TP.002 Therapy Program: Multiple Sclerosis..........................................................12 7AC.003 Clinical Issues in Multiple Sclerosis............................................................13 7PC.003 MRI and Multiple Sclerosis..........................................................................13 8AC.003 Neuromyelitis Optica: Scientific and Clinical Update................................13 Epilepsy/Clinical Neurophysiology (EEG) 1KP.006 2PC.001 3FC.003 3AS.004 4BS.005 P01 S05 PD2 P02 S15 Intractable Epilepsy: What to Do When Nothing Works............................7 How to Analyze Spells by Video-EEG............................................................8 Clinical Epilepsy...............................................................................................8 Epilepsy Highlights in the Field................................................................... 79 EEG In Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates................................9 Recognition and Management of the Many Types of Status Epilepticus.......................................................................................9 Poster Session I............................................................................................ 34 Clinical Neurophysiology Highlights in the Field....................................... 79 Epilepsy: Clinical Epilepsy........................................................................... 42 Epilepsy Poster Discussion Session........................................................... 44 Poster Session II........................................................................................... 44 Epilepsy: Clinical Neurophysiology and Imaging....................................... 52 P03 5SW.001 S25 6BS.002 P05 S55 6TP.001 7FC.005 7NF.002 Hot Topics Plenary Session......................................................................... 32 Poster Session III.......................................................................................... 56 Neurophysiologic Intraoperative Monitoring.............................................11 Epilepsy: Antiepileptic Drug Therapy......................................................... 66 Critical Care Epilepsy/EEG...........................................................................11 Poster Session V........................................................................................... 80 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials..................................... 92 Therapy Program: Epilepsy...........................................................................12 Clinical EEG....................................................................................................13 Neuro Flash: Epilepsy....................................................................................13 Ethics/Professionalism 4BS.003 4EC.001 4PC.004 P02 5BS.004 S59 Advanced Palliative Care and Symptom Management of ALS, Alzheimer’s Disease, or Parkinson’s Disease...............................................9 Ethics Colloquium..........................................................................................10 Practical Legal Issues for Neurologists.......................................................10 Poster Session II........................................................................................... 44 Case Studies: Clinical Ethics, Professionalism, and Evidence-based Care of Patients with Severe Life-limiting Neurologic Disease.......................................................................................10 Ethics Highlights in the Field....................................................................... 79 Ethics............................................................................................................. 93 General Neurology/Neurology of Systemic Disease 2BS.003 2FC.002 2FC.005 3BS.001 3FC.002 3AS.003 4BS.006 4PC.003 5PC.003 S37 P05 S47 6PC.001 6PC.004 P06 7BS.003 7FC.003 8AC.001 Global Health Challenges: Neurology in Developing Countries..................7 Neurology Update I.........................................................................................7 Continuum Test Your Knowledge: A Multiple-Choice Question Review.............................................................................................7 Can I Drive? Can I Fly?.....................................................................................8 Therapy in Neurology......................................................................................8 Clinical Pearls in Bedside Neurology.............................................................9 Bone Disease for the Practicing Neurologist................................................9 General Neurology Highlights in the Field................................................. 79 Localization in Clinical Neurology................................................................10 Emergency Neurology...................................................................................11 Neurologic Manifestations: Imaging and Therapeutics........................... 77 Poster Session V........................................................................................... 80 Neurologic Manifestations: Clinical Neurophysiology and Epidemiology......................................................................................... 91 Psychiatry for the Neurologist.....................................................................12 Women’s Neurologic Issues in Pregnancy..................................................12 Poster Session VI......................................................................................... 94 Neurologic Complications of Nutritional Deficiencies...............................12 Neurology Update II......................................................................................13 Neurologic Complications of Medical Disease..........................................13 Headache 2BS.006 Peripheral Nerve Blocks and Other Interventional Procedures for Headache and Facial Pain ...................................................7 3MR.002 Morning Report: Chronic Migraine: Basis and Tools for Management..............................................................................................8 3FC.004 Headaches in Adults.......................................................................................8 S07 Headache I.................................................................................................... 43 Contemporary Clinical Issues and Case Studies Plenary Session........... 54 P04 Poster Session IV......................................................................................... 68 S35 Headache II................................................................................................... 76 P06 Poster Session VI......................................................................................... 94 7TP.003 Therapy Program: Headache........................................................................13 8AC.004 Hot Topics in Headaches and Related Disorders.......................................13 History of Neurology S09 P02 5BS.002 5PC.004 History of Neurology.................................................................................... 43 Poster Session II........................................................................................... 44 Archival Neurologic Films.............................................................................10 History of Neurology: Landmark Case Studies of Neurological Giants..................................................................................11 121 Educational Programs and Scientific Sessions by Topic Imaging 2AC.003 2FC.004 3AC.002 4PC.001 6CS.004 7SC.001 7PC.003 Update on Multiple Sclerosis I: Basic Science.............................................7 Update in Neuroimaging: Essentials and Beyond–Part I............................7 Update in Neuroimaging: Essentials and Beyond–Part II...........................8 Spine Neuroimaging: Clinical-Radiologic Correlation................................10 Neuroimaging Highlights in the Field......................................................... 79 Case Studies: Neuroimaging........................................................................12 Future of Neuroscience Conference: Frontiers in Neuroimaging: Coming Soon to a Scanner Near You................................13 MRI and Multiple Sclerosis..........................................................................13 Infectious Disease/AIDS/Prion Disease 2BS.003 IN3 3FC.005 4BS.004 P03 S27 P04 8BS.004 Global Health Challenges: Neurology in Developing Countries..................7 Global Neurology: Toxins and Infections Integrated Neuroscience Session................................................................................. 29 Infections of the Nervous System.................................................................8 Approach to Acute CNS Infections................................................................9 Neuro-infectious Disease Highlights in the Field...................................... 79 Poster Session III.......................................................................................... 56 Contemporary Clinical Issues and Case Studies Plenary Session........... 54 Infections...................................................................................................... 67 Poster Session IV......................................................................................... 68 Neurologic Complications of Immunosuppressive and Immunomodulatory Therapy.................................................................13 Movement Disorders 1KP.003 2FC.001 2DS.002 3DS.001 4BS.002 Movement Disorder Emergencies: Adults and Children..............................7 Movement Disorders......................................................................................7 The Dystonias: Diagnosis, Treatment, and Update on Causes...................8 Top 10 Pitfalls in the Diagnosis of Parkinson’s Disease...............................9 Introduction to the Evaluation and Therapy of Restless Legs Syndrome and Periodic Limb Movements in Sleep........................................................9 P01 Poster Session I............................................................................................ 34 S03 Movement Disorders: Epidemiology of Parkinson’s Disease................... 42 S13 Movement Disorders: Huntington’s Disease: Pathophysiology and Clinical Assessment.............................................................................. 52 S19 Movement Disorders: Dystonia.................................................................. 53 5BS.005 Hyperkinetic Movement Disorders: Diagnosis and Treatment.................10 P03 Poster Session III.......................................................................................... 56 Movement Disorders Highlights in the Field............................................. 79 S23 Movement Disorders: Parkinson’s Disease / Non-Motor Symptoms..... 66 5PC.002 Diagnosis and Management of Movement Disorders in Children............11 PD4 Movement Disorders: Parkinson’s Disease: Treatment Poster Discussion Session........................................................................... 68 P04 Poster Session IV......................................................................................... 68 S33 Current and Future Treatment of Parkinson’s Disease............................. 76 5CS.003 Case Studies: Unusual Movement Disorders.............................................11 P05 Poster Session V........................................................................................... 80 IN8 Deep Brain Stimulation: Where Are We and Where Do We Go From Here Integrated Neuroscience Session............................... 89 S43 Movement Disorders: Essential Tremor and Ataxia................................. 90 S53 Movement Disorders: Parkinson’s Disease and Atypical Parkinsonism................................................................................. 92 7BS.006 Update on Ataxias.........................................................................................12 7AC.001 Deep Brain Stimulation Management.........................................................13 7AC.002 Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists.............................................................................................13 7FC.001 Genetics in Neurology..................................................................................13 7PW.001 Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia..................................................................................13 7TP.002 Therapy Program: Movement Disorders.....................................................13 8BS.003 Balance and Gait Disorders..........................................................................13 8AC.006 Parkinson’s Disease and Movement Disorders Update.............................13 122 Neuroepidemiology/Health Services Research P01 Poster Session I............................................................................................ 34 S29 Neuroepidemiology...................................................................................... 67 Neuroepidemiology Highlights in the Field................................................ 79 P06 Poster Session VI......................................................................................... 94 Neurogenetics/Gene Therapy 1KP.009 IN1 2AC.003 2PC.002 3NF.002 3AS.006 P03 S38 7FC.001 Biological Rhythms and Neurologic Disease................................................7 Emerging Concepts in Genetics Integrated Neuroscience Session........ 25 Update on Multiple Sclerosis I: Basic Science.............................................7 Genetic Testing in Clinical Neurology...........................................................8 Neuro Flash: Neurogenetics...........................................................................9 Diagnosis and Management of Leukodystrophies.......................................9 Hot Topics Plenary Session......................................................................... 32 Poster Session III.......................................................................................... 56 Neurogenetics Highlights in the Field........................................................ 79 Neurogenetics: Basic Science and Therapeutics...................................... 77 Genetics in Neurology..................................................................................13 Neurometabolic Disorders/Neurotoxicology/Neuroendocrinology 1KP.009 2DS.005 3DS.004 4PC.005 6CS.003 7FC.001 Biological Rhythms and Neurologic Disease................................................7 Important Drug Interactions for Neurologists and Psychiatrists................8 Mitochondrial Disorders in Neurology..........................................................9 Neurotoxicology............................................................................................10 Case Studies: Adult Metabolic Disorders...................................................12 Genetics in Neurology..................................................................................13 Neuromuscular Disease/Clinical Neurophysiology (EMG)/Anterior Horn/ Autonomic Disorders/Peripheral Nerve 1KP.002 2BS.002 2AC.005 2SW.001 2NP.001 3FC.006 3SW.001 P01 S06 4PC.002 4PC.003 P02 S16 PD3 P03 IN6 S26 P04 S36 5CS.002 6BS.005 P05 S46 S48 S55 S56 P06 Diagnosis and Management of Motor Neuron Disease: ALS.....................7 Update on Myotonias.....................................................................................7 Neuromuscular Junction Disorders...............................................................7 EMG Skills Workshop: Basic..........................................................................7 Neurology Skills Pavilion: Neuromuscular Bedside Rounds........................8 Peripheral Neuropathy....................................................................................8 Advanced Techniques in EMG and Neuromuscular Disease......................8 Poster Session I............................................................................................ 34 Neuromuscular Junction and Muscle Disorders....................................... 43 Evaluation and Management of Autonomic Disorders..............................10 Localization in Clinical Neurology................................................................10 Poster Session II........................................................................................... 44 Anterior Horn: Clinical Studies.................................................................... 53 Anterior Horn: Therapeutics Poster Discussion Session.......................... 56 Poster Session III.......................................................................................... 56 Autonomic/Neuroendocrinology/Pain and Palliative Care Highlights in the Field......................................................................... 79 Contemporary Clinical Issues and Case Studies Plenary Sessions......... 54 Emerging Treatments in Neuromuscular Disease Integrated Neuroscience Session.............................................................. 64 Peripheral Nerve: Clinical Advances in Peripheral Neuropathy.............. 67 Poster Session IV......................................................................................... 68 Anterior Horn: Spinal Muscular Atrophy.................................................... 77 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease............................................................11 Small Fiber Neuropathies: Somatic, Autonomic, or a Mixture of Both......................................................................................11 Neuromuscular Highlights in the Field....................................................... 79 Poster Session V........................................................................................... 80 Peripheral Nerve: Molecular Mechanisms of Peripheral Neuropathy............................................................................ 91 Autonomic Disorders: Frontiers of Autonomic Neurology........................ 91 Clinical Neurophysiology: Intraoperative Neurophysiologic Monitoring; Evoked Potentials.................................................................... 92 Anterior Horn: Basic Science...................................................................... 93 Poster Session VI......................................................................................... 94 Educational Programs and Scientific Sessions by Topic 7BS.002 7AC.005 7PC.005 7TP.001 8BS.002 8AC.005 Rapid Quantitation in EMG: Learning Accurate and Efficient Motor Unit Potential Analysis.......................................................12 Clinical EMG I................................................................................................13 Clinical Trials Session................................................................................ 101 Clinical EMG II...............................................................................................13 Therapy Program: Neuromuscular Disease................................................13 Autoimmune Testing in Neuropathy: Indications for the Practicing Clinician............................................................................13 Clinical Approach to Muscle Disease..........................................................13 Neuro-oncology S39 6PC.003 P06 7BS.005 7AC.004 IN10 Neuro-oncology: Paraneoplastic Disorders............................................... 77 Frontiers in Clinical Neuroscience Plenary Session.................................. 78 Neuro-oncology Highlights in the Field...................................................... 79 Neuro-oncology Update I: Primary Brain Tumors.......................................12 Poster Session VI......................................................................................... 94 Case Studies in Neuro-oncology.................................................................12 Neuro-oncology Update II: Systemic Cancer..............................................13 Molecular Markers and Targets in Neuro-oncology Integrated Neuroscience Session............................................................ 103 Neuro-ophthalmology/Neuro-otology 1KP.008 2BS.004 3FC.007 3DS.003 3NF.004 5BS.003 S28 P04 6BS.004 6CS.001 7PC.002 7NP.001 8AC.007 Top 10 Neuro-ophthalmic Diagnoses You Can’t Afford to Miss.................7 Canalith Repositioning for Benign Paroxysmal Positional Vertigo.............7 Neuro-ophthalmology.....................................................................................8 Common and Important Ophthalmoscopic Findings....................................9 Neuro Flash: Neuro-Ophthalmology..............................................................9 Neuro-ophthelmology/Neuro-otology Highlights in the Field................. 79 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia........................................................................10 Neuro-ophthalmology/ Neuro-otology....................................................... 67 Poster Session IV......................................................................................... 68 Nystagmus: An Organized Approach..........................................................11 Now You See It, Now You Know It; (Nearly) Pathognomonic Signs in Neuro-ophthalmology Findings..........................12 Emergency Room Neuro-ophthalmology....................................................13 Neurology Skills Pavilion: Neuro-ophthalmology and Neurovestibular Exam Lab....................................................................13 Neuro-otology...............................................................................................13 Neural Repair/Rehabilitation 2DS.006 3AC.003 3PC.002 3AS.002 3AS.005 P02 P05 S57 Implications of Combat-Related Traumatic Brain Injury..............................8 Traumatic Brain Injury.....................................................................................8 Traumatic Spinal Cord Injury..........................................................................9 Stroke Rehabilitation for Spatial Neglect: Win-Win Treatment Science..........................................................................9 Brain Computer Interfaces: Frontiers in Neurology and Neuroscience.........................................................................9 Neural Repair/Spine Highlights in the Field............................................... 79 Poster Session II........................................................................................... 44 Contemporary Clinical Issues and Case Studies Plenary Session........... 54 Poster Session V........................................................................................... 80 Neural Repair and Neurorehabilitation...................................................... 93 Pain 3FC.001 4BS.003 6PC.005 Challenging Pain Patients...............................................................................8 Advanced Palliative Care and Symptom Management of ALS, Alzheimer’s Disease, or Parkinson’s Disease......................................9 Autonomic/Neuroendocinology/Pain and Palliative Care Highlights in the Field......................................................................... 79 Common Spine Disorders.............................................................................12 Practice Management 1FC.001 The Practice of Neurology: Issues in Coding and Reimbursement.............7 1EC.001 BRAINS Colloquium........................................................................................7 1NP.001 Neurology Skills Pavilion: Health Information Technology for Neurology: The Electronic Frontier......................................7 1KP.005 Starting Your Career: The Early Years...........................................................7 2EC.001 Patient Safety Colloquium: Diagnostic Errors in Neurology........................7 2AC.002 Making Sure Your Electronic Health Record System is a Success.............7 2LS.001 E/M: Minimize Mistakes, Maximize Reimbursement..................................7 2LS.002 Bulletproof Your Practice: What You Need to Know About Compliance and Regulatory Issues to Stay Ahead of the Curve................7 2EC.002 Practice Colloquium: Are You Ready? Meeting Practice Challenges Posed by Performance, Payers, & Policy...................................8 2PC.006 Bedside Evidence-Based Medicine: How to Deconstruct Articles in Order to Take Care of Patients.....................................................8 2DS.003 Practice Survival for Neurologists: Business Strategies for Success....................................................................................8 3LS.001 Primary and Comprehensive Stroke Centers: The Future of Stroke Care..............................................................................9 4LS.001 Telemedicine Increases Options for Successful Stroke Treatment: Nuts and Bolts...........................................................................10 Research/Education 1AC.001 1EP.001 1PC.001 2BS.005 2AC.004 2PC.004 3BS.002 3EC.001 P01 4EC.002 S20 Resident Basic Science I: Neuropathology...................................................7 Clerkship and Program Directors Conference..............................................7 Resident Basic Science II: Clinical Application of Neuropathology..........................................................................................7 Clinical Grant Writing.....................................................................................7 Clinical Research Methods I..........................................................................7 Clinical Research Methods II.........................................................................8 Career Development for Clinician Educators................................................8 Education Colloquium: International Education...........................................8 Poster Session I............................................................................................ 34 NIH Sponsored Clinical Trials in Neurology: What’s Going On? How to Participate? How Can We Do Better?............................................10 Neurologic Education................................................................................... 53 Sleep Disorders 2FC.003 2DS.004 4BS.002 S04 P02 P03 6CS.002 Neurology of Sleep..........................................................................................7 The Interface of Sleep and Neurologic Disorders........................................8 Introduction to the Evaluation and Therapy of Restless Legs Syndrome and Periodic Limb Movements in Sleep.............................9 Sleep Medicine Highlights in the Field....................................................... 79 Sleep Disorders............................................................................................ 42 Poster Session II........................................................................................... 44 Poster Session III.......................................................................................... 56 Case Studies: Sleep Medicine.....................................................................12 Spinal Cord/Nerve Root Disorders 2PC.005 2DS.006 3PC.002 3AS.005 4PC.001 6PC.005 Myelopathies...................................................................................................8 Implications of Combat-Related Traumatic Brain Injury..............................8 Traumatic Spinal Cord Injury..........................................................................9 Brain Computer Interfaces: Frontiers in Neurology and Neuroscience.........................................................................9 Neural Repair/Spine Highlights in the Field............................................... 79 Spine Neuroimaging: Clinical-Radiologic Correlation................................10 Common Spine Disorders.............................................................................12 Women’s Issues 4BS.006 6PC.004 8AC.002 Bone Disease for the Practicing Neurologist................................................9 Child Neurology/Women’s Issues Highlights in the Field........................ 79 Women’s Neurologic Issues in Pregnancy..................................................12 Women’s Issues In Cerebrovascular Diseases...........................................13 123 Exhibitor Listing Exhibit Hours: Monday, April 12, 5:00 p.m.–7:00 p.m. / Tuesday, April 13, 11:30 a.m.–5:00 p.m. Wednesday, April 14, 11:30 a.m.–5:00 p.m. / Thursday, April 15, 11:30 a.m.–4:00 p.m. Lundbeck Inc. (formerly Ovation Pharmaceuticals) (847) 282-1000 The AAN would like to acknowledge the following exhibitors’ participation in the 62nd Annual Meeting: Accera (303) 999-3700 Biogen Idec, Inc. (617) 914-7074 Acorda Therapeutics (914) 347-4300 BioMed Central Ltd +44 203 192 2000 Admar Neurodiagnostic Instruments 1-800-331-3957 Bioness, Inc. (800) 211-9136 Allergan, Inc. (714) 246-4500 Boehringer Ingelheim Pharmaceuticals, Inc. (203) 798-9988 Alzheimer’s Association (312) 335-5897 Borm Bruckmeier Publishing (310) 414-8300 AMBU, Inc. (800) 262-8462 Boston Scientific Neurovascular (510) 440-7701 American Association of Neuromuscular & Electrodiagnostic Medicine Foundation (507) 288-0100 Bozeman Deaconess Hospital (406) 599-0674 American Association of Neuromuscular and Electrodiagnostic Medicine (507) 288-0100 Cambridge University Press (212) 924-3900 Canadian Epilepsy Alliance (604) 807-8683 American Board of Psychiatry & Neurology (847) 229-6500 Canadian League Against Epilepsy (519) 433-4073 American Parkinson Disease Association (718) 981-8001 CareFusion (formerly Cardinal Health) (608) 273-5000 APBD Research Foundation (212) 290-2546 CleveMed (216) 791-6720 Athena Diagnostics, Inc. (800) 394-4493 Clinical Neurology News (973) 290-8200 Aurora Health Care (800) 307-7497 Clinical Neurology and Neurophysiology Symposium 2011 +9722 652-0574 Austrian Society of Neurology +43-512-8091-19 Baxter (847) 940-2000 Bayer HealthCare Pharmaceuticals (973) 305-5000 Baylor Health Care System (972) 860-8505 Benign Essential Blepharospasm Research Foundation, Inc. (409) 832-0788 124 Cadwell Laboratories, Inc. (509) 735-6481 Cure PSP - Society for Progressive Supranuclear Palsy (PSP), Inc. (410) 785-7004 Genzyme Therapeutics (617) 252-7500 Cyberonics, Inc. (800) 332-1375 Grass Technologies, An AstroMed, Inc. Subsidary (401) 828-4000 Demos Medical Publishing (212) 683-0072 DigiTrace SleepMed (803) 779-5454 Duchenne Connect/Parent Project Muscular Dystrophy (404) 778-0553 Dystonia Medical Research Foundation (312) 755-0198 Electrical Geodesics, Inc. (541) 687-7962 Electro-Cap International, Inc. (937) 456-6099 Elekta, Inc. (770) 670-2592 EMD Serono, Inc. (781) 681-2329 EMD Serono, Inc. (781) 681-2477 Endo Pharmaceuticals Inc. (610) 459-7273 Equinox Health Solutions Inc (213) 712-7402 European Federation of Neurological Societies (EFNS) +39-055-4362-098 European Neurological Society +41-61-686-7711 CNS Vital Signs (888) 750-6941 Fold Rx Pharmaceuticals, Inc. (617) 252-5500 Community Health Systems (800) 367-6813 Forest Pharmaceuticals, Inc. (212) 224-6698 Compumedics USA, LTD. (704) 749-3200 GBS/CIDP Foundation International (610) 667-0131 Congressionally Directed Medical Research Programs (CDMRP) (301) 619-7071 Genzyme Corporation (617) 252-7549 Glycominds Inc. (650) 269-3420 HCA Physician Recruitment (866) 889-0203 Health and Science Opinion Research (760) 598-3770 Health Match BC (604) 736-5920 Heidelberg Engineering (800) 931-2230 HRA Research (973) 240-1200 IgG America, Inc. (877) 674-9700 In-Step Mobility Products, Inc. (847) 676-1275 International Essential Tremor Foundation (IETF) (913) 341-3880 Ipsen (650) 624-4900 Jari Electrode Supply (408) 847-1895 Kadlec Health System (509) 942-2115 Karger Publishers (860) 675-7834 Kronus, Inc. (208) 377-4800 La Lettre Du Neurologue 33-1-466-76283 Lilly USA, LLC (317) 276-2000 Lions Club International (630) 571-5466 Lippincott Williams & Wilkins Wolters Kluwer Health (215) 521-8300 Magnolia Regional Health Center (662) 293-7683 Magstim (905) 582-1139 Magventure A/S Denmark +45 4-499-8444 MAP Pharmaceuticals, Inc. (650) 386-3100 McKesson (206) 441-2400 Natus Medical Incorporated (650) 802-0400 NeuroBrain Diagnostic (954) 985-5633 NeurogesX, Inc. (650) 358-3300 Neurology Reviews (973) 206-3434 NeuroMetrix, Inc. (781) 890-9989 Nexstim, Inc. (608) 852-5785 Medivation (415) 543-3470 Nextgen Healthcare Information Systems, Inc. (215) 657-7010 MedLink Corporation (619) 640-4660 Nihon Kohden America, Inc. (800) 325-0283 Medtronic, Inc. (763) 514-4000 Novartis Pharmaceuticals Corporation (862) 778-8300 Merck & Co, Inc. (267) 305-5000 Merz Pharmaceuticals, LLC (336) 856-2003 Minnesota Epilepsy Group, P.A. (651) 241-5285 Multigon Industries, Inc. (914) 376-5200 Multiple Sclerosis Association of America (856) 488-4500 National Headache Foundation (312) 274-2650 National Institute of Neurological Disorders and Stroke (NINDS) (301) 496-5751 National Multiple Sclerosis Society (212) 476-0457 NationalRad (877) SDI-NMSI National Spasmodic Dysphonia Association (800) 795-6732 National Spasmodic Torticollis Association (714) 378-9837 Nature Publishing Group (212) 726-9200 Origin Biomed Inc. (902) 404-3908 Oxford University Press (212) 726-6000 Pamlab, LLC (985) 893-4097 Parkinson’s Disease Foundation, Inc. (212) 923-4700 Pfizer Inc (212) 773-2323 Practical Neurology (484) 581-1834 PracticeLink.com - The Online Physician Job Bank 1 (800) 776-8383 Professional Risk Management Services, Inc. (703) 907-3800 Questcor Pharmaceuticals (510) 400-0700 Restless Legs Syndrome Foundation, Inc. (507) 287-6465 Rochester Electro-Medical, Inc. (813) 963-2933 Sage Publications (805) 410-7239 Santhera Pharmaceuticals (USA), Inc. (617) 886-5161 Saunders/Mosby-Elsevier, Inc. (215) 239-3490 Science Trax LLC (800) 620-1179 Screen, Inc (206) 517-5087 Sepracor, Inc. (508) 481-6700 Spinal Muscular Atrophy Foundation (646) 253-7100 Society for Vascular & Interventional Neurology (414) 389-8613 Walgreens-Option Care (847) 964-8186 WE MOVE (Worldwide Education and Awareness for Movement Disorders) (212) 875-8312 Wiley-Blackwell (781) 388-8361 World Association of Sleep Medicine (WASM) (514) 874-1998 World Parkinson Congress (646) 388-7650 WR Medical Electronics Co. (651) 430-1200 Zogenix (858) 436-3377 Solstice Neurosciences, Inc. (267) 620-8044 Springer (212) 460-1500 St. Vincent Healthcare (406) 237-4003 Talecris Biotherapeutics Inc. (919) 316-6300 TEVA Neuroscience, Inc. (816) 718-1624 The Churkendoose Project - The Handle Institute (704) 755-0200 The Electrode Store (360) 829-0400 The Movement Disorder Society (414) 276-2145 Tourette Syndrome Association (718) 224-2999 Transgenomic, Inc. (402) 452-5400 UCB, Inc. (800) 477-7877 United Council for Neurologic Subspecialties (UCNS) (651) 332-8681 UpToDate (800) 998-6374 US Bioservices Specialty Pharmacy (888) 518-7246 Current as of 2/10/2010 125 62ND Annual Meeting Committee Members and Staff Annual Meeting Committees Meeting Management Committee Stanley Fahn, MD, FAAN, Chair Neil A. Busis, MD, FAAN Terrence L. Cascino, MD, FAAN Cynthia L. Comella, MD, FAAN John Corboy, MD, FAAN Robert C. Griggs, MD, FAAN Jonathan P. Hosey, MD, FAAN Carlayne E. Jackson, MD, FAAN Ralph F. Józefowicz, MD, FAAN Robert T. Leshner, MD, FAAN John C. Morris, MD, FAAN Sandra F. Olson, MD, FAAN Stefan M. Pulst, MD, FAAN Steven P. Ringel, MD, FAAN Stephen M. Sergay, MB BCh, FAAN Bruce Sigsbee, MD, FAAN Austin J. Sumner, MD, FAAN Thomas R. Swift, MD, FAAN Patrick Toalson Scientific Program Subcommittee Cynthia L. Comella, MD, FAAN, Chair Imran I. Ali, MD, FAAN Peter R. Bergethon, MD Allison Brashear, MD, FAAN John W. Engstrom, MD, FAAN Charles C. Flippen, II, MD, FAAN Frederick G. Flynn, DO, FAAN Daniel B. Hier, MD, MBA, FAAN Jonathan P. Hosey, MD, FAAN Steven L. Lewis, MD, FAAN Jennifer R. Molano, MD John C. Morgan, MD, PhD Mark L. Moster, MD, FAAN Joseph E. Safdieh, MD Pradeep K. Sahota, MD, FAAN Joseph I. Sirven, MD, FAAN A. Gordon Smith, MD Barney J. Stern, MD, FAAN Laura J. Balcer, MD, MSCE Robert H. Baloh, MD, PhD Eric Cheng, MD William P. Cheshire, Jr., MD, FAAN F. Michael Cutrer, MD, FAAN Janis Daly, MS, PhD Charles S. DeCarli, MD, FAAN Bradford Dickerson, MD Edward J. Dropcho, MD Patricia A. Evans, MD, FAAP, FAAN Gloria Galloway, MD, FAAN Claude Hemphill, III, MD, FAAN Vern C. Juel, MD Brett M. Kissela, MD, FAAN Peter J. Koehler, MD, PhD, FAAN Sookyong Koh, MD, PhD Steven L. Lewis, MD, FAAN Nicholas J. Maragakis, MD Alireza Minagar, MD, FAAN Avindra Nath, MBBS, FAAN Raul G. Nogueira, MD Louis J. Ptacek, MD, FAAN Joseph I. Sirven, MD, FAAN Olaf Stuve, MD, PhD Bradley V. Vaughn, MD, FAAN Emmanuelle Waubant, MD Theresa A. Zesiewicz, MD, FAAN Annual Meeting Subcommittee Abstract Reviewers Education Committee Cynthia L. Comella, MD, FAAN, Chair Thomas D. Bird, MD, FAAN Richard D. Brower, MD, FAAN Seemant Chaturvedi, MD, FAAN John B. Chawluk, MD, FAAN Bruce A. C. Cree, MD, PhD Neill R. Graff-Radford, MD, FAAN Carlayne E. Jackson, MD, FAAN David W. Loring, PhD Jonathan W. Mink, MD, PhD, FAAN Todd D. Rozen, MD, FAAN Science Committee Stefan M. Pulst, MD, FAAN, Chair Brenda Banwell, MD David Q. Beversdorf, MD Merit E. Cudkowicz, MD, MSC Neill R. Graff-Radford, MD, FAAN 126 Carlayne E. Jackson, MD, FAAN Karen C. Johnston, MD, MSC Samia J. Khoury, MD Richard D. King, MD, PhD Mark F. Mehler, MD Jose G. Merino, MD, MPhil Massimo Pandolfo, MD Walter A. Rocca, MD, MPH Raymond P. Roos, MD, FAAN Natalia Sana Rost, MD Nina F. Schor, MD, PhD Jeffery M. Vance, MD, PhD Walter J. Koroshetz, MD, FAAN Steve Alexander, MD Imran Ali, MD, FAAN Muhammad Al-Lozi, MD Anthony Amato, MD Liana Apostolova, MD Sheena Aurora, MD Alon Avidan, MD, MPH Rohit Bakshi, MD, FAAN Amit Bar-Or, MD, FRCPC Richard Bedlack, MD, PhD Jeffrey Bennett, MD, PhD James Bernat, MD, FAAN Bibiana Bielekova, MD Christopher Boes, MD Aaron Boster, MD Andrea Bozoki, MD Richard Brower, MD, FAAN Robert Brown, MD, FAAN Jeffrey Burns, MD Rami Burstein, PhD Paul Carney, MD Jose Cavazos, MD, PhD, FAAN Kevin Chapman, MD Thomas Chelimsky, MD, FAAN Peter Chin, MD Tanuja Chitnis, MD Michael Chopp, PhD Emma Ciafaloni, MD, FAAN Jeffrey Cohen, MD Steven Cramer, MD Kirk Daffner, MD Nabila Dahodwala, MD Josep Dalmau, MD, PhD Philip De Jager, MD, PhD Mahlon DeLong, MD Elliot Dimberg, MD Michael Dowling, MD, PhD Eric Eggenberger, DO, FAAN Mitchell Elkind, MD, MS, FAAN Stewart Factor, DO, FAAN Camilo Fadul, MD, FAAN Elizabeth Finger, MD Marc Fisher, MD, FAAN Nathan Fountain, MD Edward Fox, MD, PhD Robert Fox, MD, FAAN Michael Frankel, MD Giovanni Frisoni, MD William Gaillard, MD Charlene Gamaldo, MD Christopher Goetz, MD, FAAN Ralf Gold, MD Myla Goldman, MD Errol Gordon, MD Philip Gorelick, MD, FAAN Benjamin Greenberg, MD Rishi Gupta, MD May Han, MD Judith Heidebrink, MD Kenneth Heilman, MD, FAAN Bernhard Hemmer, MD Victor Henderson, MD, FAAN Andrew Hershey, MD, PhD Lawrence Hirsch, MD, FAAN Fuki Hisama, MD Ahmet Hoke, MD, PhD James Howard, MD, FAAN Aatif Husain, MD Costantino Iadecola, MD Matilde Inglese, MD, PhD Kurt Jaeckle, MD, FAAN Cheryl Jay, MD Barbara Jobst, MD Karen Johnston, MD, MSC S. Claiborne Johnston, MD, PhD Keith Josephs, MD Tudor Jovin, MD Brian Kaspar, PhD Roger E. Kelley, Jr. MD, FAAN Omar Khan, MD, PhD Ramesh Khurana, MD, FAAN Chelsea Kidwell, MD Bernd Kieseier, MD Richard King, MD, PhD Revere Kinkel, MD, FAAN Mariko Kita, MD Christine Klein, MD Dawn Kleindorfer, MD Annette Langer-Gould, MD James Leverenz, MD Richard Lewis, MD, FAAN Jun Li, MD, PhD Italo Linfante, MD Richard Lipton, MD, FAAN Eng Lo, MD Catherine Lomen-Hoerth, MD, PhD Elan Louis, MD, MS, FAAN Sylvia Lucas, MD, PhD David Lynch, MD, PhD Eugene Major, PhD Ruth-Ann Marrie, MD Katherine Mathews, MD Stephan Mayer, MD Micheline McCarthy, MD, PhD, FAAN Louise McCullough, MD, PhD Matthew Meriggioli, MD Brett Meyer, MD Timothy Miller, MD, PhD Margherita Milone, MD Nancy Minshew, MD, FAAN Thomas Montine, MD, PhD Lauren Moo, MD Anil Nair, MD Robert Naismith, MD David Newman-Toker, MD, PhD Thanh Nguyen, MD Martin Niethammer, MD, PhD Katherine Noe, MD, PhD Marc Nuwer, MD, PhD, FAAN Anne Louise Oaklander, MD, PhD, FAAN Michael Okun, MD Bruce Ovbiagele, MD Andrew Pachner, MD Soojin Park, MD Henry Paulson, MD, PhD, FAAN Steven Pavlakis, MD, FAAN Victoria Pelak, MD Daniel Pelletier, MD Brian Popko, PhD Svetlana Pundik, MD Joseph Quinn, MD Jeffrey Raizer, MD Amy Rauchway, DO Daniel Reich, MD, PhD Caterina Rosano, MD, MPH Heidi Roth, MD Julie Rowin, MD Walter Royal, MD Devon Rubin, MD, FAAN Robert Ruff, MD, PhD, FAAN Seward Rutkove, MD Marwan Sabbagh, MD, FAAN Joseph Safdieh, MD Juan Sanchez-Ramos, MD, PhD Paola Sandroni, MD, PhD, FAAN Jeffrey Saver, MD, FAAN Sean Savitz, MD Ernestina Saxton, MD, PhD Nikolaos Scarmeas, MD Julie Schneider, MD, MS Lori Schuh, MD, FAAN Robert Schwendimann, MD, FAAN Kathleen Shannon, MD Anthony Shapira, MD Nancy Sicotte, MD, FAAN Cathy Sila, MD, FAAN Lisa Silbert, MD John Sims, MD J. Robinson Singleton, MD B. Joy Snider, MD, PhD Evan Snyder MD, PhD Mark Stacy, MD, FAAN John Stern, MD, FAAN Gretchen Tietjen, MD Ann Tilton, MD, FAAN David Tirschwell, MD Bryan Traynor, MD Ryan Uitti, MD, FAAN Angela Vincent, MBBS, MSc Cheryl Waters, MD, FAAN Nathaniel Watson, MD Martina Wiedau-Pazos, MD Heinz Wiendl, MD Dean Wingerchuk, MD, FAAN Elaine Wirrell, MD George Wittenberg, MD, PhD Gil Wolfe, MD, FAAN David Wolk, MD Michael Wong, MD, PhD Daniel Woo, MD Gregory Worrell, MD Thoru Yamada, MD George York, MD, FAAN Scott Zamvil, MD, PhD Lorne Zinman, MD Robert Zivadinov, MD Stephan Zuchner, MD Susan Dunlop Annual Meeting Staff Naomi Reeves Catherine M. Rydell, CAE Director, Development Alberta Zais Director, Corporate Relations Cheryl Alementi Senior Administrator, Education Elizabeth Busch Administrator, Grants Bridget Farley Manager, Exhibits and Corporate Relations Sarah Glover Senior Specialist, Conference Management Julie Grengs Senior Specialist, Research, Education, and Development Andy Halverson Promotions Project Manager, Center for Research, Education, and Development Kevin Heinz Senior Manager, Education and Science Terry Heinz Administrator, Grants and Research Erin Jackson Program Manager, Scientific Programs Kyle Krause Administrator, Scientific Programs Valerie Mendoza Manager, Conference Management Amy Nostdahl Program Manager, Education Programs Tina Novack Executive Assistant, Executive Administration Lucy Persaud Program Manager, Education Nancy Poechmann Program Manager, Education Julie Ratzloff Senior Manager, Conference Management Administrator, Programming and Logistics Chief Executive Officer AAN, AAN Professional Association, AAN Foundation, and AAN Enterprises, Inc. Kristine Retka Christine E. Phelps Senior Administrator, Exhibits & Affiliate Meetings Deputy Executive Director AAN and AAN Foundation Kris Fridgen Senior Director, Center for Research, Education, and Development Susan Rodmyre Administrator, Corporate Relations Franziska Schwarz Lori Strachota Program Manager, Conference Management Wendy Vokaty Senior Specialist, Center for Research, Education, and Development Director, Education 127 Offices and Hours of Operations AAN Alliance Booth and Registration MTCC North Building (Level 200) Lost and Found (Registration) MTCC South Building (Level 600) Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:30 a.m.–4:00 p.m. Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m. Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m. AAN Research Area MTCC South Building (Level 600) Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. AAN Meeting Information MTCC South Building (Level 600) and North Building (Level 200) Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m. Monday, April 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–8:00 p.m. Tuesday, April 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m. Wednesday, April 14–Friday, April 16 . . . . . . . . . . . 6:00 a.m.–7:30 p.m. Saturday, April 17 (North Building Level 200 only) . . . . . . 6:00 a.m.–1:00 p.m. Academy Central MTCC South Building (Level 600) Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Materials Distribution MTCC South Building (Level 600) Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m. Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m. Materials Distribution MTCC North Building (Level 200) Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m. BrainPAC Booth MTCC South Building (Level 600) Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Exhibitor Registration MTCC South Building (Level 600) Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m. Sunday, April 11–Wednesday, April 14 . . . . . . . . . . 6:30 a.m.–6:30 p.m. Thursday, April 15 . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–12:00 p.m. Housing Desk MTCC South Building (Level 600) Saturday, April 11–Thursday, April 15 . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Friday, April 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–2:00 p.m. Internet and Message Center MTCC South Building (Level 600) Saturday, April 10–Sunday, April 11 . . . . . . . . . . . . 6:30 a.m.–6:30 p.m. Monday, April 12–Friday, April 16 . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Internet and Message Center MTCC North Building (Level 200) Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–1:00 p.m. 2010 Annual Meeting Supporters Current as of 2/8/10 ThankYou Lost and Found (Registration) MTCC North Building (Level 200) Acorda Therapeutics, Inc. Forest Laboratories, Inc. Pfizer Inc/Medivation, Inc. Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m. 4/11 Newspaper Belly Band 4/12 Door Drop Insert Marketing Meeting Administration Office MTCC South Building (Level 600) 4/12 Door Drop Marketing Genzmye Corporation Corporate Therapeutic Update 4/12 Door Drop Insert Marketing 4/13 Door Drop Insert Marketing Exhibit Guide Saturday, April 10–Friday, April 16 . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Banner Marketing Exhibit Guide PSAV Presentation Services Membership MTCC South Building (Level 600) Corporate Therapeutic Update Residents Scholarship Fund Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m. Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m. Exhibit Guide Glycominds Inc. Allergan, Inc. 4/12 Door Drop Insert Marketing Groff Trust 4/13 Door Drop Insert Marketing Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m. Corporate Therapeutic Update Ipsen Pharma Neurology Community Information TBD Exhibit Guide 4/12 Door Drop Insert Marketing Exhibit Hall Presentation Stage Exhibit Guide Press Room MTCC South Building (Room 803AB) Resident/Medical Student Scholarship Fund Kronus Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10:00 a.m.–6:00 p.m. Monday, April 12–Thursday, April 15 . . . . . . . . . . . . 7:00 a.m.–7:00 p.m. Residents Scholarship Fund Lundbeck Inc. Membership MTCC North Building (Level 200) Registration MTCC South Building (Level 600) Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–7:00 p.m. Sunday, April 11–Friday, April 16 . . . . . . . . . . . . . . . 6:30 a.m.–6:30 p.m. Registration MTCC North Building (Level 200) American Board of Psychiatry and Neurology (ABPN) Exhibit Guide Bayer Healthcare Pharmaceuticals, Inc. 7AC.003 Clinical Issues in MS Eli Lilly and Company Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:30 a.m.–9:00 a.m. 2BS.001 ADHD Across the Lifespan Speaker Ready Room MTCC North Building (Room 205AB) Residents Scholarship Fund Saturday, April 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . 8:00 a.m.–6:30 p.m. Sunday, April 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m. Monday, April 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–8:00 p.m. Tuesday, April 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–6:30 p.m. Wednesday, April 14–Friday, April 16 . . . . . . . . . . . 6:00 a.m.–7:30 p.m. Saturday, April 17 . . . . . . . . . . . . . . . . . . . . . . . . . . . 6:00 a.m.–1:00 p.m. Celebration for Research Gold Sponsor Exhibit Guide EMD Serono, Inc. EMD Serono, Inc./Pfizer Inc 4/12 Door Drop Insert Marketing Banner Marketing Carpet Marketing Exhibit Hall Opening Reception Banner Marketing Exhibit Guide 2BS.006 Peripheral Nerve Block Exhibit Guide 4/12 Door Drop Insert Marketing Banner Marketing Medtronic, Inc. 7AC.001 Deep Brain Stimulation Management Celebration for Research – Neuro Film Festival Questcor Pharmaceuticals, Inc. Residents Scholarship Fund Sepracor Inc. Banner Marketing Teva Neuroscience, Inc. 6TP.002 Therapy Program: Multiple Sclerosis 4/13 Door Drop Marketing 4/13 Door Drop Insert Marketing (2) Celebration for Research – Main Stage Residents Scholarship Fund UCB Inc. Celebration for Research – NeuroBowl Stage Merz Pharmaceuticals Inc. United Council for Neurologic Subspecialties (UCNS) 2DS.002 The Dystonias Residents Scholarship Fund Neurology Wolters Kluwer (Lippincott Williams and Wilkins) WIFI Access Exhibit Guide Shuttle Bus Service Neurology and Continuum Zogenix, Inc. 4/12 Newspaper Belly Band Neurology Now and Continuum 4/13 Exhibit Hall Coffee Break Exhibit Guide Shuttle Bus Book Bags Pfizer Inc 4/12 Door Drop Insert Marketing Corporate Therapeutic Update Exhibit Guide Current as of 2/10/10 128 Planning Your Trip to Toronto important annual meeting information Registration and Hotel Reservation Deadline: March 10, 2010 Registration, Hotel, and Travel Reservations: www.aan.com/am Registration and Hotel Travel Mail: AAN Registration and Housing c/o CMR 33 New Montgomery, Suite 1100 San Francisco, CA 94105 Airline Reservations: Carlson Wagonlit Travel Fax: Credit card reservations only (415) 979-2260 Phone: Credit card reservations only US/Canada (800) 676-4226 International (415) 979-2283 Email: Registration: [email protected] Housing: [email protected] Phone: (866) 978-1071 Fax: (866) 914-2817 Email: [email protected] Hours: Monday–Friday, 7:30 a.m.–5:00 p.m. CST Closed weekends and holidays Hours: Monday–Friday 6:00 a.m.–6:00 p.m. Pacific Standard Time Suggest an Education Program for Upcoming Meetings 2011 Annual Meeting: Honolulu The AAN invites you to submit an Education Program suggestion for the 63rd Annual Meeting, April 9 through April 16, 2011, in Honolulu. Proposals for new programs are due by May 13, 2010. Submit a proposal via the Annual Meeting website at www.aan.com/am. For questions or more information on the Annual Meeting Education Program, contact Amy Nostdahl at [email protected] or (651) 332-8687. Here are some important things to keep in mind when planning your trip: Travel Documents/Passports and Entry Requirements Visitors must have valid travel documents/passports to enter Canada to provide proof of their citizenship. Document requirements vary depending from which country you are traveling, the reason for your visit, and the length of your stay, and may include passport or a birth certificate, photo ID, and/or a visa. Learn more about travel documents and requirements at www.cic.gc.ca/english/visit/index.asp or www.toronto.ca/metropolis/english/usefulinfo.htm#customs. NOTE: Special No-Fee Passports for US Federal Government Employees In order to attend the Annual Meeting on business, it may be necessary for US government employees to obtain an official United States government no-fee passport from their appropriate agency office. Government employees should contact the appropriate office within their agency to discuss proposed dates of attendance and to confirm whether or not they will need this official passport. Currency Toronto’s currency is the Canadian Dollar; currency exchange is available at banks and kiosks throughout the city and at the airport. •For denominations under five dollars, the currency is coins •US dollars are accepted in most Toronto establishments; however you will receive change in Canadian funds and exchange rates will differ from merchant to merchant •Cash machines/ATMs are available in most banks, hotels, and shopping centers; please note that ATMs at the airport only accept ATM cards with the MasterCard logo on them IMPORTANT NOTE: Don’t forget to call your bank and credit card companies to let them know you will be traveling to Canada. Customs, Immigration, and Admissibility Upon entering Canada, you will be required to go through customs and immigration. Before you land, your flight crew will distribute a Travelers’ Customs Declaration Card for you to complete; Declaration Cards are also available at the airport upon your arrival. For more information, visit www.toronto.ca/metropolis/english/usefulinfo.htm#customs. Anyone with a criminal record (including a drunk driving conviction) may be excluded from entering Canada. If you were convicted of or committed a criminal offence outside Canada, you may overcome this criminal inadmissibility by applying for rehabilitation or you may be deemed to have been rehabilitated if at least ten years have passed since you completed the sentence imposed upon you, or since you committed the offence, if the offence is one that would, in Canada, be an indictable offence punishable by a maximum term of imprisonment of less than ten years. For more information, visit www.cic.gc.ca/english/information/applications/guides/5312ETOC.asp. Health Insurance Be sure to check with your health insurance provider about policy coverage away from home—particularly if you're insured by an HMO and/or Medicare/Medicaid. Luggage Restrictions for carry-on baggage policies and weight and size limits for checked baggage are different for international flights than for domestic flights. Be sure to check with your individual carrier as to weight and measurement restrictions and associated costs for overages. Measurements Canada uses the metric system for weights and measures. If you choose to drive in Canada, be aware the speed limits are posted in kilometers per hour instead of miles per hour. Medication If you are entering Canada with prescription drugs and syringes: keep the medication in its original, labeled container; include medical certificate with syringes showing they are for medical use and have them declared to Canadian Customs officials; bring an extra prescription in case your medication is lost and/or to attest to your need to take such prescriptions; and carry the generic name of prescription medicines. Mobile Phone Service Contact your service provider directly to inquire if service is available and/or the applicable rates. Safety Toronto’s universal number for police, fire, and medical emergencies is 911. Tax Rates and Tax Rebates Most goods and services sold or provided in Canada are subject to the 5% Goods and Services Tax (GST). In Toronto (Province of Ontario), goods are also subject to an additional 8% Provincial Sales Tax (PST). When you leave Canada, you may be eligible for a tax refund on the goods you bought in Canada if you export them within 60 days. For more information, ask for a copy of the publication called Tax Refund for Visitors to Canada from the Canada Revenue Agency at www.cra-arc.gc.ca/menu-e.html or call (800) 66VISIT (1-800-668-4748). Time Zone Toronto is in the Eastern Time Zone (the same as Detroit, New York, and Florida). For more information, visit www.aan.com/am. 130 Non-Profit Org. US Postage PAID Permit No. 3840 Minneapolis, MN 1080 Montreal Avenue St. Paul, MN 55116 register early The deadline for registering without incurring increased general registration and Education Program fees is March 10, 2010. Registrations received after March 10, 2010, will be processed at a higher rate. On-site registration opens at 8:00 a.m. on Saturday, April 10, 2010, at the Metro Toronto Convention Centre. Visit the Annual Meeting Online Upcoming Annual Meeting Dates Visit the AAN Annual Meeting website at www.aan.com/am to: 2011: Honolulu April 9–April 16, 2011 Register for the Annual Meeting Make travel and hotel arrangements Search the Education Program Learn more about special events 2012: New Orleans April 21–April 28, 2012 2013: San Diego March 16–March 23, 2013 AAN Website: www.aan.com • Annual Meeting Website: www.aan.com/am • Member Services: (800) 879-1960
© Copyright 2024